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A B S T R A C T
Background
Long-acting bronchodilators such as long-acting β-agonist (LABA), long-acting muscarinic antagonist (LAMA), and LABA/inhaled
corticosteroid (ICS) combinations have been used in people with moderate to severe chronic obstructive pulmonary disease (COPD)
to control symptoms such as dyspnoea and cough, and prevent exacerbations. A number of LABA/LAMA combinations are now
available for clinical use in COPD. However, it is not clear which group of above mentioned inhalers is most effective or if any specific
formulation works better than the others within the same group or class.
Objectives
To compare the efficacy and safety of available formulations from four different groups of inhalers (i.e. LABA/LAMA combination,
LABA/ICS combination, LAMA and LABA) in people with moderate to severe COPD. The review will update previous systematic
reviews on dual combination inhalers and long-acting bronchodilators to answer the questions described above using the strength of a
network meta-analysis (NMA).
Search methods
We identified studies from the Cochrane Airways Specialised Register, which contains several databases. We also conducted a search of
ClinicalTrials.gov and manufacturers’ websites. The most recent searches were conducted on 6 April 2018.
Selection criteria
We included randomised controlled trials (RCTs) that recruited people aged 35 years or older with a diagnosis of COPD and a baseline
forced expiratory volume in one second (FEV1) of less than 80% of predicted. We included studies of at least 12 weeks’ duration
including at least two active comparators from one of the four inhaler groups.
Data collection and analysis
We conducted NMAs using a Bayesian Markov chain Monte Carlo method. We considered a study as high risk if recruited participants
had at least one COPD exacerbation within the 12 months before study entry and as low risk otherwise. Primary outcomes were COPD
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exacerbations (moderate to severe and severe), and secondary outcomes included symptom and quality-of-life scores, safety outcomes,
and lung function. We collected data only for active comparators and did not consider placebo was not considered. We assumed a class/
group effect when a fixed-class model fitted well. Otherwise we used a random-class model to assess intraclass/group differences. We
supplemented the NMAs with pairwise meta-analyses.
Main results
We included a total of 101,311 participants from 99 studies (26 studies with 32,265 participants in the high-risk population and 73
studies with 69,046 participants in the low-risk population) in our systematic review. The median duration of studies was 52 weeks in
the high-risk population and 26 weeks in the low-risk population (range 12 to 156 for both populations). We considered the quality
of included studies generally to be good.
The NMAs suggested that the LABA/LAMA combination was the highest ranked treatment group to reduce COPD exacerbations
followed by LAMA in the both populations.
There is evidence that the LABA/LAMA combination decreases moderate to severe exacerbations compared to LABA/ICS combination,
LAMA, and LABA in the high-risk population (network hazard ratios (HRs) 0.86 (95% credible interval (CrI) 0.76 to 0.99), 0.87
(95% CrI 0.78 to 0.99), and 0.70 (95% CrI 0.61 to 0.8) respectively), and that LAMA decreases moderate to severe exacerbations
compared to LABA in the high- and low-risk populations (network HR 0.80 (95% CrI 0.71 to 0.88) and 0.87 (95% CrI 0.78 to 0.97),
respectively). There is evidence that the LABA/LAMA combination reduces severe exacerbations compared to LABA/ICS combination
and LABA in the high-risk population (network HR 0.78 (95% CrI 0.64 to 0.93) and 0.64 (95% CrI 0.51 to 0.81), respectively).
There was a general trend towards a greater improvement in symptom and quality-of-life scores with the combination therapies
compared to monotherapies, and the combination therapies were generally ranked higher than monotherapies.
The LABA/ICS combination was the lowest ranked in pneumonia serious adverse events (SAEs) in both populations. There is evidence
that the LABA/ICS combination increases the odds of pneumonia compared to LAMA/LABA combination, LAMA andLABA (network
ORs: 1.69 (95% CrI 1.20 to 2.44), 1.78 (95% CrI 1.33 to 2.39), and 1.50 (95% CrI 1.17 to 1.92) in the high-risk population and
network or pairwise OR: 2.33 (95% CI 1.03 to 5.26), 2.02 (95% CrI 1.16 to 3.72), and 1.93 (95% CrI 1.29 to 3.22) in the low-risk
population respectively). There were significant overlaps in the rank statistics in the other safety outcomes including mortality, total,
COPD, and cardiac SAEs, and dropouts due to adverse events.
None of the differences in lung function met a minimal clinically important difference criterion except for LABA/LAMA combination
versus LABA in the high-risk population (network mean difference 0.13 L (95% CrI 0.10 to 0.15). The results of pairwise meta-
analyses generally agreed with those of the NMAs. There is no evidence to suggest intraclass/group differences except for lung function
at 12 months in the high-risk population.
Authors’ conclusions
The LABA/LAMA combination was the highest ranked treatment group to reduce COPD exacerbations although there was some
uncertainty in the results. LAMA containing inhalers may have an advantage over those without a LAMA for preventing COPD
exacerbations based on the rank statistics. Combination therapies appear more effective than monotherapies for improving symptom
and quality-of-life scores. ICS-containing inhalers are associated with an increased risk of pneumonia.
Our most comprehensive review including intraclass/group comparisons, free combination therapies, 99 studies, and 20 outcomes for
each high- and low-risk population summarises the current literature and could help with updating existing COPD guidelines.
P L A I N L A N G U A G E S U M M A R Y
Which long-acting inhalers are the most effective and safest for people with advanced chronic obstructive pulmonary disease
(COPD)?
What is COPD and why does a doctor prescribe an inhaler?
Chronic obstructive lung disease (COPD) is usually caused by smoking or other airway irritants. COPD damages the lungs and causes
airways to narrow which makes it difficult to breathe.
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There are two types of inhalers for COPD: rescue and maintenance. A rescue inhaler is short- and fast-acting, and used as needed for
quick relief of symptoms, whereas a maintenance inhaler is long-acting and used on a daily basis to relieve daily symptoms and reduce
flare-ups. The long-acting inhalers are usually reserved for more advanced COPD.
Does it matter which long-acting inhaler is used in people with advanced COPD?
Commonly used maintenance inhalers are grouped into four different groups: long-acting beta2-agonists (LABAs); long-acting mus-
carinic antagonists (LAMAs); LABA/inhaled corticosteroid (ICS) combinations; and LABA/LAMA combinations. Combination in-
halers are usually reserved for individuals whose single-maintenance inhaler, such as LAMA or LABA fails. There are not many head-to-
head comparisons to determine which treatment group or individual inhaler is better compared to the others. Preventing severe flare-
ups and hospital admissions is especially important to people with COPD, healthcare providers, policy makers and society.
How did we answer the question?
We collected and analysed data from 99 studies, including a total of 101,311 participants with advanced COPD, using a special method
called networkmeta-analysis, which enabled us to simultaneously compare the four inhaler groups and 28 individual inhalers (4 LABAs,
5 LAMAs, 9 LABA/ICS combinations, and 10 LABA/LAMA combinations).
What did we find?
The LABA/LAMA combinationwas the best treatment, followed by LAMA, in preventing flare-ups although there was some uncertainty
in the results. Combination inhalers (LABA/LAMA and LABA/ICS), are more effective for controlling symptoms than single-agent
therapies (LAMA and LABA), in general. The LABA/LAMA combination was better than LABA/ICS combination, especially in people
with a prior episode of flare-ups. The LABA/ICS combination had a higher incidence of severe pneumonia compared to the others.
We did not find a difference in benefits and harms, including side effects, among individual inhalers within the same treatment groups.
Conclusion
The LABA/LAMA combination is likely the best treatment in preventing COPD flare-ups. LAMA-containing inhalers appear to
have an advantage over those without LAMA for preventing flare-ups. Combination inhalers (LABA/LAMA and LABA/ICS), appear
more effective for controlling symptoms than single-agent therapies (LAMA and LABA). Inhaled steroids carry an increased risk of
pneumonia.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
LABA/LAMA compared to LABA/ ICS for chronic obstructive pulmonary disease
Patient or population: chronic obstruct ive pulmonary disease with predicted FEV1 of less than 80%
Setting: outpat ient
Intervention: LABA/ LAMA
Comparison: LABA/ ICS
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evidence
(GRADE)
Risk with LABA/ ICS Risk difference with LABA/
LAMA
Moderate to severe exac-
erbat ions: high-risk popula-
t ion
443 per 1000 34 fewer per 1000
(66 fewer to 0 fewer)
OR 0.87
(0.76 to 1.00)
3372
(1 RCT)
⊕⊕⊕©
Moderate1,2
Moderate to severe exacer-
bat ions: low-risk populat ion
89 per 1000 11 fewer per 1000
(29 fewer to 11 more)
OR 0.86
(0.65 to 1.14)
4315
(6 RCTs)
⊕⊕⊕©
Moderate1,3
Severe exacerbat ions: high-
risk populat ion
172 per 1000 17 fewer per 1000
(39 fewer to 8 more)
OR 0.88
(0.74 to 1.06)
3354
(1 RCT)
⊕⊕⊕©
Moderate1,3
Severe exacerbat ions: low-
risk populat ion
17 per 1000 6 fewer per 1000
(12 fewer to 10 more)
OR 0.66
(0.27 to 1.63)
2860
(4 RCTs)
⊕⊕⊕©
Moderate1,3
Pneumonia: high-risk popu-
lat ion
32 per 1000 12 fewer per 1000
(19 fewer to 1 fewer)
OR 0.62
(0.40 to 0.96)
3358
(1 RCT)
⊕⊕⊕©
Moderate1
Pneumonia: low-risk popu-
lat ion
8 per 1000 4 fewer per 1000
(6 fewer to 0 fewer)
OR 0.43
(0.19 to 0.97)
5395
(7 RCTs)
⊕⊕⊕©
Moderate1
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; FEV1 : f orced expiratory volume-one second; ICS: inhaled cort icosteroid; LABA: long-act ing beta2-agonist ; LAMA: long-act ing muscarinic antagonist ;
OR: odds rat io; RCT: randomised controlled trial4
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GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Optimal information size was not met.
295%CI contains the line of no dif ference.
3 We could not exclude the possibility of a clinically important dif f erence due to a wide 95%CI.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a globally
prevalent illness, characterised by chronic airway inflammation
leading to slow progression of airflow limitation (GOLD 2018).
The inflammatory nature of the disease leads to variable degrees
of small airway obstruction and destruction of lung parenchyma.
COPD accounts for more than three million deaths annually and
is the third leading cause of death worldwide. This disease is due
primarily to tobacco smoke in high-income countries; tobacco
smoking is also the primary cause of COPD in low-income coun-
tries, but air pollution and indoor biomass fuel consumption are
more frequent causes compared to high-income countries. The
disease affects men and women equally (WHO 2016). Despite
the worldwide prevalence of the disease, it remains largely under-
recognised and underdiagnosed. COPD is a costly disease, with
an estimated annual cost of USD 49.9 billion, including an indi-
rect cost estimated at approximately 41% of the total cost in the
USA and a total cost of EUR 38.7 billion in Europe (Patel 2014;
WHO 2016). Clinically, the disease is characterised by chronic
dyspnoea, productive cough and exposure to a risk factor such as
smoking. The post-bronchodilator forced expiratory volume in
one second (FEV1)/forced vital capacity (FVC) is required to be
less than 0.7 for this diagnosis (GOLD 2018). The disease course
is usually interrupted by episodes of acute exacerbation, the fre-
quency of which contributes to overall morbidity and mortality
(Suissa 2012).
Description of the intervention
Management of stable COPD
Once COPD has been diagnosed, the main goals of therapy in-
clude alleviation of symptoms and prevention of disease progres-
sion and acute exacerbations. Smoking cessation is one of themost
important non-pharmacological interventions. Annual influenza
vaccination is recommended for everyone with COPD. In obser-
vational studies, influenza vaccination was associated with fewer
outpatient visits, hospitalisations and deaths (Trucchi 2015). Pul-
monary rehabilitation has been proven to improve exercise tol-
erance while reducing symptoms and exacerbations (McCarthy
2015; Rochester 2015). Inhaled medications, the mainstay of
pharmacological therapies, are used to improve lung function,
symptoms and quality of life, as well as to reduce acute exacer-
bations. Short-acting bronchodilators are given on an as-needed
basis to provide immediate relief, and long-acting bronchodila-
tors are used as maintenance therapy in people with moderate to
very severe disease (Decramer 2012). The Global Initiative for
Chronic Obstructive Lung Disease (GOLD), recommends long-
acting bronchodilators as maintenance therapy in people experi-
encing long-term respiratory symptoms or exacerbations.(GOLD
2018).
How the intervention might work
Combination bronchodilators
Dual combination inhalers include long-acting beta-adrenocep-
tor agonist/inhaled corticosteroid (LABA/ICS) and LABA/long-
acting muscarinic antagonist (LAMA) combinations. An ICS has
anti-inflammatory effects and may reduce airway inflammation as
well as systemic inflammation, as evidenced by a reduction in C-
reactive protein (Heidari 2012). ICSs and LABAs have synergis-
tic effects when used in combination. Corticosteroids upregulate
beta2-receptors and beta2-agnoists and facilitate translocation of
steroid receptors from the cytoplasm to the nucleus (Falk 2008).
In vitro synergistic effects mentioned above may translate into
clinical benefit. Clinical studies have suggested that a LABA/ICS
combination significantly improved lung function, health status
and rate of exacerbation compared with placebo, LABA alone or
ICS alone (Nannini 2012).
Preclinical studies have suggested drug synergy between a beta2-
adrenoreceptor agonist and amuscarinic agonist. A possible mech-
anism for this synergism is that a muscarinic agonist causes less
suppression of potassium channel opening, leading to relaxation
of the airway smoothmuscle, which further promotes beta2-medi-
ated smoothmuscle relaxationby activating ion channels andother
intracellular signalling pathways (Kume 2014). Clinical studies
have demonstrated that LABA/LAMA combinations were supe-
rior to monotherapies with regard to lung function improvement
and in a recent network meta-analysis (NMA), were associated
with improved quality of life and symptom scores, and reduced
COPD exacerbations as compared with LABA or LAMA alone
(Oba 2016a).
Guidelines recommend a LABA/LAMA combination for people
whose symptoms are not well controlled with a single long-acting
bronchodilator, and a LABA/LAMA or LABA/ICS combination
for those with frequent exacerbations (i.e. two or more exacerba-
tions per year or one hospitalisation per year for an exacerbation).
A LABA/LAMA combination may be preferred to a LABA/ICS
combination, as ICSs are associated with increased risk of pneu-
monia (GOLD 2018; Oba 2016b; Wedzicha 2016).
Why it is important to do this review
Data on the efficacy and safety of LABA/LAMA combinations
are accumulating (Huisman 2015; Oba 2016a; Schlueter 2016).
However, an important clinical question is how do the efficacy
6Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and safety of LABA/LAMA combinations compare with those of
LABA/ICS combinations for people with uncontrolled symptoms
or frequent exacerbations, or both. Additional clinical studies,
including several head-to-head studies comparing LABA/LAMA
and LABA/ICS combinations (Donohue 2015; Singh 2015d;
Vogelmeier 2013a; Vogelmeier 2015; Wedzicha 2016; Zhong
2015), have been published since an NMA comparing combina-
tion inhalers focused on studies up to December 2013 (Tricco
2015). Our review updates previous systematic reviews on dual
combination inhalers and long-acting bronchodilators using the
strength of an NMA.
O B J E C T I V E S
To compare the efficacy and safety of available formulations from
four different groups of inhalers (i.e. LABA/LAMA combination,
LABA/ICS combination, LAMA and LABA) in people with mod-
erate to severe COPD. The review will update previous system-
atic reviews on dual combination inhalers and long-acting bron-
chodilators to answer the questions described above using the
strength of a network meta-analysis (NMA).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel, randomised controlled trials (RCTs), of at
least 12 weeks’ duration, published or unpublished. We did not
consider cross-over studies.
Types of participants
We included studies that recruited people aged 35 years or older
with a diagnosis of COPD, in accordance with American Thoracic
Society-European Respiratory Society (ATS/ERS 2004), GOLD
report (GOLD 2018), or equivalent criteria. Obstructive ventila-
tory defect should be at least moderate, with a baseline FEV1 less
than 80% of predicted. We excluded studies that enrolled partic-
ipants with a history of asthma or other respiratory disease.
Types of interventions
We included studies comparing at least two of the following ther-
apies. We limited treatment arms to drug formulations and doses
that were licensed in the USA or EU countries, or both, for clinical
use. We did not consider triple combination therapy (i.e. LABA/
LAMA/ICS) because it was out of scope for this review.
1. LAMA monotherapy
2. LABA monotherapy
3. Fixed-dose or free combination of LABA/ICS
4. Fixed-dose or free combination of LABA/LAMA
We allowed the use of a short-acting bronchodilator, such as salbu-
tamol( also known as albuterol), and ipratropium as rescue treat-
ment.
Types of outcome measures
Primary outcomes
1. COPD exacerbations (moderate to severe and severe)
Secondary outcomes
1. Change from baseline in St George’s Respiratory
Questionnaire (SGRQ) score and decrease in SGRQ score by 4
units or more (SGRQ responder)
2. Transition Dyspnea Index (TDI)
3. Mortality
4. Total serious adverse events (SAEs)
5. Cardiac and COPD SAEs
6. Dropouts due to adverse events
7. Change from baseline in trough FEV1
8. Pneumonia reported as SAE
We used an end-point score for dichotomous outcomes. For con-
tinuous outcomes, we used a change score reported at 3, 6, 12
months and the end of the study, when available.We defined ’mod-
erate exacerbation’ as worsening of respiratory status that requires
treatment with systemic corticosteroids or antibiotics, or both; we
defined ’severe exacerbation’ as rapid deterioration that requires
hospitalisation. The above-mentioned outcomes and their defini-
tions are well established and widely used across the medical liter-
ature.
Search methods for identification of studies
Electronic searches
We identified studies from the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Register contains trial reports identified through systematic
searches of the following bibliographic databases:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies (CRS);
2. weekly searches of MEDLINE Ovid SP 1946 to date;
3. weekly searches of Embase Ovid SP 1974 to date;
4. Monthly searches of PsycINFO Ovid SP 1967 to date;
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5. Monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature) 1937 to date;
6. Monthly searches of AMED EBSCO (Allied and
Complementary Medicine) all years to date;
7. handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings are in Appendix 1. See Appendix 2 for search terms used
to identify studies for this review.
We also conducted a search
of ClinicalTrials.gov (www.ClinicalTrials.gov) and manufacturers’
websites. We searched all sources from their inception to 6 April
2018, and we imposed no restriction on language of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We searched relevant manufac-
turers’ websites for study information. We searched for errata or
retractions from included studies published in full text on PubMed
( www.ncbi.nlm.nih.gov/pubmed) and reported within the review
the date this was done.
Data collection and analysis
Selection of studies
Two review authors (YO, NG) independently screened studies
by title and abstract to evaluate whether a study met the inclu-
sion and exclusion criteria. We selected studies that evaluated
the clinical efficacy and safety of any of the following therapies
in people with COPD: LABA/LAMA, LABA/ICS, LABA and
LAMA. We resolved disagreements by involving a third contribu-
tor Joe V Devasahayam (JVD). We recorded the selection process
in sufficient detail to complete a PRISMA flow diagram and a
’Characteristics of excluded studies’ table (Moher 2009).
Data extraction and management
Two review authors (YO, NG), independently extracted informa-
tion on study design, study size, population, interventions (drug,
dose, inhaler type, allowed co-medications), severity of illness and
end points of interest. We gathered information on whether a par-
ticipant had been unsuccessfully treated with a long-acting bron-
chodilator before entry into clinical studies. We extracted and ver-
ified data from each of the existing reviews, which were cross-
checked and verified by at least two review authors. We resolved
disagreements regarding values, inconsistencies and uncertainties
by involving a third contributor. Two review authors (YO, NG)
independently extracted outcome data from the included studies.
We noted in the ’Characteristics of included studies’ table if out-
come data were not reported in a useable way. We resolved dis-
agreements by reaching consensus or by involving a third contrib-
utor (JVD). One review author (YO) transferred data into the Re-
view Manager 5 file (Review Manager 2014). We double-checked
that data had been entered correctly by comparing data presented
in the systematic review versus study reports. A second review au-
thor (NG) spot-checked study characteristics for accuracy against
the study report.
Assessment of risk of bias in included studies
Two review authors (YO, NG) independently assessed risk of bias
for each study using the criteria outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2017). We
resolved disagreements by discussion or by consultation with an-
other contributor (JVD). We assessed risk of bias according to the
following domains.
1. Random sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
7. Other bias
We graded each potential source of bias as high, low or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised
’Risk of bias’ judgements across different studies for each of the
domains listed.We considered blinding separately for different key
outcomes when necessary (e.g. for unblinded outcome assessment,
risk of bias for all-cause mortality may have been very different
than for a patient-reported dyspnoea scale). When information
on risk of bias related to unpublished data, we noted this in the
’Risk of bias’ table. When considering treatment effects, we took
into account the risk of bias for studies that contributes to that
outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to this published protocol and
reported deviations from it in the ’Differences between protocol
and review’ section of the systematic review.
Measures of treatment effect
Network meta-analysis
We conducted NMAs using a Bayesian Markov chain Monte
Carlomethod and fitted inWinBUGS (version 1.4.3.), using code
adapted fromDias 2018, which correctly accounts for correlations
in studies with more than two arms and allows the specific data
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structures being considered. We compared each pair of treatments
by estimating an odds ratio (OR) or hazard ratio (HR) for dichoto-
mous outcomes, and a difference in mean or median for continu-
ous outcomes, along with their 95% credible intervals (CrIs). We
used a normal likelihood with an identity link for continuous out-
comes (FEV1, TDI and SGRQ) and a binomial likelihood with
a logit link for mortality, SAEs (total, cardiac and COPD), drop-
outs due to adverse events, SGRQ responders and pneumonia.
We used a shared parameter model for exacerbation outcomes,
whereby data on the log hazard ratio (lnHR and standard error)
weremodelledwith the assumption that continuous treatment dif-
ferences (lnHR) had a normal likelihood. When lnHR data were
not available, or when appropriate covariance matrices could not
be extracted or calculated for studies with more than two arms, we
modelled data on the number of participants with at least one ex-
acerbation out of the total number of participants at a given time
as lnHR by using a binomial likelihood with Cloglog link. We
used lnHR data in preference to dichotomous data when available
and considered only the HR for the first event. We assessed model
fit by comparing residual deviance to the number of data points,
and by assessing the size of the between-study standard deviation
(SD).
Direct pairwise meta-analysis
We conducted pairwise meta-analyses (MAs) considering only di-
rect evidence. We analysed dichotomous data as ORs and con-
tinuous data as mean differences (MDs) along with their 95%
confidence intervals (CIs). We undertook MAs only when this
was meaningful (i.e. if treatments, participants and the underlying
clinical question were similar enough for pooling to make sense).
When a single study reported multiple study arms, we included
only the relevant arms.
Unit of analysis issues
We analysed dichotomous data by using number of participants
(rather than events), as the unit of analysis to avoidmultiple count-
ing of data from the same participant.
Dealing with missing data
We requested additional data from the responsible author of the
included studies to verify key study characteristics and to obtain
missing numerical outcome data when possible (e.g. when a study
was identified as an abstract only). When this was not possible,
and when the missing data were thought to introduce serious bias,
we explored the impact of including such studies in the overall
assessment of results by performing a sensitivity analysis.
Assessment of heterogeneity
Assessment of similarity of participants, interventions and
study methods
We assessed similarity of participants, interventions, potential ef-
fect modifiers and study methods in all studies and across pairwise
comparisons to examine heterogeneity and inconsistency in the
NMAs. The initial editorial review for study protocol had ques-
tioned the similarity of patient populations across clinical studies
owing to the presence of potential effect modifiers. After a prelim-
inary search of clinical studies and a review of inclusion/exclusion
criteria, participant characteristics and study methods, we decided
to divide the study populations into those with and without a his-
tory of COPD exacerbations within 12 months before study en-
try, which we viewed as a potential effect modifier (Table 1). This
is consistent with the GOLD 2018 update, which recommends
treatment options based on an exacerbation history.
We assessed if there was any difference in effect modifiers across
the group pairwise comparisons especially when there was a dis-
crepancy between the NMA and pairwise MA results and inter-
preted the results accordingly.
Assessment of heterogeneity and statistical consistency
We assessed heterogeneity by comparing the between-study SD
to the size of relative treatment effects, on the log-scale for OR
and HR. We assessed consistency by comparing the model fit
and between-study heterogeneity from the NMA models versus
those from an unrelated mean-effects (inconsistency) model (Dias
2013a; Dias 2013b). We used this to determine the presence and
area of inconsistency. We also qualitatively compared the results
from direct pairwise MA versus NMA estimates to check for broad
agreement. If we identified substantial inconsistency, we explored
factors, including participant and design characteristics that may
have contributed to inconsistency (Table 2; Table 3; Table 4; Table
5; Table 6). For the pairwise MA, we tested heterogeneity among
studies with I² statistics greater than 30%, indicating substantial
heterogeneity (Higgins 2003). We used optimal information size
calculations as an objective measure of imprecision for grading
evidence, with an α of 0.05 and a β of 0.80 (Guyatt 2011a).
We addressed heterogeneity in the pairwise MAs according to the
GRADE criteria (Guyatt 2011b).
Assessment of reporting biases
We tried tominimise reporting biases from unpublished studies or
selective outcome reporting by using a broad search strategy and
by checking references of included studies and relevant systematic
reviews. For each outcome, we reported the number of studies
contributing data to the NMAs. For the pairwise MA, we assessed
small study and publication bias through visual inspection of a
funnel plot and performance of the Egger test (Egger 1997), if
more than 10 studies were being pooled.We assumed the presence
of small study bias when the number of participants was fewer than
50 per study, 1000 per pooled analysis or 100 per arm, when no
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more than 10 studies could be pooled (Dechartres 2013; Nüesch
2010).We assumed a selective reporting bias if a clinical study was
not registered (Mathieu 2009).
Data synthesis
We based model comparison on deviance information criterion
(DIC) (Spiegelhalter 2002). Differences of three points or more
were considered meaningful. If models differed by less than three
points, we selected the simplest model. We also calculated the
posterior mean of the residual deviance to assess model fit. We
considered this adequate when the posterior mean of the residual
deviance approximated the number of unconstrained data points
(Dias 2013c).
We chose a model and considered it as the primary analysis for
NMAs using the following strategy:
1. Start with fixed-class models (random- and fixed-treatment-
effects). If both fit well, choose model with lowest DIC (if
difference less than 3 choose fixed-effect model) and stop.
2. If the fixed-treatment-effect, fixed-class model does not fit
well, try the fixed-treatment-effect, random-class model - assess
fit and choose the model with the lowest DIC.
3. If neither fixed- nor random-treatment-effect models with
fixed-class fit well, try also random-treatment-effects with
random-class.
4. Choose a final model based on DIC, but interpret with
caution if model fit is poor.
We estimated the probability that each treatment group ranked at
one of the four possible positions in the class model NMAs with
rank 1 meaning that group is best for that outcome.
GRADE and ’Summary of findings’ table
We used GRADE to assess the quality of evidence as it related to
studies that contributed data to the pairwise MAs. We created a
’Summary of findings’ table including the primary outcomes and
pneumonia. We used the five GRADE considerations (study lim-
itations, consistency of effect, imprecision, indirectness and pub-
lication bias), to assess the certainty of a body of evidence as it re-
lated to studies that contributed data to pairwiseMAs for prespeci-
fied outcomes. We used methods and recommendations described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2017), and used GRADEpro GDT 2015 software. We
justified all decisions to downgrade or upgrade the certainty of
evidence by using footnotes, and we made comments to aid the
reader’s understanding of the review when necessary.
Subgroup analysis and investigation of heterogeneity
We combined the high- and low-risk populations (presence or
absence of a history of COPD exacerbation within the previous
year), and performed subgroup analyses investigating if there was
a substantial difference between them.We analysed studies of dif-
ferent duration separately (3, 6, and 12 months), for symptom
and quality-of-life scores and change from baseline in FEV1 to
minimise intransitivity because a previous study (Oba 2016a),
suggested different durations could influence treatment effects on
these outcomes. We used a formal test for subgroup interactions
provided in Review Manager 2014.
Sensitivity analysis
We used a model not used in the primary analysis (fixed-effect
or random-effects), as a sensitivity analysis for both NMAs and
pairwise MAs.
R E S U L T S
Description of studies
The study and patient characteristics including study duration,
treatment arms, and baseline pulmonary function are presented
in Table 1 and details of each study are shown in Characteristics
of included studies.
Results of the search
We identified 870 plus 166 records (original and updated search
respectively), from the Cochrane Airways Specialised Register
(CAGR) of studies, and 28 references through other sources, such
as manufactures’ websites. We searched all records in the CAGR
using the search strategy in Appendix 2 in March 2017 and again
on 6 April 2018 for the updated search. We excluded 119 stud-
ies on abstract review. We reviewed the remaining 156 studies for
further details and excluded an additional 57 studies for various
reasons as shown in Figure 1.
Included studies
We included 26 studies with 32,265 participants in the high-risk
group (one or more exacerbations in the previous 12 months), and
73 studies with 69,046 participants in the low-risk group, totaling
99 studies with a total of 101,311 randomised participants. The
numbers of included studies varied with each outcome due to
data availability and are summarised in Figure 1. Four in the low-
risk group (Hoshino 2013; Hoshino 2014; Hoshino 2015; Perng
2009), and one in the high-risk group (Sarac 2016), were single-
centre studies and the rest were multicenter studies. They were
all industry-funded studies except for Aaron 2007, Cazzola 2007,
Hoshino 2013, Hoshino 2014, Hoshino 2015, Perng 2009, and
Sarac 2016.
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Figure 1. Study flow diagram
AEs: adverse events; CAGR: Cochrane Airways Group Specialised Register; CFB: change from baseline; H:
high−risk group; L: low−risk group; NA: not applicable; NMA: network meta−analysis; SAE: serious adverse
event; SGRQ: St George’s Respiratory Questionnaire; TDI: Transition Dyspnea Index
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Table 2, Table 3, Table 4, Table 5, and Table 6 show comparisons
of study characteristics among pairwise MAs in the relevant out-
comes. The median duration of study was 52 (range 12 to 156)
and 24 (range 12 to 156) weeks in the high- and low-risk groups
respectively.
Table 7; and Table 8 present the distribution of treatment arms
across all 99 included studies, categorised by the four treatment
groups. Vilanterol is available only as a component of combination
inhalers for clinical use (i.e. it is not available as a single inhaler),
therefore we did not include vilanterol as a node in the review.
Indacaterol 27.5 µg and 600 µg twice daily, indacaterol/glycopy-
rronium 27.5 µg/25 µg twice daily, umeclidinium/vilanterol 125
µg/25 µg once daily, tiotropium/olodaterol 2.5 µg/5 µg once
daily, and aclidinium/formoterol 400 µg/6 µg twice daily were
also excluded from the analysis because they were not approved
or available for clinical use at the time of data extraction. The
network of treatments for each outcome is displayed in a corre-
sponding figure. The treatments formed a closed network, which
was amenable to a NMA except for SGRQ responders at 3 and 6
months, and TDI at 3, 6, and 12 months in the high-risk popu-
lation, and SGRQ responders at 12 months in the low-risk pop-
ulation. When fixed- or random-class models were considered, all
networks were connected and could be analysed.
Participants
The mean age, proportion of male participants and current smok-
ers, and pre-bronchodilator baseline FEV1, were 64.5 years (SD
1.5), 72.5% (SD 11.7), 39.0% (SD 6.0), and 1.06 L (SD 0.11),
in the high-risk group and 64.6 years (SD 2.4), 72.5% (SD 12.3),
46.0% (SD 8.1), and 1.31 L (SD 0.13), in the low-risk group. The
median bronchial reversibility at the baseline was 13.6% (range
7.0 to 22.4), and 14.2% (range 7.9 to 24.1), in the high- and low-
risk groups respectively.
Excluded studies
We excluded 57 studies after full-text review and we recorded
them in Characteristics of excluded studies, with reasons for ex-
clusion. We excluded 27 studies because, after we had excluded
an unapproved or unavailable dosage, there were no valid compar-
isons. Two studies became available after data extraction (Calverley
2018; Papi 2017), and we did not included them in the analysis.
We would have excluded Calverley 2018 anyway because they in-
cluded participants with coexisting reactive airway disease.
Risk of bias in included studies
We have presented ’Risk of bias’ judgements for individual studies
in the Characteristics of included studies and a summary overview
of the findings in Figure 2. Generally, we deemed the risk of bias in
the included studies to be moderate to low. There were no studies
that we should clearly have excluded from the analysis because of
differences in baseline characteristics or poor quality.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
All studies were randomised trials and most of them were indus-
try funded. We confirmed a random allocation sequence using a
validated computerised system in 60 out of 92 industry-funded
studies, and assumed an industry-standard method for the rest and
considered them to be at low risk for random sequence generation
and allocation concealment (concealment assumed by automati-
sation). We could not confirm a random allocation sequence in
four out of seven non-industry studies (Hoshino 2013; Hoshino
2014: Hoshino 2015: Sarac 2016), and we considered them to be
at unclear risk.
Blinding
The following studies were open-label or partially blinded, with
tiotropium being administered open-label, and considered to be at
a high risk of bias: Asai 2013, Bateman 2013, COMBINE 2017,
Donohue 2010, Hagedorn 2013, Hanania 2017, Hoshino 2013,
Hoshino 2014, Hoshino 2015, Kerwin 2012a, Martinez 2017a,
NCT00876694 2011, Perng 2009, Sarac 2016, Vogelmeier 2008,
Vogelmeier 2017, Wedzicha 2013. They consisted of 15.4% and
17.8% of studies in the high- and low-risk populations. The rest
of the studies were double-blinded (82.8%), and rated as having
low risk of bias (blinding of participants, personnel and outcome
assessors).
Incomplete outcome data
We rated 18 studies (18.1%), at high risk due to high attrition or
unbalanced dropouts. We gave an unclear rating to four studies
(4.0%), because of high but balanced attrition (Calverley 2003
TRISTAN), imbalanced but relatively low attrition (Ferguson
2017; Hanania 2017), and a small sample size with unknown at-
trition (Sarac 2016). We tested whether the above studies com-
promised the validity of the results by excluding them one by one
or all together in each outcome. The results are described in ’Sum-
mary of findings’ tables in the selected outcomes.
Selective reporting
We were able to locate a study protocol, and most studies reported
confirmed expected outcomes in publications.We could not locate
a preregistered protocol for five studies (Briggs 2005; Cazzola
2007: Hoshino 2013: Perng 2009: Sarac 2016), and rated them
as unclear risk of bias. Two studies reported outcomes of interest
but in an insufficient form to be incorporated into a meta-analysis
and we rated them as having high risk of bias (Hoshino 2015;
Vogelmeier 2008).
Other potential sources of bias
The vastmajority of the included studies were designed, sponsored
and conducted by pharmaceutical companies. Industry sponsor-
ship bias cannot be excluded.
Effects of interventions
See: Summary of findings for the main comparison
LABA/LAMA compared to LABA/ICS for chronic obstructive
pulmonary disease; Summary of findings 2 LABA/LAMA
compared to LAMA for chronic obstructive pulmonary disease;
Summary of findings 3 LABA/LAMA compared to LABA for
chronic obstructive pulmonary disease; Summary of findings
4 LABA/ICS compared to LAMA for chronic obstructive
pulmonary disease; Summary of findings 5LABA/ICS compared
to LABA for chronic obstructive pulmonary disease; Summary
of findings 6 LAMA compared to LABA for chronic obstructive
pulmonary disease; Summary of findings 7 Summary of findings
for network meta-analyses
1. Results: high-risk population
1.1 Outcome: exacerbations
1.1.1 Outcome: moderate to severe exacerbations
We included 21 studies of 14 interventions and four treatment
groups for this outcome (Appendix 3; Figure 3).
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Figure 3. Moderate to severe exacerbations in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 1 favour the first named treatment group. bid: twice daily; BDP:
beclomethasone; BUD: budesonide; FF: fluticasone furoate; FM: formoterol; FP: fluticasone propionate; Glyco:
glycopyrronium; ICS: inhaled corticosteroid; IND: indacaterol; LABA: long-acting beta2-agonist; LAMA: long-
acting muscarinic antagonist; qd: once daily; SAL: salmeterol; Tio: tiotropium; VI: vilanterol
1.1.1.1 Model selection and inconsistency checking
We chose a random-treatment-effects model with fixed-class ef-
fects, assuming consistency (Appendix 4).
1.1.1.2 NMA results
TheNMA included a total of 25,771 participants (LABA: 10,279,
LAMA: 6376, LABA/ICS: 8282, LABA/LAMA: 834). The me-
dian duration of follow-up was 52 weeks (range 12 to 156 weeks).
Figure 3 andTable 9 show theHR formoderate to severe exacerba-
tions for each group compared to every other. TheNMA suggested
that LABA/LAMA combination was the highest ranked treatment
group to reduce moderate to severe exacerbations (95% CrI 1st
to 2nd), followed by LAMA (95% CrI 2nd to 3rd), (Appendix
5; Table 10). HRs against LABA/ICS, LAMA, and LABA were
0.86 (95% CrI 0.76 to 0.99), 0.87 (95% CrI 0.78 to 0.99) and
0.70 (95% CrI 0.61 to 0.80), respectively (Appendix 6). LABA is
the worst ranked treatment group for this outcome (95% CrI 4th
to 4th), and all groups of interventions decrease the rate of mod-
erate to severe exacerbations compared to LABA. HRs for other
treatment groups versus LABA were 0.70 (95% CrI 0.61 to 0.80),
0.80 (95% CrI 0.75 to 0.86) and 0.80 (95% CrI 0.71 to 0.88) for
LABA/LAMA, LABA/ICS, and LAMA respectively (Appendix 6;
Summary of findings 7).
1.1.1.3 Clinical homogeneity assessment
Table 2 shows the clinical homogeneity assessment (or transitivity),
across the available comparisons. Bronchial reversibility ranged
from 7.0% to 18.3%. The mean bronchial reversibility for LABA/
ICS versus LAMA comparison was 7%, which could have under-
estimated the effects of LABA/ICS. The NMA results should be
interpreted with caution because of the difference in bronchial re-
versibility across the pairwise comparisons.
1.1.1.4 Pairwise meta-analyses
There was no direct comparison for LABA/LAMA versus LABA.
The results from pairwise MAs were consistent with the NMAs
except for LABA/LAMA versus LABA/ICS or LAMA, in which
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the 95% CI contained the line of no difference (OR 0.87, 95%
CI 0.76 to 1.00, and OR 1.06, 95% CI 0.89 to 1.27), unlike
the NMAs (HR 0.86, 95% CrI 0.76 to 0.99, and HR 0.87, 95%
CrI 0.78 to 0.99; Appendix 6). The certainty of evidence was
moderate for LABA/LAMA versus LABA/ICS or LAMA due to
a suboptimal sample size, which could explain the discrepancy
between theNMAs and pairwiseMAs.Otherwise, it wasmoderate
for LABA/ICS versus LAMAandhigh for LABA/ICS versus LABA
and LAMA versus LABA (see ’Summary of findings’ tables). There
was no difference between random and fixed analyses.
1.1.2 Outcomes: severe exacerbations
We included 13 studies of nine interventions and four treatment
groups for this outcome (Appendix 3; Figure 4 a and b).
Figure 4. Severe exacerbations in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 1 favour the first named treatment group. ICS: inhaled corticosteroid; LABA:
long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.1.2.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency. We also report results based on a random-
effects model for comparison (Appendix 4).
1.1.2.2 NMA results
This NMA included a total of 21,733 participants (LABA: 7482,
LAMA: 7723, LABA/ICS: 4965, LABA/LAMA: 1563). The me-
dian duration of follow-up was 52 weeks (range 12 to 104 weeks).
Figure 4 and Table 11 show the HR for severe exacerbations for
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each treatment group compared to every other. The NMA sug-
gested that LABA/LAMA combination was the highest ranked
treatment group to reduce severe exacerbations (95% CrI 1st to
2nd), followed by LAMA (95% CrI 1st to 3rd; Appendix 5; Table
12). HRs against LABA/ICS, LAMA, and LABA were 0.78 (95%
CrI 0.64 to 0.93), 0.89 (95% CrI 0.71 to 1.11), and 0.64 (95%
CrI 0.51to 0.81), respectively. Results using the fixed- or random-
treatment-effects assumption are very similar. There is evidence
that all treatment groups decrease the rate of severe exacerbations
compared to LABA (HRs against LABA: 0.64 (95% CrI 0.51 to
0.81), 0.83 (95% CrI 0.71 to 0.97), and 0.72 (95% CrI 0.63 to
0.82), for LABA/LAMA,LABA/ICS andLAMArespectively), and
that LABA/LAMA decreases the rate of severe exacerbations com-
pared to LABA/ICS (HR 0.78, 95% CrI 0.64 to 0.93; Appendix
6; Summary of findings 7).
1.1.2.3 Clinical homogeneity assessment
Table 4 shows the clinical homogeneity assessment across the avail-
able comparisons. Bronchial reversibility ranged from 7.0% to
22.4% and was not available in three comparisons, which could
have introduced a bias favouring an ICS-containing inhaler in a
population with a significant bronchodilator response. The NMA
results should be interpreted with caution because of the differ-
ence in and lack of data on bronchial reversibility.
1.1.2.4 Pairwise meta-analyses
Contrary to the NMAs, the pairwise MAs showed no evidence
that any treatment group was better than the others. There was
no direct comparison for LABA/LAMA versus LABA (Appendix
6). The certainty of evidence was moderate for all comparisons
due to a suboptimal information size, which could explain the
discrepancy between theNMAs and pairwise MAs (See ’Summary
of findings’ tables). There was no difference between random and
fixed analyses.
1.1.3 Rank probabilities for exacerbations
Figure 5 plots the ranks of each treatment group for severe exac-
erbations and moderate to severe exacerbations. The vertical axis
shows the probability of being ranked best, second best, third best,
or worst treatment group for each of the treatment groups. LABA/
LAMA has a high probability of being the best intervention for
both severe and moderate to severe exacerbations in the high-risk
population, with a probability of nearly 100% of being the best
treatment group to reducemoderate to severe exacerbations. LABA
has a very high probability of being the worst treatment group for
reducing both severe and moderate to severe exacerbations.
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Figure 5. Plot of rank probabilities for each treatment group
Severe exacerbations (solid line), and moderate to severe exacerbations (dashed line), in the high-risk
population ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic
antagonist
1.2 Outcome: St George’s Respiratory Questionnaire
(SGRQ) responders
1.2.1 Outcome: SGRQ responders at three and six months
There were insufficient data to perform a NMA for SGRQ re-
sponders at three and six months. The results were based on one
study for the following comparisons: LABA/LAMA versus LAMA
at six months; LABA/ICS versus LAMA at three and six months;
and LAMA versus LABA at three and six months. There is no ev-
idence to suggest any treatment group is associated with a higher
proportion of SGRQ responders compared to the others except
for LABA/LAMA versus LAMA at six months, in which LABA/
LAMA had a significantly greater proportion of SGRQ responders
compared to LAMA (OR 1.30, 95% CI 1.08 to 1.56; Appendix
6). The certainty of evidence was low to moderate.
1.2.2 Outcome: SGRQ responders at 12 months
Seven studies of 10 interventions and four treatment groups were
available for this outcome (Appendix 3; Figure 6 a and b). Note
that interventions formoterol 12µg twice daily, formoterol/budes-
onide 400µg/12 µg twice daily, and formoterol/beclomethasone
200 µg/12 µg twice daily are disconnected from the main treat-
ment network (Figure 6a), but we included them in a class/group
model.
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Figure 6. St George’s Respiratory Questionnaire responders at 12 months in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 1 favour the first named treatment group. BDP: beclomethasone; BUD:
budesonide; FM: formoterol; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting
muscarinic antagonist
1.2.2.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency. We also report results based on a random-
treatment-effects model with fixed-class effects for comparison (
Appendix 4).
1.2.2.2 NMA results
The NMA included a total of 11,089 participants (LABA: 2313,
LAMA: 3078, LABA/ICS: 3496, LABA/LAMA: 2202). Figure 6d
and Table 13 show the ORs of SGRQ responders at 12 months for
each treatment group compared to every other. There is evidence
to suggest that LABA/ICS increases the odds of response at 12
months compared to LABA (OR 1.17, 95% CrI 1.02 to 1.34),
and that LABA/LAMA increases the odds of response compared
to all other treatment groups (OR 1.21, 95% CrI 1.07 to 1.36;
OR 1.36, 95% CrI 1.18 to 1.58, and OR 1.41, 95% CrI 1.20 to
1.66, against LABA/ICS, LAMA and LABA respectively), using
the fixed-treatment-effectmodel. Results aremore uncertain when
random-treatment effects are assumed. Table 14 shows the rank
statistics for the four treatment groups (sorted by mean rank). The
highest ranked treatment group was LABA/LAMA with a median
rank of 1 (95% CrI 1st to 1st).
1.2.2.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the fixed-ef-
fect NMA except for LABA/ICS versus LABA, in which LABA/
ICS significantly increased the odds of SGRQ response compared
to LABA with the fixed-effect model (OR 1.22, 95% CI 1.03 to
1.46), but not with the random-effects model (OR 1.15, 95% CI
0.78 to 1.72). There was no direct comparison for LABA/LAMA
versus LABA. The certainty of evidence was high for LABA/
LAMA versus LABA/ICS, moderate for LABA/ICS versus LAMA
or LABA and LAMA versus LABA, and low for LABA/LAMA
versus LAMA. There was no difference between random and fixed
analyses except for LABA/ICS versus LABA, in which the differ-
ence was significant with the fixed model but not with the random
model (Appendix 6).
1.3 Change from baseline in SGRQ score
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1.3.1 Outcome: change from baseline in SGRQ score at three
months
We included nine studies of 12 interventions and four treatment
groups for this outcome (Appendix 3; Figure 7 a and b). Note that
interventions salmeterol 50 µg twice daily, formoterol 9 µg twice
daily, salmeterol 50µg twice daily + fluticasone 250µg twice daily,
salmeterol/fluticasone 50 µg/250 µg twice daily, indacaterol 150
µg once daily + budesonide 400 µg twice daily, and formoterol/
budesonide 9 µg/320 µg twice daily are disconnected from the
main treatment network (Figure 7a), but we included them in a
class/group model.
Figure 7. Change from baseline in St George’s Respiratory Questionnaire score at 3 months in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 0 favour the first named treatment group. BUD: budesonide; FM: formoterol;
FP: fluticasone propionate; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting
muscarinic antagonist; SAL: salmeterol
1.3.1.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency. We also report results based on a random-
treatment-effects model with fixed-class effects for comparison (
Appendix 4).
1.3.1.2 NMA results
The NMA included a total of 11,263 participants (LABA: 2764,
LAMA: 2992, LABA/ICS: 3220, LABA/LAMA: 2287). Figure 7d
and Table 15 show the mean difference in change from baseline
in SGRQ score at three months for each treatment group com-
pared to every other. There is evidence to suggest that both LABA/
LAMA and LABA/ICS improve SGRQ score at three months
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compared to LABA (MD−3.21, 95% CrI−4.52 to−1.92; MD
−1.82, 95% CrI −2.86 to −0.78), and LAMA monotherapies
(MD −3.31, 95% CrI −4.67to −1.97; MD −1.92, 95% CrI
−3.11 to−0.74) and that LABA/LAMA improves the score com-
pared toLABA/ICS,when the fixed-treatment-effectmodel is used
(MD −1.39, 95% CrI −2.37 to −0.42). The 95% CI exceeding
minimal clinically important difference (MCID) of 4 suggests a
possibility of clinically significant improvement favouring LABA/
LAMA over LAMA and LABA. Results are more uncertain when
considering the random-treatment-effects model although there is
evidence that LABA/LAMA improves the score compare to LABA
and LAMA monotherapies. Table 16 shows the rank statistics for
the four treatment groups (sorted by mean rank). The highest
ranked treatment group is LABA/LAMA with a median rank of 1
(95% CrI 1st to 1st).
1.3.1.3 Pairwise meta-analyses
There was no direct comparison for LABA/LAMA versus LABA.
Otherwise, the results from pairwise MAs were consistent with the
NMAs, except for LABA/ICS versus LAMA, in which the 95%
CI crossed the line of no difference with the pairwise MA (MD
−1.06, 95% CI −4.39 to 2.27) and the random-effects NMA
(MD −1.83, 95% CrI −3.76 to 0.35)) but not with the fixed-
effect NMA (MD −1.92, 95% CrI −3.11 to −0.74; Appendix
6 and Table 15). The certainty of evidence for LAMA/ICS versus
LAMA was low, as in the NMAs. A clinically important improve-
ment cannot be excluded with LABA/LAMA compared to LAMA
(MD −3.68, 95% CI −5.84 to −1.52), as well as with LABA/
ICS compared to LAMA (MD −1.06, 95% CI −4.39 to 2.27),
because the 95% CIs crossed the line of MCID of 4. Otherwise,
there is no evidence of a clinically significant difference in treat-
ment effects between treatment groups. The certainty of evidence
was high for LABA/LAMA versus LABA/ICS and LAMA versus
LABA, moderate for LABA/LAMA versus LAMA, and low for
LABA/ICS versus LABA. There was no difference between ran-
dom and fixed analyses.
1.3.2 Outcome: change from baseline in SGRQ score at six
months
We included 10 studies of 12 interventions and four treatment
groups for this outcome (Appendix 3, Figure 8 a and b). Note that
interventions formoterol 9 µg twice daily, salmeterol 50 µg twice
daily + fluticasone 250 µg twice daily, indacaterol 150 µg once
daily + budesonide 400 µg twice daily, formoterol/budesonide 9
µg/160 µg twice daily and formoterol/budesonide 9 µg/320 µg
twice daily are disconnected from the main treatment network
(Figure 8a), but we included them in a class/group model.
Figure 8. Change from baseline in St George’s Respiratory Questionnaire score at 6 months in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 0 favour the first named treatment group. BUD: budesonide; FM: formoterol;
FP: fluticasone propionate; Glyco: glycopyrronium; ICS: inhaled corticosteroid; IND: indacaterol; LABA: long-
acting beta2-agonist; LAMA: long-acting muscarinic antagonist; SAL: salmeterol
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1.3.2.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency. We also report results based on a random-
treatment-effects model with fixed-class effects for comparison (
Table 17).
1.3.2.2 NMA results
The NMA included a total of 12,967 participants (LABA: 3091,
LAMA: 3273, LABA/ICS: 4317, LABA/LAMA: 2286). Figure 8d
and Table 17 show the mean difference in change from baseline in
SGRQ score at six months for each treatment group compared to
every other. There is evidence to suggest that both LABA/LAMA
and LABA/ICS improve SGRQ score at six months compared to
LABA (MD−2.88, 95% CrI−4.03 to−1.73; MD−1.60, 95%
CrI −2.27 to −0.93), and LAMA monotherapies (MD −2.48,
95% CrI −3.72 to −1.24), and that LABA/LAMA improves the
score compared to LABA/ICS (MD −1.27, 95% CrI −2.26 to
−0.29), using a fixed-treatment-effectmodel. The 95%CI exceed-
ing MCID of 4 suggests a possibility of clinically significant im-
provement favouring LABA/LAMA over LABA. Results are more
uncertain when considering the random-treatment-effects model
although there is evidence that LABA/ICS and LABA/LAMA im-
prove the score compare to LABA. Table 18 shows the rank statis-
tics for the four treatment groups (sorted by mean rank). The
highest ranked treatment group is LABA/LAMA with a median
rank of 1 (95% CrI 1st to 1st).
1.3.2.3 Pairwise meta-analyses
The results frompairwiseMAswere consistentwith the fixed-treat-
ment-effect NMA. There was no direct comparison for LABA/
LAMA versus LABA. A clinically important improvement could
not be excluded with LABA/LAMA compared to LAMA because
the 95% CIs crossed the line of MCID of 4 (MD −2.79, 95%
CI −5.02 to −0.56). Otherwise, there is no evidence of a clini-
cally significant difference in treatment effects between treatment
groups although no clear difference was seen in the all comparisons
except for LAMA versus LABA (MD −0.70, 95% CI −1.74 to
0.34; Appendix 6). The certainty of evidence was high for LABA/
LAMA versus LABA/ICS and LAMA versus LABA, moderate for
LABA/LAMA versus LAMA, low for LABA/ICS versus LAMA,
and very low for LABA/ICS versus LABA. There was no difference
between random and fixed analyses.
1.3.3 Outcome: change from baseline in SGRQ score at 12
months
We included 14 studies of 15 interventions and four treatment
groups for this outcome (Appendix 3; Figure 9 a and b). Note
that interventions formoterol 9 to 12 µg twice daily, formoterol/
budesonide 9 µg/160 µg twice daily, formoterol/budesonide 12
µg/400µg twice daily, formoterol/beclomethasone 12µg/200µg
twice daily, and formoterol/budesonide 9 µg/320 µg twice daily
are disconnected from the main treatment network (Figure 9a)
but we included them in a class/group model.
22Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 9. Change from baseline in St George’s Respiratory Questionnaire score at 12 months in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 0 favour the first named treatment group. BDP: beclomethasone; BUD:
budesonide; FM: formoterol; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting
muscarinic antagonist
1.3.3.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency. We also report results based on a random-
effects-model for comparison (Appendix 4).
1.3.3.2 NMA results
The NMA included a total of 15,459 participants (LABA: 4021,
LAMA: 3216, LABA/ICS: 5891, LABA/LAMA: 2331). Figure 9d
and Table 19 show the mean difference in change from baseline in
SGRQ score at 12 months for each treatment group compared to
every other. There is evidence to suggest that all treatment groups
improve SGRQ score at 12 months compared to LABA (MD
−2.10, 95%CrI−3.08 to−1.13; MD−1.57, 95%CrI−2.23 to
−0.92; MD−0.98, 95% CrI−1.86 to−0.08 for LABA/LAMA,
LABA/ICS and LAMA respectively), and that LABA/LAMA im-
proves the score compared to LAMA (MD−1.12, 95%CrI−1.88
to −0.37), using the fixed-treatment-effect model. Results are
more uncertain when considering the random-treatment-effects
model although there is evidence that LABA/LAMA and LABA/
ICS improve the score compared to LABA (MD −2.31, 95%
CrI −4.17 to −0.64; MD −1.61, 95% CrI −2.52 to −0.69),
and that LABA/LAMA improves the score compared to LAMA
(MD −1.49, 95% CrI −3.16 to −0.20). The 95% CI exceed-
ing MCID of 4 suggests a possibility of clinically significant im-
provement favouring LABA/LAMA over LABA. Table 20 shows
the rank statistics for the four treatment groups (sorted by mean
rank). The highest ranked treatment group is LABA/LAMA with
a median rank of 1 (95% CrI 1st to 2nd).
1.3.3.3 Pairwise meta-analyses
There is evidence to suggest that LABA/LAMA improves SGRQ
score at 12 months compared to LABA/ICS or LAMA (MD
−1.20, 95% CI −2.34 to −0.06 or MD −3.38, 95% CI −5.83
to −0.93), and that LABA/ICS improves the score compared to
LABA (MD−1.75, 95%CI−2.61 to−0.89), although themean
differences do not reach the clinical significance of MCID of 4.
There is no evidence of significant difference for LABA/ICS versus
LAMA and LAMA versus LABA. There was no direct comparison
for LABA/LAMA versus LABA. The results were consistent with
the fixed-effect NMA except for LABA/LAMA versus LABA/ICS
and LAMA versus LABA. LABA/LAMA significantly improved
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the score compared toLABA/ICS in the pairwiseMA (MD−1.20,
95%CI−2.34 to−0.06), but not in theNMA (MD−0.52, 95%
CrI −1.42 to 0.36), and LAMA improved the score compared
to LABA in the NMA (MD −0.98, 95% CrI −1.86 to −0.08),
but not in the pairwise MA (MD−0.40, 95% CI−1.56 to 0.76;
Appendix 6). There is no evidence of clinically significant differ-
ence in any comparison except for LABA/LAMA versus LAMA, in
which the 95% CI suggested a possibility of clinically significant
improvement favouring LABA/LAMA over LAMA (MD −3.38,
95% CI−5.83 to −0.93). The certainty of evidence was high for
LABA/LAMA versus LABA/ICS and LAMA versus LABA, mod-
erate for LABA/ICS versus LABA, and low for LABA/LAMA or
LABA/ICS versus LAMA. There was no difference between ran-
dom and fixed analyses.
1.3.4 Rank probabilities for change from baseline in SGRQ
score at 3, 6, and 12 months
Figure 10 plots the ranks of SGRQ score at 3, 6, and 12 months
for each treatment group. The vertical axis shows the probability
of being ranked best, second best, third best, or worst treatment
group. LABA/LAMA has a high probability of being ranked first
at every time point whereas LABA has a high probability of being
ranked worst at 6 and 12 months.
Figure 10. Plot of rank probabilities for each treatment group
Change from baseline in St George’s Respiratory Questionnaire score at 3 (solid line), 6 (dashed line), and 12
months (dotted line), in the high-risk population ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist;
LAMA: long-acting muscarinic antagonist
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1.4 Outcome: transition dyspnoea index (TDI)
1.4.1 TDI at 3, 6, and 12 months
There were insufficient data to perform a NMA for TDI at 3,
6, and 12 months. The results were based on one trial for the
following comparisons: LABA/ICS versus LAMA at 3, 6, and 12
months and LAMA versus LABA at 3, 6, and 12 months. There is
no evidence of clinically significant improvement in TDI (MCID
of 1), with any treatment group compared to the others although
a significant difference was seen for LABA/ICS versus LAMA at
threemonths (MD0.50, 95%CI 0.18 to 0.82), and LAMA versus
LABA at 3, 6, and 12 months (MD −0.14 95% CI −0.15 to
−0.13; MD −0.19 95% CI −0.20 to −0.18; and MD −0.26
95% CI−0.27 to−0.25), favouring LABA/ICS over LAMA and
LABA over LAMA (Appendix 6). The certainty of evidence was
low for LABA/ICS versus LAMA at 12 months and moderate for
the rest of the comparisons.
1.5 Outcome: change from baseline in forced expiratory
volume in one second (FEV1)
1.5.1 Outcome: change from baseline in FEV1 at three
months
We included 11 studies of 12 interventions and four treatment
groups for this outcome (Appendix 3; Figure 11 a and b). Note
that interventions formoterol 9 µg twice daily, formoterol 12 µg
twice daily, formoterol/budesonide 9 µg/320 µg twice daily, and
formoterol/beclomethasone 12 µg/200 µg twice daily are discon-
nected from the main treatment network (Figure 11a), but we in-
cluded them in a class/group model.
Figure 11. Change from baseline in forced expiratory volume in 1 second at 3 months in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Positive values favour the first named treatment group. BDP: beclomethasone; BUD:
budesonide; FM: formoterol; ICS: inhaled corticosteroid; IND: indacaterol; LABA: long-acting beta2-agonist;
LAMA: long-acting muscarinic antagonist
1.5.1.1 Model selection and inconsistency checking
We chose a fixed-effect model with fixed-class effects, assuming
consistency. We also report results based on a random-treatment-
effectsmodel with fixed-class effects for comparison (Appendix 4).
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1.5.1.2 NMA results
The NMA included a total of 11,668 participants (LABA: 2203,
LAMA: 2010, LABA/ICS: 5192, LABA/LAMA: 2263). Figure
11d and Table 21 show the mean difference in change from base-
line in FEV1 at three months for each treatment group compared
to every other. There is evidence to suggest that all treatment
groups improve FEV1 at three months compared to LABA (MD
0.12, 95% CrI 0.10 to 0.15; MD 0.05, 95% CrI 0.04, 0.07; and
MD 0.05, 95% CrI 0.02 to 0.07 for LABA/LAMA, LABA/ICS,
and LAMA respectively), and that LABA/LAMA improves FEV1
compared to LABA/ICS and LAMA (MD 0.07, 95% CrI 0.05 to
0.09; and MD 0.07, 95% CrI 0.05 to 0.10). The difference for
LABA/LAMA versus LABA was of clinical significance favouring
LABA/LAMA (MD 0.12, 95% CrI 0.10 to 0.15). The 95% CI
reaching MCID of 0.1 L suggests a possibility of clinically signif-
icant improvement favouring LABA/LAMA over LAMA. Table
22 shows the rank statistics for the four treatment groups (sorted
by mean rank). The highest ranked treatment group was LABA/
LAMA with a median rank of 1 (95% CrI 1st to 1st), whereas
LABA was the worst ranked with a median of 4 (95% CrI 4th to
4th).
1.5.1.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs.
There is no evidence of clinically significant improvement (MCID
of 0.1 L or greater), with any treatment group compared to the
others except for LABA/LAMA versus LABA/ICS, in which the
95% CI suggested a possibility of clinically significant difference
favouring LABA/LAMAover LABA/ICS (MD0.08, 95%CI 0.06
to 0.10; Appendix 6). There was no direct comparison for LABA/
LAMA versus LABA and LAMA versus LABA. The certainty of
evidence was high for LABA/LAMAversus LABA/ICS andLABA/
ICS versus LAMA and moderate for LABA/LAMA versus LAMA
and LABA/ICS versus LABA. There was no difference between
random and fixed analyses.
1.5.2 Outcome: change from baseline in FEV1 at six months
Eleven studies of 11 interventions and four treatment groups were
available for this outcome (Appendix 3; Figure 12 a and b). Note
that interventions formoterol 9 µg twice daily, salmeterol 50 µg
twice daily + fluticasone 250 µg twice daily, indacaterol 150 µg
once daily + budesonide 400 µg twice daily, formoterol/budes-
onide 9 µg/160 µg twice daily, and formoterol/budesonide 9 µg/
320 µg twice daily are disconnected from the main treatment net-
work (Figure 12a), but we included them were in a class/group
model.
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Figure 12. Change from baseline in forced expiratory volume in 1 second at 6 months in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Positive values favour the first named treatment group. BDP: beclomethasone; BUD:
budesonide; FM: formoterol; ICS: inhaled corticosteroid; IND: indacaterol; LABA: long-acting beta2-agonist;
LAMA: long-acting muscarinic antagonist; SAL: salmeterol
1.5.2.1 Model selection and inconsistency checking
We chose a fixed-effect model with fixed-class effects, assuming
consistency. We also report results based on a random-treatment-
effectsmodel with fixed-class effects for comparison (Appendix 4).
1.5.2.2 NMA results
The NMA included a total of 10,822 participants (LABA: 2111,
LAMA: 1700, LABA/ICS: 4263, LABA/LAMA: 2748). Figure
12d and Table 23 show the mean difference in change from base-
line in FEV1 at six months for each treatment group compared to
every other. There is evidence to suggest that all treatment groups
improve FEV1 at six months compared to LABA, (MD 0.13, 95%
CrI 0.10 to 0.15; MD 0.04, 95% CrI 0.03 to 0.06; andMD 0.06,
95% CrI 0.03 to 0.08 for LABA/LAMA, LABA/ICS, and LAMA
respectively), and that LABA/LAMA improves FEV1 compared
to LABA/ICS and LAMA (MD 0.08, 95% CrI 0.06 to 0.10; and
MD 0.07, 95% CrI 0.04 to 0.09). The difference was clinically
significant (MCID of 0.1 L or greater), for LABA/LAMA ver-
sus LABA (MD 0.13, 95% CrI 0.10 to 0.15), favouring LABA/
LAMAover LABAwith the fixed-effectmodel. The 95%CI reach-
ing MCID of 0.1 L suggests a possibility of clinically significant
improvement favouring LABA/LAMA over LABA/ICS. Table 24
shows the rank statistics for the four treatment groups (sorted by
mean rank). The highest ranked treatment group is LABA/LAMA
with a median rank of 1 (95% CrI 1st to 1st), whereas LABA was
the worst ranked with a median of 4 (95% CrI 4th to 4th).
1.5.2.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs.
There is no evidence of clinically significant improvement (MCID
of 0.1 L or greater), with any treatment group compared to the oth-
ers except for LABA/LAMAversus LABA/ICS or LAMA, inwhich
the 95% CI suggested a possibility of clinically significant dif-
ference favouring LABA/LAMA over LABA/ICS or LAMA (MD
0.09, 95% CI 0.07 to 0.11; or MD 0.06, 95% CI 0.02 to 0.10;
Appendix 6). There was no direct comparison for LABA/LAMA
versus LABA and LAMA versus LABA. The certainty of evidence
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was high for LABA/LAMA versus LABA/ICS and moderate for
LABA/LAMA versus LAMA and LABA/ICS versus LAMA or
LABA. There was no difference between random and fixed anal-
yses.
1.5.3 Outcome: change from baseline in FEV1 at 12 months
We included 13 studies of 13 interventions and four treatment
groups for this outcome (Appendix 3; Figure 13a and b). Note
that interventions formoterol 9 µg twice daily, formoterol 12 µg
twice daily, formoterol/budesonide 9 µg/160 µg twice daily, for-
moterol/budesonide 12 µg/400 µg twice daily, and formoterol/
beclomethasone 12 µg/200 µg twice daily are disconnected from
the main treatment network (Figure 13a), but we included them
in a class/group model.
Figure 13. Change from baseline in forced expiratory volume in 1 second at 12 months in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Positive values favour the first named treatment group. BDP: beclomethasone; BUD:
budesonide; FM: formoterol; ICS: inhaled corticosteroid; IND: indacaterol; LABA: long-acting beta2-agonist;
LAMA: long-acting muscarinic antagonist
1.5.3.1 Model selection and inconsistency checking
We chose a fixed-effect model with fixed-class effects, assuming
consistency. We also report results based on a random-treatment-
effectsmodel with fixed-class effects for comparison (Appendix 4).
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1.5.3.2 NMA results
The NMA included a total of 11,171 participants (LABA: 1944,
LAMA: 1919, LABA/ICS: 4982, LABA/LAMA: 2326). Figure
13d and Table 25 show the mean difference in change from base-
line in FEV1 at 12 months for each treatment group compared to
every other. There is evidence to suggest that all treatment groups
improve FEV1 at 12 months compared to LABA (MD 0.12, 95%
CrI 0.08 to 0.16; MD 0.05, 95% CrI 0.03 to 0.07; andMD 0.08,
95% CrI 0.04 to 0.12 for LABA/LAMA, LABA/ICS, and LAMA
respectively), and that LABA/LAMA improves FEV1 compared
to LABA/ICS (MD 0.07, 95% CrI 0.04 to 0.1). The 95% CI
containing MCID of 0.1 L suggests a possibility of clinically sig-
nificant improvement favouring LABA/LAMA over LABA/ICS
and LABA and favouring LAMA over LABA. Table 26 shows the
rank statistics for the four treatment groups (sorted bymean rank).
The highest ranked treatment group is LABA/LAMA with a me-
dian rank of 1 (95% CrI 1st to 1st), whereas LABA was the worst
ranked with a median of 4 (95% CrI 4th to 4th).
1.5.3.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs
except for LABA/LAMA versus LAMA, in which there is evidence
of significant improvement favouring LABA/LAMA over LAMA
(MD 0.05, 95% CI 0.01 to 0.09). There was no direct compar-
ison for LABA/LAMA versus LABA and LAMA versus LABA.
Otherwise there is no evidence of clinically significant improve-
ment (MCID of 0.1 L) with any treatment group compared to the
others (Appendix 6). The certainty of evidence was very low for
LABA/ICS versus LAMA andmoderate for the rest of the available
comparisons. There was no difference between random and fixed
analyses.
1.5.4 Rank probabilities for change from baseline in FEV1 at
3, 6, and 12 months
Figure 14 plots the ranks of each treatment group for FEV1 at 3,
6 and 12 months. The vertical axis shows the probability of being
the best, second best, third best, or worst treatment group. LABA/
LAMA has nearly 100% probability of being ranked first at all
time points with LABA having a very high probability of being
the worst intervention at all time points.
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Figure 14. Plot of rank probabilities for each treatment group
Change from baseline in forced expiratory volume in 1 second at 3 (solid line), 6 months (dashed line) and 12
months in the high-risk population. ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-
acting muscarinic antagonist
1.6 Outcome: mortality
Twenty-four studies of 18 interventions and four treatment groups
were available for this outcome (Appendix 3; Figure 15 a and b).
Note that interventions formoterol 9µg twice daily, formoterol 12
µg twice daily, salmeterol 50 µg twice daily + fluticasone 250 µg
twice daily, indacaterol 150 µg once daily + budesonide 400 µg
twice daily, formoterol/budesonide 9 µg/160 µg twice daily, for-
moterol/budesonide 9 µg/320 µg twice daily, formoterol/budes-
onide 12 µg/400 µg twice daily, and formoterol/beclomethasone
12 µg/200 µg twice daily are disconnected from the main treat-
ment network (Figure 15a), but we included them in a class/group
model.
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Figure 15. Mortality in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 1 favour the first named treatment group. BDP: beclomethasone; BUD:
budesonide; FM: formoterol; ICS: inhaled corticosteroid; IND: indacaterol; LABA: long-acting beta2-agonist;
LAMA: long-acting muscarinic antagonist; SAL: salmeterol
1.6.1 Model selection and inconsistency checking
We chose a fixed-effect model with fixed-class effects, assuming
consistency, although results should be interpreted with caution
due to some evidence of inconsistency. We also report results based
on a random-treatment-effects model with fixed-class effects for
comparison (Appendix 4).
1.6.2 NMA results
TheNMA included a total of 31,674 participants (LABA: 11,182,
LAMA: 7853, LABA/ICS: 10,084, LABA/LAMA: 2555). The
median duration of follow-up was 52 weeks (range 12 to 156
weeks). Figure 15d andTable 27 show theORofmortality for each
treatment group compared to every other. There was no evidence
to suggest that any treatment group increased or decreased the
odds of mortality compared to any other. Table 28 shows the rank
statistics for the four treatment groups (sorted by mean rank). All
treatment groups have high uncertainty in ranks as expected, due
to no treatment effect being identified for any treatment group.
1.6.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs.
There was no direct comparison for LABA/LAMA versus LABA
(Appendix 6). The certainty of evidence was low for LABA/ICS
versus LABA and moderate for the rest of available comparisons.
There was no difference between random and fixed analyses.
1.7 Outcome: serious adverse events (SAEs)
1.7.1 Outcome: total SAEs
The analysis for total SAEs included 24 studies of 18 interven-
tions and four treatment groups. We included a total of 31,721
participants (LABA: 10,942, LAMA: 7853, LABA/ICS: 10,371,
LABA/LAMA: 2555; Appendix 3; Figure 16 a and b). Themedian
duration of follow-up was 52 weeks (range 12 to 156 weeks). Note
that interventions formoterol 9 µg twice daily, formoterol 12 µg
twice daily, indacaterol 150 µg once daily + budesonide 400 µg
twice daily, formoterol/budesonide 9 µg/320 µg twice daily, for-
moterol/budesonide 9 µg/160 µg twice daily, formoterol/budes-
onide 12 µg/400 µg twice daily, formoterol/beclomethasone 12
µg/200 µg twice daily and salmeterol 50 µg twice daily + fluti-
casone 250 µg twice daily are disconnected from the main treat-
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ment network (Figure 16a), but we included them in a class/group
model.
Figure 16. Total serious adverse events in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. BDP: beclomethasone; BUD: budesonide; FM: formoterol; ICS: inhaled corticosteroid; IND:
indacaterol; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist; SAL: salmeterol
1.7.1.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency. We also report results based on a random-
treatment-effects model with fixed-class effects for comparison (
Appendix 4).
1.7.2 Outcome: chronic obstructive pulmonary disease
(COPD) SAEs
The analysis for COPD SAEs included 20 studies of 14 interven-
tions and four treatment groups.We included a total of 28,614par-
ticipants (LABA: 9675, LAMA: 7697, LABA/ICS: 8835, LABA/
LAMA: 2407; Appendix 3; Figure 17 a and b). The median dura-
tion of follow-up was 52 weeks (range 12 to 156 weeks). Note that
interventions formoterol 9 µg twice daily, salmeterol 50 µg twice
daily + fluticasone 250 µg twice daily, indacaterol 150 µg once
daily + budesonide 400 µg twice daily, formoterol/budesonide 9
µg/160 µg twice daily and formoterol/budesonide 9 µg/320 µg
twice daily are disconnected from the main treatment network
(Figure 17a), but we included them in a class/group model.
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Figure 17. Chronic obstructive pulmonary disease serious adverse events in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. BUD: budesonide; FM: formoterol; ICS: inhaled corticosteroid; IND: indacaterol; LABA: long-
acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.7.2.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency.We also report results based on the random-
treatment-effects model with fixed-class effects for comparison (
Appendix 4).
1.7.3 Outcome: cardiac SAEs
The analysis for cardiac SAEs included 19 studies of 16 interven-
tions and four treatment groups (Appendix 3; Figure 18 a and
b). We included a total of 29,045 participants (LABA: 10,016,
LAMA: 7567, LABA/ICS: 9055, LABA/LAMA: 2407). The me-
dian duration of follow-up was 52 weeks (range 12 to 156 weeks).
Note that interventions formoterol 9 µg twice daily, formoterol
12 µg twice daily, salmeterol 50 µg twice daily + fluticasone 250
µg twice daily, indacaterol 150 µg once daily + budesonide 400
µg twice daily, formoterol/budesonide 9 µg/160 µg twice daily,
formoterol/budesonide 9 µg/320 µg twice daily, and formoterol/
beclomethasone 12 µg/200 µg twice daily are disconnected from
the main treatment network (Figure 18a), but we included them
in a class/group model.
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Figure 18. Cardiac serious adverse events in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects BDP: beclomethasone; BUD: budesonide; FM: formoterol; FP: fluticasone propionate; ICS:
inhaled corticosteroid; IND: indacaterol; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic
antagonist; SAL: salmeterol
1.7.3.1 Model selection and inconsistency checking
We chose a random-treatment-effects model with fixed-class ef-
fects, assuming consistency. We also report results based on the
fixed-treatment-effect model with fixed-class effects for compari-
son (Appendix 4).
1.7.4 NMA results
Table 29 shows the OR of each type of adverse event for each
treatment group compared to every other. For total SAEs there
is evidence to suggest that LABA/ICS increases the odds of SAEs
compared to LAMA (OR 1.14, 95% CrI 1.02 to 1.27), and that
LAMA decreases the odds of SAEs compared to LABA (OR 0.88,
95% CrI 0.81 to 0.97), although this effect was only seen in the
fixed-effect model. For COPD SAEs there is evidence to suggest
that LABA/ICS increases the odds of SAEs compared to LAMA
(OR 1.22 95% CrI 1.05 to 1.42), and that LAMA decreases the
odds of SAEs compared to LABA (OR 0.77, 95% CrI 0.68 to
0.87), and this was seen in both models. No difference between
treatment groups was evident for cardiac SAEs.
1.7.5 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs
except for LABA/ICS versus LAMA for COPD SAEs in which the
NMA suggested LABA/ICS increased the odds of COPD SAEs
compared to LAMA (OR 1.22, 95% CrI 1.05 to 1.42), whereas
the pairwise MA did not (OR 0.99, 95% CI 0.33 to 2.96). There
was no direct comparison for LABA/LAMAversus LABA for total,
COPD, and cardiac SAEs.Table 30 shows the certainty of evidence
for each treatment group compared to every other. There was no
difference between random and fixed analyses (Appendix 6).
1.8 Outcome: dropouts due to adverse events
We included 25 studies of 18 interventions and four treatment
groups for this outcome (Appendix 3; Figure 19 a and b). Note
that interventions formoterol 9 µg twice daily, formoterol 12 µg
twice daily, salmeterol 50 µg twice daily + fluticasone 250 µg
twice daily, indacaterol 150 µg once daily + budesonide 400 µg
twice daily, formoterol/budesonide 9 µg/320 µg twice daily, for-
moterol/budesonide 9 µg/160 µg twice daily, formoterol/budes-
onide 12 µg/400 µg twice daily, and formoterol/beclomethasone
12 µg/200 µg twice daily are disconnected from the main treat-
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ment network (Figure 19a), but we included them in a class/group
model.
Figure 19. Dropouts due to adverse events in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 1 favour the first named treatment group. BDP: beclomethasone; BUD:
budesonide; FM: formoterol; FP: fluticasone propionate; ICS: inhaled corticosteroid; IND: indacaterol; LABA:
long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist; SAL: salmeterol
1.8.1 Model selection and inconsistency checking
We chose a fixed-effect model with fixed-class effects, assuming
consistency. We also report results based on a random-treatment-
effectsmodel with fixed-class effects for comparison (Appendix 4).
1.8.2 NMA results
TheNMA included a total of 32,230 participants (LABA: 11,197,
LAMA: 7853, LABA/ICS: 10,625, LABA/LAMA: 2555). The
median duration of follow-up was 52 weeks (range 12 to 156
weeks). Figure 19d and Table 31 show the OR of dropout due
to adverse events for each treatment group compared to every
other. There was no evidence to suggest that any treatment group
increased or decreased the odds of dropout compared to any other.
Table 32 shows the rank statistics for the four treatment groups
(sorted by mean rank). All treatment groups have high uncertainty
in ranks as expected, due to no treatment effect being identified
for any treatment group.
1.8.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs.
There was no direct comparison for LABA/LAMA versus LABA
(Appendix 6). The certainty of evidence was high for LAMA ver-
sus LABA, moderate for LABA/LAMA versus LABA/ICS, LABA/
ICS versus LAMA, and low for LABA/LAMA versus LAMA and
LABA/ICS versus LABA. There was no difference between ran-
dom and fixed analyses.
1.9 Outcome: pneumonia
We included 24 studies of 18 interventions and four treatment
groups for this outcome (Appendix 3; Figure 20 a and b).Note that
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interventions formoterol 9µg twice daily, formoterol 12 µg twice
daily, formoterol/budesonide 9µg/160µg twice daily, formoterol/
budesonide 9 µg/320 µg twice daily, formoterol/budesonide 12
µg/400 µg twice daily, formoterol/beclomethasone 12 µg/200
µg twice daily, indacaterol 150 µg once daily + budesonide 400
µg twice daily, and salmeterol 50 µg twice daily + fluticasone 250
µg twice daily are disconnected from the main treatment network
(Figure 20a), but we included them in a class/group model.
Figure 20. Pneumonia in the high-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 1 favour the first named treatment group. BDP: beclomethasone; BUD:
budesonide; FM: formoterol; FP: fluticasone propionate; ICS: inhaled corticosteroid; IND: indacaterol; LABA:
long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist; SAL: salmeterol
1.9.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency. We also report results based on a random-
treatment-effects model with fixed-class effects for comparison.
Results should be interpretedwith some cautiondue topoormodel
fit, which can be attributed to studies with zero cells (Appendix
4).
1.9.2 NMA results
The NMA included a total of 31,812 participants (LABA: 10991,
LAMA: 7853, LABA/ICS: 10413, LABA/LAMA: 2555). Theme-
dian duration of follow-up was 52 weeks (range 12 to 156 weeks).
Figure 20d and Table 33 show the OR of pneumonia for each
treatment group compared to every other. There is evidence to
suggest that LABA/ICS increases the odds of pneumonia com-
pared to the other treatment groups (OR 1.69, 95% CrI 1.20 to
2.44; OR 1.78, 95% CrI 1.33 to 2.39; OR 1.50, 95% CrI 1.17
to 1.92 for LABA/LAMA, LAMA and LABA respectively), but
no evidence of differences across other comparisons (Appendix 6
Summary of findings 7). Table 34 shows the rank statistics for the
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four treatment groups (sorted by mean rank). The highest ranked
treatment group was LAMA with a median rank of 1st but with
wide credible intervals (1st to 3rd), whereas LABA/ICSwas ranked
the worst (median = 4, 95% CrI 4th to 4th).
1.9.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs.
There was no direct comparison for LABA/LAMA versus LABA
(Appendix 6). The certainty of evidence was moderate for the all
available comparisons (see ’Summary of findings’ tables). There
was no difference between random and fixed analyses.
2. Results: low-risk population
2.1 Outcome: exacerbations
2.1.1 Outcome: moderate to severe exacerbations
We included 38 studies of 22 interventions and four treatment
groups for this outcome (Appendix 3; Figure 21 a and b). Note
that interventions indacaterol 75 µg once daily and indacaterol/
glycopyrronium 27.5 µg/15.6 µg twice daily are disconnected
from the main treatment network (Figure 21a), but we included
them in a class/group model.
Figure 21. Moderate to severe exacerbations in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 1 favour the first named treatment group. ACL: aclidinium; BUD: budesonide;
FF: fluticasone furoate; FM: formoterol; FP: fluticasone propionate; Glyco: glycopyrronium; ICS: inhaled
corticosteroid; IND: indacaterol; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist;
MF:mometasone furoate; SAL: salmeterol; Tio: tiotropium; UMEC: umeclidinium; VI: vilanterol
2.1.1.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency.We also report results based on the random-
treatment-effects model with fixed-class effects for comparison (
Appendix 4).
2.1.1.2 NMA results
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The NMA included a total of 31,406 participants (LABA: 6845,
LAMA: 7364, LABA/ICS: 9592, LABA/LAMA: 7605). The me-
dian duration of follow-up was 24 weeks (range 12 to 156 weeks).
Figure 21d and Table 35 show theHR formoderate to severe exac-
erbations for each treatment group compared to every other. There
is evidence that all treatment groups of interventions decrease the
rate of moderate to severe exacerbations compared to LABA (HR
0.78, 95% CrI 0.67 to 0.90; HR 0.89, 95% CrI 0.84 to 0.96;
HR 0.87, 95% CrI 0.78 to 0.97 for LABA/LAMA, LABA/ICS
and LAMA respectively; Appendix 7; Summary of findings 7), al-
though there is added uncertainty for the comparison with LAMA
in the random-effects model. Table 36 shows the rank statistics
for the four treatment groups (sorted by mean rank). The highest
ranked treatment group is LABA/LAMA with a median rank of
1 (95% CrI 1st to 2nd) with LABA the worst ranked treatment
group (95% CrI 4th to 4th).
2.1.1.3 Clinical homogeneity assessment
Table 37 shows the clinical homogeneity assessment across the
available comparisons. Bronchial reversibility ranged from 11.1%
to 17.5%, which could have introduced a bias favouring an ICS-
containing inhaler in a population with a significant bronchodila-
tor response. The NMA results should be interpreted with cau-
tion because of the difference in bronchial reversibility across the
pairwise comparisons.
2.1.1.4 Pairwise meta-analyses
The results from pairwiseMAs were consistent with theNMAs ex-
cept for LAMAversus LABA, inwhich the 95%CI crossed the line
of no difference with the pairwise MA (OR 0.92, 95% CI 0.79 to
1.07; Appendix 7). The certainty of evidence was moderate for the
LAMA versus LABA comparison due to a suboptimal information
size, which could explain the difference. Otherwise, the certainty
of evidence wasmoderate for LABA/LAMAversus LABA/ICS and
LABA/ICS versus LABA, and low for LABA/LAMAversus LAMA
and LABA/ICS versus LAMA (see: ’Summary of findings’ tables).
There was no difference between random and fixed analyses.
2.1.2 Outcome: severe exacerbations
We included 31 studies of 18 interventions and four treatment
groups for this outcome (Appendix 3; Figure 22 a and b).
Figure 22. Severe exacerbations in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 1 favour the first named treatment group. ICS: inhaled corticosteroid; IND:
indacaterol; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
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2.1.2.1 Model selection and inconsistency checking
We chose a fixed-effect model with fixed-class effects, assuming
consistency.We also report results based on the random-treatment-
effectsmodel with fixed-class effects for comparison (Appendix 4).
2.1.2.2 NMA results
The NMA included a total of 36,285 participants (LABA: 4963,
LAMA: 17856, LABA/ICS: 7302, LABA/LAMA: 6164). Theme-
dian duration of follow-up was 24 weeks (range 12 to 156 weeks).
Figure 22d and Table 38 show the HR for severe exacerbations for
each treatment group compared to every other. There is no evi-
dence that any treatment group reduces severe exacerbations com-
pared to the others, although uncertainty is large for some com-
parisons. HRs for LABA/LAMA versus LABA/ICS, LABA, and
LAMA were 0.71 (95% CrI 0.47 to 1.08), 0.90, (95% CrI 0.6 to
1.31), and 0.72 (95% CrI 0.48 to 1.02), respectively (Appendix 7;
Summary of findings 7). Table 39 shows the rank statistics for the
four treatment groups (sorted by mean rank). There is consider-
able uncertainty in the ranks, which is consistent with there being
no evidence of a difference in treatment effects between treatment
groups. The highest ranked treatment group is LABA/LAMAwith
a median rank of 1 (95% CrI 1st to 3rd).
2.1.2.3 Clinical homogeneity assessment
Table 5 shows the clinical homogeneity assessment across the avail-
able comparisons. Bronchial reversibility ranged from 11.1% to
18.3%. The average bronchial reversibility for LABA/ICS versus
LAMA was 11.1% which could have underestimated the effects
of LABA/ICS. The NMA results should be interpreted with cau-
tion because of the difference in bronchial reversibility across the
pairwise comparisons.
2.1.2.4 Pairwise meta-analyses
The results frompairwiseMAswere consistentwith theNMAs and
showed no evidence that any treatment group reduced severe ex-
acerbations compared to the others (Appendix 7). ORs for LABA/
LAMA versus LABA/ICS, LAMA, and LABA were 0.66 (95% CI
0.27 to 1.63), 0.99 ( 95%CI 0.57 to 1.72), and 0.78 (95%CI 0.55
to 1.12). The certainty of evidence was high for LABA/ICS ver-
sus LABA, moderate for LABA/LAMA versus LABA/ICS, LABA/
LAMA versus LAMA, and LABA/LAMA versus LABA, and low
for LABA/ICS versus LAMA and LAMA versus LABA (see ’Sum-
mary of findings’ tables). There was no difference between random
and fixed analyses.
2.1.3 Rank probabilities for exacerbations
Figure 23 plots the ranks of each treatment group for severe exac-
erbations and moderate to severe exacerbations. The vertical axis
shows the probability of being ranked best, second best, third best,
or worst treatment group. LABA/LAMA has a high probability of
being the best intervention for both severe and moderate to se-
vere exacerbations in the low-risk population with a probability of
about 90% of being the best treatment group to reduce moderate
to severe exacerbations. LABA has a high probability of being the
worst treatment group for reducing moderate to severe exacerba-
tions and has a very small probability of ranking among the best
treatment groups for reducing both severe and moderate to severe
exacerbations.
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Figure 23. Plot of rank probabilities for each treatment group for chronic obstructive pulmonary disease exacerbations
in the low-risk population
Severe exacerbations (solid line), and moderate/severe exacerbations (dashed line), in the low-risk population
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.2 Outcome: St George’s Respiratory Questionnaire
(SGRQ) responders
2.2.1 Outcome: SGRQ responders at three months
We included 22 studies of 17 interventions and four treatment
groups for this outcome (Appendix 3; Figure 24 a and b).Note that
interventions formoterol 4.5µg twice daily, formoterol 9µg twice
daily, glycopyrronium 15.6 µg twice daily, tiotropium 5 µg once
daily, indacaterol/glycopyrronium 27.5 µg/15.6 µg twice daily
and olodaterol/tiotropium 5 µg/5 µg once daily are disconnected
from the main treatment network (Figure 24a), but we included
them in a class/group model.
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Figure 24. St George’s Respiratory Questionnaire score responders at 3 months in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values greater than 1 favour the first named treatment group. FM: formoterol; Glyco:
glycopyrronium; ICS: inhaled corticosteroid; IND: indacaterol; LABA: long-acting beta2-agonist; LAMA: long-
acting muscarinic antagonist; Olo: olodaterol; Tio: tiotropium
2.2.1.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency.We also report results based on the random-
treatment-effects model with fixed-class effects for comparison (
Appendix 4).
2.2.1.2 NMA results
The NMA included a total of 14,351 participants (LABA: 2371,
LAMA: 5356, LABA/ICS: 2213, LABA/LAMA: 4411). Figure
24d and Table 40 show the OR of SGRQ responders at three
months for each treatment group compared to every other. There
is evidence to suggest that LABA/LAMA, LABA/ICS, and LABA
increase the odds of SGRQ response at three months compared to
LAMA (OR 1.33, 95% CrI 1.19 to 1.48; OR 1.24, 95% CrI 1.07
to 1.43; OR 1.37, 95% CrI 1.18 to 1.61)). Table 41 shows the
rank statistics for the four treatment groups (sorted bymean rank).
The highest ranked treatment group was LABA with a median
rank of 1 although with large uncertainty (95% CrI 1st to 3rd),
whereas LAMA was ranked the worst (median = 4, 95% CrI 4th
to 4th).
2.2.1.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs
except for LABA/ICS versus LAMA (Appendix 7), in which the
95% CI crossed the line of no difference with the pairwise MA
(OR 1.26 (95% CI 0.92 to 1.74), low confidence due to a wide
95% CI and a small sample size). There was no direct compari-
son for LABA/LAMA versus LABA. Otherwise, the certainty of
evidence was high for LAMA/LABA versus LAMA, and LAMA
versus LABA, and moderate for LABA/LAMA versus LABA/ICS,
and low for LABA/ICS versus LABA. There was no difference be-
tween random and fixed analyses.
2.2.2 Outcome: SGRQ responders at six months
We included 18 studies of 19 interventions and four treatment
groups for this outcome (Appendix 3; Figure 25 a and b).
41Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 25. St George’s Respiratory Questionnaire score responders at 6 months in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values greater than 1 favour the first named treatment group. ICS: inhaled corticosteroid;
LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.2.2.1 Model selection and inconsistency checking
We chose a random-treatment-effects model with a fixed-class ef-
fect, assuming consistency (Appendix 4).
2.2.2.2 NMA results
The NMA included a total of 20,385 participants (LABA: 8259,
LAMA: 5164, LABA/ICS: 2721, LABA/LAMA: 4241). Figure
25d and Table 42 show theOR of SGRQ responders at six months
for each treatment group compared to every other. There is evi-
dence to suggest that LABA/LAMA increases SGRQ responders
at six months compared to both LAMA and LABA monothera-
pies (OR 1.26, 95% CrI 1.10 to 1.42; OR 1.28, 95% CrI 1.11
to 1.47). Table 43 shows the rank statistics for the four treatment
groups (sorted bymean rank). The highest ranked treatment group
is LABA/LAMA with a median rank of 1 (95% CrI 1st - 2nd),
with LAMA and LABA the worst ranked treatment groups.
2.2.2.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs
across all comparisons for SGRQ responders at six months
(Appendix 7). There is evidence to suggest that LABA/LAMA in-
creases SGRQ responders at six months compared to both LAMA
and LABA monotherapies (OR 1.26, 95% CI 1.15 to 1.37; OR
1.20, 95%CI 1.06 to 1.37). The certainty of evidence was moder-
ate for LABA/LAMA versus LAMA and LABA/ICS versus LABA
and low for LABA/LAMA versus LABA/ICS, LABA/LAMA ver-
sus LABA, and LAMA versus LABA. There was no direct com-
parison for LABA/ICS versus LAMA. There was no difference be-
tween random and fixed analyses.
2.2.3 Rank probabilities for SGRQ responders at three and
six months
Figure 26 plots the ranks of SGRQ responders at three and six
months for each treatment group. The vertical axis shows the prob-
ability of being ranked best, second best, third best, or worst treat-
ment group. There is uncertainty as to the ranking of treatment
groups at three months but LAMA is clearly ranked worst. LABA
has the highest probability of being ranked first at three months
but there is also a small probability that it is ranked third or last. At
six months, LABA/LAMA has nearly 100% probability of being
the best.
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Figure 26. Plot of rank probabilities for each treatment group for St George’s Respiratory Questionnaire responders in
the low-risk population
St George’s Respiratory Questionnaire responders at 3 (solid line), and 6 months (dashed line), in the low-risk
population ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic
antagonist
2.2.4 Outcome: SGRQ responders at 12 months
2.2.4.1 Pairwise meta-analyses
There is evidence to suggest LABA/ICS is associated with a sig-
nificantly higher proportion in SGRQ responders at 12 months
compared to LABA (OR 1.42, 95% CI 1.18 to 1.70; moderate-
certainty evidence). There was no direct comparison for LABA/
LAMA versus LABA/ICS and LABA/ICS versus LAMA. There
is no evidence of significant differences for LABA/LAMA versus
LAMA or LABA (moderate-certainty evidence), and LAMA ver-
sus LABA (low-certainty evidence; Appendix 7).
2.3 Outcome: change from baseline in SGRQ score
2.3.1 Outcome: change from baseline in SGRQ score at three
months
We included 28 studies of 19 interventions and four treatment
groups for this outcome (Appendix 3; Figure 27 a and b).Note that
interventions formoterol 4.5µg twice daily, formoterol 9µg twice
daily, glycopyrronium 15.6 µg twice daily, tiotropium 5 µg once
daily, indacaterol/glycopyrronium 27.5 µg/15.6 µg twice daily,
and olodaterol/tiotropium 5 µg/5 µg once daily are disconnected
from the main treatment network (Figure 27a), but we included
them in a class/group.
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Figure 27. Change from baseline in SGRQ score at 3 months in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 0 favour the first named treatment group. FM: formoterol; Glyco:
glycopyrronium; ICS: inhaled corticosteroid; IND: indacaterol; LABA: long-acting beta2-agonist; LAMA: long-
acting muscarinic antagonist; Olo: olodaterol; Tio: tiotropium
2.3.1.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency.We also report results based on the random-
treatment-effects model with fixed-class effects for comparison (
Appendix 4).
2.3.1.2 NMA results
The NMA included a total of 20,594 participants (LABA: 3933,
LAMA: 7849, LABA/ICS: 2396, LABA/LAMA: 6416). Figure
27d and Table 44 show the mean difference in change from base-
line in SGRQ score at threemonths for each treatment group com-
pared to every other. There is evidence to suggest that both LABA/
LAMA and LABA/ICS improve SGRQ score at three months
compared to LAMA (MD −1.64, 95% CrI −2.2 to −1.08; MD
−1.68, 95% CrI −2.59 to −0.78), although the MDs do not
reach the clinical significance of MCID of 4. There is no evidence
of differences across the other comparisons. Table 45 shows the
rank statistics for the four treatment groups (sorted bymean rank).
The highest ranked treatment groups are LABA/ICS and LABA/
LAMA, both with a median rank of 2 (95% CrI 1st to 3rd).
2.3.1.3 Pairwise meta-analyses
There is evidence to suggest that LABA/LAMA improves SGRQ
score at three months compared to LAMA (MD −1.60, 95% CI
−2.19 to−1.01), and that LAMA improves the score compared to
LABA (MD 1.84, 95%CI 0.87 to 2.80), but the mean differences
do not reach the clinical significance ofMCID of 4. There is no ev-
idence of differences across the other comparisons, however, a clin-
ically significant difference cannot be excluded favouring LABA/
LAMA over LABA given its 95% CI crossing the line of MCID of
4 (MD−1.29, 95% CI −4.29, 1.71; Appendix 7). The certainty
of evidence for LABA/ICS versus LAMA and LAMA versus LABA
was moderate due to a suboptimal information size, which could
explain discrepancies with the NMA results. Otherwise all other
results were consistent with the NMAs. The certainty of evidence
was moderate for LABA/LAMA versus LAMA or LABA and high
for LABA/LAMAversus LABA/ICS andLABA/ICS versus LABA.
There was no difference between random and fixed analyses.
2.3.2 Outcome: change from baseline in SGRQ score at six
months
We included 20 studies of 17 interventions and four treatment
groups for this outcome (Appendix 3; Figure 28 a and b).
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Figure 28. Change from baseline in St George’s Respiratory Questionnaire score at 6 months in the low-risk population.
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 0 favour the first named treatment group. FM: formoterol; Glyco:
glycopyrronium; ICS: inhaled corticosteroid; IND: indacaterol; LABA: long-acting beta2-agonist; LAMA: long-
acting muscarinic antagonist; Olo: olodaterol; Tio: tiotropium
2.3.2.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency.We also report results based on the random-
treatment-effects model with fixed-class effects for comparison (
Appendix 4).
2.3.2.2 NMA results
The NMA included a total of 16,508 participants (LABA: 4351,
LAMA: 4454, LABA/ICS: 2880, LABA/LAMA: 4823). Figure
28d and Table 46 show the mean difference in change from base-
line in SGRQ score at six months for each treatment group com-
pared to every other. There is evidence to suggest that both LABA/
LAMA and LABA/ICS reduce SGRQ score compared to LABA at
six months (MD −1.36, 95% CrI −2.12 to −0.60; MD −1.14,
95%CrI−1.90 to−0.37), and that LABA/LAMA reduces SGRQ
score compared to LAMA (MD−1.18, 95%CrI−1.80 to -0.56),
although the differences do not reach the clinical significance of
MCID of 4. Table 47 shows the rank statistics for the four treat-
ment groups (sorted bymean rank). The highest ranked treatment
group was LABA/LAMA with a median rank of 1 (95% CrI 1st
to 2nd).
2.3.2.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs
and there is no evidence of clinically significant improvement in
SGRQ score at six months (MCID of 4 or greater), with any
treatment group compared to the others (Appendix 7). There were
no data available for LABA/ICS versus LAMA. The certainty of
evidence was high for LAMA versus LABA, moderate for LABA/
LAMA versus LAMA or LABA and LABA/ICS versus LABA, and
low for LABA/LAMA versus LABA/ICS. There was no difference
between random and fixed analyses.
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2.3.3 Outcome: change from baseline in SGRQ score at 12
months
We included six studies of 10 interventions and four treatment
groups for this outcome (Appendix 3; Figure 29 a and b). Note
that interventions salmeterol 50 µg twice daily and salmeterol/
fluticasone 50 µg/500 µg twice daily are disconnected from the
main treatment network (Figure 29a), but we included them in a
class/group model.
Figure 29. Change from baseline in SGRQ score at 12 months in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 0 favour the first named treatment group. FP: fluticasone propionate; ICS:
inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist; SAL:
salmeterol
2.3.3.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency.We also report results based on the random-
treatment-effects model with fixed-class effects for comparison (
Appendix 4).
2.3.3.2 NMA results
The NMA included a total of 6849 participants (LABA: 2021,
LAMA: 2163, LABA/ICS: 873, LABA/LAMA: 1792). Figure 29d
and Table 48 show the mean difference in change from baseline
in SGRQ score at 12 months for each treatment group compared
to every other. There is some evidence to suggest that LABA/ICS
improves SGRQ score at 12 months compared to LABA using
the fixed-effect model (MD −1.69, 95% CrI −2.81 to −0.57).
Both LABA/LAMA and LABA/ICS showed a reduction in SGRQ
score compared to LAMA when using the fixed effect model (MD
−0.89, 95% CrI −1.66 to −0.11) and MD −1.85, 95% CrI
−3.28 to −0.43). Increased uncertainty in the random-effects
model leads to inconclusive results and the mean differences do
not reach the clinical significance of MCID of 4. Table 49 shows
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the rank statistics for the four treatment groups (sorted by mean
rank). The highest ranked treatment group is LABA/ICS with a
median rank of 1 (95% CrI 1st to 2nd).
2.3.3.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs
and there is no evidence that any treatment group is associatedwith
clinically significant improvement in SGRQ score at 12 months
compared to the others (Appendix 7). The certainty of evidence
was high for LABA/LAMAversus LABA andLAMAversus LABA,
moderate for LABA/ICS versus LABA, and very low for LABA/
LAMA versus LAMA. There was no direct comparison for LABA/
LAMA versus LABA/ICS and LABA/ICS versus LAMA. There
was no difference between random and fixed analyses.
2.3.4 Rank probabilities for change from baseline in SGRQ
score
Figure 30 plots the ranks of SGRQ score at 3, 6 and 12 months
for each treatment group. The vertical axis shows the probability
of being ranked best, second best, third best, or worst treatment
group. LABA and LAMA have a high probability of ranking 3rd
or 4th at all time points whereas LABA/ICS has a high probability
of being the best at 12 months.
Figure 30. Plot of rank probabilities for each treatment group
Change from baseline in St George’s Respiratory Questionnaire score at 3 (solid line), 6 (dashed line), and 12
months (dotted line), in the low-risk population ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist;
LAMA: long-acting muscarinic antagonist
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2.4 Outcome: transitional dyspnoea index (TDI)
2.4.1 Outcome: TDI at three months
We included 30 studies of 19 interventions and four treatment
groups for this outcome (Appendix 3; Figure 31 a and b). Note
that interventions glycopyrronium 15.6 µg twice daily and inda-
caterol/glycopyrronium 27.5 µg/15.6 µg twice daily are discon-
nected from the main treatment network (Figure 31a), but we in-
cluded them in a class/group model.
Figure 31. Transition Dyspnea Index at 3 months in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Positive values favour the first named treatment group. FM: formoterol; Glyco: glycopyrronium;
ICS: inhaled corticosteroid; IND: indacaterol; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic
antagonist; Olo: olodaterol; Tio: tiotropium
2.4.1.1 Model selection and inconsistency checking
We chose a random-treatment-effects model with fixed-class ef-
fects, assuming consistency. We also report results for a fixed-
treatment-effect model with random-class effects for comparison
(Appendix 4).
2.4.1.2 NMA results
The NMA included a total of 21,750 participants (LABA: 5113,
LAMA: 7046, LABA/ICS: 2838, LABA/LAMA: 6753). Figure
31d and Table 50 show the mean difference in TDI score at three
months for each treatment group compared to every other, using
the two models. There is evidence to suggest that LABA/LAMA
increases TDI at three months compared to all other treatment
groups (MD 0.35, 95% CrI 0.12 to 0.56; MD 0.54, 95% CrI
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0.36 to 0.73; MD 0.44, 95%CrI 0.20 to 0.67 against LABA/ICS,
LAMA and LABA), although the MDs do not reach the clinical
significance of MCID of 1. There is no evidence of differences
across the other treatment groups using the model with random-
treatment and fixed-class effects. Table 51 shows the rank statis-
tics for the four treatment groups (sorted by mean rank) for the
preferred model. The highest ranked treatment group was LABA/
LAMA with a median rank of 1 (95% CrI 1st to 1st).
2.4.1.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs
and there is no evidence that any treatment group is associatedwith
clinically significant improvement inTDI at threemonths (MCID
of 1), compared to the others, despite a significant difference in
some comparisons (Appendix 7). The certainty of evidence was
high for LABA/ICS versus LABA, moderate for LABA/LAMA
versus LAMA, low for LABA/LAMA versus LABA/ICS or LABA,
and very low for LABA/ICS versus LAMA.Therewas nodifference
between random and fixed analyses.
2.4.2 Outcome: TDI at six months
We included 18 studies of 16 interventions and four treatment
groups for this outcome (Appendix 3; Figure 32 a and b).
Figure 32. Transition Dyspnea Index at 6 months in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Positive values favour the first named treatment group. ICS: inhaled corticosteroid; LABA:
long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.4.2.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency. We also report results based on a random-
treatment-effects model with fixed-class effects for comparison (
Appendix 4).
2.4.2.2 NMA results
The NMA included a total of 14,315 participants (LABA: 3878,
LAMA: 3977, LABA/ICS: 1825, LABA/LAMA: 4635). Figure
32d and Table 52 show the mean difference in TDI score at six
months for each treatment group compared to every other. There is
evidence to suggest that LABA/LAMA increasesTDI at sixmonths
compared to LAMA and LABA monotherapies (MD 0.33, 95%
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CrI 0.18 to 0.47; MD 0.37, 95% CrI 0.21, 0.52), although the
MDs do not reach the clinical significance of MCID of 1. There is
no evidence of differences across the other comparisons. Table 53
shows the rank statistics for the four treatment groups (sorted by
mean rank). The highest ranked treatment group is LABA/LAMA
with a median rank of 1 (95% CrI 1st to 2nd).
2.4.2.3 Pairwise meta-analyses
There was no direct comparison for LABA/ICS versus LAMA.
Otherwise, the results from pairwise MAs were consistent with
the NMAs and there is no evidence that any treatment group is
associated with clinically significant improvement in TDI at six
months (MCID of 1), compared to the others (Appendix 7). The
certainty of evidence was high for LABA/LAMA versus LABA/
ICS and LABA/ICS versus LABA, moderate for LABA/LAMA
versus LAMA or LABA, and low for LAMA versus LABA. There
was no difference between random and fixed analyses .
2.4.3 Outcome: TDI at 12 months
We included six studies of 10 interventions and three treatment
groups for this outcome (Appendix 3; Figure 33 a and b).
Figure 33. Transition Dyspnea Index at 12 months in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Positive values favour the first named treatment group. ICS: inhaled corticosteroid; LABA:
long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.4.3.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency.We also report results based on the random-
treatment-effects model with fixed-class effects for comparison (
Appendix 4).
2.4.3.2 NMA results
The NMA included a total of 38,861 participants (LABA: 3908,
LAMA: 32,624, LABA/ICS: 0, LABA/LAMA: 2329). Figure 33d
and Table 54 show themean difference in TDI score at 12 months
for each treatment group compared to every other. There is evi-
dence to suggest that LABA/LAMA increases TDI at 12 months
compared to LAMA and LABA monotherapies (MD 0.20, 95%
CrI 0.09 to 0.32; MD 0.30, 95% CrI 0.17 to 0.42). There is no
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evidence of differences across other comparisons. Table 55 shows
the rank statistics for the three treatment groups (sorted by mean
rank). The highest ranked treatment group was LABA/LAMA
with a median rank of 1 (95% CrI 1st to 1st).
2.4.3.3 Pairwise meta-analyses
There was no direct comparison for LABA/LAMA versus LABA/
ICS and LABA/ICS versus LAMA or LABA. Otherwise, the re-
sults from pairwise MAs were consistent with theNMAs and there
is no evidence that any treatment group is associated with clini-
cally significant improvement in TDI at 12 months (MCID of 1),
compared to the others (Appendix 7). The certainty of evidence
was high for LAMA versus LAMA, moderate for LABA/LAMA
versus LAMA, and very low for LABA/LAMAversus LABA. There
was no difference between random and fixed analyses.
2.4.4 Rank probabilities for TDI
Figure 34 plots the ranks of TDI score for each treatment group
at three and six months only. Ranks at 12 months are not plotted
as only three treatment groups were available for comparison. The
vertical axis shows the probability of being ranked best, second
best, third best, or worst treatment group. LABA/LAMA has the
highest probability of being ranked first at six months and nearly
100% probability of being the best at three months. There is
uncertainty in the ranking of the other interventions.
Figure 34. Plot of rank probabilities for each treatment group for Transition Dyspnea Index
Transition Dyspnea Index score at 3 and 6 months in the low-risk population. ICS: inhaled corticosteroid; LABA:
long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
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2.5 Outcome: change from baseline in forced expiratory
volume in one second (FEV1)
2.5.1 Outcome: change from baseline in FEV1 at three
months
We included 50 studies of 23 interventions and four treatment
groups for this outcome (Appendix 3; Figure 35 a and b). Note
that interventions indacaterol 75 µg once daily, glycopyrronium
15.6 µg twice daily and indacaterol/glycopyrronium 27.5/12.5
µg twice daily are disconnected from the main treatment network
(Figure 35a), but we included them in a class/group model.
Figure 35. Change from baseline in forced expiratory volume in 1 second at 3 months in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Positive values favour the first named treatment group. ICS: inhaled corticosteroid; LABA:
long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.5.1.1 Model selection and inconsistency checking
We chose a random-treatment-effects model with fixed-class ef-
fects, assuming consistency (Appendix 4).
2.5.1.2 NMA results
The NMA included a total of 30,962 participants (LABA: 6725,
LAMA: 9977, LABA/ICS: 6126, LABA/LAMA: 8134) Figure 35d
and Table 56 show the mean difference in change from baseline
in FEV1 at three months for each treatment group compared to
every other. There is evidence to suggest that LABA/LAMA and
LABA/ICS increase FEV1 at three months compared to LAMA
(MD 0.08, 95% CrI 0.06 to 0.09; MD 0.02, 95% CrI 0 to 0.04),
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and LABA (MD 0.09, 95% CrI 0.07 to 0.11; 0.03 95% CrI
0.01 to 0.05), monotherapies and that LABA/LAMA improves
FEV1 compared to LABA/ICS (MD0.05, 95%CrI 0.03 to 0.07).
The 95% CI exceeding MCID of 0.1 L suggests a possibility of
clinically significant improvement favouring LABA/LAMA over
LABA. Table 57 shows the rank statistics for the four treatment
groups (sorted bymean rank). The highest ranked treatment group
was LABA/LAMA with a median rank of 1 (95% CrI 1st to 1st).
2.5.1.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs
and there is no evidence that any treatment group is associatedwith
clinically significant improvement (MCID of 0.1 L) in change
from baseline in FEV1 at three months compared to the others
(Appendix 7). However, a clinically significant improvement in
change from baseline in FEV1 at threemonths cannot be excluded
favouring LABA/LAMAover LABA/ICS (MD0.08, 95%CI 0.03
to 0.12; low-certainty evidence), and LABA (MD 0.07, 95% CI
0.03 to 0.12; very low-certainty evidence), given the 95%CI cross-
ing the line of MCID of 0.1 L. Otherwise, the certainty of evi-
dence was moderate for LABA/ICS versus LABA, low for LABA/
LAMA versus LABA/ICS or LAMA, LABA/ICS versus LAMA,
and LAMA versus LABA. There was no difference between ran-
dom and fixed analyses except for LABA/ICS versus LAMA, in
which the random-effects model had a wider 95% CI containing
the line of no difference (MD 0.02, 95% CI −0.02 to 0.06).
2.5.2 Outcome: change from baseline in FEV1 at six months
We included 30 studies of 21 interventions and four treatment
groups for this outcome (Appendix 3; Figure 36 a and b).
Figure 36. Change from baseline in forced expiratory volume in 1 second at 6 months in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot (deviance points
from the fixed-effect model with random-treatment-group effect on the x-axis and from the fixed-effect
inconsistency model with random-class effect on the y-axis); d. plot of relative effects. Positive values favour
the first named treatment group. ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-
acting muscarinic antagonist
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2.5.2.1 Model selection and inconsistency checking
We chose a random-treatment-effects model with fixed-class ef-
fects, assuming consistency. We also report results for a fixed-
treatment-effect model with random-class effects for comparison.
However, there is weak evidence of potential inconsistency in
this network and results should be interpreted with some caution
(Appendix 4).
2.5.2.2 NMA results
The NMA included a total of 21,224 participants (LABA: 5959,
LAMA: 6360, LABA/ICS: 2155, LABA/LAMA: 6750). Figure
36d and Table 58 show the mean difference in change from base-
line in FEV1 at six months for each treatment group compared
to every other. There is evidence to suggest that LABA/LAMA in-
creases FEV1 at sixmonths compared to all other treatment groups
(MD 0.05, 95% CrI 0.03 to 0.08; MD 0.06, 95% CrI 0.05 to
0.08;MD0.08, 95%CrI 0.06 to 0.09 against LABA/ICS, LAMA,
and LABA respectively), and that LAMA slightly increases FEV1
compared to LABA (MD 0.01, 95% CrI 0.00 to 0.03), in the
random-effects-model with fixed-class effects although the mean
differences do not reach the clinical significance of MCID of 0.1
L. Table 59 shows the rank statistics for the four treatment groups
(sorted by mean rank). The highest ranked treatment group was
LABA/LAMA with a median rank of 1 (95% CrI 1st to 1st). Re-
sults are more uncertain when considering the fixed-treatment-
effect model with random-class effects.
2.5.2.3 Pairwise meta-analyses
The results from pairwiseMAs were consistent with theNMAs ex-
cept for LABA/ICS versus LABA inwhich LABA/ICS significantly
increased FEV1 at sixmonths compared to LABA (MD0.04, 95%
CI 0.01 to 0.07). There is no evidence of clinically significant im-
provement (MCID of 0.1 L or greater) with any treatment group
compared to the others, except for LABA/LAMA versus LABA/
ICS in which its 95% CI suggested a possibility of clinically sig-
nificant difference favouring LABA/LAMA over LABA/ICS (MD
0.10, 95% CI 0.05 to 0.15; Appendix 7). The certainty of evi-
dence was high for LABA/LAMA versus LABA/ICS and LABA/
ICS versus LAMA, and moderate for LABA/LAMA versus LAMA
and LABA/ICS versus LABA. There was no difference between
random and fixed analyses.
2.5.3 Outcome: change from baseline in FEV1 at 12 months
We included 13 studies of 13 interventions and three treatment
groups for this outcome (Appendix 3; Figure 37 a and b).
Figure 37. Change from baseline in forced expiratory volume in 1 second at 12 months in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot (deviance points
from the fixed-effect model with random-class effect on the x-axis and from the fixed-effect inconsistency
model with random-class effect on the y-axis); d. plot of relative effects. Positive values favour the first named
treatment group. ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic
antagonist
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2.5.3.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with random-class ef-
fects, assuming consistency. We also reported results for a ran-
dom-treatment-effects model with fixed-class effects for compar-
ison. However, there is weak evidence of potential inconsistency
in the latter model so results should be interpreted with caution
(Appendix 4).
2.5.3.2 NMA results
The NMA included a total of 10,676 participants (LABA: 3577,
LAMA: 4057, LABA/ICS: 0, LABA/LAMA: 3042). Figure 37d
and Table 60 show the mean difference in change from baseline in
FEV1 at 12 months for each treatment group compared to every
other. There is evidence to suggest that LABA/LAMA increases
FEV1 at 12 months compared to LABA (MD 0.08, 95% CrI 0.02
to 0.14). However there is high uncertainty in the results. Com-
parisons based on the random-treatment-effects model with fixed
class are more precise with similar MDs. The 95% CI contain-
ing MCID of 0.1 L in both models (MD 0.08, 95% CrI 0.02
to 0.14 and MD 0.08, 95% CrI 0.06 to 0.1), suggests a possibil-
ity of clinically significant improvement favouring LABA/LAMA
over LABA. Table 61 shows the rank statistics for the three treat-
ment groups (sorted bymean rank). The highest ranked treatment
group was LABA/LAMA with a median rank of 1 (95% CrI 1st
to 2nd).
The random-class effects model assumes that treatment effects
within a class or group can vary. Table 62 reports the mean dif-
ference of each individual intervention compared to formoterol 9
to 12 µg twice daily. Tiotropium 18 µg once daily, tiotropium
5 µg once daily, and all the interventions in the LABA/LAMA
group (formoterol/glycopyrronium 9.6 µg/18 µg twice daily, in-
dacaterol/glycopyrronium 27.5 µg/15.6 µg twice daily, inda-
caterol/glycopyrronium 110 µg/50 µg once daily, olodaterol/
tiotropium 5 µg/5 µg once daily and formoterol/aclidinium 12
µg/400 µg twice daily) showed an increase in FEV1 at 12 months
compared to formoterol 9 to 12 µg twice daily.
2.5.3.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMA
(the random-treatment-effects model with fixed classes), except
for LAMA versus LABA, in which there was a significant improve-
ment with LAMA compared to LABA (MD 0.02, 95%CI 0.01 to
0.03; Appendix 7). However, there is no evidence that any treat-
ment group is associated with clinically significant improvement
(MCID of 0.1 L), compared to the others (very low-certainty evi-
dence). Appendix 7 shows the certainty of evidence for the rest of
the comparisons. There was no difference between random and
fixed analyses.
2.5.4 Rank probabilities for change from baseline in FEV1
Figure 38 plots the ranks of each treatment group for FEV1 at three
and six months only. We have not plotted ranks at 12 months, as
only three treatment groups were available for comparison. The
vertical axis shows the probability of being the best, second best,
third best, or worst treatment group. LABA/LAMA has nearly
100% probability of being ranked first at three and six months,
with LABA having a very high probability of being the worst
intervention at three and six months.
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Figure 38. Plot of rank probabilities for each treatment group in change in forced expiratory volume in 1 second in the
low-risk population
Change from baseline in forced expiratory volume in 1 second at 3 (solid line), and 6 months (dashed line). ICS:
inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.6 Outcome: mortality
We included 51 studies of 27 interventions and four treatment
groups for this outcome (Appendix 3; Figure 39 a and b).
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Figure 39. Mortality in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 1 favour the first named treatment group. ICS: inhaled corticosteroid; LABA:
long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.6.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency. We also report results based on a random-
treatment-effects model with fixed-class effects for comparison.
Results should be interpretedwith some cautiondue topoormodel
fit, which can be attributed to studies with zero cells (Appendix
4).
2.6.2 NMA results
TheNMA included a total of 56,493 participants (LABA: 11,488,
LAMA: 25,324, LABA/ICS: 7586, LABA/LAMA: 12,095). The
median duration of follow-up was 24 weeks (range 12 to 156
weeks). Figure 39d andTable 63 show theORofmortality for each
treatment group compared to every other. There was no evidence
to suggest that any treatment group increased or decreased the
odds of mortality compared to any other.
Table 64 shows the rank statistics for the four treatment groups
(sorted by mean rank). The highest ranked treatment group was
LABA/ICSwith amedian rank of 1 (95%CrI 1st to 4th), although
the wide CrIs around the mean highlight the uncertainty in the
results.
2.6.3 Pairwise meta-analyses
The results from pairwise MAs were consistent with the NMAs
and there is no evidence to suggest that any treatment group in-
creased or decreased the odds of mortality compared to any other
(Appendix 7). The certainty of evidence was moderate for all com-
parisons. There was no difference between random and fixed anal-
yses.
2.7 Outcome: serious adverse events (SAEs)
SAEs were separated into total SAEs, COPD SAEs and cardiac
SAEs.
2.7.1 Outcome: total SAEs
The analysis for total SAEs included 67 studies of 30 interven-
tions and four treatment groups. We included a total of 64,855
participants (LABA: 13,703, LAMA: 27,712, LABA/ICS: 8609,
LABA/LAMA: 14,831; Appendix 3, Figure 40 a and b). The me-
dian duration of follow-up was 24 weeks (range 12 to 156 weeks).
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Figure 40. Total serious adverse events in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot ICS: inhaled
corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.7.1.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency.We also report results based on the random-
treatment-effects model with fixed-class effects for comparison (
Appendix 4).
2.7.2 Outcome: COPD SAEs
The analysis for COPD SAEs included 63 studies of 30 interven-
tions and four treatment groups (Appendix 3; Figure 41 a and
b). We included a total of 61,759 participants (LABA: 12,981,
LAMA: 27,819, LABA/ICS: 7971, LABA/LAMA: 12,988)
58Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 41. Chronic obstructive pulmonary disease serious adverse events in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot ICS: inhaled
corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.7.2.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency.We also report results based on the random-
treatment-effects model with fixed-class effects for comparison.
Results should be interpretedwith some cautiondue topoormodel
fit, which can be attributed to studies with zero cells (Appendix
4).
2.7.3 Outcome: cardiac SAEs
The analysis for cardiac SAEs included 58 studies of 29 interven-
tions and four treatment groups (Appendix 3; Figure 42 a and
b). We included a total of 62,007 participants (LABA: 12,581,
LAMA: 24,747, LABA/ICS: 10,303, LABA/LAMA: 14,376).
59Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 42. Cardiac serious adverse events in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot ICS: inhaled
corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.7.3.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency.We also report results based on the random-
treatment-effects model with fixed-class effects for comparison.
Results should be interpretedwith some cautiondue topoormodel
fit, which can be attributed to studies with zero cells.
2.7.4 NMA results
Table 65 shows the OR of each type of adverse event for each
treatment group compared to every other. For total SAEs there
was evidence of an increase in the odds of an event for LABA/ICS
compared to LABA (OR 1.13, 95% CrI 1.01 to 1.27), although
only if we used the fixed-effect model. For cardiac and COPD
SAEs, there was no evidence that any treatment group increases
or decreases the odds of an event compared to any other.
2.7.5 Pairwise meta-analyses
There is no evidence to suggest that any treatment group increases
or decreases the odds of an event compared to the others with
pairwise MAs. The results were consistent with the NMAs except
for LABA/ICS versus LABA, in which LABA/ICS was associated
with a significant increase in total SAEs compared to LABA with
the fixed-effect NMA but not with the pairwise MAs or random-
effects NMA (Appendix 7; Table 65). Table 66 shows the certainty
of evidence for each treatment group compared to every other.
There was no difference between random and fixed analyses.
2.8 Outcome: dropouts due to serious adverse events (SAEs)
We included 65 studies of 29 interventions and four treatment
groups for this outcome (Appendix 3; Figure 43 a and b).
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Figure 43. Dropouts due to adverse events in the low-risk population.
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot; d: plot of
relative effects. Values less than 1 favour the first named treatment group. ICS: inhaled corticosteroid; LABA:
long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.8.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency.We also report results based on the random-
treatment-effects model with fixed-class effects for comparison.
Results should be interpretedwith some cautiondue topoormodel
fit (Appendix 4).
2.8.2 NMA results
TheNMA included a total of 62,831 participants (LABA: 13,074,
LAMA: 27,155, LABA/ICS: 8394, LABA/LAMA: 14,208). The
median duration of follow-up was 24 weeks (range 12 to 156
weeks). Figure 43d and Table 67 show the OR of dropouts due
to adverse events for each treatment group compared to every
other. There was no evidence to suggest that any treatment group
increased or decreased the odds of dropout compared to any other
except for LAMA versus LABA (OR 0.84, 95% CrI 0.72 to 0.97).
Table 68 shows the rank statistics for the four treatment groups
(sorted by mean rank). The highest ranked treatment group was
LAMA with a median rank of 1 (95% CrIs 1st to 3rd), although
the wide CrIs around the mean highlight the uncertainty in the
results.
2.8.3 Pairwise meta-analyses
There is no evidence to suggest that any treatment group increases
or decreases the odds of an event compared to the others with
pairwise MAs. The results were consistent with the NMAs except
for LAMA versus LABA, in which LAMA was associated with a
significant decrease in dropouts due to adverse events compared
to LABA in the NMA (OR 0.84, 95% CrI 0.72 to 0.97), but not
in the pairwise MA (OR 0.90, 95% CI 0.73 to 1.10; Appendix 7).
The certainty of evidence was moderate for LABA/ICS or LAMA
versus LABA, low for LABA/LAMA versus LABA/ICS or LAMA
and LABA/ICS versus LAMA, and very low for LABA/LAMA
versus LABA. There was no difference between random and fixed
analyses.
2.9 Outcome: pneumonia
We included 61 studies of 29 interventions and four treatment
groups for this outcome (Appendix 3; Figure 44 a and b).
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Figure 44. Pneumonia in the low-risk population
a: network diagram of interventions; b: network diagram of treatment groups; c: deviance plot (deviance points
from the fixed-effect model with fixed-class effect and from the fixed-effect inconsistency model with fixed-
class effect); d: plot of relative effects. Values less than 1 favour the first named treatment group. ICS: inhaled
corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.9.1 Model selection and inconsistency checking
We chose a fixed-treatment-effect model with fixed-class effects,
assuming consistency. We also report results based on a random-
treatment-effects model with fixed-class effects and informative
prior distribution on the heterogeneity parameter for comparison.
Results should be interpreted with caution due to potential incon-
sistency in the data (Appendix 4).
2.9.2 NMA results
TheNMA included a total of 61,157 participants (LABA: 12,640,
LAMA: 26,596, LABA/ICS: 7518, LABA/LAMA: 14,403). The
median duration of follow-up was 24 weeks (range 12 to 156
weeks). Figure 44d and Table 69 show the OR of pneumonia for
each treatment group compared to every other. There is evidence
to suggest that LABA/ICS increases the odds of pneumonia com-
pared to LAMA and LABA (OR 2.02, 95% CrI 1.16 to 3.72; OR
1.93, 95% CrI 1.29 to 3.22), but no evidence of differences across
other comparisons (Appendix 7; Summary of findings 7). Table
70 shows the rank statistics for the four treatment groups (sorted
by mean rank). The highest ranked treatment group was LAMA
with a median rank of 1 (95% CrI 1st to 3rd), although note the
uncertainty in all the rankings.
2.9.3 Clinical homogeneity assessment
Table 6 shows the clinical homogeneity assessment across the avail-
able comparisons. Pre-bronchodilator baseline FEV1 ranged from
1.14L to1.34L.The comparisons of LABA/ICS versusmonother-
apies had a lower baseline FEV1 compared with those of LABA/
LAMA versus monotherapies, which could have introduced a bias
against LABA/ICS. The NMA results should be interpreted with
caution because of the difference in the baseline FEV1 across the
pairwise comparisons.
2.9.4 Pairwise meta-analyses
The results from pairwise MAs suggest that LABA/ICS increases
the odds of pneumonia compared to LABA/LAMA and LABA
(OR 2.33, 95% CI 1.03 to 5.26; OR 1.64, 95% CI 1.25 to 2.14).
The difference was significant for LABA/LAMAversus LABA/ICS
with the pairwiseMAs (moderate-certainty evidence), but notwith
theNMAs, and significant for LABA/ICS versus LAMA (OR2.02,
95% CrI 1.16 to 3.72), with the NMA but not with the pairwise
MA (OR 5.82, 95% CI 0.70 to 48.80; low-certainty evidence;
Appendix 7). The certainty of evidence was high for LABA/ICS
versus LABA,moderate for LABA/LAMAversus LAMAor LABA,
and LAMA versus LABA (see ’Summary of findings’ tables). The
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aforementioneddifference in the baseline FEV1across the pairwise
comparisons may have affected the NMA results. There was no
difference between random and fixed analyses.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
LABA/LAMA compared to LAMA for chronic obstructive pulmonary disease
Patient or population: chronic obstruct ive pulmonary disease with predicted FEV1 of less than 80%
Setting: outpat ient
Intervention: LABA/ LAMA
Comparison: LAMA
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evidence
(GRADE)
Risk with LAMA Risk difference with LABA/
LAMA
Moderate to severe exac-
erbat ions: high-risk popula-
t ion
561 per 1000 14 more per 1000
(29 fewer to 58 more)
OR 1.06
(0.89 to 1.27)
2206
(1 RCT)
⊕⊕⊕©
Moderate1,2,3
Moderate to severe exacer-
bat ions: low-risk populat ion
108 per 1000 7 fewer per 1000
(34 fewer to 28 more)
OR 0.93
(0.66 to 1.30)
5192
(8 RCTs)
⊕⊕©©
Low2,3,4,5
Severe exacerbat ions: high-
risk populat ion
397 per 1000 72 fewer per 1000
(169 fewer to 36 more)
OR 0.73
(0.45 to 1.16)
304
(1 RCT)
⊕⊕⊕©
Moderate2,3
Severe exacerbat ions: low-
risk populat ion
17 per 1000 0 fewer per 1000
(7 fewer to 12 more)
OR 0.99
(0.57 to 1.72)
4937
(7 RCTs)
⊕⊕⊕©
Moderate2,3,4
Pneumonia: high-risk popu-
lat ion
30 per 1000 1 fewer per 1000
(12 fewer to 17 more)
OR 0.98
(0.59 to 1.61)
2510
(2 RCTs)
⊕⊕⊕©
Moderate2,3,4
Pneumonia: low-risk popu-
lat ion
6 per 1000 1 more per 1000
(1 fewer to 4 more)
OR 1.23
(0.84 to 1.81)
18,538
(22 RCTs)
⊕⊕⊕©
Moderate3,4,6
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; FEV1 : f orced expiratory volume-one second; ICS: inhaled cort icosteroid; LABA: long-act ing beta2-agonist ; LAMA: long-act ing muscarinic antagonist ;
OR: odds rat io; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Results were unchanged when open t iotropium arm was excluded.
2Optimal information size was not met.
3 We could not exclude the possibility of a clinically important dif f erence due to a wide 95%CI.
4Results were unchanged when studies with open t iotropium arm were excluded one by one or all together.
5Moderate heterogeneity (I² = 30% to 60%).
6Results were unchanged when studies with uneven and/ or high dropouts were excluded one by one or all together.
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LABA/LAMA compared to LABA for chronic obstructive pulmonary disease
Patient or population: chronic obstruct ive pulmonary disease with predicted FEV1 of less than 80%
Setting: outpat ient
Intervention: LABA/ LAMA
Comparison: LABA
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evidence
(GRADE)
Risk with LABA Risk difference with LABA/
LAMA
Moderate to severe exac-
erbat ions: high-risk popula-
t ion
- - - 0
(0 RCTs)
-
Moderate to severe exacer-
bat ions: low-risk populat ion
166 per 1000 33 fewer per 1000
(56 fewer to 4 fewer)
OR 0.77
(0.62 to 0.97)
2488
(5 RCTs)
⊕⊕⊕©
Moderate1
Severe exacerbat ions: high-
risk populat ion
- - - 0
(0 RCTs)
-
Severe exacerbat ions: low-
risk populat ion
59 per 1000 12 fewer per 1000
(25 fewer to 7 more)
OR 0.78
(0.55 to 1.12)
2898
(6 RCTs)
⊕⊕⊕©
Moderate1,2
Pneumonia: high-risk popu-
lat ion
- - - 0
(0 RCTs)
-
Pneumonia: low-risk popu-
lat ion
7 per 1000 4 more per 1000
(0 fewer to 10 more)
OR 1.54
(0.95 to 2.49)
8252
(10 RCTs)
⊕⊕⊕©
Moderate2
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; FEV1 : f orced expiratory volume-one second; ICS: inhaled cort icosteroid; LABA: long-act ing beta2-agonist ; LAMA: long-act ing muscarinic antagonist ;
OR: odds rat io; RCT: randomised controlled trial
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GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Optimal information size was not met.
2A clinically important dif f erence cannot be excluded due to a wide 95% CI.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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LABA/ ICS compared to LAMA for chronic obstructive pulmonary disease (COPD)
Patient or population: chronic obstruct ive pulmonary disease with predicted FEV1 of less than 80%
Setting: outpat ient
Intervention: LABA/ ICS
Comparison: LAMA
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evidence
(GRADE)
Risk with LAMA Risk difference with LABA/
ICS
Moderate to severe exac-
erbat ions: high-risk popula-
t ion
504 per 1000 28 more per 1000
(26 fewer to 81 more)
OR 1.12
(0.90 to 1.39)
1580
(2 RCTs)
⊕⊕⊕©
Moderate1,2
Moderate to severe exacer-
bat ions: low-risk populat ion
35 per 1000 13 fewer per 1000
(26 fewer to 22 more)
OR 0.63
(0.24 to 1.66)
623
(1 RCT)
⊕⊕©©
Low1,3
Severe exacerbat ions: high-
risk populat ion
112 per 1000 27 more per 1000
(5 fewer to 67 more)
OR 1.28
(0.95 to 1.73)
1580
(2 RCTs)
⊕⊕⊕©
Moderate1,2
Severe exacerbat ions: low-
risk populat ion
3 per 1000 6 more per 1000
(2 fewer to 83 more)
OR 3.05
(0.32 to 29.47)
623
(1 RCT)
⊕⊕©©
Low1,2
Pneumonia: high-risk popu-
lat ion
28 per 1000 21 more per 1000
(2 more to 52 more)
OR 1.80
(1.06 to 3.06)
1580
(2 RCTs)
⊕⊕⊕©
Moderate1
Pneumonia: low-risk popu-
lat ion
0 per 1000 0 fewer per 1000
(0 fewer to 0 fewer)
OR 5.82
(0.70 to 48.80)
885
(2 RCTs)
⊕⊕©©
Low1,2,3
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; FEV1 : f orced expiratory volume-one second; ICS: inhaled cort icosteroid; LABA: long-act ing beta2-agonist ; LAMA: long-act ing muscarinic antagonist ;
OR: odds rat io; RCT: randomised controlled trial
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GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Optimal information size was not met.
2 We could not exclude the possibility of a clinically important dif f erence due to a wide 95%CI.
3Signif icant small study ef fects are possible due to small sample sizes in the included studies.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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LABA/ ICS compared to LABA for chronic obstructive pulmonary disease (COPD): a network meta-analysis
Patient or population: chronic obstruct ive pulmonary disease with predicted FEV1 of less than 80%
Setting: outpat ient
Intervention: LABA/ ICS
Comparison: LABA
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evidence
(GRADE)
Risk with LABA Risk difference with LABA/
ICS
Moderate to severe exac-
erbat ions: high-risk popula-
t ion
430 per 1000 51 fewer per 1000
(69 fewer to 28 fewer)
OR 0.81
(0.75 to 0.89)
9041
(10 RCTs)
⊕⊕⊕⊕
High1
Moderate to severe exacer-
bat ions: low-risk populat ion
454 per 1000 46 fewer per 1000
(86 fewer to 5 fewer)
OR 0.83
(0.70 to 0.98)
6689
(6 RCTs)
⊕⊕⊕©
Moderate2
Severe exacerbat ions: high-
risk populat ion
94 per 1000 8 fewer per 1000
(23 fewer to 11 more)
OR 0.91
(0.74 to 1.13)
4216
(5 RCTs)
⊕⊕⊕©
Moderate1,3,4
Severe exacerbat ions: low-
risk populat ion
130 per 1000 7 more per 1000
(11 fewer to 26 more)
OR 1.06
(0.90 to 1.24)
6482
(6 RCTs)
⊕⊕⊕⊕
High
Pneumonia: high-risk popu-
lat ion
14 per 1000 6 more per 1000
(0 fewer to 15 more)
OR 1.46
(1.03 to 2.08)
12586
(14 RCTs)
⊕⊕⊕©
Moderate5
Pneumonia: low-risk popu-
lat ion
29 per 1000 18 more per 1000
(7 more to 31 more)
OR 1.64
(1.25 to 2.14)
6705
(6 RCTs)
⊕⊕⊕⊕
High
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; FEV1 : f orced expiratory volume-one second; ICS: inhaled cort icosteroid; LABA: long-act ing beta2-agonist ; LAMA: long-act ing muscarinic antagonist ;
OR: odds rat io; RCT: randomised controlled trial
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GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Results were unchanged when we excluded studies with uneven dropouts, one by one or all together.
2Moderate heterogeneity (I² = 30% to 60%).
3Optimal information size not met.
4 We could not exclude the possibility of a clinically important dif f erence due to a wide 95%CI.
5Several studies had a high dropout rate and 95% CI crossed/ uncrossed the line of no dif ference when we excluded a study
with a high dropout rate.
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LAMA compared to LABA for chronic obstructive pulmonary disease
Patient or population: chronic obstruct ive pulmonary disease with predicted FEV1 of less than 80%
Setting: outpat ient
Intervention: LAMA
Comparison: LABA
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evidence
(GRADE)
Risk with LABA Risk difference with LAMA
Moderate to severe exac-
erbat ions: high-risk popula-
t ion
385 per 1000 40 fewer per 1000
(63 fewer to 20 fewer)
OR 0.84
(0.76 to 0.92)
7376
(1 RCT)
⊕⊕⊕⊕
High
Moderate to severe exacer-
bat ions: low-risk populat ion
198 per 1000 13 fewer per 1000
(35 fewer to 11 more)
OR 0.92
(0.79 to 1.07)
4567
(5 RCTs)
⊕⊕⊕©
Moderate1,2
Severe exacerbat ions: high-
risk populat ion
151 per 1000 16 fewer per 1000
(29 fewer to 1 more)
OR 0.88
(0.78 to 1.01)
7376
(1 RCT)
⊕⊕⊕©
Moderate2
Severe exacerbat ions: low-
risk populat ion
30 per 1000 10 fewer per 1000
(19 fewer to 4 more)
OR 0.64
(0.36 to 1.13)
3320
(4 RCTs)
⊕⊕©©
Low2,3,4
Pneumonia: high-risk popu-
lat ion
17 per 1000 3 fewer per 1000
(7 fewer to 2 more)
OR 0.83
(0.61 to 1.13)
10,815
(2 RCTs)
⊕⊕⊕©
Moderate4
Pneumonia: low-risk popu-
lat ion
7 per 1000 0 fewer per 1000
(3 fewer to 5 more)
OR 1.01
(0.61 to 1.69)
11,338
(10 RCTs)
⊕⊕⊕©
Moderate4
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; FEV1 : f orced expiratory volume-one second; ICS: inhaled cort icosteroid; LABA: long-act ing beta2-agonist ; LAMA: long-act ing muscarinic antagonist ;
OR: odds rat io; RCT: randomised controlled trial
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GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Results were unchanged when we excluded studies with open-label t iotropium arm, one by one or all together.
2Optimal information size was not met.
395%CI no longer contained the line of no dif ference when we excluded a study with open-label t iotropium arm.
4A clinically important dif f erence cannot be excluded due to a wide 95% CI.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Patient or population: chronic obstruct ive pulmonary disease with predicted FEV1 of less than 80%
Settings: outpat ient
Outcomes Anticipated absolute effects* (95% CrI) Relative effect
(95% CrI)
No of participants
(studies)
Risk with LABA Risk difference with LABA/LAMA
Moderate to severe exacerba-
t ions: high-risk populat ion
427 per 1000 106 fewer per 1000
(139 fewer to 68 fewer)
HR 0.70
(0.61 to 0.80)
11,113
(21 RCTs)
Moderate to severe exacerba-
t ions: low-risk populat ion
250 per 1000 52 fewer per 1000
(76 fewer to 25 more)
HR 0.78
(0.67 to 0.90)
14,450
(28 RCTs)
Severe exacerbat ions: high-risk
populat ion
142 per 1000 48 fewer per 1000
(66 fewer to 26 fewer)
HR 0.64
(0.51 to 0.81)
9,045
(13 RCTs)
Severe exacerbat ions: low-risk
populat ion
92 per 1000 24 fewer per 1000
(44 fewer to 2 more)
HR
0.72 (0.48 to 1.02)
11,127
(31 RCTs)
Risk with LABA Risk difference with LABA/ ICS Relative effect
(95% CrI)
No of participants
(studies)
Moderate to severe exacerba-
t ions: high-risk populat ion
427 per 1000 66 fewer per 1000
(87 fewer to 46 fewer)
HR 0.80
(0.75 to 0.86)
18,561
(21 RCTs)
Moderate to severe exacerba-
t ions: low-risk populat ion
250 per 1000 24 fewer per 1000 (37 fewer to 10
fewer)
HR 0.89
(0.84 to 0.96)
16,437
(28 RCTs)
Severe exacerbat ions: high-risk
populat ion
142 per 1000 23 fewer per 1000 (39 fewer to 4
fewer)
HR 0.83
(0.71 to 0.97)
12,447
(13 RCTs)
Severe exacerbat ions: low-risk
populat ion
92 per 1000 2 more per 1000 (10 fewer to 15
more)
HR 1.01
(0.72 to 1.28)
12,265
(31 RCTs)
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Risk with LABA Risk difference with LAMA Relative effect
(95% CrI)
No of participants
(studies)
Moderate to severe exacerba-
t ions: high-risk populat ion
427 per 1000 69 fewer per 1000
(99 fewer to 40 fewer)
HR 0.80
(0.71 to 0.88)
16,655
(21 RCTs)
Moderate to severe exacerba-
t ions: low-risk populat ion
250 per 1000 27 fewer per 1000 (48 fewer to 5
fewer)
HR 0.87
(0.78 to 0.97)
14,209
(28 RCTs)
Severe exacerbat ions: high-risk
populat ion
142 per 1000 37 fewer per 1000 (49 fewer to 24
fewer)
HR 0.72
(0.63 to 0.82)
15,205
(13 RCTs)
Severe exacerbat ions: low-risk
populat ion
92 per 1000 15 fewer per 1000 (29 fewer to 2
more)
HR HR 0.80
(0.56 to 1.05)
22,819
(31 RCTs)
Risk with LABA/ ICS Risk difference with LABA/LAMA Relative effect
(95% CrI)
No of participants
(studies)
Pneumonia: high-risk populat ion 24 per 1000 10 fewer per 1000
(14 fewer to 4 fewer)
OR 1.69
(1.2 to 2.44)
13,546
(24 RCTs)
Pneumonia: low-risk populat ion 24 per 1000 8 fewer per 1000 (13 fewer to 0
fewer)
OR 1.64
(0.99 to 2.94)
27,043
(61 RCTs)
Risk with LABA/ ICS Risk difference with LAMA Relative effect
(95% CrI)
No of participants
(studies)
Pneumonia: high-risk populat ion 24 per 1000 10 fewer per 1000
(14 fewer to 6 fewer)
OR 1.78
(1.33 to 2.39)
18,844
(24 RCTs)
Pneumonia: low-risk populat ion 24 per 1000 11 fewer per 1000 (16 fewer to 4
fewer)
OR 2.02
(1.16 to 3.72)
39,236
(31 RCTs)
Risk with LABA/ ICS Risk difference with LABA Relative effect
(95% CrI)
No of participants
(studies)
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Pneumonia: high-risk populat ion 24 per 1000 8 fewer per 1000
(11 fewer to 3 fewer)
OR 1.50
(1.17 to 1.92)
21,404
(24 RCTs)
Pneumonia: low-risk populat ion 24 per 1000 11 fewer per 1000 (14 fewer to 7
fewer)
OR 1.93
(1.29 to 3.22)
20,158
(61 RCTs)
*The risk in the intervention group (and its 95% credible interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CrI).
CrI: credible interval; FEV1 : f orced expiratory volume-one second; HR: hazard rat io; ICS: inhaled cort icosteroid; LABA: long-act ing beta2-agonist ; LAMA: long-act ing muscarinic
antagonist ; OR: odds rat io; RCT: randomised controlled trial
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
Weassumed a class/group effect in all treatment groups because the
random-class-effectsmodel did not significantly improvemodel fit
compared to the fixed-class-effects model except for change from
baseline in FEV1 at 12 months in the low-risk population, which
argues against intraclass/group differences in any of the treatment
groups we analysed. We have summarised the results in Appendix
6, Appendix 7, and Appendix 5.
The NMAs suggested that LABA/LAMA combination was the
highest ranked treatment group to reduce moderate to severe and
severe exacerbations, followed by LAMA. There is evidence that
LABA/LAMA significantly reduces moderate to severe exacerba-
tions compared to all others, and severe exacerbations compared
to LABA/ICS and LABA in the high-risk population.
The LABA/ICS combination was ranked third for moderate to
severe exacerbations and severe exacerbations in the high-risk pop-
ulation and ranked fourth for the severe exacerbations in the low-
risk population. LABA was the worst ranked, except for severe ex-
acerbations in the low-risk population, for which theywere ranked
third.
In the pairwise MAs, there was no definite evidence that LABA/
LAMA or LAMA reduced moderate to severe or severe exacer-
bations compared to LABA/ICS in both populations, although a
clinically meaningful reduction could not be excluded due to a
wide 95% CI.
With regard to symptom and quality-of-life scores, the combi-
nation therapies, LABA/LAMA and LABA/ICS were generally
ranked higher than monotherapies in both populations. LAMA/
LABA was ranked higher than LABA/ICS in the high-risk pop-
ulation. There were significant overlaps in the rank statistics be-
tween LABA/LAMA and LABA/ICS as well as between LAMA
and LABA in the low-risk population.
In the high-risk population of pairwise MAs, the LABA/LAMA
combination significantly increased SGRQ responders compared
to LAMA at six months, LABA/ICS at 12 months, and LAMA at
12 months (Appendix 6).
In the low-risk population of pairwise MAs, the LABA/LAMA
combination significantly increased SGRQ responders compared
to LAMA at three and six months and LABA at six months (
Appendix 7).
The LABA/ICS combination significantly increased SGRQ re-
sponders compared to LABA at 12 months and the odds ratio
of SGRQ response was significantly lower with LAMA compared
to LABA at three months. Otherwise, none of the differences in
symptom and quality-of-life scores met theMCID criteria of clin-
ical significance in either high- or low-risk populations.
The LABA/ICS combination was the lowest ranked in pneumo-
nia SAEs in the high- and low-risk populations. In the high-risk
population, LABA/ICS significantly increased the odds of pneu-
monia compared to LAMA/LABA, LAMA, and LABA both in
the NMA and pairwise MAs. In the low-risk population, LABA/
ICS increased the odds of pneumonia compared to LAMA and
LABA in the NMA and compared to LABA/LAMA and LABA in
the pairwise MAs.
There were significant overlaps in the rank statistics in the other sa-
fety outcomes. LABA/ICS significantly increased total SAEs com-
pared to LABA, and LAMA significantly reduced COPD SAEs
compared to LABA, both in the NMAs and pairwise MAs. In the
low-risk population, LABA/ICS significantly increased total SAEs
and LAMA significantly reduced dropouts due to adverse events
compared to LABA in the NMAs but not in the pairwise MAs.
Otherwise, there was no evidence to suggest that any treatment
group increased the odds of SAEs or dropout compared to the
others.
With regard to pre-bronchodilator FEV1, the highest ranked treat-
ment group was LABA/LAMA with a median rank of 1 whereas
LABA was the worst ranked with a median of 4 at all time points.
LABA/ICS and LAMA were ranked second or third. In the pair-
wise MAs, a significant difference was seen in some comparisons
but the 95% CIs crossed the line of MCID of 0.1 L, suggesting
none of the differences was clinically meaningful.
Overall completeness and applicability of
evidence
The study results are not applicable to those with a milder form of
COPD because people with mild COPD do not usually require a
maintenance inhaler therapy and we did not include them in our
analysis.
We also excluded people with asthma, although the baseline bron-
chodilator response was quite significant in some studies despite
the exclusion (Table 1). It is unclear whether efficacies of ICS/
LABA would be different in people without a history of asthma
but with a significant bronchodilator response, which is usually
seen in a more severe form of the disease. Cardiac SAEs could
have been underestimated due to the exclusion of people with a
significant cardiovascular comorbidity in a majority of included
studies.
We excluded drug formulations or doses that were not approved or
available for clinical use, as well as nebulised medications. There-
fore, the results are not applicable for nebulised or off-label use of
available medications.
Otherwise, we included a total of 101,311 participants from 99
studies from across the world to be as comprehensive as possible.
We used a Bayesian shared parameter model for COPD exacerba-
tions andwere able to avoid losing a substantial amount of relevant
data (e.g. 6 out of 13 studies in severe exacerbations in the high-
risk population). We were able to collect a substantial amount of
data from manufacturers’ websites and ClinicalTrials.gov due to
greater transparency from pharmaceutical companies.
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Quality of the evidence
All included studies were RCTs, and the quality of included RCTs
was generally good (Figure 2). Nineteen studies had an open
tiotropium arm and 16 studies had relatively uneven dropouts.
The results were unchanged in most of comparisons when we ex-
cluded those studies one by one or all together in the pairwise
analyses. Otherwise, we downgraded the certainty rating by one
or even two levels in some comparisons.
We had a total of 189 head-to-head comparisons in the pairwise
MAs and the certainty of evidence was high, moderate, low and
very low in 40, 99, 39, and 11 comparisons respectively. The
primary reason for downgradingwas a suboptimal information size
or a wide 95% CI. Our confidence in the findings increased when
the NMAs supported the pairwise results with a much greater
information size. The results should be interpreted with caution
for those derived from a small sample size or with low or very low
certainty of evidence, or both (see ’Summary of findings’ tables;
Appendix 6; Appendix 7).
We found no evidence of inconsistency or effect modifiers when
we compared the model fit and between-study heterogeneity from
NMAmodels with those from an unrelated effects (inconsistency)
model except for mortality in the high-risk population, as well as
in change from baseline in FEV1 at six months, cardiac SAEs, and
pneumonia in the low-risk population.
The results from the NMAs and pairwise MAs were consistent,
which would make significant inconsistency less likely except for
pneumonia in the low-risk population (Appendix 6; Appendix 7).
The mean baseline FEV1 of between-treatment group compar-
isons for pneumonia in the low-risk population, ranged from 1.14
L to 1.34 L (Table 6), which could be a potential effect modifier
and possibly explain the inconsistency in this outcome. Therefore
the NMA results of this outcome should be interpreted cautiously
and in relation to the results from direct comparisons.
Potential biases in the review process
Incorporating indirect comparisons increases information size and
statistical power. However it could introduce bias if there is a dif-
ference in participants, co-interventions, or trial methodology be-
tween contrasts in a network (intransitivity), which is an inherent
issue to a NMA. We took several measures to assess and minimise
intransitivity.
1. We reviewed the study population after the first draft of our
protocol and divided the entire population into high- and low-
risk populations because we thought such differences in the
study population could introduce intransitivity. We acknowledge
that blood eosinophil counts could be an effect modifier for
LABA/ICS but available data were insufficient to include them
as a covariate as a way of exploring subgroup effects.
2. We constructed summary tables organised by treatment
group pair-wise comparisons (Table 2; Table 3; Table 4; Table 5;
Table 6), for the primary outcomes in both populations and also
in pneumonia in the low-risk population to assess clinical and
methodological similarities/dissimilarities of the studies.
3. We performed NMAs and pairwise MAs to address possible
intransitivity when there was a discrepancy between them
(Appendix 6; Appendix 7).
4. We analysed several outcomes at different time points (e.g.
3, 6, and 12 months), when feasible.
5. We assessed consistency using the inconsistency models,
acknowledged a possibility of intransitivity when suspected, and
interpreted the results accordingly.
Agreements and disagreements with other
studies or reviews
There are an increasing number of systematic reviews comparing
LAMA/LABA with existing maintenance inhalers (Farne 2015;
Oba 2016a; Oba 2016b). Our results are essentially similar to the
existing reports but there are some differences in data collection
and interpretations of the results.
Chen 2017 concluded that, “LAMA were associated with a greater
reduction in acute exacerbations and fewer adverse effects com-
pared with LABA.” They analysed all severities of exacerbation
(mild, moderate, and severe), and adverse event (serious and non-
serious), including vilanterol, which was not approved or avail-
able for clinical use whereas our study analysed moderate to se-
vere and severe exacerbations and SAEs (i.e. serious only), exclud-
ing vilanterol, which would be of greater clinical relevance in our
opinion.
Horita 2017 reported “LAMA+LABA has fewer exacerbations…
And more frequent improvement in quality of life as measured
by an increase over 4 units or more of the SGRQ” compared to
LABA/ICS. They included all severities of COPD exacerbation
and analysed SGRQ responders at all time points combined to-
gether whereas we separated out moderate to severe and severe ex-
acerbations and assessed SGRQ responders at different time points
because previous reports suggested that a proportion of SGRQ
responders changed over time after study entry.
Kew 2014 compared LABA/ICS, LAMA, LABA, and placebo,
and concluded, “Quality of life and lung function were improved
most on combination inhalers (LABA and ICS) and least on ICS
alone at 6 and at 12 months.”We did not include ICS because it is
now not commonly used as monotherapy in COPD and empha-
sised clinical significance/insignificance of the reported differences
based on the recommended MCIDs.
Rodrigo 2017 concluded “The greater efficacy and comparable
safety profiles observed with LABA/LAMA combinations versus
LAMA or LABA/ICS” and “LABA/LAMA significantly reduced
moderate/severe exacerbation rate compared with LABA/ICS”,
which was based on two studies. Our pairwise analyses included
seven studies for moderate to severe exacerbations (one in the
high-risk and six in the low-risk populations) and five studies for
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severe exacerbations (one in the high-risk and four in the low-
risk populations). In addition, we performed NMAs with much
greater statistical power and addressed uncertainty surrounding
these outcomes, taking effect modifiers into consideration.
Schlueter 2016 concluded “All LAMA/LABAFDCswere found to
have similar efficacy and safety”, which agrees with our results. We
examined a class/group effect not only in LABA/LAMA combina-
tions but also in LABA/ICS combinations, LAMAs, and LABAs.
Welsh 2013 compared LABA/ICS versus tiotropium (LAMA),
and concluded, “The relative efficacy and safety of combined in-
halers and tiotropium remains uncertain” because of missing out-
come data. We examined the proportion of missing data in each
outcome, which varied widely, and downgraded the certainty of
evidence accordingly.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In conclusion, long-acting β-agonist/long-acting muscarinic an-
tagonist (LABA/LAMA), may have an advantage over LABA/
inhaled corticosteroid (ICS), to reduce chronic obstructive pul-
monary disease (COPD), exacerbations in the high-risk popula-
tion and overmonotherapies to improve participant-reported out-
comes, such as symptoms and perceived health status, in people
with or without a history of COPD exacerbations. LAMAmay be
preferred over LABA to reduce COPD exacerbations, especially in
the high-risk population. ICS-containing inhalers are associated
with an increased risk of pneumonia.
Implications for research
The efficacy of maintenance inhaler therapies appears modest at
best. Research and development of a new therapy, such as triple
combination therapy, which would have a greater impact on con-
trolling symptoms and preventing exacerbations, are much de-
sired. Meanwhile further investigation on how best to use the ex-
isting inhaler therapies in subgroups of patients, such as in those
with blood eosinophilia and varying degrees of bronchial reactiv-
ity would be helpful. There is a need for more studies evaluating
COPD subpopulations or phenotypes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aaron 2007
Methods Design: randomised, double-blind, placebo-controlled, parallel-group trial
Duration: 52 weeks
Location: 27 Canadian medical centres
Participants Population: 304 adults, with a clinical history of moderate or severe COPD as defined
by ATS and GOLD criteria, were randomised to
1. tiotropium + salmeterol (148)
2. tiotropium (156)
Baseline characteristics:mean age 68 years. COPD severity moderate-severe with mean
FEV1 predicted of 38%. 56% men
Inclusion criteria: at least 1 exacerbation of COPD that required treatment with sys-
temic corticosteroids or antibiotics within the 12 months before randomisation; age >
35 years; a history of≥ 10 pack-years of cigarette smoking; documented chronic airflow
obstruction, with an FEV1/FVC ratio ≤ 0.70 and a post-bronchodilator FEV1 < 65%
of the predicted value
Exclusion criteria: history of physician-diagnosed asthma before 40 years of age; history
of physician-diagnosed chronic congestive heart failure with known persistent severe left
ventricular dysfunction; people receiving oral prednisone; people with a known hyper-
sensitivity or intolerance to tiotropium, salmeterol, or fluticasone-salmeterol; history of
severe glaucoma or severe urinary tract obstruction, previous lung transplantation or
lung volume reduction surgery, or diffuse bilateral bronchiectasis; and people who were
pregnant or were breastfeeding
Interventions Inhaler device
1. tiotropium + salmeterol: tiotropium 18 µg once daily using a HandiHaler +
salmeterol 25 µg/puff, 2 puffs twice daily using a pressurised metered-dose inhaler
using a spacer device
2. tiotropium + placebo: tiotropium, 18 µg once daily, + placebo inhaler, 2 puffs
twice daily
Allowed co-medications: as-needed albuterol, antileukotrienes, and methylxanthines
Outcomes Primary: proportion of participants with ≥ 1 exacerbation of COPD
Secondary: mean number of COPD exacerbations per patient-year; total number of
exacerbations that resulted in urgent visits to a healthcare provider or emergency depart-
ment; the number of hospitalisations for COPD; the total number of hospitalisations
for all causes; changes in health-related QoL, dyspnoea, lung function
Notes Funding: Canadian Institutes of Health Research and OntarioThoracic Society
Identifiers: ISRCTN29870041
Risk of bias
Bias Authors’ judgement Support for judgement
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Aaron 2007 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation was done through central
allocation of a randomisation schedule that
was prepared from a computer-generated
random listing of the 3 treatment alloca-
tions, blocked in variable blocks of 9 or 12
and stratified by site
Allocation concealment (selection bias) Low risk Randomisation was done through central
allocation of a randomisation schedule that
was prepared from a computer-generated
random listing of the 3 treatment alloca-
tions, blocked in variable blocks of 9 or 12
and stratified by site
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The assembled data from the visit for the
suspected exacerbation were presented to a
blinded adjudication committee for review,
and the committee confirmed whether
the encounter met the study definition of
COPD exacerbation. The statistician who
performed the analysis was initially blinded
to patient group assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of people who stopped
drug therapy was high but even in both
groups. 74 (47%) participants withdrew
from the tiotropium + placebo group and
64 (43%) participants on salmeterol +
tiotropium group but the breakdown for
withdrawal was similar between tiotropium
vs tiotropium + salmeterol arms
Selective reporting (reporting bias) Low risk The study reported results for all listed pri-
mary and secondary outcomes
Agusti 2014
Methods Design: a randomized, double-blind, double-dummy, multicentre, parallel-group study
Duration: 12 weeks
Location: Belgium, France, Germany, Italy, Philippines, Poland, Russian Federation,
Spain, Ukraine
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Agusti 2014 (Continued)
Participants Population
1. Fluticasone propionate/salmeterol (500/50 µg) 262
2. Fluticasone furoate/vilanterol (100/25 µg) 266
Baseline characteristics: age 62.9 (SD 8.59) female:male 95:433
Inclusion criteria
Adults aged > 40 years, with a smoking history of o10 pack-years and a postbronchodila-
tor FEV1/FVC ratio of < 0.70 and a FEV1 < 70% predicted. Patients had to have
experienced at least one moderate COPD exacerbation (requiring treatment with oral
corticosteroid/antibiotic) or severe exacerbation (leading to hospitalisation) within the
past 3 years
Exclusion criteria
A current diagnosis of asthma, serious underlying disease or infections, hospitalisation
due to COPD within 12 weeks of screening, or acute worsening of COPD (defined as
use of corticosteroids or antibiotics) within 6 weeks of screening
Interventions 1. Fluticasone furoate 100 µg/vilanterol 25 µg once daily
2. Fluticasone propionate 500 µg/salmeterol 50 µg twice daily
Inhaler device: ELLIPTA DPI
Allowed co-medications: salbutamol as needed, ipratropium, mucolytics
Outcomes Primary: CFB trough in 24-h weighted-mean FEV1 on treatment day 84
Notes Funding: GlaxoSmithKline
Identifiers: NCT01342913, 113107
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The study used an interactive voice-re-
sponse system as a means for central allo-
cation of drug in accordance with the ran-
domisation schedule
Allocation concealment (selection bias) Low risk The study used an interactive voice-re-
sponse system as a means for central allo-
cation of drug in accordance with the ran-
domisation schedule
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The investigator and treating physician
were blinded till an emergency arose
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Agusti 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low in both included
groups (6.1 % in salmeterol/fluticasone
propionate and 8.65 in fluticasone furo-
rate/vilanterol group)
Selective reporting (reporting bias) Low risk Trial registration located. Outcomes well
reported
Anzueto 2009
Methods Design: randomised, double-blind, parallel-group, multicentre study
Duration: 52 weeks (+ 4-week run-in)
Location: 98 centres in the USA and Canada
Participants Population: 797 participants were randomised to
1. salmeterol alone (403)
2. salmeterol/fluticasone combination therapy (394)
Baseline characteristics
Age (mean years): salmeterol 65.3, salmeterol/fluticasone 65.4
% male: salmeterol 57, salmeterol/fluticasone 51
% FEV1 predicted (pre bronchodilator): salmeterol 33.9, salmeterol/fluticasone 34.1
Pack-years (mean): salmeterol 56.5, salmeterol/fluticasone 57.8
Inclusion criteria: > 40 years of age with a diagnosis of COPD, history of cigarette
smoking 10 pack-years, a pre-albuterol FEV1/FVC 0.70, a FEV 150% of predicted
normal and a documented history of ≥ 1 COPD exacerbations the year prior to the
study that required treatment with antibiotics, OCS, and/or hospitalisation
Exclusion criteria: current diagnosis of asthma, a respiratory disorder other thanCOPD,
historical or current evidence of a clinically significant uncontrolled disease, or had a
COPD exacerbation that was not resolved at screening
Interventions 1. Salmeterol 50 µg twice daily (LABA)
2. Salmeterol/fluticasone 50/250 µg twice daily (LABA/ICS
Inhaler device: Diskus
Allowed co-medications: as-needed albuterol was provided for use throughout the study.
As-needed ipratropiumwas not provided; however, it could be used during the study. The
use of concurrent inhaled long-acting bronchodilators (beta2-agonist and anticholiner-
gic), ipratropium/albuterol combination products, oral beta-agonists, ICS, leukotriene
modifiers, inhaled nedocromil and cromolyn, theophylline preparations, ritonavir and
other investigational medications were not allowed during the treatment period. OCS
and antibiotics were allowed for the acute treatment of a COPD exacerbation
Outcomes Annual rate of moderate/severe exacerbations, time to first moderate/severe exacerbation,
the annual rate of exacerbations requiring OCS, and pre-dose FEV1. Diary records and
health status measured on the SGRQ
Notes Funding: GlaxoSmithKline
Identifiers: NCT00115492, GSK NCT00115492
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Anzueto 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The study used an interactive voice-re-
sponse system as a means for central allo-
cation of drug in accordance with the ran-
domisation schedule
Allocation concealment (selection bias) Low risk The study used an interactive voice-re-
sponse system as a means for central allo-
cation of drug in accordance with the ran-
domisation schedule
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (assumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The investigator and treating physician
were blinded till an emergency arose
Incomplete outcome data (attrition bias)
All outcomes
High risk The withdrawal rates were very high, 39%
discontinued in salmeterol arm and 32%
in salmeterol/fluticasone arm. More par-
ticipants were withdrawn due to lack of
efficacy and exacerbation with salmeterol/
fluticasone arm compared with salmeterol
arm (8.2% vs 5.3%)
Selective reporting (reporting bias) Low risk Study reported all outcomes stated in the
protocol
Asai 2013
Methods Design: multicentre, randomised, open-label, parallel-group study
Duration: 52 weeks
Location: 35 centres in Japan
Participants Population
1. Indacaterol/glycopyrrolate 110 µg/50 µg (QVA149) (119)
2. Tiotropium (39)
Baseline characteristics: age 69.3 (SD 6.8), female:male 95.6:4.4%
Inclusion criteria: severe stable COPD (stage 2 or stage 3), a smoking history of at least
10 pack-years, postbronchodilator FEV1 ≥ 30% and < 80% of the predicted normal,
and postbronchodilator FEV1/FVC ≤ 0.7 at visit 2
Exclusion criteria: pregnant women or nursing mothers, concomitant pulmonary dis-
ease, a history of asthma, malignancy of any organ system, certain cardiovascular comor-
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Asai 2013 (Continued)
bid conditions, and alpha-1 antitrypsin deficiency
Interventions Inhaler device
1. QVA149 (indacaterol/glycopyrrolate 110 µg/50 µg) once daily delivered via
Concept1
2. tiotropium (18 µg once daily) delivered via HandiHaler
Allowed co-medications: not described
Outcomes Primary: number of participants with AEs, SAEs or death
Notes Funding: Novartis
Identifiers: NCT01285492, CQVA149A1301, ARISE
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout was relatively low but uneven
between 2 groups (14.0% in indacaterol/
glycopyrrolate and 2.6 % in tiotropium
group)
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
Bateman 2013
Methods Design: multicentre, randomised, double-blind, parallel-group, placebo- and active-
controlled trial
Duration: 26 weeks (+ 2-week run-in)
Location: academic and clinical research centres inEurope,NorthAmerica, SouthAmer-
ica, Asia (India, Japan, Philippines), Australia, China, South Africa and Taiwan
Participants Population: 2143 participants were randomised to
1. indacaterol/glycopyrrolate (474)
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Bateman 2013 (Continued)
2. indacaterol (477)
3. glycopyrronium (475)
4. open-label tiotropium (483)
5. placebo (234)
We did not include placebo arm in this analysis.
Baseline characteristics:
Age (mean years): indacaterol 63.6, glycopyrronium 64.3, tiotropium 63.5, placebo 64,
4
% male: indacaterol 74.4, glycopyrronium 77.2, tiotropium 75.0, placebo 72.8
% FEV1 predicted: indacaterol 54.9, glycopyrronium 55.1, tiotropium 55.1, placebo
55.2
Inclusion criteria: participants were aged 40 years, had moderate-severe stable COPD
(GOLD stages 2 or 3 (2008 criteria)), and a smoking history of 10 pack-years. At
screening, they were required to have a post-bronchodilator FEV1 > 30% and < 80% of
predicted normal and postbronchodilator FEV1/FVC ≤ 0.70
Exclusion criteria: respiratory tract infectionwithin 4weeks prior to visit 1; concomitant
pulmonary disease; history of asthma; lung cancer or a history of lung cancer; history
of certain cardiovascular comorbid conditions; known history and diagnosis of alpha-
1 antitrypsin deficiency; in the active phase of a supervised pulmonary rehabilitation
programme; contraindicated for inhaled anticholinergic agents and 2 agonists; other
protocol-defined inclusion/exclusion criteria may apply
Interventions 1. Indacaterol 150 µg once daily (LABA)
2. Glycopyrronium 50 µg once daily (LAMA)
3. Tiotropium 18 µg once daily (LAMA): open-label
4. Placebo (placebo)
Inhaler device: all medications were administered once daily in the morning via the
Breezhaler® device except for tiotropium, which was administered open-label via the
HandiHaler® device
Allowed co-medications: participants remained on a stable dose of ICS and salbutamol/
albuterol was available for use as rescue medication throughout the study
Outcomes Trough FEV1, dyspnoea, health status measured on the SGRQ score, rescue medication
use and safety
Notes Funding: Novartis
Identifiers: NCT01202188
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No specific details of sequence generation
but done electronically and presumed valid
Allocation concealment (selection bias) Low risk Eligible patients were assigned a randomi-
sation number via Interactive Response
Technology (IRT), linking the patient to
a treatment arm and specific unique med-
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Bateman 2013 (Continued)
ication number for the study drug. The
randomisation number was not communi-
cated to the investigator contacting the IRT
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding procedures were sound, but
tiotropium was delivered open-label which
introduced bias for these comparisons.
Blinding of participants, investigator staff,
personnel performing assessments and data
analysts was maintained by ensuring ran-
domisation data remained strictly confi-
dential and inaccessible to anyone involved
in the study until the time of unblind-
ing. In addition, the identity of the treat-
ments was concealed by the use of study
drugs that were all identical in packaging,
labelling, and schedule of administration,
appearance, taste and odour. Unblinding
occurred in the case of emergencies and at
the conclusion of the study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropoutwas relatively low and even among
active comparators (8.0% in indacaterol/
glycopyrronium, 11.7% in indacaterol,
11.2% in glycopyrronium, and 8.7% in
tiotropium) and more than 99% were in-
cluded in the analysis
Selective reporting (reporting bias) Low risk Prospectively registered and well reported
with additional online supplemental mate-
rial available
BI 205.137 2001
Methods See Brusasco 2003
Participants Population: 385 participants were randomised to salmeterol (192) and tiotropium (193)
See Brusasco 2003
Interventions See Brusasco 2003
Outcomes See Brusasco 2003
Notes Funding: Boehringer Ingelheim
Identifiers: NCT02173691
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BI 205.137 2001 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Brusasco 2003
Allocation concealment (selection bias) Low risk See Brusasco 2003
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See Brusasco 2003
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See Brusasco 2003
Incomplete outcome data (attrition bias)
All outcomes
Low risk See Brusasco 2003
Selective reporting (reporting bias) Low risk See Brusasco 2003
Bogdan 2011
Methods Design: randomised, double-blind, placebo-controlled, parallel-group, multinational,
phase 3, efficacy and safety study
Duration: 12 weeks
Location: Bulgaria, Japan, Romania, Russian Federation, Ukraine
Participants Population
1. Formoterol 4.5 µg twice daily (206)
2. Formoterol 9 µg twice daily (199)
Baseline characteristics: age 66.75 years (SD 9.4), female:male 74:539
Inclusion criteria
• Men or women aged > 40 with a clinical diagnosis of COPD and current COPD
symptoms
• Current or previous smoker with a smoking history of 10 or more pack-years
• Lung function parameters: FEV1/FVC ≤ 70%, post-bronchodilator and post-
bronchodilator FEV1 < 80% of predicted normal value
Exclusion criteria
• History and/or current clinical diagnosis of asthma or atopic diseases such as
allergic rhinitis
• Use of inhaled glucocorticosteroids within 4 weeks prior to visit 2
• Any relevant cardiovascular disorder as judged by the investigator or any current
respiratory tract disorder other than COPD
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Bogdan 2011 (Continued)
Interventions Inhaler device
1. Formoterol Turbuhaler 4.5 µg
2. Formoterol Turbuhaler 9 µg
3. Turbuhaler placebo
Allowed co-medications: salbutamol as rescue, short-acting anticholinergics
Outcomes Primary: FEV1 (L) 60 min post-dose
Notes Funding: AstraZeneca
Identifiers: NCT00628862, D5122C00001
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low and even between 2
groups (5.3% in formoterol 4.5 and 8.5%
in formoterol 9 group)
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
Briggs 2005
Methods Design: randomised, double-blind, double-dummy, parallel-group study
Duration: 12 weeks
Location: 50 centres located in 8 countries, including Finland, Greece, Italy, Portugal,
Sweden, Turkey, UK and USA
Participants Population n = 653
1. Tiotropium: (328)
2. Salmeterol (325)
Baseline characteristics: mean age (tiotropium: 64.2 years, salmeterol 64.6 years); gen-
der (tiotropium 65%male, salmeterol 68%male); mean % predicted FEV1 (tiotropium
37.7%, salmeterol 37.7%); mean smoking pack-year history (tiotropium 55.6 years, sal-
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Briggs 2005 (Continued)
meterol 56.1 years)
Inclusion criteria: aged≥ 40 years, cigarette smoking history of≥ 10 pack-years, clinical
diagnosis of COPD, with FEV1 % predicted ≤ 60% and FVC ≤ 70%
Exclusion criteria: history of asthma, allergic rhinitis, atopy or a total (absolute) blood
eosinophil count ≥ 600 mm; significant medical condition that could preclude partici-
pation for the full duration of the trial or interfere with the interpretation of the study
results; taking systemic corticosteroids at unstable doses or in daily doses of≥ 10 mg (or
its equivalent); using beta-blockers, cromones, or anti-leukotrienes prior to enrolment
in the trial; experienced a respiratory tract infection or a COPD exacerbation within
30 days of randomisation; using oxygen for > 1 h/d and unable to refrain from its use
during pulmonary function testing; actively participating in a rehabilitation programme
or had completed such a programme during the previous 30 days
Interventions 1. Tiotropium, 18 µg once daily via the HandiHaler device; or
2. Salmeterol, 2 actuations of 25 µg each, twice daily via a metered-dose inhaler
Inhaler device: HandiHaler device for tiotropium, MDI for salmeterol
Allowed co-medications: as-needed albuterol, ICS
Outcomes Primary: the co-primary efficacy outcomes were average post-dose FEV1 over 12 h and
peak FEV1 after 12 weeks of treatment. Average FEV1 was estimated from the AUC
from 0-12 h. Secondary: secondary outcomes including morning pre-dose FEV1, FEV1
at each time point over 12 h, corresponding FVC parameters, incidence and frequency of
COPD exacerbations (the number or percentage of participants with at least one COPD
exacerbation, time to first exacerbation, number of exacerbations, and exacerbation days)
, rescue medication use, and incidence of SAEs
Notes Funding: Boehringer Ingelheim and Pfizer
Identifiers: 205.264
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Boehringer Ingelheim generated the ran-
domisation list using a validated system,
which involved a pseudo-random number
generator so that the resulting treatment
sequence was both reproducible and non-
predictable
Allocation concealment (selection bias) Low risk All investigational medication for each par-
ticipant was identified by a unique med-
ication number. Each eligible participant
was assigned the lowest medication num-
ber available to the investigator at the time
of randomisation
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Briggs 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Boehringer Ingelheim was responsible for
preparing and coding study medication in
a blinded fashion (Boehringer Ingelheim
study drug and control were indistinguish-
able). Participants, investigators and study
personnel remained blinded with regard to
the treatment assignments up to database
lock
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk In all studies, a selection of standard respi-
ratory endpoints like pulmonary function,
SGRQ, TDI, treadmill tolerance, and ex-
acerbations were used. Outcome assessors
remained blinded with regard to the treat-
ment assignments up to database lock
Incomplete outcome data (attrition bias)
All outcomes
Low risk The withdrawal rates were relatively small
and even between the groups (tiotropium
8.8%, salmeterol 12.6%)
Selective reporting (reporting bias) Unclear risk Unable to locate protocol
Brusasco 2003
Methods Design: pooled results from2 randomised, double-blind, double-dummy, parallel-group
studies
Duration: 6 months (+ 2-week run-in period)
Location: studies were performed in 18 countries The only difference in the two studies
was the duration of serial spirometry in the clinic (12 h in one study, 3 h in the second)
Participants Population: 807 participants were randomised to
1. salmeterol (405)
2. tiotropium (402)
Baseline characteristics:
Age (mean years): salmeterol, 64.1; placebo, 64.6
% male: salmeterol, 75.1; placebo, 76.3
% FEV1 predicted: salmeterol 37.7; placebo, 38.7
Pack-years (mean): salmeterol, 44.8; placebo, 42.4
Inclusion criteria: participants were required to have relatively stable airway obstruction
with FEV1 < 65% of predicted normal and < 70% of FVC, > 40 years of age, with a
smoking history of > 10 pack-years
Exclusion criteria: history of asthma, allergic rhinitis or atopy or with an increased total
eosinophil count; use of supplemental oxygen or an upper respiratory tract infection in
the 6 weeks before screening; significant disease other than COPD (significant disease
was defined as a disease that, in the opinion of the investigator, would put the patient at
risk because of participation in the study, or a disease that would influence the results of
the study.)
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Brusasco 2003 (Continued)
Interventions 1. Salmeterol 50 µg twice daily (LABA)
2. Tiotropium 18 µg once daily (LAMA)
3. Placebo (placebo)
Inhaler device: metered dose
Allowed co-medications: participants were allowed to continue previously prescribed
regular inhaled steroids or regular oral steroids, not exceeding a dose equivalent to ap-
proximately 10 mg prednisone daily. We could not find the number of participants tak-
ing these medications during the study
Outcomes Mean CFB on the SGRQ and number whose score decreased by at least 4 units; exacer-
bations (number, time to first exacerbation); hospital admissions; FEV1; FVC; dyspnoea
(evaluated using the BDI and the TDI); diary card data
Notes Funding: Boehringer Ingelheim
Identifiers: NCT02172287, NCT02173691, 205.130, and 205.137
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Boehringer Ingelheim generated the ran-
domisation list using a validated system,
which involved a pseudo-random number
generator so that the resulting treatment
sequence was both reproducible and non-
predictable
Allocation concealment (selection bias) Low risk All investigational medication for each par-
ticipant was identified by a unique med-
ication number. Each eligible participant
was assigned the lowest medication num-
ber available to the investigator at the time
of randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Boehringer Ingelheim was responsible for
preparing and coding study medication in
a blinded fashion (Boehringer Ingelheim
study drug and control were indistinguish-
able). Participants, investigators and study
personnel remained blinded with regard to
the treatment assignments up to database
lock. Double-dummy technique was used
to blind different application devices
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk In all studies, a selection of standard respi-
ratory endpoints like pulmonary function,
SGRQ, TDI, treadmill tolerance and ex-
acerbations were used. Outcome assessors
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Brusasco 2003 (Continued)
remained blinded with regard to the treat-
ment assignments up to database lock
Incomplete outcome data (attrition bias)
All outcomes
Low risk The withdrawal rates were relatively
even between groups (salmeterol 18.8%,
tiotropium 15.4%)
Selective reporting (reporting bias) Low risk Results for all expected and specified out-
comes were reported except for FEV1 out-
come (secondary outcome), which was not
reported in a way that we could include in
the quantitative synthesis
Buhl 2011
Methods Design: randomised, placebo-controlled, double-blind, double-dummy
Duration: 12 weeks
Location: 223 centres in 22 countries: Austria, Belgium, Canada, Colombia, Denmark,
Finland, France, Germany, Greece, Hungary, Israel, Italy, Mexico, Norway, Poland, Rus-
sia,
Slovakia, Spain, Switzerland, Turkey, UK and USA
Participants Population: n = 1598
1. Tiotropium (797)
2. Indacaterol (801)
Baseline characteristics
Mean age (tiotropium: 63.6 years, indacaterol 63.4 years);
Gender (tiotropium 70% male, indacaterol 67%);
Mean% predicted FEV1 (tiotropium 54.3%, indacaterol 54.6%);
Mean smoking pack-year history (tiotropium 41.8 years, indacaterol 43.2 years)
Inclusion criteria: diagnosis of COPD, smoking history of at least 10 pack-years, post-
bronchodilator FEV1 < 80% and ≥ 30%of the predicted normal value, post-bron-
chodilator FEV1/FVC ≤ 70%
Exclusion criteria: received systemic corticosteroids or antibiotics and/or were hospi-
talised for a COPD exacerbation in the 6 weeks prior to screening, respiratory tract
infection within 6 weeks prior to screening, concomitant pulmonary disease, history of
asthma, diabetes type 1 or uncontrolled diabetes type 2, lung cancer or history of lung
cancer, history of certain cardiovascular comorbid conditions
Interventions Inhaler device
1. Tiotropium, 18 µg once daily via the HandiHaler device
2. Indacaterol 150 µg delivered via a single-dose DPI
Allowed co-medications: as-needed albuterol, ICS
Outcomes Primary: trough FEV1 24 h post-dose after 12 weeks of treatment
Secondary: FEV1 AUC 5 min-4 h post-dose on day 1, week 4 and week 12. Rescue
medication use over 12 weeks. Safety and tolerability
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Buhl 2011 (Continued)
Notes Funding: Novartis
Identifiers: NCT00900731, CQAB149B2350
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The study used an interactive voice-re-
sponse system as a means for central allo-
cation of drug in accordance with the ran-
domisation schedule
Allocation concealment (selection bias) Low risk The study used an interactive voice-re-
sponse system as a means for central allo-
cation of drug in accordance with the ran-
domisation schedule
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators, study staff performing the as-
sessments and data analysts were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were low and even
(tiotropium 7.6%, indacaterol 7.5%)
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
Buhl 2015a
Methods Design: randomised, double-blind, parallel-group, multicentre
Duration: 52 weeks
Location: see Buhl 2015a&b
Participants Population: 2624 participants
1. Tiotropium 5 µg + olodaterol 5 µg fixed-dose combination once daily
2. Tiotropium 2.5 µg + olodaterol 5 µg fixed-dose combination once daily
3. Olodaterol 5 µg once daily
4. Tiotropium 5 µg once daily
5. Tiotropium 2.5 µg once daily
Baseline characteristics:mean age 64.2 years. COPD severity wasGOLD stage 2 (FEV1
50%-80% predicted) in 50% of participants, stage 3 (30%-50% predicted) in 39% of
participants, and stage 4 (< 30% predicted) in 11% of participants, with mean FEV1 of
50% predicted. 74% were men. 38% were current smokers. 48% were taking ICS. 86%
had comorbidity at baseline
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Buhl 2015a (Continued)
Inclusion criteria: outpatients aged > 40 years with a history of moderate-very severe
COPD (GOLD stage 2-4); post-bronchodilator FEV1 < 80%of predicted normal; post-
bronchodilator FEV1/FVC ≤ 70%; current or ex-smokers with a smoking history of >
10 pack-years
Exclusion criteria: clinically relevant abnormal baseline laboratory parameters or a his-
tory of asthma; MI within 1 year of screening; unstable or life-threatening cardiac ar-
rhythmia; known active TB; clinically evident bronchiectasis; cystic fibrosis or life-threat-
ening pulmonary obstruction; hospitalised for heart failure within the past year; diag-
nosed thyrotoxicosis or paroxysmal tachycardia; previous thoracotomy with pulmonary
resection; regular use of daytime oxygen if people were unable to abstain during clinic
visits; or currently enrolled in a pulmonary rehabilitation programme (or completed in
the 6 weeks before screening)
Interventions Inhaler device
1. Tiotropium 5 µg + olodaterol 5 µg fixed-dose combination via Respimat once
daily
2. Tiotropium 2.5 µg + olodaterol 5 µg fixed-dose combination via Respimat once
daily
3. Olodaterol 5 µg Respimat once daily
4. Tiotropium 5 µg Respimat once daily
5. Tiotropium 2.5 µg Respimat once daily
Allowed co-medications: as-needed salbutamol, ICS, theophylline
Outcomes Primary:
1. FEV1 AUC (0-3 h) response on day 169
2. Trough FEV1 response on day 170
3. SGRQ total score on day 169 from the 2 twin trials, Buhl 2015a
(NCT01431274) and Buhl 2015b (NCT01431287) These outcomes were also
measured at days 85 and 365
Notes Funding: Boehringer Ingelheim
Identifiers: NCT01431274, 1237.5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Buhl 2015a&b
Allocation concealment (selection bias) Low risk See Buhl 2015a&b
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See Buhl 2015a&b
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk See Buhl 2015a&b
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Buhl 2015a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk See Buhl 2015a&b
Selective reporting (reporting bias) Low risk See Buhl 2015a&b
Buhl 2015a&b
Methods Design: randomised, double-blind, parallel-group, multicentre
Duration: 52 weeks
Location: 25 countries including Australia, Brazil, Canada, South Africa USA and EU
countries, including UK
Participants Population: 5163 participants
1. Tiotropium 5 µg + olodaterol 5 µg fixed-dose combination once daily
2. Tiotropium 2.5 µg + olodaterol 5 µg fixed-dose combination once daily
3. Olodaterol 5 µg once daily
4. Tiotropium 5 µg once daily
5. Tiotropium 2.5 µg once daily
Baseline characteristics: see Buhl 2015a and Buhl 2015b
Inclusion criteria: outpatients aged > 40 years with a history of moderate-very severe
COPD (GOLD stages 2-4); post-bronchodilator FEV1 < 80% of predicted normal;
postbronchodilator FEV1/FVC < 70%; current or ex-smokers with a smoking history
of > 10 pack-years
Exclusion criteria: clinically relevant abnormal baseline laboratory parameters or a his-
tory of asthma; MI within 1 year of screening; unstable or life-threatening cardiac ar-
rhythmia; known active TB; clinically evident bronchiectasis; cystic fibrosis or life-threat-
ening pulmonary obstruction; hospitalised for heart failure within the past year; diag-
nosed thyrotoxicosis or paroxysmal tachycardia; previous thoracotomy with pulmonary
resection; regular use of daytime oxygen if people were unable to abstain during clinic
visits; or currently enrolled in a pulmonary rehabilitation programme (or completed in
the 6 weeks before screening)
Interventions Inhaler device
1. Tiotropium 5 µg + olodaterol 5 µg fixed-dose combination via Respimat once
daily
2. Tiotropium 2.5 µg + olodaterol 5 µg fixed-dose combination via Respimat once
daily
3. Olodaterol 5 µg Respimat once daily
4. Tiotropium 5 µg Respimat once daily
5. Tiotropium 2.5 µg Respimat once daily
Allowed co-medications: as-needed salbutamol, ICS, theophylline
Outcomes Primary:
1. FEV1 AUC (0-3 h) response on day 169
2. Trough FEV1 response on day 170
3. SGRQ total score on day 169 from the 2 twin trials, Buhl 2015a
(NCT01431274) and Buhl 2015b (NCT01431287). These outcomes were also
measured at days 85 and 365
111Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Buhl 2015a&b (Continued)
Notes Funding: Boehringer Ingelheim
Identifiers: NCT01431274, NCT01431287, 1237.5, 1237.6
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The study used an interactive voice-re-
sponse system as a means for central allo-
cation of drug in accordance with the ran-
domisation schedule
Allocation concealment (selection bias) Low risk The study used an interactive voice-re-
sponse system as a means for central allo-
cation of drug in accordance with the ran-
domisation schedule
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind for all arms
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrwal was uneven among compara-
tors of interest (18.3% in olodaterol 5,
13.7% in tiotropium 5 and 10.7% in
tiotropium/olodaterol 5/5 arms)
Selective reporting (reporting bias) Low risk Prospectively registered and well reported
Buhl 2015b
Methods Design: randomised, double-blind, parallel-group, multicentre
Duration: 52 weeks
Location: see Buhl 2015a&b
Participants Population: 2539 participants
1. Tiotropium 5 µg + olodaterol 5 µg fixed-dose combination once daily
2. Tiotropium 2.5 µg + olodaterol 5 µg fixed-dose combination once daily
3. Olodaterol 5 µg once daily
4. Tiotropium 5 µg once daily
5. Tiotropium 2.5 µg once daily
Baseline characteristics: mean age 63.8 years
COPD severity was GOLD stage 2 (FEV1 50%-80% predicted) in 50% of participants,
stage 3 (30%-50% predicted) in 38%, and stage 4 (< 30% predicted) in 12% of partici-
pants, with mean FEV1 of 50% predicted. 72% were men. 36% were current smokers.
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Buhl 2015b (Continued)
47% were taking ICS. 87% had comorbidity at baseline
Inclusion criteria: outpatients aged > 40 years with a history of moderate-very severe
COPD (GOLD stage 2-4); post-bronchodilator FEV1 < 80% of predicted normal;
postbronchodilator FEV1/FVC ≤ 70%; current or ex-smokers with a smoking history
of > 10 pack-years
Exclusion criteria: clinically relevant abnormal baseline laboratory parameters or a his-
tory of asthma; MI within 1 year of screening; unstable or life-threatening cardiac ar-
rhythmia; known active TB; clinically evident bronchiectasis; cystic fibrosis or life-threat-
ening pulmonary obstruction; hospitalised for heart failure within the past year; diag-
nosed thyrotoxicosis or paroxysmal tachycardia; previous thoracotomy with pulmonary
resection; regular use of daytime oxygen if people were unable to abstain during clinic
visits; or currently enrolled in a pulmonary rehabilitation programme (or completed in
the 6 weeks before screening)
Interventions Inhaler device
1. Tiotropium 5 µg + olodaterol 5 µg fixed-dose combination via Respimat once
daily
2. Tiotropium 2.5 µg + olodaterol 5 µg fixed-dose combination via Respimat once
daily
3. Olodaterol 5 µg Respimat once daily
4. Tiotropium 5 µg Respimat once daily
5. Tiotropium 2.5 µg Respimat once daily
Allowed co-medications: as-needed salbutamol, ICS, theophylline
Outcomes Primary:
1. FEV1 AUC (0-3 h) response on day 169
2. Trough FEV1 response on day 170
3. SGRQ total score on day 169 from the 2 twin trials, Buhl 2015a
(NCT01431274) and Buhl 2015b (NCT01431287) These outcomes were also
measured at days 85 and 365
Notes Funding: Boehringer Ingelheim
Identifiers: NCT01431287, 1237.6
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Buhl 2015a&b
Allocation concealment (selection bias) Low risk See Buhl 2015a&b
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See Buhl 2015a&b
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Buhl 2015b (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk See Buhl 2015a&b
Incomplete outcome data (attrition bias)
All outcomes
High risk See Buhl 2015a&b
Selective reporting (reporting bias) Low risk See Buhl 2015a&b
Buhl 2015c
Methods Design: multicentre, randomised, parallel-group, blinded study
Duration: 26 weeks
Location: Germany
Participants Population
1. Indacaterol/glycopyrronium 110/50 µg (476)
2. Tiotropium 18 µg + formoterol 12 µg (458)
Baseline characteristics: age 62.9 (SD 8.29) female:male 319:615
Inclusion criteria
1. Male or female adults aged ≥ 40 years
2. Moderate-severe COPD (GOLD 2010)
3. Smoking history of at least 10 pack-years
4. Post-bronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value and
post-bronchodilator FEV1/FVC ≤ 70%
Exclusion criteria
• Pregnant women or nursing mothers or women of child-bearing potential not
using adequate contraception
• History of long QT syndrome
• Type 1 or uncontrolled type 2 diabetes
• COPD exacerbation or respiratory tract infection within 6 weeks prior to
screening
• History of asthma
• Pulmonary lobectomy, lung volume reduction surgery, or lung transplantation
• Concomitant pulmonary disease
• Requiring LTOT (> 15 h/d)
Interventions Inhaler device
1. QVA149 (indacaterol/glycopyrronium) 110/50 µg a single-dose DPI
2. Tiotropium proprietary inhaler (HandiHaler)
3. formoterol capsules Aerolizer device
Allowed co-medications: salbutamol as a rescue and ICS
Outcomes Primary: SGRQ-C total score after 26 weeks of treatment (non-inferiority analysis)
Notes Funding: Novartis
Identifiers: NCT01574651, CQVA149ADE01
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Buhl 2015c (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A validated system that automated the ran-
dom assignment of treatment arms to ran-
domisation numbers in the specified ratio
Allocation concealment (selection bias) Low risk A validated system that automated the ran-
dom assignment of treatment arms to ran-
domisation numbers in the specified ratio
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigator staff, personnel performing
assessments, and data analysts remained
blinded from randomisation until database
lock
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low in both included
groups (12.8 % in indacaterol/glycopy-
rronium and 11.4% in tiotropium + for-
moterol)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Calverley 2003
Methods Design: randomised, double-blind, placebo-controlled, parallel-group study
Duration: 52 weeks (+ 2-week run-in)
Location: 109 centres in 15 countries or regions
Participants Population: 1022 participants were randomised to
1. formoterol (255)
2. budesonide (257)
3. formoterol/budesonide combination (254)
4. placebo (256)
Baseline characteristics:
Mean age (years): formoterol 63, budesonide 64, formoterol/budesonide 64, placebo 65
% male: formoterol 75, budesonide 74, formoterol/budesonide 78, placebo 75
% FEV1 predicted: formoterol 36, budesonide, formoterol/budesonide, placebo 36
Pack-years: formoterol 38, budesonide 39, formoterol/budesonide 39, placebo 39
Inclusion criteria: men and women > 40 years old; history of at least 10 pack-years;
COPD for at least 2 years; ≤ 70% FEV1/FVC, FEV1 < 50% predicted; ≥ 1 COPD
exacerbations requiring medication in previous 2-12 months
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Calverley 2003 (Continued)
Exclusion criteria: history of asthma or seasonal allergic rhinitis before age 40; any
relevant cardiovascular disorders or other disease
Interventions 1. Formoterol 9 µg twice daily (LABA)
2. Budesonide 400 µg twice daily (ICS)
3. Formoterol/budesonide 9/320 µg twice daily (LABA/ICS)
4. Placebo (placebo)
Inhaler device: DPI
Allowed co-medications: terbutaline (0.5 mg) as needed; maximum 3-week course of
OCS and antibiotics were allowed in the event of exacerbations; parenteral steroids and/
or nebulised treatment were allowed at emergency visits
Medications excludedduring the study periodwere oxygen therapy; beta-blocking agents;
ICSs; disodiumcromoglycate; leukotriene antagonists or 5-lipoxygenase inhibitors; other
bronchodilators; antihistamines and medications containing ephedrine
Outcomes SGRQ, COPD exacerbations, FEV1, FVC, morning and evening PEF, diary card data
Notes Funding: AstraZeneca
Identifiers: SD-039-0670
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised to treatment.
No details of sequence generation methods
but assumed to adhere to usual AstraZeneca
methods
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study reported as double-blind (partici-
pants and investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No subjective assessor-rated outcomeswere
reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal was high and uneven in the
arms of interest (formoterol, 43.5%; budes-
onide/formoterol 29.1%). Study used ITT
analysis and all hypothesis testing but no
information regarding method of imputa-
tion was provided
Selective reporting (reporting bias) Low risk Could not locate protocol but all relevant
outcomes were reported
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Calverley 2003 TRISTAN
Methods Design: randomised, double-blind, placebo-controlled, parallel-group design
Duration: 52 weeks (+ 2-week run-in period)
Location: 196 centres in 25 countries
Participants Population: 1466 participants were randomised to
1. salmeterol (372)
2. fluticasone (375)
3. salmeterol/fluticasone combination (358)
4. placebo (361)
Baseline characteristics:
Mean age (years): salmeterol 63.2, fluticasone 63.5, salmeterol/fluticasone 62.7, placebo
63.4
% male: salmeterol 70, fluticasone 69.5, salmeterol/fluticasone 75.4, placebo 75
% FEV1 predicted: salmeterol 44.3, fluticasone 45.0, salmeterol/fluticasone 44.8,
placebo 44.2
Pack-years: salmeterol 43.7, fluticasone 41.5, salmeterol/fluticasone 42.0, placebo 43.4
Inclusion criteria: 10-pack-year history of cigarette smoking; a history of cough pro-
ductive of sputum on most days for at least 3 months of the year, for at least 2 years; doc-
umented history of COPD exacerbations each year for the previous 3 years, including at
least 1 exacerbation in the last year that required oral corticosteroids and/or antibiotics; a
baseline (pre-bronchodilator) FEV1 25% to 70% of predicted normal; poor reversibility
of airflow obstruction (defined as an increase < 10% of predicted normal FEV1 value 30
min after inhalation of 400 µg salbutamol) and FEV1/FVC ratio ≤ 70%
Exclusion criteria: respiratory disorders other than COPD; received systemic corticos-
teroids, high doses of ICS or antibiotics in the 4 weeks before the 2-week run-in
Interventions 1. Salmeterol 50 µg twice daily (LABA)
2. Fluticasone 500 µg twice daily (ICS)
3. Salmeterol/fluticasone 50/500 µg twice daily (LABA/ICS)
4. Placebo (placebo)
Inhaler device: multi-dose dry powder
Allowed co-medications: inhaled salbutamol was used as relief medication throughout
the study, and regular treatment with anticholinergics, mucolytics and theophylline was
allowed. Medications not allowed during the study period were ICSs and LABAs
Outcomes SGRQ, COPD exacerbations, FEV1 (at least 6 h after medication), pretreatment FVC
and post-bronchodilator FEV1 and FVC, morning PEF, diary card data
Notes Funding: GlaxoSmithKline
Identifiers: SFCB3024
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk We used a randomisation schedule gener-
ated by the patient allocation for clinical
trials program to assign patients to study
treatment groups
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Calverley 2003 TRISTAN (Continued)
Allocation concealment (selection bias) Low risk Every participating centre was supplied
with a list of participant numbers (assigned
to patients at their first visit) and a list of
treatment numbers. Patients who satisfied
the eligibility criteria were assigned the next
sequential treatment number from the list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drugs were labelled in away to ensure
that both the participant and the investiga-
tor were unaware of the allocated treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No subjective assessor-rated outcomes and
investigators remained blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal relatively evenbut high in both
groups (salmeterol 32.0%, placebo 38.8%)
but the ITT population, consisting of all
participants who were randomised to treat-
ment and received at least 1 dose of the
study medication, was used for all analyses
of efficacy and safety. Unclear whatmethod
of imputation was used for each outcome
Selective reporting (reporting bias) Low risk All outcomes stated in the protocol were
reported in detail.
Calverley 2007
Methods Design: multicentre, randomised, double-blind, parallel-group, placebo-controlled
study
Duration: 3 years (156 weeks), (+ 3-week run-in period)
Location: 466 centres in 42 countries comprising 190 centres in USA, 134 centres in
Western Europe, 46 centres in Eastern Europe, 37 centres in Asia Pacific, and 59 centres
in other regions
Participants Population: 6184 participants were randomised to
1. salmeterol (1542)
2. fluticasone (1551)
3. salmeterol/fluticasone combination (1546)
4. placebo (1545)
Baseline characteristics:
Mean age (years): salmeterol 65.1, fluticasone 65.0, salmeterol/fluticasone 65.0, placebo
65.0
% male: salmeterol 76.3, fluticasone 75.4, salmeterol/fluticasone 75.1, placebo 76.3
% FEV1 predicted: salmeterol 43.6, fluticasone 44.1, salmeterol/fluticasone 44.3,
placebo 44.1
Pack-years: salmeterol 49.3, fluticasone 49.2, salmeterol/fluticasone 47.0, placebo 48.6
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Calverley 2007 (Continued)
Inclusion criteria:male or female current or former smokers; history of at least 10 pack-
years; clinical diagnosis of COPD; aged 40-80 years inclusive, with pre-bronchodilator
FEV1 < 60% predicted at entry to the study
Exclusion criteria: current diagnosis of asthma; current respiratory disorders other than
COPD; lung volume reduction surgery and/or transplant; serious uncontrolled disease;
evidence of alcohol, drug or solvent abuse; hypersensitivity to ICS, bronchodilators or
lactose; deficiency of alpha1-antitrypsin; exacerbation during run-in period
Interventions 1. Salmeterol 50 µg twice daily (LABA)
2. Fluticasone 500 µg twice daily (ICS)
3. Salmeterol/fluticasone 50/500 µg twice daily (LABA/ICS)
4. Placebo (placebo)
Inhaler device: multi-dose dry powder
Allowed co-medications: Ventolin as relief, inhaled long-acting bronchodilators and
long-term OCS (theophyllines long- and short-acting, SABAs and short-acting anti-
cholinergic agents allowed)
Medications not allowed during the study period were ICS, inhaled long-acting bron-
chodilators, long-term OCS and LTOT
Outcomes SGRQ, COPD exacerbations, adjusted mean change FEV1
Notes Funding: GlaxoSmithKline
Identifiers: NCT0026821, GSK SCO30003, TORCH
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from protocol: “Subjects will be as-
signed to study treatment in accordance
with the randomisation schedule, which
will be generated using the GW computer
programPatientAllocation forClinical Tri-
als.”
Allocation concealment (selection bias) Low risk Quote fromprotocol: “Subjectswill be cen-
trally randomised to one of the four treat-
ment groups via the System for Central Al-
location of Drug and will be stratified by
smoking status”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote from protocol: “Once the database
has been frozen, the treatment allocations
will be unblinded and all of the analy-
ses detailed in this document will be per-
formed. The treatment allocations will be
unblinded using standard GSK systems.
The database will be frozen by BDS Respi-
ratory Data Management, GSK”
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Calverley 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk An independent clinical end point com-
mittee, whose members were unaware of
the treatment assignments, determined the
primary cause of death and whether death
was related to COPD. No other outcomes
were assessor-rated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates quite similar but both
high by the end of the 36-month treatment
period. Acceptable methods of imputation
used in all cases. For any participant who
withdraws prematurely from the study, all
available data up to the time of discontin-
uation were included in the analyses. Mor-
tality data were collected for participants
who withdrew early
Selective reporting (reporting bias) Low risk All relevant outcomes stated in the protocol
were reported in detail
Calverley 2010
Methods Design: double-blind, double-dummy, randomised, active-controlled, parallel-group
study
Duration: 48 weeks (+ 4 week run-in)
Location: conducted at 76 centres in 8 countries across Europe
Participants Population: 718 participants were randomised to
1. formoterol (239)
2. formoterol/budesonide combination (242)
3. formoterol/beclomethasone combination (237)
Baseline characteristics
Age (mean years): budesonide/formoterol 64.1, formoterol 63.7
% male: budesonide/formoterol 81.5, formoterol 81.1
% FEV1 predicted: budesonide/formoterol 42.3, formoterol 42.5
Pack-years (mean): budesonide/formoterol 37.8, formoterol 39.7
Inclusion criteria: hospital outpatients with severe stable COPD according to the
GOLD criteria; aged 40 years with a diagnosis of symptomatic COPD for > 2 years, at
least a 20 pack-years smoking history, a post-bronchodilator FEV1 between 30% and
50% of the predicted normal and at least 0.7 L absolute value and a pre-dose FEV1/FVC
of 0.7; at least 1 exacerbation requiring medical intervention (OCS and/or antibiotic
treatment and/or need for a visit to an emergency department and/or hospitalisation)
within 2-12 months before the screening visit and to be clinically stable for the 2 months
before study entry; change in FEV1 < 12% of predicted normal value 30 min following
inhalation of 200 µg of salbutamol MDI
Exclusion criteria:history of asthma, allergic rhinitis or other atopic disease, variability of
symptoms fromday today and frequent symptoms at night and earlymorning (suggestive
of asthma); receiving LTOT or they had a lower respiratory tract infection or had been
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hospitalised for an acute COPD exacerbation within 2 months before screening or
during the run-in period. Treatment with oral, injectable or depot corticosteroids and
antibiotics, long-acting antihistamines or changes in the dose of an oral modified release
theophylline in the 2 months preceding screening and during the run-in period were
excluded
Interventions 1. Formoterol 12 µg twice daily (LABA)
2. Formoterol/budesonide 12/400 µg twice daily (LABA/ICS)
Inhaler device: DPI
Allowed co-medications: not described
Outcomes Change in pre-dose morning FEV1 and mean rate of COPD exacerbations per partici-
pant per year, FVC, PEF, SGRQ total score, 6MWD, BMI, BODE index, safety evalu-
ations including ECG
Notes Funding: Chiesi Farmaceutici
Identifier(s): NCT00476099
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation scheme followed a bal-
anced-block centre-stratified design and
was prepared via a computerised system
Allocation concealment (selection bias) Low risk Participants were centrally assigned, in each
centre, to one of the 3 treatment arms at the
end of the run-in period through an Inter-
active Voice/Web Response System (IXRS)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk On each study day, participants took both
active medications and matched placebo
twice daily, in order to maintain blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk On each study day, participants took both
active medications and matched placebo
twice daily, in order to maintain blinding.
In case of emergency, un-blinding of the
treatment code was done through IXRS
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12.3% withdrew from the combination
group and 14.2% from the formoterol
group. Judged to be relatively low and even
between groups, and the ITT population
were used using last observation carried for-
ward
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Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
Cazzola 2007
Methods Design: double-blind, double-dummy, randomised, parallel-group design
Duration: 12 weeks
Location: Italy
Participants Population 90 participants were randomised to
1. Fluticasone propionate/salmeterol 500/50 µg (30)
2. Tiotropium 18 µg (30)
3. Fluticasone propionate/salmeterol + tiotropium (30) - not included in this review.
Baseline characteristics: age 65.3. female:male 6:54
Inclusion criteria: aged ≥ 50 years, and were current or former smokers with a ≥
20 pack-year history. A baseline FEV1 < 50% of predicted, and a post-bronchodilator
FEV1/FVC ≤ 70% following salbutamol 400 µg
Exclusion criteria: current evidence of asthma as primary diagnosis; unstable respiratory
disease requiring oral/parenteral corticosteroids within 4 weeks prior to study entry;
upper or lower respiratory tract infection within 4 weeks of the screening visit; unstable
angina or unstable arrhythmias; concurrent use of medications that affected COPD; and
evidence of alcohol abuse
Interventions Inhaler device
1. Fluticasone propionate/salmeterol 500/50 µg Diskus
2. Tiotropium 18 µg HandiHaler
Allowed co-medications: salbutamol as rescue and theophylline
Outcomes Primary: mean CFB in predose FEV1 after 3-month treatment
Notes Funding: none reported
Identifiers: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised to receive
FSC, tiotropium or their combination by a
computer-generated list
Allocation concealment (selection bias) Low risk Participants were randomised to receive
FSC, tiotropium or their combination by a
computer-generated list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
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Cazzola 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low and even between in-
cluded groups
Selective reporting (reporting bias) Unclear risk Unable to locate protocol to check outcome
reporting
Chapman 2014
Methods Design: a randomised, blinded, double-dummy, parallel-group study
Duration: 12 weeks
Location: Canada, Croatia, Czech Republic, Estonia, France, Germany, Guatemala,
India, Republic of Korea, Latvia, Lithuania, Philippines, Poland, South Africa, Taiwan
Participants Population
1. Glycopyrronium 50 µg (123)
2. Tiotropium 18 µg (40)
Baseline characteristics: age 63.5 (SD 8.0), female:male 172:485
Inclusion criteria
• Moderate-severe stable COPD (stage 2 or stage 3) according to the current
GOLD 2010 criteria
• Post-bronchodilator FEV1 ≥ 30% and < 80% of the predicted normal, and a
post-bronchodilator FEV1/FVC < 0.70 at screening
• Current or ex-smokers who have a smoking history of at least 10 pack-years (e.g.
10 pack years = 1 pack/day x 10 years, or ½ pack/day x 20 years).
• Symptomatic patients, according to daily electronic diary data between visit 2
(day -14) and visit 3 (day 1), with a total score of ≥ 1 on at least 4 of the last 7 days
prior to visit 3
Exclusion criteria
• Pregnant or nursing (lactating) women
• Clinically relevant laboratory abnormality or a clinically significant condition
before visit 1 (in the judgment of the investigator, or the responsible Novartis
personnel)
• Narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or bladder-
neck obstruction or moderate-severe renal impairment or urinary retention. (BPH
patients who are stable on treatment can be considered)
• Receiving medications in the classes listed in the protocol as prohibited
Interventions Inhaler device
1. NVA237 (glycopyrronium) 50 µg inhalation capsules once daily, delivered via
DPI
2. Tiotropium 18 µg once daily delivered via HandiHaler device
Allowed co-medications: salbutamol/albuterol as rescue
Outcomes Primary: trough FEV1 after 12 weeks of treatment
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Chapman 2014 (Continued)
Notes Funding: Novartis
Identifiers: NCT01613326, CNVA237A2314
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study used an automated, interactive,
voice-response technology
Allocation concealment (selection bias) Low risk Study used an automated, interactive,
voice-response technology
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation data were kept strictly con-
fidential until the time of unblinding, and
were not accessible by anyone involved in
the conduct of the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low and even between two
groups (4.0% in glycopyrronium and 4.2%
in tiotropium group)
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
COMBINE 2017
Methods Design: randomised, open-label, parallel-group, 2-treatment arm, active-controlled,
fixed-dose, phase 4, clinical study
Duration: 24 weeks
Location: Argentina, Brazil, Chile, Dominican Republic, Ecuador, Honduras, Mexico,
Panama
Participants Population 242 participants were randomised to
1. Fluticasone propionate + salmeterol (133)
2. Budesonide + indacaterol (109)
Baseline characteristics: age 67.2 (SD 8.7) female:male 95:127
Inclusion criteria
1. Outpatients with stable COPD groups C and D according to the GOLD 2011
definition
2. Current or ex-smokers who have a smoking history of at least 10 pack-years
3. History of at least 1 exacerbation
Exclusion criteria
1. History or current diagnosis of ECG abnormalities
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COMBINE 2017 (Continued)
2. Diabetes type 1 or uncontrolled diabetes type 2 including patients with a history of
blood glucose levels consistently outside the normal range
3. BMI > 40 kg/m2
4. Lung cancer or a history of lung cancer
5. History of malignancy of any organ system
6. Uncontrolled or unstable, on permitted therapy, who in the opinion of the investiga-
tor, have clinically significant renal, cardiovascular, neurological, endocrine, immunolog-
ical, psychiatric, gastrointestinal, hepatic, or haematological abnormalities which could
interfere with the assessment of the efficacy and safety of the study treatment
7. Requiring oxygen therapy for chronic hypoxaemia
8. Respiratory tract infection within 6 weeks prior to visit 1
9. Concomitant pulmonary disease, e.g. pulmonary TB, bronchiectasis, sarcoidosis, in-
terstitial lung disorder or pulmonary hypertension
10. Known diagnosis of alpha-1 antitrypsin deficiency
11. History of lung surgery
Interventions 1. Budesonide + indacaterol
2. Fluticasone + salmeterol
Inhaler device
1. Budesonide 400 µg twice daily via Breezhaler device
2. Fluticasone 250 µg twice daily via Accuhaler device
3. Indacaterol 150 µg once daily via Breezhaler device
4. Salmeterol 50 µg twice daily via Diskus device
Allowed co-medications: “rescue medication” as needed
Outcomes Primary: CFB in Trough FEV1 (Non-inferiority Analysis)
Notes Funding: Novartis
Identifiers: NCT02055352, CQAB149BAR01
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
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Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout was relatively low but uneven be-
tween two groups (5.5% in budesonide/
formoterol and 15% in fluticasone propi-
onate/salmeterol)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
COSMOS-J 2016
Methods Design: multicentre, randomised, double-dummy study
Duration: 24 weeks
Location: 39 sites in Japan
Participants Population
1. Fluticasone propionate/salmeterol 250/50 µg (136)
2. Tiotropium 18 µg (126)
Baseline characteristics: age 68.3 (SD 7.02), female:male 20:385
Inclusion criteria
1. Male or female aged 40-80 years inclusive
2. Established clinical history of COPD (defined as per the GOLD definition)
3. Achieves a grade of ≥ 1 on mMRC at visit 1
4. Post-bronchodilator FEV1 of ≥ 30% to ≤ 80% of predicted normal
5. Post-bronchodilator FEV1/FVC ratio < 70%
6. Current or ex-smoker with a smoking history of > 10 pack-years. Ex-smokers are
required to have stopped smoking ≥ 6 months prior to visit 1. Ex-smokers who
stopped smoking < 6 months ago will be defined as current smokers.
7. QTc < 450 msec at visit 1; or for participants with bundle branch block QTc
should be < 480 msec
Exclusion criteria
1. Predominant asthma (comorbid asthma is not an exclusion criteria)
2. Medical diagnosis of narrow-angle glaucoma, prostatic hyperplasia or bladder
neck obstruction that in the opinion of the investigator should prevent them from
entering the study.
3. Known respiratory disorders other than COPD (e.g. lung cancer, sarcoidosis, TB
or lung fibrosis)
4. Has undergone lung surgery e.g. lung transplant and/or lung volume reduction
5. Had a chest X-ray indicating diagnosis other than COPD that might interfere
with the study (chest X-ray to be taken at visit 1, if participant has not had one and/or
CT image taken within 3 months of visit 1)
6. Requires regular (daily) or LTOT. (LTOT is defined as ≥ 12 h oxygen use per day)
7. Plans to start or to change the pulmonary rehabilitation programme during the
study period
8. Requires regular treatment with oral, parenteral, or depot corticosteroids
9. Serious, uncontrolled disease likely to interfere with the study (e.g. left ventricular
failure, anaemia, renal or hepatic disease or serious psychological disorders)
10. Has, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse
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11. Has a known or suspected hypersensitivity to β2-agonists, steroids,
anticholinergic treatments or any components of the formulations
Interventions Inhaler device
1. Salmeterol xinafoate / fluticasone propionate 50/250 µg Diskus
2. Tiotropium bromide 18 µg capsule
Allowed co-medications: salbutamol as rescue
Outcomes Primary: trough FEV1 after 12 weeks of treatment
Notes Funding: GlaxoSmithKline
Identifiers: NCT01762800, SCO116717
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low and even between two
groups (9.4% in tiotropium and 10.2 % in
fluticasone propionate/salmeterol group)
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
Covelli 2016
Methods Design: randomised, double-blind, double-dummy, multicentre, parallel-group study
Duration: 12 weeks
Location: Canada, Czechia, Germany, Poland, Romania, USA
Participants Population
1. Fluticasone furorate/vilanterol 100/25 µg (310)
2. Tiotropium 18 µg (313)
Baseline characteristics: age 62.6 (SD 8.03), female:male 221:402
Inclusion criteria
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1. Signed and dated written informed consent
2. Men or women ≥ 40 years of age
3. Women must be post-menopausal or using a highly effective method for
avoidance of pregnancy
4. Established clinical history of COPD by ATS/ERS definition
5. Post-albuterol spirometry criteria: FEV1/FVC ratio ≤ 0.70 and FEV1 ≥ 30 to ≤
70% of predicted normal (NHANES 3)
6. Former or current smoker ≥ 10 pack-years
7. A history of diagnosed CVD or a prior cardiovascular event including any of the
following:
i) established (i.e. by clinical signs or imaging studies) coronary artery disease
(CAD)
ii) established (i.e. by clinical signs or imaging studies) peripheral vascular (i.e.
arterial) disease (PVD))
iii) previous stroke
iv) objectively confirmed TIA (i.e. transient neurological deficit documented by
a health-care professional)
v) previous MI (note: MI within 6 months prior to visit 1 is exclusionary)
OR
1. Presence of one of the following cardiovascular risk factors (in addition to being a
former/current smoker):
i) current diagnosis of hypertension
ii) current diagnosis of hypercholesterolaemia
iii) diabetes mellitus treated with pharmacotherapy
Exclusion criteria
1. Current diagnosis of asthma
2. Other respiratory disorders including α1-antitrypsin deficiency as the underlying
cause of COPD, active TB, lung cancer, bronchiectasis (note: focal bronchiectasis is
not exclusionary), sarcoidosis, pulmonary fibrosis (note: focal fibrotic pulmonary
lesions are not exclusionary), pulmonary hypertension, interstitial lung diseases or
other active pulmonary diseases
3. Lung volume reduction surgery within previous 12 months
4. Clinically significant abnormalities not due to COPD by chest X-ray or CT scan
5. Hospitalised for poorly controlled COPD within 12 weeks of screening
6. Poorly controlled COPD 6 weeks prior to screening, defined as acute worsening
of COPD that is managed by the participant with corticosteroids or antibiotics or that
requires treatment prescribed by a physician
7. Lower respiratory infection requiring antibiotics 6 weeks prior to screening
8. A moderate or severe COPD exacerbation and/or a lower respiratory tract
infection (including pneumonia) during the run-in period
9. An abnormal, clinically significant finding in any liver chemistry, biochemical, or
haematology tests at screening (visit 1) or upon repeat prior to randomisation
10. An abnormal, clinically significant ECG finding at screening (visit 1) or upon
repeat prior to randomisation
11. An abnormal, clinically significant Holter finding at screening (visit 1) or upon
repeat prior to randomisation (subset of participants)
12. Historical or current evidence of clinically significant (in opinion of the
investigator) and unstable disease such as cardiovascular (e.g. participants requiring
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ICD, pacemaker requiring a ventricular pace rate set at > 60 bpm, uncontrolled
hypertension, New York Heart Association Class 4 (New York Heart Association,1994)
, known left ventricular ejection fraction < 30%), neurological, psychiatric, renal,
hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease)
, peptic ulcer disease, or haematological abnormalities
13. Carcinoma not in complete remission for at least 5 years
14. History of allergy or hypersensitivity to any of the study medications (e.g.
anticholinergic/muscarinic receptor antagonist, beta2-agonist, corticosteroid) or
components of the inhalation powder (e.g. lactose, magnesium stearate) or a medical
condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck
obstruction that, in the opinion of the study physician contraindicates study
participation or use of an inhaled anticholinergic. In addition, participants with a
history of severe milk protein allergy that, in the opinion of the Investigator,
contraindicates the participant’s participation will also be excluded
15. Known/suspected history of alcohol or drug abuse in the last 2 years
16. Women who are pregnant or lactating or plan to become pregnant
17. Participants medically unable to withhold albuterol/salbutamol for 4 h prior to
spirometry testing at each study visit
18. Use of certain medications such as bronchodilators and corticosteroids for the
protocol-specific times prior to visit 1 (the investigator will discuss the specific
medications)
19. LTOT or nocturnal oxygen therapy > 12 h/d
20. Participation in the acute phase of a pulmonary rehabilitation program within 4
weeks prior to screening or during the study
21. Failure to demonstrate adequate compliance defined as completion of the diary
card (completed all diary entries on at least 4 of the last 7 consecutive days), the ability
to withhold COPD medications and to keep clinic visit appointments
22. Non-compliance or inability to comply with study procedures or scheduled visits
23. History of psychiatric disease, intellectual deficiency, poor motivation or other
conditions that will limit the validity of informed consent to participate in the study
24. Affiliation with investigator site
25. Women who are pregnant or lactating or are planning on becoming pregnant
during the study
Interventions Inhaler device
1. Fluticasone furoate/vilanterol 100/25 µg inhalation powder
2. Tiotropium bromide 18 µg inhalation powder
Allowed co-medications: rescue medication (albuterol) and mucolytics at a constant
dosage
Outcomes Primary: CFB trough in 24-h weighted mean FEV1 on treatment day 84
Notes Funding: GlaxoSmithKline
Identifiers: NCT01627327, HZC115805
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk A central randomisation schedule was gen-
erated using a validated computerised sys-
tem (RandAll; GSK) and communicated
with a validated computerised voice-re-
sponse system, the Registration and Medi-
cation Ordering System (RAMOS; GSK)
Allocation concealment (selection bias) Low risk A central randomisation schedule was gen-
erated using a validated computerised sys-
tem (RandAll; GSK) and communicated
with a validated computerised voice-re-
sponse system, the Registration and Medi-
cation Ordering System (RAMOS; GSK)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigator and treating physician were
kept blinded unless amedical emergency or
a serious adverse medical condition arose
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout was uneven between 2 groups
(fluticasone furorate/vilanterol 6.1% and
tiotropium 12.4%)
Selective reporting (reporting bias) Low risk Outcomes stated on preregistered protocol
were well reported
D’Urzo 2014
Methods Design: phase 3, randomised, double-blind, placebo-controlled study
Duration: 24 weeks
Location: Australia, Canada, New Zealand, USA
Participants Population
1. Aclidinium/formoterol 400/12 µg (325)
2. Aclidinium 400 µg (337)
3. Formoterol 12 µg (332)
Baseline characteristics: age 63.9 (SD 8.9) female:male 782:887
Inclusion criteria
Patients aged ≥40 years were eligible if they were current or former smokers (≥10
pack-years) and diagnosed with stable, moderate to severe expiratory airflow obstruction
according toGOLDguidelines (postbronchodilator FEV1/FVC<70%andFEV1≥30%
and <80% predicted)
Exclusion criteria
COPD exacerbation or respiratory tract infection ≤6 weeks (≤3 months if hospital-
ized for exacerbation) before screening; clinically significant respiratory conditions (in-
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cluding asthma); clinically significant cardiovascular conditions including MI within the
previous 6 months; unstable angina; and, unstable arrhythmia that required changes in
pharmacological therapy or other intervention within the previous 6 months
Interventions 1. Inhaled aclidinium/formoterol 400/12 µg, twice daily
2. Inhaled aclidinium 400 µg, twice daily
3. Inhaled formoterol 12 µg, twice daily
4. Inhaled dose-matched placebo, twice daily
Inhaler device: multidose DPI
Allowed co-medications: albuterol/salbutamol as rescue, theophylline, ICS, OCS or
parenteral corticosteroids (≤ 10 mg/d or 20 mg every other day of prednisone) were
allowed if treatment was stable ≥ 4 weeks prior to screening
Outcomes Primary: CFB in 1-h morning post-dose FEV1, CFB in morning trough FEV1
Notes Funding: AstraZeneca
Identifiers: NCT01437397, LAC-MD-31
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Cardiac AEs were evaluated by an adjudi-
cation committee of independent cardiol-
ogists who were not participating in the
study and were blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively high but even
among the arms of interest (19.5% in
aclidinium/formoterol 400/12µg, 21.2%
in aclidinium 400µg, and 20.4% in for-
moterol 12µg)
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
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Methods Design: phase 3, long-term, randomised, double-blind, extension study
Duration: 28-52 weeks
Location: Australia, Canada, New Zealand, USA
Participants Population
1. Aclidinium/formoterol 400/12 µg (338)
2. Aclidinium 400 µg (340)
3. Formoterol 12 µg (339)
Baseline characteristics: age 63.2 (SD 8.8), female:male 435:483
Inclusion criteria
1. Completion of the treatment phase of the lead-in study, LAC-MD-31
2. Written informed consent obtained from the participant before the initiation of
any study specific procedures
3. No medical contraindication as judged by the primary investigator
4. Compliance with LAC-MD-31 study procedures and investigational product
dosing.
Exclusion criteria
1. No specific exclusion criteria
Interventions 1. Inhaled aclidinium/formoterol 400/12 µg, twice daily
2. Inhaled aclidinium 400 µg, twice daily
3. Inhaled formoterol 12 µg, twice daily
4. Inhaled dose-matched placebo, twice daily
Inhaler device:
Allowed co-medications: theophylline, ICS, oral or parenteral corticosteroids (10 mg/
d or 20 mg every other day prednisone) were allowed if treatment was stable within 4
weeks of the lead-in trial start. Albuterol (108 µg/puff ) or salbutamol (100 µg/puff ) were
the only rescue medications permitted during the study
Outcomes Primary: percentage of participants to experience any treatment-emergent AE
Notes Funding: AstraZeneca
Identifiers: NCT01572792, LAC-MD-36
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
Unclear risk Not described
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All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively high but even
among the arms of interest (15.8% in
aclidinium/formoterol 400/12µg, 14.9%
in aclidinium 400µg, and 16.7% in for-
moterol 12µg)
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
Dahl 2010
Methods Design: randomised double-blind double-dummy parallel-group study
Duration: 12 months (+ 2-week run-in period)
Location: Denmark, Germany, Russia, UK, USA (unclear how many centres)
Participants Population: 1732 participants were randomised to
1. formoterol (435),
2. two doses of indacaterol (437 and 428)
3. placebo (432)
Baseline characteristics
Mean age (years): formoterol 64, indacaterol (300 µg) 64, indacaterol (600 µg) 63,
placebo 63
%male: formoterol 80.2, indacaterol (300 µg) 80.3, indacaterol (600 µg) 76.9, placebo
81.5
% FEV1 predicted: formoterol 52.5, indacaterol 300 µg 51.5, indacaterol 600 µg 50.
8, placebo 52.0
Pack-years: formoterol 40, indacaterol 300 µg 40, indacaterol 600 µg 40, placebo 43
Inclusion criteria: men and women aged ≥ 40; clinical diagnosis of moderate-severe
COPD; history of at least 20 pack-years
Exclusion criteria: history of asthma; current respiratory tract infection or hospitalisa-
tion for COPD exacerbation within the previous 6 weeks
Interventions 1. Formoterol 12 µg twice daily (LABA)
2. Indacaterol 300 µg once daily (LABA)
3. Indacaterol 600 µg once daily (LABA)
4. Placebo (placebo)
Inhaler device: dry powder turbuhaler and single dose DPI
Allowed co-medications: fixed-dose combinations of ICS + LABA were replaced by
monotherapy ICS at an equivalent dose and regimen + salbutamol as needed. Participants
receiving ICS monotherapy continued treatment at a stable dose throughout the study.
OCS were not allowed, or a change in ICS was noted during the previous month
Outcomes SGRQ, COPD exacerbations, trough FEV1 and PEF, dyspnoea (baseline and transition
scores), diary card data, 6MWD, ECG, vital signs and haematology
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Notes Funding: Novartis
Identifier(s): NCT00393458
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised to treatment (1:1:1:1) with
stratification for smoking status (current/
ex-smoker) using an automated interactive
system
Allocation concealment (selection bias) Low risk Using an automated interactive system
(concealment assumed by automatisation)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Protocol states double-blind for partici-
pant, caregiver, investigator and outcomes
assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Efficacy results are presented for the mod-
ified ITT population including all ran-
domised participants who received at least
1 dose of study drug. Withdrawal relatively
high (indacaterol 300 22.7%; formoterol
25.7%) but reasons for dropout were sim-
ilar across the active comparators
Selective reporting (reporting bias) Low risk All stated and expected outcomes reported
in detail
Decramer 2013
Methods Design: phase 3b multicentre, 52-week treatment, randomised, blinded, double-
dummy, parallel-group efficacy study
Duration: 52 weeks
Location: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia,
Costa Rica, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary,
Iceland, India, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, Peru, Philippines,
Poland, Portugal, Romania, Russian Federation, Slovakia, South Africa, Spain, Sweden,
Switzerland, Taiwan, Thailand, Turkey, UK, Venezuela
Participants Population
1. Indacaterol 150 µg (1721)
2. Tiotropium 18 µg (1718)
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Baseline characteristics: age 64.0 (range 40-91) female:male 782:2657
Inclusion criteria
1. Men and women aged ≥ 40 years,
2. Signed informed consent form prior to initiation of any study-related procedure
3. Diagnosed with COPD at age ≥ 40 with a current diagnosis of severe COPD and
including: smoking history of at least 10 pack-years, both current and ex-smokers are
eligible.
4. A documented history of at least 1 moderate or severe exacerbation in the
previous 12 months
Exclusion criteria
1. Systemic corticosteroids and/or antibiotics for a COPD exacerbation in the 6
weeks prior to screening or during the run-in period
2. Respiratory tract infection within 6 weeks prior to screening
3. Concomitant pulmonary disease
4. History of asthma
5. Diabetes type 1 or uncontrolled diabetes type 2
6. Lung cancer or a history of lung cancer
7. History of certain cardiovascular comorbid condition
Interventions Inhaler device
1. Indacaterol 150 µg once daily delivered via DPI
2. Tiotropium 18 µg once daily delivered via HandiHaler
Allowed co-medications: as-needed albuterol or salbutamol, ICS
Outcomes Primary: trough FEV1
Notes Funding: Novartis
Identifiers: NCT00845728, QAB149B2348
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence was computer-
generated by an interactive voice-response
system (IVRS; Oracle America Inc, Red-
wood City, CA, USA)
Allocation concealment (selection bias) Low risk Randomisation sequence was computer-
generated by an interactive voice-response
system (IVRS; Oracle America Inc, Red-
wood City, CA, USA)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy trial
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively high but even
among the arms of interest (22.4% in in-
dacaterol, 19.9% in tiotropium)
Selective reporting (reporting bias) Low risk All stated and expected outcomes reported
in detail
Decramer 2014a
Methods Design: phase 3 multicentre, randomised, double-blind, double-dummy, parallel-group
study
Duration: 24 weeks
Location: France, Germany, Italy, Mexico, Peru, Poland, Romania, Russian Federation,
Ukraine, USA
Participants Population
1. Umeclidinium/vilanterol 62.5/25 µg (212)
2. Tiotropium 18 µg (208)
Baseline characteristics: age 62.9 (SD 9), female:male 261:582
Inclusion criteria
1. Outpatient
2. Signed and dated written informed consent
3. ≥ 40 years
4. Male and female participants
5. COPD diagnosis
6. ≥ 10 pack-year smoking history
7. Post-albuterol/salbutamol FEV1/FVC ratio of < 0.70 and post-albuterol/
salbutamol FEV1 ≤ to 70% predicted normal values
8. score of ≥ 2 on the mMRC
Exclusion criteria
1. Current diagnosis of asthma
2. Respiratory disorders other than COPD
3. Other diseases/abnormalities that are uncontrolled including cancer not in
remission for at least 5 years
4. Hospitalisation for COPD or pneumonia within 12 weeks prior to visit 1
5. Lung volume reduction surgery within 12 months prior to visit 1
6. Abnormal and clinically significant ECG at visit 1
7. Significantly abnormal finding from laboratory tests at visit 1
8. Use of depot corticosteroids within 12 weeks of visit 1
9. Use of oral or parenteral corticosteroids, antibiotics for lower respiratory tract
infection, or cytochrome P450 3A4 inhibitors, within 6 weeks of visit 1
10. Use of LABA/ICS product if LABA/ICS therapy is discontinued within 30 days
of visit 1
11. Use of ICS at a dose of > 1000 µg/day of fluticasone propionate or equivalent
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within 30 days of visit 1
12. Initiation or discontinuation of ICS within 30 days of visit 1
13. Use of tiotropium or roflumilast within 14 days of visit 1
14. Use of theophyllines, oral leukotriene inhibitors, long-acting oral beta-agonists, or
inhaled LABA within 48 h of visit 1
15. Oral SABAs within 12 h of visit 1
16. Use of LABA/ICS combination products only if discontinuing LABA therapy and
switching to ICS monotherapy within 48 h of visit 1 for the LABA component
17. Use of sodium cromoglycate or nedocromil sodium within 24 h of visit 1
18. Use of inhaled SABAs, inhaled short-acting anticholinergics, or inhaled short-
acting anticholinergic/SABA combination products within 4 h of visit 1
19. LTOT prescribed for > 12 h/d
20. Regular use of nebulised short-acting bronchodilators
Interventions 1. GSK573719/GW642444 (umeclidinium/vilanterol) 62.5/25 µg
2. GW642444 (vilanterol trifenatate) 25 µg
3. Tiotropium bromide 18 µg
Inhaler device: ELLIPTA DPI and the HandiHaler DPI
Allowed co-medications: albuterol as needed, ICS
Outcomes CFB trough FEV1 on day 169 (week 24)
Notes Funding: GlaxoSmithKline
Identifiers: NCT01316900, DB2113360
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Allocation concealment (selection bias) Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
Low risk Investigator and treating physician were
kept blinded unless amedical emergency or
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All outcomes a serious adverse medical condition arose
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively high but even
among the arms of interest (14.6% in
umeclidinium/vilanterol 62.5/25, 14.9%
in tiotropium group)
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
Decramer 2014b
Methods Design: a phase 3 multicentre, randomised, double-blind, double-dummy, parallel-
group study
Duration: 24 weeks
Location: Argentina, Australia, Canada, Chile, Germany, Republic of Korea, Mexico,
Romania, South Africa, USA
Participants Population
1. Umeclidinium/vilanterol 62.5/25 µg (217)
2. Tiotropium 18 µg (215)
Baseline characteristics: age 64.6 (SD 8.44) female:male 280:589
Inclusion criteria
1. Outpatient
2. Signed and dated written informed consent
3. ≥ 40 years old
4. Male and female participants
5. COPD diagnosis
6. ≥ 10 pack-year smoking history
7. Post-albuterol/salbutamol FEV1/FVC ratio of < 0.70 and post-albuterol/
salbutamol FEV1 of ≤ 70% predicted normal values
8. Score of ≥ 2 on the mMRC Dyspnea Scale
Exclusion criteria
1. Current diagnosis of asthma
2. Respiratory disorders other than COPD
3. Other diseases/abnormalities that are uncontrolled including cancer not in
remission for at least 5 years
4. Hospitalisation for COPD or pneumonia within 12 weeks prior to visit 1
5. Lung volume reduction surgery within 12 months prior to visit 1
6. Abnormal and clinically significant ECG at visit 1
7. Significantly abnormal finding from laboratory tests at visit 1
8. Use of depot corticosteroids within 12 weeks of visit 1
9. Use of oral or parenteral corticosteroids, antibiotics for lower respiratory tract
infection, or cytochrome P450 3A4 inhibitors, within 6 weeks of visit 1
10. Use of LABA/ICS product if LABA/ICS therapy is discontinued within 30 days
of visit 1
11. Use of ICS at a dose of > 1000 µg/day of fluticasone propionate or equivalent
within 30 days of visit 1
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12. Initiation or discontinuation of ICS within 30 days of visit 1
13. Use of tiotropium or roflumilast within 14 days of visit 1
14. Use of theophyllines, oral leukotriene inhibitors, long-acting oral beta-agonists, or
inhaled LABA within 48 h of visit 1
15. Oral SABAs within 12 h of visit 1
16. Use of LABA/ICS combination products only if discontinuing LABA therapy and
switching to ICS monotherapy within 48 h of visit 1 for the LABA component
17. Use of sodium cromoglycate or nedocromil sodium within 24 h of visit 1
18. Use of inhaled SABAs, inhaled short-acting anticholinergics, or inhaled short-
acting anticholinergic/SABA combination products within 4 h of visit 1
19. LTOT prescribed for > 12 h/d
20. Regular use of nebulised short-acting bronchodilators
Interventions 1. GSK573719/GW642444 (umeclidinium/vilanterol) 62.5/25 µg
2. GW642444 (vilanterol trifenatate) 25 µg
3. tiotropium bromide 18 µg
Inhaler device: ELLIPTA DPI and the HandiHaler DPI
Allowed co-medications: albuterol as needed, ICS
Outcomes Primary: CFB in clinic visit trough FEV1 at day 169
Notes Funding: GlaxoSmithKline
Identifiers: NCT01316913, DB2113374
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Allocation concealment (selection bias) Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigator and treating physician were
kept blinded unless amedical emergency or
a serious adverse medical condition arose
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Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout was relatively high and uneven
among the arms of interest (24.9% in
umeclidinium/vilanterol 62.5/25, 18.1%
in tiotropium group)
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
Donohue 2010
Methods Design: this study was performed in 2 stages in an adaptive seamless design
1. Participants randomised to receive indacaterol 75, 150, 300 µg, or 600 µg once
daily, formoterol 12 µg twice daily, or placebo, all double-blind, or open-label
tiotropium 18 µg once daily. An independent committee used predefined efficacy
criteria to select 2 indacaterol doses based on 2-week efficacy and safety data. These
were 150 and 300 µg .
2. The 4 treatment groups were the 2 selected doses of indacaterol, tiotropium, and
placebo. Treatment continued to 26 weeks, with additional participants recruited and
randomised
Duration: 26 weeks (+ 2 week run-in)
Location: 345 centres in 12 countries
Participants Population: 1683 participants were randomised to
1. indacaterol at 2 doses (416 and 416)
2. open-label tiotropium (415)
3. placebo (418) - not included in this review
Baseline characteristics
Age (mean years): indacaterol (150 µg) 63.4, indacaterol (300 µg) 63.3, tiotropium 64.
0, placebo 63.6
%male: indacaterol (150 µg) 62.3, indacaterol (300 µg) 63.2, tiotropium 64.8, placebo
61.0
% FEV1 predicted: indacaterol 150 µg 56.1, indacaterol 300 µg 56.3, tiotropium 53.
9, placebo 56.1
Pack-years (mean): indacaterol 150 µg 48.3, indacaterol 300 µg 50.8, tiotropium 50.0,
placebo 49.7
Inclusion criteria: Male and female adults aged 40 years, who have signed an informed
consent form prior to initiation of any study-related procedure. Co-operative outpatients
with a diagnosis of COPD (moderate-severe as classified by GOLD 2005 criteria) and
smoking history of at least 20 pack-years. Post-bronchodilator FEV1 < 80% and≥ 30%
of the predicted normal value. Post-bronchodilator FEV1/FVC < 70% (Post refers to
within 30 min of inhalation of 400 µg of salbutamol)
Exclusion criteria: lactating women; hospitalised for a COPD exacerbation in the 6
weeks prior to visit 1 or during the run-in period; requiring LTOT (> 15 h/d); respiratory
tract infection 6 weeks prior to visit 1; concomitant pulmonary disease, pulmonary TB,
or clinically significant bronchiectasis; history of asthma; type 1 or uncontrolled type 2
diabetes; contraindications for tiotropium; clinically relevant laboratory abnormalities
or a clinically significant abnormality; active cancer or a history of cancer with < 5
years disease-free survival time; history of long QT syndrome or whose QTc interval
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is prolonged; hypersensitivity to any of the study drugs or drugs with similar chemical
structures; treatment with the investigational drug (with further criteria); live attenuated
vaccinations within 30 days prior to visit 1, or during run-in period; known history
of non compliance to medication; unable to satisfactorily use a DPI device or perform
spirometry measurements
Interventions 1. Indacaterol 150 µg once daily (LABA)
2. Indacaterol 300 µg once daily (LABA)
3. Tiotropium 18 µg once daily (LAMA) - open-label
4. Placebo (placebo)
Inhaler device: 1, 2, and 4 via single-dose DPI, open-label tiotropium via HandiHaler
Allowed co-medications: participants could continue ICS monotherapy if stable for 1
month before screening; dose and regimen were to remain stable throughout the study.
Before the start of the run-in period, treatment with anticholinergic bronchodilators or
with 2-agonists was discontinued with appropriate washout, and participants receiving
fixed-combination 2-agonist/ICS were switched to ICS monotherapy at an equivalent
dose. All participants were supplied with albuterol for use as needed
Outcomes The primary efficacy outcome was trough FEV1 at 12 weeks. Additional analyses (not
adjusted for multiplicity) included TDI, health status SGRQ, and exacerbations. Serum
potassium, blood glucose, and QTc interval were measured
Notes Funding: Novartis
Identifier(s): NCT00463567 and CQAB149B2335S
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas performedusing an au-
tomated interactive voice-response system,
and was stratified by smoking status (cur-
rent or ex-smoker)
Allocation concealment (selection bias) Low risk Interactive voice-response system
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding procedures were sound, but
tiotropiumwas delivered open-label, which
introduced bias for these comparisons. On
completion of stage 1, the independent
dose selection committee had access to un-
blinded data. The only information com-
municated with the sponsor and investiga-
tors was the 2 selected indacaterol doses,
and personnel involved in the continuing
clinical study remained blinded for the re-
mainder of the study. The blinding of in-
dacaterol and placebo continued until the
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study database was locked at the end of
stage 2
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding procedures were sound, but
tiotropiumwas delivered open-label, which
introduced bias for these comparisons.
Double-blind (participant, caregiver, inves-
tigator, outcomes assessor)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Efficacy was evaluated for the ITT popu-
lation, comprising all randomised partici-
pants who received at least 1 dose of study
drug. Dropout was variable and generally
high across groups (ranging from 18%-
31%). 98.9% were included in the analysis
Selective reporting (reporting bias) Low risk Study was prospectively registered, and all
results were available from the published
reports and clinicaltrials.gov
Donohue 2013
Methods Design: a phase 3 multicentre, randomised, double-blind, placebo-controlled, parallel-
group study
Duration: 24 weeks
Location: Bulgaria, Canada, Chile, Czechia, Greece, Japan, Mexico, Poland, Russian
Federation, South Africa, Spain, Thailand, USA
Participants Population
1. Umeclidinium/vilanterol 62.5/25 (413)
2. Umeclidinium 62.5 (418)
Baseline characteristics: age 63.1 (SD 8.86) female:male 449: 1083
Inclusion criteria
1. Diagnosis of COPD
2. ≥ 10 pack-year history of cigarette smoking
3. Post-bronchodilator FEV1/FVC < 0.7
4. Predicted FEV1 of ≤ 70% of normal
5. mMRC dyspnoea score of ≥ 2
Exclusion criteria
1. Women who are pregnant, lactating, or planning to become pregnant
2. Respiratory disorders other than COPD, including a current diagnosis of asthma
3. Clinically significant non-respiratory diseases or abnormalities that are not
adequately controlled
4. Significant allergy or hypersensitivity to anticholinergics, beta-agonist, or the
excipients of magnesium stearate or lactose used in the inhaler delivery device
5. Hospitalisation for COPD or pneumonia within 12 weeks prior to screening
6. Lung volume reduction surgery within 12 weeks prior to screening
7. Abnormal and clinically significant ECG findings at screening
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8. Clinically significant laboratory findings at screening
9. Use of systemic corticosteroids, antibiotics for respiratory tract infections, strong
cytochrome P450 3A4 inhibitors, high-dose inhaled steroids (> 1000 µg fluticasone
propionate or equivalent), PDE4 inhibitors, tiotropium, oral beta2-agoinists, short-
and long-acting inhaled beta2-agonists, ipratropium, inhaled sodium cromoglycate or
nedocromil sodium, or investigational medicines for defined time periods prior to the
screening visit
10. Use of LTOT (≥ 12 h/d)
11. Regular use of nebulised treatment with short-acting bronchodilators
12. Participation in the acute phase of a pulmonary rehabilitation programme
13. A known or suspected history of alcohol or drug abuse
14. Affiliation with the investigational site
15. Previous use of GSK573719 or GW642444 alone or in combination, including
the combination of fluticasone furoate and GW64244
Interventions 1. GSK573719/GW64244 (umeclidinium/vilanterol) 62.5/25 µg
2. GSK573719 (umeclidinium) 62.5 µg
Inhaler device: DPI
Allowed co-medications: salbutamol (albuterol) as rescue medication was allowed. ICS
were allowed at a stable dose of 1000 µg/day of fluticasone propionate or equivalent
Outcomes Primary: CFB in trough FEV1 on day 169 (week 24)
Notes Funding: GlaxoSmithKline
Identifiers: NCT01313650, DB2113373
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A central randomisation schedule was
generated using a validated computerised
system (RandAll). Participants were ran-
domised using an automated, interactive
telephone-based system that registered and
randomised medication assignment
Allocation concealment (selection bias) Low risk A central randomisation schedule was
generated using a validated computerised
system (RandAll). Participants were ran-
domised using an automated, interactive
telephone-based system that registered and
randomised medication assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigator and treating physician were
kept blinded unless amedical emergency or
a serious adverse medical condition arose
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively high but even be-
tween the arms of interest (22.5% in ume-
clidinium 62.5µg , 19.6 % in umecli-
dinium/vilanterol 62.5/25µg group)
Selective reporting (reporting bias) Low risk Study was prospectively registered, and all
results were available from the published
reports and clinicaltrials.gov
Donohue 2015a
Methods Design: randomised, double-blind, parallel-group, double-dummy, placebo-controlled
trial
Duration: 7 countries (USA and European countries), 63 centres
Location: 12 weeks
Participants Population
1. Umeclidinium/vilanterol (353)
2. Fluticasone propionate/salmeterol (353)
Baseline characteristics
Age: 62.8 (SD 9.0) years
Male/female: 497/209
% pred FEV1: 49.4% (SD 10.9)
Inclusion criteria: % pred FEV1 30% -70%, mMRC ≥ 2, no recent exacerbation
Exclusion criteria: pregnancy/breast feeding, asthma, other respiratory disorders, clin-
ically significant comorbidities, hypersensitivity to any anticholinergic/muscarinic re-
ceptor antagonist, beta2-agonist, corticosteroid, history of COPD exacerbation: docu-
mented history of at least one COPD exacerbation in the 12 months prior to visit 1,
recent lung resection < 12 months, LTOT > 12 h/d, drug or alcohol abuse
Interventions 1. Umeclidinium/vilanterol (62.5/25 µg) once daily (LAMA/LABA)
2. Salmeterol/fluticasone (50/250 µg) twice daily (LABA/ICS)
3. Placebo
Inhaler device:
1. Dry white powder delivered via DPI (umeclidinium/vilanterol)
2. Dry white powder delivered via Accuhaler/Diskus (fluticasone propionate/
salmeterol)
Allowed co-medications: SABAs as rescue
Outcomes Primary: CFB in 24-h weighted-mean serial FEV1 on day 84
Notes Funding: GlaxoSmithKline
Identifiers: NCT01817764, DB2114930
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gen-
erated using a validated computer system
(RanAll, GSK)
Allocation concealment (selection bias) Low risk Central randomisation schedule was gen-
erated using a validated computer system
(RanAll, GSK)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study was double-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The site personnel involved in making
study assessment were aware of a partici-
pant’s treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rate was low and even be-
tween active comparators, 9.6% in umecli-
dinium/vilanterol arm and 10.8% in sal-
meterol/fluticasone arm
Selective reporting (reporting bias) Low risk Study was registered and the prespecified
outcomes were appropriately described
Donohue 2015b
Methods Design: randomised, double-blind, parallel-group, double-dummy, placebo-controlled
Duration: 12 weeks
Location: 7 countries (USA, Russia and European countries), 71 centres
Participants Population
1. Umeclidinium/vilanterol (349)
2. Fluticasone propionate/salmeterol (348)
Baseline characteristics
Age: 63.6 (SD 8.9) years
Male/female: 528/169
% pred FEV1: 49.5% (SD 10.9)
Inclusion criteria: % pred FEV1 30%-70%, mMRC ≥ 2, no recent exacerbation
Exclusion criteria: pregnancy/breast feeding, asthma, other respiratory disorders, clin-
ically significant comorbidities, hypersensitivity to any anticholinergic/muscarinic re-
ceptor antagonist, beta2-agonist, corticosteroid, history of COPD exacerbation: docu-
mented history of at least one COPD exacerbation in the 12 months prior to visit 1,
recent lung resection < 12 months, LTOT > 12 h/d, drug or alcohol abuse
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Interventions 1. Umeclidinium/vilanterol (62.5/25 µg) (LAMA/LABA)
2. Salmeterol/fluticasone (50/250 µg) twice daily (LABA/ICS)
Inhaler device:
1. Dry white powder delivered via DPI (umeclidinium/vilanterol)
2. Dry white powder delivered via Accuhaler/Diskus (fluticasone propionate/
salmeterol)
Allowed co-medications: SABA as rescue
Outcomes Primary: CFB in 24-h weighted-mean serial FEV1 on treatment day 84
Notes Funding: GlaxoSmithKline
Identifiers: NCT01879410, DB2114951
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gen-
erated using a validated computer system
(RanAll, GSK)
Allocation concealment (selection bias) Low risk Central randomisation schedule was gen-
erated using a validated computer system
(RanAll, GSK)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study was double-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The site personnel involved in making
study assessment were aware of a partici-
pant’s treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal ratewas lowand relatively even
between active comparators, 6.9% in ume-
clidinium/vilanterol arm and 10.9% in sal-
meterol/fluticasone arm
Selective reporting (reporting bias) Low risk Study was registered and the prespecified
outcomes were appropriately described
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Methods Design: phase 3, randomised, double-blind, parallel-group, active-control study
Duration: 52 weeks
Location: 127 centres in the USA
Participants Population
1. Aclidinium/formoterol 400/12 µg (392)
2. Formoterol 12 µg (198)
Baseline characteristics: age 64.2 (SD 9.4) female:male 265:325
Inclusion criteria
1. Current or former cigarette smokers with a cigarette smoking history of at least 10
pack-years
2. A diagnosis of stable moderate-severe COPD and stable airway obstruction as
defined by the GOLD criteria and stable airway obstruction.
Exclusion criteria
• Hospitalised for an acute COPD exacerbation within 3 months prior to visit 1
• Any respiratory tract infection (including the upper respiratory tract) or COPD
exacerbation in the 6 weeks before visit 1
• Any clinically significant respiratory conditions other than COPD
• Clinical history that suggests asthma as opposed to COPD
• Chronic use of oxygen therapy ≥ 15 h/d
• Clinically significant cardiovascular conditions
• Uncontrolled infection that may place the participant at risk resulting from HIV,
active hepatitis and/or with diagnosed active TB
• History of hypersensitivity reaction to inhaled anticholinergics
• Stage 2 hypertension, defined as systolic pressure of ≥ 160, and/or diastolic
pressure of ≥ 100
• Current diagnosis of cancer other than basal or squamous cell skin cancer
Interventions 1. Aclidinium bromide/formoterol fumarate
2. Formoterol fumarate
Inhaler device: multidose DPI
Allowed co-medications: as-needed albuterol, ICS and OCS or parenteral corticos-
teroids at doses 10 mg/d, theophylline and H1-antihistamine were permitted
Outcomes Primary: % participants to experience at least 1 treatment-emergent AE
Notes Funding: AstraZeneca
Identifiers: NCT01437540, LAC-MD-32
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out by assign-
ing participant identification numbers via
an interactive web-response system
Allocation concealment (selection bias) Low risk Randomisation was carried out by assign-
ing participant identification numbers via
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an interactive web-response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Major cardiac AEs were evaluated and clas-
sified according to the criteria
prespecified by 3 blinded independent ex-
pert cardiologists not participating in the
study
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout was relatively high (32.4% in
aclidinium/formoterol and 32.8% in for-
moterol) and breakdown for dropouts was
uneven. ITT population was used without
description of imputation
Selective reporting (reporting bias) Low risk Study was prospectively registered, and all
results were available from the published
reports
Dransfield 2014
Methods Design: randomised, multicentre, double-blind, double-dummy, parallel-group, com-
parative studies
Duration: 12 weeks
Location
Study 1: 51 centres in 6 countries (Czech Republic, Germany, Poland, Romania, Russia,
USA)
Study 2: 48 centres in 5 countries (Italy, South Africa, Spain, Ukraine, USA)
Study 3: 68 centres in 5 countries (Germany, Romania, Russia, Ukraine, USA)
Participants Population
1. Fluticasone propionate/salmeterol 250/50 µg (927)
2. Fluticasone furorate/vilanterol 100/25 µg (931)
Baseline characteristics: age 61 (SD 9), female:male 582:1276
Inclusion criteria
1. Signed and dated written informed consent
2. Men or women ≥ 40 years of age
3. Established clinical history of COPD by ATS/ERS definition
4. Women eligible to enter and participate if of non-childbearing potential, or if of
child bearing potential, had a negative serum pregnancy test at screening, and agreed to
one of the acceptable contraceptive methods listed in protocol, used consistently and
correctly
5. Former or current smoker > 10 pack-years
6. Post-albuterol spirometry criteria: FEV1/FVC ratio ≤ 0.70 and FEV1 ≤ 70% of
predicted normal (NHANES 3)
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Exclusion criteria
1. Current diagnosis of asthma
2. Other respiratory disorders including active TB, α1-antitrypsin deficiency, lung
cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial
lung diseases or other active pulmonary diseases
3. Lung volume reduction surgery within previous 12 months
4. Clinically significant abnormalities not due to COPD by chest X-ray
5. Hospitalised for poorly controlled COPD within 12 weeks of screening
6. Poorly controlled COPD 6 weeks prior to screening, defined as acute worsening
of COPD that is managed by the participant with corticosteroids or antibiotics or that
requires treatment prescribed by a physician
7. Lower respiratory infection requiring antibiotics 6 weeks prior to screening
8. Uncontrolled or clinically significant (in opinion of PI) cardiovascular,
hypertension, neurological, psychiatric, renal, hepatic, immunological, endocrine,
peptic ulcer disease, or haematological abnormalities
9. Carcinoma not in complete remission for at least 5 years
10. History of hypersensitivity to study medications (e.g. beta-agonists,
corticosteroid) or components of inhalation powder (e.g. lactose, magnesium stearate)
11. History of severe milk protein allergy that, in opinion of study physician,
contraindicates participation
12. Known/suspected history of alcohol or drug abuse in the last 2 years
13. Women who are pregnant or lactating or plan to become pregnant
14. Medically unable to withhold albuterol and/or ipratropium 4 h prior to
spirometry testing at each study visit
15. Use of certain medications such as bronchodilators and corticosteroids for the
protocol-specific times prior to visit 1 (the PI will discuss the specific medications)
16. LTOT or nocturnal oxygen therapy > 12 h/d
17. Participation in the acute phase of a pulmonary rehabilitation programme within
4 weeks prior to screening or during the study
18. Non-compliance or inability to comply with study procedures or scheduled visits
Interventions Inhaler device
1. Fluticasone furoate/vilanterol: inhalation powder 100/25 µg
2. Fluticasone propionate/salmeterol: inhalation powder 250/50 µg
Allowed co-medications: as-needed albuterol, ipratropium and mucolytics
Outcomes Primary: CFB trough in 24-h weighted mean FEV1 on treatment day 84
Notes Funding: GlaxoSmithKline
Identifiers: NCT01323621; NCT01323634;NCT01706328, HZC112352;
HZC113109; RLV116974
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
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(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Allocation concealment (selection bias) Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The investigator and treating physician
were blinded until an emergency arose
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout low in both included groups (9.
3% in fluticasone furorate/vilanterol and
9.1% in fluticasone propionate/salmeterol
group)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Feldman 2016
Methods Design: multicentre, randomised, blinded, double-dummy, parallel-group study
Duration: 12 weeks
Location: Argentina, Canada, Chile, Denmark, France, Germany, Italy, Republic of
Korea, Romania, Russian Federation, South Africa, Ukraine, USA
Participants Population
1. Umeclidinium 62.5 µg (509)
2. Tiotropium 18 µg (508)
Baseline characteristics: age 64.2 (SD 8.2), female:male 282:735
Inclusion criteria
1. Outpatients
2. Signed and dated written informed consent prior to study participation required.
3. ≥ 40 years of age at visit 1
4. Male and female participants eligible to participate in the study.
Exclusion criteria
Pregnancy, a current diagnosis of asthma or other significant respiratory disorder or other
condition that may affect respiratory function (e.g., unstable or life-threatening cardiac
disease, a neurological condition), lung volume reduction surgery, or hospitalization for
COPD/pneumonia within 12 weeks prior to Visit 1. Patients were also excluded for the
use of long-term oxygen therapy (prescribed for .12 hours per day) and use of COPD
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maintenance medications other than study medication, with the exception of ICSs
Interventions Inhaler device:
1. Umeclidinium: DPI
2. Tiotropium: Handihaler
Allowed co-medications: albuterol/salbutamol for use as a rescue medication, ICSs
Outcomes Primary: CFB in trough FEV1 on day 85
Notes Funding: GlaxoSmithKline
Identifiers: NCT02207829, GSK201316
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Allocation concealment (selection bias) Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigator and treating physician were
kept blinded unless amedical emergency or
a serious adverse medical condition arose
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low and even between two
groups.(8.3% in umeclidinium 6.7% in
tiotropium group)
Selective reporting (reporting bias) Low risk Study was prospectively registered, and all
results were available from the published
reports
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Methods Design: randomised, double-blind, parallel-group study
Duration: 12 months (+ 4-week run-in)
Location: 94 research sites in the USA and Canada
Participants Population: 782 people were randomised to
1. salmeterol (388)
2. fluticasone/salmeterol combination (394)
Baseline characteristics
Age (mean years): salmeterol 65.0, fluticasone/salmeterol 64.9
% male: salmeterol 52, fluticasone/salmeterol 58
% FEV1 predicted: salmeterol 32.8, fluticasone/salmeterol 32.8
Pack-years (mean): salmeterol 54.4, fluticasone/salmeterol 58.5
Inclusion criteria: ≥ 40 years of age with a diagnosis of COPD; a cigarette smoking
history of ≥ 10 pack-years, a pre-albuterol FEV1/FVC ≤ 0.70, a FEV1 ≤ 50% of
predicted normal and a history of ≥ 1 exacerbations of COPD in the year prior to the
study that required treatment with OCS, antibiotics, or hospitalisation
Exclusion criteria: diagnosis of asthma, a significant lung disease other than COPD,
a clinically significant and uncontrolled medical disorder including but not limited to
cardiovascular, endocrine or metabolic, neurological, psychiatric, hepatic, renal, gastric,
and neuromuscular diseases, or had a COPD exacerbation that was not resolved at
screening
Interventions 1. Salmeterol 50 µg twice daily (LABA)
2. Salmeterol/fluticasone 50/250 µg twice daily (LABA/ICS)
Inhaler device: Diskus DPI
Allowed co-medications: as-needed albuterol was provided for use throughout the
study. The use of concurrent inhaled long-acting bronchodilators (beta2-agonist and
anticholinergic), ipratropium/albuterol combination products, oral beta-agonists, ICSs,
and theophylline preparations were not allowed during the treatment period.
OCS and antibiotics were allowed for the acute treatment of COPD exacerbations
Outcomes COPD exacerbations, pre-dose FEV1, diary records of dyspnoea, night-time awakenings
due to COPD, and use of supplemental albuterol
Notes Funding: GlaxoSmithKline
Identifiers: NCT00144911, GSK SCO40043
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centre-based randomisation schedule
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout high and fairly even (30% vs
38%). More participants in salmeterol
arm compared with salmeterol/fluticasone
group were discontinued from the study
due to lack of efficacy and exacerbation
Selective reporting (reporting bias) Low risk Study was prospectively registered, and all
results were available from the published
reports and clinicaltrials.gov
Ferguson 2016
Methods Design: multicentre, randomised, double-blind, parallel-group study
Duration: 52 weeks
Location: 88 centres in 6 countries: Bulgaria (5), Finland (4), Hungary (10), Romania
(10), Spain (8), USA (51)
Participants Population: 615 participants randomised to
1. indacaterol/glycopyrrolate 27.5/15.6 µg twice daily (204)
2. indacaterol/glycopyrrolate 27.5/31.2 µg twice daily (204) - not included in this
review
3. indacaterol 75 µg daily (207)
Baseline characteristics
Age (mean): indacaterol/glycopyrrolate 27.5/15.6 (64.7), indacaterol/glycopyrrolate 27.
5/31.2 (63.9), indacaterol 75 (62.8)
Male (%): indacaterol/glycopyrrolate 27.5/15.6 (64.2), indacaterol/glycopyrrolate27.5/
31.2 (60.3), indacaterol 75 (72)
FEV1 L (pre BD): indacaterol/glycopyrrolate 27.5/15.6 (1.254), indacaterol/glycopy-
rrolate 27.5/31.2 (1.232), indacaterol 75 (1.278)
Current smokers (%): indacaterol/glycopyrrolate 27.5/15.6 (49.5), indacaterol/glycopy-
rrolate 27.5/31.2 (51.5), indacaterol 75 (51.7)
Inclusion criteria
Male and female, aged ≥ 40 years with stable COPD according to GOLD 2011;
moderate-to-severe airflow limitation, as indicated by post-bronchodilator FEV1≥ 30%
and < 80% of the predicted normal and a post-bronchodilator FEV1/FVC ratio < 0.70
at run-in; current or ex-smokers, smoking history of at least 10 pack-years; symptomatic,
as defined by a mMRC dyspnoea scale, Grade ≥ 2
Exclusion criteria
History of asthma or concomitant pulmonary disease or with a significant disease other
than COPD that could significantly confound the trial results or preclude trial com-
pletion (including cardiovascular, neurological, endocrine, immunological, psychiatric,
gastrointestinal, hepatic, or hematological abnormalities); COPD exacerbation that re-
quired treatment with antibiotics and/or systemic corticosteroids and/or hospitalisation
in the 6 weeks prior to visit 1
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Interventions 1. Indacaterol/glycopyrrolate (27.5/15.6 µg twice daily); 1 capsule (between 0700-
1100) and (between 1900-2300)
2. Indacaterol/glycopyrrolate (27.5/31.2 µg twice daily); 1 capsule (between 0700-
1100) and (between 1900-2300)
3. Indacaterol (75 µg daily).
Inhaler device: Neohaler
Allowed co-medications:
Each participant was provided with salbutamol/albuterol inhaler, which was permitted
for use as rescue medication throughout study. Nebulised salbutamol/albuterol was not
permitted. Participants had to use electronic diary to capture use of the rescue inhaler
Outcomes AEs, bronchodilator effect on mean trough FEV1 pre-dose 15 min and 45 min at week
52 and on FEV1 and FVC at all post-baseline time points, vital signs, ECG, laboratory
evaluations and time to first moderate or severe exacerbation, COPD symptoms reported
and number of puffs/day of rescue medication during 52 week treatment
Notes Funding: Novartis Pharmaceuticals Corp
Identifiers: NCT01682863
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly allocated to
treatment group in a 1:1:1 ratio (with strat-
ification for smoking status, ICS use, and
severity of airflow limitation) using inter-
active response technology
Allocation concealment (selection bias) Low risk All eligible participants were randomised
via interactive response technology (con-
cealment assumed by automatisation)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (participant,
care provider, investigator, outcomes asses-
sor)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind (participant,
care provider, investigator, outcomes asses-
sor)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively high but even in the
included arms, 13.2% in indacaterol/gly-
copyrrolate group and 11.6% in the inda-
caterol group. Efficacy was assessed in the
full analysis set, which included all ran-
domised participants who received at least
one dose of the study drug; participants in
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the full analysis set were analysed according
to the treatment to which they were ran-
domised
Selective reporting (reporting bias) Low risk All outcomes were reported in the results
summary on clinicaltrials.gov
Ferguson 2017
Methods Design: phase 3B, 6-month, double-blind, double-dummy, randomised, parallel-group,
multicentre exacerbation study
Duration: 26 weeks
Location: Argentina, Bulgaria, Chile, Czechia, Germany, Mexico, Poland, Puerto Rico,
South Africa, Spain, USA
Participants Population
1. Budesonide/formoterol 320/9 µg (606)
2. Formoterol 9 µg (613)
Baseline characteristics: age 63.5 (SD 8.67) female:male 521:698
Inclusion criteria
1. Current clinical diagnosis of COPD with COPD symptoms for > 1 year,
according to the GOLD criteria
2. Current or previous smoker with a smoking history equivalent to ≥ 10 pack-years
(1 pack year = 20 cigarettes smoked per day for 1 year)
3. Post-bronchodilator FEV1/FVC < 0.7 (70%) and FEV1 ≤ 70% of predicted
normal value
4. Documented use of a short-acting inhaled bronchodilator (β2-agonists or
anticholinergics) as rescue medication within 6 months prior to study start
5. Score of ≥ 2 on the mMRC dyspnoea scale.
6. Documented history of ≥ 1 moderate or severe COPD exacerbation(s) that
required treatment with systemic corticosteroids (a minimum 3-day course of an OCS
treatment or single depot corticosteroid injection), or hospitalisation (defined as an
inpatient stay or > 24-h stay in an observation area in the emergency department or
other equivalent facility depending on the country and healthcare system) within 2-52
weeks before visit 1 (i.e. not within the 14 days prior to visit 1). A history of an
exacerbation treated exclusively with antibiotics will not be considered adequate.
Exclusion criteria
1. A history of asthma at or after 18 years of age.
2. Significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart
failure (including significant cor pulmonale), uncontrolled hypertension as defined by
the investigator, or any other relevant cardiovascular disorder as judged by the
investigator
3. Known homozygous alpha-1 antitrypsin deficiency
4. Any significant disease or disorder (e.g. gastrointestinal, liver, renal, neurological,
musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical
impairment) which, in the opinion of the investigator, may either put the participant at
risk because of participation in the study, or influence the results of the study, or the
participant’s ability to participate in the study
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5. A history of malignancy (except basal cell carcinoma) within the past 5 years.
6. Active TB, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary
pulmonary hypertension, interstitial lung disease, or other active pulmonary diseases.
7. Participants who have needed additions or alterations to their usual maintenance
or change in formulation of rescue therapy for COPD due to worsening symptoms
within the 14 days prior to visit 1 and up to Visit 3
8. A chest radiograph (frontal and lateral) with suspicion of pneumonia or other
condition/abnormality that will require additional investigation/treatment, or put the
participant at risk because of participation in the study
9. Risk factors for pneumonia: immune suppression (HIV, lupus) or other risk for
pneumonia (e.g. neurological disorders affecting control of the upper airway, such as
Parkinson’s disease, and myasthenia gravis.)
10. Pneumonia not resolved within 14 days of visit 1
11. Moderate/severe COPD exacerbation that has not resolved within 14 days prior to
visit 1 or a moderate/severe COPD exacerbation that occurs between visit 1 and Visit 2
12. LTOT or nocturnal oxygen therapy required for > 12 h/d
13. Participants who are currently in the intensive rehabilitation phase or scheduled
to begin new participation (intensive rehabilitation phase) in a pulmonary
rehabilitation programme during the study or have started a new pulmonary
rehabilitation program within 60 days of visit 1. Participants in the maintenance phase
of pulmonary rehabilitation programme are not excluded.
14. Treatment with oral, parenteral, or intra-articular corticosteroids within 4 weeks
prior to visit 1
15. Omalizumab or any other monoclonal or polyclonal antibody therapy taken for
any reason within 6 months prior to visit 1
Interventions Inhaler device:
1. Budesonide/formoterol: pressurised MDI
2. Formoterol: Turbohaler
Allowed co-medications: albuterol/salbutamol for as-needed rescue, ICS at a dose of≤
1000 µg·day
Outcomes Primary: rate of moderate and severe COPD exacerbations defined as: worsening of≥ 2
major symptoms or worsening of 1 major symptom together with ≥ 1 minor symptom
for ≥ 2 consecutive days
Notes Funding: AstraZeneca
Identifiers: NCT02157935, D589UC00001
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
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Allocation concealment (selection bias) Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipants and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout was relatively low but uneven be-
tween two groups (budesonide/formoterol
6.4%, formoterol 10.6%)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Fukuchi 2013
Methods Design: double-blind, parallel-group, active-controlled, phase 3 study
Duration: 12 weeks
Location: 163 centres in 9 countries (India, Japan, Korea, Philippines, Poland, Russia,
Taiwan, Ukraine, Vietnam)
Participants Population: 1293 randomised to
1. Budesonide/formoterol (636)
2. Formoterol (657)
Baseline characteristics
Age (mean): budesonide/formoterol (64.5), formoterol (65.6)
Male (%): budesonide/formoterol (87.6), formoterol (90.3)
FEV1 L (post bronchodilator): budesonide/formoterol (1.14), formoterol (1.11)
Current smokers (%): budesonide/formoterol (33.8), formoterol (34.8)
Inclusion criteria
Male and female, aged ≥ 40 years with a diagnosis of moderate-severe COPD for at
least 2 years (pre-bronchodilator FEV1 50% of predicted normal, post-bronchodilator
FEV1/FVC < 70%), a current or previous smoking history of 10 pack-years, and having
at least one COPD exacerbation in the 12 months prior to study entry were eligible to
participate in the study
Exclusion criteria
History or current clinical diagnosis of asthma or atopic disease such as allergic rhinitis;
significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart failure,
uncontrolled hypertension or any other relevant cardiovascular disorder; experiencing a
COPD exacerbation during the run-in period or within 4 weeks prior to randomisation
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that required hospitalisation and/or a course of oral or parenteral steroids and requiring
regular oxygen therapy were excluded
Interventions 1. Budesonide/formoterol 160/4.5 µg, 2 inhalations twice daily
2. Formoterol 4.5 µg, 2 inhalations twice daily
Inhaler device: Turbuhaler
Allowed co-medications: salbutamol 100 µg/actuation was available as reliever medi-
cation through the treatment period. In the case of a COPD exacerbation, participants
were permitted any medication considered necessary for their patient’s safety and well-
being at the discretion of the investigator
Outcomes Change in pre-dose FEV1 from baseline to the treatment period, 1 h post-dose, pre-dose
and1h post-dose FVC,COPDsymptoms (breathlessness, cough, night-time awakenings
due to symptoms, time to first COPD exacerbation, number of COPD exacerbations
(defined as a worsening in symptoms requiring treatment with a course of systemic
steroid or hospitalisation), health-related QoL (SGRQ) and morning and evening PEF
Notes Funding: AstraZeneca
Identifiers: NCT01069289
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised 1:1 ratio to
either treatment group. Sequence genera-
tion not described, but industry-funded so
presumed electronic
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (participant,
care provider, investigator, outcomes asses-
sor)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind (participant,
care provider, investigator, outcomes asses-
sor)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low and relatively even in the
included groups (8.5% in the formoterol
group and 6.6% in the budesonide/for-
moterol group). The analysis set for efficacy
was based on the full analysis set. Available
data represent participants who had both
baseline and on-treatment data, which is
required to be included in the analysis
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Selective reporting (reporting bias) Low risk Full results were available from the pub-
lished report and on clinicaltrials.gov in ac-
cordance with the protocol
GLOW4 2012
Methods Design: multicentre, randomised, open-label, parallel-group study
Duration: 52 weeks
Location: Japan
Participants Population
1. Glycopyrrolate 50 µg (123)
2. Tiotropium 18 µg (40)
Baseline characteristics: age 68.7 (SD 7.32), female:male 4:159
Inclusion criteria
1. Moderate-severe stable COPD (stage 2 or stage 3) according to the Gold 2008
criteria
2. Current or ex-smokers who have a smoking history of at least 10 pack-years
3. Post-bronchodilator FEV1 ≥ 30% and < 80% of the predicted normal, and
postbronchodilator FEV1/FVC < 0.7 at Visit 2 (day -7)
Exclusion criteria
1. Pregnant women or nursing mothers or women of child-bearing potential not
using an acceptable method of contraception
2. LTOT
3. Lower respiratory tract infection within 6 weeks prior to visit 1
4. Concomitant pulmonary disease
5. History of asthma
6. Lung cancer or a history of lung cancer
7. History of certain cardiovascular comorbid conditions
8. Known history and diagnosis of alpha-1 antitrypsin deficiency
9. In active phase of a supervised pulmonary rehabilitation programme
10. Contraindicated for tiotropium or ipratropium treatment or who have shown an
untoward reaction to inhaled anticholinergic agents
11. Other protocol-defined inclusion/exclusion criteria may apply
Interventions Inhaler device
1. NVA237 (glycopyrronium): Breezhaler Powder for inhalation
2. Tiotropium: HandiHaler
Allowed co-medications: as-needed albuterol
Outcomes Primary: number of participants with AEs, SAEs or death
Notes Funding: Novartis
Identifiers: NCT01119937, CNVA237A1302
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low and even in both
included groups (tiotropium 17.5%, gly-
copyrronium 15.4%)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Hagedorn 2013
Methods Design: randomised, open-label, parallel-group study
Duration: 52 weeks
Location: approximately 30 study centres in Germany
Participants Population
1. Fluticasone propionate/salmeterol 500 µg/50 µg (108)
2. Fluticasone propionate 500 µg + salmeterol 50 µg (105)
Baseline characteristics: age 64.9 (SD 8.6) female:male 62:180
Inclusion criteria
1. Diagnosis of COPD based on the ATS/ERS criteria
2. Male or female participants, aged ≥ 40 years. Women must be of non-child
bearing potential
3. Have diagnosed COPD stage 3 or 4 according to GOLD criteria: a baseline post-
bronchodilator FEV1 < 50% of predicted normal and a baseline post- bronchodilator
FEV1/FVC ratio < 70%
4. Have experienced at least 2 moderate or severe COPD exacerbations leading to
medical consultation (requiring OCS or increasing dosage of OCS and/or antibiotics
or hospitalisation) within the 12 months preceding visit 1
5. Have stable COPD medication within 4 weeks prior to visit 1 (no new
medication added and no dosage changes in medication)
6. Current or ex-smokers with a smoking history of at least 10 pack-years (number
of pack-years = (number of cigarettes per day / 20) x number of years smoked, e.g. 20
cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)
7. Are currently managed at home (outpatients), are ambulatory and able to travel to
the clinic. Participants can be treated with all relevant COPD medication. This
includes vaccines, inhaled SABA as needed, short-acting or long-acting anticholinergics
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(tiotropium), systemic beta-2-agonists, theophylline, mucolytics, antioxidants, beta-1-
agonists (for cardiovascular indication), non-invasive ventilation, LTOT and can have
cor pulmonale.
8. A signed and dated written informed consent is obtained prior to participation.
9. Able to comply with the requirements of the protocol and be available for study
visits over 52 weeks.
Exclusion criteria
1. Known other respiratory disorders or signs for other respiratory disorders (e.g.
asthma, lung cancer, sarcoidosis, TB, lung fibrosis, cystic fibrosis, bronchiectasis)
2. Known history of significant inflammatory disease, other than COPD (e.g.
rheumatoid arthritis and systemic lupus erythematosus)
3. Known to be severely alpha-1-antitrypsin deficient (PI SZ or ZZ)
4. Having undergone lung surgery (e.g. lung resection including lung volume
reduction surgery, lung transplant) or participants scheduled for surgery
5. Concurrent medication from visit 1 and for the duration of the study with any of
the prohibited medications: monoamine oxidase inhibitors and tricyclic
antidepressants, and ritonavir (a highly potent cytochrome P450 3A4 inhibitor)
6. Receiving chronic or prophylactic antibiotic therapy
7. Serious, uncontrolled disease (including serious psychological disorders) likely to
interfere with the study or impact on participants’ safety
8. Evidence of alcohol, drug or solvent abuse
9. History of depression
10. History or presence of clinically significant drug sensitivity or clinically significant
allergic reaction to corticosteroids or salmeterol
11. Moderate or severe COPD exacerbation (requiring corticosteroids or increased
dosage of corticosteroids and/or antibiotics or hospitalisation) within the 4 weeks prior
to visit 1
12. Lower respiratory tract infection within the 4 weeks prior to visit 1
13. Pregnant or lactating female and female of childbearing potential
14. Participating investigator, subinvestigator, study co-ordinator, or other employee
of a participating investigator, or is an immediate family member of the before
mentioned; employee of GlaxoSmithKline (GSK)
15. Participated in an investigational drug study within 30 days prior to visit 1
Interventions Inhaler device
1. Salmeterol/fluticasone (50 µg/500 µg) twice daily fixed combination
2. Salmeterol/fluticasone (50 µg/500 µg) twice daily separate inhalers comparator
Allowed co-medications:
Outcomes Primary:mean number of exacerbations per year: negative binomial model; mean num-
ber of exacerbations per year: Poisson model (baseline through week 52)
Notes Funding: GlaxoSmithKline
Identifiers: NCT00527826, SCO107227
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively high but even in both in-
cluded groups (salmeterol/fluticasone pro-
pionate fixed 19.4% and 24.5% in salme-
terol/fluticasone propionate free combo)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Hanania 2003
Methods Design: double-blind, placebo-controlled, parallel-group, multicentre trial
Duration: 24 weeks
Location: 76 investigative sites in the USA
Participants Population: 723 randomised to
1. fluticasone propionate 250 µg (183) - not included in this review.
2. salmeterol 50 µg (177)
3. fluticasone propionate + salmeterol in combination (178)
4. placebo (185) -not included in this review.
Baseline characteristics
Age (mean): placebo (65), salmeterol (64), fluticasone propionate (63), salmeterol/flu-
ticasone (63)
Male (%): placebo (68), salmeterol (58), fluticasone propionate (66), salmeterol/flutica-
sone (61)
FEV1 L: placebo (1.289), salmeterol (1.245), fluticasone propionate (1.313), salmeterol/
fluticasone (1.252)
Current smokers (%): placebo (47), salmeterol (51), fluticasone propionate (48), salme-
terol/fluticasone (43)
Inclusion criteria
Participants were ≥ 40 years of age, were current or former smokers with a ≥ 20 pack-
year history, and had received a diagnosis of COPD, as defined by the ATS. Baseline
FEV1/FVC ratio of ≤ 70% and a baseline FEV1 of < 65% of predicted normal, but >
0.70 L (or if ≤ 0.70 L, then > 40% of predicted normal); required to have symptoms of
chronic bronchitis and moderate dyspnoea
Exclusion criteria
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Current diagnosis of asthma; use of OCS within the past 6 weeks; abnormal clinically
significant ECG; LTOT; moderate or severe exacerbation during the run-in period; and
any significant medical disorder that would place the participant at risk, interfere with
evaluations, or influence study participation
Interventions Inhaler device
1. Fluticasone propionate 250 µg Flovent Diskus; GlaxoSmithKline, Inc)
2. Salmeterol 50 µg Serevent Diskus; GlaxoSmithKline, Inc
3. Salmeterol/Fluticasone 250 µg/50 µg Advair Diskus; GlaxoSmithKline, Inc)
4. Placebo Diskus (GlaxoSmithKline, Inc; Research Triangle Park, NC)
Allowed co-medications:
Ventolin inhalation aerosol or Ventolin nebules; GlaxoSmithKline, Inc)
Outcomes Predose FEV1 and 2-h postdose FEV1; decreases in airway obstruction due to reduced
inflammation measured by comparing changes in predose FEV1 between FSC and sal-
meterol; bronchodilation measured by changes in the 2-h postdose FEV1 between FSC
and fluticasone propionate; morning PEF; dyspnoea (assessed by TDI); supplemental
albuterol use; health status (assessed by the CRDQ) symptoms of chronic bronchitis (as-
sessed by the CBSQ); exacerbations (defined by treatment, with moderate exacerbations
requiring treatment with antibiotics and/or corticosteroids, and severe exacerbations re-
quiring hospitalisation)
Notes Funding: GlaxoSmithKline, Inc,
Identifiers: SFCA3007
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified by reversibil-
ity (defined as a 12% and 200 mL increase
in FEV1 from baseline following the ad-
ministration of 400µg albuterol) and inves-
tigative site (sequence generation not de-
scribed but study was industry-sponsored)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipant and investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipant and investigator). Reported out-
comes not subject to detection bias (exacer-
bations, all-cause mortality, AEs and with-
drawal)
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Incomplete outcome data (attrition bias)
All outcomes
Low risk A total of 218 participants (placebo group,
32%; salmeterol group, 32%; fluticasone
propionate group, 27%; and fluticasone
propionate + salmeterol in combination
group, 30%) were discontinued from the
study. The breakdown of discontinuations
were similar between fluticasone propi-
onate + salmeterol in combination and sal-
meterol groups (GSK Clinical Study Re-
port). In order to account for participant
withdrawals, endpoint was used as the pri-
mary time point and was defined as the last
on-treatment post baseline assessment ex-
cluding any data from the discontinuation
visit
Selective reporting (reporting bias) Low risk All expected
and stated outcomes were meticulously re-
ported on the manufacturer’s website as
Clinical Study Report (https://www.gsk-
clinicalstudyregister.com/files2/sfca3007-
clinical-study-report-redact-v02.pdf)
Hanania 2017
Methods Design: multicentre, randomised, double-blind, parallel-group, chronic-dosing, active-
controlled, 28-week safety extension study
Duration: 52 weeks total
Location: Australia, New Zealand, USA
Participants Population
1. Glycopyrronium/formoterol 14.4/9.6 µg (1036)
2. Glycopyrronium 14.4 µg (890)
3. Formoterol 9.6 µg (890)
4. Tiotropium 18 µg (451)
Baseline characteristics: age 62.7 (SD 8.3) female:male 1439:1818
Inclusion criteria
1. Participant in/completion of previous 24-week PINNACLE phase 3 trial
2. Male or female participants at least 40 years of age and no older than 80 at visit 1
3. Participants with an established clinical history of COPD as defined by the ATS/
ERS
4. Current or former smokers with a history of at least 10 pack-years of cigarette
smoking
5. Participants with FEV1/FVC ratio of < 0.70 and FEV1 < 80% predicted normal
and ≥ 750 mL if FEV1 < 30% of predicted normal value
6. Participants willing and, in the opinion of the investigator, able to adjust current
COPD therapy as required by the protocol
Exclusion criteria
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1. Significant diseases other than COPD, i.e. disease or condition which, in the
opinion of the investigator, may put the participant at risk because of participation in
the study or may influence either the results of the study or the participant’s ability to
participate in the study
2. Current diagnosis of asthma or alpha-1 antitrypsin deficiency
3. Other active pulmonary disease such as active TB, lung cancer, bronchiectasis,
sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary pulmonary
hypertension, or uncontrolled sleep apnoea
4. Hospitalised due to poorly controlled COPD within 3 months prior to screening
or during the screening period
5. Poorly controlled COPD, defined as acute worsening of COPD that requires
treatment with OCS or antibiotics within 6 weeks prior to screening or during the
screening period
6. Lower respiratory tract infections that required antibiotics within 6 weeks prior to
screening or during the screening period
7. Unstable ischaemic heart disease, left ventricular failure, or documented MI
within 12 months of enrolment
8. Recent history of acute coronary syndrome, percutaneous coronary intervention,
coronary artery bypass graft within the past 3 months
9. Congestive heart failure NYHA Class 3/4
10. Clinically significant abnormal 12-lead ECG
11. Abnormal liver function tests defined as ALT, AST, or total bilirubin ≥ 1.5 times
ULN at visit 1 and on repeat testing
12. Cancer not in complete remission for at least 5 years
13. History of hypersensitivity to β2-agonists, glycopyrronium or other muscarinic
anticholinergics, lactose/milk protein or any component of the MDI
Interventions Inhaler device
1. Glycopyrronium/formoterol: MDI
2. Glycopyrronium: MDI
3. Fluticasone furorate: MDI
4. Open-label tiotropium: bromide inhalation powder
5. Placebo MDI
Allowed co-medications: rescue albuterol, ICS, PDE4 inhibitor
Outcomes Primary: CFB in morning-pre-dose trough FEV1 over 52 weeks
Notes Funding: Pearl Therapeutics
Identifiers: NCT01970878, PT003008-00
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Tiotropium was open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Tiotropium was open-label
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout relatively high but even among
active comparators (glycopyrronium/for-
moterol 12.8%, glycopyrronium 12.4%,
fluticasone furorate 12.2%, tiotropium 14.
0%)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Hoshino 2013
Methods Design: A randomised, open-label, 4-way study
Duration: 16 weeks
Location: Shizuoka Japan
Participants Population
1. Fluticasone propionate/salmeterol 250/50 µg (16)
2. Tiotropium 18 µg (15)
3. Salmeterol 50 µg (14)
Baseline characteristics: age 71.2 female:male 8:52
Inclusion criteria: participants were patients > 40 years of age with a diagnosis of COPD,
a cigarette smoking history > 10 pack-years, a postbronchodilator FEV 1 < 70% of the
predicted value and ratio of FEV 1/FVC < 0.70
Exclusion criteria: a current diagnosis of asthma, a clinically significant medical disorder
(other than COPD), supplemental use of oxygen for exertion or current use of some
respiratory medications (including ICS, LABAs, tiotropium, theophylline or systemic
corticosteroids)
Interventions Inhaler device
1. Fluticasone propionate/salmeterol 250/50 µg twice daily
2. Tiotropium 18 µg once daily: HandiHaler
3. Salmeterol 50 µg twice daily
Allowed co-medications: salbutamol was permitted when necessary to relieve symp-
toms. ICSs, theophylline and systemic corticosteroids were not allowed
Outcomes Airway dimensions, as assessed by CT scans, the mean change in pulmonary function
and SGRQ at 16 weeks
Notes Funding: not described
Identifiers: none provided
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Only airway dimensions were assessed in a
blinded fashion
Incomplete outcome data (attrition bias)
All outcomes
Low risk 68 participants were randomised and 60 of
them completed the study (12% dropout
rate)
Selective reporting (reporting bias) Unclear risk We could not locate a prospectively regis-
tered protocol to check all outcomes were
reported
Hoshino 2014
Methods Design: randomised, open-label, 3-way clinical trial
Duration: 16 weeks
Location: Shizuoka Japan
Participants Population: 54 patients were randomised to
1. tiotropium 18 µg once daily (16)
2. indacaterol 150 µg once daily (20)
3. tiotropium + indacaterol once daily (18)
Baseline characteristics
Age (mean): tiotropium (73), indacaterol (69), tiotropium + indacaterol (71)
Male (%): tiotropium (100), indacaterol (90), tiotropium + indacaterol (88)
FEV1 L: tiotropium (1.48), indacaterol (1.63), tiotropium + indacaterol (1.46)
Smoking (pack-years): tiotropium (63.4), indacaterol (62.8), tiotropium + indacaterol
(57.8)
Inclusion criteria
The participants were all ex-smokers, > 40 years of age with a diagnosis of COPD, a
cigarette smoking history of > 10 pack-years, a post-bronchodilator FEV1 < 70% of the
predicted value, and an FEV1/FVC < 0.70
Exclusion criteria: current diagnosis of asthma, supplemental use of oxygen for exertion
or current use of some respiratory medications
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Interventions 1. Tiotropium 18 µg once daily
2. Indacaterol 150 µg once daily
3. Tiotropium 18 µg + indacaterol 150 µg once daily
Inhaler device
1. Tiotropium: HandiHaler (Boehringer Ingelheim Pharma, Ingelheim, Germany)
2. Indacaterol: Breezhaler (Novartis, London, UK)
Allowed co-medications: concurrent use of salbutamol was permitted when necessary
to relieve symptoms
Outcomes Primary: to evaluate the superiority of tiotropium + indacaterol treatment over
tiotropium alone or indacaterol alone in its effect on airway dimensions
Secondary: mean CFB in FEV1 and QoL to week 16. Pulmonary function, CT and
assessment of QoL
Notes Funding: unknown
Identifiers: UMIN000006724
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Only CT interpretation was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rate was relatively low and
even. 62 participants were randomised and
54 of them completed the study (13%
dropout rate)
Selective reporting (reporting bias) Low risk Trial registration was located
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Methods Design: randomised, open-label, parallel-group treatment study
Duration: 16 weeks
Location: Shizuoka Japan
Participants Population: 46 patients were randomised to
1. tiotropium 18 µg once daily + indacaterol 150 µg once daily (24)
2. fluticasone propionate/salmeterol 250/50 µg twice daily (22)
Baseline characteristics
Age (mean): tiotropium + indacaterol (72), fluticasone propionate/salmeterol (69)
Male (%): tiotropium + indacaterol (81), fluticasone propionate/salmeterol (86)
FEV1 L: tiotropium + indacaterol (1.38), fluticasone propionate/salmeterol (1.36)
Smoking (pack-years): tiotropium + indacaterol (56.2), fluticasone propionate/salme-
terol (60.4)
Inclusion criteria
The participants were all ex-smokers > 40 years of age with a diagnosis of COPD; a
cigarette smoking history > 10 pack-years; a post-bronchodilator FEV1 between 30%-
80% of predicted value, and FEV1/FVC < 0.70
Exclusion criteria: current diagnosis of asthma; clinically significant medical disorder
other than COPD; supplemental use of oxygen for exertion; or exacerbation needing
treatment with antibiotics, systemic glucocorticosteroids
Interventions 1. Tiotropium (18 µg once daily) + indacaterol (150 µg once daily)
2. Fluticasone propionate/salmeterol (50/250 µg twice daily)
Inhaler device
1. Tiotropium: HandiHaler (Boehringer Ingelheim Pharma, Ingelheim, Germany)
2. Indacaterol: Breezhaler (Novartis, London, UK)
3. Advair (Glaxo Smith Kline, London, UK)
Allowed co-medications: rescue inhaler salbutamol 200 µg (Ventolin, Glaxo Smith
Kline, London, UK) was permitted when necessary to relieve symptoms throughout
study
Outcomes Primary: to demonstrate superiority of tiotropium+ indacaterol comparedwithAdvair®
for the effect on airway dimensions
Secondary: to compare the effect of tiotropium + indacaterol versus Advair® on bron-
chodilator effect and health status during the treatment period. Pulmonary function,
CT and assessment of QoL
Notes Funding: not described.
Identifiers: none provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Only airway dimensions were assessed in a
blinded fashion.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 54 participants were randomised and 46 of
them completed the study (15% dropout
rate)
Selective reporting (reporting bias) High risk We could not locate a prospectively regis-
tered protocol to check all outcomes were
reported. SGRQ outcomes not described
in detail
Jones 2011
Methods Design: pooled data from three RCTs(Donohue 2010; Dahl 2010; Kornmann 2011)
Duration: 6 months
Location:
1. Donohue 2010: Argentina, Chile, Colombia, Czech Republic, Denmark,
Ecuador, Egypt, Estonia, France, Germany, Hungary, Israel, Italy, Republic of Korea,
Latvia, Lithuania, Netherlands, Peru, Romania, Russian Federation, Slovakia, Spain,
Switzerland, Turkey, UK
2. Dahl 2010: Argentina, Canada, Germany, India, Italy, Republic of Korea, Puerto
Rico, Spain, Sweden, Taiwan, Turkey, USA
3. Kornmann 2011: Belgium, New Zealand, USA
Participants Population
1. Tiotropium 18 µg (345)
2. Formoterol 12 µg (385)
3. Salmeterol 50 µg (284)
4. Indacaterol 150 µg (620)
5. Indacaterol 300 µg (671)
Baseline characteristics: age 64 (SD 9), female:male 31:69%
Inclusion/exclusion criteria: See Donohue 2010; Dahl 2010; Kornmann 2011
Interventions 1. Tiotropium 18 µg once daily
2. Formoterol 12 µg twice daily
3. Salmeterol 50 µg twice daily
4. Indacaterol 150 µg once daily
5. Indacaterol 300 µg once daily
Inhaler device
1. Dry powder Turbuhaler
2. Single-dose DPI (indacaterol)
Allowed co-medications: as-needed albuterol, ICS
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Outcomes SGRQ responder at 6 months from 3 studies combined (Donohue 2010; Dahl 2010;
Kornmann 2011)
Notes Funding: Novartis
Identifiers: NCT00393458 (Dahl 2010), NCT00463567 (Donohue 2010), and
NCT00567996 (Kornmann 2011)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised to treatment (1:1:1:1) with
stratification for smoking status (current/
ex-smoker) using an automated interactive
system
Allocation concealment (selection bias) Low risk Using an automated interactive system
(concealment assumed by automatisation)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Protocol states double-blind for partici-
pant, caregiver, investigator and outcomes
assessor http://www.clinicaltrials.gov/ct2/
show/NCT00393458
Incomplete outcome data (attrition bias)
All outcomes
Low risk Efficacy results are presented for the mod-
ified ITT population including all ran-
domised participants who received at least
1 dose of study drug. Withdrawal relatively
high but reasons for dropout were similar
across the active comparators
Selective reporting (reporting bias) Low risk All stated and expected outcomes reported
in detail
Kalberg 2016
Methods Design: multicentre, randomised, blinded, triple-dummy, parallel-group study
Duration: 14 weeks
Location: 86 centres across Argentina, Chile, Estonia, France, Germany, Hungary, Italy,
Peru, Poland, Romania, the Russian Federation and Slovakia
Participants Population: 961 patients were randomised
1. Umeclidinium/vilanterol (482)
2. Tiotropium + indacaterol (479)
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Baseline characteristics
Age (mean): umeclidinium/vilanterol (64), tiotropium + indacaterol (64)
Male (%): umeclidinium/vilanterol (74), tiotropium + indacaterol (71)
FEV1L (pre bronchodilator): umeclidinium/vilanterol (1.369), tiotropium+ indacaterol
(1.357)
Current smokers (%): umeclidinium/vilanterol (41), tiotropium + indacaterol (46)
Inclusion criteria
Participants were ≥ 40 years of age; had an established clinical history of COPD, were
current or former
cigarette smokers with a history of smoking of ≥ 10 pack-years; had pre- and post-
bronchodilator FEV1 values of ≤ 70 % predicted; had pre- and postbronchodilator
FEV1/FVC ratios of < 0.70; had a score of ≥ 2 on the mMRC l Dyspnea Scale; and had
a QTc interval (corrected for the heart rate, according to Fridericia’s formula) of < 450
or < 480 ms for participants with bundle branch block
Exclusion criteria
Participants were excluded from the study if they were of childbearing potential (unless
theywere practicing acceptable birth controlmethods); had a current diagnosis of asthma;
had alpha-1 antitrypsin deficiency, an active lung infection (such as TB), lung cancer,
or another clinically significant disease/abnormality; abnormal ECG; had a history of
allergy or hypersensitivity to specific medications, had been hospitalised for COPD or
pneumonia within 12 weeks prior to visit 1; had undergone lung volume reduction
surgery within 12 months prior to visit 1; were receiving LTOT; or were enrolled actively
in pulmonary rehab
Interventions 1. Umeclidinium/vilanterol 62.5/25 µg once daily + placebo (HandiHaler) +
placebo (Breezehaler)
2. Tiotropioum 18 µg once daily via a HandiHaler + indacaterol 150 µg once daily
via a Breezhaler + placebo (Ellipta inhaler)
Inhaler device
1. Ellipta
2. HandiHaler
3. Breezhaler
Allowed co-medications: all participants had albuterol provided for as-needed use
Outcomes Primary: to determine whether the efficacy of umeclidinium/vilanterol was non-inferior
to that of tiotropium + indacaterol as assessed by the trough FEV1
Secondary: weighted mean FEV1 over 0-6 h postdose at day 84, calculated from the
predose FEV1 values (obtained 30 and 5 min before dosing) and the postdose FEV1
measurements at 1, 3, and 6 h
Notes Funding: GlaxoSmithKline
Identifiers: NCT02257385; GSK116961
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Participants were randomised in accor-
dance with a centralised randomisation
schedule, using a randomisation code gen-
erated by a validated computerised system
(RandAll Version NG, GSK). Participants
were randomised using an interactive voice-
recognition system
Allocation concealment (selection bias) Low risk Computer-generated randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk All participants and investigators were
blinded to the assigned treatment during
the study. However, exact physical placebo
matches for the tiotropium and indacaterol
capsules and for the indacaterol blister
packs were not available, although they
were closely matched in colour
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Safeguards were in place to prevent the
unblinding of study personnel, and study
blinding co-ordinators independent of
other clinical trial procedureswere involved
in the preparation and administration of
treatment to participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk In total, 917 participants (95%) com-
pleted the study. The most common rea-
son for study withdrawal was AEs, which
accounted for a similar proportion of par-
ticipants withdrawing from each treatment
group
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
Kardos 2007
Methods Design: randomised, double-blind, parallel-group study
Duration: 44 weeks
Location: 95 respiratory centres in Germany
Participants Population: 994 participants were randomised to
1. salmeterol/fluticasone 50 µg/500 µg twice daily (507)
2. salmeterol 50 µg twice daily (487)
Baseline characteristics
Age (mean): salmeterol/fluticasone (63.8), salmeterol (64)
Male (%): salmeterol/fluticasone (74), salmeterol (77.6)
FEV1 L (pre bronchodilator): salmeterol/fluticasone (1.13), salmeterol (1.12)
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Current smokers (%): salmeterol/fluticasone (40.6), salmeterol (44.4)
Inclusion criteria: outpatients with severe COPD, defined according to GOLD stages
3 and 4, FEV1/FVC of ≤ 70%, age of ≥ 40 years, smoking history of ≥ 10 pack-years,
history ≥ 2 exacerbations in the last year before the study
Exclusion criteria: COPD exacerbations, hospital admissions, or change in COPD
therapy during the 4 weeks before visit 1 or run-in period. Asthma, need for LTOT or
chronic systemic steroid
Interventions Inhaler device
1. Diskus (GlaxoWellcome GmbH&Co, Bad Oldesloe, Germany)
Allowed co-medications: inhaled salbutamol was used as reliever medication, and reg-
ular treatment with short-acting bronchodilators, antioxidants/mucolytics, oral SABAs,
and theophylline
Outcomes Primary: number of moderate and severe exacerbations in each treatment group
Secondary: time to first exacerbation, prebronchodilator PEF, post-bronchodilator
FEV1, and disease-specific QoL as evaluated by the SGRQ, which investigated 3 differ-
ent domains consisting of activity, symptom, and impact scores
Notes Funding: GlaxoSmithKline
Identifiers: SCO30006
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Consecutive numbers were assigned to par-
ticipants that determined the blinded treat-
ment based on a centrally generated list
with blocks of 6. Industry-funded
Allocation concealment (selection bias) Low risk Consecutive numbers were assigned to par-
ticipants that determined the blinded treat-
ment based on a centrally generated list
with blocks of 6
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (presumed par-
ticipant and investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the study population, there were 99
withdrawals (19.5%) in the salmeterol/flu-
ticasone group and 103 (21.1%) in the sal-
meterol group, bothmainly due toAEs that
were primarily linked to COPD deteriora-
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Kardos 2007 (Continued)
tion
Selective reporting (reporting bias) Unclear risk Unable to locate protocol to check outcome
reporting
Kerwin 2012a
Methods Design: randomised, double-blind, placebo-controlled, parallel-group study, with open-
label tiotropium
Duration: 52 weeks
Location: 170 centres in 18 countries: Argentina, Canada, Chile, France, Germany,
Hungary, Israel, Italy, Korea, Mexico, Netherlands, New Zealand, Peru, Poland, Russia,
South Africa,Thailand, USA
Participants Population: 1066 patients were randomised to 1 of 3 study groups:
1. glycopyrronium bromide (NVA237) 50 µg daily (529)
2. tiotropium 18 µg daily (268)
3. placebo (269)
Baseline characteristics
Age (mean): glycopyrronium bromide 63.5 (SD 9.1), placebo 63.6 SD 9.1), tiotropium
63.9 (SD 8.2)
Male (%): glycopyrronium bromide (64.6), placebo (64.6), tiotropium (62.9)
FEV1 L (pre bronchodilator): glycopyrronium bromide 1.3 (SD 0.5), placebo (1.4 SD
0.5), tiotropium 1.3 (SD 0.5)
Current smokers (%): glycopyrronium bromide (45.3), placebo (46.3), tiotropium (44.
2)
Inclusion criteria
≥ 40 years of age, with a smoking history of ≥ 10 pack-years, a diagnosis of moderate-
severe stable COPD, post-bronchodilator FEV1 ≥ 30% and < 80% of the predicted
normal, and postbronchodilator FEV1/FVC < 0.70 were enrolled
Exclusion criteria: lower respiratory tract infection in the 6 weeks prior to screening;
concomitant pulmonary disease, history of asthma, malignancy of any organ system,
long QT syndrome at screening, symptomatic prostatic hyperplasia, bladder-neck ob-
struction, moderate/severe renal impairment, urinary retention, narrow-angle glaucoma,
a known history of α1-antitrypsin deficiency; participation in the active phase of a su-
pervised pulmonary rehabilitation programme; and contraindications for tiotropium or
ipratropium or history of adverse reactions to inhaled anticholinergics
Interventions Inhaler device:
1. Glycopyrronium bromide (NVA237) via Breezhaler® device
2. Placebo via Breezhaler® device
3. Tiotropium via HandiHaler® device
Allowed co-medications: inhaled or intranasal corticosteroids and H1 antagonists were
permitted in participants who had been stabilised on a recommended and constant dose
prior to study entry. Participants were provided with a salbutamol/albuterol inhaler to
be used as rescue medication during the study
Outcomes Trough FEV1 at week 12, dyspnoea, QoL, exacerbations
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Kerwin 2012a (Continued)
Notes Funding: Novartis
Identifiers: NCT00929110
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised 2:1:1 ratio (se-
quence generation not described, but in-
dustry-funded so presumed electronic)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively high but even be-
tween included groups (22.3% in glycopy-
rronium and 23.1% in tiotropium group)
. Efficacy was assessed in the FAS, which
included all randomised participants who
received at least one dose of the study drug;
participants in the FAS were analysed ac-
cording to the treatment towhich theywere
randomised
Selective reporting (reporting bias) Low risk Full results in the published report and
on clinicaltrials.gov in accordance with the
protocol
Kerwin 2017
Methods Design: randomized, double-dummy, parallel group, multicenter trial
Duration: 12 weeks
Location: Argentina, Estonia, Germany, Korea, Republic of, Norway, Russian Federa-
tion, South Africa, Sweden, Ukraine, United States
Participants Population
1. Umeclidinium/Vilanterol 62.5/25 µg (247)
2. Tiotropium 18 µg) (247)
Baseline characteristics: age 64.4 (SD 8.71), female:male 171:323
Inclusion criteria
40 years of age with a diagnosis of COPD according to the American Thoracic Society/
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EuropeanRespiratory Society definition, a post-salbutamol FEV1 of < 70% and >50% of
normal predicted values, amMRCDyspnea Scale score of >1 at screening, and tiotropium
was prescribed for at least 3 months prior to screening
Exclusion criteria
use of ICS or maintenance COPD medications other than tiotropium in the 3 months
prior to screening (including other LAMAs, LABAs, LAMA/LABA combinations, ICS/
LABA combinations, phosphodiesterase-4 inhibitors, theophyllines, and oral β2-ago-
nists), a current diagnosis of asthma, respiratory diseases other than COPD considered
clinically significant by the study investigator, and more than one moderate-to-severe
COPD exacerbation in the past 12 months
Interventions Inhaler device
1. Umeclidinium/Vilanterol Inhalation Powder
2. Tiotropium Inhalation Powder
Allowed co-medications: as-needed albuterol
Outcomes Primary: Change from baseline in trough FEV1 on Day 85
Notes Funding: GlaxoSmithKline
Identifiers: NCT01899742, DB2116960
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomized in a 1:1 ratio us-
ing a random code generator and assigned
to treatment group via an interactive voice/
web recognition system
Allocation concealment (selection bias) Low risk Patients were randomized in a 1:1 ratio us-
ing a random code generator and assigned
to treatment group via an interactive voice/
web recognition system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk blinded, double-dummy study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Staff involved with safety and efficacy as-
sessments were not present during dosing
in the clinic to maintain blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout rates were low and even in both
included groups (6.9 % in umeclidinium/
vilanterol group and 6.5% in tiotropium
group )
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Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Koch 2014
Methods Design: phase 3, multicentre, randomised, double-blind, double-dummy, placebo-con-
trolled, parallel-group studies
Duration: 48 weeks
Location: Argentina, Brazil, Canada, Croatia, Czech Republic, Denmark, Finland, Ger-
many,HongKong, India, Italy, Korea, Republic of,Malaysia,Norway, Philippines, South
Africa, Spain, Sweden, Thailand, Ukraine
Participants Population
1. Study 1222.13: olodaterol (5 µg) 227, formoterol (12 µg) 227
2. Study 1222.14: olodaterol (5 µg) 232, formoterol (12 µg) 233
Baseline characteristics
1. Study 1222.13 age 63.8 (8.7) female:male 198:706.
2. Study 1222.14 age 64.2 (SD 8.7) female:male 176:758
Inclusion criteria
1. Diagnosis of COPD with post-bronchodilator FEV1 < 80% of predicted normal
and a post-bronchodilator FEV1/FVC < 70% at visit 1
2. Male or female, ≥ 40 years of age
3. Current or ex-smokers with a smoking history of > 10 pack-years
Exclusion criteria
1. Clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis;
all participants with an SGOT > x2 ULN, SGPT > x2 ULN, bilirubin > x2 ULN or
creatinine > x2 ULN
2. History of asthma and/or total blood eosinophil count > 600/mm3
3. Thyrotoxicosis, paroxysmal tachycardia (> 100 BPM)
4. History of MI within 1 year of screening visit, unstable or life-threatening cardiac
arrhythmia, hospitalisation for heart failure within the past year, known active TB, a
malignancy for which patient has undergone resection, radiation therapy or
chemotherapy within last 5 years, life-threatening pulmonary obstruction, cystic
fibrosis, clinically evident bronchiectasis, significant alcohol or drug abuse
5. Previous thoracotomy with pulmonary resection
6. Currently being treated with oral beta-adrenergics or OCS medication at unstable
doses (i.e. < 6 weeks on a stable dose), or at doses > the equivalent of 10 mg of
prednisone/d or 20 mg every other day.
7. Regular use of daytime oxygen therapy for > 1 h/d
8. Completed a pulmonary rehabilitation programme in the 6 weeks prior to the
screening visit (visit 1) or currently in a pulmonary rehabilitation programme
9. Pregnant or nursing women
10. Women of childbearing potential not using two effective methods of birth control
(one barrier and one non-barrier)
Interventions Inhaler device:
1. Olodaterol via Respimat
2. Formoterol Aerolizer inhaler
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Koch 2014 (Continued)
Allowed co-medications: albuterol as needed, short-acting antimuscarinic agents,
LAMAs, ICS, and xanthines
Outcomes FEV1, TDI, SGRQ
Notes Funding:Merck
Identifiers: NCT00793624, NCT00796653, 1222.13, 1222.14
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low in both included
groups (olodaterol16%, formoterol 12%)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Kornmann 2011
Methods Design: randomised, double-blind, placebo-controlled, parallel-group study
Duration: 26 weeks
Location: 142 centres in 15 countries (Canada, Colombia, Czech Republic, Denmark,
Finland, France, Germany, Hungary, Iceland, India, Italy, Peru, Russian Federation,
Slovakia, Taiwan)
Participants Population: 998 patients were randomised to
1. indacaterol 150 µg daily (333)
2. salmeterol 50 µg twice daily (334)
3. placebo (335) - not included in this review.
Baseline characteristics
Age (mean): indacaterol 63 (SD 8.7), salmeterol 63 (SD 9.2), placebo 64 (SD 8.6)
Male (%): indacaterol (72), salmeterol (75), placebo (77)
FEV1 L (pre BD): indacaterol 1.5 (SD 0.49), salmeterol 1.5 (SD 0.49), placebo 1.5 (SD
0.47)
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Current smokers (%): indacaterol (46), salmeterol (46), placebo (45)
Inclusion criteria: ≥ 40 years with clinical diagnosis of moderate-severe COPD and
smoking history of ≥ 20 pack-years
Exclusion criteria: asthma
Interventions Inhaler device: DPI
Allowed co-medications: participants were permitted concomitant medication with
ICS, if dose and regimen were stable for 1 month prior to screening. Salbutamol was
provided for use as needed (but not < 6 h before study assessments)
Outcomes Trough FEV1 after 12 weeks, efficacy outcomes, safety and tolerability
Notes Funding: Novartis
Identifiers: NCT00567996
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1:1 ratio (with stratification for smoking
status) using an automated system
Allocation concealment (selection bias) Low risk Automated system used for randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Triple (participant, investigator, outcomes
assessor)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Triple (participant, investigator, outcomes
assessor)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively low and even be-
tween active comparators (13.2% in inda-
caterol and 15.0% in salmeterol group)
Selective reporting (reporting bias) Low risk All outcomes were reported in the results
summary on clinicaltrials.gov
Koser 2010
Methods Design: randomised, double-blind, parallel-group study
Duration: 12 weeks
Location: 16 research sites in the USA
Participants Population: 247 patients were randomised to
1. Fluticasone propionate/salmeterol 250/50 µg twice-daily (126)
2. Fluticasone propionate/salmeterol hydrofluoroalkane 230/42 µg (121)
Baseline characteristics
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Age (mean): fluticasone propionate/salmeterol Diskus (63.4), fluticasone propionate/
salmeterol MDI (61.6)
Male (%): fluticasone propionate/salmeterol Diskus (52), fluticasone propionate/salme-
terol MDI (55)
FEV1 L (pre bronchodilator): fluticasone propionate/salmeterol Diskus (1.39), flutica-
sone propionate/salmeterol MDI (1.47)
Current smokers (%): fluticasone propionate/salmeterol Diskus (62), fluticasone propi-
onate/salmeterol MDI (61)
Inclusion criteria
1. Diagnosis of COPD
2. Current or former smokers with at least a 10 pack-year history
3. Aged > 40 years
4. Post-bronchodilator FEV1 of > 0.70 L and < 70% predicted normal (or if FEV1 <
0.70 L, then > 40% of predicted normal value), and a post-albuterol FEV1/FVC ratio
of < 0.70
Exclusion criteria
1. Asthma
2. Clinically significant and uncontrolled medical disorder
3. COPD exacerbation/infection that required corticosteroids and/or antibiotics
that did not resolve within 30 days of visit 1
4. Abnormal ECG at screening
5. BMI > 40kg/m2
6. Use of nocturnal positive pressure such as CPAP or BiPAP
Interventions Inhaler device:
1. Fluticasone propionate/salmeterol: Diskus
2. Fluticasone propionate/salmeterol hydrofluoroalkane: MDI
Allowed co-medications: none
Outcomes Mean CFB in FEV1 2 h post-dose, mean CFB in morning pre-dose FEV1 and PEF
Notes Funding: GlaxoSmithKline
Identifiers:NCT00633217, ADC111117
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised treatment assignment was
provided to the investigative site by means
of an interactive voice-response system at
the time participants were randomised
Allocation concealment (selection bias) Low risk Randomised treatment assignment was
provided to the investigative site by means
of an interactive voice-response system at
the time participants were randomised
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (participant and investiga-
tor)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind (participant and investiga-
tor)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates 12.4% in the fluti-
casone propionate/salmeterol hydrofluo-
roalkane and 18.3 % in the Diskus group.
Reasons for dropout were similar between
2 groups
The primary analysis population was the
ITT population
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
Mahler 2002
Methods Design: randomised, double-blind, placebo-controlled, parallel-group study
Duration: 24 weeks
Location: 64 centres in the USA
Participants Population: 674 patients were randomised to 4 arms
1. fluticasone 500 µg (168) - not included in this review.
2. salmeterol 50 µg (160)
3. fluticasone/salmeterol 500/50 µg (165)
4. placebo (181) - not included in this review.
Baseline characteristics
Age (mean): placebo (64), salmeterol (63.5), fluticasone (64.4), fluticasone/salmeterol
(61.9)
Male (%): placebo (75), salmeterol (64), fluticasone (61), fluticasone/salmeterol (62)
FEV1 L (pre BD): placebo (1.317), salmeterol (1.237), fluticasone (1.233), fluticasone/
salmeterol (1.268)
Current smokers (%): placebo (54), salmeterol (46), fluticasone (46), fluticasone/salme-
terol (46)
Inclusion criteria: ≥ 40 years of age, were current or former smokers with ≥ 20 pack-
year history, and COPD. Baseline FEV1/FVC of < 70% and a baseline FEV1 < 65%
of predicted but > 0.70 L. Participants were required to have daily cough productive of
sputum for 3 months of the year for 2 consecutive years and dyspnoea
Exclusion criteria: asthma, OCS use within the past 6 weeks, abnormal clinically sig-
nificant ECG, LTOT, moderate or severe exacerbation during the run-in period
Interventions Inhaler device:
1. Fluticasone propionate (Flovent Diskus GlaxoSmith-Kline)
2. Salmeterol (Serevent Diskus; Glaxo-SmithKline, Research Triangle Park,NC)
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3. Fluticasone/salmeterol (Advair Diskus; Glaxo-SmithKline)
Allowed co-medications: albuterol as needed
Outcomes Change in predose FEV1 values, change in 2-h postdose FEV1 values, morning PEF,
supplemental albuterol use, dyspnoea, and exacerbations
Notes Funding: GlaxoSmithKline
Identifiers: SFCA3006
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised treatment assignment was
provided to the investigative site by means
of an interactive voice-response system at
the time participants were randomised
Allocation concealment (selection bias) Low risk Randomised treatment assignment was
provided to the investigative site by means
of an interactive voice-response system at
the time participants were randomised
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No details provided but outcomes not sub-
ject to detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk A total of 234 participants (38%, 28%,
40%, and 32% for placebo, salme-
terol, fluticasone, and fluticasone/salme-
terol groups, respectively). Reasons for
withdrawal were similar across the groups.
Dropouts addressed with various methods
including multiple imputation, analysis of
only completers, and recursive regression
imputation
Selective reporting (reporting bias) Low risk Protocol was located. Outcomes were well
reported
183Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mahler 2012a
Methods Design: randomised, double-blind, controlled, parallel-group
Duration: 12 weeks
Location: 186 centres in 14 countries; Argentina (10), Australia (6), Colombia (5), Den-
mark (5), Germany (25), Greece (4), Guatemala (5), Mexico (5), Peru (6), Philippines
(2), South Africa (6), Spain (13), Turkey (13) and USA (81)
Participants Population: 1131 patients were randomised to
1. Tiotropium 18 µg + indacaterol 150 µg daily (570)
2. Tiotropium 18 µg + placebo daily (561)
Baseline characteristics: age (mean): tiotropium + indacaterol (64), tiotropium +
placebo (63.4)
Male (%): tiotropium + indacaterol (70), tiotropium + placebo (67)
FEV1 L (pre BD): tiotropium + indacaterol (1.15), tiotropium + placebo (1.15)
Current smokers (%): tiotropium + indacaterol (40), tiotropium + placebo (36)
Inclusion criteria: aged≥ 40 years with moderate-severe COPDwith a smoking history
≥10 pack-years and postbronchodilator FEV1≤ 65% and≥ 30% of predicted normal,
and post-bronchodilator FEV1/FVC < 70% at screening
Exclusion criteria: history of asthma or had experienced a respiratory tract infection or
COPD exacerbation within the previous 6 weeks
Interventions Inhaler device:
1. Indacaterol/placebo via a single-dose DPI device
2. Tiotropium via HandiHaler®
Allowed co-medications: salbutamol (albuterol in the USA) was available for as-needed
use. Participants receiving ICS at baseline continued treatment (or were switched to ICS
monotherapy if taken as a fixed combination with a bronchodilator) at equivalent dose
and regimen during the study
Outcomes FEV1 standardised (with respect to length of time) AUC from 5 min to 8 h post-dose
at the end of treatment
Trough FEV1 24 h post-dose at the end of treatment
Notes Funding: Novartis Pharmaceuticals
Identifiers: NCT00846586
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation (1:1) was performed using
an automated interactive voice-response
systemandwas stratified byCOPDseverity
(moderate or severe), with balance main-
tained at country level
Allocation concealment (selection bias) Low risk Balance maintained at country level. Auto-
mated randomisation
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and staff at participating cen-
tres were unaware of treatment assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, investigators, those perform-
ing the assessments and data analysts were
blinded unless an emergency arose
Incomplete outcome data (attrition bias)
All outcomes
Low risk Completion rates were similar (93%-94%)
between treatment groups and studies
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
Mahler 2012b
Methods Design: randomised, double-blind, controlled, parallel-group
Duration: 12 weeks
Location: 182 centres in 11 countries; Argentina (9), Canada (16), Colombia (3), Czech
Republic (9), Hungary (4), India (9), Netherlands (6), Philippines (3), Slovakia (10),
Spain (11), USA (102)
Participants Population: 1142 patients were randomised to
1. tiotropium 18 µg + indacaterol 150 µg daily (572)
2. tiotropium 18 µg + placebo daily (570)
Baseline characteristics
Age (mean): tiotropium + indacaterol (63.1), tiotropium + placebo (62.8)
Male (%): tiotropium + indacaterol (63), tiotropium + placebo (68)
FEV1 L (pre BD): tiotropium + indacaterol (1.14), tiotropium + placebo (1.15)
Current smokers (%): tiotropium + indacaterol (38), tiotropium + placebo (43)
Inclusion criteria: aged≥ 40 years with moderate-severe COPDwith a smoking history
≥ 10 pack-years and postbronchodilator FEV1≤ 65% and≥ 30% of predicted normal,
and post-bronchodilator FEV1/forced vital capacity < 70% at screening
Exclusion criteria: history of asthma or had experienced a respiratory tract infection or
COPD exacerbation within the previous 6 weeks
Interventions Inhaler device:
1. Indacaterol/placebo via a single-dose DPI device
2. Tiotropium via HandiHaler®
Allowed co-medications: salbutamol (albuterol in the USA) was available for as-needed
use. Participants receiving ICS at baseline continued treatment (or were switched to ICS
monotherapy if taken as a fixed combination with a bronchodilator) at equivalent dose
and regimen during the study
Outcomes FEV1 standardised (with respect to length of time) AUC from 5 min to 8 h post-dose
at the end of treatment
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Notes Funding: Novartis
Identifiers: NCT00877383
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation (1:1) was performed using
an automated interactive voice-response
systemandwas stratified byCOPDseverity
(moderate or severe), with balance main-
tained at country level
Allocation concealment (selection bias) Low risk Balance maintained at country level. Auto-
mated randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and staff at participating cen-
tres were unaware of treatment assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, investigators, those perform-
ing the assessments and data analysts were
blinded unless an emergency arose
Incomplete outcome data (attrition bias)
All outcomes
Low risk Completion rates were high and similar
(94%-95%) between treatment groups
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
Mahler 2015a
Methods Design: randomised, double-blind, parallel-group, placebo and active-controlled studies
Duration: 12 weeks
Location: USA, Canada, Philippines, Poland, Romania, Spain, Ukraine and Vietnam
Participants Population: patients were randomised into 1 of 4 arms (combined population from
Mahler 2015a and Mahler 2015b)
1. Indacaterol/glycopyrrolate (indacaterol 27.5/15.6 µg twice daily) (508),
2. Indacaterol (indacaterol 27.5 µg twice daily) (511),
3. Glycopyrrolate (15.6 µg twice daily) (511)
4. Placebo (508)
Baseline characteristics (pooled analysis ofMahler 2015aand Mahler 2015b)
Age (mean): indacaterol/glycopyrronium (63.4), indacaterol (63.7), glycopyrronium
(63.4), placebo (63.2)
Male (%): indacaterol/glycopyrronium (63.4), indacaterol (65.8), glycopyrronium (63.
8), placebo (60.2)
FEV1 L (pre bronchodilator): indacaterol/glycopyrronium (1.264), indacaterol (1.280)
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, glycopyrronium (1.258), placebo (1.250)
Current smokers (%): indacaterol/glycopyrronium (50.4), indacaterol (52.1), glycopy-
rronium (52.3), placebo (51.6)
Inclusion criteria: ≥ 40 years of age; stable but symptomatic moderate-severe COPD
according to the GOLD 2011 criteria; smoking history of at least 10 years
Exclusion criteria: COPD exacerbation requiring antibiotics and/or systemic steroids
in last 6 weeks prior to visit 1, long QT syndrome, respiratory tract infection within 4
weeks of screening, history of asthma
Interventions Inhaler device: all treatments were delivered via the Neohaler device (Novartis Pharma
AG, Basel, Switzerland)
Allowed co-medications: participants continued to use fixed doses of ICSs if they had
been previously prescribed. AlbuterolMDI was allowed as rescuemedication throughout
the treatment period
Outcomes Standardised AUC for FEV1 between 0-12 h at end of treatment period, also change in
SGRQ total score from baseline and in the percentage of responders
Notes Funding: Novartis
Identifiers: NCT 01727141
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk All eligible participants were randomised
via interactive response technology in 1:1:
1:1 ratio
Allocation concealment (selection bias) Low risk All eligible participants were randomised
via interactive response technology in 1:1:
1:1 ratio
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The identity of the treatments was con-
cealed by the use of study drugs thatwere all
identical in packaging, labelling, schedul-
ing of administration, appearance, taste
and odour
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quadruple masking (participant, care
provider, investigator, outcomes assessor)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Completion rates were high and similar
(97%-99%) among active comparators
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
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Mahler 2015b
Methods Design: randomised, double-blind, parallel-group, placebo and active-controlled studies
Duration: 12 weeks
Location: USA, Colombia, Egypt, France, Guatemala, Hungary, Panama, Slovakia and
Slovenia
Participants Population: patients were randomised into 1 of 4 arms (combined population from
Mahler 2015a and Mahler 2015b)
1. Indacaterol/glycopyrrolate (indacaterol 27.5/15.6 µg twice daily) (508),
2. Indacaterol (indacaterol 27.5 µg twice daily) (511),
3. Glycopyrrolate (15.6 µg twice daily) (511)
4. Placebo (508)
Baseline characteristics (pooled analysis ofMahler 2015aand Mahler 2015b)
Age (mean): indacaterol/glycopyrronium (63.4), indacaterol (63.7), glycopyrronium
(63.4), placebo (63.2)
Male (%): indacaterol/glycopyrronium (63.4), indacaterol (65.8), glycopyrronium (63.
8), placebo (60.2)
FEV1 L (pre BD): indacaterol/glycopyrronium (1.264), indacaterol (1.280), glycopy-
rronium (1.258), placebo (1.250)
Current smokers (%): indacaterol/glycopyrronium (50.4), indacaterol (52.1), glycopy-
rronium (52.3), placebo (51.6)
Inclusion criteria: ≥ 40 years of age; stable but symptomatic moderate-severe COPD
according to the GOLD 2011 criteria
Exclusion criteria: COPD exacerbation requiring antibiotics and/or systemic steroids
in last 6 weeks prior to visit 1, long QT syndrome, respiratory tract infection within 4
weeks of screening, history of asthma
Interventions Inhaler device: all treatments were delivered via the Neohaler device (Novartis Pharma
AG, Basel, Switzerland)
Allowed co-medications: participants continued to use fixed doses of ICS if they had
been previously prescribed. AlbuterolMDI was allowed as rescuemedication throughout
the treatment period
Outcomes Standardised AUC for FEV1 between 0-12 h at end of treatment period, also change in
SGRQ total score from baseline and in the percentage of responders
Notes Funding: Novartis
Identifiers: NCT01712516
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk All eligible participants were randomised
via interactive response technology in 1:1:
1:1 ratio
Allocation concealment (selection bias) Low risk All eligible participants were randomised
via interactive response technology in 1:1:
1:1 ratio
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Mahler 2015b (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The identity of the treatments was con-
cealed by the use of study drugs thatwere all
identical in packaging, labelling, schedul-
ing of administration, appearance, taste
and odour
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quadruple masking (participant, care
provider, investigator, outcomes assessor)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Completion rates were high and similar
(96%-98%) among active comparators
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
Mahler 2016
Methods Design: randomised, multicentre, double-blind, parallel-group study
Duration: 52 weeks
Location: 65 centres in the USA
Participants Population: 507 patients were randomised to
1. Glycopyrronium 15.6 µg twice daily (251)
2. Indacaterol 75 µg daily (256)
Baseline characteristics:
Age (mean): glycopyrronium (63.3), indacaterol (63.2)
Male (%): glycopyrronium (56.2), indacaterol (58.2)
FEV1 L (pre BD): glycopyrronium (1.24), indacaterol (1.25)
Current smokers (%): glycopyrronium (54.2), indacaterol (55.5)
Inclusion criteria: aged ≥ 40 years with stable COPD (GOLD 2011 levels 2 and 3),
who were current or ex-smokers with a smoking history of at least 10 pack-years, who
presented with post-bronchodilator FEV1 ≥ 30% and < 80% of the predicted normal,
and a post-bronchodilator FEV1/FVC < 0.70, and with a mMRC Dyspnea Scale grade
of at least 2
Exclusion criteria: history of long QT syndrome, clinically significant ECG abnormal-
ity, clinically significant CVD, renal abnormalities, history of asthma, and COPD exac-
erbations that required treatment with antibiotics and/or systemic corticosteroids and/
or hospitalisation within the 6 weeks before the screening or during the screening and
run-in periods
Interventions Inhaler device: both treatment arms used low-resistance, single-dose, DPI (Neohaler™
device)
Allowed co-medications: stable background treatment with ICS was permitted to be
continued throughout the study. During the study, participants were provided with
albuterol as a rescue medication
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Outcomes Safety and tolerability in terms of AE reporting rates. Time to first moderate or severe
COPD exacerbations. Pre-dose trough FEV1 at week 52. FEV1 and FVCmeasurements
at all post-baseline time points, and rescue medication use over 52 weeks of treatment
period
Notes Funding: Novartis
Identifiers: NCT01697696
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A patient randomisation list was produced
by the IRT provider using a validated sys-
tem that automated the random assign-
ment of patient numbers to randomisation
numbers. A separate medication list was
produced by Novartis Drug Supply Man-
agement using a validated system that au-
tomated the random assignment of medi-
cation numbers to study drug packs con-
taining each of the study drugs
Allocation concealment (selection bias) Low risk A patient randomisation list was produced
by the IRT provider using a validated sys-
tem that automated the random assign-
ment of patient numbers to randomisation
numbers. A separate medication list was
produced by Novartis Drug Supply Man-
agement using a validated system that au-
tomated the random assignment of medi-
cation numbers to study drug packs con-
taining each of the study drugs
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quadruple masking (participant, care
provider, investigator, outcomes assessor)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quadruple masking (participant, care
provider, investigator, outcomes assessor)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 18%of participants discontinued the study
before the end of treatment period, discon-
tinuation rates and reasons were similar be-
tween both groups
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Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
Maleki-Yazdi 2014
Methods Design: multicentre, randomised, double-dummy, parallel-group study
Duration: 24 weeks
Location: 71 centres in 8 countries (Bulgaria, Canada, Germany, Hungary, Romania,
Russia, Spain, and USA)
Participants Population: 905 patients were randomised to
1. umeclidinium bromide + vilanterol 62.5/25 µg once-daily (454)
2. tiotropium 18 µg daily (451)
Baseline characteristics
Age (mean): umeclidinium/vilanterol (61.9), tiotropium (62.7)
Male (%): umeclidinium/vilanterol (68), tiotropium (67)
FEV1 L (post BD): umeclidinium/vilanterol (1.41), tiotropium (1.41)
Current smokers (%): umeclidinium/vilanterol (59), tiotropium (54)
Inclusion criteria: aged≥ 40 years with moderate-very severe COPD and an established
clinical history of COPD as defined by ATS/ERS guidelines
Exclusion criteria: hospitalised for COPD or pneumonia within 12 weeks prior to visit
1
Interventions Inhaler device
1. Umeclidinium/vilanterol via DPI, ELLIPTA DPI;
2. Tiotropium via Handi-Haler
Allowed co-medications: use of albuterol/salbutamol provided by GlaxoSmithKline via
MDI as relief medication was permitted, but was withheld for≤ 4 h prior to spirometry
testing. ICS at a consistent dose of up to 1000 µg/day of fluticasone propionate or
equivalent were permitted and recorded
Outcomes Trough FEV1 at day 169, weighted mean FEV1 over 0-6 h post-dose at day 168
Notes Funding: GlaxoSmithKline
Identifiers: NCT01777334, ZEP117115
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation code was generated us-
ing a GlaxoSmithKline validated comput-
erised system, RandAll
Allocation concealment (selection bias) Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
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Maleki-Yazdi 2014 (Continued)
tomated, interactive telephone-based sys-
tem and the link to the randomisation
schedule was kept confidential from all staff
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-dummydesignwas used for retain-
ing the blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The investigator and treating physician
were blinded till an emergency arose
Incomplete outcome data (attrition bias)
All outcomes
Low risk Most participants
completed the study (88%, umeclidinium/
vilanterol group; 86%, tiotropium group).
Reasons for dropout were similar between
2 groups
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
Martinez 2017a
Methods Design: randomised, double-blind, chronic-dosing, placebo-controlled, parallel-group,
multicentre study
Duration: 24 weeks
Location: Australia, New Zealand, USA
Participants Population
1. Glycopyrronium/formoterol 14.4/9.6 µg (526)
2. Glycopyrronium 14.4 µg (451)
3. Formoterol 9.6 µg (452)
4. Tiotropium (18 µg) (451)
Baseline characteristics: age 62.8 (SD 8.4) female:male 914:1182
Inclusion criteria
1. Male or female participants ≥ 40 years of age and < 80 at visit 1
2. Established clinical history of COPD as defined by ATS/ERS
3. Current or former smokers with a history of at least 10 pack-years of cigarette
smoking.
4. Average of the -60 and the -30 min pre-dose FEV1 assessments must be < 80%
predicted normal value calculated using NHANES 3 reference equations
5. Willing and, in the opinion of the investigator, able to adjust current COPD
therapy as required by the protocol
Exclusion criteria
1. Significant diseases other than COPD, i.e. disease or condition which, in the
opinion of the investigator, may put the participant at risk because of participation in
the study or may influence either the results of the study or the participant’s ability to
participate in the study
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2. Current diagnosis of asthma or alpha-1 antitrypsin deficiency
3. Other active pulmonary disease such as active TB, lung cancer, bronchiectasis,
sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary pulmonary
hypertension, or uncontrolled sleep apnoea
4. Hospitalised due to poorly controlled COPD within 3 months prior to screening
or during the screening period
5. Poorly controlled COPD, defined as acute worsening of COPD that requires
treatment with OCS or antibiotics within 6 weeks prior to screening or during the
screening period
6. Lower respiratory tract infections that required antibiotics within 6 weeks prior to
screening or during the screening period
7. Unstable ischaemic heart disease, left ventricular failure, or documented MI
within 12 months of enrolment
8. Recent history of acute coronary syndrome, percutaneous coronary intervention,
coronary artery bypass graft within the past 3 months
9. Congestive heart failure NYHA Class 3/4)
10. Clinically significant abnormal 12-lead ECG
11. Abnormal liver function tests defined as AST, ALT, or total bilirubin ≥ 1.5 times
ULN at visit 1 and on repeat testing
12. Cancer not in complete remission for at least 5 years
13. History of hypersensitivity to β2-agonists, glycopyrronium or other muscarinic
anticholinergics, lactose/milk protein or any component of the MDI
Interventions Inhaler device
1. Glycopyrronium/formoterol: MDI
2. Glycopyrronium: MDI
3. Fluticasone furorate: MDI
4. Open-label tiotropium: bromide inhalation powder
5. Placebo: MDI
Allowed co-medications: rescue albuterol, ICS, PDE4 inhibitor
Outcomes Primary: CFB in morning pre-dose trough FEV1 at week 24 (time frame: baseline and
at week 24)
Notes Funding: Pearl Therapeutics
Identifiers: NCT01854645
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Tiotropium was open-label
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Tiotropium was open-label
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout relatively high and uneven among
active comparators (glycopyrronium/for-
moterol 18.6%, glycopyrronium 23.5%,
fluticasone furorate 18.1%, tiotropium 13.
7%)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Martinez 2017b
Methods Design: randomised, double-blind, chronic-dosing, placebo-controlled, parallel-group,
multi centre study
Duration: 24 weeks
Location: USA
Participants Population
1. Glycopyrronium/formoterol 14.4/9.6 µg (510)
2. Glycopyrronium 14.4 µg (439)
3. Formoterol 9.6 µg (438)
Baseline characteristics: age 62.9 (SD 8.3) female:male 723:886
Inclusion criteria
1. Male or female, ≥ 40 years of age and < 80 at visit 1
2. Established clinical history of COPD as defined by the ATS/ERS
3. Current or former smokers with a history of at least 10 pack-years of cigarette
smoking
4. FEV1/FVC ratio of < 0.70 and FEV1 < 80% predicted normal and ≥ 750 mL if
FEV1 < 30% of predicted normal value
5. Willing and, in the opinion of the investigator, able to adjust current COPD
therapy as required by the protocol
Exclusion criteria
1. Significant diseases other than COPD, i.e. disease or condition which, in the
opinion of the investigator, may put the participant at risk because of participation in
the study or may influence either the results of the study or the participant’s ability to
participate in the study
2. Current diagnosis of asthma or alpha-1 antitrypsin deficiency
3. Other active pulmonary disease such as active TB, lung cancer, bronchiectasis,
sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary pulmonary
hypertension, or uncontrolled sleep apnoea
4. Hospitalised due to poorly controlled COPD within 3 months prior to screening
or during the screening period
5. Poorly controlled COPD, defined as acute worsening of COPD that requires
treatment with OCS or antibiotics within 6 weeks prior to screening or during the
screening period
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6. Lower respiratory tract infections that required antibiotics within 6 weeks prior to
screening or during the screening period
7. Unstable ischaemic heart disease, left ventricular failure, or documented MI
within 12 months of enrolment
8. Recent history of acute coronary syndrome, percutaneous coronary intervention,
coronary artery bypass graft within the past 3 months
9. Congestive heart failure (NYHA Class 3/4)
10. Clinically significant abnormal 12-lead ECG
11. Abnormal liver function tests defined as AST, ALT, or total bilirubin ≥ 1.5 times
ULN at visit 1 and on repeat testing
12. Cancer not in complete remission for at least 5 years
13. History of hypersensitivity to β2-agonists, glycopyrronium or other muscarinic
anticholinergics, lactose/milk protein or any component of the MDI
Interventions Inhaler device:
1. Glycopyrronium/formoterol: MDI
2. Glycopyrronium: MDI
3. Fluticasone furorate: MDI
4. Open-label tiotropium: bromide inhalation powder
5. Placebo: MDI
Allowed co-medications: rescue albuterol, ICS, PDE4 inhibitor
Outcomes Primary: CFB in morning pre-dose trough FEV1
Notes Funding: Pearl Therapeutics
Identifiers: NCT01854658
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout relatively high and uneven among
active comparators (glycopyrronium/for-
moterol 21.2%, glycopyrronium 17.0%,
fluticasone furorate 15.6%, tiotropium 26.
3%)
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Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
NCT00876694 2011
Methods Design: multicentre, randomised, open-label, parallel-group study
Duration: 52 weeks
Location: Japan
Participants Population
1. Indacaterol 300 µg (125)
2. Salmeterol 50 µg (61)
Baseline characteristics: age 69.1 (SD 7.97) female:male 10:176
Inclusion criteria
1. Diagnosis of COPD (moderate-to-severe as classified by the GOLD criteria)
2. Smoking history of at least 20 pack-years
3. Post-bronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value
4. Post-bronchodilator FEV1/FVC (forced vital capacity) < 70%
Exclusion criteria: a COPD exacerbation in the 6 weeks prior to visit 1 or during the
run-in period, concomitant pulmonary disease, asthma, diabetes type 1 or uncontrolled
diabetes type 2, lung cancer or a history of lung cancer, certain cardiovascular comorbid
conditions
Interventions Inhaler device
1. Indacaterol 300 µg once daily via DPI
2. Salmeterol 50 µg twice daily via Diskus
Allowed co-medications: salbutamol as rescue
Outcomes Long-term safety and tolerability (particularly with regard to ECG, laboratory tests, vital
signs and AEs) of indacaterol
Notes Funding: Novartis
Identifiers: NCT00876694 2011, CQAB149B1303
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively low and even be-
tween two groups (16.8% in indacaterol,
19.7% in salmeterol group)
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
NCT01536262 2014
Methods Design: randomised, double-blind, parallel-group study
Duration: 52 weeks
Location: Japan, multicentre
Participants Population
1. Olodaterol 5 µg (41)
2. Tiotropium + olodaterol 2.5/5 µg (40)
3. Tiotropium + olodaterol 5/5 µg (41)
Baseline characteristics: age 69.9 (SD 7.3), F:M 5:117
Inclusion criteria
1. Diagnosis of COPD
2. Relatively stable airway obstruction with post FEV1 < 80% predicted normal and
post FEV1/FVC < 70%
3. Male or female Japanese patients, ≥ 40 years of age
4. Smoking history of > 10 pack-years.
Exclusion criteria
1. Significant disease other than COPD
2. Clinically relevant abnormal lab values
3. History of asthma
4. Significant comorbidities
5. Known active TB
6. Malignancy treated by resection, radiation therapy or chemotherapy within last 5
years
7. Other pulmonary diseases
8. Regular use of daytime oxygen therapy for > 1 h/d
9. Pregnant or nursing women
10. Women of childbearing potential not using a highly effective method of birth
control
11. Narrow-angle glaucoma or micturition disorder due to prostatic hyperplasia
Interventions Inhaler device
1. Tiotropium + olodaterol FDC once-daily inhalation: Respimat
2. Olodaterol once daily inhalation: Respimat
3. Tiotropium and Olodaterol FDC once-daily inhalation: Respimat
Allowed co-medications:
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NCT01536262 2014 (Continued)
Outcomes Primary: number (%) of participants with drug-related AEs
Notes Funding: Boehringer Ingelheim
Identifiers: NCT01536262 2014, 1237.22
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout was highwith olodaterol 5 µg (19.
5%) uneven compared with tiotropium/
olodaterol 5/5 µg (4.9%). Analysed using
treated set: this participant set included all
participants who received at least 1 dose
of treatment. Imputaion method not de-
scribed
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
Ohar 2014
Methods Design: randomised, parallel-group study
Duration: 26 weeks
Location: 103 centres in Argentina, Norway and USA
Participants Population
1. Fluticasone propionate/salmeterol 250/50 µg (314)
2. Salmeterol 50 µg (325)
Baseline characteristics: age 62.9 (SD 9.22) female:male 291:348
Inclusion criteria: > 40 years of age and a historical FEV1/FVC < 0.7, recent event
(within 14 days of randomisation) of: < 10-day hospitalisation for an acute COPD
exacerbation, or exacerbation requiring treatment with OCS or OCS + antibiotics in an
ER, or during a physician’s office visit. If the index event was office-based, a 6-month
history of hospitalisations attributed to acute exacerbation of COPD was also required
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Exclusion criteria: diagnosis of pneumonia, congestive heart failure, or other complicat-
ing comorbidities, previous lung resection surgery (e.g. lobectomy and pneumonectomy)
within the year preceding visit 1 (screening, asthma as primary diagnosis), lung cancer,
cystic fibrosis, pulmonary fibrosis, active TB, or sarcoidosis, clinically significant cardiac
arrhythmias, current malignancy or a previous history of cancer in remission for < 5 years
(localised basal cell or squamous cell carcinoma of the skin that had been resected was
not excluded), pregnancy, hypersensitivity to any beta-agonist, sympathomimetic drug,
or corticosteroid
Interventions 1. Salmeterol 50 µg twice daily (LABA)
2. Salmeterol/fluticasone 50/250 µg twice daily (LABA/ICS)
Inhaler device: Diskus dry powder
Allowed co-medications: albuterol as needed. Tiotropium
Outcomes Pre-dose FEV1, exacerbation outcomes
Notes Funding: GlaxoSmithKline
Identifiers: NCT01110200, ADC113874
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Allocation concealment (selection bias) Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No details provided but outcomes not sub-
ject to detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout rates were high (fluticasone pro-
pionate/salmeterol 22.7%, salmeterol 25.
7%) but the reasons for dropout were sim-
ilar between two groups. ITT population
with endpoint analysis was used for miss-
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ing data and premature withdrawal
Selective reporting (reporting bias) Low risk All outcomes were reported in the results
summary on clinicaltrials.gov
Pepin 2014
Methods Design: multicentre, randomised, double-blind, parallel-group, chronic-dosing, active-
and placebo-controlled study
Duration: 12 weeks
Location: Argentina, France, Germany, Italy, Norway, Russian Federation, Ukraine
Participants Population
1. Fluticasone furorate/vilanterol 100/25 µg (127)
2. Tiotropium 18 µg (130)
Baseline characteristics: age 67.3 (7.28) female:male 37/220
Inclusion criteria
1. Outpatients
2. Signed and dated written informed consent to participate
3. Male or female participants
4. ≥ 40 years of age at screening (visit 1)
5. Clinical history of COPD in accordance with ATS/ERS definition
6. Current or prior history of ≥ 10 pack-years of cigarette smoking at screening
(visit 1)
7. Measured post-albuterol/salbutamol FEV1 < 70% of predicted at screening (visit
1)
8. Measured post-albuterol/salbutamol FEV1/FVC ratio of ≤ 0.70 at screening
(visit 1)
9. Hospitalised or treated with OCS or antibiotics for their COPD within the last 3
years prior to screening (visit 1)
Exclusion criteria: BMI of ≤ to 35
Interventions Inhaler device
1. Fluticasone furoate (GW685698)/vilanterol (GW642444) 100/25 µg: Novel DPI
2. Tiotropium (18 µg) administered once daily via a HandiHaler
Allowed co-medications: salbutamol/albuterol as needed
Outcomes Primary: mean CFB in aortic pulse wave velocity at the end of the 12-week treatment
period (day 84)
Notes Funding: GlaxoSmithKline
Identifiers: NCT01395888, HZC115247
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Interactive voice-response system
Allocation concealment (selection bias) Low risk Interactive voice-response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigator and treating physician were
kept blinded unless amedical emergency or
a serious adverse medical condition arose
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low and even between two
groups (11.8% in fluticasone furorate/vi-
lanterol and 13.1% in tiotropium group)
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
Perng 2009
Methods Design: randomised (not double-blinded) clinical trial
Duration: 12 weeks
Location: Taiwan
Participants Population
1. Salmeterol/fluticasone propionate 500/50 µg (33)
2. Tiotropium 18 µg (34)
Baseline characteristics: age 73.2. female:male 4/63
Inclusion criteria: clinical diagnosis of COPD, aged 40-85 years; were a current or
former smoker (history 20 pack-years); had a post-bronchodilator FEV1 ≤ 80% of the
predicted value and FEV1/FVC < 70%
Exclusion criteria: no history of asthma, atopy (as defined by a positive reaction to
one or more allergen in a fluoroenzyme immunoassay) or any other active lung disease.
Participants were either newly diagnosed or had not taken corticosteroids (either oral
or inhaled), or any other bronchodilators or theophylline, for a minimum of 3 months
prior to the commencement of the study
Interventions Inhaler device
1. Salmeterol/fluticasone propionate 25/250 µg Evohaler (GlaxoSmithKline)
2. Tiotropium 18 µg HandiHaler (Boehringer Ingelheim)
Allowed co-medications: not described
Outcomes Pulmonary function, serum C reactive protein, sputum induction and assessment of
health-related QoL
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Perng 2009 (Continued)
Notes Funding: None reported
Identifiers: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed using a
computer-generated list of random num-
bers
Allocation concealment (selection bias) Low risk Randomisation was performed using a
computer-generated list of random num-
bers
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low and relatively even be-
tween 2 groups (10% in salmeterol/flutica-
sone propionate and 14.7 % in tiotropium
group)
Selective reporting (reporting bias) Unclear risk Unable to locate protocol to check outcome
reporting
RADIATE 2016
Methods Design: multicentre, randomised, double-blind, parallel-group, placebo- and active-
controlled study
Duration: 52 weeks
Location: Belgium, Bulgaria, Greece, Hungary, Ireland, Russian Federation, Slovakia,
Spain, Turkey, UK
Participants Population
1. Indacaterol/glycopyrronium 110/50 µg (407)
2. Tiotropium 18 µg (405)
Baseline characteristics: age 64.5 (SD 8.14) female:male 318:898
Inclusion criteria
1. Male and female adults aged ≥ 40 years
2. Stable COPD according to GOLD 2011 strategy
3. Airflow limitation indicated by a post-bronchodilator FEV1 ≥ 30% and < 80%
of the predicted normal, and a post-bronchodilator FEV1/FVC < 0.70
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4. Current or ex-smokers with a smoking history of at least 10 pack-years
5. mMRC ≥ grade 2
Exclusion criteria
1. History of long QT syndrome or prolonged QTc
2. COPD exacerbation that required treatment with antibiotics and/or systemic
corticosteroids and/or hospitalisation in the 6 weeks prior to visit 1
3. Type I or uncontrolled type 2 diabetes
4. History of asthma or have concomitant pulmonary disease
5. Paroxysmal (e.g. intermittent) atrial fibrillation. Only patients with persistent
atrial fibrillation and controlled with a rate control strategy for at least six months
could be eligible.
6. Clinically significant renal, cardiovascular, neurological, endocrine,
immunological, psychiatric, gastrointestinal, hepatic, or hematological abnormalities
that could interfere with the assessment of safety
Interventions Inhaler device
1. Indacaterol/glycopyrronium (QVA149) 110/50 µg Novartis Concept1 DPI
2. Tiotropium 18 µg HandiHaler DPI
Allowed co-medications: rescue albuterol
Outcomes Primary: number of patients with serious AEs
Notes Funding: Novartis
Identifiers: NCT01610037, CQVA149A2339
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low in both included
groups (tiotropium 12.6%, indacaterol/
glycopyrronium 14.5%)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
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Rennard 2009
Methods Design: randomised, double-blind, double-dummy, parallel-group, active- and placebo-
controlled, multicentre study
Duration: 52 weeks (+ 2-week run-in period)
Location: 237 sites in the USA, Europe and Mexico
Participants Population: 1964 participants were randomised to
1. formoterol (495)
2. formoterol/budesonide at two doses (494 and 494)
3. placebo (481)
Baseline characteristics
Age (mean years): formoterol 62.9, formoterol/budesonide (9/320 µg) 63.2, formoterol/
budesonide (9/160 µg) 63.6, placebo 62.9
% male: formoterol 65.3, formoterol/budesonide (9/320 µg) 62.3, formoterol/budes-
onide (9/160 µg) 62.8, placebo 65.3
% FEV1 predicted: formoterol 39.3, formoterol/budesonide (9/320 µg) 38.6, for-
moterol/budesonide (9/160 µg) 39.6, placebo 40.8
Pack-years (median): formoterol 40, formoterol/budesonide (9/320 µg) 40, formoterol/
budesonide (9/160 µg) 40, placebo 40
Inclusion criteria: men and women aged ≥ 40 years; moderate-severe COPD for > 2
years; history of at least 10 pack-years
Exclusion criteria: history of asthma or seasonal rhinitis before age 40; significant/
unstable cardiovascular disorder; significant respiratory tract disorder other than COPD;
homozygous alpha1-antitrypsin deficiency or other clinically significant comorbidities
precluding participation
Interventions 1. Formoterol 12 µg twice daily (LABA)
2. Formoterol/budesonide 9/320 µg (LABA/ICS)
3. Formoterol/budesonide 9/160 µg (LABA/ICS)
4. Placebo
Inhaler device: DPI
Allowed co-medications: salbutamol was allowed as relief medication. Previous ICSs
were discontinued, and disallowed medication included long-acting anticholinergics;
inhaled LABAs or SABAs (other than salbutamol); oral beta-adrenoreceptor agonists;
ephedrine; leukotriene receptor agonists; xanthine derivatives except for short-term use
Outcomes SGRQ,COPDexacerbations, pre-dose FEV1, 1h post-dose FEV1,morning and evening
PEF
Notes Funding: AstraZeneca
Identifier(s): NCT00206167
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, parallel-group study (no spe-
cific details, industry sponsored)
Allocation concealment (selection bias) Unclear risk No details provided
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Rennard 2009 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Tomaintain blinding, participants received
both a pressurised MDI and a DPI con-
taining either active treatment or double-
dummy placebo as appropriate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Included outcomes unlikely to be affected
by detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rate was high (budesonide/for-
moterol 320/9 µg 27.1%, budesonide/for-
moterol 160/9 µg 28.9%, formoterol 31.
7%) but the reasons for withdrawal were
similar across the groups
Selective reporting (reporting bias) Low risk Study was prospectively registered, and all
results were available from the published
report
Rheault 2016
Methods Design: multicentre, randomised, open-label, 2-arm, parallel-group study
Duration: 12 weeks
Location: Argentina, Chile, Czechia, Germany, Hungary, Norway, Romania, Russian
Federation, Spain, Sweden
Participants Population
1. Umeclidinium 62.5 µg (516)
2. Glycopyrronium 44 µg (518)
Baseline characteristics: age 64.01 (SD 8.3) female:male 329:705
Inclusion criteria
1. Outpatient
2. Signed and dated written informed consent prior to study participation
3. ≥ 40 years at visit 1
4. Male and female participants
5. Women of:
i) non-child-bearing potential i.e. physiologically incapable of becoming
pregnant, including any women who is post-menopausal or surgically sterile. Surgically
sterile women are defined as those with a documented hysterectomy and/or bilateral
oophorectomy or tubal ligation. Post-menopausal women are defined as being
amenorrhoeic for > 1 year with an appropriate clinical profile, e.g. age appropriate, >
45 years, in the absence of hormone replacement therapy
ii) child-bearing potential, with negative pregnancy test at screening, and agrees
to use one of the acceptable contraceptive methods consistently and correctly i.e. in
accordance with the approved product label and the instructions of the physician for
the duration of the study - screening to follow-up contact
6. Established clinical history of COPD in accordance with the definition by the
ATS/ERS
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7. Current or former cigarette smokers with a history of cigarette smoking of ≥ 10
pack-years (number of pack-years = (number of cigarettes per day / 20) x number of
years smoked (e.g. 20 cigarettes/day for 10 years, or 10 cigarettes/day for 20 years both
equal 10 pack-years)). Former smokers are defined as those who have stopped smoking
for at least 6 months prior to visit 1. Pipe and/or cigar use cannot be used to calculate
pack-year history
8. Pre and post-albuterol/salbutamol FEV1/FVC ratio of < 0.70 and a post-
albuterol/salbutamol FEV1 of ≥ 30% and ≤ 70% of predicted normal values at visit 1.
Predicted values will be based upon the ERS Global Lung Function Initiative
9. A score of ≥2 on the modified mMRC at visit 1
Exclusion criteria
1. Current diagnosis of asthma
2. Other respiratory disorders: known alpha-1 antitrypsin deficiency, active lung
infections (such as TB), and lung cancer. Any other significant respiratory conditions
3. Participants considered unlikely to survive the duration of the study period or
with any rapidly progressing disease or immediate life-threatening illness (e.g. cancer).
In addition, any participant with any condition (e.g. neurological condition) that is
likely to affect respiratory function
4. Unstable or life threatening cardiac disease: LAMA should be used with caution
in participants with severe CVD. In the opinion of the investigator, use should only be
considered if the benefit is likely to outweigh the risk in conditions such as: MI or
unstable angina in the last 6 months, unstable or life threatening cardiac arrhythmia
requiring intervention in the last 3 months, NYHA Class 4 heart failure
5. Antimuscarinic effects: participants with medical conditions such as narrow-angle
glaucoma, urinary retention, prostatic hypertrophy, or bladder neck obstruction should
only be included if, in the opinion of the study physician, the benefit outweighs the risk
6. Hospitalisation for COPD or pneumonia within 12 weeks prior to visit 1
7. Lung volume reduction surgery within the 12 months prior to visit 1
8. Abnormal findings based on 12-Lead ECG: e.g. atrial fibrillation with rapid
ventricular rate > 120 bpm; sustained or nonsustained ventricular tachycardia; second
degree heart block Mobitz type 2 or third degree heart block (unless pacemaker or
defibrillator had been inserted)
9. Inability to withhold albuterol/salbutamol for the 4-h period required prior to
spirometry testing at each study visit
10. LTOT, described as oxygen therapy prescribed for greater than 12 h/d. As-needed
oxygen use (i.e. ≤ 12 h/d) is not exclusionary.
11. Regular use (prescribed for use every day, not for as-needed use) of short-acting
bronchodilators (e.g. albuterol/salbutamol) via nebulised therapy
12. Known or suspected history of alcohol or drug abuse within 2 years prior to visit 1
Interventions Inhaler device:
Umeclidinium 62.5 µg DPI
Glycopyrronium bromide as inhalation capsules, 44 µg per capsule, BREEZHALER
inhalers
Allowed co-medications: ICSs. albuterol/salbutamol for as-needed rescue medication
Outcomes Primary: CFB in trough FEV1 on day 85
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Notes Funding: GlaxoSmithKline
Identifiers: NCT02236611, 201315 (GSK)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Allocation concealment (selection bias) Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low in both included groups
(umeclidinium 5.0%, glycopyrronium 6.
6%)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Rossi 2014
Methods Design: randomised, double-blind, parallel-group study
Duration: 26 weeks.
Location: Argentina, Colombia, Italy, Malaysia, Mexico, Netherlands, Spain, Switzer-
land, UK
Participants Population
1. Fluticasone propionate/salmeterol 500/50 µg (288)
2. Salmeterol 50 µg (293)
Baseline characteristics: age 66.0 (SD 8.49) female:male 180:401
Inclusion criteria
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1. Moderate COPD (stage 2)
2. Able to perform spirometry assessments
3. Current or ex-smokers
4. On treatment with the FDC of salmeterol 50 µg/fluticasone propionate 500 µg
DPI twice daily for the treatment of COPD for ≥ 3 months directly preceding visit 1
Exclusion criteria
1. Having had a COPD exacerbation that required treatment with antibiotics and/
or OCS and/or hospitalisation in the past year
2. History of, or current ECG abnormality
3. Asthma
Interventions Inhaler device:
1. Indacaterol DPI
2. Salmeterol/fluticasone DPI
Allowed co-medications: salbutamol as rescue
Outcomes Primary: trough FEV1 at 12 weeks (imputed by using the last observation carried
forward method)
Notes Funding: Novartis
Identifiers: NCT01555138, CQAB149B2401
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants, investigator staff,
personnel performing assessments and data
analysts was maintained by ensuring ran-
domisation data remained strictly confi-
dential and inaccessible to anyone involved
in the study until the time of unblinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low in both included
groups (indacaterol 16.0%, salmeterol/flu-
ticasone propionate 13.2%)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
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Sarac 2016
Methods Design: an open, prospective, randomised trial
Duration: 52 weeks
Location: Turkey
Participants Population
1. Futicasone propionate/salmeterol 500/50 µg (22)
2. Tiotropium 18 µg (22)
Baseline characteristics: age 66.6 female:male 2/42
Inclusion criteria: 35-80 years old, they had a smoking history of 10 pack-years or more,
their FEV1 level was between 50% and 80% and they reported at least one exacerbation
in the preceding year
Exclusion criteria: a prior diagnosis of asthma, previous documentation of bronchial
hyperreactivity, history of allergy and/or atopy, presence of congestive heart failure or
any other cardiopulmonary disease that might interfere with the participant’s follow-up
Interventions Inhaler device
1. Salmeterol 50 µg/fluticasone 500 µg combination as DPI (Diskus)
2. Tiotropium DPI (HandiHaler)
Allowed co-medications: short-acting bronchodilators as needed
Outcomes COPD exacerbations, CAT score, 6MWD, AEs
Notes Funding: none reported
Identifiers: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clear how many dropped out
Selective reporting (reporting bias) Unclear risk Could not locate protocol to check out-
come reporting
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SCO100470 2006
Methods Design: multicentre, randomised, double-blind, double dummy, parallel-group design
Duration: 6 months (+ run-in of unclear duration)
Location: conducted at 135 centres in 20 countries
Participants Population: 1050 people were randomised to
1. fluticasone (532)
2. fluticasone/salmeterol combination (518)
Baseline characteristics
Age (mean years): salmeterol 63.7, fluticasone/salmeterol 63.5
% male: salmeterol 77.3, fluticasone/salmeterol 78.4
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: Male or female, aged 40-80 years with an established history of
GOLD stage 2 COPD; poor reversibility of airflow obstruction (defined as ≤ 10%
increase in FEV1 as a percentage of the normal predicted value); a minimum score of 2
on the mMRC Scale, and a smoking history of > 10 pack-years. In addition, participants
had to achieve a composite symptom score of 120 (out of 400 maximum score, measured
using visual analogue scales) on at least 4 of the last 7 days of the run-in period, and to
have a BDI score of 7 units at visit 2
Exclusion criteria: asthma or atopic disease, lung disease likely to confound the drug
response other than COPD, recent exacerbation (within 4 weeks or screening or during
run-in); LTOT or pulmonary rehabilitation or had taken tiotropium bromide, ICSs or
anti-leukotriene medication within 14 days of visit 1
Interventions 1. Salmeterol 50 µg twice daily (LABA)
2. Salmeterol/fluticasone 50/500 µg twice daily (LABA/ICS)
Inhaler device: Diskus accuhaler
Allowed co-medications: not reported
Outcomes TDI, CFB in trough FEV1, CFB in trough FVC and FVC/FEV1 ratio, TDI focal score,
CFB in post-dose FEV1, FVC and FVC/FEV1 ratio, CFB in mean morning PEF, CFB
in SGRQ
Notes Funding: GlaxoSmithKline
Identifier(s): SCO100470 (GSK)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised to treatment
via an interactive voice-response system
Allocation concealment (selection bias) Low risk Participants were randomised to treatment
via an interactive voice-response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (participants
and personnel/investigators)
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SCO100470 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators were blinded (presumed in-
vestigators were also outcomes assessors)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout low and even between groups (11.
4% vs 13.9%). The ITT population (all
participants randomised and confirmed as
having received at least 1 dose of double-
blind study medication), was the primary
population for analysis of all efficacy and
health outcomes variables; the safety pop-
ulation (identical to the ITT population),
was used for analysis of all safety variables
Selective reporting (reporting bias) Low risk All stated outcomes were reported and no
expected outcomes were missing
SCO40034 2005
Methods Design: randomised, double-blind, double-dummy, multicentre, parallel-group ex-
ploratory study
Duration: 12 weeks
Location: 17 centres in the Netherlands
Participants Population: 125 adults with a clinical history of moderate-severe COPD
1. Fluticasone 500 µg + salmeterol 50 µg twice daily + placebo
2. Tiotropium 18 µg once daily + placebo to match fluticasone + salmeterol
Baseline characteristics: age mean 63.7 (fluticasone/salmeterol) 65.3 (tiotropium) fe-
male:male 18:43 (fluticasone/salmeterol), 14:50 (tiotropium), white 100%
Inclusion criteria: aged 40-80 years inclusive. Post-bronchodilator FEV1 < 70% of
predicted normal. Participants must have had a smoking history (current or former
smokers) of > 10 pack-years
Exclusion criteria: within 4 weeks prior to visit 1; COPD exacerbation; received oral,
parenteral or depot corticosteroids for a COPD exacerbation; received antibiotic therapy
and/or been hospitalised for either a lower respiratory tract infection or for COPD
exacerbation, or had any changes in their COPD medication
Interventions Inhaler device
1. Combination of fluticasone 500 µg and salmeterol 50 µg twice daily via Diskus
inhaler + placebo capsules to match tiotropium delivered once daily via the
HandiHaler inhaler
2. Tiotropium 18 µg once daily via HandiHaler + placebo to match FPS Diskus
combination product delivered twice daily
Allowed co-medications: albuterol as rescue
Outcomes Since this study was primarily an exploratory study to compare the effect of fluticasone/
salmeterol with tiotropium on clinical efficacy, a primary endpoint was not identified
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SCO40034 2005 (Continued)
Notes Funding: GlaxoSmithKline
Identifiers: SCO40034 (GSK)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Allocation concealment (selection bias) Low risk A validated computerised system (RandAll;
GlaxoSmithKline, UK) - using the Regis-
tration and Medication Ordering System
(RAMOS; GlaxoSmithKline, UK), an au-
tomated, interactive telephone-based sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Someone who was not directly involved in
the study received and documented all re-
turned medication in a drug accountabil-
ity log. A separate accountability log was
maintained for each participant and partic-
ipants administered their own study medi-
cation without the investigator or site per-
sonnel being present. Participants were un-
blinded only when knowledge of the treat-
ment was essential for the clinical manage-
ment or welfare of the participant. Cases of
unblinding were to be reported and docu-
mented immediately
Incomplete outcome data (attrition bias)
All outcomes
High risk 117/125 (94%) completed the study, but
withdrawals were imbalanced with 1 (2%)
from the fluticasone/salmeterol arm and 7
(11%) from the tiotropium arm
Selective reporting (reporting bias) High risk Uable to locate protocol. Clinical study re-
port not available through GlaxoSmithK-
line
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SCO40041 2008
Methods Design: randomised, double-blind parallel-group trial
Duration: 3 years
Location: 31 centres in the USA
Participants Population: 186 people were randomised to
1. Salmeterol 50 µg twice daily (94)
2. Fluticasone/salmeterol combination 50/250 µg twice daily (92)
Baseline characteristics
Age (mean years): salmeterol 65.9, fluticasone/salmeterol 65.4
% male: salmeterol 62.8, fluticasone/salmeterol 59.8
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: male/female participants with an established clinical history of
COPD (including a history of exacerbations), a baseline (pre-bronchodilator) FEV1 <
70% of the predicted normal value, a baseline (pre-bronchodilator) FEV1/FVC ratio
70%, have at least one evaluable native hip and have a smoking history of 10 pack-years
Exclusion criteria: history of or evidence for metabolic bone diseases other than osteo-
porosis or osteopenia. Asthma, chronic lung disease other than COPD. LTOT > 12 h/
d. Chronic steroid use
Interventions 1. Salmeterol 50 µg twice daily (LABA)
2. Salmeterol/fluticasone 50/250 µg twice daily (LABA/ICS)
Inhaler device: Diskus
Allowed co-medications: albuterol/salbutamol, theophyllines, short- and long-acting
anti-cholinergic agents, Combivent
Outcomes Change in bone mineral density at the lumbar spine and hip, AEs, SAEs, fatal SAEs
Notes Funding: GlaxoSmithKline
Identifier(s): NCT00355342, GSK SCO40041
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised to treatment
via an interactive voice-response system
Allocation concealment (selection bias) Low risk Participants were randomised to treatment
via an interactive voice-response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind (participants
and personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind (participants
and personnel/investigators)
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal was very high in both groups
(39% and 41%) but breakdown for with-
drawals was similar between two groups
Selective reporting (reporting bias) Low risk Study was prospectively registered, and all
outcomeswere reported in theGSK clinical
study report
Sharafkhaneh 2012
Methods Design: randomised, double-blind, double-dummy, parallel-group, multicentre study
Duration: 12 months (+ 2 week run-in)
Location: 180 study sites in the USA, Central and South America, and South Africa
Participants Population: 1219 participants were randomised to
1. formoterol (404)
2. formoterol/budesonide combination, 2 doses (407 and 408)
Baseline characteristics
Age (mean years): formoterol 62.5, formoterol/budesonide (9/320) 63.8, formoterol/
budesonide1 60 62.8
% male: formoterol 56.8, formoterol/budesonide (9/320) 64.4, formoterol/budesonide
(9/160) 64.7
% FEV1 predicted: formoterol 37.5, formoterol/budesonide (9/320) 37.9, formoterol/
budesonide (9/160) 37.6
Pack-years (mean): formoterol 43, formoterol/budesonide (9/320) 46, formoterol/
budesonide (9/160) 44
Inclusion criteria: current or ex-smokers with a smoking history of 10 pack-years,
aged ≥ 40 years, with a clinical diagnosis of COPD with symptoms for > 2 years.
Participants were required to have a history of 1 COPD exacerbation requiring treatment
with a course of systemic corticosteroids, antibiotics, or both, within 12 months before
screening (visit 1) and documented use of an inhaled short-acting bronchodilator as
rescue medication. At screening, a pre-bronchodilator FEV1 of 50% of predicted normal
and a pre-bronchodilator FEV1/FVC of < 70% also were required
Exclusion criteria: current, previous (within past 60 days), or planned enrolment in a
COPD pulmonary rehabilitation programme, treatment with OCS, and incidence of a
COPD exacerbation or any other significant medical diagnosis between the screening
and randomisation visits
Interventions 1. Formoterol 9 µg twice daily (LABA)
2. Formoterol/budesonide 9/320 µg twice daily (LABA/ICS)
3. Formoterol/budesonide 9/160 µg twice daily (LABA/ICS)
Inhaler device: 1, DPI; 2 and 3 pressurised metered dose
Allowed co-medications: albuterol pressurized MDI 90 µg 2 inhalations was provided
for as-needed use during screening and run-in, and throughout the study
Outcomes COPD exacerbations, FEV1, FVC, morning and evening PEF, diary card symptoms,
rescue medication use, BODE index, exercise capacity, health-relatedQoL (SGRQ), AEs
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Sharafkhaneh 2012 (Continued)
Notes Funding: AstraZeneca
Identifier(s): NCT00419744, D589CC00003 (AstraZeneca)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Assignments were made sequentially by in-
teractive voice-response system following
a computer-generated allocation schedule
produced in advance
Allocation concealment (selection bias) Low risk Assignments were made sequentially by in-
teractive voice-response system following
a computer-generated allocation schedule
produced in advance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk To maintain participant and investigator
blinding, all active treatments were pro-
vided in blinded treatment kits. Partici-
pants in the budesonide/formoterol pMDI
groups received a placebo DPI and those
in the formoterol DPI group received a
placebo pMDI
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators were blinded (presumed in-
vestigators were also outcomes assessors)
Incomplete outcome data (attrition bias)
All outcomes
High risk The withdrawal rates were high and
relatively uneven (budesonide/formoterol
320/9 µg 28.7% budesonide/formoterol
160/9 µg 28.9%, formoterol 9 µg 32.9%)
, especially compared to the low event rates
for the outcomes of interest
Selective reporting (reporting bias) Low risk All outcomes stated in the protocol were
reported in detail.
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Singh 2014
Methods Design: double-blind, parallel-group, active- and placebo-controlled, multicentre phase
3 study
Duration: 24 weeks
Location: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland,
France, Germany, Hungary, Italy, Republic of Korea, Netherlands, Poland, Romania,
Russian Federation, Slovakia, South Africa, Spain, Sweden, Ukraine, UK
Participants Population
1. Aclidinium/formoterol 400/12 µg (385)
2. Aclidinium 400 µg (385)
3. Formoterol 12 µg (384)
Baseline characteristics: age 63.2 (SD 8.0), female:male 560:1169
Inclusion criteria
1. Adult men or non-pregnant, non-lactating women aged ≥ 40.
2. Current or ex-cigarette smoker, with a smoking history of at least 10 pack-years
3. Clinical diagnosis of stable COPD according to the GOLD criteria at the
screening visit
4. FEV1/FVC at the screening visit measured between 10-15 min post-inhalation of
400 µg of salbutamol is < 70% (i.e. 100 x post-salbutamol FEV1 /FVC < 70%)
5. Diagnosis of moderate-severe COPD according to the GOLD classification
(stages 2 and 3) at the screening visit: FEV1 measured between 10-15 min post-
inhalation of 400 µg of salbutamol is 30% < FEV1 < 80% of the predicted normal
value (i.e. 100 x post-salbutamol FEV1/predicted FEV1 must be < 80% and ≥ 30%)
Exclusion criteria:
1. History or current diagnosis of asthma
2. Any respiratory tract infection (including the upper respiratory tract) or COPD
exacerbation in the 6 weeks before screening visit
3. Hospitalised for COPD exacerbation within 3 months prior to screening visit
4. Clinically significant respiratory conditions defined as: known active TB; history
of interstitial lung or massive pulmonary thromboembolic disease; pulmonary
resection or lung volume reduction surgery within 12 months prior to screening visit;
history of lung transplantation; history of bronchiectasis secondary to respiratory
diseases other than COPD (e.g. cystic fibrosis and Kartagener’s syndrom); known a1-
antitrypsin deficiency
5. Use of LTOT (≥ 15 h/d)
6. Clinically significant cardiovascular conditions defined as: MI within the 6
months prior to screening; thoracic surgery within 12 months prior to screening;
unstable angina or unstable arrhythmia which had required changes in the
pharmacological therapy or other intervention within 12 months prior to screening, or
newly diagnosed arrhythmia within the previous 3 months prior to screening;
hospitalisation within 12 months prior to screening for heart failure functional classes
3 (marked limitation of activity and only comfortable at rest) and 4 (need of complete
rest, confinement to bed or chair, discomfort at any physical activity and presence of
symptoms at rest) as per the NYHA
7. Interval corrected for heart rate “QTc” (calculated according to formulae (QTc =
QT/RR1/2) > 470 msec as indicated in the centralised reading report assessed at
screening visit
8. Clinically relevant abnormalities in the clinical laboratory tests, ECG parameters
or in the physical examination at screening, if the abnormality defined a disease state
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listed as exclusion criteria, except for those related to COPD
9. Known narrow-angle glaucoma, symptomatic bladder neck obstruction or acute
urinary retention.
10. Symptomatic non-stable prostate hypertrophy. (However, patients with well-
controlled, stable, asymptomatic benign prostatic hypertrophy were not excluded).
11. Known uncontrolled history of infection with HIV and/or active hepatitis
12. Current diagnosis of cancer other than basal or squamous cell skin cancer
13. Life expectancy of < 1 year
Interventions Inhaler device
1. Breath-actuated, multiple-dose DPI
2. Aclidinium Bromide/Formoterol Fumarate
3. Aclidinium Bromide
4. Formoterol Fumarate
Allowed co-medications: as-needed salbutamol, ICSs
Outcomes Primary: CFB in 1-h morning post-dose FEV1, CFB in morning pre-dose (trough)
FEV1
Notes Funding: AstraZeneca
Identifiers: NCT01462942, M/40464/30 (AstraZeneca)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A centralised interactive voice-response sys-
tem
Allocation concealment (selection bias) Low risk A centralised interactive voice-response sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Major adverse
cardiovascular events (MACE; a composite
of total cardiovascular death, non-fatal MI
and non-fatal stroke) were evaluated and
classified by an independent, blinded adju-
dication committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout low and even among the groups
of interest (aclidinium/formoterol (400/12
µg) 8.8 %, aclidinium (400 µg) 13.0 %,
formoterol (12 µg) 11.7%)
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Singh 2014 (Continued)
Selective reporting (reporting bias) Low risk All outcomes stated in the protocol were
reported in detail.
Singh 2015a
Methods Design: randomised, double-blind, placebo- and active-controlled parallel-group study
Duration: 12 weeks
Location: Belgium, Canada, Czech Republic, Denmark, Finland, Germany, South
Africa, Spain, UK, USA
Participants Population
1. Tiotropium/olodaterol 5/5 µg (203)
2. Tiotropium 5 µg (203)
Baseline characteristics: age 64.8 (SD 8.4) female:male 331:481
Inclusion criteria
1. Diagnosis COPD
2. Relatively stable airway obstruction with post FEV1 ≥ 30 and < 80% predicted
normal and post FEV1/FVC < 70%
3. Male or female, ≥ 40 years of age
4. Smoking history > 10 pack-years
Exclusion criteria
1. Significant diseases other than COPD
2. History of asthma
3. COPD exacerbation in previous 3 months
4. Completion of pulmonary rehabilitation programme within previous 6 weeks or
current participation in pulmonary rehabilitation programme
5. Pregnant or nursing women
6. Inability to comply with pulmonary medication restrictions
Interventions 1. Tiotropium/olodaterol
2. Tiotropium
Inhaler device: Respimat inhaler
Allowed co-medications: as-needed salbutamol, ICS
Outcomes Primary: FEV1, SGRQ score
Notes Funding: Boehringer Ingelheim
Identifiers: NCT01964352, 1237.25
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, not defined but industry-
funded
Allocation concealment (selection bias) Unclear risk Not described
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Singh 2015a (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low in both included
groups (tiotropium 5.4%, tiotropium/olo-
daterol 4.1%)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Singh 2015a&b
Methods Design: randomised, double-blind, placebo- and active-controlled parallel-group study
Duration: 12 weeks
Location: see Singh 2015a and Singh 2015b
Participants Population: see Singh 2015a and Singh 2015b
Baseline characteristics: see Singh 2015a and Singh 2015b
Inclusion criteria
1. Diagnosis COPD
2. Relatively stable airway obstruction with post FEV1 ≥ 30 and < 80% predicted
normal and post FEV1/ FVC < 70%
3. Male or female patients, ≥ 40 years of age
4. Smoking history more than 10 pack-years
Exclusion criteria
1. Significant diseases other than COPD
2. History of asthma
3. COPD exacerbation in previous 3 months
4. Completion of pulmonary rehabilitation programme within previous 6 weeks or
current participation in pulmonary rehabilitation programme
5. Pregnant or nursing women
6. Inability to comply with pulmonary medication restrictions
Interventions 1. Tiotropium/olodaterol
2. Tiotropium
Inhaler device: Respimat inhaler
Allowed co-medications: as-needed salbutamol, ICS
Outcomes Primary: FEV1, SGRQ score
Notes Funding: Boehringer Ingelheim
Identifiers: NCT01964352, 1237.25, NCT02006732, 1237.26
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, not defined but industry-
funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low in both included
groups (See Singh 2015a and Singh 2015b)
.
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Singh 2015b
Methods Design: randomised, double-blind, placebo- and active-controlled parallel-group study
Duration: 12 weeks
Location: Australia, Austria, Canada, Germany, Greece, New Zealand, Norway, Slo-
vakia, South Africa, Sweden, USA
Participants Population
1. Tiotropium/olodaterol 5/5 µg (202)
2. Tiotropium 5 µg (203)
Baseline characteristics: age 64.6 (SD 8.4)
Inclusion criteria
1. Diagnosis COPD
2. Relatively stable airway obstruction with post FEV1 ≥ 30 and < 80% predicted
normal and post FEV1/FVC < 70%
3. Male or female patients, 40 years of age or more
4. Smoking history more than 10 pack-years
Exclusion criteria:
1. Significant diseases other than COPD
2. History of asthma
3. COPD exacerbation in previous 3 months
4. Completion of pulmonary rehabilitation programme within previous 6 weeks or
current participation in pulmonary rehabilitation programme
5. Pregnant or nursing women
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6. Inability to comply with pulmonary medication restrictions
Interventions 1. Tiotropium/olodaterol
2. Tiotropium
Inhaler device: Respimat inhaler
Allowed co-medications: as-needed salbutamol, ICS
Outcomes Primary Outcome Measures: FEV1, SGRQ score.
Notes Funding: Boehringer Ingelheim
Identifiers: NCT02006732, 1237.26
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, not defined but industry-
funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low in both included
groups (tiotropium 2.0%, tiotropium/olo-
daterol 5.9%)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Singh 2015c
Methods Design: randomised, double-blind, parallel-group, double-dummy, placebo-controlled
trial
Duration: 12 weeks
Location: 8 countries (mainly EU), 79 centres
Participants Population
1. Umeclidinium/vilanterol 62.5/25 µg (358)
2. Fluticasone propionate/salmeterol 50/250 µg (358)
Baseline characteristics
Age: 61.6 years (SD 8.0)
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Male/female: 515/201
% predicted FEV1: 50.6% (SD 10.7%)
Inclusion criteria: % predicted FEV1 30%-70%, mMRC ≥ 2, without recent exacer-
bation
Exclusion criteria: pregnancy/breast feeding, asthma, other respiratory disorders, clini-
cally significant comorbidities, hypersensitivity to any anticholinergic/muscarinic recep-
tor antagonist, beta2-agonist, corticosteroid, history of COPD exacerbation: a docu-
mented history of at least 1 COPD exacerbation in the 12 months prior to visit 1, recent
lung resection < 12 months, LTOT > 12 h/d, drug or alcohol abuse
Interventions 1. Umeclidinium/vilanterol (62.5/25 µg). LAMA/LABA
2. Salmeterol/fluticasone (50/500 µg) twice daily. LABA/ICS
Inhaler device:
1. Umeclidinium/vilanterol: dry white powder DPI
2. Fluticasone propionate/salmeterol: Accuhaler/Diskus
Allowed co-medications: SABA as rescue
Outcomes Primary: CFB in 0-24 h weighted mean serial FEV1 at day 84
Notes Funding: GlaxoSmithKline
Identifiers: NCT01822899, DB2116134 (GSK)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gen-
erated using a validated computer system
(RanAll, GSK)
Allocation concealment (selection bias) Low risk Central randomisation schedule was gen-
erated using a validated computer system
(RanAll, GSK)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study was double-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The investigator and treating physician
were kept blinded unless an emergency
arose
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rate was low and even be-
tween active comparators, 6.7% in umecli-
dinium/vilanterol arm and 5.0% in salme-
terol/fluticasone arm
Selective reporting (reporting bias) Low risk Study was registered and the prespecified
outcomes were appropriately described
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Szafranski 2003
Methods Design: randomised, double-blind, placebo-controlled, parallel-group, multicentre
study
Duration: 12 months (+ 2-week run-in period)
Location: 89 centres from 11 countries
Participants Population: 812 participants were randomised to
1. formoterol 12 µg twice daily (201)
2. budesonide 400 µg twice daily (198)
3. formoterol/budesonide combination 9/320 µg twice daily (208)
4. placebo (205)
Baseline characteristics
Age (mean years): formoterol 63, budesonide 64, formoterol/budesonide 64, placebo 65
% male: formoterol 76, budesonide 80, formoterol/budesonide 76, placebo 83
% FEV1 predicted: formoterol 36, budesonide 37, formoterol/budesonide 36, placebo
36
Pack-years (mean): formoterol 45, budesonide 44, formoterol/budesonide 44, placebo
45
Inclusion criteria: men and women aged ≥ 40 years; symptoms for > 2 years; history
of at least 10 pack-years
Exclusion criteria: history of asthma or seasonal rhinitis before 40 years of age; relevant
CVDs; use of beta-blockers; current respiratory tract disorders other than COPD or any
other significant diseases or disorders; requiring regular use of oxygen therapy; exacerba-
tion during run-in
Interventions 1. Formoterol 12 µg twice daily (LABA)
2. Budesonide 400 µg twice daily (ICS)
3. Formoterol/budesonide 9/320 µg twice daily (LABA/ICS)
4. Placebo
Inhaler device: dry powder Turbuhaler
Allowed co-medications: terbutaline (0.5 mg) as reliever. Disallowed medication in-
cluded parenteral steroids, oral steroids, antibiotics and nebulised treatment from4weeks
before; ICS from 2 weeks before; inhaled LABA from 48 h before; inhaled SABA from
6 h before; other bronchodilators from 6-48 h before
Outcomes SGRQ, COPD exacerbations, FEV1, vital capacity, morning and evening PEF, diary
card data
Notes Funding: AstraZeneca
Identifier(s): SD-039-CR-0629 (AstraZeneca)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A total of 812 participants were ran-
domised (no other details, industry-spon-
sored)
Allocation concealment (selection bias) Unclear risk No details
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (presumed participant and
investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators were blinded (presumed in-
vestigators were also outcomes assessors)
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal high and uneven between
groups (formoterol 32%, formoterol/
budesonide 28%). Higher withdrawal rate
due to COPD deterioration with for-
moterol (14%) vs formoterol/budesonide
(10%). An ITT analysis was used
Selective reporting (reporting bias) High risk QoL (primary) stated as outcome but not
reported in enough detail to include in
meta-analysis. Safety and exacerbation out-
comes were not reported in enough detail
Tashkin 2008
Methods Design: randomised, double-blind, double-dummy, placebo-controlled, parallel-group,
multicentre study
Duration: 6 months (+ 2-week run-in period)
Location: 194 centres in the USA, Czech Republic, the Netherlands, Poland and South
Africa
Participants Population: 1704 participants were randomised to
1. formoterol (284),
2. budesonide (275),
3. formoterol/budesonide combination: three doses (281, 277 and 287, one of
which was not included in the review as they were delivered in separate inhalers)
4. and placebo (300)
Baseline characteristics
Age (mean years): formoterol 63.5, budesonide 63.4, formoterol/budesonide (9/160)
63.6, formoterol/budesonide (9/320) 63.1, placebo 63.2
% male: formoterol 65.5, budesonide 67.6, formoterol/budesonide (9/160) 64.4, for-
moterol/budesonide (9/320) 67.9, placebo 69
% FEV1 predicted: formoterol 39.6, budesonide 39.7, formoterol/budesonide (9/160)
39.9, formoterol/budesonide (9/320) 39.1, placebo 41.3
Pack-years (median): formoterol 40, budesonide 41, formoterol/budesonide (9/160) 40,
formoterol/budesonide (9/320) 40, placebo 40
Inclusion criteria: male and female current or former smokers; history of at least 10
pack-years; clinical diagnosis of COPD; > 40 years; symptoms for > 2 years; at least
1 exacerbation treated with systemic corticosteroids and/or antibacterials within 1-12
months before screening
Exclusion criteria: history of asthma or seasonal rhinitis before age 40; significant/
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unstable CVD; significant respiratory tract disorder other than COPD; homozygous
alpha1-antitrypsin deficiency or other clinically significant co morbidities precluding
participation
Interventions 1. Formoterol 12 µg twice daily (LABA)
2. Budesonide 320 µg twice daily (ICS)
3. Formoterol/budesonide 9/160 µg twice daily in one inhaler (LABA/ICS)
4. Formoterol/budesonide 9/320 µg twice daily in one inhaler (LABA/ICS)
5. Placebo
Inhaler device: DPI
Allowed co-medications: allowedmedications were ephedrine-free antitussives andmu-
colytics; nasal corticosteroids; stable-dose non-nebulised ipratropium; cardioselective
beta-adrenoceptor antagonists; salbutamol as rescue; oral steroids, xanthines, inhaled
beta-agonists and ipratropium as medication for exacerbations. Medications disallowed
during the study period were long-acting anticholinergics; inhaled LABAs or SABAs
(other than salbutamol); oral beta-adrenoreceptor agonists; ephedrine; leukotriene re-
ceptor agonists and xanthine derivatives except for short-term use
Outcomes SGRQ including number of people reaching threshold for minimal clinically important
difference from baseline (4 units), COPD exacerbations per patient year, pre-dose FEV1
and 1-hour post-dose FEV1, dyspnoea, morning and evening PEF
Notes Funding: AstraZeneca
Identifier(s): NCT00206154, D5899C00002 (SHINE)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible participants were randomised in
balanced blocks according to a computer-
generated randomisation scheme at each
site
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Tomaintain blinding, participants received
both a pressurised MDI and a DPI con-
taining either active treatment or placebo,
or combinations of active treatment and
placebo, as appropriate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double-dummy. Investiga-
tors were blinded (presumed investigators
were also outcomes assessors)
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal rates were
higher with formoterol (21.5% formoterol,
14.1% budesonide/formoterol 320/9, and
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13.5% budesonide/formoterol 160/9) and
more participants were discontinue due to
AE with formoterol (12% formoterol, 7.
6% budesonide/formoterol 320/9 µg, and
7.1% budesonide/formoterol 160/9 µg) )
. The efficacy analysis set included all ran-
domised patients who received at least one
dose of study medication and contributed
sufficient data for at least one co-primary
or secondary efficacy endpoint
Selective reporting (reporting bias) Low risk All stated outcomes were reported in full
and included in the quantitative synthesis
Tashkin 2009
Methods Design: randomised, double-blind, active-control, parallel-group trial
Duration: 12 weeks
Location: 35 centres across the USA, of which the majority were primary care centres
Participants Population: 255 adults with a clinical history of COPD randomised to
1. tiotropium + formoterol (124 participants)
2. tiotropium (131 participants)
Baseline characteristics: mean age 64 years. COPD severity mild-severe. 67% men
Inclusion criteria: men and non-pregnant women aged > 40 years who had a clinical
history of COPD. Each participant had a post-bronchodilator FEV1 < 70% and > 30%
predicted normal or > 0.75 L, whichever was less, at run-in, and FEV1/FVC < 0.70
at screening and run-in. Daytime and/or night-time symptoms of COPD, including
dyspnoea, must have been present on ≥ 4 of the 7 days before the baseline visit
Exclusion criteria: current or previous history of asthma or other significant medical
condition that may have interfered with study treatment as assessed by the investigator,
smoking cessationwithin the previous 3months, ventilator support for respiratory failure
within the previous year, the use of oxygen (≥ 2 L/min or for > 2 h/d), initiation of
pulmonary rehabilitation within the previous 3 months, the requirement for nasal
continuous positive airway pressure or bilevel positive airway pressure, clinically signifi-
cant lung disease other than COPD (i.e. bronchiectasis, sarcoidosis, pulmonary fibrosis,
TB), sleep apnoea, chronic narrow-angle glaucoma, symptomatic prostatic hyperplasia
or bladder neck obstruction, and the need for chronic or prophylactic antibiotic therapy
Interventions Inhaler device
1. Formoterol (Foradil Aerolizer) 12 µg twice daily and tiotropium (HandiHaler) 18
µg once daily in the morning delivered via 2 separate inhalers
2. Formoterol-matched placebo twice daily and tiotropium 18 µg once daily
delivered via 2 separate inhalers
Allowed co-medications: as-needed albuterol, ICS
Outcomes Primary: normalised AUC for FEV1 measured 0-4 h post-morning dose at the last visit
Secondary: changes from baseline in trough (mean of values obtained 10 and 30 min
pre-dose) FEV1 and FVC, weekly morning and evening PEF, symptom severity scores,
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TDI, and health-related QoL (SGRQ) scores, number and severity of exacerbations,
the global therapeutic response, discontinuations because of worsening COPD, and
% participants achieving targeted improvements in the SGRQ and TDI scores, use of
rescue albuterol, nocturnal awakenings requiring rescue albuterol, changes in study or
concomitant medications, and AEs
Notes Funding: Schering Corporation
Identifiers: NCT00139932
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised sequentially
as they qualified for the study according to
a pre-generated computer code labelled on
the medication kit
Allocation concealment (selection bias) Low risk Participants were randomised sequentially
as they qualified for the study according to
a pre-generated computer code labelled on
the medication kit
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number of withdrawals in the different
groups was relatively low but uneven (14.
5% with formoterol + tiotropium, 6.1%
with tiotropium + placebo)
Selective reporting (reporting bias) Low risk Results for all listed primary and secondary
outcomes were reported
Tashkin 2012a
Methods See Tashkin 2012a&b
Participants See Tashkin 2012a&b
Interventions See Tashkin 2012a&b
Outcomes See Tashkin 2012a&b
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Notes Funding:Merck & Co/Schering-Plough
Identifiers: NCT00383435, Merck P04230AM4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The sponsor’s statistician produced a computer-generated ran-
domisation schedule with treatment codes in blocks using com-
puter software. Randomisation was stratified according to the
participant’s smoking status at the time of randomisation
Allocation concealment (selection bias) Low risk Randomised treatment assignment was provided to the inves-
tigative site by means of an interactive voice-response system
at the time participants were randomised
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Protocol describes the study masking as double-blind (partici-
pant, investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A prospective statistical analysis plan for evaluation of pooled
results was completed before unblinding of the 2 studies
Incomplete outcome data (attrition bias)
All outcomes
Low risk See Tashkin 2012a&b
Selective reporting (reporting bias) Low risk Study was prospectively registered, and all results were available
from the published reports and clinicaltrials.gov
Tashkin 2012a&b
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 6 months (+ 2-week run-in period)
Location: 131 centres located in South America, Asia, Africa, Europe andNorth America
Participants Population: 1055 participants were randomised to
1. formoterol (209)
2. mometasone (210)
3. formoterol/mometasone combination (two doses; 217 and 207)
4. placebo (212)
Baseline characteristics
Age (mean years): formoterol 59.6, mometasone 59.8, formoterol/mometasone (10/400
µg) 59.7, formoterol/mometasone (10/200 µg) 60.9, placebo 58.8
% male: formoterol 72.7, mometasone 78.1, formoterol/mometasone (10/400 µg) 78.
8, formoterol/mometasone (10/200 µg) 77.8, placebo 80.2
% FEV1 predicted: not reported
Pack-years (mean): formoterol 40.3, mometasone 40.0, formoterol/mometasone (10/
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400 µg) 39.7, formoterol/mometasone (10/200 µg) 41.7, placebo 40.3
Inclusion criteria: men and women aged ≥ 40 years; history of at least 10 pack-years;
moderate-severe COPD for at least 2 years; predicted FEV1 between 25% and 60%
normal
Exclusion criteria: exacerbation in the 4weeks before randomisation; significantmedical
illness; diagnosis of asthma, lung cancer or alpha1-antitrypsin deficiency, lobectomy,
pneumonectomy, lung volume reduction surgery or ocular problems
Interventions 1. Formoterol 10 µg twice daily (LABA)
2. Mometasone 400 µg twice daily (ICS)
3. Formoterol/mometasone 10/400 µg twice daily (LABA/ICS)
4. Formoterol/mometasone 10/200 µg twice daily (LABA/ICS)
5. Placebo (placebo)
Inhaler device: metered dose
Allowed co-medications: participants were given open-label, SABA/short-acting anti-
cholinergic fixed-dose combination to use as relief medication throughout the study
All long-acting COPD treatments (LABA, ICS, LABA/ICS FDC or long-acting anti-
cholinergics), supplemental oxygen and beta-blocking agents were not allowed during
the study period
Outcomes SQRQ, reported as both final scores and the number of people experiencing a MCID
(improvement or worsening by 4 units), COPD exacerbations, serial FEV1 post-dose,
standardised FEV1 AUC, systemic and ocular effects
Notes Funding: Merck & Co/Schering-Plough
Identifier(s): NCT00383435 (Tashkin 2012a), NCT00383721 (Tashkin 2012b),
P04229AM4, P04230AM4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The sponsor’s statistician produced a com-
puter-generated randomisation schedule
with treatment codes in blocks using com-
puter software. Randomisation was strati-
fied according to the participant’s smoking
status at the time of randomisation
Allocation concealment (selection bias) Low risk Randomised treatment assignment was
provided to the investigative site by means
of an interactive voice-response system at
the time participants were randomised
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Protocol describes the study masking as
double-blind (participant, investigator)
229Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tashkin 2012a&b (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A prospective statistical analysis plan for
evaluation of pooled results was completed
before unblinding of the 2 studies (Tashkin
2012a and Tashkin 2012b).
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were relatively low and
even among active comparators (18.9% in
formoterol/mometasone 10/400 µg, 18.
4% in formoterol/mometasone 10/200µg,
and 17.7% in formoterol)
Selective reporting (reporting bias) Low risk Study was prospectively registered, and all
results were available from the published
reports and clinicaltrials.gov
Tashkin 2012b
Methods See Tashkin 2012a&b
Participants See Tashkin 2012a&b
Interventions See Tashkin 2012a&b
Outcomes See Tashkin 2012a&b
Notes Funding:Merck & Co/Schering-Plough
Identifiers: NCT00383721, Merck P04229AM4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The sponsor’s statistician produced a computer-generated ran-
domisation schedule with treatment codes in blocks using com-
puter software. Randomisation was stratified according to the
participant’s smoking status at the time of randomisation
Allocation concealment (selection bias) Low risk Randomised treatment assignment was provided to the inves-
tigative site by means of an interactive voice-response system
at the time participants were randomised
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Protocol describes the study masking as double-blind (partici-
pant, investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A prospective statistical analysis plan for evaluation of pooled
results was completed before unblinding of the 2 studies
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Incomplete outcome data (attrition bias)
All outcomes
Low risk See Tashkin 2012a&b
Selective reporting (reporting bias) Low risk Study was prospectively registered, and all results were available
from the published reports and clinicaltrials.gov
To 2012
Methods Design: multicentre, randomised, double-blind, placebo-controlled, parallel-group
study
Duration: 12 weeks
Location: Hong Kong, India, Japan, Korea, Republic of, Singapore, Taiwan
Participants Population
1. Indacaterol 150 µg (114)
2. Indacaterol 300 µg (116)
Baseline characteristics: age 66.7 (SD 8.38) female:male 12:335
Inclusion criteria
Diagnosis of moderate-to-severe COPD, as classified by the GOLD criteria and:
1. Smoking history of at least 20 pack-years
2. Post-bronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value
3. Post-bronchodilator FEV1/FVC < 70%
Exclusion criteria:
1. Hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during
the 14-day run-in period prior to randomisation
2. LTOT (> 15 h/d) for chronic hypoxaemia
3. Respiratory tract infection within 6 weeks prior to screening
4. Concomitant pulmonary disease
5. History of asthma
6. Diabetes type 1 or uncontrolled diabetes type 2
7. Lung cancer or a history of lung cancer
8. Active cancer or a history of cancer with < 5 years disease-free survival time
9. History of long QT syndrome or whose QTc interval (Bazett’s) measured at
screening or randomisation is prolonged
10. Vaccinated with live attenuated vaccines within 30 days prior to screening or
during the run-in period
11. Inability to successfully use a DPI device or perform spirometry measurements
Interventions Inhaler device
1. Indacaterol: powder-filled capsules with a single-dose DPI
Allowed co-medications: as-needed salbutamol, ICS
Outcomes Primary: trough FEV1 24 h post-dose at the end of treatment (week 12 + 1 day, day 85)
Notes Funding: Novartis
Identifiers: NCT00794157, CQAB149B1302
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised (1:1:1) using
a validated automated system
Allocation concealment (selection bias) Low risk Participants were randomised (1:1:1) using
a validated automated system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low and even in both
included groups (8.8% in indacaterol 150
µg and 8.6% in indacaterol 300 µg group)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Troosters 2016
Methods Design: randomised, partially double-blinded, placebo-controlled parallel-group study
Duration: 12 weeks
Location: Australia, Austria, Belgium, Canada, Denmark, Germany, New Zealand,
Poland, Portugal, UK, USA
Participants Population
1. Tiotropium/olodaterol 5/5 µg (76)
2. Tiotropium 5 µg (76)
Baseline characteristics: age 64.8 (SD 6.6) female:male 103:200
Inclusion criteria
1. Signed informed consent consistent with International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use - Good Clinical Practice guidelines prior to participation in the trial,
which includes medication washout and restrictions
2. Diagnosis of COPD and must meet the following spirometric criteria:
i) relatively stable airway obstruction with a post-bronchodilator FEV1 ≥30%
and < 80% of predicted normal
ii) GOLD grade 2-3,
iii) post-bronchodilator Tiffeneau index < 70% at visit 1
3. Male or female patients, aged ≥ 40 years and ≤ 75 years
4. Current or ex-smokers with a smoking history of more than 10 pack-years.
Patients who had never smoked cigarettes were excluded.
Exclusion criteria
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1. Significant disease other than COPD
2. Clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis
3. History of asthma
4. Diagnosis of paroxysmal tachycardia (> 100 bpm)
5. History of MI within 1 year of screening visit
6. Unstable or life-threatening cardiac arrhythmia
7. Hospitalised for heart failure within the past year
8. Known active TB
9. Malignancy treated by resection, radiation therapy or chemotherapy within last 5
years
10. History of life-threatening pulmonary obstruction and current chronic respiratory
failure
11. History of cystic fibrosis
12. Clinically evident bronchiectasis
13. Undergone thoracotomy with pulmonary resection
14. Currently being treated with any oral ß-adrenergics
15. Currently being treated with OCS medication at unstable doses (i.e. < 6 weeks on
a stable dose) or at doses > the equivalent of 10 mg of prednisone/d or 20 mg every
other day.
16. Regular use of daytime oxygen therapy for > 1 h/d and in the investigators’
opinion will be unable to abstain from the use of oxygen therapy during clinic visits
Interventions 1. Tiotropium + olodaterol
2. Tiotropium
Inhaler device: Respimat Inhaler
Allowed co-medications: salbutamol as rescue, ICS
Outcomes Primary: endurance time during endurance shuttle walk test to symptom limitation
After 8 Weeks
Notes Funding: Boehringer Ingelheim
Identifiers: NCT02085161
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Partially double-blinded, as it was not pos-
sible to blind the group receiving exercise
training
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of outcome assessors
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Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout was relatively low but uneven be-
tween included arms (tiotropium 13.2%,
tiotropium/olodaterol 6.6%)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Vincken 2014
Methods Design: multicentre, randomised, double-blind, parallel-group study
Duration: 12 weeks
Location: Belgium, Bulgaria, Greece, Hungary, Ireland, Russian Federation, Slovakia,
Spain, Turkey, UK
Participants Population
1. Indacaterol + glycopyrronium 110/50 µg (226)
2. Indacaterol 150 µg (221)
Baseline characteristics: age 63.7 (SD 8.07) female:male 81/366
Inclusion criteria
1. Moderate-severe stable COPD stage 2 or stage 3 according to GOLD criteria
2. Post-bronchodilator FEV1 ≥ 30% and/or < 80% of the predicted normal, and a
post-bronchodilator FEV1/FVC < 0.70 at screening
3. Current or ex-smokers who have a smoking history of at least 10 pack-years
4. Symptomatic patients according to daily diary data
Exclusion criteria
1. Pregnant or nursing (lactating) women
2. Women of child-bearing potential unless using adequate contraception
3. Type I or uncontrolled type 2 diabetes
4. History of long time interval between start of Q wave and end of T wave in the
heart’s electrical cycle (QT) syndrome or whose QTc measured at screening (visit 2)
(Fridericia’s method) is prolonged
5. Paroxysmal (e.g. intermittent) atrial fibrillation
6. Clinically significant ECG or laboratory abnormality at screening (visit 2)
Interventions Inhaler device: glycopyrronium (NVA237) 50 µg and indacaterol 150 µg supplied as
blistered capsules for inhalation
Allowed co-medications: as-needed salbutamol, ICSs
Outcomes Primary: trough FEV1 (time frame: 12 weeks)
Notes Funding: Novartis
Identifiers: NCT01604278, CNVA237A2316
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk An automated, interactive, voice-response
technology
Allocation concealment (selection bias) Low risk An automated, interactive, voice-response
technology
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, investigators, site staff, asses-
sors and data analysts were blind to the
identity of the treatment from the time of
randomisation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low and even in both
included groups (6.2% in indacaterol +
glycopyrronium and 5.8% in indacaterol
group)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Vogelmeier 2008
Methods Design: randomised, partially blinded, placebo-controlled trial
Duration: 6 months (+ 2-week run-in)
Location: outpatient and specialist clinics at 86 centres in 8 countries
Participants Population: 847 participants were randomised to
1. tiotropium + formoterol (207)
2. formoterol (210)
3. tiotropium (221)
4. placebo (209) - not included in this review
Baseline characteristics
Age (mean years): formoterol 61.8, tiotropium 63.4, placebo 62.5
% male: formoterol 75.7, tiotropium 79.2, placebo 77.5
% FEV1 predicted: formoterol 51.6, tiotropium 51.6, placebo 51.1
Pack-years (mean): formoterol 35.4, tiotropium 38.6, placebo 40.1
Inclusion criteria: men and women aged ≥ 40; history of at least 10 pack-years; FEV1
< 70% predicted normal; FEV1/FVC < 70%
Exclusion criteria: respiratory tract infection or hospitalised for an acute exacerbation
within the month before screening; clinically significant condition other than COPD
such as ischaemic heart disease
Interventions 1. Tiotropium 18 µg once daily (LAMA) + formoterol 10 µg twice daily (LABA)
2. Formoterol 10 µg twice daily (LABA)
3. Tiotropium 18 µg once daily (LAMA) - open-label
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4. Placebo
Inhaler device:
1. Multi-dose DPI
2. Tiotropium open-label
Allowed co-medications: salbutamol as rescue (but not in the 8 h before a study visit);
ICS were allowed at a stable daily dose. Any participants receiving fixed combinations of
ICS and beta2-agonists were switched to receive the same dose of ICS and on-demand
salbutamol
Outcomes SGRQ, COPD exacerbations, FEV1 and FEV measured at 5 min, 2 h and 3 h post-
dose, PEF, 6MWD, haematology, blood chemistry, ECG, diary card data
Notes Funding: Novartis
Identifier(s): NCT00134979, CFOR258F2402
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was not stratified (no other
information given but assumed to follow
convention Novartis sequence generation
methods)
Allocation concealment (selection bias) Low risk Randomisation was not stratified (no other
information given but assumed to follow
convention Novartis sequence generation
methods)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Tiotropium was delivered open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Tiotropium was delivered open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rate was relatively low (12%-
13%) and even across active comparators.
The ITT population consisted of all ran-
domised participants who received ≥ 1
dose of study medication. This population
was used for efficacy and safety analyses
Selective reporting (reporting bias) High risk FEV1 and SGRQ outcomes only provided
in graphical form only with inexact P value
236Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vogelmeier 2011
Methods Design: randomised, double-blind, double-dummy, parallel-group study
Duration: 1 year (+ 2-week run-in)
Location: 725 centres in 25 countries
Participants Population: 7376 participants were randomised to
1. tiotropium (3707)
2. salmeterol (3669)
Baseline characteristics
Age (mean years): salmeterol 62.8, tiotropium 62.9
% male: salmeterol 74.9, tiotropium 74.4
% FEV1 predicted: salmeterol 49.4, tiotropium 49.2
Pack-years (mean): salmeterol 37.8, tiotropium 38.8
Inclusion criteria: ≥ 40 years of age; smoking history of ≥ 10 pack-years; a diagnosis
of COPD; a FEV1 after bronchodilation of < 70% of the predicted value; a ratio of
FEV1/FVC of < 70%, and a documented history of at least one exacerbation leading
to treatment with systemic glucocorticoids or antibiotics or hospitalisation within the
previous year
Exclusion criteria: significant disease other than COPD; diagnosis of asthma; life-
threatening pulmonary obstruction, or a history of cystic fibrosis; active TB; narrow-
angle glaucoma;MI or hospital admission for heart failure within the year prior to visit 1;
cardiac arrhythmia requiring medical or surgical treatment; severe CVD; hypersensitivity
to components of study drugs; respiratory infection or exacerbation in the 4 weeks prior
to visit 1
Interventions 1. Salmeterol 50 µg twice daily (LABA) + HandiHaler placebo
2. Tiotropium 18 µg once daily (LAMA) + pMDI placebo
Inhaler device: HandiHaler and pMDI
Allowed co-medications: participants’ usual COPDmedications except for anticholin-
ergic drugs and LABA, during the double blind treatment phase
Outcomes Primary: time to first exacerbation
Secondary: time-to-event end points, number-of-event end points, SAEs, and death
Notes Funding: Boehringer Ingelheim and Pfizer
Identifier(s): NCT00563381
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation list was generated by the
sponsor using a validated system involving
a pseudo random-number generator. Par-
ticipants were randomised in a 1:1 ratio
in blocks of 4,with equal allocationof treat-
ment within each block per country site
Allocation concealment (selection bias) Low risk Participants were randomised to treatment
via an interactive voice-response system
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(Perceptive Informatics Inc., Berlin, Ger-
many)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was maintained by allocation of a
dummy placeboMDI to those randomised
to the tiotropium arm and a dummy
placebo HandiHaler to those in the salme-
terol arm.Tiotropiumandplacebo capsules
were identical in size and colour and were
therefore indistinguishable
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A committee assessing cause of death was
blind to treatment group. Review authors
judged that other outcomes were blind too
Incomplete outcome data (attrition bias)
All outcomes
Low risk The efficacy and safety analyses included
all the participants who underwent ran-
domisation and who received ≥ 1 dose of
the study medication. Fewer participants
in the tiotropium group than in the salme-
terol group withdrew from the study pre-
maturely: 585 participants (15.8%) vs 648
participants (17.7%) but both were judged
to be low over a year and considering im-
putation of missing values
Selective reporting (reporting bias) Low risk Outcomes were well reported in the publi-
cations and on clinicaltrials.gov
Vogelmeier 2013a
Methods Design: randomised, double-blind, parallel-group, double-dummy, placebo-controlled
study
Duration: 26 weeks
Location: 10 countries and 92 centres (mainly EU countries)
Participants Population
1. Indacaterol/glycopyrronium (258)
2. Fluticasone propionate/salmeterol (264)
Baseline characteristics:
Age: indacaterol/glycopyrronium, 63.2 years (SD8.2); salmeterol/fluticasone , 63.4 years
(SD 7.7)
Male/female: indacaterol/glycopyrronium, 181/77; salmeterol/fluticasone , 189/75
% predicted FEV1: indacaterol/glycopyrronium, 60.5% (SD 10.5%); salmeterol/fluti-
casone , 60.0% (SD 10.7%)
Inclusion criteria: COPD stage 2/3 without recent exacerbation
Exclusion criteria: pregnancy, significant comorbidities, history of malignancy, COPD
exacerbations within the last year, LTOT, asthma, other concomitant lung disease, lung
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transplant
Interventions 1. Indacaterol/glycopyrronium (110/50 µg) once daily
2. Salmeterol/fluticasone (50/500 µg) twice daily
Inhaler device:
1. indacaterol/glycopyrronium: DPI
2. fluticasone propionate/salmeterol: dry inhalation powder delivered via Accuhaler
Allowed co-medications: SABA as rescue
Outcomes Primary outcome: FEV1 AUC (0-12 h)
Notes Funding: Novartis
Identifiers: NCT01315249, CQVA149A2313
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Investigators used an automated, inter-
active-response technology to assign ran-
domisation numbers to participants
Allocation concealment (selection bias) Low risk Investigators used an automated, inter-
active-response technology to assign ran-
domisation numbers to participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study was double-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation data were kept strictly con-
fidential until the time of unblinding and
were not accessible by anyone else involved
in the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal was relatively low and even be-
tween active comparators, 17.0% in inda-
caterol/glycopyrronium arm and 17.0% in
salmeterol/fluticasone arm
Selective reporting (reporting bias) Low risk Study was registered and the prespecified
outcomes were appropriately described
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Methods Design: randomised, double-blind, parallel-group, double-dummy, placebo-controlled
trial
Duration: 24 weeks
Location: 14 countries and 126 centres (mainly EU countries)
Participants Population
1. Aclidinium/formoterol (467)
2. Fluticasone propionate/salmeterol (466)
Baseline characteristics: age: 63.4 years (SD 7.8). Male/female: 607/326
Inclusion criteria: % predicted FEV1 < 80%, CAT ≥ 10, without recent exacerbation
Exclusion criteria: pregnancy, significant comorbidities, history of malignancy, COPD
exacerbations within the last 3 months, LTOT (> 15 h/d), asthma, other concomitant
lung disease
Interventions 1. Aclidinium/formoterol (400/12 µg) twice daily
2. Salmeterol/fluticasone (50/500 µg) twice daily
Inhaler device:
1. Aclidinium/formoterol: Genuair/Pressair
2. Fluticasone propionate/salmeterol: Accuhaler
Allowed co-medications: salbutamol as rescue
Outcomes Primary: peak FEV1 at week 24
Notes Funding: Almirall/ AstraZeneca
Identifiers: NCT01908140, M/40464/39, 2013-000116-14
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try- funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal was relatively low and even be-
tween active comparators, 14.1% in acli-
dinium/formoterol arm and 17.0% in sal-
meterol/fluticasone arm
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Selective reporting (reporting bias) Low risk Study was registered and the prespecified
outcomes were appropriately described
Vogelmeier 2017
Methods Design: prospective, multicentre, randomised open-label study
Duration: 12-weeks
Location: 673 centres in 23 countries: Austria (12), Belgium (40), Czech Republic (35)
, Denmark (5), Estonia (6), France (32), Germany (236), Greece (5), Hungary (18),
Ireland (6), Italy (72), Latvia (7), Lithuania (9), Norway (12), Poland (9), Portugal (11)
, Romania (8), Russia (18), Slovakia (16), Slovenia (4), Spain (50), Sweden (12), UK
(50)
Participants Population:
• LABA/ICS 274
• Indacaterol/glycopyrronium (822)
Baseline characteristics: age LABA/ICS 64.4 (SD 9), indacaterol/glycopyrronium 64.
7 (SD 8.7); female/male: LABA/ICS 106/168, indacaterol/glycopyrronium 286/536
Inclusion criteria
1. Male and female adults aged ≥ 40 years
2. Moderate COPD according to the GOLD 2013 criteria
3. Current or ex-smokers who have a smoking history of at least 10 pack-years
4. Airflow limitation indicated by a postbronchodilator FEV1 ≥ 50% and < 80% of
the predicted normal value and a post-bronchodilator FEV1/FVC < 0.7 at visit 2
5. mMRC score ≥ 1 at visit 1
Exclusion criteria
1. Narrow-angle glaucoma
2. Urinary retention
3. Severe renal impairment, including those with end-stage renal disease requiring
dialysis
4. Asthma
5. Malignancy of any organ system
6. Documented history of > 1 COPD exacerbation requiring treatment with
systemic corticosteroids or antibiotics and/or hospitalisation in the previous 12 months
7. Clinically significant condition such as (but not limited to): unstable ischaemic
heart disease, left ventricular failure (NYHA Class 3 & 4), history of MI, arrhythmia
(excluding chronic stable atrial fibrillation)
8. BMI > 40 kg/m2
Interventions Inhaler device
1. Glycopyrronium 50 µg capsule for inhalation via DPI
2. Indacaterol maleate and glycopyrronium bromide FDC (110/50 µg) capsule for
inhalation via DPI
3. SABA
4. LABA
5. Short-acting muscarinic antagonist
6. ICS
Allowed co-medications: not described. The list of prohibited medication (Table 5-2)
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not available
Outcomes Primary: trough FEV1 at week 12 for group: glycopyrronium vs short-acting bron-
chodilators (SABA and/or Short-acting muscarinic antagonist as monotherapy or in free
or FDC)
Notes Funding: Novartis
Identifiers: NCT01985334, CQVA149A3401
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively low and even be-
tween groups (14.6% in LABA/ICS group
and 19% in indacaterol/glycopyrronium
group)
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
Wedzicha 2008
Methods Design: multicentre, randomised, double-blind, double-dummy controlled trial
Duration: 2 years (+ 2-week run-in)
Location: 179 centres from 20 countries
Participants Population: 1323 participants were randomised to
1. Tiotropium (665)
2. Salmeterol/fluticasone combination (658)
Baseline characteristics
Age (mean years): tiotropium 65, salmeterol/fluticasone 64
% male: tiotropium 84, Salmeterol/fluticasone 81
% FEV1 predicted: tiotropium 39.4, salmeterol/fluticasone 39.1
Pack-years (mean): tiotropium 39.5, salmeterol/fluticasone 41.3
Inclusion criteria: aged 40-80 years, with a smoking history of ≥ 10 pack-years, a
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clinical history ofCOPDexacerbations, a post-bronchodilator FEV1of < 50%predicted,
reversibility to 400 µg salbutamol ≤ 10% predicted FEV1, and a score of ≥ 2 on the
mMRC dyspnoea scale
Exclusion criteria: any respiratory disorder other than COPD or who required daily
LTOT (> 12 h/d)
Interventions 1. Tiotropium 18 µg once daily (LAMA) + Diskus/Accuhaler placebo
2. Salmeterol/fluticasone 50/500 µg (LABA/ICS) + HandiHaler placebo
Inhaler device: Diskus/Accuhaler and HandiHaler
Allowed co-medications: after randomisation, in addition to study medication, par-
ticipants were allowed SABAs for relief therapy and standardised short courses of oral
systemic corticosteroids and/or antibiotics where indicated for treatment of COPD ex-
acerbations
Outcomes Primary: health care utilisation exacerbation rate.
Secondary: health status measured by SGRQ, mortality, AEs, and study withdrawal
Notes Funding: GlaxoSmithKline
Identifier(s): NCT00361959
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised using a pre-
defined, computer-generated, central ran-
domisation list. Treatment allocation was
stratified by centre and smoking status on
a 1:1 basis, in line with current guidelines.
The block size used was 4
Allocation concealment (selection bias) Low risk Telephone-based, interactive voice-
response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The investigator and treating physician
were kept blinded unless an emergency
arose
Incomplete outcome data (attrition bias)
All outcomes
High risk 1323 were randomised and comprised the
ITT population. Withdrawal was high in
both groups and uneven after 2 years (35.
3 and 42%). A higher proportion of par-
ticipants was withdrawn due to COPD ex-
acerbation and consent withdrawal with
tiotropium group compared to SFC group
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Selective reporting (reporting bias) Low risk Outcomes were well reported in the pub-
lications, and matched the study protocol
(although results have not been posted on
clinicaltrials.gov)
Wedzicha 2013
Methods Design: randomised, double-blind, parallel-group study
Duration: 64 weeks
Location: 345 study locations
Participants Population: 2224 participants were randomised to
1. open-label tiotropium (742)
2. glycopyrronium (741)
3. indacaterol/glycopyrronium (741)
Baseline characteristics
Age (mean years): glycopyrronium 63.1, tiotropium 63.6
% male: glycopyrronium 73.2, tiotropium 75.0
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: male or female adults aged ≥ 40 years, who had signed an informed
consent form prior to initiation of any study-related procedure; severe-very severe COPD
(stage 3 or 4) according to the GOLD 2008 criteria; current or ex-smokers with a
smoking history of at least 10 pack-years (defined as 20 cigarettes a day for 10 years,
or 10 cigarettes a day for 20 years); postbronchodilator FEV1 < 50% of the predicted
normal value, and post-bronchodilator FEV1/FVC < 0.70 at visit 2; documented history
of at least 1 COPD exacerbation in the previous 12 months that required treatment with
systemic glucocorticosteroids and/or antibiotics
Exclusion criteria: pregnant women or nursing mothers; women of child-bearing po-
tential; requiring LTOT; COPD exacerbation that required treatment with antibiotics,
systemic steroids (oral or intravenous) or hospitalisation in the 6 weeks prior to visit 1;
respiratory tract infectionwithin 4weeks prior to visit 1; concomitant pulmonary disease;
lung lobectomy, or lung volume reduction or lung transplantation; clinically relevant
laboratory abnormality or a clinically significant condition; history of asthma, allergic
rhinitis, eczema or alpha1 antitrypsin deficiency; contraindication for study drugs
Interventions 1. Indacaterol 110 µg/glycopyrronium 50 µg (QVA149) once daily (LABA/LAMA)
2. Glycopyrronium 50 µg once daily (LAMA)
3. Tiotropium 18 µg once daily (LAMA) - open-label
Inhaler device
1. Indacaterol 110 µg/glycopyrronium 50 µg capsules for inhalation, once daily
delivered via Novartis Single Dose DPI
2. Glycopyrronium was delivered via a Novartis single-dose DPI, and tiotropium
was delivered open-label via the HandiHaler
Allowed co-medications: salbutamol could be taken as needed throughout the study
Outcomes Primary: rate of moderate/severe COPD exacerbations
Secondary: pre-dose FEV1 and FVC, rescue medication use, and the SGRQ
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Notes Funding: Novartis
Identifier(s): NCT01120691
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, not defined but industry-
funded
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding procedures were sound, but
tiotropiumwas delivered open-label, which
introduced bias for these comparisons.
Double-blind (participant, caregiver, inves-
tigator, outcomes assessor)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding procedures were sound, but
tiotropiumwas delivered open-label, which
introduced bias for these comparisons.
Double-blind (participant, caregiver, inves-
tigator, outcomes assessor)
Incomplete outcome data (attrition bias)
All outcomes
Low risk The full analysis set included > 99% of
the randomised population. 25% dropped
out overall, and dropout was relatively even
across groups (24% and 27%)
Selective reporting (reporting bias) Low risk Outcomes were fully reported on clinical-
trials.gov
Wedzicha 2014
Methods Design: a phase 3, double-blind, randomised, 2-arm parallel-group study
Duration: 48 weeks
Location: UK
Participants Population
1. Beclomethasone dipropionate/formoterol 200/12 µg (601)
2. Formoterol 12 µg (596)
Baseline characteristics: age 64.3 female:male 372:818
Inclusion criteria
1. Severe COPD
2. At least one COPd exacerbation in previous year
Exclusion criteria
1. Asthma, allergic rhinitis or other atopic disease
2. Unstable concurrent disease:
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3. Evidence of heart failure
Interventions Inhaler device
1. Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg/per metered
dose
2. Formoterol fumarate 12 µg per metered dose
Allowed co-medications: as-needed salbutamol, theophylline and tiotropium
Outcomes Primary: exacerbation rate change in pre-dose FEV1 (time frame: 0-4-12-24-36-48
weeks)
Notes Funding: Chiesi Farmaceutici S.p.A
Identifiers:NCT00929851, CCD-0906-PR-0016, 2009-012546-23 ( EudraCTNum-
ber )
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively high but even in both
included groups (13% in beclomethasone
dipropionate/formoterol and 16.9% in for-
moterol group)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Wedzicha 2016
Methods Design: randomised, double-blind, parallel-group, double-dummy, placebo-controlled
trial
Duration: 52 weeks
Location: 43 countries, 496 centres
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Participants Population
1. indacaterol/glycopyrronium (1678)
2. salmeterol/fluticasone (1680)
Baseline characteristics: age: 64.6 years (SD 7.8). Male/female: 2557/805. % predicted
FEV1: 44.1% (SD 9.5%)
Inclusion criteria: COPD % predicted FEV1 25%-60%, mMRC ≥ 2, with recent
exacerbation
Exclusion criteria: pregnancy, significant comorbidities, history of malignancy, LTOT,
asthma, other concomitant lung disease, lung transplant
Interventions 1. Indacaterol/glycopyrronium (110/50 µg) once daily
2. Salmeterol/fluticasone (50/500 µg) twice daily
Inhaler device
1. Indacaterol/glycopyrronium: DPI
2. Salmeterol/fluticasone: dry inhalation powder delivered via Accuhaler
Allowed co-medications: salbutamol as rescue
Outcomes Primary: rate of COPD exacerbations per year
Notes Funding: Novartis
Identifiers: NCT01782326, CQVA149A2318
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised via interac-
tive response technology to 1 of the treat-
ment arms
Allocation concealment (selection bias) Low risk Participants were randomised via interac-
tive response technology to 1 of the treat-
ment arms
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study was double-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, investigator staff, assessors,
and data analysts were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal was relatively low and even
between 2 groups, 16.6% in indacaterol/
glycopyrronium arm and 19.0% in salme-
terol/ fluticasone arm
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Selective reporting (reporting bias) Low risk Study was registered and the prespecified
outcomes were appropriately described
Wise 2013
Methods Design: randomised, active-controlled, double-blind, double-dummy, parallel-group
design, multicentre study
Duration: 120 weeks
Location: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China,
Colombia, Croatia, Denmark, Finland, France, Georgia, Germany, Greece, Guatemala,
Hungary, India, Ireland, Israel, Italy, Republic of Korea, Latvia, Lithuania, Malaysia,
Mexico, Netherlands, New Zealand, Norway, Panama, Peru, Philippines, Poland, Por-
tugal, Puerto Rico, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain,
Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey, Ukraine, UK, USA
Participants Population
1. Tiotropium inhalation solution 5 µg (5705)
2. Tiotropium inhalation capsules 18 µg (5687)
Baseline characteristics: age 65.0 (SD 9.1) female:male 4879:12,237
Inclusion criteria
1. Signed informed consent consistent with International Conference on
Harmonization Good Clinical Practice (ICH-GCP) guidelines prior to participation in
the trial, which includes medication washout and restrictions
2. Male or female patients ≥ 40 years
3. Current or ex-smokers with a smoking history of ≥ 10 pack-years. (Patients who
have never smoked cigarettes excluded)
4. Diagnosis of COPD (P06-12085),
5. Relatively stable airway obstruction with a post-bronchodilator FEV1 ≤ 70% of
predicted normal and post-bronchodilator FEV1/FVC ≤ 70%
6. Able to inhale from the HandiHaler® and the Respimat® devices
Exclusion criteria
1. Significant diseases other than COPD. A significant disease is defined as a disease
or condition which, in the opinion of the investigator, may put the participant at risk
because of participation in the study or may influence the participant’s ability to
participate in the study
2. Recent history (i.e. ≤ 6 months) of MI
3. Unstable or life-threatening cardiac arrhythmia requiring intervention or change
in drug therapy during the last year
4. Hospitalisation for cardiac failure (NYHA Class 3 or 4) during the past year
5. Known active TB
6. History of asthma, cystic fibrosis, clinically evident bronchiectasis, interstitial lung
disease, or pulmonary thromboembolic disease
7. History of thoracotomy with pulmonary resection.
8. Malignancy for which the participant had undergone resection, radiation,
chemotherapy or biological treatments within the last 5 years. Participants with treated
basal cell carcinoma were allowed.
9. Known respiratory infection or exacerbation of COPD in the 4 weeks prior to
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randomisation.
10. Known narrow-angle glaucoma
11. Known significant symptomatic prostatic hyperplasia or bladder-neck obstruction.
Participants whose symptoms were controlled on treatment may have been included.
12. Use of systemic corticosteroid medication at unstable doses (i.e. < 6 weeks on
stable dose) or at doses > the equivalent of 10 mg prednisolone/d
13. Using supplemental oxygen therapy for > 12 h/d
Interventions Inhaler device
1. Tiotropium inhalation solution delivered by the Respimat Inhaler
2. Tiotropium inhalation capsules delivered by the HandiHaler
Allowed co-medications: as-needed salbutamol/albuterol. All classes of maintenance
respiratory medications
Outcomes Primary: mortality, COPD exacerbations
Notes Funding: Boehringer Ingelheim
Identifiers: NCT01126437
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Interactive voice- or web-response system
Allocation concealment (selection bias) Low risk Interactive voice- or web-response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Scientific Steering Committee met every 6
months to review both the progress and
blinded study data
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was high but even in both in-
cluded groups (23.2% in tiotropium 5 µg
and 23.0% in tiotropium 18 µg group)
Selective reporting (reporting bias) Low risk Located trial registration and protocol -
outcomes well reported
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Methods Design: multicentre, randomised, double-blind, placebo-controlled, parallel-group
study
Duration: 26 weeks
Location: Hong Kong, India, Japan, Republic of Korea, Singapore, Taiwan
Participants Population
1. Indacaterol 150 µg (187)
2. Indacaterol 300 µg (188)
Baseline characteristics: age 66.7 (SD 8.38) female:male 12:335
Inclusion criteria
Diagnosis of moderate-severe COPD, as classified by the GOLD criteria and:
1. Smoking history of at least 20 pack-years
2. Post-bronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value
3. Post-bronchodilator FEV1/FVC < 70%
Exclusion criteria
1. Hospitalised for a COPD exacerbation in the 6 weeks prior to screening or during
the 14-day run-in period prior to randomisation
2. LTOT (> 15 h/d) for chronic hypoxaemia
3. Respiratory tract infection within 6 weeks prior to screening
4. Concomitant pulmonary disease
5. History of asthma
6. Diabetes type 1 or uncontrolled diabetes type 2
7. Lung cancer or a history of lung cancer
8. Active cancer or a history of cancer with < 5 years disease-free survival time
9. History of long QT syndrome or whose QTc interval (Bazett’s) measured at
screening or randomisation is prolonged
10. Vaccinated with live attenuated vaccines within 30 days prior to screening or
during the run-in period
11. Unable to successfully use a DPI device or perform spirometry measurements
Interventions Inhaler device: indacaterol was supplied in powder-filled capsules with a single-dose
DPI
Allowed co-medications: salbutamol as rescue. ICSs and slow-release theophylline
Outcomes Primary: trough FEV1 24 h post-dose at the end of treatment (week 12 + 1 day, day 85)
Notes Funding: Novartis
Identifiers: NCT00794157, CQAB149B2333
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low and even between in-
cluded arms (8.8% in indacaterol 150 µg
and 9.4% in indacaterol 300 µg arm)
Selective reporting (reporting bias) Low risk Located trial registration - outcomes well
reported
Zhong 2015
Methods Design: randomised, double-blind, parallel-group, double-dummy, placebo-controlled
trial
Duration: 26 weeks
Location: 4 countries and 56 centres (recruited mainly in China)
Participants Population
1. Indacaterol/glycopyrronium (372)
2. Fluticasone propionate/salmeterol (369)
Baseline characteristics
Age: indacaterol/glycopyrronium 64.8 years (SD 7.8); fluticasone propionate/salmeterol
65.3 years (SD 7.9)
Male/female: 672/69
% predicted FEV1: indacaterol/glycopyrronium 51.6% (SD 12.8%), fluticasone propi-
onate/salmeterol 52.0% (SD 12.9%)
Inclusion criteria: COPD stage 2/3; mMRC ≥ 2, without recent exacerbation
Exclusion criteria: pregnancy, significant comorbidities, COPD exacerbations within
the last year, LTOT (> 12 h/d), asthma, other concomitant lung disease
Interventions 1. Indacaterol/glycopyrronium (110/50 µg) once daily
2. Fluticasone propionate/salmeterol (500/50 µg) twice daily
Inhaler device:
1. Indacaterol/glycopyrronium: DPI
2. Fluticasone propionate/salmeterol: dry inhalation powder delivered via Accuhaler
Allowed co-medications: inhaled SABAs as rescue
Outcomes Primary: trough FEV1 following 26 weeks of treatment to demonstrate the non-inferi-
ority of indacaterol/glycopyrronium to fluticasone propionate/salmeterol
Notes Funding: Novartis
Identifiers: NCT01709903, CQVA149A2331
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised via interac-
tive response technology to 1 of the treat-
ment arms
Allocation concealment (selection bias) Low risk Participants were randomised via interac-
tive response technology to 1 of the treat-
ment arms
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study was double-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants from the investi-
gator staff, assessors, and data analysts was
maintained by ensuring that the randomi-
sation data were kept strictly confidential
until the time of unblinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal was low and even between
two groups, 7.8% in indacaterol/glycopy-
rronium arm and 10.4% in fluticasone pro-
pionate/salmeterol arm
Selective reporting (reporting bias) Low risk Study was registered and the prespecified
outcomes were appropriately described
ZuWallack 2014a
Methods Design:multicentre, randomised, double-blind, placebo-controlled, parallel-group trial
Duration: 12 weeks
Location: 90 centres across the USA
Participants Population: 1132 adults, with a clinical history of moderate-severe COPD as defined
by GOLD criteria (FEV1 < 80% and ≥ 30% predicted), were randomised to
1. Tiotropium + olodaterol (567)
2. Tiotropium + placebo (565)
Baseline characteristics: mean age 64 years. 50% men. Mean FEV1 1.45 L (54%
predicted)
Inclusion criteria:men and women aged≥ 40 years with a clinical diagnosis of COPD,
a smoking history ≥ 10 pack-years, and post-bronchodilator FEV1 < 80% and ≥ 30%
predicted, with FEV1/FVC < 70%
Exclusion criteria: participants who were on prednisolone at an unstable dose (i.e.
changed in < 6 weeks) or > 10 mg/day, oxygen use > 1 h/d, pulmonary rehabilitation
in the last 6 weeks, participants who had significant disease other than COPD (e.g.
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asthma, history of life-threatening pulmonary obstruction, cystic fibrosis, clinically ev-
ident bronchiectasis, active TB, previous thoracotomy with resection, thyrotoxicosis,
paroxysmal tachycardia, unstable or life-threatening cardiac arrhythmia, MI or hospital-
isation for heart failure in the previous year, malignancy requiring treatment in the last
5 years)
Interventions Inhaler device
1. Olodaterol 5 µg through DPI Respimat, once daily + tiotropium 18 µg through
DPI HandiHaler, once daily
2. Placebo to olodaterol + tiotropium 18 µg through DPI HandiHaler, once daily
Allowed co-medications: ICS, oral (≤ 10 mg prednisone per day, or equivalent) and in-
jected steroids, cromolyn sodium/nedocromil sodium, antihistamines, antileukotrienes,
methylxanthines, mucolytics, and theophyllines were permitted. Albuterol as rescue
Outcomes Primary:AUC for FEV1measured 0-3 h post-morning dose after 12 weeks of treatment.
Also trough FEV1 after 12 weeks of treatment
Secondary: change in FEV1, SGRQ, FVC AUC 0-3 h, change in peak and trough FVC
after 12 weeks’ treatment, and rescue medication use over the 12-week period
Notes Funding: Boehringer Ingelheim
Identifiers: NCT01694771
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An automated and validated randomisa-
tion tool (interactive response technolo-
gies) was used to randomise participants to
each treatment arm, and to randomise the
medication numbers on each kit to the dif-
ferent products
Allocation concealment (selection bias) Low risk An automated and validated randomisa-
tion tool (interactive response technolo-
gies) was used to randomise participants to
each treatment arm, and to randomise the
medication numbers on each kit to the dif-
ferent products
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors and data analysts were blinded to
the identity of the treatment from the time
of randomisation until database lock
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ZuWallack 2014a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of withdrawals were relatively
low and even in each group (40 participants
in both groups, 7%)
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
ZuWallack 2014a&b
Methods Design:multicentre, randomised, double-blind, placebo-controlled, parallel-group trial
Duration: 12 weeks
Location: 90 centres across the USA
Participants Population: 2267 adults, with a clinical history of moderate-severe COPD as defined
by GOLD criteria (FEV1 < 80% and ≥ 30% predicted), were randomised to
1. Tiotropium + olodaterol (1133)
2. Tiotropium + placebo (1134)
Baseline characteristics: mean age 64 years. 50% men. Mean FEV1 1.45 L (54%
predicted)
Inclusion criteria:men and women aged≥ 40 years with a clinical diagnosis of COPD,
a smoking history ≥ 10 pack-years, and post-bronchodilator FEV1 < 80% and ≥ 30%
predicted, with FEV1/FVC < 70%
Exclusion criteria: participants who were on prednisolone at an unstable dose (i.e.
changed in < 6 weeks) or > 10 mg/day, oxygen use > 1 h/d, pulmonary rehabilitation
in the last 6 weeks, participants who had significant disease other than COPD (e.g.
asthma, history of life-threatening pulmonary obstruction, cystic fibrosis, clinically ev-
ident bronchiectasis, active TB, previous thoracotomy with resection, thyrotoxicosis,
paroxysmal tachycardia, unstable or life-threatening cardiac arrhythmia, MI or hospital-
isation for heart failure in the previous year, malignancy requiring treatment in the last
5 years)
Interventions Inhaler device
1. Olodaterol 5 µg through DPI Respimat, once daily + tiotropium 18 µg through
DPI HandiHaler, once daily
2. Placebo to olodaterol + tiotropium 18 µg through DPI HandiHaler, once daily
Allowed co-medications: ICS, oral (≤ 10 mg prednisone/d, or equivalent) and in-
jected steroids, cromolyn sodium/nedocromil sodium, antihistamines, antileukotrienes,
methylxanthines, mucolytics, and theophyllines were permitted. Albuterol as rescue
Outcomes Primary:AUC for FEV1measured 0-3 h post-morning dose after 12 weeks of treatment.
Also trough FEV1 after 12 weeks of treatment
Secondary: change in FEV1, SGRQ, FVC AUC 0-3 h, change in peak and trough FVC
after 12 weeks’ treatment, and rescue medication use over the 12-week period
Notes Funding: Boehringer Ingelheim
Identifiers: NCT01694771, NCT01696058
Risk of bias
254Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An automated and validated randomisa-
tion tool (interactive response technolo-
gies) was used to randomise participants to
each treatment arm, and to randomise the
medication numbers on each kit to the dif-
ferent products
Allocation concealment (selection bias) Low risk An automated and validated randomisa-
tion tool (interactive response technolo-
gies) was used to randomise participants to
each treatment arm, and to randomise the
medication numbers on each kit to the dif-
ferent products
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors and data analysts were blinded to
the identity of the treatment from the time
of randomisation until database lock
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of withdrawals were relatively
low and even in each group ( SeeZuWallack
2014a and ZuWallack 2014b)
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
ZuWallack 2014b
Methods Design:multicentre, randomised, double-blind, placebo-controlled, parallel-group trial
Duration: 12 weeks
Location: 90 centres across the USA
Participants Population: 1135 adults, with a clinical history of moderate-severe COPD as defined
by GOLD criteria (FEV1 < 80% and ≥ 30% predicted), were randomised to
1. Tiotropium + olodaterol (566)
2. Tiotropium + placebo (569)
Baseline characteristics: mean age 64 years. 50% men. Mean FEV1 1.45 L (54%
predicted)
Inclusion criteria:men and women aged≥ 40 years with a clinical diagnosis of COPD,
a smoking history ≥ 10 pack-years, and post-bronchodilator FEV1 < 80% and ≥ 30%
predicted, with FEV1/FVC < 70%
Exclusion criteria: participants who were on prednisolone at an unstable dose (i.e.
changed in < 6 weeks) or > 10 mg/day, oxygen use > 1 h/d, pulmonary rehabilitation
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ZuWallack 2014b (Continued)
in the last 6 weeks, participants who had significant disease other than COPD (e.g.
asthma, history of life-threatening pulmonary obstruction, cystic fibrosis, clinically ev-
ident bronchiectasis, active TB, previous thoracotomy with resection, thyrotoxicosis,
paroxysmal tachycardia, unstable or life-threatening cardiac arrhythmia, MI or hospital-
isation for heart failure in the previous year, malignancy requiring treatment in the last
5 years)
Interventions Inhaler device
1. Olodaterol 5 µg through DPI Respimat, once daily + tiotropium 18 µg through
DPI HandiHaler, once daily
2. Placebo to olodaterol + tiotropium 18 µg through DPI HandiHaler, once daily
Allowed co-medications: ICS, oral (10 mg prednisone per day, or equivalent) and in-
jected steroids, cromolyn sodium/nedocromil sodium, antihistamines, antileukotrienes,
methylxanthines, mucolytics, and theophyllines were permitted. Albuterol as rescue
Outcomes Primary:AUC for FEV1measured 0-3 h post-morning dose after 12 weeks of treatment.
Also trough FEV1 after 12 weeks of treatment
Secondary: change in FEV1, SGRQ, FVC AUC 0-3 h, change in peak and trough FVC
after 12 weeks’ treatment, and rescue medication use over the 12-week period
Notes Funding: Boehringer Ingelheim
Identifiers: NCT01696058
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An automated and validated randomisa-
tion tool (interactive response technolo-
gies) was used to randomise participants to
each treatment arm, and to randomise the
medication numbers on each kit to the dif-
ferent products
Allocation concealment (selection bias) Low risk An automated and validated randomisa-
tion tool (interactive response technolo-
gies) was used to randomise participants to
each treatment arm, and to randomise the
medication numbers on each kit to the dif-
ferent products
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk People performing the assessments and
data analysts were blinded to the identity
of the treatment from the time of randomi-
sation until database lock
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ZuWallack 2014b (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of withdrawals were relatively
low and even in each group ((31/569; 5.
5%) and 43/566; 7.5%))
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
6MWD: 6-minute walk distance; AEs: adverse events; ALT: alanine transaminase; AST: aspartate transaminase; ATS: American
Thoracic Society; AUC: area under curve; BDI: Baseline Dyspnea Index; BiPAP: bilevel positive airway pressure; BMI: body mass
index; BODE: body-mass index, airflow obstruction, dyspnoea, and exercise; BPH: benign prostatic hypertrophy; BPM: beats
per minute; CAT: Chronic obstructive pulmonary disease Assessment Test; CBSQ: Chronic Bronchitis Symptom Questionnaire;
CFB: change from baseline; COPD: chronic obstructive pulmonary disease; CPAP: continuous positive airway pressure; CRDQ:
Chronic Respiratory Disease Questionnaire; CT: computed tomography; CVD: cardiovascular disease; DPI: dry powder inhaler;
ECG: electrocardiogram; ER: emergency room; ERS: European Respiratory Society; FDC: fixed-dose combination; FEV1: forced
expiratory volume in 1 second; FF: fluticasone furoate; FP: fluticasone propionate; FVC: forced vital capacity; GOLD: Global
Initiative for Chronic Obstructive Lung Disease; ICS: inhaled corticosteroids; IRT: interactive response technology ; ITT: intention
to treat; LABA: long-acting beta-adrenoceptor agonist; LAMA: long-acting muscarinic antagonist; LTOT: long term oxygen therapy;
LVRS: lung volume reduction surgery;MCID:minimal clinically important difference;MDI:metered-dose inhaler;MI:myocardial
infarction; modified;mMRC:modified Medical Research Council;NHANES:National Health and Nutrition Examination Survey;
NYHA: New York Heart Association; OCS: oral corticosteroids; PDE4: phosphodiesterase 4; PEF: peak expiratory flow; PI:
principal investigator; pred: predicted; QoL: quality of life; QTc: corrected QT interval; SABA: short-acting beta2-adrenergic
agonist SAL: salmeterol;SD: standard deviation; SGOT: serum glutamic-oxaloacetic transaminase; SGPT: serum glutamate pyruvate
transaminase; SGRQ: St George’s Respiratory Questionnaire; TB: tuberculosis; TDI: Transition Dyspnea Index; TIA: transient
ischaemic attack; ULN: upper limit of normal; VI: vilanterol
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
1237.20 2-week study
1237.4 4-week study
1237.7 Cross-over study
Bateman 2010 No qualified comparison (formulation and/or dose not approved)
Beeh 2014 Cross-over study
Beeh 2016 Cross-over study
Berton 2016 3-week cross-over study
Celli 2014 No qualified comparison (formulation and/or dose not approved)
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CQAB149BIL01 No qualified comparison (indacaterol vs LABA)
CQMF149F2202 No qualified comparison (formulation and/or dose not approved)
D’Urzo 2013 No qualified comparison (formulation and/or dose not approved)
Dahl 2013 4-week study
Donohue 2014 No qualified comparison (formulation and/or dose not approved)
Donohue 2016b Cross-over study
Dransfield 2013 No qualified comparison (formulation and/or dose not approved)
Fang 2008 Poor-quality study (dropout rate too high)
Ferguson 2014 No qualified comparison (formulation and/or dose not approved)
Gelb 2013 No qualified comparison (formulation and/or dose not approved)
HZC113108 No qualified comparison (formulation and/or dose not approved)
Jones 1997 No qualified comparison (formulation and/or dose not approved)
Jones 2012 No qualified comparison (formulation and/or dose not approved)
Kerwin 2012b No qualified comparison (formulation and/or dose not approved)
Kerwin 2013 No qualified comparison (formulation and/or dose not approved)
Kurashima 2009 Cross-over study
Lipson 2018 Results were not available at the time of data extraction
Magnussen 2012 8-week study
Mahler 2014 6-week study
Mahmud 2007 COPD not defined. Insufficient data
Make 2014 Abstract only. Insufficient information
Maltais 2014a Cross-over study
Maltais 2014b Cross-over study
Maltais 2018 No qualified comparison (formulation and/or dose not approved)
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Martinez 2013 No qualified comparison (formulation and/or dose not approved)
MORACTO1 6-week study
MORACTO2 6-week study
PT003016-00 No comparator, 4-week study
Rabe 2008 6-week study
Rennard 2013 No qualified comparison (formulation and/or dose not approved)
Rossi 2012 6-week study
SCO100646 Cross-over study
Siler 2017 No qualified comparison (formulation and/or dose not approved)
Singh 2016 Cross-over study
Tashkin 2016 7-day cross-over study
To 2011 Insufficient data. Abstract only
Van Noord 2010 6-week study
Vestbo 2016 Did not meet inclusion criteria (fluticasone furorate/vilanterol compared with existing maintenance treatment)
Vogelmeier 2010a No qualified comparison (dose not approved)
Vogelmeier 2010b 14-day study
Vogelmeier 2013b Spin-off of Vogelmeier 2011
Watz 2016 Cross-over study
Wouters 2005 Did not meet inclusion criteria
Zheng 2015 No qualified comparison (formulation and/or dose not approved)
COPD: chronic obstructive pulmonary disease; LABA: long-acting beta-adrenoceptor agonist
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Characteristics of studies awaiting assessment [ordered by study ID]
Calverley 2018
Methods Design: randomised, double-blind, active-controlled parallel-group study
Duration: 52 weeks
Location: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Den-
mark, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Ireland, Italy, Japan, Republic
of Korea, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal,
Romania, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Tai-
wan, Thailand, Turkey, Ukraine, UK, USA, Vietnam
Participants Population
1. Tiotropium 5 µg (3941)
2. Tiotropium 5 µg + olodaterol 5 µg (3939)
Baseline characteristics:mean age 66.4 (SD 8.5); female:male 2254:5626 (28.6%:71.4%). Mean post-bronchodila-
tor FEV1 1.18 L
Inclusion criteria
1. Male or female patients, ≥ 40 years of age
2. Diagnosis of COPD with a documented post-bronchodilator FEV1 < 60% of predicted normal and a post-
bronchodilator FEV1/FVC < 70% at visit 1
3. Documented history of at least 1 moderate-severe COPD exacerbation in the previous 12 months requiring
treatment with systemic corticosteroids and/or antibiotics and/or related hospitalisation
4. Symptomatically stable as defined by: no evidence of COPD exacerbation requiring use of either antibiotics
and/or steroids 4 weeks prior to visit 1 and no evidence of change in their usual COPD medication 4 weeks prior to
visit 1
5. Current or ex-smokers with a smoking history of > 10 pack-years
Exclusion criteria
1. Significant disease other than COPD
2. Unstable COPD requiring oral steroids, phosphodiesterase 4 inhibitor, oral or patch beta-adrenergics
3. Pregnancy
Interventions Inhaler device
1. Tiotropium + olodaterol high-dose, FDC. Once daily 2 puffs solution for inhalation Respimat
2. Tiotropium. Once daily 2 puffs solution for inhalation Respimat
Allowed co-medications: salbutamol as rescue. ICSs
Outcomes Primary: annualised rate of moderate-severe COPD exacerbations during the actual treatment period. (time frame:
from first intake of study medication until 1 day after last intake of study medication, up to 361 days). Annualised
rate of moderate-severe COPD exacerbations during the actual treatment period was calculated per treatment per
patient−year. The actual treatment period was defined as the interval from first intake of study medication until 1
day after last intake of study medication
Notes Funding: Boehringer Ingelheim
Identifiers: NCT02296138
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Papi 2017
Methods Design: a multicentre, randomised, double-blind, active-controlled, parallel-group study
Duration: 52 weeks
Location: Bulgaria, Germany, Hungary, Republic of Korea, Latvia, Lithuania, Macedonia, the former Yugoslav,
Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine, and UK
Participants Population
1. Fluticasone/formoterol (Flutiform) 500 µg/20µg (587)
2. Fluticasone/formoterol (Flutiform) 250 µg/20µg (588)
3. Formoterol 500 µg/20µg (590)
Baseline characteristics: average age 63-64, male/female 0.75:0.25
Inclusion criteria:
1. Male or female participants aged ≥ 40 years at screening visit
2. Smoking history of ≥ 10 pack-years.
3. Diagnosis of COPD
4. History of ≥ moderate or severe COPD exacerbations in previous year
5. Willing and able to replace current COPD therapy with study medication
6. Able to demonstrate correct use of a pressurised MDI without a spacer
7. Willing and able to attend all study visits and complete study assessments
8. Able to provide signed informed consent
Exclusion criteria
1. Ongoing moderate or severe exacerbation of COPD
2. Current diagnosis of asthma
3. Documented evidence of α1-antitrypsin deficiency as the underlying cause of COPD
4. Other active respiratory disease such as active TB, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis,
pulmonary hypertension, interstitial lung disease, cystic fibrosis, bronchiolitis obliterans
5. Previous lung resection
6. Use of LTOT at least 12 h daily or mechanical ventilation
7. Chest X-ray or CT scan that reveals evidence of clinically significant abnormalities reflective of active disease
not believed to be due to COPD
8. Evidence of uncontrolled CVD
9. Evidence of clinically significant renal, hepatic, gastrointestinal, or psychiatric disease
10. Current malignancy or a previous history of cancer that has been in remission for < 5 years (basal cell or
squamous cell carcinoma of the skin which has been resected is not excluded)
11. Clinically significant sleep apnoea requiring use of CPAP device or non-invasive positive pressure ventilation
device
12. Participation in the acute phase of a pulmonary rehabilitation programme within 4 weeks prior to screening or
during the study
13. Known or suspected history of drug or alcohol abuse in the last 2 years
14. Requiring treatment with any of the prohibited concomitant medications
15. Known or suspected hypersensitivity or contraindication to any of the study drugs or excipients
16. Received an investigational drug within 30 days of the screening visit (12 weeks if an oral or injectable steroid)
Interventions Inhaler device
1. Fluticasone/formoterol 250/10 µg Flutiform (2 puffs twice daily)
2. Fluticasone/formoterol 125/5 µg Flutiform (2 puffs twice daily)
3. Formoterol 12 µg (1 puff twice daily)
Allowed co-medications: SABA as rescue
Outcomes Annual rate of moderate and severe COPD exacerbations (time frame: 52 weeks)
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Papi 2017 (Continued)
Notes Funding:Mundipharma Research Limited
Identifiers: NCT01946620
COPD: chronic obstructive pulmonary disease; CPAP: continuous positive airway pressure; CT: computed tomography; CVD: car-
diovascular disease; FDC: fixed dose combination; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; LTOT:
long-term oxygen therapy;MDI: metered dose inhaler
Characteristics of ongoing studies [ordered by study ID]
AMPLIFY
Trial name or title A 24 week treatment, multicentre, randomized, double blinded, double dummy, parallel-group, clinical
trial evaluating the efficacy and safety of aclidinium bromide 400 µg/formoterol fumarate 12 µg fixed-
dose combination bid compared with each monotherapy (aclidinium bromide 400 µg bid and formoterol
fumarate 12 µg bid) and tiotropium 18 µg qd when administered to patients with stable chronic obstructive
pulmonary disease
Methods Interventional (clinical study)
Participants 1595 participants
Interventions 1. Aclidinium/formoterol
2. Aclidinium
3. Formoterol
4. Tiotropium
5. Placebo
Outcomes 1. CFB in 1-h morning post-dose FEV1 of aclidinium bromide/formoterol fumarate 400 µg/12 µg
compared to AB 400 µg at week 24. (time frame: baseline 1-h post-dose and week 24 )
2. CFB in morning pre-dose (trough) FEV1 of aclidinium bromide/formoterol fumarate 400 µg/12 µg
compared to formoterol fumarate 12 µg at week 24. (time frame: baseline morning pre-dose and week 24)
3. CFB in morning pre-dose (trough) FEV1 at week 24 comparing aclidinium bromide 400 µg versus
tiotropium 18 µg to demonstrate non-inferiority (time frame: baseline morning pre-dose and week 24 )
Starting date 5 July 2016
Contact information AstraZeneca
Notes NCT02796677
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AVANT
Trial name or title A 24-week treatment, randomised, parallel-group, double blinded, double-dummy,multicentre study to assess
the efficacy and safety of aclidinium bromide/formoterol fumarate compared with individual components and
placebo and aclidinium bromide compared with placebo when administered to patients with stable chronic
obstructive pulmonary disease
Methods Interventional (clinical study)
Participants 1060 participants
Interventions 1. Aclidinium/formoterol
2. Aclidinium
3. Formoterol
4. Tiotropium
5. Placebo
Outcomes 1. CFB in 1-h morning post-dose FEV1 (time frame: week 24 )
2. CFB in morning pre-dose (trough) FEV1 (time frame: week 24 )
3. CFB in trough FEV1 (time frame: week 24 )
Starting date 24 January 2017
Contact information AstraZeneca
Notes NCT03022097
FLASH
Trial name or title A 12-week treatment, multicentre, randomized, double-blind, double-dummy, parallel group study to assess
the efficacy and safety of switching from salmeterol/fluticasone to QVA149 (indacaterol maleate/glycopyrro-
nium bromide) in symptomatic COPD patients
Methods Interventional (clinical study)
Participants 492 participants
Interventions 1. Indacaterol/glycopyrronium
2. Fluticasone propionate/salmeterol
Outcomes 1. CFB in trough pre-dose FEV1 in both arms (time frame: week 12)
Starting date 6 August 2015
Contact information Novartis Pharmaceuticals +41613241111
Notes NCT02516592
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FLT3510
Trial name or title A randomised double-blind, double-dummy parallel group study to compare the efficacy and safety of fluti-
casone propionate/formoterol fumarate (Flutiform®) 500 µg/20 µg bid and 250 µg/10 µg bid versus salme-
terol/fluticasone (Seretide®) 50 µg/500 µg bid in participants with chronic obstructive pulmonary disease
(COPD)
Methods Interventional (clinical study)
Participants 923 participants
Interventions 1. Fluticasone propionate/formoterol fumarate 500 µg/20 µg twice daily and 250 µg/10 µg twice daily
2. Salmeterol/fluticasone 50 µg/500 µg twice daily
Outcomes 1. Average pre-dose FEV1 (time frame: 26 weeks )
Starting date September 2014
Contact information Mundipharma Research Limited
Notes NCT02195375
PINNACLE 4
Trial name or title A randomized, double-blind, chronic dosing (24 weeks), placebo-controlled, parallel group, multicentre study
to assess the efficacy and safety of PT003, PT005, and PT001 in participants with moderate to very severe
COPD, compared with placebo
Methods Interventional (clinical study)
Participants 1759 participants
Interventions 1. Glycopyrronium/formoterol
2. Glycopyrronium
3. Formoterol
4. Placebo
Outcomes 1. CFB in morning pre-dose trough FEV1 of treatment (time frame: at week 24)
Starting date 30 March 2015
Contact information Pearl Therapeutics
Notes NCT02343458
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PT010006
Trial name or title A randomized, double-blind, parallel-group, 24-week, chronic-dosing, multicentre study to assess the efficacy
and safety of PT010, PT003, and PT009 compared with Symbicort® Turbuhaler® as an active control in
participants with moderate to very severe chronic obstructive pulmonary disease
Methods Interventional (clinical study)
Participants 1800 participants
Interventions 1. Glycopyrronium/formoterol
2. Budesonide/formoterol
3. Budesonide/formoterol
Outcomes 1. CFB in morning pre-dose trough FEV1 (time frame: 24 weeks)
Starting date 10 August 2015
Contact information Pearl Therapeutics
Notes NCT02497001
CFB: change from baseline; FEV1: forced expiratory volume in 1 second
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D A T A A N D A N A L Y S E S
Comparison 1. LABA/LAMA vs LABA/ICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Moderate to severe exacerbations 7 7687 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.74, 1.00]
1.1 High-risk 1 3372 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.76, 1.00]
1.2 Low-risk 6 4315 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.65, 1.14]
2 Severe exacerbations 5 6214 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.46, 1.27]
2.1 High-risk 1 3354 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.74, 1.06]
2.2 Low-risk 4 2860 Odds Ratio (M-H, Random, 95% CI) 0.66 [0.27, 1.63]
3 SGRQ responders at 3 months 4 2397 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.92, 1.27]
3.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Low-risk 4 2397 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.92, 1.27]
4 SGRQ responders at 6 months 1 427 Odds Ratio (M-H, Random, 95% CI) 1.29 [0.88, 1.89]
4.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Low-risk 1 427 Odds Ratio (M-H, Random, 95% CI) 1.29 [0.88, 1.89]
5 SGRQ responders at 12 months 1 3195 Odds Ratio (M-H, Random, 95% CI) 1.25 [1.09, 1.43]
5.1 HIgh-risk 1 3195 Odds Ratio (M-H, Random, 95% CI) 1.25 [1.09, 1.43]
5.2 Low-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Change from baseline in SGRQ
at 3 months
6 6342 Mean Difference (IV, Random, 95% CI) -0.49 [-1.41, 0.43]
6.1 High-risk 1 3195 Mean Difference (IV, Random, 95% CI) -1.30 [-2.35, -0.25]
6.2 Low-risk 5 3147 Mean Difference (IV, Random, 95% CI) -0.03 [-1.02, 0.96]
7 Change from baseline in SGRQ
at 6 months
3 4360 Mean Difference (IV, Random, 95% CI) -1.18 [-2.20, -0.16]
7.1 High-risk 1 3195 Mean Difference (IV, Random, 95% CI) -1.20 [-2.28, -0.12]
7.2 Low-risk 2 1165 Mean Difference (IV, Random, 95% CI) -0.99 [-4.12, 2.14]
8 Change from baseline in SGRQ
at 12 months
1 3195 Mean Difference (IV, Random, 95% CI) -1.20 [-2.34, -0.06]
8.1 High-risk 1 3195 Mean Difference (IV, Random, 95% CI) -1.20 [-2.34, -0.06]
8.2 Low-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 TDI at 3 months 6 4152 Mean Difference (IV, Random, 95% CI) 0.40 [0.02, 0.78]
9.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Low-risk 6 4152 Mean Difference (IV, Random, 95% CI) 0.40 [0.02, 0.78]
10 TDI at 6 months 3 1780 Mean Difference (IV, Random, 95% CI) 0.13 [-0.24, 0.51]
10.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Low-risk 3 1780 Mean Difference (IV, Random, 95% CI) 0.13 [-0.24, 0.51]
11 Change from baseline in FEV1
at 3 months
7 6466 Mean Difference (IV, Random, 95% CI) 0.08 [0.04, 0.11]
11.1 High-risk 1 3192 Mean Difference (IV, Random, 95% CI) 0.08 [0.06, 0.10]
11.2 Low-risk 6 3274 Mean Difference (IV, Random, 95% CI) 0.08 [0.03, 0.12]
12 Change from baseline in FEV1
at 6 months
4 5292 Mean Difference (IV, Random, 95% CI) 0.09 [0.07, 0.11]
12.1 High-risk 1 3192 Mean Difference (IV, Random, 95% CI) 0.09 [0.07, 0.11]
12.2 Low-risk 3 2100 Mean Difference (IV, Random, 95% CI) 0.10 [0.05, 0.15]
13 Change from baseline in FEV1
at 12 months
1 3192 Mean Difference (IV, Random, 95% CI) 0.06 [0.04, 0.08]
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13.1 High-risk 1 3192 Mean Difference (IV, Random, 95% CI) 0.06 [0.04, 0.08]
13.2 Low-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Mortality 9 8796 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.61, 1.68]
14.1 High-risk 1 3358 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.57, 1.77]
14.2 Low-risk 8 5438 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.35, 3.23]
15 Total SAE 9 8796 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.75, 1.07]
15.1 High-risk 1 3358 Odds Ratio (M-H, Random, 95% CI) 0.91 [0.76, 1.08]
15.2 Low-risk 8 5438 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.64, 1.22]
16 COPD SAE 9 8796 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.54, 1.27]
16.1 High-risk 1 3358 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.70, 1.07]
16.2 Low-risk 8 5438 Odds Ratio (M-H, Random, 95% CI) 0.80 [0.39, 1.64]
17 Cardiac SAE 9 8796 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.61, 1.24]
17.1 High-risk 1 3358 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.58, 1.29]
17.2 Low-risk 8 5438 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.43, 1.89]
18 Dropouts due to adverse events 9 8796 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.74, 1.07]
18.1 High-risk 1 3358 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.69, 1.13]
18.2 Low-risk 8 5438 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.68, 1.19]
19 Pneumonia 8 8753 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.39, 0.84]
19.1 High-risk 1 3358 Odds Ratio (M-H, Random, 95% CI) 0.62 [0.40, 0.96]
19.2 Low-risk 7 5395 Odds Ratio (M-H, Random, 95% CI) 0.43 [0.19, 0.97]
Comparison 2. LABA/LAMA vs LAMA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Moderate to severe exacerbations 9 7398 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.75, 1.23]
1.1 High-risk 1 2206 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.89, 1.27]
1.2 Low-risk 8 5192 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.66, 1.30]
2 Severe exacerbations 8 5241 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.59, 1.36]
2.1 High-risk 1 304 Odds Ratio (M-H, Random, 95% CI) 0.73 [0.45, 1.16]
2.2 Low-risk 7 4937 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.57, 1.72]
3 SGRQ responders at 3 months 9 4490 Odds Ratio (M-H, Random, 95% CI) 1.32 [1.16, 1.51]
3.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Low-risk 9 4490 Odds Ratio (M-H, Random, 95% CI) 1.32 [1.16, 1.51]
4 SGRQ responders at 6 months 10 10255 Odds Ratio (M-H, Random, 95% CI) 1.26 [1.17, 1.37]
4.1 High-risk 1 2019 Odds Ratio (M-H, Random, 95% CI) 1.30 [1.08, 1.56]
4.2 Low-risk 9 8236 Odds Ratio (M-H, Random, 95% CI) 1.26 [1.15, 1.37]
5 SGRQ responders at 12 months 2 4015 Odds Ratio (M-H, Random, 95% CI) 1.19 [1.04, 1.35]
5.1 High-risk 1 1743 Odds Ratio (M-H, Random, 95% CI) 1.27 [1.04, 1.55]
5.2 Low-risk 1 2272 Odds Ratio (M-H, Random, 95% CI) 1.13 [0.95, 1.34]
6 Change from baseline in SGRQ
at 3 months
12 10259 Mean Difference (IV, Random, 95% CI) -1.74 [-2.31, -1.18]
6.1 High-risk 1 2064 Mean Difference (IV, Random, 95% CI) -3.68 [-5.84, -1.52]
6.2 Low-risk 11 8195 Mean Difference (IV, Random, 95% CI) -1.60 [-2.19, -1.01]
7 Change from baseline in SGRQ
at 6 months
11 9217 Mean Difference (IV, Random, 95% CI) -1.31 [-1.93, -0.70]
7.1 High-risk 1 2019 Mean Difference (IV, Random, 95% CI) -2.79 [-5.02, -0.56]
7.2 Low-risk 10 7198 Mean Difference (IV, Random, 95% CI) -1.20 [-1.83, -0.57]
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8 Change from baseline in SGRQ
at 12 months
5 6000 Mean Difference (IV, Random, 95% CI) -1.15 [-2.24, -0.06]
8.1 High-risk 1 2206 Mean Difference (IV, Random, 95% CI) -3.38 [-5.83, -0.93]
8.2 Low-risk 4 3794 Mean Difference (IV, Random, 95% CI) -0.87 [-1.64, -0.10]
9 TDI at 3 months 10 7027 Mean Difference (IV, Random, 95% CI) 0.48 [0.34, 0.62]
9.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Low-risk 10 7027 Mean Difference (IV, Random, 95% CI) 0.48 [0.34, 0.62]
10 TDI at 6 months 7 6099 Mean Difference (IV, Random, 95% CI) 0.32 [0.17, 0.46]
10.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Low-risk 7 6099 Mean Difference (IV, Random, 95% CI) 0.32 [0.17, 0.46]
11 TDI at 12 months 4 5257 Mean Difference (IV, Random, 95% CI) 0.21 [0.10, 0.33]
11.1 High-risk 1 304 Mean Difference (IV, Random, 95% CI) -0.38 [-1.28, 0.52]
11.2 Low-risk 3 4953 Mean Difference (IV, Random, 95% CI) 0.22 [0.11, 0.34]
12 Change from baseline in FEV1
at 3 months
18 12891 Mean Difference (IV, Random, 95% CI) 0.07 [0.06, 0.08]
12.1 High-risk 1 1982 Mean Difference (IV, Random, 95% CI) 0.06 [0.02, 0.09]
12.2 Low-risk 17 10909 Mean Difference (IV, Random, 95% CI) 0.07 [0.06, 0.09]
13 Change from baseline in FEV1
at 6 months
14 11002 Mean Difference (IV, Random, 95% CI) 0.06 [0.05, 0.07]
13.1 High-risk 1 1780 Mean Difference (IV, Random, 95% CI) 0.06 [0.02, 0.10]
13.2 Low-risk 13 9222 Mean Difference (IV, Random, 95% CI) 0.06 [0.05, 0.07]
14 Change from baseline in FEV1
at 12 months
7 8072 Mean Difference (IV, Random, 95% CI) 0.06 [0.04, 0.08]
14.1 High-risk 1 2206 Mean Difference (IV, Random, 95% CI) 0.05 [0.01, 0.09]
14.2 Low-risk 6 5866 Mean Difference (IV, Random, 95% CI) 0.06 [0.04, 0.08]
15 Mortality 24 20683 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.75, 1.36]
15.1 High-risk 2 2510 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.66, 1.69]
15.2 Low-risk 22 18173 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.66, 1.43]
16 Total SAE 25 21453 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.92, 1.12]
16.1 High-risk 2 2510 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.80, 1.20]
16.2 Low-risk 23 18943 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.91, 1.16]
17 COPD SAE 22 20101 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.86, 1.17]
17.1 High-risk 1 2206 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.84, 1.39]
17.2 Low-risk 21 17895 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.79, 1.17]
18 Cardiac SAE 22 20736 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.78, 1.25]
18.1 High-risk 1 2206 Odds Ratio (M-H, Random, 95% CI) 0.80 [0.53, 1.20]
18.2 Low-risk 21 18530 Odds Ratio (M-H, Random, 95% CI) 1.09 [0.82, 1.45]
19 Dropouts due to adverse events 26 21877 Odds Ratio (M-H, Random, 95% CI) 1.10 [0.96, 1.27]
19.1 High-risk 2 2510 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.75, 1.41]
19.2 Low-risk 24 19367 Odds Ratio (M-H, Random, 95% CI) 1.12 [0.96, 1.31]
20 Pneumonia 24 21048 Odds Ratio (M-H, Random, 95% CI) 1.13 [0.83, 1.53]
20.1 High-risk 2 2510 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.59, 1.61]
20.2 Low-risk 22 18538 Odds Ratio (M-H, Random, 95% CI) 1.23 [0.84, 1.81]
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Comparison 3. LABA/LAMA vs LABA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Moderate to severe exacerbations 5 2488 Odds Ratio (M-H, Random, 95% CI) 0.77 [0.62, 0.97]
1.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Low-risk 5 2488 Odds Ratio (M-H, Random, 95% CI) 0.77 [0.62, 0.97]
2 Severe exacerbations 6 2898 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.55, 1.12]
2.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Low-risk 6 2898 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.55, 1.12]
3 SGRQ responders at 6 months 6 5870 Odds Ratio (M-H, Random, 95% CI) 1.30 [1.10, 1.53]
3.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Low-risk 6 5870 Odds Ratio (M-H, Random, 95% CI) 1.30 [1.10, 1.53]
4 SGRQ responders at 12 months 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
4.1 High-risk 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Low-risk 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Change from baseline in SGRQ
at 3 months
1 Mean Difference (IV, Random, 95% CI) Totals not selected
5.1 High-risk 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Low-risk 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 Change from baseline in SGRQ
at 6 months
5 3649 Mean Difference (IV, Random, 95% CI) -1.09 [-1.96, -0.22]
6.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Low-risk 5 3649 Mean Difference (IV, Random, 95% CI) -1.09 [-1.96, -0.22]
7 Change from baseline in SGRQ
at 12 months
2 2507 Mean Difference (IV, Random, 95% CI) -0.69 [-1.64, 0.25]
7.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Low-risk 2 2507 Mean Difference (IV, Random, 95% CI) -0.69 [-1.64, 0.25]
8 TDI at 3 months 3 3342 Mean Difference (IV, Random, 95% CI) 0.52 [0.31, 0.74]
8.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Low-risk 3 3342 Mean Difference (IV, Random, 95% CI) 0.52 [0.31, 0.74]
9 TDI at 6 months 4 4126 Mean Difference (IV, Random, 95% CI) 0.40 [0.23, 0.57]
9.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Low-risk 4 4126 Mean Difference (IV, Random, 95% CI) 0.40 [0.23, 0.57]
10 TDI at 12 months 3 4516 Mean Difference (IV, Random, 95% CI) 0.42 [0.06, 0.77]
10.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Low-risk 3 4516 Mean Difference (IV, Random, 95% CI) 0.42 [0.06, 0.77]
11 Change from baseline in FEV1
at 3 months
4 2469 Mean Difference (IV, Random, 95% CI) 0.07 [0.03, 0.12]
11.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Low-risk 4 2469 Mean Difference (IV, Random, 95% CI) 0.07 [0.03, 0.12]
12 Change from baseline in FEV1
at 6 months
8 6144 Mean Difference (IV, Random, 95% CI) 0.07 [0.06, 0.08]
12.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Low-risk 8 6144 Mean Difference (IV, Random, 95% CI) 0.07 [0.06, 0.08]
13 Change from baseline in FEV1
at 12 months
6 5063 Mean Difference (IV, Random, 95% CI) 0.07 [0.06, 0.09]
13.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Low-risk 6 5063 Mean Difference (IV, Random, 95% CI) 0.07 [0.06, 0.09]
14 Mortality 10 7930 Odds Ratio (M-H, Random, 95% CI) 1.19 [0.68, 2.09]
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14.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Low-risk 10 7930 Odds Ratio (M-H, Random, 95% CI) 1.19 [0.68, 2.09]
15 Total SAE 11 8699 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.91, 1.22]
15.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Low-risk 11 8699 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.91, 1.22]
16 COPD SAE 8 7068 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.83, 1.40]
16.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Low-risk 8 7068 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.83, 1.40]
17 Cardiac SAE 11 8699 Odds Ratio (M-H, Random, 95% CI) 1.19 [0.69, 2.07]
17.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Low-risk 11 8699 Odds Ratio (M-H, Random, 95% CI) 1.19 [0.69, 2.07]
18 Dropuouts due to adverse
events
13 9202 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.68, 1.29]
18.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Low-risk 13 9202 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.68, 1.29]
19 Pneumonia 10 8252 Odds Ratio (M-H, Random, 95% CI) 1.54 [0.95, 2.49]
19.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Low-risk 10 8252 Odds Ratio (M-H, Random, 95% CI) 1.54 [0.95, 2.49]
Comparison 4. LABA/ICS vs LAMA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Moderate to severe exacerbations 3 2203 Odds Ratio (M-H, Random, 95% CI) 1.09 [0.88, 1.34]
1.1 high-risk 2 1580 Odds Ratio (M-H, Random, 95% CI) 1.12 [0.90, 1.39]
1.2 Low-risk 1 623 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.24, 1.66]
2 Severe exacerbations 3 2203 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.97, 1.63]
2.1 High-risk 2 1580 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.96, 1.61]
2.2 Low-risk 1 623 Risk Ratio (M-H, Random, 95% CI) 3.03 [0.32, 28.96]
3 SGRQ responders at 3 months 2 823 Odds Ratio (M-H, Random, 95% CI) 1.17 [0.89, 1.55]
3.1 High-risk 1 214 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.56, 1.65]
3.2 Low-risk 1 609 Odds Ratio (M-H, Random, 95% CI) 1.26 [0.92, 1.74]
4 SGRQ responders at 6 months 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
4.1 High-risk 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Low-risk 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 SGRQ responders at 12 months 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
5.1 High-risk 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Low-risk 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 SGRQ responder at 2 years 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
6.1 High-risk 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Low-risk 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Change from baseline in SGRQ
at 3 months
3 814 Mean Difference (IV, Random, 95% CI) -1.37 [-3.04, 0.30]
7.1 High-risk 1 214 Mean Difference (IV, Random, 95% CI) -1.06 [-4.39, 2.27]
7.2 Low-risk 2 600 Mean Difference (IV, Random, 95% CI) -1.48 [-3.41, 0.45]
8 Change from baseline in SGRQ
at 6 months
1 Mean Difference (IV, Random, 95% CI) Totals not selected
8.1 High-risk 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Low-risk 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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9 Change from baseline in SGRQ
at 12 months
1 Mean Difference (IV, Random, 95% CI) Totals not selected
9.1 High-risk 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Low-risk 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Change from baseline in SGRQ
at 2 years
1 Mean Difference (IV, Random, 95% CI) Totals not selected
10.1 High-risk 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Low-risk 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 TDI at 3 months 2 1323 Mean Difference (IV, Random, 95% CI) 0.50 [0.20, 0.81]
11.1 High-risk 1 1198 Mean Difference (IV, Random, 95% CI) 0.50 [0.18, 0.82]
11.2 Low-risk 1 125 Mean Difference (IV, Random, 95% CI) 0.51 [-0.39, 1.41]
12 TDI at 6 months 1 Mean Difference (IV, Random, 95% CI) Totals not selected
12.1 High-risk 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Low-risk 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 TDI at 12 months 1 Mean Difference (IV, Random, 95% CI) Totals not selected
13.1 High-risk 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Low-risk 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 TDI at 2 years 1 Mean Difference (IV, Random, 95% CI) Totals not selected
14.1 High-risk 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Low-risk 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Change from baseline in FEV1
at 3 months
8 2379 Mean Difference (IV, Random, 95% CI) 0.02 [-0.02, 0.05]
15.1 High-risk 2 1353 Mean Difference (IV, Random, 95% CI) 0.01 [-0.02, 0.04]
15.2 Low-risk 6 1026 Mean Difference (IV, Random, 95% CI) 0.02 [-0.02, 0.06]
16 Change from baseline in FEV1
at 6 months
2 1301 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.02]
16.1 High-risk 1 1071 Mean Difference (IV, Random, 95% CI) -0.01 [-0.04, 0.02]
16.2 Low-risk 1 230 Mean Difference (IV, Random, 95% CI) -0.00 [-0.06, 0.06]
17 Change from baseline in FEV1
at 12 months
2 933 Mean Difference (IV, Random, 95% CI) -0.01 [-0.08, 0.05]
17.1 High-risk 2 933 Mean Difference (IV, Random, 95% CI) -0.01 [-0.08, 0.05]
17.2 Low-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Change from baseline in FEV1
at 2 years
1 Mean Difference (IV, Random, 95% CI) Totals not selected
18.1 High-risk 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Low-risk 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Mortality 5 2395 Odds Ratio (M-H, Random, 95% CI) 0.52 [0.31, 0.88]
19.1 High-risk 2 1580 Odds Ratio (M-H, Random, 95% CI) 0.53 [0.31, 0.90]
19.2 Low-risk 3 815 Odds Ratio (M-H, Random, 95% CI) 0.48 [0.06, 3.82]
20 Total SAE 5 2590 Odds Ratio (M-H, Random, 95% CI) 1.25 [1.00, 1.55]
20.1 High-risk 2 1580 Odds Ratio (M-H, Random, 95% CI) 1.29 [1.03, 1.63]
20.2 Low-risk 3 1010 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.49, 1.77]
21 COPD SAE 5 2590 Odds Ratio (M-H, Random, 95% CI) 1.33 [0.99, 1.78]
21.1 High-risk 2 1580 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.33, 2.96]
21.2 Low-risk 3 1010 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.21, 4.99]
22 Cardiac SAE 3 2208 Odds Ratio (M-H, Random, 95% CI) 0.61 [0.34, 1.08]
22.1 High-risk 1 1323 Odds Ratio (M-H, Random, 95% CI) 0.67 [0.39, 1.15]
22.2 Low-risk 2 885 Odds Ratio (M-H, Random, 95% CI) 0.16 [0.02, 1.34]
23 Dropouts due to adverse events 6 2657 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.73, 1.34]
23.1 High-risk 2 1580 Odds Ratio (M-H, Random, 95% CI) 1.04 [0.74, 1.47]
23.2 Low-risk 4 1077 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.35, 1.71]
24 Pneumonia 4 2465 Odds Ratio (M-H, Random, 95% CI) 1.93 [1.15, 3.23]
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24.1 High-risk 2 1580 Odds Ratio (M-H, Random, 95% CI) 1.80 [1.06, 3.06]
24.2 Low-risk 2 885 Odds Ratio (M-H, Random, 95% CI) 5.82 [0.70, 48.80]
Comparison 5. LABA/ICS vs LABA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Moderate to severe exacerbations 16 15730 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.77, 0.89]
1.1 High-risk 10 9041 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.75, 0.89]
1.2 Low-risk 6 6689 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.70, 0.98]
2 Severe exacerbations 11 10698 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.14]
2.1 High-risk 5 4216 Odds Ratio (M-H, Random, 95% CI) 0.91 [0.74, 1.13]
2.2 Low-risk 6 6482 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.90, 1.24]
3 SGRQ responders at 3 months 2 1427 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.73, 1.11]
3.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Low-risk 2 1427 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.73, 1.11]
4 SGRQ responders at 6 months 4 4618 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.96, 1.22]
4.1 High-risk 0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Low-risk 4 4618 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.96, 1.22]
5 SGRQ responders at 12 months 4 4349 Odds Ratio (M-H, Random, 95% CI) 1.24 [0.95, 1.60]
5.1 High-risk 3 2337 Odds Ratio (M-H, Random, 95% CI) 1.15 [0.78, 1.72]
5.2 Low-risk 1 2012 Odds Ratio (M-H, Random, 95% CI) 1.42 [1.18, 1.70]
6 SGRQ responders at 3 years 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 High-risk 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Low-risk 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Change from baseline in SGRQ
at 3 months
4 3602 Mean Difference (IV, Random, 95% CI) -1.53 [-2.48, -0.58]
7.1 High-risk 3 2552 Mean Difference (IV, Random, 95% CI) -1.81 [-2.99, -0.64]
7.2 Low-risk 1 1050 Mean Difference (IV, Random, 95% CI) -1.00 [-2.61, 0.61]
8 Change from baseline in SGRQ
at 6 months
9 7857 Mean Difference (IV, Random, 95% CI) -1.32 [-1.94, -0.70]
8.1 High-risk 5 3687 Mean Difference (IV, Random, 95% CI) -1.40 [-2.53, -0.26]
8.2 Low-risk 4 4170 Mean Difference (IV, Random, 95% CI) -1.18 [-1.97, -0.40]
9 Change from baseline in SGRQ
at 12 months
9 8322 Mean Difference (IV, Random, 95% CI) -1.75 [-2.44, -1.06]
9.1 High-risk 8 6605 Mean Difference (IV, Random, 95% CI) -1.75 [-2.61, -0.89]
9.2 Low-risk 1 1717 Mean Difference (IV, Random, 95% CI) -1.70 [-2.82, -0.58]
10 Change from baseline in SGRQ
at 3 years
1 Mean Difference (IV, Random, 95% CI) Totals not selected
10.1 High-risk 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Low-risk 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 TDI at 3 months 4 1968 Mean Difference (IV, Random, 95% CI) 0.13 [-0.26, 0.52]
11.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Low-risk 4 1968 Mean Difference (IV, Random, 95% CI) 0.13 [-0.26, 0.52]
12 TDI at 6 months 4 1917 Mean Difference (IV, Random, 95% CI) 0.21 [-0.09, 0.50]
12.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Low-risk 4 1917 Mean Difference (IV, Random, 95% CI) 0.21 [-0.09, 0.50]
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13 Change from baseline in FEV1
at 3 months
12 7829 Mean Difference (IV, Random, 95% CI) 0.05 [0.04, 0.06]
13.1 High-risk 5 4435 Mean Difference (IV, Random, 95% CI) 0.05 [0.03, 0.07]
13.2 Low-risk 7 3394 Mean Difference (IV, Random, 95% CI) 0.05 [0.04, 0.06]
14 Change from baseline in FEV1
at 6 months
11 6555 Mean Difference (IV, Random, 95% CI) 0.04 [0.03, 0.06]
14.1 High-risk 7 4560 Mean Difference (IV, Random, 95% CI) 0.05 [0.03, 0.07]
14.2 Low-risk 4 1995 Mean Difference (IV, Random, 95% CI) 0.04 [0.01, 0.07]
15 Change from baseline in FEV1
at 12 months
8 4628 Mean Difference (IV, Random, 95% CI) 0.05 [0.03, 0.07]
15.1 High-risk 8 4628 Mean Difference (IV, Random, 95% CI) 0.05 [0.03, 0.07]
15.2 Low-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Change from baseline in FEV1
at 3 years
1 Mean Difference (IV, Random, 95% CI) Totals not selected
16.1 High-risk 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Low-risk 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Mortality 21 19681 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.79, 1.11]
17.1 High-risk 15 12976 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.69, 1.30]
17.2 Low-risk 6 6705 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.76, 1.15]
18 Total SAE 20 19204 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.94, 1.13]
18.1 High-risk 14 12499 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.89, 1.09]
18.2 Low-risk 6 6705 Odds Ratio (M-H, Random, 95% CI) 1.17 [0.92, 1.47]
19 COPD SAE 17 16397 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.83, 1.04]
19.1 High-risk 11 9692 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.78, 1.07]
19.2 Low-risk 6 6705 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.80, 1.12]
20 Cardiac SAE 17 17085 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.77, 1.27]
20.1 High-risk 11 10380 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.68, 1.38]
20.2 Low-risk 6 6705 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.78, 1.21]
21 Dropouts due to adverse events 21 19713 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.80, 0.98]
21.1 High-risk 15 13008 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.77, 1.00]
21.2 Low-risk 6 6705 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.77, 1.06]
22 Pneumonia 20 19291 Odds Ratio (M-H, Random, 95% CI) 1.48 [1.14, 1.92]
22.1 High-risk 14 12586 Odds Ratio (M-H, Random, 95% CI) 1.46 [1.03, 2.08]
22.2 Low-risk 6 6705 Odds Ratio (M-H, Random, 95% CI) 1.64 [1.25, 2.14]
Comparison 6. LAMA vs LABA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Moderate to severe exacerbations 6 11943 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.79, 0.93]
1.1 High-risk 1 7376 Odds Ratio (M-H, Random, 95% CI) 0.84 [0.76, 0.92]
1.2 Low-risk 5 4567 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.79, 1.07]
2 Severe exacerbations 5 10696 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.53, 1.10]
2.1 High-risk 1 7376 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.78, 1.01]
2.2 Low-risk 4 3320 Odds Ratio (M-H, Random, 95% CI) 0.64 [0.36, 1.13]
3 SGRQ responders at 3 months 2 4495 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.64, 1.13]
3.1 High-risk 1 2999 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.84, 1.12]
3.2 Low-risk 1 1496 Odds Ratio (M-H, Random, 95% CI) 0.73 [0.59, 0.89]
4 SGRQ responders at 6 months 8 11831 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.92, 1.15]
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4.1 High-risk 1 2829 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.93, 1.25]
4.2 Low-risk 7 9002 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.89, 1.16]
5 SGRQ responders at 12 months 2 4709 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.91, 1.15]
5.1 High-risk 1 2587 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.86, 1.17]
5.2 Low-risk 1 2122 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.88, 1.26]
6 Change from baseline in SGRQ
at 3 months
4 7191 Mean Difference (IV, Random, 95% CI) 1.13 [-0.09, 2.34]
6.1 High-risk 1 3019 Mean Difference (IV, Random, 95% CI) 0.10 [-0.82, 1.02]
6.2 Low-risk 3 4172 Mean Difference (IV, Random, 95% CI) 1.84 [0.87, 2.80]
7 Change from baseline in SGRQ
at 6 months
7 7972 Mean Difference (IV, Random, 95% CI) -0.39 [-1.03, 0.25]
7.1 High-risk 1 2848 Mean Difference (IV, Random, 95% CI) -0.70 [-1.74, 0.34]
7.2 Low-risk 6 5124 Mean Difference (IV, Random, 95% CI) -0.25 [-1.09, 0.58]
8 Change from baseline in SGRQ
at 12 months
3 5397 Mean Difference (IV, Random, 95% CI) -0.08 [-0.79, 0.62]
8.1 High-risk 1 2606 Mean Difference (IV, Random, 95% CI) -0.40 [-1.56, 0.76]
8.2 Low-risk 2 2791 Mean Difference (IV, Random, 95% CI) 0.10 [-0.79, 0.99]
9 TDI at 3 months 4 7881 Mean Difference (IV, Random, 95% CI) -0.14 [-0.37, 0.09]
9.1 High-risk 1 3024 Mean Difference (IV, Random, 95% CI) -0.14 [-0.15, -0.13]
9.2 Low-risk 3 4857 Mean Difference (IV, Random, 95% CI) -0.18 [-0.63, 0.27]
10 TDI at 6 months 5 7444 Mean Difference (IV, Random, 95% CI) -0.12 [-0.24, 0.01]
10.1 High-risk 1 2863 Mean Difference (IV, Random, 95% CI) -0.19 [-0.20, -0.18]
10.2 Low-risk 4 4581 Mean Difference (IV, Random, 95% CI) 0.00 [-0.17, 0.18]
11 TDI at 12 months 4 7421 Mean Difference (IV, Random, 95% CI) 0.02 [-0.25, 0.29]
11.1 High-risk 1 2610 Mean Difference (IV, Random, 95% CI) -0.26 [-0.27, -0.25]
11.2 Low-risk 3 4811 Mean Difference (IV, Random, 95% CI) 0.15 [-0.11, 0.40]
12 Change from baseline in FEV1
at 3 months
8 5420 Mean Difference (IV, Random, 95% CI) -0.00 [-0.02, 0.02]
12.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Low-risk 8 5420 Mean Difference (IV, Random, 95% CI) -0.00 [-0.02, 0.02]
13 Change from baseline in FEV1
at 6 months
10 7770 Mean Difference (IV, Random, 95% CI) 0.02 [0.00, 0.03]
13.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Low-risk 10 7770 Mean Difference (IV, Random, 95% CI) 0.02 [0.00, 0.03]
14 Change from baseline in FEV1
at 12 months
5 5353 Mean Difference (IV, Random, 95% CI) 0.02 [0.01, 0.03]
14.1 High-risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Low-risk 5 5353 Mean Difference (IV, Random, 95% CI) 0.02 [0.01, 0.03]
15 Mortality 13 22844 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.75, 1.24]
15.1 High-risk 2 10815 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.66, 1.16]
15.2 Low-risk 11 12029 Odds Ratio (M-H, Random, 95% CI) 1.33 [0.79, 2.25]
16 Total SAE 14 23191 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.87, 1.02]
16.1 High-risk 2 10815 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.81, 1.00]
16.2 Low-risk 12 12376 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.88, 1.15]
17 COPD SAE 12 22136 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.71, 1.04]
17.1 High-risk 2 10815 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.69, 0.91]
17.2 Low-risk 10 11321 Odds Ratio (M-H, Random, 95% CI) 0.91 [0.65, 1.27]
18 Cardiac SAE 12 22153 Odds Ratio (M-H, Random, 95% CI) 1.12 [0.91, 1.38]
18.1 High-risk 2 10815 Odds Ratio (M-H, Random, 95% CI) 1.09 [0.83, 1.44]
18.2 Low-risk 10 11338 Odds Ratio (M-H, Random, 95% CI) 1.16 [0.83, 1.61]
19 Dropuouts due to adverse
events
14 22755 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.78, 1.02]
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19.1 High-risk 2 10815 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.78, 1.05]
19.2 Low-risk 12 11940 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.72, 1.10]
20 Pneumonia 12 22153 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.68, 1.13]
20.1 High-risk 2 10815 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.61, 1.13]
20.2 Low-risk 10 11338 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.61, 1.69]
Analysis 1.1. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 1 Moderate to severe exacerbations.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 1 Moderate to severe exacerbations
Study or subgroup LABA/LAMA LABA/ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2016 686/1675 751/1697 59.1 % 0.87 [ 0.76, 1.00 ]
Subtotal (95% CI) 1675 1697 59.1 % 0.87 [ 0.76, 1.00 ]
Total events: 686 (LABA/LAMA), 751 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.053)
2 Low-risk
Donohue 2015a 12/353 11/353 3.2 % 1.09 [ 0.48, 2.51 ]
Donohue 2015b 9/349 11/348 2.8 % 0.81 [ 0.33, 1.98 ]
Singh 2015c 8/358 3/358 1.3 % 2.70 [ 0.71, 10.28 ]
Vogelmeier 2013a 18/258 21/264 5.1 % 0.87 [ 0.45, 1.67 ]
Vogelmeier 2016 74/467 77/466 16.3 % 0.95 [ 0.67, 1.35 ]
Zhong 2015 44/372 68/369 12.2 % 0.59 [ 0.39, 0.89 ]
Subtotal (95% CI) 2157 2158 40.9 % 0.86 [ 0.65, 1.14 ]
Total events: 165 (LABA/LAMA), 191 (LABA/ICS)
Heterogeneity: Tau2 = 0.03; Chi2 = 6.59, df = 5 (P = 0.25); I2 =24%
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 3832 3855 100.0 % 0.86 [ 0.74, 1.00 ]
Total events: 851 (LABA/LAMA), 942 (LABA/ICS)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.67, df = 6 (P = 0.35); I2 =10%
Test for overall effect: Z = 1.92 (P = 0.054)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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Analysis 1.2. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 2 Severe exacerbations.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 2 Severe exacerbations
Study or subgroup LABA/LAMA LABA/ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2016 259/1675 288/1679 58.3 % 0.88 [ 0.74, 1.06 ]
Subtotal (95% CI) 1675 1679 58.3 % 0.88 [ 0.74, 1.06 ]
Total events: 259 (LABA/LAMA), 288 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 Low-risk
Donohue 2015a 2/353 4/353 7.9 % 0.50 [ 0.09, 2.73 ]
Donohue 2015b 4/349 4/348 11.1 % 1.00 [ 0.25, 4.02 ]
Singh 2015c 3/358 0/358 2.8 % 7.06 [ 0.36, 137.16 ]
Zhong 2015 6/372 16/369 19.9 % 0.36 [ 0.14, 0.93 ]
Subtotal (95% CI) 1432 1428 41.7 % 0.66 [ 0.27, 1.63 ]
Total events: 15 (LABA/LAMA), 24 (LABA/ICS)
Heterogeneity: Tau2 = 0.27; Chi2 = 4.34, df = 3 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI) 3107 3107 100.0 % 0.76 [ 0.46, 1.27 ]
Total events: 274 (LABA/LAMA), 312 (LABA/ICS)
Heterogeneity: Tau2 = 0.11; Chi2 = 5.65, df = 4 (P = 0.23); I2 =29%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Chi2 = 0.39, df = 1 (P = 0.53), I2 =0.0%
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Analysis 1.3. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 3 SGRQ responders at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 3 SGRQ responders at 3 months
Study or subgroup LABA/LAMA LABA/ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Donohue 2015a 171/315 173/316 26.2 % 0.98 [ 0.72, 1.34 ]
Donohue 2015b 169/322 143/309 26.3 % 1.28 [ 0.94, 1.75 ]
Singh 2015c 168/330 168/337 27.9 % 1.04 [ 0.77, 1.41 ]
Vogelmeier 2013a 116/230 119/238 19.6 % 1.02 [ 0.71, 1.46 ]
Subtotal (95% CI) 1197 1200 100.0 % 1.08 [ 0.92, 1.27 ]
Total events: 624 (LABA/LAMA), 603 (LABA/ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 1197 1200 100.0 % 1.08 [ 0.92, 1.27 ]
Total events: 624 (LABA/LAMA), 603 (LABA/ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 4 SGRQ responders at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 4 SGRQ responders at 6 months
Study or subgroup LABA/LAMA LABA/ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Vogelmeier 2013a 117/211 106/216 100.0 % 1.29 [ 0.88, 1.89 ]
Subtotal (95% CI) 211 216 100.0 % 1.29 [ 0.88, 1.89 ]
Total events: 117 (LABA/LAMA), 106 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI) 211 216 100.0 % 1.29 [ 0.88, 1.89 ]
Total events: 117 (LABA/LAMA), 106 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 5 SGRQ responders at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 5 SGRQ responders at 12 months
Study or subgroup LABA/LAMA LABA/ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 HIgh-risk
Wedzicha 2016 788/1602 696/1593 100.0 % 1.25 [ 1.09, 1.43 ]
Subtotal (95% CI) 1602 1593 100.0 % 1.25 [ 1.09, 1.43 ]
Total events: 788 (LABA/LAMA), 696 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 3.11 (P = 0.0018)
2 Low-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1602 1593 100.0 % 1.25 [ 1.09, 1.43 ]
Total events: 788 (LABA/LAMA), 696 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 3.11 (P = 0.0018)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 6 Change from baseline in SGRQ at 3
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 6 Change from baseline in SGRQ at 3 months
Study or subgroup LABA/LAMA LABA/ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2016 1593 -3.2 (15.17) 1602 -1.9 (15.21) 35.1 % -1.30 [ -2.35, -0.25 ]
Subtotal (95% CI) 1593 1602 35.1 % -1.30 [ -2.35, -0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.016)
2 Low-risk
Donohue 2015a 312 -6.33 (11.62) 313 -6.79 (11.59) 18.3 % 0.46 [ -1.36, 2.28 ]
Donohue 2015b 321 -7.23 (13.29) 307 -5.67 (13.18) 15.1 % -1.56 [ -3.63, 0.51 ]
Singh 2015c 329 -5.1 (11.35) 336 -5.64 (11.35) 19.8 % 0.54 [ -1.19, 2.27 ]
Vogelmeier 2013a 242 -5.43 (20.55) 246 -6.83 (20.45) 5.8 % 1.40 [ -2.24, 5.04 ]
Zhong 2015 372 -7.18 (25.17) 369 -6 (24.99) 5.9 % -1.18 [ -4.79, 2.43 ]
Subtotal (95% CI) 1576 1571 64.9 % -0.03 [ -1.02, 0.96 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.78, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 3169 3173 100.0 % -0.49 [ -1.41, 0.43 ]
Heterogeneity: Tau2 = 0.34; Chi2 = 6.76, df = 5 (P = 0.24); I2 =26%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 2.98, df = 1 (P = 0.08), I2 =66%
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Analysis 1.7. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 7 Change from baseline in SGRQ at 6
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 7 Change from baseline in SGRQ at 6 months
Study or subgroup LABA/LAMA LABA/ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2016 1602 -3.5 (15.61) 1593 -2.3 (15.57) 89.3 % -1.20 [ -2.28, -0.12 ]
Subtotal (95% CI) 1602 1593 89.3 % -1.20 [ -2.28, -0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.030)
2 Low-risk
Vogelmeier 2013a 231 -6.42 (30.56) 238 -5.72 (29.9) 3.5 % -0.70 [ -6.17, 4.77 ]
Zhong 2015 354 -7.51 (25.93) 342 -6.38 (25.39) 7.2 % -1.13 [ -4.94, 2.68 ]
Subtotal (95% CI) 585 580 10.7 % -0.99 [ -4.12, 2.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
Total (95% CI) 2187 2173 100.0 % -1.18 [ -2.20, -0.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 1.8. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 8 Change from baseline in SGRQ at 12
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 8 Change from baseline in SGRQ at 12 months
Study or subgroup LABA/LAMA LABA/ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2016 1602 -3.1 (16.41) 1593 -1.9 (16.36) 100.0 % -1.20 [ -2.34, -0.06 ]
Subtotal (95% CI) 1602 1593 100.0 % -1.20 [ -2.34, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.038)
2 Low-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1602 1593 100.0 % -1.20 [ -2.34, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 9 TDI at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 9 TDI at 3 months
Study or subgroup LABA/LAMA LABA/ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Donohue 2015a 309 3.3 (2.81) 316 3 (2.84) 19.0 % 0.30 [ -0.14, 0.74 ]
Donohue 2015b 323 3 (2.88) 307 2.6 (2.98) 18.7 % 0.40 [ -0.06, 0.86 ]
Singh 2015c 334 2 (2.56) 338 2.1 (2.39) 20.5 % -0.10 [ -0.47, 0.27 ]
Vogelmeier 2013a 224 2.03 (5.81) 236 1.45 (5.75) 8.6 % 0.58 [ -0.48, 1.64 ]
Vogelmeier 2017 811 1.949 (3.54) 269 0.85 (3.21) 18.8 % 1.10 [ 0.64, 1.55 ]
Zhong 2015 348 2.62 (4.48) 337 2.4 (4.37) 14.4 % 0.22 [ -0.44, 0.88 ]
Subtotal (95% CI) 2349 1803 100.0 % 0.40 [ 0.02, 0.78 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 16.37, df = 5 (P = 0.01); I2 =69%
Test for overall effect: Z = 2.05 (P = 0.041)
Total (95% CI) 2349 1803 100.0 % 0.40 [ 0.02, 0.78 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 16.37, df = 5 (P = 0.01); I2 =69%
Test for overall effect: Z = 2.05 (P = 0.041)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 10 TDI at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 10 TDI at 6 months
Study or subgroup LABA/LAMA LABA/ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Vogelmeier 2013a 212 2.36 (5.65) 213 1.6 (5.49) 12.3 % 0.76 [ -0.30, 1.82 ]
Vogelmeier 2016 353 1.9 (3.19) 341 1.9 (3.14) 62.3 % 0.0 [ -0.47, 0.47 ]
Zhong 2015 335 3.02 (4.87) 326 2.86 (4.8) 25.4 % 0.16 [ -0.58, 0.90 ]
Subtotal (95% CI) 900 880 100.0 % 0.13 [ -0.24, 0.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 900 880 100.0 % 0.13 [ -0.24, 0.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 11 Change from baseline in FEV1 at 3
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 11 Change from baseline in FEV1 at 3 months
Study or subgroup LABA/LAMA LABA/ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2016 1597 0.07 (0.288) 1595 -0.01 (0.288) 17.3 % 0.08 [ 0.06, 0.10 ]
Subtotal (95% CI) 1597 1595 17.3 % 0.08 [ 0.06, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.65 (P < 0.00001)
2 Low-risk
Donohue 2015a 312 0.154 (0.235) 317 0.07 (0.239) 15.4 % 0.08 [ 0.04, 0.12 ]
Donohue 2015b 349 0.185 (0.258) 348 0.09 (0.261) 15.2 % 0.10 [ 0.06, 0.14 ]
Hoshino 2015 22 0.214 (0.0123) 21 0.2 (0.0165) 18.1 % 0.02 [ 0.01, 0.02 ]
Singh 2015c 333 0.151 (0.23) 338 0.06 (0.23) 15.7 % 0.09 [ 0.05, 0.12 ]
Vogelmeier 2013a 258 0.29 (0.626) 235 0.2 (0.521) 7.6 % 0.09 [ -0.01, 0.19 ]
Zhong 2015 372 0.183 (0.482) 369 0.08 (0.519) 10.7 % 0.10 [ 0.03, 0.17 ]
Subtotal (95% CI) 1646 1628 82.7 % 0.08 [ 0.03, 0.12 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 45.27, df = 5 (P<0.00001); I2 =89%
Test for overall effect: Z = 3.40 (P = 0.00067)
Total (95% CI) 3243 3223 100.0 % 0.08 [ 0.04, 0.11 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 66.03, df = 6 (P<0.00001); I2 =91%
Test for overall effect: Z = 4.05 (P = 0.000051)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 1.12. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 12 Change from baseline in FEV1 at 6
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 12 Change from baseline in FEV1 at 6 months
Study or subgroup LABA/LAMA LABA/ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2016 1597 0.049 (0.292) 1595 -0.04 (0.296) 84.8 % 0.09 [ 0.07, 0.11 ]
Subtotal (95% CI) 1597 1595 84.8 % 0.09 [ 0.07, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.26 (P < 0.00001)
2 Low-risk
Vogelmeier 2013a 212 0.24 (0.641) 216 0.16 (0.558) 2.7 % 0.08 [ -0.03, 0.19 ]
Vogelmeier 2016 468 0.27 (0.627) 463 0.18 (0.602) 5.7 % 0.09 [ 0.01, 0.17 ]
Zhong 2015 372 0.163 (0.482) 369 0.05 (0.519) 6.8 % 0.11 [ 0.04, 0.18 ]
Subtotal (95% CI) 1052 1048 15.2 % 0.10 [ 0.05, 0.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.97 (P = 0.000073)
Total (95% CI) 2649 2643 100.0 % 0.09 [ 0.07, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 3 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 9.15 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.66), I2 =0.0%
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Analysis 1.13. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 13 Change from baseline in FEV1 at 12
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 13 Change from baseline in FEV1 at 12 months
Study or subgroup LABA/LAMA LABA/ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2016 1597 0.015 (0.3) 1595 -0.05 (0.304) 100.0 % 0.06 [ 0.04, 0.08 ]
Subtotal (95% CI) 1597 1595 100.0 % 0.06 [ 0.04, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.89 (P < 0.00001)
2 Low-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1597 1595 100.0 % 0.06 [ 0.04, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.89 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 14 Mortality.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 14 Mortality
Study or subgroup LABA/LAMA LABA/ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2016 24/1678 24/1680 79.2 % 1.00 [ 0.57, 1.77 ]
Subtotal (95% CI) 1678 1680 79.2 % 1.00 [ 0.57, 1.77 ]
Total events: 24 (LABA/LAMA), 24 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
2 Low-risk
Donohue 2015a 0/353 1/353 2.5 % 0.33 [ 0.01, 8.19 ]
Donohue 2015b 2/349 3/348 8.0 % 0.66 [ 0.11, 3.99 ]
Hoshino 2015 0/22 0/21 Not estimable
Singh 2015c 1/358 0/358 2.5 % 3.01 [ 0.12, 74.10 ]
Vogelmeier 2013a 0/258 1/264 2.5 % 0.34 [ 0.01, 8.38 ]
Vogelmeier 2016 1/467 0/466 2.5 % 3.00 [ 0.12, 73.83 ]
Vogelmeier 2017 0/811 0/269 Not estimable
Zhong 2015 2/372 0/369 2.8 % 4.99 [ 0.24, 104.22 ]
Subtotal (95% CI) 2990 2448 20.8 % 1.06 [ 0.35, 3.23 ]
Total events: 6 (LABA/LAMA), 5 (LABA/ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.07, df = 5 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.92)
Total (95% CI) 4668 4128 100.0 % 1.01 [ 0.61, 1.68 ]
Total events: 30 (LABA/LAMA), 29 (LABA/ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.07, df = 6 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 1.15. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 15 Total SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 15 Total SAE
Study or subgroup LABA/LAMA LABA/ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2016 308/1678 334/1680 60.8 % 0.91 [ 0.76, 1.08 ]
Subtotal (95% CI) 1678 1680 60.8 % 0.91 [ 0.76, 1.08 ]
Total events: 308 (LABA/LAMA), 334 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
2 Low-risk
Donohue 2015a 6/353 10/353 3.0 % 0.59 [ 0.21, 1.65 ]
Donohue 2015b 11/349 13/348 4.7 % 0.84 [ 0.37, 1.90 ]
Hoshino 2015 0/22 0/21 Not estimable
Singh 2015c 7/358 2/358 1.3 % 3.55 [ 0.73, 17.21 ]
Vogelmeier 2013a 13/258 14/264 5.2 % 0.95 [ 0.44, 2.06 ]
Vogelmeier 2016 35/467 33/466 12.1 % 1.06 [ 0.65, 1.74 ]
Vogelmeier 2017 22/811 6/269 3.8 % 1.22 [ 0.49, 3.05 ]
Zhong 2015 20/372 35/369 9.3 % 0.54 [ 0.31, 0.96 ]
Subtotal (95% CI) 2990 2448 39.2 % 0.88 [ 0.64, 1.22 ]
Total events: 114 (LABA/LAMA), 113 (LABA/ICS)
Heterogeneity: Tau2 = 0.04; Chi2 = 7.46, df = 6 (P = 0.28); I2 =20%
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 4668 4128 100.0 % 0.89 [ 0.75, 1.07 ]
Total events: 422 (LABA/LAMA), 447 (LABA/ICS)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.50, df = 7 (P = 0.38); I2 =7%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 1.16. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 16 COPD SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 16 COPD SAE
Study or subgroup LABA/LAMA LABA/ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2016 182/1678 207/1680 49.4 % 0.87 [ 0.70, 1.07 ]
Subtotal (95% CI) 1678 1680 49.4 % 0.87 [ 0.70, 1.07 ]
Total events: 182 (LABA/LAMA), 207 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
2 Low-risk
Donohue 2015a 1/353 3/353 3.3 % 0.33 [ 0.03, 3.20 ]
Donohue 2015b 4/349 4/348 7.9 % 1.00 [ 0.25, 4.02 ]
Hoshino 2015 0/22 0/21 Not estimable
Singh 2015c 3/358 0/358 2.0 % 7.06 [ 0.36, 137.16 ]
Vogelmeier 2013a 1/258 3/264 3.3 % 0.34 [ 0.03, 3.28 ]
Vogelmeier 2016 13/467 8/466 16.1 % 1.64 [ 0.67, 3.99 ]
Vogelmeier 2017 3/811 1/269 3.3 % 1.00 [ 0.10, 9.61 ]
Zhong 2015 6/372 17/369 14.8 % 0.34 [ 0.13, 0.87 ]
Subtotal (95% CI) 2990 2448 50.6 % 0.80 [ 0.39, 1.64 ]
Total events: 31 (LABA/LAMA), 36 (LABA/ICS)
Heterogeneity: Tau2 = 0.29; Chi2 = 9.01, df = 6 (P = 0.17); I2 =33%
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 4668 4128 100.0 % 0.83 [ 0.54, 1.27 ]
Total events: 213 (LABA/LAMA), 243 (LABA/ICS)
Heterogeneity: Tau2 = 0.08; Chi2 = 9.08, df = 7 (P = 0.25); I2 =23%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.83), I2 =0.0%
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Analysis 1.17. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 17 Cardiac SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 17 Cardiac SAE
Study or subgroup LABA/LAMA LABA/ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2016 45/1678 52/1680 76.8 % 0.86 [ 0.58, 1.29 ]
Subtotal (95% CI) 1678 1680 76.8 % 0.86 [ 0.58, 1.29 ]
Total events: 45 (LABA/LAMA), 52 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.47)
2 Low-risk
Donohue 2015a 0/353 1/353 1.2 % 0.33 [ 0.01, 8.19 ]
Donohue 2015b 2/349 1/348 2.2 % 2.00 [ 0.18, 22.16 ]
Hoshino 2015 0/22 0/21 Not estimable
Singh 2015c 1/358 0/358 1.2 % 3.01 [ 0.12, 74.10 ]
Vogelmeier 2013a 2/258 1/264 2.2 % 2.05 [ 0.19, 22.80 ]
Vogelmeier 2016 4/467 3/466 5.6 % 1.33 [ 0.30, 5.99 ]
Vogelmeier 2017 2/811 1/269 2.2 % 0.66 [ 0.06, 7.34 ]
Zhong 2015 4/372 8/369 8.6 % 0.49 [ 0.15, 1.64 ]
Subtotal (95% CI) 2990 2448 23.2 % 0.90 [ 0.43, 1.89 ]
Total events: 15 (LABA/LAMA), 15 (LABA/ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.09, df = 6 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 4668 4128 100.0 % 0.87 [ 0.61, 1.24 ]
Total events: 60 (LABA/LAMA), 67 (LABA/ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.10, df = 7 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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Analysis 1.18. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 18 Dropouts due to adverse events.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 18 Dropouts due to adverse events
Study or subgroup LABA/LAMA LABA/ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2016 129/1678 145/1680 55.7 % 0.88 [ 0.69, 1.13 ]
Subtotal (95% CI) 1678 1680 55.7 % 0.88 [ 0.69, 1.13 ]
Total events: 129 (LABA/LAMA), 145 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
2 Low-risk
Donohue 2015a 7/353 10/353 3.6 % 0.69 [ 0.26, 1.84 ]
Donohue 2015b 9/349 14/348 4.7 % 0.63 [ 0.27, 1.48 ]
Hoshino 2015 0/22 0/21 Not estimable
Singh 2015c 24/358 18/358 8.6 % 1.36 [ 0.72, 2.55 ]
Vogelmeier 2013a 22/258 27/264 9.8 % 0.82 [ 0.45, 1.48 ]
Vogelmeier 2016 22/467 23/466 9.5 % 0.95 [ 0.52, 1.73 ]
Vogelmeier 2017 18/811 3/269 2.3 % 2.01 [ 0.59, 6.89 ]
Zhong 2015 11/372 18/369 5.8 % 0.59 [ 0.28, 1.28 ]
Subtotal (95% CI) 2990 2448 44.3 % 0.90 [ 0.68, 1.19 ]
Total events: 113 (LABA/LAMA), 113 (LABA/ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.49, df = 6 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 4668 4128 100.0 % 0.89 [ 0.74, 1.07 ]
Total events: 242 (LABA/LAMA), 258 (LABA/ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.50, df = 7 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 1.19. Comparison 1 LABA/LAMA vs LABA/ICS, Outcome 19 Pneumonia.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 1 LABA/LAMA vs LABA/ICS
Outcome: 19 Pneumonia
Study or subgroup LABA/LAMA LABA/ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2016 34/1678 54/1680 77.4 % 0.62 [ 0.40, 0.96 ]
Subtotal (95% CI) 1678 1680 77.4 % 0.62 [ 0.40, 0.96 ]
Total events: 34 (LABA/LAMA), 54 (LABA/ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.033)
2 Low-risk
Donohue 2015a 1/353 4/353 3.0 % 0.25 [ 0.03, 2.23 ]
Donohue 2015b 2/349 4/348 5.0 % 0.50 [ 0.09, 2.72 ]
Singh 2015c 0/358 1/358 1.4 % 0.33 [ 0.01, 8.19 ]
Vogelmeier 2013a 0/258 2/264 1.6 % 0.20 [ 0.01, 4.25 ]
Vogelmeier 2016 2/467 4/466 5.0 % 0.50 [ 0.09, 2.73 ]
Vogelmeier 2017 1/811 0/269 1.4 % 1.00 [ 0.04, 24.56 ]
Zhong 2015 2/372 4/369 5.0 % 0.49 [ 0.09, 2.71 ]
Subtotal (95% CI) 2968 2427 22.6 % 0.43 [ 0.19, 0.97 ]
Total events: 8 (LABA/LAMA), 19 (LABA/ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 6 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.041)
Total (95% CI) 4646 4107 100.0 % 0.57 [ 0.39, 0.84 ]
Total events: 42 (LABA/LAMA), 73 (LABA/ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.46, df = 7 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.85 (P = 0.0044)
Test for subgroup differences: Chi2 = 0.61, df = 1 (P = 0.43), I2 =0.0%
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Analysis 2.1. Comparison 2 LABA/LAMA vs LAMA, Outcome 1 Moderate to severe exacerbations.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 1 Moderate to severe exacerbations
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2013 419/729 828/1477 23.6 % 1.06 [ 0.89, 1.27 ]
Subtotal (95% CI) 729 1477 23.6 % 1.06 [ 0.89, 1.27 ]
Total events: 419 (LABA/LAMA), 828 (LAMA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 Low-risk
Bateman 2013 85/474 174/953 19.8 % 0.98 [ 0.73, 1.30 ]
Decramer 2014a 14/212 11/208 6.9 % 1.27 [ 0.56, 2.86 ]
Decramer 2014b 26/217 14/215 8.9 % 1.95 [ 0.99, 3.85 ]
Donohue 2013 27/413 33/418 12.1 % 0.82 [ 0.48, 1.38 ]
Kerwin 2017 2/247 8/247 2.3 % 0.24 [ 0.05, 1.16 ]
Maleki-Yazdi 2014 16/454 29/451 9.9 % 0.53 [ 0.28, 0.99 ]
Tashkin 2009 21/124 14/131 8.1 % 1.70 [ 0.82, 3.52 ]
Vogelmeier 2008 13/207 23/221 8.4 % 0.58 [ 0.28, 1.17 ]
Subtotal (95% CI) 2348 2844 76.4 % 0.93 [ 0.66, 1.30 ]
Total events: 204 (LABA/LAMA), 306 (LAMA)
Heterogeneity: Tau2 = 0.12; Chi2 = 15.80, df = 7 (P = 0.03); I2 =56%
Test for overall effect: Z = 0.43 (P = 0.67)
Total (95% CI) 3077 4321 100.0 % 0.96 [ 0.75, 1.23 ]
Total events: 623 (LABA/LAMA), 1134 (LAMA)
Heterogeneity: Tau2 = 0.06; Chi2 = 16.51, df = 8 (P = 0.04); I2 =52%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Chi2 = 0.45, df = 1 (P = 0.50), I2 =0.0%
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Analysis 2.2. Comparison 2 LABA/LAMA vs LAMA, Outcome 2 Severe exacerbations.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 2 Severe exacerbations
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Aaron 2007 48/148 62/156 34.0 % 0.73 [ 0.45, 1.16 ]
Subtotal (95% CI) 148 156 34.0 % 0.73 [ 0.45, 1.16 ]
Total events: 48 (LABA/LAMA), 62 (LAMA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 Low-risk
Bateman 2013 10/474 14/953 18.0 % 1.45 [ 0.64, 3.28 ]
Decramer 2014a 5/212 4/208 8.4 % 1.23 [ 0.33, 4.65 ]
Decramer 2014b 10/217 3/215 8.7 % 3.41 [ 0.93, 12.58 ]
Donohue 2013 8/413 14/418 16.3 % 0.57 [ 0.24, 1.37 ]
Kerwin 2017 0/247 2/247 1.8 % 0.20 [ 0.01, 4.15 ]
Maleki-Yazdi 2014 2/454 4/451 5.4 % 0.49 [ 0.09, 2.71 ]
Vogelmeier 2008 3/207 5/221 7.3 % 0.64 [ 0.15, 2.69 ]
Subtotal (95% CI) 2224 2713 66.0 % 0.99 [ 0.57, 1.72 ]
Total events: 38 (LABA/LAMA), 46 (LAMA)
Heterogeneity: Tau2 = 0.13; Chi2 = 7.97, df = 6 (P = 0.24); I2 =25%
Test for overall effect: Z = 0.03 (P = 0.98)
Total (95% CI) 2372 2869 100.0 % 0.90 [ 0.59, 1.36 ]
Total events: 86 (LABA/LAMA), 108 (LAMA)
Heterogeneity: Tau2 = 0.07; Chi2 = 8.91, df = 7 (P = 0.26); I2 =21%
Test for overall effect: Z = 0.52 (P = 0.61)
Test for subgroup differences: Chi2 = 0.70, df = 1 (P = 0.40), I2 =0.0%
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Analysis 2.3. Comparison 2 LABA/LAMA vs LAMA, Outcome 3 SGRQ responders at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 3 SGRQ responders at 3 months
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LAMA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Decramer 2014a 106/178 95/169 8.2 % 1.15 [ 0.75, 1.76 ]
Decramer 2014b 111/174 99/179 8.2 % 1.42 [ 0.93, 2.18 ]
Donohue 2013 216/359 188/347 14.8 % 1.28 [ 0.95, 1.72 ]
Kerwin 2017 104/242 117/245 11.1 % 0.82 [ 0.58, 1.18 ]
Mahler 2015a 141/246 112/243 11.1 % 1.57 [ 1.10, 2.24 ]
Mahler 2015b 141/238 122/237 10.8 % 1.37 [ 0.95, 1.97 ]
Maleki-Yazdi 2014 244/437 199/419 17.3 % 1.40 [ 1.07, 1.83 ]
Singh 2015a 104/196 80/192 9.2 % 1.58 [ 1.06, 2.36 ]
Singh 2015b 102/197 79/192 9.2 % 1.54 [ 1.03, 2.29 ]
Subtotal (95% CI) 2267 2223 100.0 % 1.32 [ 1.16, 1.51 ]
Total events: 1269 (LABA/LAMA), 1091 (LAMA)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.71, df = 8 (P = 0.29); I2 =18%
Test for overall effect: Z = 4.16 (P = 0.000031)
Total (95% CI) 2267 2223 100.0 % 1.32 [ 1.16, 1.51 ]
Total events: 1269 (LABA/LAMA), 1091 (LAMA)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.71, df = 8 (P = 0.29); I2 =18%
Test for overall effect: Z = 4.16 (P = 0.000031)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 LABA/LAMA vs LAMA, Outcome 4 SGRQ responders at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 4 SGRQ responders at 6 months
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2013 408/684 711/1335 18.7 % 1.30 [ 1.08, 1.56 ]
Subtotal (95% CI) 684 1335 18.7 % 1.30 [ 1.08, 1.56 ]
Total events: 408 (LABA/LAMA), 711 (LAMA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0063)
2 Low-risk
Bateman 2013 281/441 514/880 11.7 % 1.25 [ 0.99, 1.58 ]
Buhl 2015a%b 563/979 465/955 20.3 % 1.43 [ 1.19, 1.71 ]
D’Urzo 2017 194/335 180/337 7.0 % 1.20 [ 0.88, 1.63 ]
Decramer 2014a 94/168 92/158 3.4 % 0.91 [ 0.59, 1.41 ]
Decramer 2014b 103/155 104/169 3.1 % 1.24 [ 0.79, 1.95 ]
Donohue 2013 188/317 172/312 6.5 % 1.19 [ 0.86, 1.63 ]
Maleki-Yazdi 2014 237/445 196/430 9.2 % 1.36 [ 1.04, 1.77 ]
Martinez 2017a 187/503 294/860 12.4 % 1.14 [ 0.91, 1.43 ]
Martinez 2017b 169/430 126/362 7.7 % 1.21 [ 0.91, 1.62 ]
Subtotal (95% CI) 3773 4463 81.3 % 1.26 [ 1.15, 1.37 ]
Total events: 2016 (LABA/LAMA), 2143 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.29, df = 8 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 4.98 (P < 0.00001)
Total (95% CI) 4457 5798 100.0 % 1.26 [ 1.17, 1.37 ]
Total events: 2424 (LABA/LAMA), 2854 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.39, df = 9 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 5.67 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.76), I2 =0.0%
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Analysis 2.5. Comparison 2 LABA/LAMA vs LAMA, Outcome 5 SGRQ responders at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 5 SGRQ responders at 12 months
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2013 341/600 582/1143 42.0 % 1.27 [ 1.04, 1.55 ]
Subtotal (95% CI) 600 1143 42.0 % 1.27 [ 1.04, 1.55 ]
Total events: 341 (LABA/LAMA), 582 (LAMA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
2 Low-risk
Hanania 2003 411/995 490/1277 58.0 % 1.13 [ 0.95, 1.34 ]
Subtotal (95% CI) 995 1277 58.0 % 1.13 [ 0.95, 1.34 ]
Total events: 411 (LABA/LAMA), 490 (LAMA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Total (95% CI) 1595 2420 100.0 % 1.19 [ 1.04, 1.35 ]
Total events: 752 (LABA/LAMA), 1072 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0092)
Test for subgroup differences: Chi2 = 0.76, df = 1 (P = 0.38), I2 =0.0%
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Analysis 2.6. Comparison 2 LABA/LAMA vs LAMA, Outcome 6 Change from baseline in SGRQ at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 6 Change from baseline in SGRQ at 3 months
Study or subgroup LABA/LAMA LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2013 694 -8.31 (23.84) 1370 -4.63 (23.18) 6.9 % -3.68 [ -5.84, -1.52 ]
Subtotal (95% CI) 694 1370 6.9 % -3.68 [ -5.84, -1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.34 (P = 0.00083)
2 Low-risk
Asai 2013 119 -4.5 (10.91) 39 -2.7 (7.84) 3.3 % -1.80 [ -4.95, 1.35 ]
Bateman 2013 474 -9.4 (24.1) 953 -7.56 (23.74) 4.6 % -1.84 [ -4.48, 0.80 ]
Decramer 2014a 178 -7.48 (13.29) 169 -6.84 (13.241) 4.1 % -0.64 [ -3.43, 2.15 ]
Decramer 2014b 174 -9.79 (14.274) 179 -7.53 (12.609) 4.1 % -2.26 [ -5.07, 0.55 ]
Donohue 2013 359 -8.17 (13.04) 347 -6.95 (13.62) 8.3 % -1.22 [ -3.19, 0.75 ]
Kerwin 2017 247 -4.07 (10.62) 247 -4.12 (10.88) 9.0 % 0.05 [ -1.85, 1.95 ]
Mahler 2015a 246 -6.4 (11.8) 243 -4.8 (11.7) 7.4 % -1.60 [ -3.68, 0.48 ]
Mahler 2015b 238 -7.5 (13.1) 237 -6 (13.2) 5.8 % -1.50 [ -3.87, 0.87 ]
Maleki-Yazdi 2014 445 -7.02 (10.27) 430 -4.93 (10.31) 17.4 % -2.09 [ -3.45, -0.73 ]
Singh 2015a%b 393 -4.97 (13) 384 -2.88 (13.1) 9.6 % -2.09 [ -3.93, -0.25 ]
ZuWallack 2014a%b 1039 -5.982 (14.99) 1055 -4.13 (15.14) 19.4 % -1.85 [ -3.14, -0.56 ]
Subtotal (95% CI) 3912 4283 93.1 % -1.60 [ -2.19, -1.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.69, df = 10 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 5.32 (P < 0.00001)
Total (95% CI) 4606 5653 100.0 % -1.74 [ -2.31, -1.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 8.01, df = 11 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 6.02 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.32, df = 1 (P = 0.07), I2 =70%
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Analysis 2.7. Comparison 2 LABA/LAMA vs LAMA, Outcome 7 Change from baseline in SGRQ at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 7 Change from baseline in SGRQ at 6 months
Study or subgroup LABA/LAMA LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2013 684 -8.94 (24.45) 1335 -6.15 (23.64) 7.5 % -2.79 [ -5.02, -0.56 ]
Subtotal (95% CI) 684 1335 7.5 % -2.79 [ -5.02, -0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
2 Low-risk
Asai 2013 119 -4.5 (11.7) 39 -0.3 (8.16) 3.4 % -4.20 [ -7.51, -0.89 ]
Bateman 2013 441 -9.82 (23.7) 880 -8.45 (23.36) 5.1 % -1.37 [ -4.07, 1.33 ]
D’Urzo 2014 256 -6.57 (11.84) 257 -6.44 (11.86) 8.8 % -0.13 [ -2.18, 1.92 ]
Decramer 2014a 207 -6.87 (14.68) 203 -7.62 (14.96) 4.5 % 0.75 [ -2.12, 3.62 ]
Decramer 2014b 217 -9.95 (14.4363) 215 -9.78 (13.92973) 5.2 % -0.17 [ -2.85, 2.51 ]
Donohue 2013 413 -8.07 (15.22) 418 -7.25 (15.4) 8.5 % -0.82 [ -2.90, 1.26 ]
Maleki-Yazdi 2014 454 -7.27 (11.46) 451 -5.17 (11.64) 16.0 % -2.10 [ -3.61, -0.59 ]
Martinez 2017a 432 -3.3 (12.06) 739 -1.84 (11.94) 17.7 % -1.46 [ -2.89, -0.03 ]
Martinez 2017b 430 -3 (11.82) 362 -2.2 (11.8) 13.4 % -0.80 [ -2.45, 0.85 ]
Singh 2014 338 -7.16 (12.8693) 327 -5.8 (12.84) 9.7 % -1.36 [ -3.31, 0.59 ]
Subtotal (95% CI) 3307 3891 92.5 % -1.20 [ -1.83, -0.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 8.43, df = 9 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.73 (P = 0.00019)
Total (95% CI) 3991 5226 100.0 % -1.31 [ -1.93, -0.70 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 10.25, df = 10 (P = 0.42); I2 =2%
Test for overall effect: Z = 4.18 (P = 0.000029)
Test for subgroup differences: Chi2 = 1.82, df = 1 (P = 0.18), I2 =45%
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Analysis 2.8. Comparison 2 LABA/LAMA vs LAMA, Outcome 8 Change from baseline in SGRQ at 12
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 8 Change from baseline in SGRQ at 12 months
Study or subgroup LABA/LAMA LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2013 729 -9.61 (27.68) 1477 -6.23 (27.48) 14.8 % -3.38 [ -5.83, -0.93 ]
Subtotal (95% CI) 729 1477 14.8 % -3.38 [ -5.83, -0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.70 (P = 0.0068)
2 Low-risk
Asai 2013 119 -2.9 (10.99) 39 -0.6 (9.92) 7.6 % -2.30 [ -5.99, 1.39 ]
D’Urzo 2017 335 -3.646 (15.76) 337 -4.31 (15.55) 15.6 % 0.66 [ -1.71, 3.03 ]
Hanania 2017 995 -3.3 (11.27) 1277 -2.24 (11.051) 41.7 % -1.06 [ -1.99, -0.13 ]
RADIATE 2016 343 -6.79 (12.611) 349 -6.12 (13.695) 20.3 % -0.67 [ -2.63, 1.29 ]
Subtotal (95% CI) 1792 2002 85.2 % -0.87 [ -1.64, -0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.38, df = 3 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
Total (95% CI) 2521 3479 100.0 % -1.15 [ -2.24, -0.06 ]
Heterogeneity: Tau2 = 0.52; Chi2 = 6.05, df = 4 (P = 0.20); I2 =34%
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Chi2 = 3.67, df = 1 (P = 0.06), I2 =73%
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Analysis 2.9. Comparison 2 LABA/LAMA vs LAMA, Outcome 9 TDI at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 9 TDI at 3 months
Study or subgroup LABA/LAMA LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 474 2.44 (3.44) 953 1.92 (3.45) 14.2 % 0.52 [ 0.14, 0.90 ]
Buhl 2015a%b 992 2.136 (3.024) 978 1.7 (3.033) 28.5 % 0.43 [ 0.17, 0.70 ]
Decramer 2014a 179 2.2 (2.68) 184 2 (2.85) 6.3 % 0.20 [ -0.37, 0.77 ]
Decramer 2014b 161 2.6 (2.9) 172 1.8 (3) 5.1 % 0.80 [ 0.17, 1.43 ]
Donohue 2013 372 2.3 (2.85) 359 2 (2.85) 12.0 % 0.30 [ -0.11, 0.71 ]
Kerwin 2017 233 2.3 (2.58) 235 1.9 (2.64) 9.1 % 0.40 [ -0.07, 0.87 ]
Mahler 2015a 246 1.94 (3.3) 246 1.48 (3.3) 6.0 % 0.46 [ -0.12, 1.04 ]
Mahler 2015b 233 2.88 (3.8) 232 1.88 (3.8) 4.3 % 1.00 [ 0.31, 1.69 ]
Singh 2015a 196 1.939 (2.7) 193 1.33 (2.7) 7.1 % 0.61 [ 0.07, 1.15 ]
Singh 2015b 197 1.531 (2.625) 192 0.95 (2.65) 7.4 % 0.58 [ 0.06, 1.11 ]
Subtotal (95% CI) 3283 3744 100.0 % 0.48 [ 0.34, 0.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.45, df = 9 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 6.58 (P < 0.00001)
Total (95% CI) 3283 3744 100.0 % 0.48 [ 0.34, 0.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.45, df = 9 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 6.58 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 LABA/LAMA vs LAMA, Outcome 10 TDI at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 10 TDI at 6 months
Study or subgroup LABA/LAMA LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 474 2.72 (2.83) 953 2.36 (2.79) 22.4 % 0.36 [ 0.05, 0.67 ]
Buhl 2015a%b 992 1.98 (2.99) 978 1.63 (3.002) 30.9 % 0.35 [ 0.09, 0.62 ]
D’Urzo 2014 260 2.02 (3.2249) 263 1.56 (3.24) 7.0 % 0.46 [ -0.09, 1.01 ]
Decramer 2014a 207 2.3 (2.88) 203 2.4 (2.85) 7.0 % -0.10 [ -0.65, 0.45 ]
Decramer 2014b 217 2.3 (4.419276) 215 2.1 (2.932576) 4.3 % 0.20 [ -0.51, 0.91 ]
Donohue 2013 336 2.4 (2.93) 326 2.2 (2.89) 11.0 % 0.20 [ -0.24, 0.64 ]
Singh 2014 344 2.51 (1.11283) 331 2.11 (3.09) 17.3 % 0.40 [ 0.05, 0.75 ]
Subtotal (95% CI) 2830 3269 100.0 % 0.32 [ 0.17, 0.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.16, df = 6 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 4.20 (P = 0.000027)
Total (95% CI) 2830 3269 100.0 % 0.32 [ 0.17, 0.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.16, df = 6 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 4.20 (P = 0.000027)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 LABA/LAMA vs LAMA, Outcome 11 TDI at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 11 TDI at 12 months
Study or subgroup LABA/LAMA LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Aaron 2007 148 1.4 (3.96) 156 1.78 (4.08) 1.6 % -0.38 [ -1.28, 0.52 ]
Subtotal (95% CI) 148 156 1.6 % -0.38 [ -1.28, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
2 Low-risk
Buhl 2015a%b 992 2.058 (3.118) 978 1.74 (3.159) 17.3 % 0.32 [ 0.04, 0.60 ]
D’Urzo 2017 335 1.812 (4.59) 337 1.6 (4.42) 2.9 % 0.22 [ -0.47, 0.90 ]
Hanania 2017 1002 0.5 (1.62) 1309 0.3 (1.54) 78.2 % 0.20 [ 0.07, 0.33 ]
Subtotal (95% CI) 2329 2624 98.4 % 0.22 [ 0.11, 0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.74 (P = 0.00018)
Total (95% CI) 2477 2780 100.0 % 0.21 [ 0.10, 0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.29, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.60 (P = 0.00031)
Test for subgroup differences: Chi2 = 1.68, df = 1 (P = 0.20), I2 =40%
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Analysis 2.12. Comparison 2 LABA/LAMA vs LAMA, Outcome 12 Change from baseline in FEV1 at 3
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 12 Change from baseline in FEV1 at 3 months
Study or subgroup LABA/LAMA LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2013 666 0.17 (0.387) 1316 0.12 (0.328) 6.2 % 0.06 [ 0.02, 0.09 ]
Subtotal (95% CI) 666 1316 6.2 % 0.06 [ 0.02, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.14 (P = 0.0017)
2 Low-risk
Asai 2013 113 0.209 (0.173) 38 0.14 (0.156) 2.8 % 0.07 [ 0.01, 0.13 ]
Buhl 2015a 521 0.146 (0.205) 520 0.07 (0.205) 8.8 % 0.08 [ 0.05, 0.10 ]
Buhl 2015b 497 0.147 (0.201) 498 0.09 (0.201) 8.7 % 0.06 [ 0.03, 0.08 ]
Decramer 2014a 193 0.18 (0.248) 181 0.11 (0.255) 3.6 % 0.07 [ 0.02, 0.12 ]
Decramer 2014b 181 0.203 (0.2064) 188 0.11 (0.2347) 4.3 % 0.09 [ 0.05, 0.14 ]
Donohue 2013 371 0.182 (0.218) 358 0.13 (0.244) 6.4 % 0.05 [ 0.02, 0.08 ]
Hoshino 2014 18 0.165 (0.013) 16 0.06 (0.119) 2.9 % 0.11 [ 0.05, 0.17 ]
Kerwin 2017 247 0.064 (0.242) 247 -0.02 (0.2389) 4.7 % 0.09 [ 0.04, 0.13 ]
Mahler 2012a 561 0.23 (0.497) 549 0.15 (0.492) 2.9 % 0.08 [ 0.02, 0.14 ]
Mahler 2012b 565 0.2 (0.428) 564 0.12 (0.427) 3.7 % 0.08 [ 0.03, 0.13 ]
Mahler 2015a 256 0.201 (0.23) 260 0.09 (0.229) 5.2 % 0.11 [ 0.07, 0.15 ]
Mahler 2015b 246 0.208 (0.223) 249 0.13 (0.224) 5.2 % 0.08 [ 0.04, 0.12 ]
Maleki-Yazdi 2014 423 0.19 (0.2417) 408 0.08 (0.2253) 6.8 % 0.11 [ 0.08, 0.14 ]
RADIATE 2016 373 0.1752 (0.20198) 373 0.08 (0.19606) 7.7 % 0.10 [ 0.07, 0.13 ]
Singh 2015a 200 0.163 (0.184) 200 0.14 (0.198) 5.6 % 0.03 [ -0.01, 0.07 ]
Singh 2015b 199 0.163 (0.183) 197 0.12 (0.182) 5.9 % 0.04 [ 0.00, 0.07 ]
ZuWallack 2014a 548 0.195 (0.211) 551 0.13 (0.211) 8.7 % 0.06 [ 0.04, 0.09 ]
Subtotal (95% CI) 5512 5397 93.8 % 0.07 [ 0.06, 0.09 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 25.85, df = 16 (P = 0.06); I2 =38%
Test for overall effect: Z = 12.75 (P < 0.00001)
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Study or subgroup LABA/LAMA LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 6178 6713 100.0 % 0.07 [ 0.06, 0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 26.90, df = 17 (P = 0.06); I2 =37%
Test for overall effect: Z = 13.10 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.11, df = 1 (P = 0.29), I2 =10%
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Analysis 2.13. Comparison 2 LABA/LAMA vs LAMA, Outcome 13 Change from baseline in FEV1 at 6
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 13 Change from baseline in FEV1 at 6 months
Study or subgroup LABA/LAMA LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2013 604 0.16 (0.371) 1176 0.1 (0.36) 7.0 % 0.06 [ 0.02, 0.10 ]
Subtotal (95% CI) 604 1176 7.0 % 0.06 [ 0.02, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.26 (P = 0.0011)
2 Low-risk
Asai 2013 113 0.198 (0.174) 37 0.12 (0.14) 4.1 % 0.08 [ 0.03, 0.14 ]
Bateman 2013 474 0.17 (0.544) 424 0.08 (0.494) 3.0 % 0.09 [ 0.02, 0.16 ]
Buhl 2015a 521 0.112 (0.205) 520 0.05 (0.205) 9.7 % 0.06 [ 0.04, 0.09 ]
Buhl 2015b 497 0.119 (0.201) 498 0.07 (0.201) 9.6 % 0.05 [ 0.03, 0.08 ]
D’Urzo 2014 271 0.095 (0.19754) 266 0.07 (0.196) 7.6 % 0.03 [ 0.00, 0.06 ]
Decramer 2014a 177 0.211 (0.243) 173 0.12 (0.245) 4.6 % 0.09 [ 0.04, 0.14 ]
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Study or subgroup LABA/LAMA LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Decramer 2014b 161 0.208 (0.228394) 175 0.15 (0.238118) 4.8 % 0.06 [ 0.01, 0.11 ]
Donohue 2013 330 0.171 (0.229) 322 0.12 (0.226) 7.3 % 0.05 [ 0.02, 0.09 ]
Maleki-Yazdi 2014 454 0.205 (0.243) 451 0.09 (0.244) 8.0 % 0.11 [ 0.08, 0.14 ]
Martinez 2017a 429 0.126 (0.201) 734 0.09 (0.2) 9.9 % 0.04 [ 0.01, 0.06 ]
Martinez 2017b 433 0.116 (0.21) 367 0.06 (0.209) 8.6 % 0.05 [ 0.02, 0.08 ]
RADIATE 2016 356 0.1557 (0.21754) 358 0.07 (0.20358) 8.2 % 0.08 [ 0.05, 0.12 ]
Singh 2014 349 0.083 (0.22418) 332 0.06 (0.219) 7.6 % 0.03 [ -0.01, 0.06 ]
Subtotal (95% CI) 4565 4657 93.0 % 0.06 [ 0.05, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 27.18, df = 12 (P = 0.01); I2 =56%
Test for overall effect: Z = 8.27 (P < 0.00001)
Total (95% CI) 5169 5833 100.0 % 0.06 [ 0.05, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 27.19, df = 13 (P = 0.01); I2 =52%
Test for overall effect: Z = 8.88 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
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Analysis 2.14. Comparison 2 LABA/LAMA vs LAMA, Outcome 14 Change from baseline in FEV1 at 12
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 14 Change from baseline in FEV1 at 12 months
Study or subgroup LABA/LAMA LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2013 729 0.14 (0.421) 1477 0.09 (0.427) 12.6 % 0.05 [ 0.01, 0.09 ]
Subtotal (95% CI) 729 1477 12.6 % 0.05 [ 0.01, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.0090)
2 Low-risk
Asai 2013 104 0.189 (0.173) 37 0.05 (0.17) 6.5 % 0.14 [ 0.07, 0.20 ]
Buhl 2015a 521 0.099 (0.205) 520 0.04 (0.205) 17.3 % 0.06 [ 0.04, 0.09 ]
Buhl 2015b 497 0.093 (0.201) 498 0.04 (0.201) 17.2 % 0.05 [ 0.03, 0.08 ]
D’Urzo 2017 335 0.038 (0.275) 337 0.03 (0.275) 11.3 % 0.01 [ -0.03, 0.05 ]
Hanania 2017 1021 0.133 (0.179) 1317 0.09 (0.181) 21.4 % 0.05 [ 0.03, 0.06 ]
RADIATE 2016 333 0.1468 (0.22933) 346 0.06 (0.22433) 13.7 % 0.09 [ 0.06, 0.13 ]
Subtotal (95% CI) 2811 3055 87.4 % 0.06 [ 0.04, 0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 17.00, df = 5 (P = 0.005); I2 =71%
Test for overall effect: Z = 5.42 (P < 0.00001)
Total (95% CI) 3540 4532 100.0 % 0.06 [ 0.04, 0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 17.05, df = 6 (P = 0.01); I2 =65%
Test for overall effect: Z = 6.03 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
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Analysis 2.15. Comparison 2 LABA/LAMA vs LAMA, Outcome 15 Mortality.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 15 Mortality
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Aaron 2007 6/148 4/156 5.4 % 1.61 [ 0.44, 5.81 ]
Wedzicha 2013 23/729 47/1477 34.7 % 0.99 [ 0.60, 1.65 ]
Subtotal (95% CI) 877 1633 40.1 % 1.06 [ 0.66, 1.69 ]
Total events: 29 (LABA/LAMA), 51 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Low-risk
Asai 2013 1/119 0/39 0.9 % 1.00 [ 0.04, 25.05 ]
Bateman 2013 1/474 4/953 1.9 % 0.50 [ 0.06, 4.50 ]
Buhl 2015a%b 18/1029 17/1033 20.0 % 1.06 [ 0.55, 2.08 ]
D’Urzo 2014 1/335 3/337 1.7 % 0.33 [ 0.03, 3.22 ]
D’Urzo 2017 1/182 0/194 0.9 % 3.21 [ 0.13, 79.42 ]
Decramer 2014a 1/212 0/208 0.9 % 2.96 [ 0.12, 73.01 ]
Decramer 2014b 1/217 2/215 1.5 % 0.49 [ 0.04, 5.48 ]
Donohue 2013 3/413 3/418 3.5 % 1.01 [ 0.20, 5.04 ]
Hanania 2017 4/1036 5/1341 5.1 % 1.04 [ 0.28, 3.87 ]
Kerwin 2017 1/247 0/247 0.9 % 3.01 [ 0.12, 74.30 ]
Mahler 2012a 2/570 0/561 1.0 % 4.94 [ 0.24, 103.09 ]
Mahler 2012b 1/572 2/570 1.5 % 0.50 [ 0.04, 5.50 ]
Mahler 2015a 0/258 1/262 0.9 % 0.34 [ 0.01, 8.32 ]
Mahler 2015b 0/250 0/251 Not estimable
Maleki-Yazdi 2014 2/454 2/451 2.3 % 0.99 [ 0.14, 7.08 ]
RADIATE 2016 10/407 5/405 7.6 % 2.02 [ 0.68, 5.95 ]
Singh 2015a 2/203 2/203 2.3 % 1.00 [ 0.14, 7.17 ]
Singh 2015b 1/202 0/203 0.9 % 3.03 [ 0.12, 74.82 ]
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Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Tashkin 2009 0/124 0/131 Not estimable
Troosters 2016 0/76 1/76 0.9 % 0.33 [ 0.01, 8.20 ]
Vogelmeier 2008 0/207 0/221 Not estimable
ZuWallack 2014a%b 3/1133 10/1134 5.3 % 0.30 [ 0.08, 1.09 ]
Subtotal (95% CI) 8720 9453 59.9 % 0.98 [ 0.66, 1.43 ]
Total events: 53 (LABA/LAMA), 57 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 10.75, df = 18 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
Total (95% CI) 9597 11086 100.0 % 1.01 [ 0.75, 1.36 ]
Total events: 82 (LABA/LAMA), 108 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.29, df = 20 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Analysis 2.16. Comparison 2 LABA/LAMA vs LAMA, Outcome 16 Total SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 16 Total SAE
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Aaron 2007 9/148 10/156 1.2 % 0.95 [ 0.37, 2.40 ]
Wedzicha 2013 167/729 344/1477 22.5 % 0.98 [ 0.79, 1.21 ]
Subtotal (95% CI) 877 1633 23.6 % 0.98 [ 0.80, 1.20 ]
Total events: 176 (LABA/LAMA), 354 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
2 Low-risk
Asai 2013 19/119 2/39 0.4 % 3.52 [ 0.78, 15.83 ]
Bateman 2013 22/474 48/953 3.7 % 0.92 [ 0.55, 1.54 ]
Buhl 2015a%b 169/1029 172/1033 18.5 % 0.98 [ 0.78, 1.24 ]
D’Urzo 2014 19/335 17/337 2.2 % 1.13 [ 0.58, 2.22 ]
D’Urzo 2017 14/182 15/194 1.7 % 0.99 [ 0.47, 2.12 ]
Decramer 2014a 7/212 13/208 1.1 % 0.51 [ 0.20, 1.31 ]
Decramer 2014b 22/217 9/215 1.6 % 2.58 [ 1.16, 5.75 ]
Donohue 2013 21/413 27/418 2.9 % 0.78 [ 0.43, 1.40 ]
Hanania 2017 114/1036 139/1341 14.5 % 1.07 [ 0.82, 1.39 ]
Kerwin 2017 7/247 6/247 0.8 % 1.17 [ 0.39, 3.54 ]
Mahler 2012a 21/570 17/561 2.4 % 1.22 [ 0.64, 2.35 ]
Mahler 2012b 19/572 18/570 2.3 % 1.05 [ 0.55, 2.03 ]
Mahler 2015a 10/258 8/262 1.1 % 1.28 [ 0.50, 3.30 ]
Mahler 2015b 6/250 12/251 1.0 % 0.49 [ 0.18, 1.33 ]
Maleki-Yazdi 2014 16/454 17/451 2.1 % 0.93 [ 0.47, 1.87 ]
RADIATE 2016 55/407 55/405 6.2 % 0.99 [ 0.67, 1.49 ]
Singh 2014 23/385 16/385 2.3 % 1.47 [ 0.76, 2.82 ]
Singh 2015a 4/203 6/203 0.6 % 0.66 [ 0.18, 2.37 ]
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Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Singh 2015b 6/202 12/203 1.0 % 0.49 [ 0.18, 1.32 ]
Tashkin 2009 7/124 7/131 0.9 % 1.06 [ 0.36, 3.11 ]
Troosters 2016 3/76 11/76 0.6 % 0.24 [ 0.06, 0.91 ]
Vogelmeier 2008 10/207 10/221 1.2 % 1.07 [ 0.44, 2.63 ]
ZuWallack 2014a%b 64/1133 53/1134 7.1 % 1.22 [ 0.84, 1.77 ]
Subtotal (95% CI) 9105 9838 76.4 % 1.03 [ 0.91, 1.16 ]
Total events: 658 (LABA/LAMA), 690 (LAMA)
Heterogeneity: Tau2 = 0.00; Chi2 = 23.07, df = 22 (P = 0.40); I2 =5%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 9982 11471 100.0 % 1.01 [ 0.92, 1.12 ]
Total events: 834 (LABA/LAMA), 1044 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 23.24, df = 24 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 2.17. Comparison 2 LABA/LAMA vs LAMA, Outcome 17 COPD SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 17 COPD SAE
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2013 107/729 203/1477 37.9 % 1.08 [ 0.84, 1.39 ]
Subtotal (95% CI) 729 1477 37.9 % 1.08 [ 0.84, 1.39 ]
Total events: 107 (LABA/LAMA), 203 (LAMA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
2 Low-risk
Asai 2013 4/119 0/39 0.3 % 3.08 [ 0.16, 58.45 ]
Bateman 2013 10/474 16/953 3.8 % 1.26 [ 0.57, 2.80 ]
Buhl 2015a%b 71/1029 65/1033 20.0 % 1.10 [ 0.78, 1.56 ]
Decramer 2014a 5/212 3/208 1.2 % 1.65 [ 0.39, 7.00 ]
Decramer 2014b 7/217 1/215 0.5 % 7.13 [ 0.87, 58.48 ]
Donohue 2013 7/413 12/418 2.7 % 0.58 [ 0.23, 1.50 ]
Hanania 2017 32/1036 45/1341 11.4 % 0.92 [ 0.58, 1.46 ]
Kerwin 2017 0/247 2/247 0.3 % 0.20 [ 0.01, 4.15 ]
Mahler 2012a 6/570 11/561 2.4 % 0.53 [ 0.20, 1.45 ]
Mahler 2012b 9/572 9/570 2.8 % 1.00 [ 0.39, 2.53 ]
Mahler 2015a 2/258 4/262 0.8 % 0.50 [ 0.09, 2.78 ]
Mahler 2015b 1/250 5/251 0.5 % 0.20 [ 0.02, 1.70 ]
Maleki-Yazdi 2014 2/454 2/451 0.6 % 0.99 [ 0.14, 7.08 ]
RADIATE 2016 20/407 18/405 5.7 % 1.11 [ 0.58, 2.13 ]
Singh 2014 4/385 7/385 1.6 % 0.57 [ 0.16, 1.95 ]
Singh 2015a 1/203 1/203 0.3 % 1.00 [ 0.06, 16.10 ]
Singh 2015b 1/202 1/203 0.3 % 1.00 [ 0.06, 16.18 ]
Tashkin 2009 0/124 1/131 0.2 % 0.35 [ 0.01, 8.66 ]
Troosters 2016 1/76 2/76 0.4 % 0.49 [ 0.04, 5.56 ]
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(. . . Continued)
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Vogelmeier 2008 1/207 1/221 0.3 % 1.07 [ 0.07, 17.19 ]
ZuWallack 2014a%b 18/1133 20/1134 5.9 % 0.90 [ 0.47, 1.71 ]
Subtotal (95% CI) 8588 9307 62.1 % 0.96 [ 0.79, 1.17 ]
Total events: 202 (LABA/LAMA), 226 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 13.41, df = 20 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 9317 10784 100.0 % 1.00 [ 0.86, 1.17 ]
Total events: 309 (LABA/LAMA), 429 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 13.91, df = 21 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 0.50, df = 1 (P = 0.48), I2 =0.0%
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Analysis 2.18. Comparison 2 LABA/LAMA vs LAMA, Outcome 18 Cardiac SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 18 Cardiac SAE
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2013 33/729 83/1477 32.7 % 0.80 [ 0.53, 1.20 ]
Subtotal (95% CI) 729 1477 32.7 % 0.80 [ 0.53, 1.20 ]
Total events: 33 (LABA/LAMA), 83 (LAMA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Low-risk
Bateman 2013 1/474 11/953 1.3 % 0.18 [ 0.02, 1.41 ]
Buhl 2015a%b 19/1029 19/1033 13.6 % 1.00 [ 0.53, 1.91 ]
D’Urzo 2014 2/335 1/337 1.0 % 2.02 [ 0.18, 22.36 ]
D’Urzo 2017 1/182 4/194 1.2 % 0.26 [ 0.03, 2.37 ]
Decramer 2014a 0/212 0/208 Not estimable
Decramer 2014b 2/217 0/215 0.6 % 5.00 [ 0.24, 104.76 ]
Donohue 2013 4/413 6/418 3.5 % 0.67 [ 0.19, 2.40 ]
Hanania 2017 21/1036 22/1341 15.4 % 1.24 [ 0.68, 2.27 ]
Kerwin 2017 2/247 0/247 0.6 % 5.04 [ 0.24, 105.54 ]
Mahler 2012a 5/570 5/561 3.6 % 0.98 [ 0.28, 3.42 ]
Mahler 2012b 2/572 4/570 1.9 % 0.50 [ 0.09, 2.72 ]
Mahler 2015a 4/258 0/262 0.7 % 9.28 [ 0.50, 173.30 ]
Mahler 2015b 1/250 2/251 1.0 % 0.50 [ 0.05, 5.55 ]
Maleki-Yazdi 2014 2/454 5/451 2.1 % 0.39 [ 0.08, 2.04 ]
RADIATE 2016 13/407 8/405 7.0 % 1.64 [ 0.67, 3.99 ]
Singh 2014 3/385 1/385 1.1 % 3.02 [ 0.31, 29.12 ]
Singh 2015a 1/203 1/203 0.7 % 1.00 [ 0.06, 16.10 ]
Singh 2015b 3/202 3/203 2.2 % 1.01 [ 0.20, 5.04 ]
Troosters 2016 1/76 0/76 0.5 % 3.04 [ 0.12, 75.80 ]
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(. . . Continued)
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Vogelmeier 2008 2/207 3/221 1.7 % 0.71 [ 0.12, 4.29 ]
ZuWallack 2014a%b 13/1133 9/1134 7.7 % 1.45 [ 0.62, 3.41 ]
Subtotal (95% CI) 8862 9668 67.3 % 1.09 [ 0.82, 1.45 ]
Total events: 102 (LABA/LAMA), 104 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 14.94, df = 19 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
Total (95% CI) 9591 11145 100.0 % 0.98 [ 0.78, 1.25 ]
Total events: 135 (LABA/LAMA), 187 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 16.43, df = 20 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 1.49, df = 1 (P = 0.22), I2 =33%
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Analysis 2.19. Comparison 2 LABA/LAMA vs LAMA, Outcome 19 Dropouts due to adverse events.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 19 Dropouts due to adverse events
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Aaron 2007 6/148 8/156 1.6 % 0.78 [ 0.26, 2.31 ]
Wedzicha 2013 59/729 114/1477 17.3 % 1.05 [ 0.76, 1.46 ]
Subtotal (95% CI) 877 1633 18.9 % 1.03 [ 0.75, 1.41 ]
Total events: 65 (LABA/LAMA), 122 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
2 Low-risk
Asai 2013 11/119 0/39 0.2 % 8.37 [ 0.48, 145.44 ]
Bateman 2013 6/474 24/953 2.3 % 0.50 [ 0.20, 1.22 ]
Buhl 2015a%b 37/1029 43/1033 9.2 % 0.86 [ 0.55, 1.34 ]
D’Urzo 2014 21/335 16/337 4.2 % 1.34 [ 0.69, 2.62 ]
D’Urzo 2017 6/182 6/194 1.4 % 1.07 [ 0.34, 3.37 ]
Decramer 2014a 10/212 9/208 2.2 % 1.09 [ 0.44, 2.75 ]
Decramer 2014b 20/217 11/215 3.2 % 1.88 [ 0.88, 4.03 ]
Donohue 2013 23/413 34/418 6.2 % 0.67 [ 0.39, 1.15 ]
Hanania 2017 12/290 10/389 2.5 % 1.64 [ 0.70, 3.84 ]
Kerwin 2017 5/247 4/247 1.1 % 1.26 [ 0.33, 4.73 ]
Mahler 2012a 20/570 10/561 3.1 % 2.00 [ 0.93, 4.32 ]
Mahler 2012b 14/572 16/570 3.5 % 0.87 [ 0.42, 1.80 ]
Mahler 2015a 10/258 6/262 1.8 % 1.72 [ 0.62, 4.80 ]
Mahler 2015b 5/250 2/251 0.7 % 2.54 [ 0.49, 13.22 ]
Maleki-Yazdi 2014 18/454 14/451 3.7 % 1.29 [ 0.63, 2.62 ]
Martinez 2017a 39/526 55/902 10.3 % 1.23 [ 0.81, 1.89 ]
Martinez 2017b 23/510 14/439 4.0 % 1.43 [ 0.73, 2.82 ]
RADIATE 2016 27/407 22/405 5.5 % 1.24 [ 0.69, 2.21 ]
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(. . . Continued)
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Singh 2014 16/385 17/385 3.8 % 0.94 [ 0.47, 1.89 ]
Singh 2015a 3/203 3/203 0.7 % 1.00 [ 0.20, 5.01 ]
Singh 2015b 2/202 7/203 0.7 % 0.28 [ 0.06, 1.36 ]
Troosters 2016 4/76 5/76 1.0 % 0.79 [ 0.20, 3.06 ]
Vogelmeier 2008 8/207 13/221 2.3 % 0.64 [ 0.26, 1.59 ]
ZuWallack 2014a%b 39/1133 27/1134 7.5 % 1.46 [ 0.89, 2.40 ]
Subtotal (95% CI) 9271 10096 81.1 % 1.12 [ 0.96, 1.31 ]
Total events: 379 (LABA/LAMA), 368 (LAMA)
Heterogeneity: Tau2 = 0.01; Chi2 = 23.99, df = 23 (P = 0.40); I2 =4%
Test for overall effect: Z = 1.46 (P = 0.14)
Total (95% CI) 10148 11729 100.0 % 1.10 [ 0.96, 1.27 ]
Total events: 444 (LABA/LAMA), 490 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 24.51, df = 25 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.61), I2 =0.0%
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Analysis 2.20. Comparison 2 LABA/LAMA vs LAMA, Outcome 20 Pneumonia.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 2 LABA/LAMA vs LAMA
Outcome: 20 Pneumonia
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Aaron 2007 1/148 0/156 0.9 % 3.18 [ 0.13, 78.75 ]
Wedzicha 2013 23/729 49/1477 36.7 % 0.95 [ 0.57, 1.57 ]
Subtotal (95% CI) 877 1633 37.6 % 0.98 [ 0.59, 1.61 ]
Total events: 24 (LABA/LAMA), 49 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Low-risk
Asai 2013 2/119 0/39 1.0 % 1.68 [ 0.08, 35.77 ]
Bateman 2013 2/474 6/953 3.6 % 0.67 [ 0.13, 3.33 ]
Buhl 2015a%b 18/1029 7/1033 12.1 % 2.61 [ 1.09, 6.27 ]
D’Urzo 2014 2/335 1/337 1.6 % 2.02 [ 0.18, 22.36 ]
D’Urzo 2017 1/182 0/194 0.9 % 3.21 [ 0.13, 79.42 ]
Decramer 2014a 0/212 2/208 1.0 % 0.19 [ 0.01, 4.07 ]
Decramer 2014b 2/217 2/215 2.4 % 0.99 [ 0.14, 7.10 ]
Donohue 2013 2/413 0/418 1.0 % 5.09 [ 0.24, 106.24 ]
Hanania 2017 15/1036 15/1341 18.0 % 1.30 [ 0.63, 2.67 ]
Kerwin 2017 1/247 0/247 0.9 % 3.01 [ 0.12, 74.30 ]
Mahler 2012a 2/570 2/561 2.4 % 0.98 [ 0.14, 7.01 ]
Mahler 2012b 4/572 0/570 1.1 % 9.03 [ 0.49, 168.14 ]
Mahler 2015a 0/258 2/262 1.0 % 0.20 [ 0.01, 4.22 ]
Mahler 2015b 1/250 0/251 0.9 % 3.02 [ 0.12, 74.59 ]
Maleki-Yazdi 2014 0/454 2/451 1.0 % 0.20 [ 0.01, 4.13 ]
RADIATE 2016 3/407 6/405 4.8 % 0.49 [ 0.12, 1.99 ]
Singh 2014 3/385 0/385 1.1 % 7.05 [ 0.36, 137.04 ]
Singh 2015a 1/203 1/203 1.2 % 1.00 [ 0.06, 16.10 ]
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(. . . Continued)
Study or subgroup LABA/LAMA LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Tashkin 2009 0/124 1/131 0.9 % 0.35 [ 0.01, 8.66 ]
Troosters 2016 0/76 1/76 0.9 % 0.33 [ 0.01, 8.20 ]
Vogelmeier 2008 0/207 0/221 Not estimable
ZuWallack 2014a%b 3/1133 5/1134 4.5 % 0.60 [ 0.14, 2.51 ]
Subtotal (95% CI) 8903 9635 62.4 % 1.23 [ 0.84, 1.81 ]
Total events: 62 (LABA/LAMA), 53 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 16.64, df = 20 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 9780 11268 100.0 % 1.13 [ 0.83, 1.53 ]
Total events: 86 (LABA/LAMA), 102 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.71, df = 22 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Chi2 = 0.52, df = 1 (P = 0.47), I2 =0.0%
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Analysis 3.1. Comparison 3 LABA/LAMA vs LABA, Outcome 1 Moderate to severe exacerbations.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 1 Moderate to severe exacerbations
Study or subgroup LABA/LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LABA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 85/474 103/476 49.2 % 0.79 [ 0.57, 1.09 ]
D’Urzo 2014 24/211 22/198 13.4 % 1.03 [ 0.56, 1.90 ]
Donohue 2016a 51/220 33/115 19.3 % 0.75 [ 0.45, 1.25 ]
Singh 2014 11/182 23/195 9.0 % 0.48 [ 0.23, 1.02 ]
Vogelmeier 2008 13/207 17/210 9.0 % 0.76 [ 0.36, 1.61 ]
Subtotal (95% CI) 1294 1194 100.0 % 0.77 [ 0.62, 0.97 ]
Total events: 184 (LABA/LAMA), 198 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.40, df = 4 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.025)
Total (95% CI) 1294 1194 100.0 % 0.77 [ 0.62, 0.97 ]
Total events: 184 (LABA/LAMA), 198 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.40, df = 4 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.025)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 LABA/LAMA vs LABA, Outcome 2 Severe exacerbations.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 2 Severe exacerbations
Study or subgroup LABA/LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LABA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 10/474 12/476 17.5 % 0.83 [ 0.36, 1.95 ]
D’Urzo 2014 1/211 4/198 2.6 % 0.23 [ 0.03, 2.08 ]
Donohue 2016a 7/220 8/115 11.7 % 0.44 [ 0.16, 1.24 ]
Ferguson 2016 48/204 56/206 63.6 % 0.82 [ 0.53, 1.29 ]
Singh 2014 2/182 1/195 2.2 % 2.16 [ 0.19, 23.98 ]
Vogelmeier 2008 3/207 1/210 2.4 % 3.07 [ 0.32, 29.79 ]
Subtotal (95% CI) 1498 1400 100.0 % 0.78 [ 0.55, 1.12 ]
Total events: 71 (LABA/LAMA), 82 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.51, df = 5 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
Total (95% CI) 1498 1400 100.0 % 0.78 [ 0.55, 1.12 ]
Total events: 71 (LABA/LAMA), 82 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.51, df = 5 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 LABA/LAMA vs LABA, Outcome 3 SGRQ responders at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 3 SGRQ responders at 6 months
Study or subgroup LABA/LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LABA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 281/441 279/443 16.4 % 1.03 [ 0.79, 1.36 ]
Buhl 2015a%b 563/979 427/954 22.1 % 1.67 [ 1.40, 2.00 ]
D’Urzo 2014 195/335 174/332 14.7 % 1.26 [ 0.93, 1.72 ]
D’Urzo 2017 194/335 164/332 14.7 % 1.41 [ 1.04, 1.91 ]
Martinez 2017a 187/503 151/434 16.7 % 1.11 [ 0.85, 1.45 ]
Martinez 2017b 139/352 144/430 15.4 % 1.30 [ 0.97, 1.74 ]
Subtotal (95% CI) 2945 2925 100.0 % 1.30 [ 1.10, 1.53 ]
Total events: 1559 (LABA/LAMA), 1339 (LABA)
Heterogeneity: Tau2 = 0.02; Chi2 = 11.46, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 3.12 (P = 0.0018)
Total (95% CI) 2945 2925 100.0 % 1.30 [ 1.10, 1.53 ]
Total events: 1559 (LABA/LAMA), 1339 (LABA)
Heterogeneity: Tau2 = 0.02; Chi2 = 11.46, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 3.12 (P = 0.0018)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours LABA Favours LABA/LAMA
323Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.4. Comparison 3 LABA/LAMA vs LABA, Outcome 4 SGRQ responders at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 4 SGRQ responders at 12 months
Study or subgroup LABA/LAMA LABA Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
2 Low-risk
Hanania 2017 411/995 314/845 1.19 [ 0.99, 1.44 ]
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Analysis 3.5. Comparison 3 LABA/LAMA vs LABA, Outcome 5 Change from baseline in SGRQ at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 5 Change from baseline in SGRQ at 3 months
Study or subgroup LABA/LAMA LABA
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
2 Low-risk
Bateman 2013 474 -9.4 (24.1) 476 -8.11 (23.05) -1.29 [ -4.29, 1.71 ]
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Analysis 3.6. Comparison 3 LABA/LAMA vs LABA, Outcome 6 Change from baseline in SGRQ at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 6 Change from baseline in SGRQ at 6 months
Study or subgroup LABA/LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 441 -9.82 (23.7) 443 -8.72 (22.5) 8.1 % -1.10 [ -4.15, 1.95 ]
D’Urzo 2014 256 -6.57 (11.84) 254 -4.7 (11.79) 17.9 % -1.87 [ -3.92, 0.18 ]
Martinez 2017a 432 -3.3 (12.06) 371 -2.7 (11.94) 27.2 % -0.60 [ -2.26, 1.06 ]
Martinez 2017b 430 -3 (11.82) 352 -2.3 (11.82) 27.1 % -0.70 [ -2.37, 0.97 ]
Singh 2014 338 -7.16 (12.8693) 332 -5.58 (12.94) 19.7 % -1.58 [ -3.53, 0.37 ]
Subtotal (95% CI) 1897 1752 100.0 % -1.09 [ -1.96, -0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.34, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
Total (95% CI) 1897 1752 100.0 % -1.09 [ -1.96, -0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.34, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours LABA/LAMA Favours LABA
325Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.7. Comparison 3 LABA/LAMA vs LABA, Outcome 7 Change from baseline in SGRQ at 12
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 7 Change from baseline in SGRQ at 12 months
Study or subgroup LABA/LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
D’Urzo 2017 335 -3.646 (15.76) 332 -4.06 (15.54) 15.7 % 0.41 [ -1.96, 2.79 ]
Hanania 2017 995 -3.3 (11.27) 845 -2.4 (11.12) 84.3 % -0.90 [ -1.93, 0.13 ]
Subtotal (95% CI) 1330 1177 100.0 % -0.69 [ -1.64, 0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
Total (95% CI) 1330 1177 100.0 % -0.69 [ -1.64, 0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 LABA/LAMA vs LABA, Outcome 8 TDI at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 8 TDI at 3 months
Study or subgroup LABA/LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 474 2.44 (3.44) 476 2.18 (3.43) 24.4 % 0.26 [ -0.18, 0.70 ]
Buhl 2015a%b 992 2.136 (3.024) 984 1.51 (3.043) 64.2 % 0.63 [ 0.36, 0.90 ]
Vincken 2014 207 2.5 (3.31) 209 2.01 (3.33) 11.5 % 0.49 [ -0.15, 1.13 ]
Subtotal (95% CI) 1673 1669 100.0 % 0.52 [ 0.31, 0.74 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.02, df = 2 (P = 0.36); I2 =1%
Test for overall effect: Z = 4.74 (P < 0.00001)
Total (95% CI) 1673 1669 100.0 % 0.52 [ 0.31, 0.74 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.02, df = 2 (P = 0.36); I2 =1%
Test for overall effect: Z = 4.74 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 LABA/LAMA vs LABA, Outcome 9 TDI at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 9 TDI at 6 months
Study or subgroup LABA/LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 474 2.72 (2.83) 476 2.47 (2.76) 23.0 % 0.25 [ -0.11, 0.61 ]
Buhl 2015a%b 992 1.98 (2.99) 984 1.56 (3.01) 41.6 % 0.42 [ 0.16, 0.68 ]
D’Urzo 2014 260 2.02 (3.2249) 263 1.52 (3.24) 9.5 % 0.50 [ -0.05, 1.05 ]
Singh 2014 344 2.51 (1.11283) 333 2.06 (2.92) 25.9 % 0.45 [ 0.12, 0.78 ]
Subtotal (95% CI) 2070 2056 100.0 % 0.40 [ 0.23, 0.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 4.55 (P < 0.00001)
Total (95% CI) 2070 2056 100.0 % 0.40 [ 0.23, 0.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 4.55 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 LABA/LAMA vs LABA, Outcome 10 TDI at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 10 TDI at 12 months
Study or subgroup LABA/LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Buhl 2015a%b 992 2.058 (3.118) 984 1.41 (3.168) 37.6 % 0.65 [ 0.37, 0.92 ]
D’Urzo 2017 335 1.812 (4.59) 332 1.32 (4.48) 17.2 % 0.49 [ -0.20, 1.18 ]
Hanania 2017 1002 0.5 (1.62) 871 0.3 (1.51) 45.2 % 0.20 [ 0.06, 0.34 ]
Subtotal (95% CI) 2329 2187 100.0 % 0.42 [ 0.06, 0.77 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 8.22, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 2.31 (P = 0.021)
Total (95% CI) 2329 2187 100.0 % 0.42 [ 0.06, 0.77 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 8.22, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 LABA/LAMA vs LABA, Outcome 11 Change from baseline in FEV1 at 3
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 11 Change from baseline in FEV1 at 3 months
Study or subgroup LABA/LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Buhl 2015a 521 0.146 (0.205) 519 0.06 (0.205) 25.4 % 0.09 [ 0.06, 0.11 ]
Buhl 2015b 497 0.147 (0.201) 503 0.05 (0.202) 25.4 % 0.10 [ 0.08, 0.12 ]
Ferguson 2016 192 0.166 (0.219) 199 0.1 (0.221) 21.9 % 0.07 [ 0.03, 0.11 ]
Hoshino 2014 18 0.165 (0.013) 20 0.14 (0.0149) 27.3 % 0.03 [ 0.02, 0.03 ]
Subtotal (95% CI) 1228 1241 100.0 % 0.07 [ 0.03, 0.12 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 48.48, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 3.10 (P = 0.0019)
Total (95% CI) 1228 1241 100.0 % 0.07 [ 0.03, 0.12 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 48.48, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 3.10 (P = 0.0019)
Test for subgroup differences: Not applicable
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Analysis 3.12. Comparison 3 LABA/LAMA vs LABA, Outcome 12 Change from baseline in FEV1 at 6
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 12 Change from baseline in FEV1 at 6 months
Study or subgroup LABA/LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 474 0.17 (0.544) 435 0.09 (0.501) 2.7 % 0.08 [ 0.01, 0.15 ]
Buhl 2015a 521 0.112 (0.205) 519 0.03 (0.205) 19.8 % 0.08 [ 0.05, 0.10 ]
Buhl 2015b 497 0.119 (0.201) 503 0.03 (0.202) 19.7 % 0.08 [ 0.06, 0.11 ]
D’Urzo 2014 271 0.095 (0.19754) 268 0.05 (0.196) 11.1 % 0.05 [ 0.01, 0.08 ]
Ferguson 2016 192 0.138 (0.231) 199 0.08 (0.234) 5.8 % 0.06 [ 0.01, 0.11 ]
Martinez 2017a 429 0.126 (0.201) 367 0.06 (0.203) 15.5 % 0.06 [ 0.04, 0.09 ]
Martinez 2017b 433 0.116 (0.21) 350 0.06 (0.208) 14.2 % 0.06 [ 0.03, 0.08 ]
Singh 2014 349 0.083 (0.22418) 337 0 (0.22) 11.1 % 0.09 [ 0.05, 0.12 ]
Subtotal (95% CI) 3166 2978 100.0 % 0.07 [ 0.06, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.32, df = 7 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 12.40 (P < 0.00001)
Total (95% CI) 3166 2978 100.0 % 0.07 [ 0.06, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.32, df = 7 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 12.40 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 LABA/LAMA vs LABA, Outcome 13 Change from baseline in FEV1 at 12
months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 13 Change from baseline in FEV1 at 12 months
Study or subgroup LABA/LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Buhl 2015a 521 0.099 (0.205) 519 0 (0.205) 21.8 % 0.10 [ 0.07, 0.12 ]
Buhl 2015b 497 0.093 (0.201) 503 0.01 (0.202) 21.7 % 0.08 [ 0.06, 0.11 ]
D’Urzo 2017 335 0.038 (0.275) 332 0 (0.273) 11.8 % 0.03 [ -0.01, 0.08 ]
Ferguson 2016 192 0.116 (0.234) 199 0.04 (0.238) 10.0 % 0.08 [ 0.03, 0.13 ]
Hanania 2017 1021 0.133 (0.179) 871 0.07 (0.181) 29.8 % 0.07 [ 0.05, 0.08 ]
NCT01536262 2014 39 0.143 (0.156) 34 0.08 (0.157) 4.9 % 0.07 [ 0.00, 0.14 ]
Subtotal (95% CI) 2605 2458 100.0 % 0.07 [ 0.06, 0.09 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 9.06, df = 5 (P = 0.11); I2 =45%
Test for overall effect: Z = 8.54 (P < 0.00001)
Total (95% CI) 2605 2458 100.0 % 0.07 [ 0.06, 0.09 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 9.06, df = 5 (P = 0.11); I2 =45%
Test for overall effect: Z = 8.54 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.14. Comparison 3 LABA/LAMA vs LABA, Outcome 14 Mortality.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 14 Mortality
Study or subgroup LABA/LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LABA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 1/474 2/476 5.4 % 0.50 [ 0.05, 5.54 ]
Buhl 2015a%b 18/1029 14/1038 63.2 % 1.30 [ 0.64, 2.63 ]
D’Urzo 2014 1/335 1/332 4.1 % 0.99 [ 0.06, 15.91 ]
D’Urzo 2017 1/182 0/192 3.0 % 3.18 [ 0.13, 78.61 ]
Donohue 2016a 5/392 1/198 6.7 % 2.55 [ 0.30, 21.94 ]
Ferguson 2016 1/204 5/206 6.7 % 0.20 [ 0.02, 1.71 ]
Hanania 2017 4/1036 2/890 10.8 % 1.72 [ 0.31, 9.42 ]
NCT01536262 2014 0/41 0/41 Not estimable
Vincken 2014 0/226 0/221 Not estimable
Vogelmeier 2008 0/207 0/210 Not estimable
Subtotal (95% CI) 4126 3804 100.0 % 1.19 [ 0.68, 2.09 ]
Total events: 31 (LABA/LAMA), 25 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.27, df = 6 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
Total (95% CI) 4126 3804 100.0 % 1.19 [ 0.68, 2.09 ]
Total events: 31 (LABA/LAMA), 25 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.27, df = 6 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 3.15. Comparison 3 LABA/LAMA vs LABA, Outcome 15 Total SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 15 Total SAE
Study or subgroup LABA/LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LABA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 22/474 26/476 6.3 % 0.84 [ 0.47, 1.51 ]
Buhl 2015a%b 169/1029 181/1038 40.3 % 0.93 [ 0.74, 1.17 ]
D’Urzo 2014 19/335 15/332 4.4 % 1.27 [ 0.63, 2.55 ]
D’Urzo 2017 14/182 14/192 3.6 % 1.06 [ 0.49, 2.29 ]
Donohue 2016a 38/392 21/198 6.7 % 0.90 [ 0.52, 1.59 ]
Ferguson 2016 26/204 24/206 6.1 % 1.11 [ 0.61, 2.00 ]
Hanania 2017 114/1036 78/890 23.2 % 1.29 [ 0.95, 1.74 ]
NCT01536262 2014 3/41 5/41 0.9 % 0.57 [ 0.13, 2.55 ]
Singh 2014 23/385 14/384 4.6 % 1.68 [ 0.85, 3.31 ]
Vincken 2014 5/226 5/221 1.4 % 0.98 [ 0.28, 3.42 ]
Vogelmeier 2008 10/207 8/210 2.4 % 1.28 [ 0.50, 3.31 ]
Subtotal (95% CI) 4511 4188 100.0 % 1.06 [ 0.91, 1.22 ]
Total events: 443 (LABA/LAMA), 391 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.58, df = 10 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 4511 4188 100.0 % 1.06 [ 0.91, 1.22 ]
Total events: 443 (LABA/LAMA), 391 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.58, df = 10 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 3.16. Comparison 3 LABA/LAMA vs LABA, Outcome 16 COPD SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 16 COPD SAE
Study or subgroup LABA/LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LABA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 10/474 15/476 10.3 % 0.66 [ 0.29, 1.49 ]
Buhl 2015a%b 71/1029 67/1038 56.8 % 1.07 [ 0.76, 1.52 ]
Ferguson 2016 8/204 10/206 7.5 % 0.80 [ 0.31, 2.07 ]
Hanania 2017 32/1036 19/890 20.5 % 1.46 [ 0.82, 2.60 ]
NCT01536262 2014 2/41 2/41 1.7 % 1.00 [ 0.13, 7.46 ]
Singh 2014 4/385 1/384 1.4 % 4.02 [ 0.45, 36.14 ]
Vincken 2014 1/226 2/221 1.2 % 0.49 [ 0.04, 5.41 ]
Vogelmeier 2008 1/207 0/210 0.7 % 3.06 [ 0.12, 75.50 ]
Subtotal (95% CI) 3602 3466 100.0 % 1.08 [ 0.83, 1.40 ]
Total events: 129 (LABA/LAMA), 116 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.05, df = 7 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 3602 3466 100.0 % 1.08 [ 0.83, 1.40 ]
Total events: 129 (LABA/LAMA), 116 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.05, df = 7 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 3.17. Comparison 3 LABA/LAMA vs LABA, Outcome 17 Cardiac SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 17 Cardiac SAE
Study or subgroup LABA/LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LABA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 1/474 8/476 5.9 % 0.12 [ 0.02, 0.99 ]
Buhl 2015a%b 19/1029 15/1038 23.7 % 1.28 [ 0.65, 2.54 ]
D’Urzo 2014 2/335 3/332 7.5 % 0.66 [ 0.11, 3.97 ]
D’Urzo 2017 1/182 2/192 4.6 % 0.52 [ 0.05, 5.84 ]
Donohue 2016a 8/392 4/198 13.3 % 1.01 [ 0.30, 3.40 ]
Ferguson 2016 5/204 4/206 11.7 % 1.27 [ 0.34, 4.79 ]
Hanania 2017 21/1036 5/890 17.1 % 3.66 [ 1.38, 9.75 ]
NCT01536262 2014 2/41 0/41 3.0 % 5.25 [ 0.24, 112.88 ]
Singh 2014 3/385 0/384 3.1 % 7.04 [ 0.36, 136.69 ]
Vincken 2014 0/226 1/221 2.7 % 0.32 [ 0.01, 8.01 ]
Vogelmeier 2008 2/207 3/210 7.5 % 0.67 [ 0.11, 4.07 ]
Subtotal (95% CI) 4511 4188 100.0 % 1.19 [ 0.69, 2.07 ]
Total events: 64 (LABA/LAMA), 45 (LABA)
Heterogeneity: Tau2 = 0.21; Chi2 = 13.73, df = 10 (P = 0.19); I2 =27%
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI) 4511 4188 100.0 % 1.19 [ 0.69, 2.07 ]
Total events: 64 (LABA/LAMA), 45 (LABA)
Heterogeneity: Tau2 = 0.21; Chi2 = 13.73, df = 10 (P = 0.19); I2 =27%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 3.18. Comparison 3 LABA/LAMA vs LABA, Outcome 18 Dropuouts due to adverse events.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 18 Dropuouts due to adverse events
Study or subgroup LABA/LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LABA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 6/474 24/476 7.3 % 0.24 [ 0.10, 0.60 ]
Buhl 2015a%b 37/1029 51/1038 13.3 % 0.72 [ 0.47, 1.11 ]
D’Urzo 2014 21/335 14/332 9.6 % 1.52 [ 0.76, 3.04 ]
D’Urzo 2017 6/182 4/192 4.6 % 1.60 [ 0.44, 5.77 ]
Donohue 2016a 26/392 13/198 9.7 % 1.01 [ 0.51, 2.01 ]
Ferguson 2016 5/204 12/206 6.0 % 0.41 [ 0.14, 1.17 ]
Hanania 2017 12/290 4/213 5.4 % 2.26 [ 0.72, 7.09 ]
Martinez 2017a 39/526 22/452 11.7 % 1.57 [ 0.91, 2.68 ]
Martinez 2017b 23/510 21/438 10.8 % 0.94 [ 0.51, 1.72 ]
NCT01536262 2014 2/41 6/41 3.0 % 0.30 [ 0.06, 1.58 ]
Singh 2014 16/385 14/384 9.2 % 1.15 [ 0.55, 2.38 ]
Vincken 2014 3/226 4/221 3.6 % 0.73 [ 0.16, 3.30 ]
Vogelmeier 2016 8/207 6/210 5.9 % 1.37 [ 0.47, 4.01 ]
Subtotal (95% CI) 4801 4401 100.0 % 0.94 [ 0.68, 1.29 ]
Total events: 204 (LABA/LAMA), 195 (LABA)
Heterogeneity: Tau2 = 0.15; Chi2 = 23.45, df = 12 (P = 0.02); I2 =49%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 4801 4401 100.0 % 0.94 [ 0.68, 1.29 ]
Total events: 204 (LABA/LAMA), 195 (LABA)
Heterogeneity: Tau2 = 0.15; Chi2 = 23.45, df = 12 (P = 0.02); I2 =49%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 3.19. Comparison 3 LABA/LAMA vs LABA, Outcome 19 Pneumonia.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 3 LABA/LAMA vs LABA
Outcome: 19 Pneumonia
Study or subgroup LABA/LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/LAMA), 0 (LABA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 2/474 2/476 5.9 % 1.00 [ 0.14, 7.16 ]
Buhl 2015a%b 18/1029 14/1038 46.3 % 1.30 [ 0.64, 2.63 ]
D’Urzo 2014 2/335 3/332 7.1 % 0.66 [ 0.11, 3.97 ]
D’Urzo 2017 1/182 0/192 2.2 % 3.18 [ 0.13, 78.61 ]
Donohue 2016a 4/392 1/198 4.7 % 2.03 [ 0.23, 18.29 ]
Ferguson 2016 4/204 2/206 7.9 % 2.04 [ 0.37, 11.26 ]
Hanania 2017 15/1036 4/890 18.7 % 3.25 [ 1.08, 9.84 ]
NCT01536262 2014 0/41 1/41 2.2 % 0.33 [ 0.01, 8.22 ]
Singh 2014 3/385 0/384 2.6 % 7.04 [ 0.36, 136.69 ]
Vogelmeier 2008 0/207 1/210 2.2 % 0.34 [ 0.01, 8.31 ]
Subtotal (95% CI) 4285 3967 100.0 % 1.54 [ 0.95, 2.49 ]
Total events: 49 (LABA/LAMA), 28 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.17, df = 9 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
Total (95% CI) 4285 3967 100.0 % 1.54 [ 0.95, 2.49 ]
Total events: 49 (LABA/LAMA), 28 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.17, df = 9 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 LABA/ICS vs LAMA, Outcome 1 Moderate to severe exacerbations.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 1 Moderate to severe exacerbations
Study or subgroup LABA/ICS LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 high-risk
Pepin 2014 7/127 9/130 4.3 % 0.78 [ 0.28, 2.17 ]
Wedzicha 2008 408/658 392/665 91.0 % 1.14 [ 0.91, 1.42 ]
Subtotal (95% CI) 785 795 95.2 % 1.12 [ 0.90, 1.39 ]
Total events: 415 (LABA/ICS), 401 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
2 Low-risk
Covelli 2016 7/310 11/313 4.8 % 0.63 [ 0.24, 1.66 ]
Subtotal (95% CI) 310 313 4.8 % 0.63 [ 0.24, 1.66 ]
Total events: 7 (LABA/ICS), 11 (LAMA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 1095 1108 100.0 % 1.09 [ 0.88, 1.34 ]
Total events: 422 (LABA/ICS), 412 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.76, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 1.27, df = 1 (P = 0.26), I2 =21%
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Analysis 4.2. Comparison 4 LABA/ICS vs LAMA, Outcome 2 Severe exacerbations.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 2 Severe exacerbations
Study or subgroup LABA/ICS LAMA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Pepin 2014 4/127 5/130 4.0 % 0.82 [ 0.23, 2.98 ]
Wedzicha 2008 105/658 84/665 94.7 % 1.26 [ 0.97, 1.65 ]
Subtotal (95% CI) 785 795 98.7 % 1.24 [ 0.96, 1.61 ]
Total events: 109 (LABA/ICS), 89 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
2 Low-risk
Covelli 2016 3/310 1/313 1.3 % 3.03 [ 0.32, 28.96 ]
Subtotal (95% CI) 310 313 1.3 % 3.03 [ 0.32, 28.96 ]
Total events: 3 (LABA/ICS), 1 (LAMA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 1095 1108 100.0 % 1.26 [ 0.97, 1.63 ]
Total events: 112 (LABA/ICS), 90 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.01, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Chi2 = 0.59, df = 1 (P = 0.44), I2 =0.0%
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Analysis 4.3. Comparison 4 LABA/ICS vs LAMA, Outcome 3 SGRQ responders at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 3 SGRQ responders at 3 months
Study or subgroup LABA/ICS LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Pepin 2014 52/106 54/108 26.3 % 0.96 [ 0.56, 1.65 ]
Subtotal (95% CI) 106 108 26.3 % 0.96 [ 0.56, 1.65 ]
Total events: 52 (LABA/ICS), 54 (LAMA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
2 Low-risk
Covelli 2016 145/304 128/305 73.7 % 1.26 [ 0.92, 1.74 ]
Subtotal (95% CI) 304 305 73.7 % 1.26 [ 0.92, 1.74 ]
Total events: 145 (LABA/ICS), 128 (LAMA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Total (95% CI) 410 413 100.0 % 1.17 [ 0.89, 1.55 ]
Total events: 197 (LABA/ICS), 182 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 0.72, df = 1 (P = 0.40), I2 =0.0%
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Analysis 4.4. Comparison 4 LABA/ICS vs LAMA, Outcome 4 SGRQ responders at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 4 SGRQ responders at 6 months
Study or subgroup LABA/ICS LAMA Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2008 211/603 190/633 1.26 [ 0.99, 1.59 ]
2 Low-risk
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Analysis 4.5. Comparison 4 LABA/ICS vs LAMA, Outcome 5 SGRQ responders at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 5 SGRQ responders at 12 months
Study or subgroup LABA/ICS LAMA Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2008 194/606 180/621 1.15 [ 0.90, 1.47 ]
2 Low-risk
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Analysis 4.6. Comparison 4 LABA/ICS vs LAMA, Outcome 6 SGRQ responder at 2 years.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 6 SGRQ responder at 2 years
Study or subgroup LABA/ICS LAMA Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2008 193/603 169/626 1.27 [ 1.00, 1.63 ]
2 Low-risk
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Analysis 4.7. Comparison 4 LABA/ICS vs LAMA, Outcome 7 Change from baseline in SGRQ at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 7 Change from baseline in SGRQ at 3 months
Study or subgroup LABA/ICS LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Pepin 2014 106 -6.03 (13.24) 108 -4.97 (11.5) 25.2 % -1.06 [ -4.39, 2.27 ]
Subtotal (95% CI) 106 108 25.2 % -1.06 [ -4.39, 2.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
2 Low-risk
Covelli 2016 274 -3.9 (11.77) 259 -2.52 (11.68) 70.3 % -1.38 [ -3.37, 0.61 ]
Perng 2009 33 -12 (19.05) 34 -9 (13.39) 4.5 % -3.00 [ -10.91, 4.91 ]
Subtotal (95% CI) 307 293 74.8 % -1.48 [ -3.41, 0.45 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 413 401 100.0 % -1.37 [ -3.04, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
-10 -5 0 5 10
Favours LABA/ICS Favours LAMA
344Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.8. Comparison 4 LABA/ICS vs LAMA, Outcome 8 Change from baseline in SGRQ at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 8 Change from baseline in SGRQ at 6 months
Study or subgroup LABA/ICS LAMA
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2008 493 -2.42 (14.62) 506 -0.45 (14.69) -1.97 [ -3.79, -0.15 ]
2 Low-risk
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Analysis 4.9. Comparison 4 LABA/ICS vs LAMA, Outcome 9 Change from baseline in SGRQ at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 9 Change from baseline in SGRQ at 12 months
Study or subgroup LABA/ICS LAMA
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2008 433 -2.55 (15.19) 414 -1.56 (14.32) -0.99 [ -2.98, 1.00 ]
2 Low-risk
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Analysis 4.10. Comparison 4 LABA/ICS vs LAMA, Outcome 10 Change from baseline in SGRQ at 2 years.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 10 Change from baseline in SGRQ at 2 years
Study or subgroup LABA/ICS LAMA
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2008 377 -2.81 (16.35) 353 -1.77 (14.61) -1.04 [ -3.29, 1.21 ]
2 Low-risk
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Analysis 4.11. Comparison 4 LABA/ICS vs LAMA, Outcome 11 TDI at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 11 TDI at 3 months
Study or subgroup LABA/ICS LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2008 599 0.7 (2.81) 599 0.2 (2.9) 88.6 % 0.50 [ 0.18, 0.82 ]
Subtotal (95% CI) 599 599 88.6 % 0.50 [ 0.18, 0.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.03 (P = 0.0024)
2 Low-risk
SCO40034 2005 61 0.459 (2.579) 64 -0.05 (2.559) 11.4 % 0.51 [ -0.39, 1.41 ]
Subtotal (95% CI) 61 64 11.4 % 0.51 [ -0.39, 1.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 660 663 100.0 % 0.50 [ 0.20, 0.81 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 3.23 (P = 0.0013)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 4.12. Comparison 4 LABA/ICS vs LAMA, Outcome 12 TDI at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 12 TDI at 6 months
Study or subgroup LABA/ICS LAMA
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2008 561 0.8 (3.03) 542 0.5 (3.09) 0.30 [ -0.06, 0.66 ]
2 Low-risk
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Analysis 4.13. Comparison 4 LABA/ICS vs LAMA, Outcome 13 TDI at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 13 TDI at 12 months
Study or subgroup LABA/ICS LAMA
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2008 491 1.1 (3.3) 451 1.1 (2.97) 0.0 [ -0.40, 0.40 ]
2 Low-risk
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Analysis 4.14. Comparison 4 LABA/ICS vs LAMA, Outcome 14 TDI at 2 years.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 14 TDI at 2 years
Study or subgroup LABA/ICS LAMA
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2008 428 1.4 (3.28) 386 1.2 (3.22) 0.20 [ -0.25, 0.65 ]
2 Low-risk
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Analysis 4.15. Comparison 4 LABA/ICS vs LAMA, Outcome 15 Change from baseline in FEV1 at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 15 Change from baseline in FEV1 at 3 months
Study or subgroup LABA/ICS LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Pepin 2014 112 0.117 (0.234) 112 0.08 (0.232) 11.3 % 0.04 [ -0.02, 0.10 ]
Wedzicha 2008 547 0.02 (0.208) 582 0.02 (0.218) 16.0 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 659 694 27.3 % 0.01 [ -0.02, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.21, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Low-risk
Cazzola 2007 26 0.14 (0.056) 26 0.14 (0.066) 15.0 % 0.00 [ -0.03, 0.03 ]
COSMOS-J 2016 120 -0.007 (0.2069) 114 0 (0.1893) 12.7 % -0.01 [ -0.06, 0.04 ]
Covelli 2016 268 0.098 (0.218) 249 0.09 (0.221) 14.4 % 0.01 [ -0.03, 0.04 ]
Hoshino 2013 16 0.115 (0.018) 15 0.04 (0.012) 17.2 % 0.07 [ 0.06, 0.08 ]
Perng 2009 33 0.129 (0.322) 34 0.13 (0.239) 4.7 % 0.00 [ -0.14, 0.14 ]
SCO40034 2005 61 0.248 (0.237) 64 0.23 (0.235) 8.7 % 0.01 [ -0.07, 0.10 ]
Subtotal (95% CI) 524 502 72.7 % 0.02 [ -0.02, 0.06 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 33.66, df = 5 (P<0.00001); I2 =85%
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 1183 1196 100.0 % 0.02 [ -0.02, 0.05 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 51.33, df = 7 (P<0.00001); I2 =86%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 4.16. Comparison 4 LABA/ICS vs LAMA, Outcome 16 Change from baseline in FEV1 at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 16 Change from baseline in FEV1 at 6 months
Study or subgroup LABA/ICS LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2008 547 0.01 (0.223) 524 0.02 (0.228) 83.2 % -0.01 [ -0.04, 0.02 ]
Subtotal (95% CI) 547 524 83.2 % -0.01 [ -0.04, 0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
2 Low-risk
COSMOS-J 2016 117 -0.019 (0.2293) 113 -0.02 (0.2355) 16.8 % 0.00 [ -0.06, 0.06 ]
Subtotal (95% CI) 117 113 16.8 % 0.00 [ -0.06, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Total (95% CI) 664 637 100.0 % -0.01 [ -0.03, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 4.17. Comparison 4 LABA/ICS vs LAMA, Outcome 17 Change from baseline in FEV1 at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 17 Change from baseline in FEV1 at 12 months
Study or subgroup LABA/ICS LAMA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Sarac 2016 22 0.04 (0.188) 22 0.01 (0.047) 36.0 % 0.03 [ -0.05, 0.11 ]
Wedzicha 2008 469 -0.02 (0.269) 420 0.02 (0.274) 64.0 % -0.04 [ -0.08, 0.00 ]
Subtotal (95% CI) 491 442 100.0 % -0.01 [ -0.08, 0.05 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.40, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Low-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 491 442 100.0 % -0.01 [ -0.08, 0.05 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.40, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 4.18. Comparison 4 LABA/ICS vs LAMA, Outcome 18 Change from baseline in FEV1 at 2 years.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 18 Change from baseline in FEV1 at 2 years
Study or subgroup LABA/ICS LAMA
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Wedzicha 2008 414 -0.03 (0.242) 372 -0.02 (0.276) -0.01 [ -0.05, 0.03 ]
2 Low-risk
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Analysis 4.19. Comparison 4 LABA/ICS vs LAMA, Outcome 19 Mortality.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 19 Mortality
Study or subgroup LABA/ICS LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Pepin 2014 0/127 2/130 2.9 % 0.20 [ 0.01, 4.24 ]
Wedzicha 2008 21/658 38/665 90.8 % 0.54 [ 0.32, 0.94 ]
Subtotal (95% CI) 785 795 93.7 % 0.53 [ 0.31, 0.90 ]
Total events: 21 (LABA/ICS), 40 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.34 (P = 0.019)
2 Low-risk
Covelli 2016 0/310 2/313 2.9 % 0.20 [ 0.01, 4.20 ]
Perng 2009 1/33 1/34 3.4 % 1.03 [ 0.06, 17.20 ]
SCO40034 2005 0/61 0/64 Not estimable
Subtotal (95% CI) 404 411 6.3 % 0.48 [ 0.06, 3.82 ]
Total events: 1 (LABA/ICS), 3 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 1189 1206 100.0 % 0.52 [ 0.31, 0.88 ]
Total events: 22 (LABA/ICS), 43 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.01, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
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Analysis 4.20. Comparison 4 LABA/ICS vs LAMA, Outcome 20 Total SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 20 Total SAE
Study or subgroup LABA/ICS LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Pepin 2014 7/127 8/130 4.3 % 0.89 [ 0.31, 2.53 ]
Wedzicha 2008 215/658 179/665 84.3 % 1.32 [ 1.04, 1.67 ]
Subtotal (95% CI) 785 795 88.7 % 1.29 [ 1.03, 1.63 ]
Total events: 222 (LABA/ICS), 187 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
2 Low-risk
COSMOS-J 2016 8/136 8/126 4.6 % 0.92 [ 0.34, 2.53 ]
Covelli 2016 10/310 10/313 5.9 % 1.01 [ 0.41, 2.46 ]
SCO40034 2005 1/61 2/64 0.8 % 0.52 [ 0.05, 5.85 ]
Subtotal (95% CI) 507 503 11.3 % 0.93 [ 0.49, 1.77 ]
Total events: 19 (LABA/ICS), 20 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 1292 1298 100.0 % 1.25 [ 1.00, 1.55 ]
Total events: 241 (LABA/ICS), 207 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.67, df = 4 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Chi2 = 0.90, df = 1 (P = 0.34), I2 =0.0%
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Analysis 4.21. Comparison 4 LABA/ICS vs LAMA, Outcome 21 COPD SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 21 COPD SAE
Study or subgroup LABA/ICS LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Pepin 2014 2/127 5/130 3.1 % 0.40 [ 0.08, 2.10 ]
Wedzicha 2008 113/658 86/665 93.4 % 1.40 [ 1.03, 1.89 ]
Subtotal (95% CI) 785 795 96.6 % 0.99 [ 0.33, 2.96 ]
Total events: 115 (LABA/ICS), 91 (LAMA)
Heterogeneity: Tau2 = 0.41; Chi2 = 2.11, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 0.03 (P = 0.98)
2 Low-risk
COSMOS-J 2016 1/136 1/126 1.1 % 0.93 [ 0.06, 14.96 ]
Covelli 2016 2/310 1/313 1.5 % 2.03 [ 0.18, 22.46 ]
SCO40034 2005 0/61 1/64 0.8 % 0.34 [ 0.01, 8.61 ]
Subtotal (95% CI) 507 503 3.4 % 1.02 [ 0.21, 4.99 ]
Total events: 3 (LABA/ICS), 3 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Total (95% CI) 1292 1298 100.0 % 1.33 [ 0.99, 1.78 ]
Total events: 118 (LABA/ICS), 94 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.98, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.058)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 4.22. Comparison 4 LABA/ICS vs LAMA, Outcome 22 Cardiac SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 22 Cardiac SAE
Study or subgroup LABA/ICS LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Wedzicha 2008 23/658 34/665 93.0 % 0.67 [ 0.39, 1.15 ]
Subtotal (95% CI) 658 665 93.0 % 0.67 [ 0.39, 1.15 ]
Total events: 23 (LABA/ICS), 34 (LAMA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
2 Low-risk
COSMOS-J 2016 0/136 1/126 3.2 % 0.31 [ 0.01, 7.59 ]
Covelli 2016 0/310 5/313 3.9 % 0.09 [ 0.00, 1.64 ]
Subtotal (95% CI) 446 439 7.0 % 0.16 [ 0.02, 1.34 ]
Total events: 0 (LABA/ICS), 6 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.091)
Total (95% CI) 1104 1104 100.0 % 0.61 [ 0.34, 1.08 ]
Total events: 23 (LABA/ICS), 40 (LAMA)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.03, df = 2 (P = 0.36); I2 =1%
Test for overall effect: Z = 1.71 (P = 0.087)
Test for subgroup differences: Chi2 = 1.66, df = 1 (P = 0.20), I2 =40%
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Analysis 4.23. Comparison 4 LABA/ICS vs LAMA, Outcome 23 Dropouts due to adverse events.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 23 Dropouts due to adverse events
Study or subgroup LABA/ICS LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Pepin 2014 7/127 6/130 7.2 % 1.21 [ 0.39, 3.69 ]
Wedzicha 2008 67/658 66/665 70.4 % 1.03 [ 0.72, 1.47 ]
Subtotal (95% CI) 785 795 77.6 % 1.04 [ 0.74, 1.47 ]
Total events: 74 (LABA/ICS), 72 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
2 Low-risk
COSMOS-J 2016 13/136 8/126 10.8 % 1.56 [ 0.62, 3.90 ]
Covelli 2016 6/310 12/313 9.2 % 0.50 [ 0.18, 1.34 ]
Perng 2009 1/33 2/34 1.5 % 0.50 [ 0.04, 5.79 ]
SCO40034 2005 0/61 2/64 1.0 % 0.20 [ 0.01, 4.32 ]
Subtotal (95% CI) 540 537 22.4 % 0.78 [ 0.35, 1.71 ]
Total events: 20 (LABA/ICS), 24 (LAMA)
Heterogeneity: Tau2 = 0.15; Chi2 = 3.84, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 0.62 (P = 0.53)
Total (95% CI) 1325 1332 100.0 % 0.99 [ 0.73, 1.34 ]
Total events: 94 (LABA/ICS), 96 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.31, df = 5 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 0.45, df = 1 (P = 0.50), I2 =0.0%
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Analysis 4.24. Comparison 4 LABA/ICS vs LAMA, Outcome 24 Pneumonia.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 4 LABA/ICS vs LAMA
Outcome: 24 Pneumonia
Study or subgroup LABA/ICS LAMA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Pepin 2014 2/127 0/130 2.9 % 5.20 [ 0.25, 109.37 ]
Wedzicha 2008 37/658 22/665 91.3 % 1.74 [ 1.02, 2.99 ]
Subtotal (95% CI) 785 795 94.1 % 1.80 [ 1.06, 3.06 ]
Total events: 39 (LABA/ICS), 22 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
2 Low-risk
COSMOS-J 2016 2/136 0/126 2.9 % 4.70 [ 0.22, 98.91 ]
Covelli 2016 3/310 0/313 3.0 % 7.14 [ 0.37, 138.74 ]
Subtotal (95% CI) 446 439 5.9 % 5.82 [ 0.70, 48.80 ]
Total events: 5 (LABA/ICS), 0 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.10)
Total (95% CI) 1231 1234 100.0 % 1.93 [ 1.15, 3.23 ]
Total events: 44 (LABA/ICS), 22 (LAMA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.64, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.012)
Test for subgroup differences: Chi2 = 1.10, df = 1 (P = 0.29), I2 =9%
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Analysis 5.1. Comparison 5 LABA/ICS vs LABA, Outcome 1 Moderate to severe exacerbations.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 1 Moderate to severe exacerbations
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Anzueto 2009 208/394 234/403 6.2 % 0.81 [ 0.61, 1.07 ]
Calverley 2003 TRISTAN 193/358 197/372 5.7 % 1.04 [ 0.78, 1.39 ]
Ferguson 2008 211/391 230/385 6.0 % 0.79 [ 0.59, 1.05 ]
Ferguson 2017 171/606 204/613 8.2 % 0.79 [ 0.62, 1.01 ]
Fukuchi 2013 76/636 111/657 4.9 % 0.67 [ 0.49, 0.91 ]
Kardos 2007 210/507 241/487 7.7 % 0.72 [ 0.56, 0.93 ]
Ohar 2014 102/314 115/325 4.5 % 0.88 [ 0.63, 1.22 ]
SCO40041 2008 49/92 55/94 1.4 % 0.81 [ 0.45, 1.44 ]
Sharafkhaneh 2012 342/807 182/403 8.4 % 0.89 [ 0.70, 1.14 ]
Wedzicha 2014 264/601 294/596 9.4 % 0.80 [ 0.64, 1.01 ]
Subtotal (95% CI) 4706 4335 62.5 % 0.81 [ 0.75, 0.89 ]
Total events: 1826 (LABA/ICS), 1863 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.02, df = 9 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 4.57 (P < 0.00001)
2 Low-risk
Calverley 2007 1039/1533 1065/1521 20.7 % 0.90 [ 0.77, 1.05 ]
Hanania 2003 61/178 55/177 2.5 % 1.16 [ 0.74, 1.80 ]
Mahler 2002 61/165 60/160 2.4 % 0.98 [ 0.62, 1.53 ]
Rossi 2014 44/288 63/293 2.7 % 0.66 [ 0.43, 1.01 ]
SCO100470 2006 89/518 108/532 5.0 % 0.81 [ 0.60, 1.11 ]
Tashkin 2012a%b 88/880 69/444 4.2 % 0.60 [ 0.43, 0.85 ]
Subtotal (95% CI) 3562 3127 37.5 % 0.83 [ 0.70, 0.98 ]
Total events: 1382 (LABA/ICS), 1420 (LABA)
Heterogeneity: Tau2 = 0.02; Chi2 = 8.15, df = 5 (P = 0.15); I2 =39%
Test for overall effect: Z = 2.18 (P = 0.029)
Total (95% CI) 8268 7462 100.0 % 0.83 [ 0.77, 0.89 ]
Total events: 3208 (LABA/ICS), 3283 (LABA)
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(. . . Continued)
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 14.48, df = 15 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 5.35 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 5.2. Comparison 5 LABA/ICS vs LABA, Outcome 2 Severe exacerbations.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 2 Severe exacerbations
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Anzueto 2009 39/385 50/393 8.2 % 0.77 [ 0.50, 1.21 ]
Calverley 2003 TRISTAN 32/358 35/372 6.4 % 0.95 [ 0.57, 1.56 ]
Ferguson 2008 42/391 46/385 8.2 % 0.89 [ 0.57, 1.38 ]
Fukuchi 2013 24/636 30/657 5.4 % 0.82 [ 0.47, 1.42 ]
Ohar 2014 43/314 39/325 7.5 % 1.16 [ 0.73, 1.85 ]
Subtotal (95% CI) 2084 2132 35.6 % 0.91 [ 0.74, 1.13 ]
Total events: 180 (LABA/ICS), 200 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.77, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
2 Low-risk
Calverley 2007 400/1533 373/1521 60.7 % 1.09 [ 0.92, 1.28 ]
Hanania 2003 0/118 1/124 0.2 % 0.35 [ 0.01, 8.61 ]
Mahler 2002 3/114 2/117 0.5 % 1.55 [ 0.25, 9.48 ]
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(. . . Continued)
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rossi 2014 2/288 1/293 0.3 % 2.04 [ 0.18, 22.64 ]
SCO100470 2006 5/518 10/532 1.4 % 0.51 [ 0.17, 1.50 ]
Tashkin 2012a%b 7/880 6/444 1.3 % 0.59 [ 0.20, 1.75 ]
Subtotal (95% CI) 3451 3031 64.4 % 1.06 [ 0.90, 1.24 ]
Total events: 417 (LABA/ICS), 393 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.91, df = 5 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 5535 5163 100.0 % 1.00 [ 0.88, 1.14 ]
Total events: 597 (LABA/ICS), 593 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.93, df = 10 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 1.25, df = 1 (P = 0.26), I2 =20%
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Analysis 5.3. Comparison 5 LABA/ICS vs LABA, Outcome 3 SGRQ responders at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 3 SGRQ responders at 3 months
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/ICS), 0 (LABA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Rossi 2014 109/257 114/255 36.8 % 0.91 [ 0.64, 1.29 ]
SCO100470 2006 272/452 291/463 63.2 % 0.89 [ 0.68, 1.17 ]
Subtotal (95% CI) 709 718 100.0 % 0.90 [ 0.73, 1.11 ]
Total events: 381 (LABA/ICS), 405 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 709 718 100.0 % 0.90 [ 0.73, 1.11 ]
Total events: 381 (LABA/ICS), 405 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 LABA/ICS vs LABA, Outcome 4 SGRQ responders at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 4 SGRQ responders at 6 months
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA/ICS), 0 (LABA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Calverley 2007 417/1009 379/1021 44.9 % 1.19 [ 1.00, 1.43 ]
Rossi 2014 118/242 118/238 11.1 % 0.97 [ 0.68, 1.38 ]
SCO100470 2006 266/413 281/422 17.5 % 0.91 [ 0.68, 1.21 ]
Tashkin 2012a%b 441/841 218/432 26.5 % 1.08 [ 0.86, 1.37 ]
Subtotal (95% CI) 2505 2113 100.0 % 1.08 [ 0.96, 1.22 ]
Total events: 1242 (LABA/ICS), 996 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.98, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Total (95% CI) 2505 2113 100.0 % 1.08 [ 0.96, 1.22 ]
Total events: 1242 (LABA/ICS), 996 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.98, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 LABA/ICS vs LABA, Outcome 5 SGRQ responders at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 5 SGRQ responders at 12 months
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Calverley 2003 TRISTAN 147/320 149/320 23.4 % 0.98 [ 0.71, 1.33 ]
Calverley 2010 111/470 59/233 20.8 % 0.91 [ 0.63, 1.31 ]
Kardos 2007 211/507 146/487 25.8 % 1.66 [ 1.28, 2.16 ]
Subtotal (95% CI) 1297 1040 70.0 % 1.15 [ 0.78, 1.72 ]
Total events: 469 (LABA/ICS), 354 (LABA)
Heterogeneity: Tau2 = 0.10; Chi2 = 9.85, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Low-risk
Calverley 2007 424/993 351/1019 30.0 % 1.42 [ 1.18, 1.70 ]
Subtotal (95% CI) 993 1019 30.0 % 1.42 [ 1.18, 1.70 ]
Total events: 424 (LABA/ICS), 351 (LABA)
Heterogeneity: not applicable
Test for overall effect: Z = 3.80 (P = 0.00015)
Total (95% CI) 2290 2059 100.0 % 1.24 [ 0.95, 1.60 ]
Total events: 893 (LABA/ICS), 705 (LABA)
Heterogeneity: Tau2 = 0.05; Chi2 = 11.22, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Chi2 = 0.85, df = 1 (P = 0.36), I2 =0.0%
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Analysis 5.6. Comparison 5 LABA/ICS vs LABA, Outcome 6 SGRQ responders at 3 years.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 6 SGRQ responders at 3 years
Study or subgroup LABA/ICS LABA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
2 Low-risk
Calverley 2007 275/932 252/984 1.15 [ 1.00, 1.33 ]
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Analysis 5.7. Comparison 5 LABA/ICS vs LABA, Outcome 7 Change from baseline in SGRQ at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 7 Change from baseline in SGRQ at 3 months
Study or subgroup LABA/ICS LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Anzueto 2009 314 -0.04 (9.87) 289 2.24 (9.47) 37.7 % -2.28 [ -3.82, -0.74 ]
Ferguson 2008 343 -0.38 (23.61) 313 -0.02 (22.4) 7.2 % -0.36 [ -3.88, 3.16 ]
Fukuchi 2013 636 -4.37 (19.1) 657 -2.9 (19.4) 20.4 % -1.47 [ -3.57, 0.63 ]
Subtotal (95% CI) 1293 1259 65.3 % -1.81 [ -2.99, -0.64 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.11, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0024)
2 Low-risk
SCO100470 2006 518 -8.8 (13.2) 532 -7.8 (13.38) 34.7 % -1.00 [ -2.61, 0.61 ]
Subtotal (95% CI) 518 532 34.7 % -1.00 [ -2.61, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 1811 1791 100.0 % -1.53 [ -2.48, -0.58 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.75, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Chi2 = 0.64, df = 1 (P = 0.42), I2 =0.0%
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Analysis 5.8. Comparison 5 LABA/ICS vs LABA, Outcome 8 Change from baseline in SGRQ at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 8 Change from baseline in SGRQ at 6 months
Study or subgroup LABA/ICS LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Anzueto 2009 285 -0.83 (11.09) 259 1.46 (10.57) 9.8 % -2.29 [ -4.11, -0.47 ]
Calverley 2003 TRISTAN 271 -3.4 (11.9) 268 -3.8 (10.8) 8.9 % 0.40 [ -1.52, 2.32 ]
Ferguson 2008 309 0.09 (23.34) 271 -0.18 (22.09) 2.7 % 0.27 [ -3.43, 3.97 ]
Ferguson 2017 589 -0.855 (8.941) 593 0.44 (9.452) 22.3 % -1.30 [ -2.35, -0.25 ]
Tashkin 2008 558 -4.1 (12.04) 284 -1.24 (11.35) 11.4 % -2.86 [ -4.52, -1.20 ]
Subtotal (95% CI) 2012 1675 55.0 % -1.40 [ -2.53, -0.26 ]
Heterogeneity: Tau2 = 0.80; Chi2 = 8.09, df = 4 (P = 0.09); I2 =51%
Test for overall effect: Z = 2.42 (P = 0.016)
2 Low-risk
Calverley 2007 941 -3.4 (11.35) 906 -2.1 (11.14) 22.9 % -1.30 [ -2.33, -0.27 ]
SCO100470 2006 518 -10.3 (15.25) 532 -9.7 (15.22) 9.6 % -0.60 [ -2.44, 1.24 ]
Tashkin 2012a 403 -6.58 (14.74) 201 -6.18 (14.72) 5.6 % -0.40 [ -2.89, 2.09 ]
Tashkin 2012b 438 -7.05 (13.98) 231 -4.93 (13.95) 6.9 % -2.12 [ -4.34, 0.10 ]
Subtotal (95% CI) 2300 1870 45.0 % -1.18 [ -1.97, -0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.49, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 2.94 (P = 0.0032)
Total (95% CI) 4312 3545 100.0 % -1.32 [ -1.94, -0.70 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 9.82, df = 8 (P = 0.28); I2 =19%
Test for overall effect: Z = 4.17 (P = 0.000030)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
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Analysis 5.9. Comparison 5 LABA/ICS vs LABA, Outcome 9 Change from baseline in SGRQ at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 9 Change from baseline in SGRQ at 12 months
Study or subgroup LABA/ICS LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Anzueto 2009 251 -1.16 (11.14) 237 2.17 (10.82) 10.4 % -3.33 [ -5.28, -1.38 ]
Calverley 2003 TRISTAN 237 -4.5 (12.9) 224 -2.4 (10.9) 8.6 % -2.10 [ -4.28, 0.08 ]
Calverley 2010 470 -4.02 (12.94) 233 -2.9 (13.28) 9.4 % -1.12 [ -3.19, 0.95 ]
Ferguson 2008 268 0.09 (22.48) 268 -0.9 (23.28) 3.0 % 0.99 [ -2.88, 4.86 ]
Kardos 2007 408 -2.9 (17.8) 384 -0.7 (17.2) 7.1 % -2.20 [ -4.64, 0.24 ]
Rennard 2009 895 -4.61 (13.62) 446 -2.9 (13.3) 15.4 % -1.71 [ -3.23, -0.19 ]
Sharafkhaneh 2012 741 -5.62 (15.43) 357 -5.71 (15.31) 10.5 % 0.09 [ -1.85, 2.03 ]
Wedzicha 2014 595 -3.55 (15.61) 591 -0.77 (15.39) 12.2 % -2.78 [ -4.54, -1.02 ]
Subtotal (95% CI) 3865 2740 76.7 % -1.75 [ -2.61, -0.89 ]
Heterogeneity: Tau2 = 0.44; Chi2 = 9.80, df = 7 (P = 0.20); I2 =29%
Test for overall effect: Z = 3.97 (P = 0.000071)
2 Low-risk
Calverley 2007 873 -3.7 (11.82) 844 -2 (11.91) 23.3 % -1.70 [ -2.82, -0.58 ]
Subtotal (95% CI) 873 844 23.3 % -1.70 [ -2.82, -0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0030)
Total (95% CI) 4738 3584 100.0 % -1.75 [ -2.44, -1.06 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 9.81, df = 8 (P = 0.28); I2 =18%
Test for overall effect: Z = 4.97 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
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Analysis 5.10. Comparison 5 LABA/ICS vs LABA, Outcome 10 Change from baseline in SGRQ at 3 years.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 10 Change from baseline in SGRQ at 3 years
Study or subgroup LABA/ICS LABA
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Calverley 2007 681 -1.2 (13.31) 634 1 (13.09) -2.20 [ -3.63, -0.77 ]
2 Low-risk
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Analysis 5.11. Comparison 5 LABA/ICS vs LABA, Outcome 11 TDI at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 11 TDI at 3 months
Study or subgroup LABA/ICS LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Hanania 2003 94 1.5 (3.23) 93 1.5 (2.91) 16.4 % 0.0 [ -0.88, 0.88 ]
Mahler 2002 87 1.9 (3.22) 92 1 (2.78) 16.4 % 0.90 [ 0.02, 1.78 ]
Rossi 2014 288 1.69 (8.64) 293 1.89 (8.54) 7.2 % -0.20 [ -1.60, 1.20 ]
SCO100470 2006 505 1.9 (2.697) 516 1.9 (2.726) 60.0 % 0.0 [ -0.33, 0.33 ]
Subtotal (95% CI) 974 994 100.0 % 0.13 [ -0.26, 0.52 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 3.72, df = 3 (P = 0.29); I2 =19%
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI) 974 994 100.0 % 0.13 [ -0.26, 0.52 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 3.72, df = 3 (P = 0.29); I2 =19%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 5.12. Comparison 5 LABA/ICS vs LABA, Outcome 12 TDI at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 12 TDI at 6 months
Study or subgroup LABA/ICS LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Hanania 2003 81 2.3 (3.03) 84 1.8 (3.31) 9.2 % 0.50 [ -0.47, 1.47 ]
Mahler 2002 71 2.3 (3.15) 79 1.4 (3.06) 8.7 % 0.90 [ -0.10, 1.90 ]
Rossi 2014 288 2.7 (9.37) 293 2.58 (9.29) 3.8 % 0.12 [ -1.40, 1.64 ]
SCO100470 2006 505 2.5 (2.697) 516 2.4 (2.726) 78.3 % 0.10 [ -0.23, 0.43 ]
Subtotal (95% CI) 945 972 100.0 % 0.21 [ -0.09, 0.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.62, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
Total (95% CI) 945 972 100.0 % 0.21 [ -0.09, 0.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.62, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 5.13. Comparison 5 LABA/ICS vs LABA, Outcome 13 Change from baseline in FEV1 at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 13 Change from baseline in FEV1 at 3 months
Study or subgroup LABA/ICS LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Anzueto 2009 340 -0.021 (0.313) 314 -0.05 (0.338) 3.4 % 0.03 [ -0.02, 0.08 ]
Calverley 2003 TRISTAN 309 0.134 (0.264) 326 0.08 (0.258) 5.1 % 0.06 [ 0.02, 0.10 ]
Ferguson 2008 352 0.022 (0.326) 315 -0.04 (0.286) 3.9 % 0.06 [ 0.02, 0.11 ]
Fukuchi 2013 636 0.044 (0.252) 657 0.01 (0.256) 11.0 % 0.03 [ 0.00, 0.06 ]
Wedzicha 2014 595 0.081 (0.244) 591 0.01 (0.219) 12.1 % 0.07 [ 0.04, 0.10 ]
Subtotal (95% CI) 2232 2203 35.5 % 0.05 [ 0.03, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.29, df = 4 (P = 0.26); I2 =24%
Test for overall effect: Z = 5.40 (P < 0.00001)
2 Low-risk
Hanania 2003 144 0.166 (0.246) 135 0.11 (0.216) 2.9 % 0.06 [ 0.00, 0.11 ]
Hoshino 2013 16 0.115 (0.018) 14 0.06 (0.021) 42.4 % 0.05 [ 0.04, 0.07 ]
Mahler 2002 86 0.137 (0.179) 91 0.1 (0.222) 2.4 % 0.04 [ -0.02, 0.10 ]
Rossi 2014 288 0.074 (0.628) 293 0.04 (0.616) 0.8 % 0.03 [ -0.07, 0.13 ]
SCO100470 2006 508 0.074 (0.27) 517 0.05 (0.273) 7.6 % 0.03 [ -0.01, 0.06 ]
Tashkin 2012a 416 0.085 (0.271) 208 0 (0.27) 4.2 % 0.09 [ 0.04, 0.13 ]
Tashkin 2012b 443 0.08 (0.281) 235 0.05 (0.28) 4.3 % 0.03 [ -0.01, 0.08 ]
Subtotal (95% CI) 1901 1493 64.5 % 0.05 [ 0.04, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.35, df = 6 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 8.59 (P < 0.00001)
Total (95% CI) 4133 3696 100.0 % 0.05 [ 0.04, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.64, df = 11 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 10.75 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 5.14. Comparison 5 LABA/ICS vs LABA, Outcome 14 Change from baseline in FEV1 at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 14 Change from baseline in FEV1 at 6 months
Study or subgroup LABA/ICS LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Anzueto 2009 306 0.001 (0.427) 275 -0.05 (0.353) 4.3 % 0.05 [ -0.01, 0.12 ]
Calverley 2003 TRISTAN 298 0.122 (0.287) 310 0.05 (0.24) 9.8 % 0.07 [ 0.03, 0.11 ]
Ferguson 2008 321 -0.012 (3.297) 277 -0.06 (2.713) 0.1 % 0.05 [ -0.43, 0.53 ]
Ferguson 2017 606 0.008 (0.21) 613 -0.03 (0.198) 33.1 % 0.03 [ 0.01, 0.06 ]
Ohar 2014 280 0.14 (0.351) 271 0.04 (0.313) 5.6 % 0.10 [ 0.04, 0.16 ]
SCO40041 2008 80 0.148 (0.769) 81 0.05 (0.738) 0.3 % 0.10 [ -0.13, 0.33 ]
Tashkin 2008 558 0.08 (0.206) 284 0.05 (0.19) 22.3 % 0.03 [ 0.00, 0.06 ]
Subtotal (95% CI) 2449 2111 75.5 % 0.05 [ 0.03, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 7.55, df = 6 (P = 0.27); I2 =21%
Test for overall effect: Z = 4.81 (P < 0.00001)
2 Low-risk
Hanania 2003 124 0.165 (0.289) 119 0.1 (0.259) 3.7 % 0.06 [ -0.01, 0.13 ]
Mahler 2002 70 0.133 (0.133) 76 0.09 (0.197) 5.9 % 0.04 [ -0.01, 0.10 ]
Rossi 2014 288 0.039 (0.662) 293 0.02 (0.65) 1.5 % 0.02 [ -0.08, 0.13 ]
SCO100470 2006 508 0.06 (0.293) 517 0.02 (0.296) 13.4 % 0.04 [ 0.00, 0.07 ]
Subtotal (95% CI) 990 1005 24.5 % 0.04 [ 0.01, 0.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.60, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0025)
Total (95% CI) 3439 3116 100.0 % 0.04 [ 0.03, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 8.18, df = 10 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 6.37 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 5.15. Comparison 5 LABA/ICS vs LABA, Outcome 15 Change from baseline in FEV1 at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 15 Change from baseline in FEV1 at 12 months
Study or subgroup LABA/ICS LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Anzueto 2009 269 -0.017 (0.349) 246 -0.1 (0.334) 7.8 % 0.08 [ 0.02, 0.14 ]
Calverley 2003 TRISTAN 269 0.113 (0.286) 255 0.02 (0.255) 11.3 % 0.10 [ 0.05, 0.14 ]
Calverley 2010 470 0.08 (0.28) 233 0.03 (0.28) 12.2 % 0.05 [ 0.01, 0.09 ]
Ferguson 2008 276 -0.012 (0.375) 235 -0.08 (0.261) 8.6 % 0.07 [ 0.01, 0.13 ]
Kardos 2007 408 0.07 (0.343) 384 0.05 (0.333) 11.0 % 0.02 [ -0.03, 0.07 ]
Rennard 2009 121 0.1 (0.11) 124 0.06 (0.11) 21.4 % 0.04 [ 0.01, 0.07 ]
SCO40041 2008 73 0.095 (0.769) 68 0.05 (0.734) 0.5 % 0.05 [ -0.20, 0.29 ]
Sharafkhaneh 2012 798 0.07 (0.175) 399 0.04 (0.17) 27.3 % 0.03 [ 0.01, 0.05 ]
Subtotal (95% CI) 2684 1944 100.0 % 0.05 [ 0.03, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 10.41, df = 7 (P = 0.17); I2 =33%
Test for overall effect: Z = 5.22 (P < 0.00001)
2 Low-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2684 1944 100.0 % 0.05 [ 0.03, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 10.41, df = 7 (P = 0.17); I2 =33%
Test for overall effect: Z = 5.22 (P < 0.00001)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
LABA LABA/ICS
375Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.16. Comparison 5 LABA/ICS vs LABA, Outcome 16 Change from baseline in FEV1 at 3 years.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 16 Change from baseline in FEV1 at 3 years
Study or subgroup LABA/ICS LABA
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
SCO40041 2008 56 0.111 (0.681) 55 0.08 (0.779) 0.04 [ -0.24, 0.31 ]
2 Low-risk
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Analysis 5.17. Comparison 5 LABA/ICS vs LABA, Outcome 17 Mortality.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 17 Mortality
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Anzueto 2009 4/385 6/393 1.9 % 0.68 [ 0.19, 2.42 ]
Calverley 2003 5/254 13/255 2.7 % 0.37 [ 0.13, 1.06 ]
Calverley 2003 TRISTAN 4/358 5/372 1.7 % 0.83 [ 0.22, 3.11 ]
Calverley 2010 6/470 0/233 0.4 % 6.53 [ 0.37, 116.50 ]
Ferguson 2008 6/391 3/385 1.5 % 1.98 [ 0.49, 7.99 ]
Ferguson 2017 4/606 4/613 1.6 % 1.01 [ 0.25, 4.06 ]
Fukuchi 2013 4/636 5/657 1.7 % 0.83 [ 0.22, 3.09 ]
Kardos 2007 7/507 9/487 3.0 % 0.74 [ 0.27, 2.01 ]
Ohar 2014 4/314 3/325 1.3 % 1.38 [ 0.31, 6.24 ]
Rennard 2009 9/989 2/494 1.3 % 2.26 [ 0.49, 10.50 ]
SCO40041 2008 5/92 7/94 2.1 % 0.71 [ 0.22, 2.34 ]
Sharafkhaneh 2012 16/815 10/403 4.7 % 0.79 [ 0.35, 1.75 ]
Szafranski 2003 6/208 6/201 2.3 % 0.97 [ 0.31, 3.04 ]
Tashkin 2008 7/558 1/284 0.7 % 3.60 [ 0.44, 29.37 ]
Wedzicha 2014 11/601 8/596 3.6 % 1.37 [ 0.55, 3.43 ]
Subtotal (95% CI) 7184 5792 30.5 % 0.95 [ 0.69, 1.30 ]
Total events: 98 (LABA/ICS), 82 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 10.56, df = 14 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
2 Low-risk
Calverley 2007 193/1533 205/1521 67.6 % 0.92 [ 0.75, 1.14 ]
Hanania 2003 0/178 0/177 Not estimable
Mahler 2002 0/165 0/160 Not estimable
Rossi 2014 2/288 0/293 0.3 % 5.12 [ 0.24, 107.16 ]
SCO100470 2006 3/518 3/532 1.2 % 1.03 [ 0.21, 5.11 ]
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(. . . Continued)
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Tashkin 2012a%b 1/888 1/452 0.4 % 0.51 [ 0.03, 8.15 ]
Subtotal (95% CI) 3570 3135 69.5 % 0.93 [ 0.76, 1.15 ]
Total events: 199 (LABA/ICS), 209 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.41, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 10754 8927 100.0 % 0.94 [ 0.79, 1.11 ]
Total events: 297 (LABA/ICS), 291 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.95, df = 18 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 5.18. Comparison 5 LABA/ICS vs LABA, Outcome 18 Total SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 18 Total SAE
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Anzueto 2009 82/394 71/403 5.8 % 1.23 [ 0.86, 1.75 ]
Calverley 2003 TRISTAN 62/358 69/372 5.1 % 0.92 [ 0.63, 1.34 ]
Calverley 2010 43/478 14/238 2.1 % 1.58 [ 0.85, 2.95 ]
Ferguson 2008 91/391 81/385 6.1 % 1.14 [ 0.81, 1.60 ]
Ferguson 2017 49/606 63/613 4.9 % 0.77 [ 0.52, 1.14 ]
Fukuchi 2013 43/636 45/657 4.1 % 0.99 [ 0.64, 1.52 ]
Kardos 2007 76/507 88/487 6.2 % 0.80 [ 0.57, 1.12 ]
Ohar 2014 75/314 82/325 5.6 % 0.93 [ 0.65, 1.33 ]
Rennard 2009 148/989 89/494 7.9 % 0.80 [ 0.60, 1.07 ]
SCO40041 2008 33/92 36/94 2.3 % 0.90 [ 0.50, 1.63 ]
Sharafkhaneh 2012 140/815 74/403 7.0 % 0.92 [ 0.68, 1.26 ]
Szafranski 2003 43/208 37/201 3.3 % 1.16 [ 0.71, 1.89 ]
Tashkin 2008 61/558 23/284 3.1 % 1.39 [ 0.84, 2.30 ]
Wedzicha 2014 106/601 94/596 7.3 % 1.14 [ 0.84, 1.55 ]
Subtotal (95% CI) 6947 5552 70.9 % 0.99 [ 0.89, 1.09 ]
Total events: 1052 (LABA/ICS), 866 (LABA)
Heterogeneity: Tau2 = 0.00; Chi2 = 13.07, df = 13 (P = 0.44); I2 =1%
Test for overall effect: Z = 0.27 (P = 0.78)
2 Low-risk
Calverley 2007 665/1533 617/1521 18.0 % 1.12 [ 0.97, 1.30 ]
Hanania 2003 8/178 5/177 0.7 % 1.62 [ 0.52, 5.05 ]
Mahler 2002 9/165 7/160 0.8 % 1.26 [ 0.46, 3.47 ]
Rossi 2014 17/288 5/293 0.8 % 3.61 [ 1.31, 9.93 ]
SCO100470 2006 35/518 29/532 3.1 % 1.26 [ 0.76, 2.09 ]
Tashkin 2012a%b 96/888 54/452 5.7 % 0.89 [ 0.63, 1.27 ]
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(. . . Continued)
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 3570 3135 29.1 % 1.17 [ 0.92, 1.47 ]
Total events: 830 (LABA/ICS), 717 (LABA)
Heterogeneity: Tau2 = 0.03; Chi2 = 7.38, df = 5 (P = 0.19); I2 =32%
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 10517 8687 100.0 % 1.03 [ 0.94, 1.13 ]
Total events: 1882 (LABA/ICS), 1583 (LABA)
Heterogeneity: Tau2 = 0.01; Chi2 = 23.04, df = 19 (P = 0.24); I2 =18%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 1.68, df = 1 (P = 0.20), I2 =40%
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Analysis 5.19. Comparison 5 LABA/ICS vs LABA, Outcome 19 COPD SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 19 COPD SAE
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Anzueto 2009 34/394 38/403 5.5 % 0.91 [ 0.56, 1.47 ]
Calverley 2003 40/254 55/255 6.3 % 0.68 [ 0.43, 1.07 ]
Calverley 2003 TRISTAN 38/358 39/372 5.8 % 1.01 [ 0.63, 1.63 ]
Ferguson 2008 37/391 39/385 5.7 % 0.93 [ 0.58, 1.49 ]
Ferguson 2017 2/606 0/613 0.1 % 5.07 [ 0.24, 105.92 ]
Fukuchi 2013 24/636 28/657 4.2 % 0.88 [ 0.50, 1.54 ]
Ohar 2014 47/314 51/325 6.9 % 0.95 [ 0.61, 1.45 ]
0.01 0.1 1 10 100
Favours LABA/ICS Favours LABA
(Continued . . . )
380Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rennard 2009 68/989 39/494 7.7 % 0.86 [ 0.57, 1.30 ]
SCO40041 2008 11/92 11/94 1.6 % 1.02 [ 0.42, 2.50 ]
Sharafkhaneh 2012 65/815 34/403 6.9 % 0.94 [ 0.61, 1.45 ]
Tashkin 2008 30/558 11/284 2.6 % 1.41 [ 0.70, 2.86 ]
Subtotal (95% CI) 5407 4285 53.3 % 0.92 [ 0.78, 1.07 ]
Total events: 396 (LABA/ICS), 345 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.72, df = 10 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
2 Low-risk
Calverley 2007 298/1533 307/1521 40.6 % 0.95 [ 0.80, 1.14 ]
Hanania 2003 0/178 2/177 0.1 % 0.20 [ 0.01, 4.13 ]
Mahler 2002 2/165 2/160 0.3 % 0.97 [ 0.13, 6.97 ]
Rossi 2014 3/288 1/293 0.2 % 3.07 [ 0.32, 29.72 ]
SCO100470 2006 5/518 10/532 1.1 % 0.51 [ 0.17, 1.50 ]
Tashkin 2012a%b 40/888 20/452 4.3 % 1.02 [ 0.59, 1.76 ]
Subtotal (95% CI) 3570 3135 46.7 % 0.95 [ 0.80, 1.12 ]
Total events: 348 (LABA/ICS), 342 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.41, df = 5 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 8977 7420 100.0 % 0.93 [ 0.83, 1.04 ]
Total events: 744 (LABA/ICS), 687 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.21, df = 16 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.77), I2 =0.0%
0.01 0.1 1 10 100
Favours LABA/ICS Favours LABA
381Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.20. Comparison 5 LABA/ICS vs LABA, Outcome 20 Cardiac SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 20 Cardiac SAE
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Anzueto 2009 16/394 19/403 8.3 % 0.86 [ 0.43, 1.69 ]
Calverley 2003 TRISTAN 11/358 22/372 7.5 % 0.50 [ 0.24, 1.06 ]
Ferguson 2008 17/391 12/385 7.3 % 1.41 [ 0.67, 3.00 ]
Ferguson 2017 12/606 12/613 6.6 % 1.01 [ 0.45, 2.27 ]
Fukuchi 2013 3/636 5/657 2.7 % 0.62 [ 0.15, 2.60 ]
Ohar 2014 10/314 23/325 7.2 % 0.43 [ 0.20, 0.92 ]
Rennard 2009 19/989 14/494 8.1 % 0.67 [ 0.33, 1.35 ]
SCO40041 2008 9/92 8/94 4.9 % 1.17 [ 0.43, 3.17 ]
Sharafkhaneh 2012 30/815 9/403 7.3 % 1.67 [ 0.79, 3.56 ]
Tashkin 2008 7/558 3/284 2.9 % 1.19 [ 0.31, 4.64 ]
Wedzicha 2014 18/601 5/596 4.9 % 3.65 [ 1.35, 9.89 ]
Subtotal (95% CI) 5754 4626 67.7 % 0.97 [ 0.68, 1.38 ]
Total events: 152 (LABA/ICS), 132 (LABA)
Heterogeneity: Tau2 = 0.16; Chi2 = 18.87, df = 10 (P = 0.04); I2 =47%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Low-risk
Calverley 2007 160/1533 168/1521 18.3 % 0.94 [ 0.75, 1.18 ]
Hanania 2003 2/178 0/177 0.7 % 5.03 [ 0.24, 105.49 ]
Mahler 2002 0/165 2/160 0.7 % 0.19 [ 0.01, 4.02 ]
Rossi 2014 5/288 1/293 1.3 % 5.16 [ 0.60, 44.43 ]
SCO100470 2006 9/518 7/532 4.9 % 1.33 [ 0.49, 3.59 ]
Tashkin 2012a%b 16/888 9/452 6.5 % 0.90 [ 0.40, 2.06 ]
Subtotal (95% CI) 3570 3135 32.3 % 0.97 [ 0.78, 1.21 ]
Total events: 192 (LABA/ICS), 187 (LABA)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.02, df = 5 (P = 0.41); I2 =0%
Test for overall effect: Z = 0.28 (P = 0.78)
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Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 9324 7761 100.0 % 0.99 [ 0.77, 1.27 ]
Total events: 344 (LABA/ICS), 319 (LABA)
Heterogeneity: Tau2 = 0.08; Chi2 = 23.92, df = 16 (P = 0.09); I2 =33%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 5.21. Comparison 5 LABA/ICS vs LABA, Outcome 21 Dropouts due to adverse events.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 21 Dropouts due to adverse events
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Anzueto 2009 37/394 39/403 4.5 % 0.97 [ 0.60, 1.55 ]
Calverley 2003 20/254 20/255 2.4 % 1.00 [ 0.53, 1.92 ]
Calverley 2003 TRISTAN 46/358 61/372 5.9 % 0.75 [ 0.50, 1.14 ]
Calverley 2010 15/478 5/238 1.0 % 1.51 [ 0.54, 4.20 ]
Ferguson 2008 26/391 33/385 3.5 % 0.76 [ 0.45, 1.30 ]
Ferguson 2017 3/606 5/613 0.5 % 0.60 [ 0.14, 2.54 ]
Fukuchi 2013 21/636 28/657 3.0 % 0.77 [ 0.43, 1.37 ]
Kardos 2007 61/507 61/487 7.0 % 0.96 [ 0.65, 1.40 ]
Ohar 2014 28/314 28/325 3.3 % 1.04 [ 0.60, 1.80 ]
Rennard 2009 117/989 60/494 9.1 % 0.97 [ 0.70, 1.35 ]
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Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SCO40041 2008 15/92 13/94 1.5 % 1.21 [ 0.54, 2.72 ]
Sharafkhaneh 2012 79/815 50/403 7.1 % 0.76 [ 0.52, 1.10 ]
Szafranski 2003 16/208 12/201 1.7 % 1.31 [ 0.60, 2.85 ]
Tashkin 2008 41/558 34/284 4.4 % 0.58 [ 0.36, 0.94 ]
Wedzicha 2014 26/601 28/596 3.4 % 0.92 [ 0.53, 1.58 ]
Subtotal (95% CI) 7201 5807 58.2 % 0.88 [ 0.77, 1.00 ]
Total events: 551 (LABA/ICS), 477 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.67, df = 14 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.047)
2 Low-risk
Calverley 2007 289/1533 303/1521 31.2 % 0.93 [ 0.78, 1.12 ]
Hanania 2003 9/178 6/177 0.9 % 1.52 [ 0.53, 4.36 ]
Mahler 2002 11/165 11/160 1.3 % 0.97 [ 0.41, 2.30 ]
Rossi 2014 14/288 14/293 1.7 % 1.02 [ 0.48, 2.18 ]
SCO100470 2006 25/518 37/532 3.7 % 0.68 [ 0.40, 1.14 ]
Tashkin 2012a%b 28/888 20/452 2.9 % 0.70 [ 0.39, 1.26 ]
Subtotal (95% CI) 3570 3135 41.8 % 0.90 [ 0.77, 1.06 ]
Total events: 376 (LABA/ICS), 391 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.04, df = 5 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Total (95% CI) 10771 8942 100.0 % 0.89 [ 0.80, 0.98 ]
Total events: 927 (LABA/ICS), 868 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.80, df = 20 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.76), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours LABA/ICS Favours LABA
384Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.22. Comparison 5 LABA/ICS vs LABA, Outcome 22 Pneumonia.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 5 LABA/ICS vs LABA
Outcome: 22 Pneumonia
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Anzueto 2009 13/394 8/403 6.8 % 1.68 [ 0.69, 4.11 ]
Calverley 2003 8/254 7/255 5.4 % 1.15 [ 0.41, 3.23 ]
Calverley 2003 TRISTAN 7/358 9/372 5.7 % 0.80 [ 0.30, 2.18 ]
Calverley 2010 12/470 1/233 1.5 % 6.08 [ 0.79, 47.03 ]
Ferguson 2008 18/391 5/385 5.7 % 3.67 [ 1.35, 9.98 ]
Ferguson 2017 0/606 5/613 0.8 % 0.09 [ 0.01, 1.65 ]
Fukuchi 2013 2/636 1/657 1.1 % 2.07 [ 0.19, 22.88 ]
Kardos 2007 23/507 7/487 7.3 % 3.26 [ 1.39, 7.67 ]
Ohar 2014 7/314 5/325 4.4 % 1.46 [ 0.46, 4.65 ]
Rennard 2009 10/989 8/494 6.3 % 0.62 [ 0.24, 1.58 ]
SCO40041 2008 7/92 7/94 4.9 % 1.02 [ 0.34, 3.04 ]
Sharafkhaneh 2012 17/815 7/403 6.9 % 1.21 [ 0.50, 2.93 ]
Tashkin 2008 3/558 1/284 1.3 % 1.53 [ 0.16, 14.77 ]
Wedzicha 2014 15/601 9/596 7.6 % 1.67 [ 0.72, 3.85 ]
Subtotal (95% CI) 6985 5601 65.8 % 1.46 [ 1.03, 2.08 ]
Total events: 142 (LABA/ICS), 80 (LABA)
Heterogeneity: Tau2 = 0.11; Chi2 = 17.69, df = 13 (P = 0.17); I2 =26%
Test for overall effect: Z = 2.11 (P = 0.035)
2 Low-risk
Calverley 2007 138/1533 82/1521 25.0 % 1.74 [ 1.31, 2.30 ]
Hanania 2003 0/178 1/177 0.6 % 0.33 [ 0.01, 8.15 ]
Mahler 2002 2/165 0/160 0.7 % 4.91 [ 0.23, 103.04 ]
Rossi 2014 2/288 0/293 0.7 % 5.12 [ 0.24, 107.16 ]
SCO100470 2006 2/518 4/532 2.2 % 0.51 [ 0.09, 2.81 ]
Tashkin 2012a%b 10/888 5/452 5.0 % 1.02 [ 0.35, 3.00 ]
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(. . . Continued)
Study or subgroup LABA/ICS LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 3570 3135 34.2 % 1.64 [ 1.25, 2.14 ]
Total events: 154 (LABA/ICS), 92 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.70, df = 5 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.62 (P = 0.00029)
Total (95% CI) 10555 8736 100.0 % 1.48 [ 1.14, 1.92 ]
Total events: 296 (LABA/ICS), 172 (LABA)
Heterogeneity: Tau2 = 0.05; Chi2 = 22.64, df = 19 (P = 0.25); I2 =16%
Test for overall effect: Z = 2.96 (P = 0.0030)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
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Analysis 6.1. Comparison 6 LAMA vs LABA, Outcome 1 Moderate to severe exacerbations.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 1 Moderate to severe exacerbations
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Vogelmeier 2011 1277/3707 1414/3669 72.5 % 0.84 [ 0.76, 0.92 ]
Subtotal (95% CI) 3707 3669 72.5 % 0.84 [ 0.76, 0.92 ]
Total events: 1277 (LAMA), 1414 (LABA)
Heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.00026)
2 Low-risk
Bateman 2013 174/953 103/476 8.8 % 0.81 [ 0.62, 1.06 ]
Briggs 2005 30/328 36/325 2.5 % 0.81 [ 0.48, 1.35 ]
Brusasco 2003 129/402 142/405 7.6 % 0.88 [ 0.65, 1.17 ]
0.5 0.7 1 1.5 2
Favours LAMA Favours LABA
(Continued . . . )
386Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Donohue 2010 79/415 148/832 7.1 % 1.09 [ 0.80, 1.47 ]
Vogelmeier 2008 23/221 17/210 1.5 % 1.32 [ 0.68, 2.55 ]
Subtotal (95% CI) 2319 2248 27.5 % 0.92 [ 0.79, 1.07 ]
Total events: 435 (LAMA), 446 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.52, df = 4 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 6026 5917 100.0 % 0.86 [ 0.79, 0.93 ]
Total events: 1712 (LAMA), 1860 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.47, df = 5 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.69 (P = 0.00023)
Test for subgroup differences: Chi2 = 0.94, df = 1 (P = 0.33), I2 =0.0%
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Analysis 6.2. Comparison 6 LAMA vs LABA, Outcome 2 Severe exacerbations.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 2 Severe exacerbations
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Vogelmeier 2011 503/3707 553/3669 55.0 % 0.88 [ 0.78, 1.01 ]
Subtotal (95% CI) 3707 3669 55.0 % 0.88 [ 0.78, 1.01 ]
Total events: 503 (LAMA), 553 (LABA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.065)
2 Low-risk
Bateman 2013 14/953 12/476 16.2 % 0.58 [ 0.26, 1.26 ]
Briggs 2005 4/328 9/325 8.2 % 0.43 [ 0.13, 1.42 ]
Brusasco 2003 12/402 20/405 17.8 % 0.59 [ 0.29, 1.23 ]
Vogelmeier 2008 5/221 1/210 2.8 % 4.84 [ 0.56, 41.76 ]
Subtotal (95% CI) 1904 1416 45.0 % 0.64 [ 0.36, 1.13 ]
Total events: 35 (LAMA), 42 (LABA)
Heterogeneity: Tau2 = 0.08; Chi2 = 3.93, df = 3 (P = 0.27); I2 =24%
Test for overall effect: Z = 1.55 (P = 0.12)
Total (95% CI) 5611 5085 100.0 % 0.76 [ 0.53, 1.10 ]
Total events: 538 (LAMA), 595 (LABA)
Heterogeneity: Tau2 = 0.06; Chi2 = 5.94, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Chi2 = 1.21, df = 1 (P = 0.27), I2 =18%
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Analysis 6.3. Comparison 6 LAMA vs LABA, Outcome 3 SGRQ responders at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 3 SGRQ responders at 3 months
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Decramer 2013 725/1503 732/1496 53.2 % 0.97 [ 0.84, 1.12 ]
Subtotal (95% CI) 1503 1496 53.2 % 0.97 [ 0.84, 1.12 ]
Total events: 725 (LAMA), 732 (LABA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
2 Low-risk
Buhl 2011 320/753 375/743 46.8 % 0.73 [ 0.59, 0.89 ]
Subtotal (95% CI) 753 743 46.8 % 0.73 [ 0.59, 0.89 ]
Total events: 320 (LAMA), 375 (LABA)
Heterogeneity: not applicable
Test for overall effect: Z = 3.09 (P = 0.0020)
Total (95% CI) 2256 2239 100.0 % 0.85 [ 0.64, 1.13 ]
Total events: 1045 (LAMA), 1107 (LABA)
Heterogeneity: Tau2 = 0.03; Chi2 = 5.33, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 5.33, df = 1 (P = 0.02), I2 =81%
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Analysis 6.4. Comparison 6 LAMA vs LABA, Outcome 4 SGRQ responders at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 4 SGRQ responders at 6 months
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Decramer 2013 707/1421 673/1408 18.9 % 1.08 [ 0.93, 1.25 ]
Subtotal (95% CI) 1421 1408 18.9 % 1.08 [ 0.93, 1.25 ]
Total events: 707 (LAMA), 673 (LABA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 Low-risk
Bateman 2013 514/880 279/443 12.4 % 0.83 [ 0.65, 1.04 ]
Brusasco 2003 174/356 153/354 9.3 % 1.26 [ 0.93, 1.69 ]
Buhl 2015a%b 465/955 427/954 16.2 % 1.17 [ 0.98, 1.40 ]
D’Urzo 2017 180/337 164/332 9.0 % 1.17 [ 0.87, 1.59 ]
Jones 2011 165/345 1042/1960 12.8 % 0.81 [ 0.64, 1.02 ]
Martinez 2017a 294/860 151/434 12.0 % 0.97 [ 0.76, 1.24 ]
Martinez 2017b 126/362 144/430 9.4 % 1.06 [ 0.79, 1.42 ]
Subtotal (95% CI) 4095 4907 81.1 % 1.02 [ 0.89, 1.16 ]
Total events: 1918 (LAMA), 2360 (LABA)
Heterogeneity: Tau2 = 0.02; Chi2 = 12.31, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 5516 6315 100.0 % 1.03 [ 0.92, 1.15 ]
Total events: 2625 (LAMA), 3033 (LABA)
Heterogeneity: Tau2 = 0.01; Chi2 = 12.80, df = 7 (P = 0.08); I2 =45%
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.54), I2 =0.0%
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Analysis 6.5. Comparison 6 LAMA vs LABA, Outcome 5 SGRQ responders at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 5 SGRQ responders at 12 months
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Decramer 2013 646/1314 626/1273 57.5 % 1.00 [ 0.86, 1.17 ]
Subtotal (95% CI) 1314 1273 57.5 % 1.00 [ 0.86, 1.17 ]
Total events: 646 (LAMA), 626 (LABA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 1.0)
2 Low-risk
Hanania 2017 490/1277 314/845 42.5 % 1.05 [ 0.88, 1.26 ]
Subtotal (95% CI) 1277 845 42.5 % 1.05 [ 0.88, 1.26 ]
Total events: 490 (LAMA), 314 (LABA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Total (95% CI) 2591 2118 100.0 % 1.02 [ 0.91, 1.15 ]
Total events: 1136 (LAMA), 940 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.67), I2 =0.0%
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Analysis 6.6. Comparison 6 LAMA vs LABA, Outcome 6 Change from baseline in SGRQ at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 6 Change from baseline in SGRQ at 3 months
Study or subgroup LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Decramer 2013 1514 -4.5 (12.7) 1505 -4.6 (13) 35.1 % 0.10 [ -0.82, 1.02 ]
Subtotal (95% CI) 1514 1505 35.1 % 0.10 [ -0.82, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
2 Low-risk
Bateman 2013 953 -7.56 (23.74) 476 -8.11 (23.05) 14.9 % 0.55 [ -2.01, 3.11 ]
Buhl 2011 753 -3 (11.64) 743 -5.1 (12.06) 30.7 % 2.10 [ 0.90, 3.30 ]
Donohue 2010 415 -3.5 (17.66) 832 -5.4 (17.67) 19.2 % 1.90 [ -0.18, 3.98 ]
Subtotal (95% CI) 2121 2051 64.9 % 1.84 [ 0.87, 2.80 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 3.74 (P = 0.00019)
Total (95% CI) 3635 3556 100.0 % 1.13 [ -0.09, 2.34 ]
Heterogeneity: Tau2 = 0.88; Chi2 = 7.71, df = 3 (P = 0.05); I2 =61%
Test for overall effect: Z = 1.82 (P = 0.069)
Test for subgroup differences: Chi2 = 6.55, df = 1 (P = 0.01), I2 =85%
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Analysis 6.7. Comparison 6 LAMA vs LABA, Outcome 7 Change from baseline in SGRQ at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 7 Change from baseline in SGRQ at 6 months
Study or subgroup LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Decramer 2013 1432 -5.2 (13.8) 1416 -4.5 (14.4) 33.4 % -0.70 [ -1.74, 0.34 ]
Subtotal (95% CI) 1432 1416 33.4 % -0.70 [ -1.74, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 Low-risk
Bateman 2013 880 -8.45 (23.36) 443 -8.72 (22.5) 6.0 % 0.27 [ -2.33, 2.87 ]
Brusasco 2003 402 -4.2 (14.03) 405 -2.8 (14.09) 10.5 % -1.40 [ -3.34, 0.54 ]
D’Urzo 2014 257 -6.44 (11.86) 254 -4.7 (11.79) 9.5 % -1.74 [ -3.79, 0.31 ]
Martinez 2017a 739 -1.84 (11.94) 371 -2.7 (11.94) 17.4 % 0.86 [ -0.63, 2.35 ]
Martinez 2017b 362 -2.2 (11.8) 352 -2.3 (11.82) 13.1 % 0.10 [ -1.63, 1.83 ]
Singh 2014 327 -5.8 (12.84) 332 -5.58 (12.94) 10.2 % -0.22 [ -2.19, 1.75 ]
Subtotal (95% CI) 2967 2157 66.6 % -0.25 [ -1.09, 0.58 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 5.82, df = 5 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.59 (P = 0.55)
Total (95% CI) 4399 3573 100.0 % -0.39 [ -1.03, 0.25 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 6.34, df = 6 (P = 0.39); I2 =5%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
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Analysis 6.8. Comparison 6 LAMA vs LABA, Outcome 8 Change from baseline in SGRQ at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 8 Change from baseline in SGRQ at 12 months
Study or subgroup LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Decramer 2013 1325 -4.9 (14.8) 1281 -4.5 (15.5) 37.0 % -0.40 [ -1.56, 0.76 ]
Subtotal (95% CI) 1325 1281 37.0 % -0.40 [ -1.56, 0.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Low-risk
D’Urzo 2017 337 -4.306 (15.55) 332 -4.06 (15.54) 9.0 % -0.25 [ -2.60, 2.11 ]
Hanania 2017 1277 -2.24 (11.051) 845 -2.4 (11.12) 54.0 % 0.16 [ -0.80, 1.12 ]
Subtotal (95% CI) 1614 1177 63.0 % 0.10 [ -0.79, 0.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
Total (95% CI) 2939 2458 100.0 % -0.08 [ -0.79, 0.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Chi2 = 0.45, df = 1 (P = 0.50), I2 =0.0%
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Analysis 6.9. Comparison 6 LAMA vs LABA, Outcome 9 TDI at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 9 TDI at 3 months
Study or subgroup LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Decramer 2013 1511 1.55 (0.15) 1513 1.69 (0.15) 40.6 % -0.14 [ -0.15, -0.13 ]
Subtotal (95% CI) 1511 1513 40.6 % -0.14 [ -0.15, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 25.66 (P < 0.00001)
2 Low-risk
Bateman 2013 953 1.92 (3.45) 476 2.18 (3.43) 19.3 % -0.26 [ -0.64, 0.12 ]
Buhl 2011 737 1.43 (4.83) 729 2.01 (4.81) 14.1 % -0.58 [ -1.07, -0.09 ]
Buhl 2015a%b 978 1.702 (3.033) 984 1.51 (3.043) 26.1 % 0.20 [ -0.07, 0.46 ]
Subtotal (95% CI) 2668 2189 59.4 % -0.18 [ -0.63, 0.27 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 8.82, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 4179 3702 100.0 % -0.14 [ -0.37, 0.09 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 9.44, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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Analysis 6.10. Comparison 6 LAMA vs LABA, Outcome 10 TDI at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 10 TDI at 6 months
Study or subgroup LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Decramer 2013 1436 1.46 (0.16) 1427 1.65 (0.16) 61.4 % -0.19 [ -0.20, -0.18 ]
Subtotal (95% CI) 1436 1427 61.4 % -0.19 [ -0.20, -0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 31.77 (P < 0.00001)
2 Low-risk
Bateman 2013 953 2.36 (2.79) 476 2.47 (2.76) 12.5 % -0.11 [ -0.41, 0.19 ]
Buhl 2015a%b 978 1.627 (3.002) 984 1.56 (3.01) 15.4 % 0.07 [ -0.20, 0.33 ]
D’Urzo 2014 263 1.56 (3.24) 263 1.52 (3.24) 4.4 % 0.04 [ -0.51, 0.59 ]
Singh 2014 331 2.11 (3.09) 333 2.06 (2.92) 6.3 % 0.05 [ -0.41, 0.51 ]
Subtotal (95% CI) 2525 2056 38.6 % 0.00 [ -0.17, 0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.81, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.96)
Total (95% CI) 3961 3483 100.0 % -0.12 [ -0.24, 0.01 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.55, df = 4 (P = 0.24); I2 =28%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Chi2 = 4.74, df = 1 (P = 0.03), I2 =79%
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Analysis 6.11. Comparison 6 LAMA vs LABA, Outcome 11 TDI at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 11 TDI at 12 months
Study or subgroup LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Decramer 2013 1322 1.75 (0.16) 1288 2.01 (0.17) 33.6 % -0.26 [ -0.27, -0.25 ]
Subtotal (95% CI) 1322 1288 33.6 % -0.26 [ -0.27, -0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 40.21 (P < 0.00001)
2 Low-risk
Buhl 2015a%b 978 1.736 (3.159) 984 1.41 (3.168) 24.6 % 0.32 [ 0.05, 0.60 ]
D’Urzo 2017 337 1.596 (4.42) 332 1.32 (4.48) 10.7 % 0.27 [ -0.40, 0.95 ]
Hanania 2017 1309 0.3 (1.54) 871 0.3 (1.51) 31.1 % 0.0 [ -0.13, 0.13 ]
Subtotal (95% CI) 2624 2187 66.4 % 0.15 [ -0.11, 0.40 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 4.63, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 3946 3475 100.0 % 0.02 [ -0.25, 0.29 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 34.08, df = 3 (P<0.00001); I2 =91%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Chi2 = 9.67, df = 1 (P = 0.00), I2 =90%
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Analysis 6.12. Comparison 6 LAMA vs LABA, Outcome 12 Change from baseline in FEV1 at 3 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 12 Change from baseline in FEV1 at 3 months
Study or subgroup LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Briggs 2005 328 0.088 (0.181) 325 0.07 (0.198) 13.4 % 0.02 [ -0.01, 0.05 ]
Buhl 2011 595 0.12 (0.244) 562 0.13 (0.237) 13.7 % -0.01 [ -0.04, 0.02 ]
Buhl 2015a 520 0.07 (0.205) 519 0.06 (0.205) 14.4 % 0.01 [ -0.01, 0.04 ]
Buhl 2015b 498 0.088 (0.201) 503 0.05 (0.202) 14.4 % 0.04 [ 0.02, 0.07 ]
Donohue 2010 349 0.15 (0.227) 700 0.17 (0.263) 12.9 % -0.02 [ -0.05, 0.01 ]
Hoshino 2013 15 0.044 (0.012) 14 0.06 (0.021) 17.2 % -0.02 [ -0.03, -0.01 ]
Hoshino 2014 16 0.056 (0.119) 20 0.14 (0.0149) 7.3 % -0.08 [ -0.14, -0.02 ]
Mahler 2016 229 0.104 (0.34) 227 0.09 (0.339) 6.7 % 0.01 [ -0.05, 0.08 ]
Subtotal (95% CI) 2550 2870 100.0 % 0.00 [ -0.02, 0.02 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 29.49, df = 7 (P = 0.00012); I2 =76%
Test for overall effect: Z = 0.21 (P = 0.84)
Total (95% CI) 2550 2870 100.0 % 0.00 [ -0.02, 0.02 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 29.49, df = 7 (P = 0.00012); I2 =76%
Test for overall effect: Z = 0.21 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 6.13. Comparison 6 LAMA vs LABA, Outcome 13 Change from baseline in FEV1 at 6 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 13 Change from baseline in FEV1 at 6 months
Study or subgroup LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Bateman 2013 424 0.08 (0.494) 435 0.09 (0.501) 3.3 % -0.01 [ -0.08, 0.06 ]
Brusasco 2003 209 -0.013 (0.188) 213 -0.01 (0.19) 9.1 % 0.00 [ -0.04, 0.04 ]
Buhl 2015a 520 0.05 (0.205) 519 0.03 (0.205) 14.4 % 0.02 [ -0.01, 0.04 ]
Buhl 2015b 498 0.068 (0.201) 503 0.03 (0.202) 14.4 % 0.03 [ 0.01, 0.06 ]
D’Urzo 2014 266 0.066 (0.196) 268 0.05 (0.196) 10.1 % 0.02 [ -0.02, 0.05 ]
Donohue 2010 321 0.13 (0.235) 651 0.14 (0.277) 10.1 % -0.01 [ -0.04, 0.02 ]
Mahler 2016 229 0.079 (0.4) 227 0.09 (0.398) 2.8 % -0.01 [ -0.08, 0.07 ]
Martinez 2017a 734 0.09 (0.2) 367 0.06 (0.203) 14.2 % 0.03 [ 0.00, 0.05 ]
Martinez 2017b 367 0.063 (0.209) 350 0.06 (0.208) 11.4 % 0.00 [ -0.03, 0.03 ]
Singh 2014 332 0.056 (0.219) 337 0 (0.22) 10.1 % 0.06 [ 0.02, 0.09 ]
Subtotal (95% CI) 3900 3870 100.0 % 0.02 [ 0.00, 0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 13.43, df = 9 (P = 0.14); I2 =33%
Test for overall effect: Z = 2.69 (P = 0.0071)
Total (95% CI) 3900 3870 100.0 % 0.02 [ 0.00, 0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 13.43, df = 9 (P = 0.14); I2 =33%
Test for overall effect: Z = 2.69 (P = 0.0071)
Test for subgroup differences: Not applicable
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Analysis 6.14. Comparison 6 LAMA vs LABA, Outcome 14 Change from baseline in FEV1 at 12 months.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 14 Change from baseline in FEV1 at 12 months
Study or subgroup LAMA LABA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low-risk
Buhl 2015a 520 0.036 (0.205) 519 0 (0.205) 19.5 % 0.04 [ 0.01, 0.06 ]
Buhl 2015b 498 0.04 (0.201) 503 0.01 (0.202) 19.5 % 0.03 [ 0.00, 0.05 ]
D’Urzo 2017 337 0.03 (0.275) 332 0 (0.273) 7.0 % 0.03 [ -0.02, 0.07 ]
Hanania 2017 1317 0.086 (0.181) 871 0.07 (0.181) 50.5 % 0.02 [ 0.00, 0.03 ]
Mahler 2016 229 0.056 (0.319) 227 0.06 (0.321) 3.5 % 0.00 [ -0.06, 0.05 ]
Subtotal (95% CI) 2901 2452 100.0 % 0.02 [ 0.01, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.49, df = 4 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.17 (P = 0.000030)
Total (95% CI) 2901 2452 100.0 % 0.02 [ 0.01, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.49, df = 4 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.17 (P = 0.000030)
Test for subgroup differences: Not applicable
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Analysis 6.15. Comparison 6 LAMA vs LABA, Outcome 15 Mortality.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 15 Mortality
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Decramer 2013 26/1718 24/1721 20.2 % 1.09 [ 0.62, 1.90 ]
Vogelmeier 2011 64/3707 78/3669 56.7 % 0.81 [ 0.58, 1.13 ]
Subtotal (95% CI) 5425 5390 76.9 % 0.87 [ 0.66, 1.16 ]
Total events: 90 (LAMA), 102 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
2 Low-risk
Bateman 2013 4/953 2/476 2.2 % 1.00 [ 0.18, 5.47 ]
Briggs 2005 1/328 0/325 0.6 % 2.98 [ 0.12, 73.46 ]
Brusasco 2003 1/402 6/405 1.4 % 0.17 [ 0.02, 1.38 ]
Buhl 2011 2/801 0/797 0.7 % 4.99 [ 0.24, 104.05 ]
Buhl 2015a%b 17/1033 14/1038 12.4 % 1.22 [ 0.60, 2.50 ]
D’Urzo 2014 3/337 1/332 1.2 % 2.97 [ 0.31, 28.73 ]
D’Urzo 2017 0/194 0/192 Not estimable
Donohue 2010 2/415 1/832 1.1 % 4.02 [ 0.36, 44.51 ]
Hanania 2017 5/1341 2/890 2.3 % 1.66 [ 0.32, 8.58 ]
Mahler 2016 2/251 1/256 1.1 % 2.05 [ 0.18, 22.73 ]
Vogelmeier 2008 0/221 0/210 Not estimable
Subtotal (95% CI) 6276 5753 23.1 % 1.33 [ 0.79, 2.25 ]
Total events: 37 (LAMA), 27 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.35, df = 8 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
Total (95% CI) 11701 11143 100.0 % 0.96 [ 0.75, 1.24 ]
Total events: 127 (LAMA), 129 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.02, df = 10 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 1.91, df = 1 (P = 0.17), I2 =48%
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Analysis 6.16. Comparison 6 LAMA vs LABA, Outcome 16 Total SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 16 Total SAE
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Decramer 2013 255/1718 263/1721 19.2 % 0.97 [ 0.80, 1.16 ]
Vogelmeier 2011 545/3707 606/3669 42.2 % 0.87 [ 0.77, 0.99 ]
Subtotal (95% CI) 5425 5390 61.4 % 0.90 [ 0.81, 1.00 ]
Total events: 800 (LAMA), 869 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
2 Low-risk
Bateman 2013 48/953 26/476 2.8 % 0.92 [ 0.56, 1.50 ]
BI 205.137 2001 16/193 23/192 1.5 % 0.66 [ 0.34, 1.30 ]
Briggs 2005 8/328 18/325 0.9 % 0.43 [ 0.18, 1.00 ]
Buhl 2011 30/801 22/797 2.1 % 1.37 [ 0.78, 2.40 ]
Buhl 2015a%b 172/1033 181/1038 12.8 % 0.95 [ 0.75, 1.19 ]
D’Urzo 2014 17/337 15/332 1.3 % 1.12 [ 0.55, 2.29 ]
D’Urzo 2017 15/194 14/192 1.2 % 1.07 [ 0.50, 2.27 ]
Donohue 2010 34/415 67/832 3.6 % 1.02 [ 0.66, 1.57 ]
Hanania 2017 139/1341 78/890 7.9 % 1.20 [ 0.90, 1.61 ]
Mahler 2016 33/251 34/256 2.5 % 0.99 [ 0.59, 1.65 ]
Singh 2014 16/385 14/384 1.3 % 1.15 [ 0.55, 2.38 ]
Vogelmeier 2008 10/221 8/210 0.7 % 1.20 [ 0.46, 3.09 ]
Subtotal (95% CI) 6452 5924 38.6 % 1.01 [ 0.88, 1.15 ]
Total events: 538 (LAMA), 500 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.83, df = 11 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Total (95% CI) 11877 11314 100.0 % 0.94 [ 0.87, 1.02 ]
Total events: 1338 (LAMA), 1369 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.43, df = 13 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Chi2 = 1.79, df = 1 (P = 0.18), I2 =44%
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Analysis 6.17. Comparison 6 LAMA vs LABA, Outcome 17 COPD SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 17 COPD SAE
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Decramer 2013 121/1718 147/1721 22.3 % 0.81 [ 0.63, 1.04 ]
Vogelmeier 2011 270/3707 335/3669 28.4 % 0.78 [ 0.66, 0.92 ]
Subtotal (95% CI) 5425 5390 50.6 % 0.79 [ 0.69, 0.91 ]
Total events: 391 (LAMA), 482 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 3.31 (P = 0.00094)
2 Low-risk
Bateman 2013 16/953 15/476 5.9 % 0.52 [ 0.26, 1.07 ]
BI 205.137 2001 8/193 11/192 3.7 % 0.71 [ 0.28, 1.81 ]
Briggs 2005 3/328 10/325 2.0 % 0.29 [ 0.08, 1.07 ]
Buhl 2011 6/801 7/797 2.8 % 0.85 [ 0.28, 2.55 ]
Buhl 2015a%b 65/1033 67/1038 16.1 % 0.97 [ 0.68, 1.38 ]
Donohue 2010 7/415 18/832 4.1 % 0.78 [ 0.32, 1.87 ]
Hanania 2017 45/1341 19/890 9.1 % 1.59 [ 0.92, 2.74 ]
Mahler 2016 11/251 12/256 4.5 % 0.93 [ 0.40, 2.15 ]
Singh 2014 7/385 1/384 0.8 % 7.09 [ 0.87, 57.93 ]
Vogelmeier 2008 1/221 0/210 0.3 % 2.86 [ 0.12, 70.70 ]
Subtotal (95% CI) 5921 5400 49.4 % 0.91 [ 0.65, 1.27 ]
Total events: 169 (LAMA), 160 (LABA)
Heterogeneity: Tau2 = 0.09; Chi2 = 13.95, df = 9 (P = 0.12); I2 =35%
Test for overall effect: Z = 0.56 (P = 0.57)
Total (95% CI) 11346 10790 100.0 % 0.86 [ 0.71, 1.04 ]
Total events: 560 (LAMA), 642 (LABA)
Heterogeneity: Tau2 = 0.03; Chi2 = 15.72, df = 11 (P = 0.15); I2 =30%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Chi2 = 0.57, df = 1 (P = 0.45), I2 =0.0%
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Analysis 6.18. Comparison 6 LAMA vs LABA, Outcome 18 Cardiac SAE.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 18 Cardiac SAE
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Decramer 2013 51/1718 54/1721 29.0 % 0.94 [ 0.64, 1.39 ]
Vogelmeier 2011 63/3707 50/3669 31.3 % 1.25 [ 0.86, 1.82 ]
Subtotal (95% CI) 5425 5390 60.4 % 1.09 [ 0.83, 1.44 ]
Total events: 114 (LAMA), 104 (LABA)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.05, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Low-risk
Bateman 2013 11/953 8/476 5.2 % 0.68 [ 0.27, 1.71 ]
Buhl 2011 6/801 6/797 3.4 % 0.99 [ 0.32, 3.10 ]
Buhl 2015a%b 19/1033 15/1038 9.4 % 1.28 [ 0.65, 2.53 ]
D’Urzo 2014 1/337 3/332 0.9 % 0.33 [ 0.03, 3.15 ]
D’Urzo 2017 4/194 2/192 1.5 % 2.00 [ 0.36, 11.05 ]
Donohue 2010 10/415 16/832 6.9 % 1.26 [ 0.57, 2.80 ]
Hanania 2017 22/1341 5/890 4.6 % 2.95 [ 1.11, 7.82 ]
Mahler 2016 9/251 12/256 5.6 % 0.76 [ 0.31, 1.83 ]
Singh 2014 1/385 0/384 0.4 % 3.00 [ 0.12, 73.87 ]
Vogelmeier 2008 3/221 3/210 1.7 % 0.95 [ 0.19, 4.76 ]
Subtotal (95% CI) 5931 5407 39.6 % 1.16 [ 0.83, 1.61 ]
Total events: 86 (LAMA), 70 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.92, df = 9 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 11356 10797 100.0 % 1.12 [ 0.91, 1.38 ]
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(. . . Continued)
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 200 (LAMA), 174 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.01, df = 11 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.80), I2 =0.0%
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Analysis 6.19. Comparison 6 LAMA vs LABA, Outcome 19 Dropuouts due to adverse events.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 19 Dropuouts due to adverse events
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Decramer 2013 96/1718 101/1721 16.7 % 0.95 [ 0.71, 1.27 ]
Vogelmeier 2011 264/3707 292/3669 33.3 % 0.89 [ 0.75, 1.05 ]
Subtotal (95% CI) 5425 5390 49.9 % 0.90 [ 0.78, 1.05 ]
Total events: 360 (LAMA), 393 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Low-risk
Bateman 2013 24/953 24/476 5.0 % 0.49 [ 0.27, 0.87 ]
Buhl 2011 27/801 31/797 5.9 % 0.86 [ 0.51, 1.46 ]
Buhl 2015a%b 43/1033 51/1038 9.0 % 0.84 [ 0.55, 1.27 ]
D’Urzo 2014 16/337 14/332 3.1 % 1.13 [ 0.54, 2.36 ]
D’Urzo 2017 6/194 4/192 1.1 % 1.50 [ 0.42, 5.40 ]
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(. . . Continued)
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Donohue 2010 17/415 55/832 5.3 % 0.60 [ 0.35, 1.05 ]
Hanania 2017 10/389 4/213 1.3 % 1.38 [ 0.43, 4.45 ]
Mahler 2016 22/251 26/256 4.7 % 0.85 [ 0.47, 1.54 ]
Martinez 2017a 55/902 22/452 6.3 % 1.27 [ 0.76, 2.11 ]
Martinez 2017b 14/439 21/438 3.5 % 0.65 [ 0.33, 1.30 ]
Singh 2014 17/385 14/384 3.2 % 1.22 [ 0.59, 2.51 ]
Vogelmeier 2008 13/221 6/210 1.8 % 2.13 [ 0.79, 5.70 ]
Subtotal (95% CI) 6320 5620 50.1 % 0.89 [ 0.72, 1.10 ]
Total events: 264 (LAMA), 272 (LABA)
Heterogeneity: Tau2 = 0.03; Chi2 = 14.13, df = 11 (P = 0.23); I2 =22%
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 11745 11010 100.0 % 0.89 [ 0.78, 1.02 ]
Total events: 624 (LAMA), 665 (LABA)
Heterogeneity: Tau2 = 0.01; Chi2 = 14.33, df = 13 (P = 0.35); I2 =9%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 6.20. Comparison 6 LAMA vs LABA, Outcome 20 Pneumonia.
Review: Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network
meta-analysis
Comparison: 6 LAMA vs LABA
Outcome: 20 Pneumonia
Study or subgroup LAMA LABA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High-risk
Decramer 2013 24/1718 29/1721 22.4 % 0.83 [ 0.48, 1.43 ]
Vogelmeier 2011 54/3707 64/3669 49.9 % 0.83 [ 0.58, 1.20 ]
Subtotal (95% CI) 5425 5390 72.3 % 0.83 [ 0.61, 1.13 ]
Total events: 78 (LAMA), 93 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
2 Low-risk
Bateman 2013 6/953 2/476 2.6 % 1.50 [ 0.30, 7.47 ]
Buhl 2011 2/801 3/797 2.1 % 0.66 [ 0.11, 3.98 ]
Buhl 2015a%b 7/1033 14/1038 8.0 % 0.50 [ 0.20, 1.24 ]
D’Urzo 2014 1/337 3/332 1.3 % 0.33 [ 0.03, 3.15 ]
D’Urzo 2017 0/194 0/192 Not estimable
Donohue 2010 4/415 5/832 3.8 % 1.61 [ 0.43, 6.03 ]
Hanania 2017 15/1341 4/890 5.4 % 2.51 [ 0.83, 7.57 ]
Mahler 2016 5/251 4/256 3.8 % 1.28 [ 0.34, 4.82 ]
Singh 2014 0/385 0/384 Not estimable
Vogelmeier 2008 0/221 1/210 0.6 % 0.32 [ 0.01, 7.78 ]
Subtotal (95% CI) 5931 5407 27.7 % 1.01 [ 0.61, 1.69 ]
Total events: 40 (LAMA), 36 (LABA)
Heterogeneity: Tau2 = 0.03; Chi2 = 7.40, df = 7 (P = 0.39); I2 =5%
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 11356 10797 100.0 % 0.88 [ 0.68, 1.13 ]
Total events: 118 (LAMA), 129 (LABA)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.83, df = 9 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.52), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Study characteristics of included trials
High-risk group
Study Num-
ber of par-
ticipants
Study dura-
tion
(weeks)
Arms
included
(drug, dose
in µg, dos-
ing
frequency)
Mean age
(years)
Male (%) Current
smoker (%)
Prebron-
chodilator
FEV1 (L)
Bronchial
reversibility
(%)
Aaron 2007 304 52 Tio 18 once
daily + SAL
50 twice
daily
Tio 18 once
daily
68 56 26 1.01 NR
Agusti 2014 528 12 FP/
SAL 500/50
twice daily
FF/VI
100/25 once
daily
63 82 NR 1.29 11.8
Anzueto
2009
797 52 FP/
SAL 250/50
twice daily
SAL 50
twice daily
65 54 43 0.98 21
Calverley
2003
509 52 BUD/FM
320/9 twice
daily
FM 9 twice
daily
63 76 35 0.99 NR
Calverley
2003
TRISTAN
730 52 FP/
SAL 500/50
twice daily
SAL 50
twice daily
63 75 51 1.28 7.8
Calverley
2010
703 48 BDP/
FM 200/12
twice daily
BUD/
FM 400/12
twice daily
64 81 37 1.15 NR
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Table 1. Study characteristics of included trials (Continued)
FM12 twice
daily
COMBINE
2017
222 24 FP 250
twice daily +
SAL 50
twice daily
BUD 400
twice daily +
IND 150
once daily
67 57 NR NR NR
Decramer
2013
3439 52 IND 150
once daily
Tio 18 once
daily
64 77 34 NR NR
Ferguson
2008
776 52 FP/
SAL 250/50
twice daily
SAL 50
twice daily
65 55 39 0.94 24.2
Ferguson
2017
1219 26 BUD/FM
320/9 twice
daily
FM 9 twice
daily
64 57 NR NR NR
Fukuchi
2013
1293 12 BUD/FM
320/9 twice
daily
FM 9 twice
daily
65 89 34 0.96 13.6
Hagedorn
2013
213 52 FP/
SAL 500/50
twice daily
FP 500
+ SAL 50
twice daily
65 71 29 1.05 NR
Kardos
2007
994 44 FP/
SAL 500/50
twice daily
SAL 50
twice daily
64 76 42 1.13 7
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Table 1. Study characteristics of included trials (Continued)
Ohar 2014 639 26 FP/
SAL 250/50
twice daily
SAL 50
twice daily
63 91 NR 1.11 13.6
Pepin 2014 257 12 FF/VI
100/25 once
daily
Tio 18 once
daily
67 86 46 1.27 8.5
Rennard
2009
1483 52 BUD/FM
320/9 twice
daily
BUD/FM
160/9 twice
daily
FM 9 twice
daily
63 64 42 1.00 NR
Sarac 2016 44 52 FP/
SAL 500/50
twice daily
Tio 18 once
daily
67 95 NR NR NR
SCO40041
2008
186 156 FP/
SAL 250/50
twice daily
SAL 50
twice daily
66 61 42 1.14 15.2
Sharafkhaneh
2012
1218 52 BUD/FM
320/9 twice
daily
BUD/FM
160/9 twice
daily
FM 9 twice
daily
63 62 36 1.00 NR
Szafranski
2003
409 52 BUD/FM
320/9 twice
daily
FM 9 twice
daily
64 76 34 0.98 NR
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Table 1. Study characteristics of included trials (Continued)
Tashkin
2008
842 24 BUD/FM
320/9 twice
daily
BUD/FM
160/9 twice
daily
FM 9 twice
daily
63 66 45 1.04 NR
Vogelmeier
2011
7376 52 SAL 50
twice daily
Tio 18 once
daily
63 75 48 NR NR
Wedzicha
2008
1323 104 FP/
SAL 250/50
twice daily
Tio 18 once
daily
65 83 38 1.05 6.7
Wedzicha
2013
2206 64 IND/Glyco
110/50 once
daily
Glyco 50
once daily
Tio 18 once
daily
63 75 38 0.90 18.3
Wedzicha
2014
1197 48 BDP/
FM 200/12
twice daily
FM12 twice
daily
64 69 40 1.05 10.8
Wedzicha
2016
3358 52 IND/Glyco
110/50 once
daily
FP/
SAL 500/50
twice daily
65 76 40 1.00 22.4
Low-risk group
Study Num-
ber of par-
ticipants
Study dura-
tion
(weeks)
Arms
included
(drug, dose
in µg, dos-
ing
Mean age
(years)
Male (%) Current
smoker (%)
Prebron-
chodilator
FEV1 (L)
Bronchial
reversibility
(%)
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Table 1. Study characteristics of included trials (Continued)
frequency)
Asai 2013 158 52 IND/Glyco
110/50 once
daily
Tio 18 once
daily
69 96 NR NR NR
BI 205.137
2001
385 12 SAL 50
twice daily
Tio 18 once
daily
NR NR NR NR NR
Bateman
2013
1903 26 IND/Glyco
110/50 once
daily
Glyco 50
once daily
Tio 18 once
daily
IND 150
once daily
64 75 40 1.30 20.4
Bogdan
2011
405 12 FM 4.5
twice daily
FM 9 twice
daily
67 87 NR 1.30 10.6
Briggs 2005 653 12 SAL 50
twice daily
Tio 18 once
daily
64 67 36 1.05 NR
Brusasco
2003
807 24 SAL 50
twice daily
Tio 18 once
daily
64 76 NR 1.09 NR
Buhl 2011 1598 12 IND 150
once daily
Tio 18 once
daily
64 69 45 1.33 13.9
Buhl
2015a&b
3100 52 Tio/Olo 5/5
once daily
Tio 5 once
daily
Olo 5 once
daily
64 73 37 1.20 14.2
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Table 1. Study characteristics of included trials (Continued)
Buhl 2015c 934 26 IND/Glyco
110/50 once
daily
Tio 18 once
daily +
FM 12 twice
daily
63 66 49 1.33 19.4
Calverley
2007
3054 156 FP/
SAL 500/50
twice daily
SAL 50
twice daily
65 75 43 1.11 10.2
Cazzola
2007
52 12 FP/
SAL 500/50
twice daily
Tio 18 once
daily
65 90 38 NR 12.3
Chapman
2014
657 12 Glyco 50
once daily
Tio 18 once
daily
64 74 45 NR NR
COSMOS-J
2016
262 24 FP/
SAL 250/50
twice daily
Tio 18 once
daily
68 95 40 NR NR
Covelli
2016
623 12 FF/VI
100/25 once
daily
TIO 18
once daily
63 65 52 1.35 13
D’Urzo
2014
994 24 ACL/
FM 400/12
twice daily
ACL 400
twice daily
FM12 twice
daily
64 52 51 1.35 17.4
D’Urzo
2017
568 52 ACL/
FM 400/12
twice daily
63 50 56 1.34 18.3
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Table 1. Study characteristics of included trials (Continued)
ACL 400
twice daily
FM 12 twice
daily
Dahl 2010 871 52 IND 300
once daily
FM12 twice
daily
64 80 NR 1.29 10
Decramer
2014a
420 24 UMEC/
VI 62.5/25
once daily
Tio 18 once
daily
63 69 47 1.31 11.6
Decramer
2014b
432 24 UMEC/
VI 62.5/25
once daily
Tio 18 once
daily
65 68 45 1.17 15.2
Donohue
2010
1247 26 IND150
once daily
IND 300
once daily
Tio 18 once
daily
64 63 NR 1.50 15.5
Donohue
2013
831 24 UMEC/
VI 62.5/25
once daily
UMEC 62.
5 once daily
63 71 50 1.23 13.9
Donohue
2015a
706 12 UMEC/
VI 62.5/25
once daily
FP/
SAL 250/50
twice daily
63 70 43 1.32 11.3
Donohue
2015b
697 12 UMEC/
VI 62.5/25
once daily
FP/
SAL 250/50
twice daily
64 76 52 1.34 13.3
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Table 1. Study characteristics of included trials (Continued)
Donohue
2016a
590 56 ACL/
FM 400/12
twice daily
FM12 twice
daily
64 55 46 1.31 NR
Dransfield
2014
1858 12 FP/
SAL 250/50
twice daily
FF/VI
100/25 once
daily
61 69 55 1.34 12
Feldman
2016
1017 12 UMEC62.5
once daily
Tio 18 once
daily
64 72 51 1.36 12.1
Ferguson
2016
410 52 IND/Glyco
27.5/15.6
twice daily
IND 75
once daily
63 68 51 1.25 22.4
GLOW4
2012
163 52 Glyco 50
once daily
Tio 18 once
daily
69 98 NR NR NR
Hanania
2003
355 24 FP/
SAL 250/50
twice daily
SAL 50
twice daily
64 60 47 1.21 20.7
Hoshino
2013
45 16 FP/
SAL 250/50
twice daily
Tio 18 once
daily
SAL 50
twice daily
71 87 NR 1.35 NR
Hoshino
2014
54 16 TIO 18
once daily +
IND 150
once daily
IND 150
71 93 NR 1.53 NR
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Table 1. Study characteristics of included trials (Continued)
once daily
Tio 18 once
daily
Hoshino
2015
43 16 TIO 18
once daily +
IND 150
once daily
FP/
SAL 250/50
twice daily
71 84 NR 1.37 NR
Kalberg
2016
961 12 UMEC/
VI 62.5/25
once daily
Tio 18 once
daily + IND
150 once
daily
64 73 43 1.23 12.3
Kerwin
2012a
792 52 Glyco 50
once daily
Tio 18 once
daily
64 64 45 1.30 16.3
Kerwin
2017
494 12 UMEC/
VI 62.5/25
once daily
Tio 18 once
daily
64 66 50 1.65 7.9
Koch 2014 919 48 Olo 5 once
daily
FM12 twice
daily
64 80 34 1.26 12.3
Kornmann
2011
667 26 IND 150
once daily
SAL 50
twice daily
63 74 46 1.35 11.5
Koser 2010 247 12 FP/
SAL 250/50
twice daily
FP/
SAL 230/42
twice daily
63 53 62 1.27 12.7
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Table 1. Study characteristics of included trials (Continued)
Mahler
2002
325 24 FP/
SAL 500/50
twice daily
SAL 50
twice daily
63 63 46 1.25 20.9
Mahler
2012a
1131 12 Tio 18 once
daily + IND
150 once
daily
Tio 18 once
daily
64 69 38 1.15 16.9
Mahler
2012b
1142 12 Tio 18 once
daily + IND
150 once
daily
Tio 18 once
daily
63 66 40 1.14 16.4
Mahler
2015a;
Mahler
2015b
1530 12 IND/Glyco
27.5/15.6
twice daily
Glyco 15.6
twice daily
64 64 52 1.27 22.8
Mahler
2016
507 52 IND 75
once daily
Glyco 15.6
twice daily
63 57 55 1.25 21.2
Maleki-
Yazdi 2014
905 24 UMEC/
VI 62.5/25
once daily
Tio 18 once
daily
62 68 57 1.26 13.4
Martinez
2017a
1880 24 Glyco/FM
18/9.6 twice
daily
Glyco 18
twice daily
Tio 18 once
daily
FM 9.6
twice daily
63 56 54 1.25 19.8
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Table 1. Study characteristics of included trials (Continued)
Martinez
2017b
1387 24 Glyco/FM
18/9.6 twice
daily
Glyco 18
twice daily
FM 9.6
twice daily
63 55 54 NR 19.2
NCT00876694
2011
186 52 IND 300
once daily
SAL 50
twice daily
69 95 NR NR NR
NCT01536262
2014
82 52 Tio/Olo 5/5
once daily
Olo 5 once
daily
70 96 NR NR NR
Perng 2009 67 12 FP/
SAL 500/50
twice daily
Tio 18 once
daily
73 94 61 1.21 NR
Hanania
2017
3267 52 Glyco/FM
18/9.6 twice
daily
Glyco 18
twice daily
Tio 18 once
daily
FM 9.6
twice daily
63 56 54 NR 19.6
RADIATE
2016
812 52 IND/Glyco
110/50 once
daily
Tio 18 once
daily
64 72 NR NR NR
Rheault
2016
1034 12 UMEC62.5
once daily
Glyco 50
once daily
64 69 48 1.34 13.2
Rossi 2014 581 26 FP/
SAL 500/50
twice daily
66 69 36 1.54 9.7
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Table 1. Study characteristics of included trials (Continued)
IND 150
once daily
SCO100470
2006
1050 24 FP/
SAL 500/50
twice daily
SAL 50
twice daily
64 78 43 1.67 NR
SCO40034
2005
125 12 FP/
SAL 500/50
twice daily
Tio 18 once
daily
65 74 NR 1.37 NR
Singh 2014 1154 24 ACL/
FM 400/12
twice daily
ACL 400
twice daily
FM12 twice
daily
63 67 47 1.41 NR
Singh 2015a 406 12 Tio/Olo 5/5
once daily
Tio 5 once
daily
65 59 52 1.31 14.5
Singh
2015b
405 12 Tio/Olo 5/5
once daily
Tio 5 once
daily
65 65 45 1.38 14.5
Singh 2015c 716 12 UMEC/
VI 62.5/25
once daily
FP/
SAL 250/50
twice daily
62 72 59 1.44 10.8
Tashkin
2009
255 12 Tio 18 once
daily +
FM 12 twice
daily
Tio 18 once
daily
64 66 47 NR NR
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Table 1. Study characteristics of included trials (Continued)
Tashkin
2012a&b
1340 26-52 MF/
FM 400/10
twice daily
MF/
FM 200/10
twice daily
FM10 twice
daily
60 75 49 1.21 8.9
To 2012 230 12 IND 150
once daily
IND 300
once daily
67 97 34 1.24 15
Troosters
2016
152 12 Tio/Olo 5/5
once daily
Tio 5 once
daily
65 68 NR NR NR
Vincken
2014
447 12 IND/Glyco
110/50 once
daily
IND 150
once daily
64 81 42 1.46 19.5
Vogelmeier
2008
638 24 Tio 18 once
daily +
FM 10 twice
daily
Tio 18 once
daily
FM10 twice
daily
63 78 NR 1.50 10.8
Vogelmeier
2013a
522 26 IND/Glyco
110/50 once
daily
FP/
SAL 500/50
twice daily
63 71 48 1.45 20.4
Vogelmeier
2016
933 24 ACL/
FM 400/12
twice daily
FP/
SAL 500/50
twice daily
63 65 NR 1.38 11.8
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Table 1. Study characteristics of included trials (Continued)
Vogelmeier
2017
1080 12 IND/Glyco
110/50 once
daily
ICS/LABA
free or fixed
65 64 49 NR NR
Wise 2013 11392 120 Tio 5 once
daily
Tio 18 once
daily
65 72 38 NR NR
Yao 2014 375 26 IND 150
once daily
IND 300
once daily
66 95 22 1.13 14.7
Zhong 2015 741 26 IND/Glyco
110/50 once
daily
FP/
SAL 500/50
twice daily
65 91 26 1.08 24.1
ZuWallack
2014a&b
2267 12 Tio 18 once
daily +Olo 5
once daily
Tio 18 once
daily
64 52 49 1.25 16
ACL: aclidinium; BDP: beclomethasone; BUD: budesonide; FEV1: forced expiratory volume in 1 second; FF: fluticasone furoate;
FM: formoterol;Glyco: glycopyrrolate; FP: fluticasone propionate; IND: indacaterol;MF:mometasone furoate;NR: not reported;
Olo: olodaterol; SAL: salmeterol; Tio: tiotropium; UMEC: umeclidinium; VI: vilanterol
Table 2. Study characteristics of treatment group pair-wise comparisons and clinical homogeneity assessment in moderate to
severe exacerbations in the high-risk population
Compari-
son
Compar-
isons
Num-
ber of par-
ticipants
Mean age
(years)
Male (%) Current
smoker (%)
Baseline
FEV1
(L) prebron-
chodilator
Baseline
FEV1 (L)
postbron-
chodilator
Bronchial
reversibility
%
LABA/
LAMA vs
LABA/ICS
1 3372 65 76 40 NA 1.2 NA
LABA/
LAMA vs
1 2206 63 75 38 0.9 1.04 18.3
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Table 2. Study characteristics of treatment group pair-wise comparisons and clinical homogeneity assessment in moderate to
severe exacerbations in the high-risk population (Continued)
LAMA
LABA/
LAMA vs
LABA
0 0 NA NA NA NA NA NA
LABA/ICS
vs LAMA
2 1580 65 83 39 1.09 1.16 7
LABA/ICS
vs LABA
10 9049 64 69 40 1.05 1.19 13.6
LAMA vs
LABA
2 10,815 63 76 44 NA 1.32 NA
FEV1: forced expiratory volume in 1 second; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting
muscarinic antagonist; NA: not applicable
Table 3. Study characteristics of treatment group pair-wise comparisons and clinical homogeneity assessment in moderate to
severe exacerbations in the low-risk population
Comparison Comparisons Number of
participants
Mean age
(years)
Male % Current
smoker %
Baseline
FEV1 (L) pre-
bronchodilator
Bronchial re-
versibility (%)
LABA/
LAMA vs
LABA/ICS
6 4315 63 74 45 1.33 14.9
LABA/
LAMA vs
LAMA
8 5192 63 71 47 1.32 14.7
LABA/
LAMA vs
LABA
5 2488 64 68 44 1.36 17.5
LABA/ICS vs
LAMA
1 623 63 65 52 1.35 13
LABA/ICS vs
LABA
6 6689 64 74 44 1.27 11.1
LAMA vs
LABA
5 4567 64 71 39 1.3 17.1
FEV1: forced expiratory volume in 1 second; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting
muscarinic antagonist
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Table 4. Study characteristics of treatment group pair-wise comparisons and clinical homogeneity assessment in severe
exacerbations in the high-risk population
Comparison Comparisons Number of
participants
Mean age
(years)
Male (%) Current
smoker (%)
Baseline FEV1
(L) postbron-
chodilator
Bronchial re-
versibility (%)
LABA/
LAMA vs
LABA/ICS
1 3354 65 76 40 1 22.4
LABA/
LAMA vs
LAMA
1 304 68 56 26 1.01 NA
LABA/
LAMA vs
LABA
0 0 NA NA NA NA NA
LABA/ICS vs
LAMA
2 1580 65 83 39 1.09 7
LABA/ICS vs
LABA
5 4216 64 74 41 1.04 15.9
LAMA vs
LABA
1 7376 63 76 48 NA NA
FEV1: forced expiratory volume in 1 second; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting
muscarinic antagonist; NA: not applicable
Table 5. Study characteristics of treatment group pair-wise comparisons and clinical homogeneity assessment in severe
exacerbations in the low-risk population
Compari-
son
Compar-
isons
Num-
ber of par-
ticipants
Mean age
(years)
Male (%) Current
smoker (%)
Baseline
FEV1 (L) %
prebron-
chodilator
Bronchial
reversibility
(%)
Baseline
FEV1 (L)
postbron-
chodilator
LABA/
LAMA vs
LABA/ICS
6 2860 63 74 45 1.33 14.9 1.5
LABA/
LAMA vs
LAMA
7 4973 63 72 41 1.33 15.1 1.49
LABA/
LAMA vs
LABA
6 2898 64 67 45 1.35 18.3 1.55
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Table 5. Study characteristics of treatment group pair-wise comparisons and clinical homogeneity assessment in severe
exacerbations in the low-risk population (Continued)
LABA/ICS
vs LAMA
1 623 63 65 52 1.35 13 1.48
LABA/ICS
vs LABA
6 6482 64 74 44 1.27 11.1 1.32
LAMA vs
LABA
4 3320 64 74 39 1.23 18.2 1.54
FEV1: forced expiratory volume in 1 second; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting
muscarinic antagonist
Table 6. Study characteristics of treatment group pair-wise comparisons and clinical homogeneity assessment in pneumonia
in the low-risk population
Comparison Comparisons Number of
participants
Mean age
(years)
Male (%) Current
smoker (%)
Baseline FEV1
(L) prebron-
chodilator
Bronchial re-
versibility %
LABA/
LAMA vs
LABA/ICS
7 5395 64 72 46 1.33 14.9
LABA/
LAMA vs
LAMA
21 19,043 64 68 47 1.27 16.7
LABA/
LAMA vs
LABA
11 8556 64 65 43 1.30 15.8
LABA/ICS vs
LAMA
4 2465 65 80 43 1.16 8.7
LABA/ICS vs
LABA
16 15,992 64 72 41 1.14 11
LAMA vs
LABA
12 22,351 63 70 43 1.34 16.8
FEV1: forced expiratory volume in 1 second; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting
muscarinic antagonist
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Table 7. Distribution of studies by individual treatment node in the high-risk population
Class Treatment node (drug, dose µg, dosing frequency) Studies
LABA Salmeterol 50 twice daily Anzueto 2009; Calverley 2003 TRISTAN; Ferguson
2008; Kardos 2007; Ohar 2014; SCO40041 2008;
Vogelmeier 2011
Formoterol 9-12 twice daily Calverley2003;Calverley 2010; Ferguson 2017; Fukuchi
2013; Rennard 2009; Sharafkhaneh 2012; Szafranski
2003; Tashkin 2008; Wedzicha 2014
Indacaterol 150 once daily Bateman 2013; Decramer 2013
LAMA Tiotripium 18 once daily Aaron 2007; Asai 2013; Covelli 2016; Decramer 2013;
Pepin 2014; Sarac 2016; Vogelmeier 2011; Wedzicha
2008; Wedzicha 2013
Glycopyrrolate 50 once daily Bateman 2013; Wedzicha 2013
LABA/ICS Salmetrol/fluticasone 50/250 twice daily Anzueto 2009; Ferguson 2008; Ohar 2014; SCO40041
2008; Wedzicha 2008
Salmetrol/fluticasone 50/500 twice daily Agusti 2014; Calverley 2003; Hagedorn 2013; Kardos
2007; Sarac 2016; Wedzicha 2016
Formoterol/budesonide 9/160 twice daily Rennard 2009; Sharafkhaneh 2012; Tashkin 2008
Formoterol/budesonide 9/320 twice daily Calverley 2003; Ferguson 2017; Fukuchi 2013; Rennard
2009; Sharafkhaneh 2012; Szafranski 2003; Tashkin
2008
Formoterol/budesonide 12/400 twice daily DPI Calverley 2010
Formoterol/beclomethasone 12/200 twice daily Calverley 2010; Wedzicha 2014
Salmeterol 50 twice daily + fluticasone 250 twice dailya COMBINE 2017
Salmeterol 50 twice daily + fluticasone 500 twice dailya Hagedorn 2013
Vilanterol/fluticasone 25/100 once daily Agusti 2014; Covelli 2016; Pepin 2014;
Indacaterol 150 once daily + budesonide 400 twice daily
a
COMBINE 2017
LABA/LAMA Indacaterol/glycopyrrolate 27.5/15.6 twice daily Ferguson 2016
Indacaterol/glycopyrrolate 110/50 once daily Asai 2013; Bateman 2013; Wedzicha 2013; Wedzicha
2016
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Table 7. Distribution of studies by individual treatment node in the high-risk population (Continued)
Salmeterol 50 twice daily + tiotropium 18 once dailya Aaron 2007
aFree combination
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 8. Distribution of studies by individual treatment node in the low-risk population
Class Treatment node (drug, dose µg, dosing frequency) Studies
LABA Salmeterol 50 twice daily BI 205.137 2001; Briggs 2005; Brusasco 2003; Calverley
2007; Hanania 2003; Hoshino 2013; Jones 2011;
Kornmann 2011; Mahler 2002; NCT00876694 2011;
SCO100470 2006
Formoterol 4.5 twice daily Bogdan 2011
Formoterol 9-12 twice daily Bogdan 2011; Calverley 2010; Dahl 2010; Donohue
2016a; D’Urzo 2014; D’Urzo 2017; Hanania 2017;
Jones 2011; Koch 2014; Martinez 2017a; Martinez
2017b; Singh 2014; Tashkin 2012a&b; Vogelmeier 2008
Indacaterol 75 once daily Ferguson 2016; Mahler 2016
Indacaterol 150 once daily Buhl 2011; Donohue 2010; Hoshino 2014; Jones 2011;
Kornmann 2011; Rossi 2014; To 2012; Yao 2014;
Vincken 2014
Indacaterol 300 once daily Dahl 2010;Donohue 2010; Jones 2011;NCT00876694
2011; To 2012; Yao 2014
Olodaterol 5 once daily Buhl 2015a&b; NCT01536262 2014; Koch 2014
LAMA Tiotripium 18 once daily BI 205.137 2001; Briggs 2005; Brusasco 2003; Buhl
2011; Cazzola 2007; Chapman 2014; COSMOS-J
2016; Covelli 2016; Decramer 2014a; Decramer 2014b;
Donohue 2010; Fang 2008; Feldman 2016; GLOW4
2012; Hanania 2017; Hoshino 2013; Hoshino 2014;
Kerwin 2012a; Kerwin 2017; Mahler 2012a; Mahler
2012b;Maleki-Yazdi 2014;Martinez 2017a; Perng2009;
RADIATE 2016; SCO40034 2005; Tashkin 2009;
Vogelmeier 2008; Wise 2013; ZuWallack 2014a&b
Tiotripium 5 once daily Buhl 2015a; Buhl 2015b; Singh 2015a&b; Troosters
2016; Wise 2013
Aclidinium 400 twice daily D’Urzo 2014; D’Urzo 2017; Singh 2014
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Table 8. Distribution of studies by individual treatment node in the low-risk population (Continued)
Umeclidinium 62.5 once daily Donohue 2013; Feldman 2016; Rheault 2016
Glycopyrrolate 15.6 twice daily Hanania 2017; Mahler 2015a; Mahler 2015b; Mahler
2016; Martinez 2017a; Martinez 2017b
Glycopyrrolate 50 once daily Chapman 2014; GLOW4 2012; Kerwin 2012a; Rheault
2016
LABA/ICS Salmetrol/fluticasone 50/250 twice daily COSMOS-J 2016; Donohue 2015a; Donohue 2015b;
Dransfield 2014; Fang 2008; Hanania 2003; Hoshino
2013 ; Hoshino 2015; Koser 2010; Singh 2015d
Salmetrol/fluticasone 50/500 twice daily Calverley 2007; Cazzola 2007; Mahler 2002; Perng
2009; Rossi 2014; SCO100470 2006; SCO40034 2005;
Vogelmeier 2013a; Vogelmeier 2016; Zhong 2015
Salmetrol/fluticasone 42/230 (HFA) twice daily Koser 2010
Formoterol/budesonide 9/320 twice daily Calverley 2010
Formoterol/mometasone 200/10 twice daily Tashkin 2012a&b
Formoterol/mometasone 400/10 twice daily Tashkin 2012a&b
Vilanterol/fluticasone 25/100 once daily Covelli 2016; Dransfield 2014
LABA/LAMA Vilaterol/umeclidinium 25/62.5 once daily Decramer 2014a; Decramer 2014b; Donohue 2013;
Donohue 2015a; Donohue 2015b; Kalberg 2016;
Kerwin 2017; Maleki-Yazdi 2014; Singh 2015d
Formoterol/glycopyrrolate 9.6/18 twice daily Hanania 2017; Martinez 2017a; Martinez 2017b
Indacaterol/glycopyrrolate 27.5/15.6 twice daily Ferguson 2016; Mahler 2015a; Mahler 2015b
Indacaterol/glycopyrrolate 110/50 once daily Buhl 2015c; RADIATE 2016; Vogelmeier 2013a;
Vogelmeier 2017; Zhong 2015
Olodaterol/tiotropium 5/5 once daily Buhl 2015a&b; NCT01536262 2014; Singh 2015a&b;
Troosters 2016
Formterol/aclidinium 12/400 twice daily Donohue 2016a; D’Urzo 2014; D’Urzo 2017; Singh
2014; Vogelmeier 2016
Indacaterol 150 once daily + tiotropium 18 once dailya Hoshino 2014; Hoshino 2015; Kalberg 2016; Mahler
2012a; Mahler 2012b
Formoterol 10-12 twice daily + tiotropium 18 once daily
a
Buhl 2015c; Tashkin 2009; Vogelmeier 2008
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Table 8. Distribution of studies by individual treatment node in the low-risk population (Continued)
Olodaterol 5 once daily + tiotropium 18 once dailya ZuWallack 2014a&b
Indacaterol 110 once daily + glycopyrrolate 50 once daily
a
Vincken 2014
aFree combination
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 9. Relative effects: moderate to severe exacerbations in the high-risk population
Treatment comparison Hazard ratios: random-effects
Median 95% CrI
LABA/LAMA v LABA/ICS 0.86 0.76 to 0.99
LABA/LAMA v LAMA 0.87 0.78 to 0.99
LABA/LAMA v LABA 0.70 0.61 to 0.80
LABA/ICS v LAMA 1.01 0.91 to 1.13
LABA/ICS v LABA 0.80 0.75 to 0.86
LAMA v LABA 0.80 0.71 to 0.88
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 10. Mean and median ranks: moderate to severe exacerbations in the high-risk population
Treatment group Rank (from random-effects model)
Mean Median 95% CrI
LABA/LAMA 1.0 1 1 to 2
LAMA 2.4 2 2 to 3
LABA/ICS 2.6 3 2 to 3
LABA 4.0 4 4 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
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Table 11. Relative effects: severe exacerbations in the high-risk population
Treatment comparison Hazard ratios: fixed-effect Hazard ratios: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA v LABA/
ICS
0.78 0.64 to 0.93 0.78 0.62 to 0.98
LABA/LAMA v LAMA 0.89 0.71 to 1.11 0.91 0.73 to 1.13
LABA/LAMA v LABA 0.64 0.51 to 0.81 0.65 0.50 to 0.84
LABA/ICS v LAMA 1.15 0.97 to 1.36 1.16 0.94 to 1.41
LABA/ICS v LABA 0.83 0.71 to 0.97 0.83 0.69 to 1.00
LAMA v LABA 0.72 0.63 to 0.82 0.72 0.60 to 0.86
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 12. Mean and median ranks: severe exacerbations in the high-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.2 1 1 to 2
LAMA 1.9 2 1 to 3
LABA/ICS 3.0 3 2 to 3
LABA 4.0 4 4 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 13. Relative effects: St. George’s Respiratory Questionnaire responders at 12 months in the high-risk population
Treatment comparison Odds ratios: fixed-effect Odds ratios: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA v LABA/
ICS
1.21 1.07 to 1.36 1.19 0.83 to 1.71
LABA/LAMA v LAMA 1.36 1.18 to 1.58 1.34 0.93 to 1.88
LABA/LAMA v LABA 1.41 1.20 to 1.66 1.38 0.89 to 2.04
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Table 13. Relative effects: St. George’s Respiratory Questionnaire responders at 12 months in the high-risk population
(Continued)
LABA/ICS v LAMA 1.13 0.98 to 1.30 1.12 0.81 to 1.54
LABA/ICS v LABA 1.17 1.02 to 1.34 1.15 0.87 to 1.49
LAMA v LABA 1.03 0.91 to 1.18 1.03 0.72 to 1.44
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 14. Mean andmedian ranks: St. George’s Respiratory Questionnaire responders at 12months in the high-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.0 1 1 to 1
LABA/ICS 2.1 2 2 to 3
LAMA 3.3 3 2 to 4
LABA 3.7 4 3 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 15. Relative effects: change from baseline in St. George’s Respiratory Questionnaire score at 3 months in the high-risk
population
Treatment comparison Mean differences - fixed effects Mean differences - random effects
Median 95% CrI Median 95% CrI
LABA/LAMA v LABA/
ICS
-1.39 (-2.37, -0.42) -1.47 (-3.74, 0.45)
LABA/LAMA v LAMA -3.31 (-4.67, -1.97) -3.32 (-5.52, -1.12)
LABA/LAMA v LABA -3.21 (-4.52, -1.92) -3.21 (-5.63, -0.81)
LABA/ICS v LAMA -1.92 (-3.11, -0.74) -1.83 (-3.76, 0.35)
LABA/ICS v LABA -1.82 (-2.86, -0.78) -1.73 (-3.25, 0.05)
LAMA v LABA 0.1 (-0.76, 0.96) 0.1 (-1.86, 2.09)
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
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Table 16. Mean and median ranks: change from baseline in St. George’s Respiratory Questionnaire score at 3 months in the
high-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.0 1 1 to 1
LABA/ICS 2.0 2 2 to 2
LABA 3.4 3 3 to 4
LAMA 3.6 4 3 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 17. Relative effects: change from baseline in St. George’s Respiratory Questionnaire score at 6 months in the high-risk
population
Treatment comparison Mean differences: fixed-effect Mean differences: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA v LABA/
ICS
−1.27 −2.26 to −0.29 −1.29 −3.03 to 0.46
LABA/LAMA v LAMA −2.48 −3.72 to −1.24 −2.6 −4.52 to −0.75
LABA/LAMA v LABA −2.88 −4.03 to −1.73 −2.9 −4.79 to −0.93
LABA/ICS v LAMA −1.21 −2.16 to −0.25 −1.31 −2.90 to 0.17
LABA/ICS v LABA −1.60 −2.27 to −0.93 −1.61 −2.61 to −0.54
LAMA v LABA −0.39 −1.27 to 0.47 −0.3 −1.74 to 1.34
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 18. Mean and median ranks: change from baseline in St. George’s Respiratory Questionnaire score at 6 months in the
high-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.0 1 1 to 1
LABA/ICS 2.0 2 2 to 2
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Table 18. Mean and median ranks: change from baseline in St. George’s Respiratory Questionnaire score at 6 months in the
high-risk population (Continued)
LAMA 3.2 3 3 to 4
LABA 3.8 4 3 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 19. Relative effects: change from baseline in St. George’s Respiratory Questionnaire score at 12 months in the high-risk
population
Treatment comparison Mean differences: fixed-effect Mean differences: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA v LABA/
ICS
−0.52 −1.42 to 0.36 −0.69 −2.46 to 0.87
LABA/LAMA v LAMA −1.12 −1.88 to −0.37 −1.49 −3.16 to −0.20
LABA/LAMA v LABA −2.10 −3.08 to −1.13 −2.31 −4.17 to −0.64
LABA/ICS v LAMA −0.59 −1.48 to 0.29 −0.79 −2.40 to 0.65
LABA/ICS v LABA −1.57 −2.23 to −0.92 −1.61 −2.52 to −0.69
LAMA v LABA −0.98 −1.86 to −0.08 −0.82 −2.29 to 0.84
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 20. Mean and median ranks: change from baseline in St. George’s Respiratory Questionnaire score at 12 months in the
high-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.1 1 1 to 2
LABA/ICS 2.0 2 1 to 3
LAMA 2.9 3 2 to 3
LABA 4.0 4 4 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
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Table 21. Relative effects: change frombaseline in forced expiratory volume in 1 second at 3months in the high-risk population
Treatment comparison Mean differences: fixed-effect Mean differences: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA v LABA/
ICS
0.07 0.05 to 0.09 0.07 0.03 to 0.10
LABA/LAMA v LAMA 0.07 0.05 to 0.10 0.07 0.04 to 0.11
LABA/LAMA v LABA 0.12 0.10 to 0.15 0.12 0.07 to 0.15
LABA/ICS v LAMA 0 −0.02 to 0.02 0.01 −0.02 to 0.04
LABA/ICS v LABA 0.05 0.04 to 0.07 0.05 0.03 to 0.07
LAMA v LABA 0.05 0.02 to 0.07 0.04 0.00 to 0.08
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 22. Mean and median ranks: change from baseline in forced expiratory volume in 1 second at 3 months in the high-
risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.0 1 1 to 1
LABA/ICS 2.4 2 2 to 3
LAMA 2.6 3 2 to 3
LABA 4.0 4 4 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 23. Relative effects: change frombaseline in forced expiratory volume in 1 second at 6months in the high-risk population
Treatment comparison Mean differences: fixed-effect Mean differences: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA v LABA/
ICS
0.08 0.06 to 0.10 0.08 0.04 to 0.12
LABA/LAMA v LAMA 0.07 0.04 to 0.09 0.07 0.02 to 0.11
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Table 23. Relative effects: change frombaseline in forced expiratory volume in 1 second at 6months in the high-risk population
(Continued)
LABA/LAMA v LABA 0.13 0.10 to 0.15 0.13 0.09 to 0.18
LABA/ICS v LAMA −0.02 −0.04 to 0.01 −0.02 −0.06 to 0.03
LABA/ICS v LABA 0.04 0.03 to 0.06 0.05 0.03 to 0.08
LAMA v LABA 0.06 0.03 to 0.08 0.06 0.02 to 0.11
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 24. Mean and median ranks: change from baseline in forced expiratory volume in 1 second at 6 months in the high-
risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.0 1 1 to 1
LAMA 2.1 2 2 to 3
LABA/ICS 2.9 3 2 to 3
LABA 4.0 4 4 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 25. Relative effects: change from baseline in forced expiratory volume in 1 second at 12 months in the high-risk
population
Treatment comparison Mean differences: fixed-effect Mean differences: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA v LABA/
ICS
0.07 0.05 to 0.09 0.07 0.04 to 0.10
LABA/LAMA v LAMA 0.04 0.01 to 0.07 0.04 0.00 to 0.08
LABA/LAMA v LABA 0.11 0.09 to 0.14 0.12 0.08 to 0.16
LABA/ICS v LAMA −0.03 −0.06 to 0.00 −0.03 −0.07 to 0.01
LABA/ICS v LABA 0.05 0.03 to 0.06 0.05 0.03 to 0.07
LAMA v LABA 0.07 0.04 to 0.11 0.08 0.04 to 0.12
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CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 26. Mean and median ranks: change from baseline in forced expiratory volume in 1 second at 12 months in the high-
risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.0 1 1 to 1
LAMA 2.0 2 2 to 2
LABA/ICS 3.0 3 3 to 3
LABA 4.0 4 4 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 27. Relative effects: mortality in the high-risk population
Treatment comparison Odds ratios: fixed-effect Odds ratios: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA v LABA/
ICS
1.12 0.75 to 1.68 1.15 0.70 to 1.95
LABA/LAMA v LAMA 0.98 0.66 to 1.42 0.99 0.62 to 1.60
LABA/LAMA v LABA 0.97 0.63 to 1.46 1.04 0.63 to 1.86
LABA/ICS v LAMA 0.87 0.65 to 1.16 0.86 0.58 to 1.26
LABA/ICS v LABA 0.86 0.66 to 1.11 0.91 0.68 to 1.23
LAMA v LABA 0.99 0.77 to 1.27 1.05 0.75 to 1.59
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 28. Mean and median ranks: mortality in the high-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/ICS 1.6 1 1 to 4
435Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 28. Mean and median ranks: mortality in the high-risk population (Continued)
LABA/LAMA 2.6 3 1 to 4
LAMA 2.8 3 1 to 4
LABA 3.0 3 1 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 29. Relative effects: serious adverse events in the high-risk population
Treatment comparison Odds ratios: fixed-effect Odds ratios: random-effects
Median 95% CrI Median 95% CrI
Total SAEs
LABA/LAMA vs
LABA/ICS
0.89 0.77 to 1.02 0.89 0.74 to 1.06
LABA/LAMA vs
LAMA
1.01 0.87 to 1.17 1.01 0.83 to 1.21
LABA/LAMA vs LABA 0.89 0.77 to 1.04 0.89 0.73 to 1.08
LABA/ICS vs LAMA 1.14 1.02 to 1.27 1.13 0.99 to 1.31
LABA/ICS vs LABA 1.01 0.92 to 1.10 1.01 0.91 to 1.12
LAMA vs LABA 0.88 0.81 to 0.97 0.89 0.78 to 1.01
COPD SAEs
LABA/LAMA vs
LABA/ICS
0.87 0.73 to 1.04 0.87 0.71 to 1.09
LABA/LAMA vs
LAMA
1.07 0.89 to 1.28 1.07 0.85 to 1.34
LABA/LAMA vs LABA 0.82 0.68 to 1.00 0.83 0.65 to 1.05
LABA/ICS vs LAMA 1.22 1.05 to 1.42 1.22 1.02 to 1.46
LABA/ICS vs LABA 0.95 0.83 to 1.08 0.94 0.81 to 1.09
LAMA vs LABA 0.77 0.68 to 0.87 0.77 0.66 to 0.91
CARDIAC SAEs
436Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 29. Relative effects: serious adverse events in the high-risk population (Continued)
LABA/LAMA vs
LABA/ICS
0.91 0.66 to 1.25 0.70 0.03 to 5.88
LABA/LAMA vs
LAMA
0.75 0.54 to 1.03 0.69 0.02 to 25.46
LABA/LAMA vs LABA 0.85 0.60 to 1.19 0.83 0.06 to 9.24
LABA/ICS vs LAMA 0.83 0.63 to 1.08 1.08 0.06 to 23.81
LABA/ICS vs LABA 0.93 0.75 to 1.16 1.27 0.37 to 5.97
LAMA vs LABA 1.13 0.89 to 1.42 1.13 0.06 to 21.22
COPD: chronic obstructive pulmonary disease; CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist;
LAMA: long-acting muscarinic antagonist;SAE: serious adverse event
Table 30. Certainty of evidence: serious adverse events in the high-risk population
Treatment comparison Total SAEs COPD SAEs Cardiac SAEs
LABA/LAMA vs LABA/ICS Moderate Moderate Moderate
LABA/LAMA vs LAMA Moderate Moderate Moderate
LABA/LAMA vs LABA NA NA NA
LABA/ICS vs LAMA Moderate Moderate Moderate
LABA/ICS vs LABA Moderate Moderate Moderate
LAMA vs LABA High High Low
COPD: chronic obstructive pulmonary disease; CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist;
LAMA: long-acting muscarinic antagonist;NA: not applicable; SAE: serious adverse event
Table 31. Relative effects: dropouts due to adverse events in the high-risk population
Treatment comparison Odds ratios: fixed-effect Odds ratios: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
0.93 0.76 to 1.14 0.93 0.73 to 1.19
LABA/LAMA vsLAMA 0.94 0.76 to 1.17 0.95 0.74 to 1.21
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Table 31. Relative effects: dropouts due to adverse events in the high-risk population (Continued)
LABA/LAMA vs LABA 0.83 0.67 to 1.03 0.83 0.65 to 1.07
LABA/ICS vs LAMA 1.01 0.87 to 1.19 1.02 0.85 to 1.22
LABA/ICS vs LABA 0.89 0.79 to 1.01 0.89 0.79 to 1.01
LAMA vs LABA 0.88 0.77 to 1.01 0.88 0.75 to 1.03
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 32. Mean and median ranks: dropouts due to adverse events in the high-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.6 1 1 to 4
LAMA 2.2 2 1 to 4
LABA/ICS 2.4 2 1 to 4
LABA 3.9 4 3 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 33. Relative effects: pneumonia in the high-risk population
Treatment comparison Odds ratios: fixed-effect Odds ratios: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
0.59 0.41 to 0.83 0.59 0.35 to 1.01
LABA/LAMA vs
LAMA
1.05 0.72 to 1.5 1.05 0.63 to 1.81
LABA/LAMA vs LABA 0.88 0.60 to 1.29 0.87 0.49 to 1.52
LABA/ICS vs LAMA 1.78 1.33 to 2.39 1.79 1.19 to 2.76
LABA/ICS vs LABA 1.50 1.17 to 1.92 1.48 1.10 to 1.98
LAMA vs LABA 0.84 0.65 to 1.09 0.83 0.54 to 1.21
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
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Table 34. Mean and median ranks: pneumonia in the high-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LAMA 1.5 1 1 to 3
LABA/LAMA 1.9 2 1 to 3
LABA 2.6 3 1 to 3
LABA/ICS 4.0 4 4 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 35. Relative effects: moderate to severe exacerbations in the low-risk population
Treatment comparison Hazard ratios: fixed-effect Hazard ratios: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
0.87 0.75 to 1.01 0.89 0.78 to 1.04
LABA/LAMA vs
LAMA
0.90 0.76 to 1.06 0.88 0.76 to 1.01
LABA/LAMA vs LABA 0.78 0.67 to 0.90 0.78 0.69 to 0.89
LABA/ICS vs LAMA 1.03 0.91 to 1.17 0.98 0.83 to 1.14
LABA/ICS vs LABA 0.89 0.84 to 0.96 0.88 0.78 to 0.96
LAMA vs LABA 0.87 0.78 to 0.97 0.89 0.78 to 1.01
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 36. Mean and median group ranks: moderate to severe exacerbations in the low-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.1 1 1 to 2
LAMA 2.2 2 1 to 3
LABA/ICS 2.6 3 2 to 3
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Table 36. Mean and median group ranks: moderate to severe exacerbations in the low-risk population (Continued)
LABA 4.0 4 4 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 37. Study characteristics of treatment group pair-wise comparisons and transitivity assessment in moderate to severe
exacerbations in the low-risk population
Comparison Comparisons Number of
participants
Mean age
(years)
Male (%) Baseline FEV1
(L) prebron-
chodilator
Current
smoker (%)
Bronchial re-
versibility (%)
LABA/
LAMA vs
LABA/ICS
6 4315 63 74 45 1.33 14.9
LABA/
LAMA vs
LAMA
8 5192 63 71 47 1.32 14.7
LABA/
LAMA vs
LABA
5 2488 64 68 44 1.36 17.5
LABA/ICS vs
LAMA
1 623 63 65 52 1.35 13
LABA/ICS vs
LABA
6 6689 64 74 44 1.27 11.1
LAMA vs
LABA
5 4567 64 71 39 1.3 17.1
CrI: credible interval; FEV1: forced expiratory volume in 1 second; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist;
LAMA: long-acting muscarinic antagonist
Table 38. Relative effects: severe exacerbations in the low-risk population
Treatment comparison Hazard ratios: fixed-effect Hazard ratios: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
0.71 0.50 to 1.02 0.71 0.47 to 1.08
LABA/LAMA vs
LAMA
0.88 0.62 to 1.24 0.90 0.60 to 1.31
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Table 38. Relative effects: severe exacerbations in the low-risk population (Continued)
LABA/LAMA vs LABA 0.73 0.51 to 1.03 0.72 0.48 to 1.02
LABA/ICS vs LAMA 1.23 0.96 to 1.57 1.25 0.86 to 1.85
LABA/ICS vs LABA 1.02 0.89 to 1.17 1.01 0.72 to 1.28
LAMA vs LABA 0.83 0.67 to 1.03 0.80 0.56 to 1.05
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 39. Mean and median ranks: severe exacerbations in the low-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.3 1 1 to 3
LAMA 1.9 2 1 to 3
LABA 3.3 3 2 to 4
LABA/ICS 3.5 4 2 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 40. Relative effects: St. George’s Respiratory Questionnaire responders at 3 months in the low-risk population
Treatment comparison Odds ratios: fixed-effect Odds ratios: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
1.07 0.94 to 1.23 1.07 0.93 to 1.23
LABA/LAMA vs
LAMA
1.33 1.19 to 1.48 1.32 1.18 to 1.49
LABA/LAMA vs LABA 0.96 0.81 to 1.15 0.96 0.79 to 1.17
LABA/ICS vs LAMA 1.24 1.07 to 1.43 1.24 1.06 to 1.45
LABA/ICS vs LABA 0.9 0.76 to 1.06 0.9 0.75 to 1.08
LAMA vs LABA 0.73 0.62 to 0.85 0.72 0.60 to 0.87
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
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Table 41. Mean and median ranks: St. George’s Respiratory Questionnaire responders at 3 months in the low-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA 1.4 1 1 to 3
LABA/LAMA 1.8 2 1 to 3
LABA/ICS 2.8 3 1 to 3
LAMA 4.0 4 4 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 42. Relative effects: SGRQ responders at 6 months in the low-risk population
Treatment comparison Odds ratios: random-effects
Median 95% CrI
LABA/LAMA vs LABA/ICS 1.22 0.99 to 1.51
LABA/LAMA vs LAMA 1.26 1.10 to 1.42
LABA/LAMA vs LABA 1.28 1.11 to 1.47
LABA/ICS vs LAMA 1.03 0.83 to 1.27
LABA/ICS vs LABA 1.05 0.87 to 1.25
LAMA vs LABA 1.02 0.90 to 1.16
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 43. Mean and median ranks: St. George’s Respiratory Questionnaire responders at 6 months in the low-risk population
Treatment group Rank (from random-effects model)
Mean Median 95% CrI
LABA/LAMA 1.0 1 1 to 2
LABA/ICS 2.7 2 1 to 4
LAMA 3.0 3 2 to 4
LABA 3.3 3 2 to 4
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CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 44. Change from baseline in St. George’s Respiratory Questionnaire score at 3 months in the low-risk population
Treatment comparison Mean differences: fixed-effect Mean differences: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
0.04 −0.79 to 0.88 0.04 −0.84 to 0.88
LABA/LAMA vs
LAMA
−1.64 −2.2 to −1.08 −1.64 −2.25 to −1.05
LABA/LAMA vs LABA −0.63 −1.86 to 0.6 −0.62 −1.95 to 0.65
LABA/ICS vs LAMA −1.68 −2.59 to −0.78 −1.68 −2.6 to −0.74
LABA/ICS vs LABA −0.67 −1.88 to 0.54 −0.67 −1.92 to 0.57
LAMA vs LABA 1.01 −0.2 to 2.22 1.02 −0.26 to 2.27
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 45. Mean and median ranks: change from baseline in St. George’s Respiratory Questionnaire score at 3 months in the
low-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/ICS 1.6 2 1 to 3
LABA/LAMA 1.7 2 1 to 3
LABA 2.8 3 1 to 4
LAMA 3.9 4 3 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 46. Relative effects: change from baseline in SGRQ score at 6 months in the low-risk population
Treatment comparison Mean differences: fixed-effect Mean differences: random-effects
Median 95% CrI Median 95% CrI
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Table 46. Relative effects: change from baseline in SGRQ score at 6 months in the low-risk population (Continued)
LABA/LAMA vs
LABA/ICS
−0.22 −1.28 to 0.82 −0.3 −1.50 to 0.93
LABA/LAMA vs
LAMA
−1.18 −1.80 to −0.56 −1.17 −1.91 to −0.48
LABA/LAMA vs LABA −1.36 −2.12 to −0.6 −1.4 −2.24 to −0.51
LABA/ICS vs LAMA −0.96 −1.98 to 0.09 −0.89 −2.08 to 0.33
LABA/ICS vs LABA −1.14 −1.90 to −0.37 −1.11 −2.01 to −0.16
LAMA vs LABA −0.18 −0.91 to 0.55 −0.21 −1.05 to 0.61
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 47. Mean and median ranks: St. George’s Respiratory Questionnaire at 6 months in the low-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.3 1 1 to 2
LABA/ICS 1.7 2 1 to 3
LAMA 3.3 3 2 to 4
LABA 3.7 4 3 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 48. Relative effects: change from baseline in St. George’s Respiratory Questionnaire score at 12 months in the low-risk
population
Treatment comparison Mean differences: fixed-effect Mean differences: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
0.97 −0.48 to 2.42 1.05 −1.78 to 3.98
LABA/LAMA vs
LAMA
−0.89 −1.66 to −0.11 −0.8 −2.05 to 0.62
LABA/LAMA vs LABA −0.72 −1.64 to 0.20 −0.65 −2.29 to 1.11
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Table 48. Relative effects: change from baseline in St. George’s Respiratory Questionnaire score at 12 months in the low-risk
population (Continued)
LABA/ICS vs LAMA −1.85 −3.28 to −0.43 −1.86 −4.63 to 1.02
LABA/ICS vs LABA −1.69 −2.81 to −0.57 −1.71 −4.02 to 0.65
LAMA vs LABA 0.16 −0.72 to 1.04 0.13 −1.48 to 1.74
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 49. Mean and median ranks: change from baseline in St. George’s Respiratory Questionnaire score at 12 months in the
low-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/ICS 1.1 1 1 to 2
LABA/LAMA 2.0 2 1 to 3
LABA 3.3 3 2 to 4
LAMA 3.6 4 3 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 50. Relative effects: Transition Dyspnea Index at 3 months in the low-risk population
Treatment comparison Mean differences: random-effects
(fixed-class)
Mean differences: fixed-effect (random-class)
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
0.35 0.12 to 0.56 0.48 0.09 to 0.99
LABA/LAMA vs
LAMA
0.54 0.36 to 0.73 0.55 0.22 to 0.90
LABA/LAMA vs LABA 0.44 0.20 to 0.67 0.47 0.09 to 0.85
LABA/ICS vs LAMA 0.19 −0.07 to 0.47 0.06 −0.43 to 0.48
LABA/ICS vs LABA 0.09 −0.18 to 0.36 −0.02 −0.48 to 0.37
LAMA vs LABA −0.1 −0.36 to 0.14 −0.08 −0.46 to 0.28
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
445Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 51. Median and mean ranks: Transition Dyspnea Index at 3 months in the low-risk population
Treatment group Rank (from random-effects, fixed-class)
Mean Median 95% CrI
LABA/LAMA 1.0 1 1 to 1
LABA/ICS 2.3 2 2 to 4
LABA 3.0 3 2 to 4
LAMA 3.7 4 2 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 52. Relative effects: Transition Dyspnea Index at 6 months in the low-risk population
Treatment comparison Mean differences: random-effects
(fixed-class)
Mean differences: fixed-effect (random-class)
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
0.15 −0.10 to 0.4 0.14 −0.14 to 0.41
LABA/LAMA vs
LAMA
0.33 0.18 to 0.47 0.32 0.15 to 0.48
LABA/LAMA vs LABA 0.37 0.21 to 0.52 0.36 0.18 to 0.55
LABA/ICS vs LAMA 0.18 −0.09 to 0.45 0.18 −0.12 to 0.50
LABA/ICS vs LABA 0.22 −0.02 to 0.46 0.22 −0.04 to 0.50
LAMA vs LABA 0.04 −0.12 to 0.21 0.04 −0.15 to 0.24
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 53. Mean and median ranks: Transition Dyspnea Index at 6 months in the low-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.1 1 1 to 2
LABA/ICS 2.0 2 1 to 4
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Table 53. Mean and median ranks: Transition Dyspnea Index at 6 months in the low-risk population (Continued)
LAMA 3.2 3 2 to 4
LABA 3.6 4 3 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 54. Relative effects: Transition Dyspnea Index at 12 months in the low-risk population
Treatment comparison Mean differences: random-effects
(fixed-class)
Mean differences: fixed-effect (random-class)
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LAMA
0.20 0.09 to 0.32 0.22 −0.05 to 0.51
LABA/LAMA vs LABA 0.30 0.17 to 0.42 0.37 0.11 to 0.71
LAMA vs LABA 0.09 −0.02 to 0.21 0.15 −0.10 to 0.46
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 55. Mean and median ranks: Transition Dyspnea Index at 12 months in the low-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.00 1 1 to 1
LAMA 2.06 2 2 to 3
LABA 2.94 3 2 to 3
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 56. Relative effects: change from baseline in forced expiratory volume in 1 second at 3 months in the low-risk population
Treatment comparison Mean differences: random-effects
Median 95% CrI
LABA/LAMA vs LABA/ICS 0.05 0.03 to 0.07
LABA/LAMA vs LAMA 0.08 0.06 to 0.09
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Table 56. Relative effects: change from baseline in forced expiratory volume in 1 second at 3 months in the low-risk population
(Continued)
LABA/LAMA vs LABA 0.09 0.07 to 0.11
LABA/ICS vs LAMA 0.02 0.00 to 0.04
LABA/ICS vs LABA 0.03 0.01 to 0.05
LAMA vs LABA 0.01 −0.01 to 0.03
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 57. Mean and median ranks: change from baseline in forced expiratory volume in 1 second at 3 months in the low-risk
population
Treatment group Rank (from random-effects model)
Mean Median 95% CrI
LABA/LAMA 1.0 1 1 to 1
LABA/ICS 2.0 2 2 to 2
LAMA 3.2 3 3 to 4
LABA 3.8 4 3 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 58. Relative effects: change from baseline in forced expiratory volume in 1 second at 6 months in the low-risk population
Treatment comparison Mean differences: random-effects Mean differences: fixed-effect (random-class)
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
0.05 0.03 to 0.08 0.05 −0.01 to 0.11
LABA/LAMA vs
LAMA
0.06 0.05 to 0.08 0.06 0.02 to 0.09
LABA/LAMA vs LABA 0.08 0.06 to 0.09 0.08 0.04 to 0.11
LABA/ICS vs LAMA 0.01 −0.02 to 0.04 0.01 −0.05 to 0.07
LABA/ICS vs LABA 0.02 −0.01 to 0.05 0.03 −0.02 to 0.08
LAMA vs LABA 0.01 0.00 to 0.03 0.02 −0.01 to 0.05
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CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 59. Mean and median ranks: change from baseline in forced expiratory volume in 1 second at 6 months in the low-risk
population
Treatment group Rank (from random-effects to fixed-class)
Mean Median 95% CrI
LABA/LAMA 1.0 1 1 to 1
LABA/ICS 2.3 2 2 to 4
LAMA 2.7 3 2 to 4
LABA 3.9 4 3 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 60. Relative effects: change frombaseline in forced expiratory volume in 1 second at 12months in the low-risk population
Treatment comparison Mean differences− fixed effects Mean differences: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LAMA
0.06 −0.01 to 0.12 0.06 0.04 to 0.08
LABA/LAMA vs LABA 0.08 0.02 to 0.14 0.08 0.06 to 0.10
LAMA vs LABA 0.02 0.00 to 0.06 0.02 0.00 to 0.04
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 61. Mean and median ranks: change from baseline in forced expiratory volume in 1 second at 12 months in the low-
risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/LAMA 1.1 1 1 to 2
LAMA 2.0 2 1 to 3
LABA 3.0 3 2 to 3
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
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Table 62. Intervention effects: change from baseline in forced expiratory volume in 1 second at 12 months in the low-risk
population
Intervention Median 95% CrI
Formoterol 9−12 twice daily Reference
Indacaterol 75 once daily 0.002 −0.029 to 0.048
Olodaterol 5 once daily 0.001 −0.018 to 0.022
Tiotripium 18 once daily 0.034 0.016 to 0.054
Tiotripium 5 once daily 0.031 0.009 to 0.056
Aclidinium 400 twice daily 0.027 −0.002 to 0.060
Glycopyrronium 15.6 twice daily 0.010 −0.006 to 0.027
Glycopyrronium 50 once daily 0.022 −0.022 to 0.062
Formoterol/glycopyrronium 9.6/18 twice
daily
0.066 0.050 to 0.081
Indacaterol/glycopyrronium 27.5/15.6
twice daily
0.083 0.034 to 0.137
Indacaterol/glycopyrronium 110/50 once
daily
0.128 0.091 to 0.165
Olodaterol/tiotropium 5/5 once daily 0.089 0.066 to 0.114
Formterol/aclidinium 12/400 twice daily 0.044 0.005 to 0.081
CrI: credible interval
Table 63. Relative effects: mortality in the low-risk population
Treatment comparison Odds ratios: fixed-effect Odds ratios: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
1.25 0.79 to 2.00 1.27 0.69 to 2.30
LABA/LAMA vs
LAMA
0.91 0.63 to 1.32 0.90 0.59 to 1.34
LABA/LAMA vs LABA 1.16 0.75 to 1.81 1.19 0.73 to 1.98
450Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 63. Relative effects: mortality in the low-risk population (Continued)
LABA/ICS vs LAMA 0.73 0.45 to 1.16 0.72 0.37 to 1.30
LABA/ICS vs LABA 0.93 0.76 to 1.14 0.94 0.59 to 1.52
LAMA vs LABA 1.28 0.83 to 1.98 1.31 0.82 to 2.22
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 64. Mean and median ranks: mortality in the low-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LABA/ICS 1.5 1 1 to 4
LABA 2.1 2 1 to 4
LABA/LAMA 3.0 3 1 to 4
LAMA 3.5 4 1 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 65. Relative effects: serious adverse events in the low-risk population
Treatment comparison Odds ratios: fixed-effect Odds ratios: random-effects
Median 95% CrI Median 95% CrI
Total SAEs
LABA/LAMA vs
LABA/ICS
0.91 0.78 to 1.05 0.91 0.77 to 1.06
LABA/LAMA vs
LAMA
1.03 0.93 to 1.15 1.03 0.92 to 1.16
LABA/LAMA vs LABA 1.02 0.91 to 1.15 1.02 0.90 to 1.16
LABA/ICS vs LAMA 1.14 0.98 to 1.32 1.14 0.97 to 1.35
LABA/ICS vs LABA 1.13 1.01 to 1.27 1.13 0.99 to 1.29
LAMA vs LABA 0.99 0.88 to 1.11 0.99 0.87 to 1.12
COPD SAEs
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Table 65. Relative effects: serious adverse events in the low-risk population (Continued)
LABA/LAMA vs
LABA/ICS
0.96 0.75 to 1.22 0.92 0.67 to 1.26
LABA/LAMA vs
LAMA
0.99 0.82 to 1.19 0.98 0.78 to 1.21
LABA/LAMA vs LABA 0.92 0.75 to 1.13 0.89 0.68 to 1.13
LABA/ICS vs LAMA 1.04 0.81 to 1.32 1.06 0.77 to 1.48
LABA/ICS vs LABA 0.96 0.82 to 1.13 0.96 0.73 to 1.25
LAMA vs LABA 0.93 0.76 to 1.14 0.9 0.71 to 1.14
Cardiac SAEs
LABA/LAMA vs
LABA/ICS
1.28 0.91 to 1.81 1.24 0.81 to 1.83
LABA/LAMA vs
LAMA
1.05 0.80 to 1.36 1.04 0.77 to 1.37
LABA/LAMA vs LABA 1.24 0.92 to 1.68 1.24 0.89 to 1.71
LABA/ICS vs LAMA 0.82 0.58 to 1.15 0.84 0.56 to 1.27
LABA/ICS vs LABA 0.97 0.79 to 1.19 0.99 0.74 to 1.41
LAMA vs LABA 1.19 0.89 to 1.59 1.19 0.88 to 1.64
COPD: chronic obstructive pulmonary disease; CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist;
LAMA: long-acting muscarinic antagonist; SAE: serious adverse event
Table 66. Certainty of evidence: serious adverse events in the low-risk population
Treatment comparison Total SAEs COPD SAEs Cardiac SAEs
LABA/LAMA vs LABA/ICS Moderate Low Moderate
LABA/LAMA vs LAMA High High Moderate
LABA/LAMA vs LABA High Moderate Moderate
LABA/ICS vs LAMA Moderate Moderate Moderate
LABA/ICS vs LABA Low High High
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Table 66. Certainty of evidence: serious adverse events in the low-risk population (Continued)
LAMA vs LABA High Low Moderate
COPD: chronic obstructive pulmonary disease; CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist;
LAMA: long-acting muscarinic antagonist; SAE: serious adverse event
Table 67. Relative effects: dropouts due to adverse events in the low-risk population
Treatment comparison Odds ratios: fixed-effect Odds ratios: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
0.99 0.83 to 1.18 0.99 0.82 to 1.2
LABA/LAMA vs
LAMA
1.09 0.95 to 1.26 1.09 0.94 to 1.28
LABA/LAMA vs LABA 0.91 0.78 to 1.06 0.91 0.77 to 1.07
LABA/ICS vs LAMA 1.11 0.92 to 1.33 1.11 0.89 to 1.37
LABA/ICS vs LABA 0.92 0.8 to 1.06 0.92 0.77 to 1.09
LAMA vs LABA 0.84 0.72 to 0.97 0.83 0.7 to 0.98
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 68. Mean and median ranks: dropouts due to adverse events in the low-risk population
Treatment group Rank (from fixed-effect model)
Mean Median 95% CrI
LAMA 1.3 1 1 to 3
LABA/ICS 2.5 3 1 to 4
LABA/LAMA 2.5 2 1 to 4
LABA 3.7 4 2 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
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Table 69. Relative effects: pneumonia in the low-risk population
Treatment comparison Odds ratios: fixed-effect Odds ratios: random-effects
Median 95% CrI Median 95% CrI
LABA/LAMA vs
LABA/ICS
0.67 0.44 to 1.01 0.61 0.34 to 1.01
LABA/LAMA vs
LAMA
1.24 0.87 to 1.77 1.23 0.82 to 1.84
LABA/LAMA vs LABA 1.21 0.83 to 1.77 1.18 0.75 to 1.81
LABA/ICS vs LAMA 1.87 1.21 to 2.91 2.02 1.16 to 3.72
LABA/ICS vs LABA 1.82 1.41 to 2.36 1.93 1.29 to 3.22
LAMA vs LABA 0.97 0.66 to 1.44 0.96 0.62 to 1.49
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 70. Mean and median ranks: pneumonia in the low-risk population
Treatment group Rank (from random-effects model)
Mean Median 95% CrI
LAMA 1.6 1 1 to 3
LABA 1.8 2 1 to 3
LABA/LAMA 2.7 3 1 to 4
LABA/ICS 4.0 4 3 to 4
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Table 71. Within-class/group standard deviation for forced expiratory volume in 1 second at 12 months in the low-risk
population: fixed-treatment-effect model with random-class
Treatment group Median 95% CrI
LABA 0.273 0.022 to 1.190
LAMA 0.109 0.005 to 0.589
LABA/ICS 0.181 0.036 to 0.612
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Table 71. Within-class/group standard deviation for forced expiratory volume in 1 second at 12 months in the low-risk
population: fixed-treatment-effect model with random-class (Continued)
LABA/LAMA 0.181 0.036 to 0.612
CrI: credible interval; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Trials Register
Electronic searches: core databases
Database Dates searched Frequency of search
CENTRAL (via the Cochrane Register of
Studies (CRS))
From inception Monthly
MEDLINE (Ovid) 1946 onwards Weekly
Embase (Ovid) 1974 onwards Weekly
PsycINFO (Ovid) 1967 onwards Monthly
CINAHL (EBSCO) 1937 onwards Monthly
AMED (EBSCO) From inception Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
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(Continued)
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
Chronic obstructive pulmonary disease (COPD) search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.
5. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
6. COPD.mp.
7. COAD.mp.
8. COBD.mp.
9. AECB.mp.
10. or/1-9
Filter to identify randomised controlled trials (RCTs)
1. exp “clinical trial [publication type)”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
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Appendix 2. Search strategy to identify relevant trials from the Cochrane Airways Trials Register
#1 MeSH DESCRIPTOR Pulmonary Disease, Chronic Obstructive Explode All
#2 MeSH DESCRIPTOR Bronchitis, Chronic
#3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)
#4 COPD:MISC1
#5 (COPD OR COAD OR COBD OR AECOPD):TI,AB,KW
#6 #1 OR #2 OR #3 OR #4 OR #5
#7 mometasone* AND formoterol*
#8 fluticasone* AND salmeterol*
#9 budesonide* AND formoterol*
#10 beclomethasone* AND formoterol*
#11 fluticasone* AND formoterol*
#12 Flutiform or Fostair or Simplyone
#13 fluticasone* AND vilanterol*
#14 mometasone* AND indacaterol*
#15 formoterol* and ciclesonide*
#16 QMF149
#17 GW685698 AND GW642444
#18 steroid* OR corticosteroid* or ICS
#19 (long-acting* or long NEXT acting*) NEAR beta*
#20 #18 AND #19
#21 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #20
#21 formoterol* AND aclidinium*
#22 indacaterol* AND glycopyrronium*
#23 indacaterol* AND tiotropium*
#24 olodaterol* AND tiotropium*
#25 vilanterol* AND umeclidinium*
#26 QVA149
#27 Ultibro or Stiolto or Duaklir Genuair
#28 Muscarinic* Next Antagonist*
#29 #19 AND #28
#30 #21 or # 22 or #23 or #24 or #25 or #26 or #27 or # 29
#31 combin* NEAR inhaler*
#32 FDC:ti,ab
#33 #21 or #30 or #31 or #32
#34 #6 AND #33
(In search line #4, MISC1 denotes the field in which the reference has been coded for condition, in this case, COPD)
Appendix 3. Tables of interventions and treatment groups in the NMAs
1. Population: high-risk
1.1.1 Moderate to severe exacerbations
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Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
3 Formoterol 9-12 µg twice daily LABA
4 Tiotropium 18 µg once daily LAMA
5 Glycopyrronium 50 µg once daily LAMA
6 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
7 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
8 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
9 Salmeterol 50 twice daily + fluticasone 500 µg twice daily LABA/ICS
10 Formoterol/budesonide 9/160 µg twice daily LABA/ICS
11 Formoterol/budesonide 9/320 µg twice daily LABA/ICS
12 Formoterol/beclomethasone 12/200 µg twice daily LABA/ICS
13 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
14 Salmeterol 50 twice daily + tiotropium 18 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.1.2 Severe exacerbations
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
3 Tiotropium 18 µg once daily LAMA
4 Glycopyrronium 50 µg once daily LAMA
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(Continued)
5 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
6 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
7 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
8 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
9 Salmeterol 50 twice daily + tiotropium 18 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.2.2 St George’s Respiratory Questionnaire responders at 12 months
Intervention Treatment group
1 Salmeterol 50 twice daily LABA
2 Indacaterol 150 once daily LABA
3 Formoterol 9-12 twice daily LABA
4 Tiotropium 18 once daily LAMA
5 Glycopyrronium 50 once daily LAMA
6 Salmeterol/fluticasone 50/250 twice daily LABA/ICS
7 Salmeterol/fluticasone 50/500 twice daily LABA/ICS
8 Formoterol/budesonide 12/400 twice daily DPI LABA/ICS
9 Formoterol/beclomethasone 12/200 twice daily LABA/ICS
10 Indacaterol/glycopyrronium 110/50 once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.3.1 Change from baseline in St George’s Respiratory Questionnaire score at 3 months
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Intervention Treatment group
1 Indacaterol 150 µg once daily LABA
2 Salmeterol 50 µg twice daily LABA
3 Formoterol 9-12 µg twice daily LABA
4 Tiotropium 18 µg once daily LAMA
5 Glycopyrronium 50 µg once daily LAMA
6 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
7 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
8 Salmeterol 50 µg twice daily + fluticasone 250 µg twice daily LABA/ICS
9 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
10 Indacaterol 150µg once daily + budesonide 400µg twice daily LABA/ICS
11 Formoterol/budesonide 9/320 µg twice daily LABA/ICS
12 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.3.2 Change from baseline in St George’s Respiratory Questionnaire score at 6 months
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
3 Formoterol 9-12 µg twice daily LABA
4 Tiotropium 18 µg once daily LAMA
5 Glycopyrronium 50 µg once daily LAMA
6 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
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(Continued)
7 Salmeterol/fluticasone 50/50 µg twice daily LABA/ICS
8 Salmeterol 50 µg twice daily + fluticasone 250 µg twice daily LABA/ICS
9 Indacaterol 150µg once daily + budesonide 400µg twice daily LABA/ICS
10 budesonide/formoterol 160/9 µg twice daily LABA/ICS
11 budesonide/formoterol 320/9 µg twice daily LABA/ICS
12 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.3.3 Change from baseline in St George’s Respiratory Questionnaire score at 12 months
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
3 Formoterol 9 µg twice daily LABA
4 Formoterol 12 µg twice daily LABA
5 Tiotropium 18 µg once daily LAMA
6 Glycopyrronium 50 µg once daily LAMA
7 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
8 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
9 Salmeterol 50 µg twice daily + fluticasone 500 µg twice daily LABA/ICS
10 Budesonide/formoterol 160/9 µg twice daily LABA/ICS
11 Budesonide/formoterol 400/12 µg twice daily LABA/ICS
12 Beclomethasone/formoterol 200/12 µg twice daily LABA/ICS
13 Budesonide/formoterol 320/9 µg twice daily LABA/ICS
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(Continued)
14 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
15 Salmeterol 50 µg twice daily + tiotropium 18 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.5.1 Change from baseline in forced expiratory volume in 1 second at 3 months
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 9 µg twice daily LABA
3 Formoterol 12 µg twice daily LABA
4 Tiotropium 18 µg once daily LAMA
5 Glycopyrronium 50 µg once daily LAMA
6 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
7 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
8 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
9 Budesonide + indacaterol 400/150 µg twice daily LABA/ICS
10 Budesonide/formoterol 320/9 µg twice daily LABA/ICS
11 Beclomethasone/formoterol 200/12 µg twice daily LABA/ICS
12 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.5.2 Change from baseline in forced expiratory volume in 1 second at 6 months
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Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 9 µg twice daily LABA
3 Tiotropium 18 µg once daily LAMA
4 Glycopyrronium 50 µg once daily LAMA
5 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
6 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
7 Salmeterol 50 twice daily + fluticasone 250 µg twice daily LABA/ICS
8 Budesonide + indacaterol 400/150 µg twice daily LABA/ICS
9 Budesonide/formoterol 160/9 µg twice daily LABA/ICS
10 Budesonide/formoterol 320/9 µg twice daily LABA/ICS
11 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.5.3 Change from baseline in forced expiratory volume in 1 second at 12 months
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 9 µg twice daily LABA
3 Formoterol 12 µg twice daily LABA
4 Tiotropium 18 µg once daily LAMA
5 Glycopyrronium 50 µg once daily LAMA
6 Budesonide/formoterol 320/9 µg twice daily LABA/ICS
7 Budesonide/formoterol 160/9 µg twice daily LABA/ICS
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(Continued)
8 Budesonide/formoterol 400/12 µg twice daily LABA/ICS
9 Beclomethasone/formoterol 200/12 µg twice daily LABA/ICS
10 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
11 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
12 Salmeterol 50 twice daily + fluticasone 500 µg twice daily LABA/ICS
13 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.6 Mortality
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
3 Formoterol 9 µg twice daily LABA
4 Formoterol 12 µg twice daily LABA
5 Tiotropium 18 µg once daily LAMA
6 Glycopyrronium 50 µg once daily LAMA
7 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
8 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
9 Salmeterol 50 µg twice daily + fluticasone 500 µg twice daily LABA/ICS
10 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
11 Salmeterol 50 twice daily + fluticasone 250 µg twice daily LABA/ICS
12 Budesonide 400µg twice daily + indacaterol 150µg once daily LABA/ICS
13 Budesonide/formoterol 320/9 µg twice daily LABA/ICS
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(Continued)
14 Budesonide/formoterol 160/9 µg twice daily LABA/ICS
15 Budesonide/formoterol 400/12 µg LABA/ICS
16 Beclomethasone/formoterol 200/12 µg LABA/ICS
17 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
18 Salmeterol 50 twice daily + tiotropium 18 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.7.1 Total serious adverse events
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
3 Formoterol 9 µg twice daily LABA
4 Formoterol 12 µg twice daily LABA
5 Tiotropium 18 µg once daily LAMA
6 Glycopyrronium 50 µg once daily LAMA
7 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
8 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
9 Salmeterol 50 µg twice daily + fluticasone 500 µg twice daily LABA/ICS
10 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
11 Budesonide 400µg twice daily + indacaterol 150µg once daily LABA/ICS
12 Budesonide/formoterol 320/9 µg twice daily LABA/ICS
13 Budesonide/formoterol 160/9 µg twice daily LABA/ICS
14 Budesonide/formoterol 400/12 µg LABA/ICS
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15 Beclomethasone/formoterol 200/12 µg LABA/ICS
16 Salmeterol 50 µg twice daily + fluticasone 250 µg twice daily LABA/ICS
17 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
18 Salmeterol 50 µg twice daily + tiotropium 18 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.7.2 Chronic obstructive pulmonary disease serious adverse events
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
3 Formoterol 9 µg twice daily LABA
4 Tiotropium 18 µg once daily LAMA
5 Glycopyrronium 50 µg once daily LAMA
6 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
7 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
8 Salmeterol 50 µg twice daily + fluticasone 250 µg twice daily LABA/ICS
9 Salmeterol 50 µg twice daily + fluticasone 500 µg twice daily LABA/ICS
10 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
11 Indacaterol 150µg once daily + budesonide 400µg twice daily LABA/ICS
12 Budesonide/formoterol 160/9 µg twice daily LABA/ICS
13 Budesonide/formoterol 320/9 µg twice daily LABA/ICS
14 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.7.3 Cardiac serious adverse events
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Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
3 Formoterol 9 µg twice daily LABA
4 Formoterol 12 µg twice daily LABA
5 Tiotropium 18 µg once daily LAMA
6 Glycopyrronium 50 µg once daily LAMA
7 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
8 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
9 Salmeterol 50 µg twice daily + fluticasone 500 µg twice daily LABA/ICS
10 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
11 Fluticasone 250 µg + salmeterol 50 µg twice daily LABA/ICS
12 Budesonide 400µg twice daily + indacaterol 150µg once daily LABA/ICS
13 Budesonide/formoterol 160/9 µg twice daily LABA/ICS
14 Budesonide/formoterol 320/9 µg twice daily LABA/ICS
15 Beclomethasone/formoterol 200/12 µg LABA/ICS
16 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.8 Dropouts due to adverse events
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
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3 Formoterol 9 µg twice daily LABA
4 Formoterol 12 µg twice daily LABA
5 Tiotropium 18 µg once daily LAMA
6 Glycopyrronium 50 µg once daily LAMA
7 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
8 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
9 Salmeterol 50 µg twice daily + fluticasone 500 µg twice daily LABA/ICS
10 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
11 Fluticasone 250 µg + salmeterol 50 µg twice daily LABA/ICS
12 Budesonide 400µg twice daily + indacaterol 150µg once daily LABA/ICS
13 Budesonide/formoterol 320/9 µg twice daily LABA/ICS
14 Budesonide/formoterol 160/9 µg twice daily LABA/ICS
15 Budesonide/formoterol 400/12 µg LABA/ICS
16 Beclomethasone/formoterol 200/12 LABA/ICS
17 Indacaterol/glycopyrronium 110/50 once daily LABA/LAMA
18 Salmeterol 50 twice daily + tiotropium 18 once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
1.9 Pneumonia
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
3 Formoterol 9 µg twice daily LABA
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4 Formoterol 12 µg twice daily LABA
5 Tiotropium 18 µg once daily LAMA
6 Glycopyrronium 50 µg once daily LAMA
7 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
8 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
9 Salmeterol 50 twice daily + fluticasone 500 µg twice daily LABA/ICS
10 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
11 Budesonide/formoterol 160/9 µg twice daily LABA/ICS
12 Budesonide/formoterol 320/9 µg twice daily LABA/ICS
13 Budesonide/formoterol 400/12 µg LABA/ICS
14 Beclomethasone/formoterol 200/12 µg LABA/ICS
15 Budesonide 400µg twice daily + indacaterol 150µg once daily LABA/ICS
16 Fluticasone 250 µg + salmeterol 50 µg twice daily LABA/ICS
17 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
18 Salmeterol 50 µg twice daily + tiotropium 18 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2 Population: low-risk
2.1.1 Moderate to severe exacerbations
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 9-12 µg twice daily LABA
3 Indacaterol 75 µg once daily LABA
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4 Indacaterol 150 µg once daily LABA
5 Indacaterol 300 µg once daily LABA
6 Tiotropium 18 µg once daily LAMA
7 Tiotropium 5 µg once daily LAMA
8 Aclidinium 400 µg twice daily LAMA
9 Umeclidinium 62.5 µg once daily LAMA
10 Glycopyrronium 50 µg once daily LAMA
11 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
12 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
13 Salmeterol/fluticasone 42/230 µg (HFA) twice daily LABA/ICS
14 Formoterol/mometasone 200/10 µg twice daily LABA/ICS
15 Formoterol/mometasone 400/10 µg twice daily LABA/ICS
16 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
17 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
18 Indacaterol/glycopyrronium 27.5/12.5 µg twice daily LABA/LAMA
19 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
20 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
21 Indacaterol 150 µg once daily + tiotropium 18 µg once daily LABA/LAMA
22 Tiotropium 18 µg once daily + formoterol 10 µg twice daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.1.2 Severe exacerbations
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Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 9-12 µg twice daily LABA
3 Indacaterol 150 µg once daily LABA
4 Tiotropium 18 µg once daily LAMA
5 Tiotropium 5 µg once daily LAMA
6 Umeclidinium 62.5 µg once daily LAMA
7 Glycopyrronium 50 µg once daily LAMA
8 Salmetrol/fluticasone 50/250 µg twice daily LABA/ICS
9 Salmetrol/fluticasone 50/500 µg twice daily LABA/ICS
10 Salmetrol/fluticasone 42/230 µg (HFA) twice daily LABA/ICS
11 Formoterol/mometasone 200/10 µg twice daily LABA/ICS
12 Formoterol/mometasone 400/10 µg twice daily LABA/ICS
13 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
14 Vilaterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
15 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
16 Formterol/aclidinium 12/400 µg twice daily LABA/LAMA
17 Indacaterol 150 µg once daily + tiotropium 18 µg once daily LABA/LAMA
18 Formoterol 10-12µg twice daily + tiotropium18µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.2.1 St George’s Respiratory Questionnaire responders at 3 months
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Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
3 Formoterol 4.5 µg twice daily LABA
4 Formoterol 9-12 µg twice daily LABA
5 Tiotropium 18 µg once daily LAMA
6 Umeclidinium 62.5 µg once daily LAMA
7 Glycopyrronium 50 µg once daily LAMA
8 Glycopyrronium 15.6 µg twice daily LAMA
9 Tiotropium 5 µg once daily LAMA
10 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
11 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
12 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
13 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
14 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
15 Indacaterol 150 µg once daily + tiotropium 18 µg once daily LABA/LAMA
16 Indacaterol/glycopyrronium 27.5/12.5 µg LABA/LAMA
17 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.2.2 St George’s Respiratory Questionnaire responders at 6 months
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Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 9-12 µg twice daily LABA
3 Indacaterol 150 µg once daily LABA
4 Indacaterol 300 µg once daily LABA
5 Tiotropium 18 µg once daily LAMA
6 Aclidinium 400 µg twice daily LAMA
7 Umeclidinium 62.5 µg once daily LAMA
8 Glycopyrronium 15.6 µg twice daily LAMA
9 Glycopyrronium 50 µg once daily LAMA
10 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
11 Formoterol/mometasone 200/10 µg twice daily LABA/ICS
12 Formoterol/mometasone 400/10 µg twice daily LABA/ICS
13 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
14 Formoterol/glycopyrronium 9.6/18 µg twice daily LABA/LAMA
15 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
16 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
17 Formoterol 10-12µg twice daily + tiotropium18µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.3.1 Change from baseline in St George’s Respiratory Questionnaire score at 3 months
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Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
3 Indacaterol 300 µg once daily LABA
4 Formoterol 4.5 µg twice daily LABA
5 Formoterol 9-12 µg twice daily LABA
6 Tiotropium 18 µg once daily LAMA
7 Umeclidinium 62.5 µg once daily LAMA
8 Glycopyrronium 50 µg once daily LAMA
9 Glycopyrronium 15.6 µg twice daily LAMA
10 Tiotropium 5 µg once daily LAMA
11 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
12 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
13 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
14 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
15 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
16 Indacaterol/ glycopyrronium 27.5/12.5 µg twice daily LABA/LAMA
17 Indacaterol 150 µg once daily + tiotropium 18 µg once daily LABA/LAMA
18 Olodaterol 5 µg once daily + tiotropium 18 µg once daily LABA/LAMA
19 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.3.2 Change from baseline in St George’s Respiratory Questionnaire score at 6 months
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Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 9-12 µg twice daily LABA
3 Indacaterol 150 µg once daily LABA
4 Indacaterol 300 µg once daily LABA
5 Tiotropium 18 µg once daily LAMA
6 Aclidinium 400 µg twice daily LAMA
7 Umeclidinium 62.5 µg once daily LAMA
8 Glycopyrronium 15.6 µg twice daily LAMA
9 Glycopyrronium 50 µg once daily LAMA
10 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
11 Formoterol/mometasone 200/10 µg twice daily LABA/ICS
12 Formoterol/mometasone 400/10 µg twice daily LABA/ICS
13 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
14 Formoterol/glycopyrronium 9.6/18 µg twice daily LABA/LAMA
15 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
16 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
17 Formoterol 10-12µg twice daily + tiotropium18µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.3.3 Change from baseline in St George’s Respiratory Questionnaire score at 12 months
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Intervention Treatment group
1 Formoterol 9-12 µg twice daily LABA
2 Salmeterol 50 µg twice daily LABA
3 Tiotropium 18 µg once daily LAMA
4 Aclidinium 400 µg twice daily LAMA
5 Glycopyrronium 15.6 µg twice daily LAMA
6 Glycopyrronium 50 µg once daily LAMA
7 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
8 Formoterol/glycopyrronium 9.6/18 µg twice daily LABA/LAMA
9 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
10 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.4.1 Transition Dyspnea Index at 3 months
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Indacaterol 150 µg once daily LABA
3 Indacaterol 300 µg once daily LABA
4 Olodaterol 5 µg once daily LABA
5 Formoterol 9-12 µg twice daily LABA
6 Tiotropium 18 µg once daily LAMA
7 Umeclidinium 62.5 µg once daily LAMA
8 Glycopyrronium 50 µg once daily LAMA
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9 Tiotropium 5 µg once daily LAMA
10 Glycopyrronium 15.6 µg twice daily LAMA
11 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
12 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
13 ICS/LABA free or fixed combination LABA/ICS
14 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
15 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
16 Indacaterol 150 µg once daily + tiotropium 18 µg once daily LABA/LAMA
17 Indacaterol 110 µg once daily + glycopyrronium 50 µg once
daily
LABA/LAMA
18 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
19 Indacaterol/glycopyrronium 27.5/12.5 µg twice daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.4.2 Transition Dyspnea Index at 6 months
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 9-12 µg twice daily LABA
3 Indacaterol 150 µg once daily LABA
4 Olodaterol 5 µg once daily LABA
5 Tiotropium 18 µg once daily LAMA
6 Tiotropium 5 µg once daily LAMA
7 Aclidinium 400 µg twice daily LAMA
8 Umeclidinium 62.5 µg once daily LAMA
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9 Glycopyrronium 50 µg once daily LAMA
10 Salmeterol/fluticasone 250/50 µg twice daily LABA/ICS
11 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
12 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
13 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
14 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
15 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
16 Formoterol 10-12µg twice daily + tiotropium18µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.4.3 Transition Dyspnea Index at 12 months
Intervention Treatment group
1 Formoterol 9-12 µg twice daily LABA
2 Indacaterol 300 µg once daily LABA
3 Olodaterol 5 µg once daily LABA
4 Tiotropium 18 µg once daily LAMA
5 Tiotropium 5 µg once daily LAMA
6 Aclidinium 400 µg twice daily LAMA
7 Glycopyrronium 15.6 µg twice daily LAMA
8 Formoterol/glycopyrronium 9.6/18 µg twice daily LABA/LAMA
9 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
10 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.5.1 Change from baseline in forced expiratory volume in 1 second at 3 months
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Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 9-12 µg twice daily LABA
3 Indacaterol 75 µg once daily LABA
4 Indacaterol 150 µg once daily LABA
5 Indacaterol 300 µg once daily LABA
6 Olodaterol 5 µg once daily LABA
7 Tiotropium 18 once daily LAMA
8 Tiotropium 5 once daily LAMA
9 Umeclidinium 62.5 µg once daily LAMA
10 Glycopyrronium 15.6 µg twice daily LAMA
11 Glycopyrronium 50 µg once daily LAMA
12 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
13 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
14 Salmeterol/fluticasone 42/230 µg (HFA) twice daily LABA/ICS
15 Formoterol/mometasone 200/10 µg twice daily LABA/ICS
16 Formoterol/mometasone 400/10 µg twice daily LABA/ICS
17 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
18 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
19 Indacaterol/glycopyrronium 27.5/15.6 µg twice daily LABA/LAMA
20 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
21 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
22 Indacaterol 150 µg once daily + tiotropium 18 µg once daily LABA/LAMA
23 Olodaterol 5 µg once daily + tiotropium 18 µg once daily LABA/LAMA
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ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.5.2 Change from baseline in forced expiratory volume in 1 second at 6 months
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 9-12 µg twice daily LABA
3 Indacaterol 75 µg once daily LABA
4 Indacaterol 150 µg once daily LABA
5 Indacaterol 300 µg once daily LABA
6 Olodaterol 5 µg once daily LABA
7 Tiotropium 18 µg once daily LAMA
8 Tiotropium 5 µg once daily LAMA
9 Aclidinium 400 µg twice daily LAMA
10 Umeclidinium 62.5 µg once daily LAMA
11 Glycopyrronium 15.6 µg twice daily LAMA
12 Glycopyrronium 50 µg once daily LAMA
13 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
14 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
15 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
16 Formoterol/glycopyrronium 9.6/18 µg twice daily LABA/LAMA
17 Indacaterol/glycopyrronium 27.5/15.6 µg twice daily LABA/LAMA
18 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
19 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
20 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
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21 Formoterol 10-12µg twice daily + tiotropium18µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.5.3 Change from baseline in forced expiratory volume in 1 second at 12 months
Intervention Treatment group
1 Formoterol 9-12 µg twice daily LABA
2 Indacaterol 75 µg once daily LABA
3 Olodaterol 5 µg once daily LABA
4 Tiotropium 18 µg once daily LAMA
5 Tiotropium 5 µg once daily LAMA
6 Aclidinium 400 µg twice daily LAMA
7 Glycopyrronium 15.6 µg twice daily LAMA
8 Glycopyrronium 50 µg once daily LAMA
9 Formoterol/glycopyrronium 9.6/18 µg twice daily LABA/LAMA
10 Indacaterol/glycopyrronium 27.5/15.6 µg twice daily LABA/LAMA
11 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
12 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
13 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.6 Mortality
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Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 4.5 µg twice daily LABA
3 Formoterol 9-12 µg twice daily LABA
4 Indacaterol 75 µg once daily LABA
5 Indacaterol 150 µg once daily LABA
6 Indacaterol 300 µg once daily LABA
7 Olodaterol 5 µg once daily LABA
8 Tiotropium 18 µg once daily LAMA
9 Tiotropium 5 µg once daily LAMA
10 Aclidinium 400 µg twice daily LAMA
11 Umeclidinium 62.5 µg once daily LAMA
12 Glycopyrronium 15.6 µg twice daily LAMA
13 Glycopyrronium 50 µg once daily LAMA
14 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
15 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
16 Formoterol/mometasone 200/10 µg twice daily LABA/ICS
17 Formoterol/mometasone 400/10 µg twice daily LABA/ICS
18 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
19 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
20 Formoterol/glycopyrronium 9.6/18 µg twice daily LABA/LAMA
21 Indacaterol/glycopyrronium 27.5/15.6 µg twice daily LABA/LAMA
22 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
23 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
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24 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
25 Indacaterol 150 µg once daily + tiotropium 18 µg once daily LABA/LAMA
26 Formoterol 10-12µg twice daily + tiotropium18µg once daily LABA/LAMA
27 Olodaterol 5 µg once daily + tiotropium 18 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.7.1 Total serious adverse events
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 4.5 µg twice daily LABA
3 Formoterol 9-12 µg twice daily LABA
4 Indacaterol 75 µg once daily LABA
5 Indacaterol 150 µg once daily LABA
6 Indacaterol 300 µg once daily LABA
7 Olodaterol 5 µg once daily LABA
8 Tiotropium 18 µg once daily LAMA
9 Tiotropium 5 µg once daily LAMA
10 Aclidinium 400 µg twice daily LAMA
11 Umeclidinium 62.5 µg once daily LAMA
12 Glycopyrronium 15.6 µg twice daily LAMA
13 Glycopyrronium 50 µg once daily LAMA
14 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
15 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
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16 Salmeterol/fluticasone 42/230 µg (HFA) twice daily LABA/ICS
17 Formoterol/mometasone 200/10 µg twice daily LABA/ICS
18 Formoterol/mometasone 400/10 µg twice daily LABA/ICS
19 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
20 ICS/LABA free or fixed combination LABA/ICS
21 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
22 Formoterol/glycopyrronium 9.6/18 µg twice daily LABA/LAMA
23 Indacaterol/glycopyrronium 27.5/15.6 µg twice daily LABA/LAMA
24 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
25 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
26 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
27 Indacaterol 150 µg once daily + tiotropium 18 µg once daily LABA/LAMA
28 Formoterol 10-12µg twice daily + tiotropium18µg once daily LABA/LAMA
29 Olodaterol 5 µg once daily + tiotropium 18 µg once daily LABA/LAMA
30 Indacaterol 110 µg once daily + glycopyrronium 50 µg once
daily
LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.7.2 Chronic obstructive pulmonary disease serious adverse events
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 4.5 µg twice daily LABA
3 Formoterol 9-12 µg twice daily LABA
4 Indacaterol 75 µg once daily LABA
5 Indacaterol 150 µg once daily LABA
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6 Indacaterol 300 µg once daily LABA
7 Olodaterol 5 µg once daily LABA
8 Tiotropium 18 µg once daily LAMA
9 Tiotropium 5 µg once daily LAMA
10 Aclidinium 400 µg twice daily LAMA
11 Umeclidinium 62.5 µg once daily LAMA
12 Glycopyrronium 15.6 µg twice daily LAMA
13 Glycopyrronium 50 µg once daily LAMA
14 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
15 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
16 Salmeterol/fluticasone 42/230 µg (HFA) twice daily LABA/ICS
17 Formoterol/mometasone 200/10 µg twice daily LABA/ICS
18 Formoterol/mometasone 400/10 µg twice daily LABA/ICS
19 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
20 ICS/LABA free or fixed combination LABA/ICS
21 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
22 Formoterol/glycopyrronium 9.6/18 µg twice daily LABA/LAMA
23 Indacaterol/glycopyrronium 27.5/15.6 µg twice daily LABA/LAMA
24 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
25 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
26 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
27 Indacaterol 150 µg once daily + tiotropium 18 µg once daily LABA/LAMA
28 Formoterol 10-12µg twice daily + tiotropium18µg once daily LABA/LAMA
485Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
29 Olodaterol 5 µg once daily + tiotropium 18 µg once daily LABA/LAMA
30 Indacaterol 110 µg once daily + glycopyrronium 50 µg once
daily
LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.7.3 Cardiac serious adverse events
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 4.5 µg twice daily LABA
3 Formoterol 9-12 µg twice daily LABA
4 Indacaterol 75 µg once daily LABA
5 Indacaterol 150 µg once daily LABA
6 Indacaterol 300 µg once daily LABA
7 Olodaterol 5 µg once daily LABA
8 Tiotropium 18 µg once daily LAMA
9 Tiotropium 5 µg once daily LAMA
10 Aclidinium 400 µg twice daily LAMA
11 Umeclidinium 62.5 µg once daily LAMA
12 Glycopyrronium 15.6 µg twice daily LAMA
13 Glycopyrronium 50 µg once daily LAMA
14 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
15 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
16 Formoterol/mometasone 200/10 µg twice daily LABA/ICS
17 Formoterol/mometasone 400/10 µg twice daily LABA/ICS
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18 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
19 ICS/LABA free or fixed combination LABA/ICS
20 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
21 Formoterol/glycopyrronium 9.6/18 µg twice daily LABA/LAMA
22 Indacaterol/glycopyrronium 27.5/15.6 µg twice daily LABA/LAMA
23 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
24 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
25 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
26 Indacaterol 150 µg once daily + tiotropium 18 µg once daily LABA/LAMA
27 Formoterol 10-12µg twice daily + tiotropium18µg once daily LABA/LAMA
28 Olodaterol 5 µg once daily + tiotropium 18 µg once daily LABA/LAMA
29 Indacaterol 110 µg once daily + glycopyrronium 50 µg once
daily
LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
2.8 Dropouts
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 4.5 µg twice daily LABA
3 Formoterol 9-12 µg twice daily LABA
4 Indacaterol 75 µg once daily LABA
5 Indacaterol 150 µg once daily LABA
6 Indacaterol 300 µg once daily LABA
7 Olodaterol 5 µg once daily LABA
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8 Tiotropium 18 µg once daily LAMA
9 Tiotropium 5 µg once daily LAMA
10 Aclidinium 400 µg twice daily LAMA
11 Umeclidinium 62.5 µg once daily LAMA
12 Glycopyrronium 15.6 µg twice daily LAMA
13 Glycopyrronium 50 µg once daily LAMA
14 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
15 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
16 Salmeterol/fluticasone 42/230 µg twice daily LABA/ICS
17 Formoterol/mometasone 200/10 µg twice daily LABA/ICS
18 Formoterol/mometasone 400/10 µg twice daily LABA/ICS
19 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
20 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
21 Formoterol/glycopyrronium 9.6/18 µg twice daily LABA/LAMA
22 Indacaterol/glycopyrronium 27.5/15.6 µg twice daily LABA/LAMA
23 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
24 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
25 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
26 Indacaterol 150 once daily + tiotropium 18 µg once daily LABA/LAMA
27 Formoterol 10-12 twice daily + tiotropium 18 µg once daily LABA/LAMA
28 Olodaterol 5 once daily + tiotropium 18 µg once daily LABA/LAMA
29 Indacaterol 110 µg once daily + glycopyrronium 50 µg once
daily
LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
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2.9 Pneumonia
Intervention Treatment group
1 Salmeterol 50 µg twice daily LABA
2 Formoterol 4.5 µg twice daily LABA
3 Formoterol 9-12 µg twice daily LABA
4 Indacaterol 75 µg once daily LABA
5 Indacaterol 150 µg once daily LABA
6 Indacaterol 300 µg once daily LABA
7 Olodaterol 5 µg once daily LABA
8 Tiotropium 18 µg once daily LAMA
9 Tiotropium 5 µg once daily LAMA
10 Aclidinium 400 µg twice daily LAMA
11 Umeclidinium 62.5 µg once daily LAMA
12 Glycopyrronium 15.6 µg twice daily LAMA
13 Glycopyrronium 50 µg once daily LAMA
14 Salmeterol/fluticasone 50/250 µg twice daily LABA/ICS
15 Salmeterol/fluticasone 50/500 µg twice daily LABA/ICS
16 Salmeterol/fluticasone 42/230 µg twice daily LABA/ICS
17 Formoterol/mometasone 200/10 µg twice daily LABA/ICS
18 Formoterol/mometasone 400/10 µg twice daily LABA/ICS
19 Vilanterol/fluticasone 25/100 µg once daily LABA/ICS
20 ICS/LABA free or fixed combination LABA/ICS
21 Vilanterol/umeclidinium 25/62.5 µg once daily LABA/LAMA
22 Formoterol/glycopyrronium 9.6/18 µg twice daily LABA/LAMA
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23 Indacaterol/glycopyrronium 27.5/15.6 µg twice daily LABA/LAMA
24 Indacaterol/glycopyrronium 110/50 µg once daily LABA/LAMA
25 Olodaterol/tiotropium 5/5 µg once daily LABA/LAMA
26 Formoterol/aclidinium 12/400 µg twice daily LABA/LAMA
27 Indacaterol 150 µg once daily + tiotropium 18 µg once daily LABA/LAMA
28 Formoterol 10-12µg twice daily + tiotropium18µg once daily LABA/LAMA
29 Olodaterol 5 µg once daily + tiotropium 18 µg once daily LABA/LAMA
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist
Appendix 4. Model fit description and statistics
Population: high-risk
Outcome: moderate to severe exacerbations
Wefitted random- and fixed-treatment-effects networkmeta-analysis (NMA)models with fixed-class effects. The random-effects model
had a better fit than the fixed-effect model with lower deviance information criterion (DIC) and between-study heterogeneity was low
(standard deviation (SD) 0.07, 95% credible interval (CrI) 0.008 to 0.14). We considered a random-class model with fixed-treatment
effects, which only slightly improved fit compared to the fixed-treatment-effect model with fixed-class. We chose the random-treatment-
effects model with fixed-class effects as it had the lowest DIC.
The inconsistency model with random treatment effects (and fixed-class effects), did not show an improvement in fit compared to
the NMA model assuming consistency, suggesting no evidence of inconsistency. Plotting each data point’s contribution to the residual
deviance in the NMA (consistency), and inconsistency models showed small improvements for two data points in the inconsistency
model with other points fitting worse (Figure 3c). Reported results are therefore based on the random-treatment-effects NMA model
with fixed-class effects assuming consistency.
DIC SD (95% CrI) Total residual
deviancea
Fixed-class-effect models
Random-effects model 42.65 0.07 (0.008 to 0.14) 24.52
Fixed-effect model 48.22 36.45
Random-effects inconsistency
model
42.04 0.05 (0.003 to 0.13) 24.31
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Random-class-effects models
Fixed-effect model 49.36 33.33
acompare to 27 data points
Outcome: severe exacerbations
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was low (SD 0.07, 95% CrI 0.003 to 0.26). We chose the fixed-effect model as it had the lowest DIC.
The inconsistency model with fixed-treatment effects (and fixed-class effects) did not show an improvement in fit compared to theNMA
model assuming consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to
the residual deviance in the NMA and inconsistency models, which showed no substantial improvement in fit for any data point (Figure
4). Reported results are therefore based on the fixed-effect NMAmodel, assuming consistency with results based on the random-effects
model also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 71.89 0.07 (0.003 to 0.26) 16.64
Fixed-effect model 70.30 17.44
Fixed-effect inconsistency
model
73.68 18.84
acompare to 19 data points
Outcome: St George’s Respiratory Questionnaire responders at 12 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. The random-effects model had a better fit than
the fixed-effect model although their DIC were comparable and between-study heterogeneity was moderate (SD 0.26, 95% CrI 0.03
to 1.01). We considered a random-class model with fixed-treatment effects but this did not meaningfully improve fit. As there were
not enough data to estimate the within-class variance for the LAMA and LABA/LAMA groups, we assumed that these were equal to
the variance in the other monotherapy and combination class respectively. We chose the fixed-treatment-effect model with fixed-class
effects as it is the simplest and had comparable DIC to the other models.
The inconsistency model with fixed-treatment effects (and fixed-class effects) did not show an improvement in fit compared to the
NMA model assuming consistency, suggesting no evidence of inconsistency. Plotting each data point’s contribution to the residual
deviance in the NMA (consistency) and inconsistency models showed some improvement in fit for data points from one study (Figure
6c). Reported results are based on the fixed-treatment-effect NMA model with fixed-class effects assuming consistency. Results based
on the random-treatment-effects model with fixed-classes are also reported for comparison.
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DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 137.86 0.16 (0.01 to 0.48) 16.91
Fixed-effect model 139.08 22.01
Fixed-effect inconsistency
model
141.81 22.78
Random-class-effects models: class 2 uses variance from class 1, class 4 from class 3
Fixed-effect model 144.12 22.17
acompare to 16 data points
Outcome: change from baseline in St George’s Respiratory Questionnaire score at 3 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was moderate (SD 0.66, 95% CrI 0.03 to 2.93). We chose the fixed-treatment-effect model as it had the lowest
DIC. The inconsistency model with fixed-treatment effects did not show an improvement in fit compared to theNMAmodel assuming
consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to the residual
deviance in the NMA (consistency), and inconsistency models, which showed an equal or better fit of points in the consistency model
compared to the inconsistency model (Figure 7c). Reported results are therefore based on the fixed-treatment-effects NMAmodel with
fixed-class effects, assuming consistency. Results based on the random-treatment-effects model with fixed-class are also reported for
comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 60.89 0.66 (0.03 to 2.93) 20.39
Fixed-effect model 59.35 21.26
Fixed-effect inconsistency
model
62.90 22.84
acompare to 19 data points
Outcome: change from baseline in St George’s Respiratory Questionnaire score at 6 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was moderate (SD 0.61, 95% CrI 0.31 to 2.03). We chose the fixed-treatment-effect model as it had the lowest
DIC.
The inconsistency model with fixed-treatment effects did not show an improvement in fit compared to the NMA model assuming
consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to the residual
492Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
deviance in the NMA (consistency) and inconsistency models, which showed an equal or better fit of points in the consistency model
compared to the inconsistency model (Figure 8c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 65.03 0.61 (0.31 to 2.03) 22.94
Fixed-effect model 64.00 25.08
Fixed-effect inconsistency
model
66.70 25.79
acompare to 22 data points
Outcome: change from baseline in St George’s Respiratory Questionnaire score at 12 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. The random-effects model had a better fit than
the fixed-effect model but comparable DIC and between-study heterogeneity was moderate (SD 0.81, 95% CrI 0.12 to 1.75). We
considered a random-class model with fixed-treatment effects which only slightly improved fit compared to the fixed-treatment-effect
model with fixed-class. As there were not enough data to estimate the within-class variance for the LAMA and LABA/LAMA groups,
we assumed that these were equal to the variance in the other monotherapy and combination group respectively. We chose the fixed-
treatment-effect model with fixed-class effects as it had the lowest DIC.
The inconsistency model with fixed-treatment effects (and fixed-class effects) did not show an improvement in fit compared to the
NMA model assuming consistency, suggesting no evidence of inconsistency. Plotting each data point’s contribution to the residual
deviance in the NMA (consistency) and inconsistency models showed a small improvement for data points from one study in the
inconsistency model with other points fitting worse (Figure 9c).
Reported results are therefore based on the fixed-effect NMA model, assuming consistency with results based on the random-effects
model also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 94.26 0.81 (0.12 to 1.75) 31.42
Fixed-effect model 96.60 39.8
Fixed-effect inconsistency
model
96.96 38.2
Random-class-effects models
Fixed-effect model 98.69 37.05
acompare to 32 data points
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Outcome: change from baseline in forced expiratory volume in 1 second at 3 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well with equivalent
DIC and low between-study heterogeneity (SD 0.01, 95% CrI 0.00 to 0.04). The fixed-effect model with fixed-class effects was chosen
as it is the simplest.
The inconsistency model with fixed-treatment effects and fixed-class effects showed a very small improvement in fit compared to
the NMA model assuming consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s
contribution to the residual deviance in the NMA (consistency) and inconsistency models, which showed no substantial improvement
in fit for any data point (Figure 11c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model −114.44 0.01 (0 to 0.04) 22.9
Fixed-effect model −114.95 26.0
Fixed-effect inconsistency
model
−115.14 24.8
acompare to 23 data points
Outcome: change from baseline in forced expiratory volume in 1 second at 6 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was low (SD = 0.02, 95% CrI 0 to 0.05). The fixed-effect model with fixed-class effects was chosen as it had the
lowest DIC.
The inconsistency model with fixed-treatment effects and fixed-class effects did not show improvement in fit compared to the NMA
model assuming consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to
the residual deviance in the NMA (consistency) and inconsistency models, which showed no substantial improvement in fit for any
data point (Figure 12c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model −103.62 0.02 (0.00 to 0.05) 22.70
Fixed-effect model −103.97 25.87
Fixed-effect inconsistency
model
−102.38 26.47
acompare to 24 data points
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Outcome: change from baseline in forced expiratory volume in 1 second at 12 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was low (SD 0.01, 95% CrI 0.00 to 0.03). The fixed-effect model with fixed-class effects was chosen as it had the
lowest DIC.
The inconsistency model with fixed-treatment effects and fixed-class effects did not show improvement in fit compared to the NMA
model assuming consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to
the residual deviance in the NMA (consistency) and inconsistency models, which showed no improvement in fit for any data point
(Figure 13c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model −128.14 0.01 (0.00 to 0.03) 26.19
Fixed-effect model −129.43 28.16
Fixed-effect inconsistency
model
−128.31 28.28
acompare to 29 data points
Outcome: mortality
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was moderate (SD 0.17, 95% CrI 0.01 to 0.49). The fixed-effect model with fixed-class effects was chosen as it
had the lowest DIC.
The inconsistency model with fixed-treatment effects and fixed-class effects showed a small improvement in fit compared to the
NMA model assuming consistency. Plotting each data point’s contribution to the residual deviance in the NMA (consistency) and
inconsistency models, which showed some improvement in fit for data points from one study suggesting a possibility of inconsistency
(Figure 15c).
Reported results are based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency although results
should be interpreted with caution due to some evidence of inconsistency. Results based on the random-treatment-effects model with
fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 271.00 0.17 (0.009 to 0.49) 51.45
Fixed-effect model 269.87 53.87
Fixed-effect inconsistency
model
268.35 50.36
acompare to 53 data points
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Outcome: total serious adverse events
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was very low (SD 0.05, 95% CrI 0.00 to 0.17). The fixed-effect model with fixed-class effects was chosen as it had
the lowest DIC.
The inconsistency model with fixed-treatment effects and fixed-class effects showed no improvement in fit compared to theNMAmodel
assuming consistency. Plotting each data point’s contribution to the residual deviance in the NMA (consistency) and inconsistency
models confirmed this as there was no improvement in fit for any data points in the inconsistency model (Figure 16c).
Reported results are based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results based on
the random-treatment-effects model with fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 378.46 0.06 (0.002 to 0.17) 49.12
Fixed-effect model 376.7 50.94
Fixed-effect inconsistency
model
379.24 51.44
acompare to 53 data points
Outcome: COPD serious adverse events
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was very low (SD 0.06, 95% CrI 0.00 to 0.21). The fixed-effect model with fixed-class effects was chosen as it had
the lowest DIC.
The inconsistency model with fixed-treatment effects and fixed-class effects showed no improvement in fit compared to theNMAmodel
assuming consistency. Plotting each data point’s contribution to the residual deviance in the NMA (consistency) and inconsistency
models confirmed this as there was no improvement in fit for any data points in the inconsistency model (Figure 17c).
Reported results are based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results based on
the random-treatment-effects model with fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 283.74 0.06 (0.002 to 0.21) 42.55
Fixed-effect model 282.07 43.21
Fixed-effect inconsistency
model
285.67 44.73
acompare to 44 data points
Outcome: cardiac serious adverse events
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We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. The random-effects model had a better fit than
the fixed-effect model with a slightly lower DIC although the posterior mean of the residual deviance was still considerably larger than
the number of data points, and the between-study heterogeneity was moderate (SD 0.28 to 95% CrI 0.02 to 0.67). Random-class
models with fixed- and random-treatment effects were fitted, which improved fit compared to the fixed-class models. As there were
not enough data to estimate the within-class variance for the LABA/LAMA group, we assumed that this was equal to the variance in
the other combination group (LABA/ICS). DIC was lowest for the random-treatment-effects model with a fixed-class so we chose this
model. However, note that this DIC differed by only 1 point from the DIC for the fixed-treatment-effect model with a fixed-class.
The inconsistency models with random-treatment effects (and fixed-class), showed no improvement in fit and DIC compared to the
NMA model assuming consistency to suggesting no evidence of inconsistency. Plotting each data point’s contribution to the residual
deviance in the NMA and inconsistency models confirmed this as there was no improvement in fit for any points in the inconsistency
model (Figure 18c).
Reported results are therefore based on the random-treatment-effects NMA model with fixed-class effects to assuming consistency.
Results based on the fixed-treatment-effect model with fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 256.42 0.28 (0.02, 0.67) 51.51
Fixed-effect model 257.45 59.83
Fixed-effect inconsistency
model
260.69 61.06
Random-class-effects models
Random-effects model 253.42 0.23 (0.01, 0.65) 44.88
Fixed-effect model 253.13 48.23
acompare to 42 data points
Outcome: dropouts due to adverse events
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was very low (SD 0.05 to 95% CrI 0.00 to 0.18). The fixed-effect model with fixed-class effects was chosen as it
had the lowest DIC.
The inconsistency model with fixed-treatment effects and fixed-class effects showed no improvement in fit compared to theNMAmodel
assuming consistency. Plotting each data point’s contribution to the residual deviance in the NMA (consistency) and inconsistency
models confirmed this as there was no improvement in fit for any data points in the inconsistency model (Figure 19c).
Reported results are based on the fixed-treatment-effect NMA model with fixed-class effects to assuming consistency. Results based on
the random-treatment-effects model with fixed-class are also reported for comparison.
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DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 344.54 0.05 (0.002 to 0.18) 45.35
Fixed-effect model 342.43 45.35
Fixed-effect inconsistency
model
345.77 46.7
acompare to 55 data points
Outcome: pneumonia
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. The posterior mean of the residual deviance was
substantially larger than the number of data points for both models and the between-study heterogeneity was moderate (SD 0.18, 95%
CrI 0.01 to 0.61). Random-class models with fixed- and random-treatment-effects were fitted and although model fit was improved, the
DIC was comparable to the fixed-class models. As there were not enough data to estimate the within-class variance for the LAMA and
LABA/LAMA groups, we assumed that these were equal to the variance in the other monotherapy and combination groups respectively.
The fixed-treatment-effect model with fixed-class had the lowest DIC so we chose this model.
The inconsistency model with fixed-treatment effects (and fixed-class), showed no improvement in fit or DIC compared to the NMA
model assuming consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to
the residual deviance in the NMA and inconsistency models, where fit was the same or better for the consistency model for most data
points (Figure 20c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison. Results should be interpreted with
some caution due to poor model fit, which can be attributed to studies with zero cells.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 280.12 0.18 (0.01 to 0.61) 60.01
Fixed-effect model 278.71 63.19
Fixed-effect inconsistency
model
282.65 65.11
Random-class-effects models
Fixed-effect model 281.64 60.95
Random-effects model 281.35 0.24 (0.01 to 0.71) 56.87
acompare to 53 data points
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Population: low-risk
Outcome: moderate to severe chronic obstructive pulmonary disease exacerbations
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. The random-effects model had a better fit than
the fixed-effect model although their DIC were comparable and between-study heterogeneity was low (SD 0.054, 95% CrI 0.002 to
0.14). We considered a random-class model with fixed-treatment effects but this did not meaningfully improve fit. We chose the fixed-
treatment-effect model with fixed-class effects as it is the simplest and had comparable DIC to the other models.
The inconsistency model with fixed-treatment effects (and fixed-class effects) did not show an improvement in fit compared to theNMA
model assuming consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to
the residual deviance in the NMA (consistency) and inconsistency models, which showed no substantial improvement in fit for any
data point (Figure 21c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects assuming consistency. Results
based on the random-treatment-effects model with fixed-classes are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 386.49 0.05 (0.002 to 0.14) 76.97
Fixed-effect model 387.13 81.9
Fixed-effect inconsistency
model
390.02 81.8
Random-class-effects models
Fixed-effect model 392.54 79.89
acompare to 72 data points
Outcome: severe chronic obstructive pulmonary disease exacerbations
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. The random-effects model had a better fit than
the fixed-effect model although the latter had lower DIC and between-study heterogeneity was low (SD 0.10, 95% CrI 0.006 to 0.43).
A random-class model with fixed-treatment effect was considered but this did not improve fit so we chose the fixed-effect model with
fixed-class effects as it had the lowest DIC.
The inconsistency model with fixed-treatment effects and fixed-class effects did not show an improvement in fit compared to the NMA
model assuming consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to
the residual deviance in the NMA (consistency), and inconsistency models, which showed no substantial improvement in fit for any
data point (Figure 22c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison.
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DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 270.29 0.10 (0.006 to 0.43) 64.82
Fixed-effect model 268.61 66.19
Fixed-effect inconsistency
model
273.57 68.36
Random-class-effects models
Fixed-effect model 275.61 68.46
acompare to 60 data points
Outcome: St George’s Respiratory Questionnaire responders at 3 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was low (SD 0.04, 95% CrI 0.002 to 0.15). We chose the fixed-treatment-effect model as it had the lowest DIC.
The inconsistency model with fixed-treatment effects did not show an improvement in fit compared to the NMA model assuming
consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to the residual
deviance in the NMA (consistency) and inconsistency models, which showed an equal or better fit of points in the consistency model
compared to the inconsistency model (Figure 24c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 337.64 0.04 (0.002 to 0.15) 39.84
Fixed-effect model 335.70 40.29
Fixed-effect inconsistency
model
339.79 42.32
acompare to 44 data points
Outcome: St George’s Respiratory Questionnaire responders at 6 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. The random-effects model had a better fit than
the fixed-effect model with a lower DIC and the between-study heterogeneity estimated was low (SD 0.14, 95% CrI 0.06 to 0.23). A
random-class model with fixed-treatment effects was fitted, which improved fit compared to the fixed treatment with fixed-class effects
model. However, we selected the random-treatment-effects model with a fixed-class as it had the lowest DIC.
The inconsistency model with random-treatment effects and fixed-class effects did not show an improvement in fit or a reduction in
the between-study heterogeneity compared to the selected NMAmodel assuming consistency, suggesting no evidence of inconsistency.
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Plotting each data point’s contribution to the residual deviance in the NMA and inconsistency models did not show substantial
improvement in fit for any data points (Figure 25c). Reported results are therefore based on the random-treatment-effects NMAmodel
with fixed-class effects (assuming consistency).
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 380.57 0.14 (0.06 to 0.23) 46.38
Fixed-effect model 391.67 70.62
Random-effects inconsistency
model
383.65 0.13 (0.05 to 0.22) 47.95
Random-class-effects models
Fixed-effect model 385.45 53.20
acompare to 47 data points
Outcome: change from baseline in St George’s Respiratory Questionnaire score at 3 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was low (SD 0.19, 95% CrI 0.006 to 0.67). We chose the fixed-treatment-effect model as it had the lowest DIC.
The inconsistency model with fixed-treatment effects did not show an improvement in fit compared to the NMA model assuming
consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to the residual
deviance in the NMA (consistency), and inconsistency models, which showed an equal or better fit of points in the consistency model
compared to the inconsistency model (Figure 27c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 170.91 0.19 (0.006 to 0.67) 43.82
Fixed-effect model 169.00 43.55
Fixed-effect inconsistency
model
174.43 45.99
acompare to 59 data points
Outcome: change from baseline in St George’s Respiratory Questionnaire score at 6 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was moderate to low (SD 0.36, 95% CrI 0.17 to 1.08). We chose the fixed-treatment-effect model as it had the
lowest DIC.
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The inconsistency model with fixed-treatment effects did not show an improvement in fit compared to the NMA model assuming
consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to the residual
deviance in the NMA (consistency), and inconsistency models, which showed no improvement in fit for any points in the inconsistency
model (Figure 28c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 149.50 0.36 (0.17 to 1.08) 45.83
Fixed-effect model 148.02 48.20
Fixed-effect inconsistency
model
151.37 49.56
acompare to 47 data points
Outcome: change from baseline in St George’s Respiratory Questionnaire score at 12 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was moderate (SD 0.61, 95% CrI 0.29 to 2.51). We chose the fixed-treatment-effect model as it had the lowest
DIC.
The inconsistency model with fixed-treatment effects did not show an improvement in fit compared to the NMA model assuming
consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to the residual
deviance in the NMA and inconsistency models, which showed an equal or better fit of points in the consistency model compared to
the inconsistency model (Figure 29c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 42.48 0.61 (0.29 to 2.51) 14.22
Fixed-effect model 41.25 15.09
Fixed-effect inconsistency
model
43.24 16.07
acompare to 15 data points
Outcome: Transition Dyspnoea Index at 3 months
We fitted random- and fixed-treatment-effects NMAmodels with fixed-class effects. The random-effects model had a better fit than the
fixed-effect model with a lower DIC and the between-study heterogeneity was moderate (SD 0.17, 95% CrI 0.02 to 0.32). We fitted a
random-class model with fixed-treatment effects, which improved fit substantially compared to the fixed-treatment-effect models with
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a fixed-class but only slightly compared to the random-treatment-effects model with a fixed-class. As there were not enough data to
estimate the within-class variance for the LABA/ICS group, we assumed that this was equal to the variance in the other combination
therapy group (LABA/LAMA).
DIC slightly favoured the fixed-treatment-effect model with a random-class over the random-treatment-effects model with a fixed-
class (difference of 3.6 points, which is close to the value for no meaningful difference). Within-class variability in the fixed-treatment-
effect model with random-class was moderate (Table 71). We chose the random-treatment-effects model with a fixed-class as it is more
interpretable. However, there is statistical uncertainty as to whether the variability observed across treatment effects is due to between-
study or within-class/group differences.
The inconsistencymodel with random-treatment effects and fixed-class did not show an improvement in fit or reduction in heterogeneity
compared to the NMA model assuming consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data
point’s contribution to the residual deviance in the NMA and inconsistency models, which showed no substantial improvement in fit
of any points in the inconsistency model (Figure 31c).
Reported results are based on the random-treatment-effects model with fixed-class NMAmodel (assuming consistency), with the results
for the fixed-treatment-effect model with random-class also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 14.34 0.17 (0.02 to 0.32) 61.72
Fixed-effect model 17.97 75.50
Random-effects inconsistency
model
18.29 0.19 (0.04 to 0.35) 62.33
Random-class-effects models
Fixed-effect model 10.71 59.48
acompare to 63 data points
Outcome: Transition Dyspnoea Index at 6 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was low (SD 0.09, 95% CrI 0.004 0 0.24). We chose the fixed-treatment-effect model as it had the lowest DIC.
The inconsistency model with fixed-treatment effects did not show an improvement in fit compared to the NMA model assuming
consistency, suggesting no evidence of inconsistency. Plotting each data point’s contribution to the residual deviance in the NMA and
inconsistency models, showed only a small improvement in fit for some points in the inconsistency model compared to the consistency
model (Figure 32c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-classes are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 2.31 0.09 (0.004 to 0.24) 36.56
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(Continued)
Fixed-effect model 0.59 37.73
Fixed-effect inconsistency
model
2.08 37.24
acompare to 41 data points
Outcome: Transition Dyspnoea Index at 12 months
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. The random-effects model had a better fit than
the fixed-effect model although their DIC was comparable and between-study heterogeneity was moderate (SD 0.16, 95% CrI 0.02 to
0.43). We fitted a random-class model with fixed-treatment effects, which improved fit compared to the fixed-treatment-effect model
with a fixed-class although with a similar DIC. Since all models had similar DIC, we chose the fixed-treatment-effect model with a
fixed-class, as it is the simplest.
The inconsistency model with fixed-treatment effects (and fixed-class), did not show an improvement in fit compared to the NMA
model assuming consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to
the residual deviance in the NMA and inconsistency models, which showed an equal or better fit of points in the consistency model
compared to the inconsistency model (Figure 33c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects assuming consistency. Results
based on the random-treatment-effects model with fixed-classes are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model -6.91 0.16 (0.01 to 0.43) 14.19
Fixed-effect model -5.15 19.59
Fixed-effect inconsistency
model
-5.15 19.59
Random-class-effects models
Fixed-effect model -5.04 15.06
acompare to 16 data points
Outcome: change from baseline in forced expiratory volume in 1 second at 3 months
We fitted random- and fixed-treatment-effects NMAmodels with fixed-class effects. The random-effects model had a better fit than the
fixed-effect model with a lower DIC and the between-study heterogeneity was moderate (SD 0.03, 95% CrI 0.02 to 0.03). A random-
class model with fixed-treatment effects was fitted which improved fit compared to the fixed-treatment-effect model with a fixed-class.
However, the random-treatment-effects model with a fixed-class was selected as it had the lowest DIC.
The inconsistency model with random-treatment effects (and fixed-class) did not show an improvement in fit compared to the NMA
model assuming consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution
to the residual deviance in the NMA and inconsistency models, which showed no substantial improvement in the fit of points in the
inconsistency model (Figure 35c).
504Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Reported results are therefore based on the random-effects NMA model with fixed-classes (assuming consistency).
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model -513.575 0.03 (0.02 to 0.03) 105.6
Fixed-effect model -421.49 229.0
Random-effects inconsistency
model
-514.67 0.02 (0.02 to 0.03) 104.4
Random-class-effects models
Fixed-effect model -481.10 155.2
acompare to 107 data points
Outcome: change from baseline in forced expiratory volume in 1 second at 6 months
We fitted random- and fixed-treatment-effects NMAmodels with fixed-class effects. The random-effects model had a better fit than the
fixed-effect model with a lower DIC and the between-study heterogeneity was moderate (SD 0.02, 95% CrI 0.007 to 0.03). We fitted a
random-class model with fixed-treatment effects, which improved fit substantially compared to the fixed-treatment-effect models with
a fixed-class but not compared to the random-treatment-effects model with a fixed-class. As there were not enough data to estimate the
within-class variance for the LABA/ICS group, we assumed that this was equal to the variance in the other combination therapy group
(LABA/LAMA).
The difference in DIC between the fixed-treatment-effect model with a random-class and the random-treatment-effects model with
a fixed-class was less than 3 points. Within-class variability in the fixed-treatment-effect model with random-class was moderate. We
chose the random-treatment-effects model with a fixed-class as it is more interpretable. However, there is statistical uncertainty as to
whether the variability observed across treatment effects is due to between-study or within-class differences.
The inconsistency model with random-treatment effects (and fixed-class) showed some improvement in fit compared to the NMA
model assuming consistency and had lower between-study heterogeneity and DIC, suggesting some evidence of inconsistency. Plotting
each data point’s contribution to the residual deviance in the NMA and inconsistency models showed that fit improved for some studies
in the inconsistency model compared to the consistency models, although for other studies fit was worse (Figure 36c).
Reported results are based on the random-treatment-effects model with fixed-class NMAmodel (assuming consistency) with the results
for the fixed-treatment-effect model with random-class also reported for comparison. However, there is weak evidence of potential
inconsistency in this network and results should be interpreted with some caution.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model -324.38 0.02 (0.007 to 0.03) 68.26
Fixed-effect model -315.31 91.40
Random-effects inconsistency
model
-328.14 0.01 (0.000 to 0.02) 66.91
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(Continued)
Random-class-effects models
Fixed-effect model -326.62 68.99
acompare to 69 data points
Within class/group standard deviation for change from baseline in FEV1 at 6 months in the low-risk population
Fixed-treatment-effect model with random-class
Median 95% CrI
LABA 0.010 (0.000 to 0.052)
LAMA 0.020 (0.003 to 0.064)
LABA/ICS 0.025 (0.009 to 0.068)
LABA/LAMA 0.025 (0.009 to 0.068)
Outcome: change from baseline in forced expiratory volume in 1 second at 12 months
We fitted random- and fixed-treatment-effects NMAmodels with fixed-class effects. The random-effects model had a better fit than the
fixed-effect model with a lower DIC and the between-study heterogeneity was moderate (SD 0.02, 95% CrI 0.01 to 0.04). We fitted a
random-class model with fixed-treatment effects, which improved fit compared to the fixed-treatment-effect model with a fixed-class.
DIC was lower in the model with fixed-treatment and random-class effects, although there was evidence of overfitting. We therefore
report results for both the random-treatment-effects model with a fixed-class and the fixed-treatment-effect model with a random-class
(Table 60). Within-class variability in the fixed-treatment-effect model with random-class was moderate. There is some evidence that
the variability observed across treatment effects may be due to within-class/group differences rather than between-study heterogeneity.
The inconsistency model with random-treatment effects and fixed-class had an improved model fit and lower between-study hetero-
geneity and DIC when compared to the equivalent consistency model.
The inconsistency model with fixed-treatment effects with random-class did not show an improvement in fit or DIC when compared
to the equivalent consistency model therefore suggesting no evidence of inconsistency. Plotting each data point’s contribution to the
residual deviance in the NMA and inconsistency models confirmed this (Figure 37c).
Reported results are based on the fixed-treatment-effect NMA model with random-classes (assuming consistency), with the results
for the random-treatment-effects model with fixed-classes also reported for comparison. However, there is weak evidence of potential
inconsistency in the latter model so results should be interpreted with caution.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model −150.21 0.02 (0.01 to 0.04) 32.70
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(Continued)
Fixed-effect model −142.19 49.03
Random-effects inconsistency
model
−154.87 0.01 (0.00 to 0.03) 29.46
Random-class-effects models
Fixed-effect model −155.96 27.93
Fixed-effect inconsistency
model
−154.3 28.87
acompare to 31 data points
Within class/group standard deviation for change from baseline in FEV1 at 12 months in the low-risk population
Fixed-treatment-effect model with random-class
Median 95% CrI
LABA 0.019 (0.001 to 0.422)
LAMA 0.018 (0.004 to 0.073)
LABA/LAMA 0.045 (0.016 to 0.158)
Outcome: mortality
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. The posterior mean of the residual deviance was
substantially larger than the number of data points for both models and the between-study heterogeneity was moderate (SD 0.15, 95%
CrI 0.007 to 0.70). We considered random-class models with fixed- and random-treatment effects but this only slightly improved fit
compared to the fixed-class models. The fixed-treatment-effect model with fixed-class had the lowest DIC so we chose this model.
The inconsistency model with fixed-treatment effects (and fixed-class) showed no improvement in fit or DIC compared to the NMA
model assuming consistency, suggesting no evidence of inconsistency (Figure 39c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison. Results should be interpreted with
some caution due to poor model fit which can be attributed to studies with zero cells.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 432.52 0.15 (0.007 to 0.70) 129.4
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(Continued)
Fixed-effect model 430.85 131.9
Fixed-effect inconsistency
model
430.73 132.4
Random-class-effects models
Fixed-effect model 435.98 134.5
acompare to 110 data points
Outcome: total serious adverse events
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. Both models fitted the data well and between-
study heterogeneity was low (SD 0.04, 95% CrI 0.00 to 0.15). We chose the fixed-effect model as it had the lowest DIC.
The inconsistency model with fixed-treatment effects (and fixed-class effects) did not show an improvement in fit compared to theNMA
model assuming consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to
the residual deviance in the NMA and inconsistency models, which showed no improvement in fit for any data point (Figure 40c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 891.21 0.04 (0 to 0.15) 145.8
Fixed-effect model 889.36 147.7
Fixed-effect inconsistency 894.82 150.2
acompare to 145 data points
Outcome: chronic obstructive pulmonary disease serious adverse events
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. The posterior mean of the residual deviance was
substantially larger than the number of data points for both models and the between-study heterogeneity was moderate (SD 0.16, 95%
CrI 0.002 to 0.38). Random-class models with fixed- and random-treatment effects were fitted and although model fit was improved
the fixed-class models had lower DIC. The fixed-treatment-effect model with fixed-class had the lowest DIC so we chose this model.
The inconsistency model with fixed-treatment effects (and fixed-class) showed no improvement in fit or DIC compared to the NMA
model assuming consistency, suggesting no evidence of inconsistency (Figure 41c). However, plotting each data point’s contribution
to the residual deviance in the NMA and inconsistency models there were a few studies with slightly improved fit in the inconsistency,
compared to the consistency model, suggesting some evidence of inconsistency (Figure 41c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison. Results should be interpreted with
some caution due to poor model fit, which can be attributed to studies with zero cells.
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DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 662.62 0.16 (0.002 to 0.38) 144.2
Fixed-effect model 661.91 151.0
Fixed-effect inconsistency 666.00 152.4
Random-class-effects models
Random-effects model 665.07 0.13 (0.006 to 0.37) 140.1
Fixed-effect model 664.86 143.9
acompare to 135 data points
Outcome: cardiac serious adverse events
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. The posterior mean of the residual deviance was
substantially larger than the number of data points for both models and the between-study heterogeneity was moderate (SD 0.16, 95%
CrI 0.006 to 0.48). We fitted random-class models with fixed- and random-treatment effects and although model fit was improved the
fixed-class models had lower DIC. The fixed-treatment-effect model with fixed-class had the lowest DIC so we chose this model.
The inconsistency model with fixed-treatment effects (and fixed-class) showed some improvement in fit or DIC compared to the NMA
model assuming consistency, suggesting evidence of inconsistency. Plotting each data point’s contribution to the residual deviance
in the NMA and inconsistency models showed improved fit for one study in the inconsistency model, suggesting some evidence of
inconsistency (Figure 42c). Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects,
assuming consistency. Results based on the random-treatment-effects model with fixed-class are also reported for comparison. Results
should be interpreted with some caution due to poor model fit, which can be attributed to studies with zero cells.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 578.42 0.17 (0.006 to 0.48) 151.2
Fixed-effect model 577.25 155.8
Fixed-effect inconsistency 572.69 149.3
Random-class-effects models
Random-effects model 581.73 0.16 (0.008 to 0.49) 147.0
Fixed-effect model 581.40 150.5
acompare to 127 data points
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Outcome: dropouts due to adverse events
We fitted random- and fixed-treatment-effect NMA models with fixed-class effects. The posterior mean of the residual deviance was
substantially larger than the number of data points for both models and the between-study heterogeneity was low (SD 0.09, 95% CrI
0.004 to 0.24). Random-class models with fixed- and random-treatment effects were fitted and although model fit was improved the
DIC was comparable to the fixed-class models. The fixed-treatment-effect model with fixed-class had the lowest DIC so we chose this
model.
The inconsistency model with fixed-treatment effects (and fixed-class) showed no improvement in fit or DIC compared to the NMA
model assuming consistency, suggesting no evidence of inconsistency. We confirmed this by plotting each data point’s contribution to
the residual deviance in the NMA and inconsistency models, where fit was the same or better for the consistency model for most data
points (Figure 43c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class are also reported for comparison. Results should be interpreted with
some caution due to poor model fit.
DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 848.0 0.09 (0.004 to 0.24) 155.6
Fixed-effect model 846.7 160.5
Fixed-effect inconsistency 849.3 160.2
Random-class-effects models
Random-effects model 847.3 0.09 (0.003 to 0.23) 144.8
Fixed-effect model 846.9 148.6
acompare to 146 data points
Outcome: pneumonia
We fitted random- and fixed-treatment-effects NMA models with fixed-class effects. There was some evidence that the posterior
distribution of the between-study heterogeneity was poorly estimated so we used an informative prior distribution, based on Turner
2012. We selected the prior distribution suggested for the between-study variance of a subjective outcome (infection, new disease), for
comparisons of pharmacological interventions.
The random-effects model had a better fit than the fixed-effect model with a lower DIC although the posterior mean of the residual
deviance was still considerably larger than the number of data points and the between-study heterogeneity was moderate (SD 0.23,
95% CrI 0.05 to 0.65). We fitted random-class models with fixed- and random-treatment effects, which improved fit slightly compared
to the fixed-class model. However, DIC was lowest for the fixed-treatment-effect model with a fixed-class so we chose this model.
The inconsistency models with fixed-treatment effects (and fixed-class) showed an improvement in fit and DIC compared to the NMA
model assuming consistency, suggesting some evidence of inconsistency.
Plotting each data point’s contribution to the residual deviance in the NMA and inconsistency models, there was some improvement
in fit for a few studies in the inconsistency model although most of the studies with high residual deviance contained zero-event arms,
of which there were many in the dataset (Figure 44c).
Reported results are therefore based on the fixed-treatment-effect NMA model with fixed-class effects, assuming consistency. Results
based on the random-treatment-effects model with fixed-class and informative prior distribution on the heterogeneity parameter are
also reported for comparison. Results should be interpreted with caution due to potential inconsistency in the data.
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DIC SD (95% CrI) Total residual deviancea
Fixed-class-effect models
Random-effects model 531.76 0.23 (0.05 to 0.65) 167.3
Fixed-effect model 532.14 174.3
Fixed-effect inconsistency
model
525.77 166.0
Random-class-effects models
Random-effects model 531.13 0.22 (0.05 to 0.61) 158.4
Fixed-effect model 531.66 162.0
acompare to 133 data points
DIC: deviance information criterion; SD: standard deviation
Appendix 5. Ranking summary
Outcome Treatment
group
High-risk population Low-risk population
Mean Median 95% CrI Mean Median 95% CrI
Moderate
to severe exac-
erbations
LABA/LAMA 1 1 (1 to 2) 1.1 1 (1 to 2)
LAMA 2.4 2 (2 to 3) 2.2 2 (1 to 3)
LABA/ICS 2.6 3 (2 to 3) 2.6 3 (2 to 3)
LABA 4 4 (4 to 4) 4 4 (4 to 4)
Severe exacer-
bations
LABA/LAMA 1.2 1 (1 to 2) 1.3 1 (1 to 3)
LAMA 1.9 2 (1 to 3) 1.9 2 (1 to 3)
LABA/ICS 3 3 (2 to 3) 3.3 3 (2 to 4)
LABA 4 4 (4 to 4) 3.5 4 (2 to 4)
SGRQ re-
sponders at 3
months
LABA NA NA NA 1.4 1 (1 to 3)
LABA/LAMA NA NA NA 1.8 2 (1 to 3)
LABA/ICS NA NA NA 2.8 3 (1 to 3)
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LAMA NA NA NA 4 4 (4 to 4)
SGRQ re-
sponders at 6
months
LABA/LAMA NA NA NA 1 1 (1 to 2)
LABA/ICS NA NA NA 2.7 2 (1 to 4)
LAMA NA NA NA 3 3 (2 to 4)
LABA NA NA NA 3.3 3 (2 to 4)
SGRQscore at
3 months
LABA/LAMA 1 1 (1 to 1) 1.7 2 (1 to 3)
LABA/ICS 2 2 (2 to 2) 1.6 2 (1 to 3)
LABA 3.4 3 (3 to 4) 2.8 3 (1 to 4)
LAMA 3.6 4 (3 to 4) 3.9 4 (3 to 4)
SGRQscore at
6 months
LABA/LAMA 1 1 (1 to 1) 1.3 1 (1 to 2)
LABA/ICS 2 2 (2 to 2) 1.7 2 (1 to 3)
LAMA 3.2 3 (3 to 4) 3.3 3 (2 to 4)
LABA 3.8 4 (3 to 4) 3.7 4 (3 to 4)
SGRQscore at
12 months
LABA/LAMA 1.1 1 (1 to 2) 2 2 (1 to 3)
LABA/ICS 2 2 (1 to 3) 1.1 1 (1 to 2)
LAMA 2.9 3 (2 to 3) 3.3 3 (2 to 4)
LABA 4 4 (4 to 4) 3.6 4 (3 to 4)
TDI at 3
months
LABA/LAMA NA NA NA 1 1 (1 to 1)
LABA/ICS NA NA NA 2.3 2 (2 to 4)
LABA NA NA NA 3 3 (2 to 4)
LAMA NA NA NA 3.7 4 (2 to 4)
TDI at 6
months
LABA/LAMA NA NA NA 1.1 1 (1 to 2)
LABA/ICS NA NA NA 2 2 (1 to 4)
LAMA NA NA NA 3.2 3 (2 to 4)
LABA NA NA NA 3.6 4 (3 to 4)
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TDI at 12
months
LABA/LAMA NA NA NA 1 1 (1 to 1)
LAMA NA NA NA 2.06 2 (2 to 3)
LABA NA NA NA 2.94 3 (2 to 3)
LABA/ICS NA NA NA NA NA NA
FEV1 at 3
months
LABA/LAMA 1 1 (1 to 1) 1 1 (1 to 1)
LABA/ICS 2.4 2 (2 to 3) 2 2 (2 to 2)
LAMA 2.6 3 (2 to 3) 3.2 3 (3 to 4)
LABA 4 4 (4 to 4) 3.8 4 (3 to 4)
FEV1 at 6
months
LABA/LAMA 1 1 (1 to 1) 1 1 (1 to 1)
LAMA 2.1 2 (2 to 3) 2.7 3 (2 to 4)
LABA/ICS 2.9 3 (2 to 3) 2.3 2 (2 to 4)
LABA 4 4 (4 to 4) 3.9 4 (3 to 4)
FEV1 at 12
months
LABA/LAMA 1 1 (1 to 1) 1.1 1 (1 to 2)
LAMA 2 2 (2 to 2) 2 2 (1 to 3)
LABA/ICS 3 3 (3 to 3) NA NA NA
LABA 4 4 (4 to 4) 3 3 (2 to 3)
Mortality LABA/ICS 1.6 1 (1 to 4) 1.5 1 (1 to 4)
LABA/LAMA 2.6 3 (1 to 4) 3 3 (1 to 4)
LAMA 2.8 3 (1 to 4) 3.5 4 (1 to 4)
LABA 3 3 (1 to 4) 2.1 2 (1 to 4)
Dropouts
due to adverse
event
LABA/LAMA 1.6 1 (1 to 4) 2.5 2 (1 to 4)
LAMA 2.2 2 (1 to 4) 1.3 1 (1 to 3)
LABA/ICS 2.4 2 (1 to 4) 2.5 3 (1 to 4)
LABA 3.9 4 (3 to 4) 3.7 4 (2 to 4)
Pneumonia LAMA 1.5 1 (1 to 3) 1.6 1 (1 to 3)
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LABA/LAMA 1.9 2 (1 to 3) 2.7 3 (1 to 4)
LABA 2.6 3 (1 to 3) 1.8 2 (1 to 3)
LABA/ICS 4 4 (4 to 4) 4 4 (3 to 4)
FEV1: forced expiratory volume in one second;ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; LAMA: long-acting
muscarinic antagonist; NA: not applicable; SGRQ: St George’s Respiratory Questionnaire; TDI: Transition Dyspnoea Index
Appendix 6. Summary of results for pairwise and network meta-analyses in the high-risk population
Moderate to severe ex-
acerbations, high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA (random-effects/
fixed-class)
HR (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.87 (0.76 to 1.00) 0.87 (0.76 to 1.00) 0.86 (0.76 to 0.99)
LABA/LAMA vs LAMA Moderate 1.06 (0.89 to 1.27) 1.06 (0.89 to 1.27) 0.87 (0.78 to 0.99)
LABA/LAMA vs LABA NA NA NA 0.70 (0.61 to 0.80)
LABA/ICS vs LAMA Moderate 1.12 (0.90 to 1.39) 1.12 (0.90 to 1.39) 1.01 (0.91 to 1.13)
LABA/ICS vs LABA High 0.81 (0.75 to 0.89) 0.81 (0.75 to 0.89) 0.80 (0.75 to 0.86)
LAMA vs LABA High 0.84 (0.76 to 0.92) 0.84 (0.76 to 0.92) 0.80 (0.71 to 0.88)
Severe exacerbations,
high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class) HR (95%
CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.88 (0.74 to 1.06) 0.88 (0.74 to 1.06) 0.78 (0.64 to 0.93)
LABA/LAMA vs LAMA Moderate 0.73 (0.45 to 1.16) 0.73 (0.45 to 1.16) 0.89 (0.71 to 1.11)
LABA/LAMA vs LABA NA NA NA 0.64 (0.51 to 0.81)
LABA/ICS vs LAMA Moderate 1.28 (0.95 to 1.73) 1.28 (0.95 to 1.73) 1.15 (0.97 to 1.36)
LABA/ICS vs LABA Moderate 0.91 (0.74 to 1.13) 0.91 (0.74 to 1.12) 0.83 (0.71 to 0.97)
LAMA vs LABA Moderate 0.88 (0.78 to 1.01) 0.88 (0.78 to 1.01) 0.72 (0.63 to 0.82)
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SGRQ responders at 3
months, high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class) MD (95%
CrI)
LABA/LAMA vs LABA/
ICS
NA NA NA NA
LABA/LAMA vs LAMA NA NA NA NA
LABA/LAMA vs LABA NA NA NA NA
LABA/ICS vs LAMA Low 0.96 (0.56 to 1.65) 0.96 (0.56 to 1.65) NA
LABA/ICS vs LABA NA NA NA NA
LAMA vs LABA Moderate 0.97 (0.84 to 1.12) 0.97 (0.84 to 1.12) NA
SGRQ responders at 6
months, high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(random-effects/
fixed-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
NA NA NA NA
LABA/LAMA vs LAMA Moderate 1.30 (1.08 to 1.56) 1.30 (1.08 to 1.56) NA
LABA/LAMA vs LABA NA NA NA NA
LABA/ICS vs LAMA Moderate 1.26 (0.99 to 1.59) 1.26 (0.99 to 1.59) NA
LABA/ICS vs LABA NA NA NA NA
LAMA vs LABA Low 1.08 (0.93 to 1.25) 1.08 (0.93 to 1.25) NA
SGRQ responders at 12
months, high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class)
OR (95% CrI)
LABA/LAMA vs LABA/
ICS
High 1.25 (1.09 to 1.43) 1.25 (1.09 to 1.43) 1.21 (1.07 to 1.36)
LABA/LAMA vs LAMA Low 1.27 (1.04 to 1.55) 1.27 (1.04 to 1.55) 1.36 (1.18 to 1.58)
LABA/LAMA vs LABA NA NA NA 1.41 (1.2 to 1.66)
LABA/ICS vs LAMA Moderate 1.15 (0.90 to 1.47) 1.15 (0.90 to 1.47) 1.13 (0.98 to 1.3)
LABA/ICS vs LABA Moderate 1.15 (0.78 to 1.72) 1.22 (1.03 to 1.46) 1.17 (1.02 to 1.34)
515Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
LAMA vs LABA Moderate 1.00 (0.86 to 1.17) 1.00 (0.86 to 1.17) 1.03 (0.91 to 1.18)
CFB in SGRQ at 3
months, high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD(95% CI)
Pairwise, fixed-effect
MD(95% CI)
NMA(fixed-effect/
fixed-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
High −1.30 (−2.35 to −0.
25)
−1.30 (−2.35 to −0.
25)
−1.39 (−2.37 to −0.
42)
LABA/LAMA vs LAMA Moderate -3.68 (-5.84 to −1.52) -3.68 (-5.84 to −1.52) -3.31 (-4.67 to −1.97)
LABA/LAMA vs LABA NA NA NA -3.21 (-4.52 to −1.92)
LABA/ICS vs LAMA Low −1.06 (-4.39 to 2.27) −1.06 (-4.39 to 2.27) −1.92 (-3.11 to −0.74)
LABA/ICS vs LABA Low −1.81 (−2.99 to −0.
64)
−1.81 (−2.99 to −0.
64)
−1.82 (−2.86 to −0.
78)
LAMA vs LABA High 0.10 (−0.82 to 1.02) 0.10 (−0.82 to 1.02) 0.10 (−0.76 to 0.96)
CFB in SGRQ at 6
months, high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD(95% CI)
Pairwise, fixed-effect
MD(95% CI)
NMA(fixed-effect/
fixed-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
High −1.20 (−2.28 to −0.
12)
−1.20 (−2.28 to −0.
12)
−1.27 (−2.26 to −0.
29)
LABA/LAMA vs LAMA Moderate −2.79 (-5.02 to −0.56) −2.79 (-5.02 to −0.56) −2.48 (-3.72 to −1.24)
LABA/LAMA vs LABA NA NA NA −2.88 (-4.03 to −1.73)
LABA/ICS vs LAMA Low −1.97 (-3.79 to −0.15) −1.97 (-3.79 to −0.15) −1.21 (−2.16 to −0.
25)
LABA/ICS vs LABA Very low −1.40 (−2.53 to −0.
26)
−1.45 (−2.17 to −0.
73)
−1.6 (−2.27 to −0.93)
LAMA vs LABA High −0.70 (−1.74 to 0.34) −0.70 (−1.74 to 0.34) −0.39 (−1.27 to 0.47)
CFB in SGRQ at 12
months, high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD(95% CI)
Pairwise, fixed-effect
MD(95% CI)
NMA(fixed-effect/
fixed-class) MD (95%
CrI)
LABA/LAMA vs LABA/
ICS
High −1.20 (−2.34 to −0.
06)
−1.20 (−2.34 to −0.
06)
−0.52 (−1.42 to 0.36)
LABA/LAMA vs LAMA Low -3.38 (-5.83 to −0.93) -3.38 (-5.83 to −0.93) −1.12 (−1.88 to −0.
37)
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LABA/LAMA vs LABA NA NA NA −2.1 (-3.08 to −1.13)
LABA/ICS vs LAMA Low −0.99 (−2.98 to 1.00) −0.99 (−2.98 to 1.00) −0.59 (−1.48 to 0.29)
LABA/ICS vs LABA Moderate −1.75 (−2.61 to −0.
89)
−1.78 (−2.49 to −1.
07)
−1.57 (−2.23 to −0.
92)
LAMA vs LABA High −0.40 (−1.56 to 0.76) −0.40 (−1.56 to 0.76) −0.98 (−1.86 to −0.
08)
TDI at 3 months, high-
risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD(95% CI)
Pairwise, fixed-effect
MD(95% CI)
NMA
LABA/LAMA vs LABA/
ICS
NA NA NA NA
LABA/LAMA vs LAMA NA NA NA NA
LABA/LAMA vs LABA NA NA NA NA
LABA/ICS vs LAMA Moderate 0.50 (0.18 to 0.82) 0.50 (0.18 to 0.82) NA
LABA/ICS vs LABA NA NA NA NA
LAMA vs LABA Moderate −0.14 (−0.15 to −0.
13)
−0.14 (−0.15 to −0.
13)
NA
TDI at 6 months, high-
risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD(95% CI)
Pairwise, fixed-effect
MD(95% CI)
NMA
LABA/LAMA vs LABA/
ICS
NA NA NA NA
LABA/LAMA vs LAMA NA NA NA NA
LABA/LAMA vs LABA NA NA NA NA
LABA/ICS vs LAMA Moderate 0.30 (−0.06 to 0.66) 0.30 (−0.06 to 0.66) NA
LABA/ICS vs LABA NA NA NA NA
LAMA vs LABA Moderate −0.19 (−0.20 to −0.
18)
−0.19 (−0.20 to −0.
18)
NA
TDI at 12 months,
high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD(95% CI)
Pairwise, fixed-effect
MD(95% CI)
NMA
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LABA/LAMA vs LABA/
ICS
NA NA NA NA
LABA/LAMA vs LAMA Moderate −0.38 (−1.28 to 0.52) −0.38 (−1.28 to 0.52) NA
LABA/LAMA vs LABA NA NA NA NA
LABA/ICS vs LAMA Low 0.00 (−0.40 to 0.40) 0.00 (−0.40 to 0.40) NA
LABA/ICS vs LABA NA NA NA NA
LAMA vs LABA Moderate −0.26 (−0.27 to −0.
25)
−0.26 (−0.27 to −0.
25)
NA
CFB in FEV1 at 3
months, high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD(95% CI)
Pairwise, fixed-effect
MD(95% CI)
NMA(fixed-effect/
fixed-class) MD (95%
CrI)
LABA/LAMA vs LABA/
ICS
High 0.08 (0.06 to 0.10) 0.08 (0.06 to 0.10) 0.07 (0.05 to 0.09)
LABA/LAMA vs LAMA Moderate 0.06 (0.02 to 0.09) 0.06 (0.02 to 0.09) 0.07 (0.05 to 0.10)
LABA/LAMA vs LABA NA NA NA 0.12 (0.10 to 0.15)
LABA/ICS vs LAMA High 0.01 (−0.02 to 0.04) 0.01 (−0.02 to 0.03) 0.00 (−0.02 to 0.02)
LABA/ICS vs LABA Moderate 0.05 (0.03 to 0.07) 0.05 (0.04 to 0.07) 0.05 (0.04 to 0.07)
LAMA vs LABA NA NA NA 0.05 (0.02 to 0.07)
CFB in FEV1 at 6
months, high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD(95% CI)
Pairwise, fixed-effect
MD(95% CI)
NMA(fixed-effect/
fixed-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
High 0.09 (0.07 to 0.11) 0.09 (0.07 to 0.11) 0.08 (0.06 to 0.10)
LABA/LAMA vs LAMA Moderate 0.06 (0.02 to 0.10) 0.06 (0.02 to 0.10) 0.07 (0.04 to 0.09)
LABA/LAMA vs LABA NA NA NA 0.13 (0.10 to 0.15)
LABA/ICS vs LAMA Moderate −0.01 (−0.04 to 0.02) −0.01 (−0.04 to 0.02) −0.02 (−0.04 to 0.01)
LABA/ICS vs LABA Moderate 0.05 (0.03 to 0.07) 0.04 (0.03 to 0.06) 0.04 (0.03 to 0.06)
LAMA vs LABA NA NA NA 0.06 (0.03 to 0.08)
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CFB in FEV1 at 12
months, high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD(95% CI)
Pairwise, fixed-effect
MD(95% CI)
NMA (random-effects/
fixed-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.06 (0.04 to 0.08) 0.06 (0.04 to 0.08) 0.07 (0.04 to 0.1)
LABA/LAMA vs LAMA Moderate 0.05 (0.01 to 0.09) 0.05 (0.01 to 0.09) 0.04 (0 to 0.08)
LABA/LAMA vs LABA NA NA NA 0.12 (0.08 to 0.16)
LABA/ICS vs LAMA Very low −0.01 (−0.08 to 0.05) −0.03 (−0.06 to 0.00) −0.03 (−0.07 to 0.01)
LABA/ICS vs LABA Moderate 0.05 (0.03 to 0.07) 0.04 (0.03 to 0.06) 0.05 (0.03 to 0.07)
LAMA vs LABA NA NA NA 0.08 (0.04 to 0.12)
Mortality, high-risk Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class)
ORa (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 1.00 (0.57 to 1.77) 1.00 (0.57 to 1.77) 1.12 (0.75 to 1.68)
LABA/LAMA vs LAMA Moderate 1.06 (0.66 to 1.69) 1.06 (0.66 to 1.69) 0.98 (0.66 to 1.42)
LABA/LAMA vs LABA NA NA NA 0.97 (0.63 to 1.46)
LABA/ICS vs LAMA Moderate 0.53 (0.31 to 0.90) 0.52 (0.31 to 0.89) 0.87 (0.65 to 1.16)
LABA/ICS vs LABA Low 0.95 (0.69 to 1.30) 0.98 (0.73 to 1.33) 0.86 (0.66 to 1.11)
LAMA vs LABA Moderate 0.87 (0.66 to 1.16) 0.87 (0.66 to 1.16) 0.99 (0.77 to 1.27)
Total SAEs, high-risk Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class)
OR (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.91 (0.76 to 1.08) 0.91 (0.76 to 1.08) 0.89 (0.77 to 1.02)
LABA/LAMA vs LAMA Moderate 0.98 (0.80 to 1.20) 0.98 (0.80 to 1.20) 1.01 (0.87 to 1.17)
LABA/LAMA vs LABA NA NA NA 0.89 (0.77 to 1.04)
LABA/ICS vs LAMA Moderate 1.29 (1.03 to 1.63) 1.29 (1.03 to 1.63) 1.14 (1.02 to 1.27)
LABA/ICS vs LABA High 0.99 (0.89 to 1.09) 0.99 (0.89 to 1.09) 1.01 (0.92 to 1.10)
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LAMA vs LABA Moderate 0.90 (0.81 to 1.00) 0.90 (0.81 to 1.00) 0.88 (0.81 to 0.97)
COPD SAEs high-risk Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class)
OR (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.87 (0.70 to 1.07) 0.87 (0.70 to 1.07) 0.87 (0.73 to 1.04)
LABA/LAMA vs LAMA Moderate 1.08 (0.84 to 1.39) 1.08 (0.84 to 1.39) 1.07 (0.89 to 1.28)
LABA/LAMA vs LABA NA NA NA 0.82 (0.68 to 1.00)
LABA/ICS vs LAMA Low 0.99 (0.33 to 2.96) 1.33 (0.99 to 1.79) 1.22 (1.05 to 1.42)
LABA/ICS vs LABA Moderate 0.92 (0.78 to 1.07) 0.92 (0.79 to 1.07) 0.95 (0.83 to 1.08)
LAMA vs LABA High 0.79 (0.69 to 0.91) 0.79 (0.69 to 0.91) 0.77 (0.68 to 0.87)
Cardiac SAEs, high-
risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(random-effects/
fixed-class)
OR (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.86 (0.58 to 1.29) 0.86 (0.58 to 1.29) 0.7 (0.03 to 5.88)
LABA/LAMA vs LAMA Low 0.80 (0.53 to 1.20) 0.80 (0.53 to 1.20) 0.69 (0.02 to 25.46)
LABA/LAMA vs LABA NA NA NA 0.83 (0.06 to 9.24)
LABA/ICS vs LAMA Moderate 0.67 (0.39 to 1.15) 0.67 (0.39 to 1.15) 1.08 (0.06 to 23.81)
LABA/ICS vs LABA Very low 0.97 (0.68 to 1.38) 0.96 (0.75 to 1.22) 1.27 (0.37 to 5.97)
LAMA vs LABA Low 1.09 (0.83 to 1.44) 1.09 (0.84 to 1.43) 1.13 (0.06 to 21.22)
Dropouts due to AEs,
high-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(random-effects/
fixed-class)
OR (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.88 (0.69 to 1.13) 0.88 (0.69 to 1.13) 0.93 (0.73 to 1.19)
LABA/LAMA vs LAMA Low 1.03 (0.75 to 1.41) 1.03 (0.75 to 1.40) 0.95 (0.74 to 1.21)
LABA/LAMA vs LABA NA NA NA 0.83 (0.65 to 1.07)
LABA/ICS vs LAMA Moderate 1.04 (0.74 to 1.47) 1.04 (0.74 to 1.47) 1.02 (0.85 to 1.22)
520Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic
review and network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
LABA/ICS vs LABA Low 0.88 (0.77 to 1.00) 0.88 (0.77 to 1.00) 0.89 (0.79 to 1.01)
LAMA vs LABA High 0.91 (0.79 to 1.04) 0.91 (0.79 to 1.04) 0.88 (0.75 to 1.03)
Pneumonia, high-risk Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class)OR (95%
CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.62 (0.40 to 0.96) 0.62 (0.40 to 0.96) 0.59 (0.41 to 0.83)
LABA/LAMA vs LAMA Moderate 0.98 (0.59 to 1.61) 0.98 (0.60 to 1.61) 1.05 (0.72 to 1.5)
LABA/LAMA vs LABA NA NA NA 0.88 (0.6 to 1.29)
LABA/ICS vs LAMA Moderate 1.80 (1.06 to 3.06) 1.82 (1.07 to 3.09) 1.78 (1.33 to 2.39)
LABA/ICS vs LABA Moderate 1.46 (1.03 to 2.08) 1.51 (1.14 to 1.99) 1.50 (1.17 to 1.92)
LAMA vs LABA Moderate 0.83 (0.61 to 1.13) 0.83 (0.62 to 1.12) 0.84 (0.65 to 1.09)
aPotential inconsistency in the date. Results should be interpreted with caution
AE: adverse event; CFB: change from baseline; HR: hazard ratio; FEV1: forced expiratory volume in one second;ICS: inhaled corti-
costeroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist; MA: meta-analysis; MD: mean difference;
NA: not applicable; NMA: network meta-analysis; OR: odds ratio; SAE: serious adverse event; SGRQ: St George’s Respiratory
Questionnaire; TDI: Transition Dyspnoea Index
Appendix 7. Summary of results for pairwise and network meta-analyses in the low-risk population
Moderate to severe ex-
acerbations, low-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class)
HR (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.86 (0.65 to 1.14) 0.84 (0.68 to 1.06) 0.87 (0.75 to 1.01)
LABA/LAMA vs LAMA Low 0.93 (0.66 to 1.30) 0.94 (0.78 to 1.14) 0.90 (0.76 to 1.06)
LABA/LAMA vs LABA Moderate 0.77 (0.62 to 0.97) 0.77 (0.62 to 0.96) 0.78 (0.67 to 0.90)
LABA/ICS vs LAMA Low 0.63 (0.24 to 1.66) 0.63 (0.24 to 1.66) 1.03 (0.91 to 1.17)
LABA/ICS vs LABA Moderate 0.83 (0.70 to 0.98) 0.85 (0.76 to 0.95) 0.89 (0.84 to 0.96)
LAMA vs LABA Moderate 0.92 (0.79 to 1.07) 0.92 (0.79 to 1.07) 0.87 (0.78 to 0.97)
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Severe exacerbations,
low-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(random-effects/
fixed-class)
HR (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.66 (0.27 to 1.63) 0.62 (0.33 to 1.19) 0.71 (0.47 to 1.08)
LABA/LAMA vs LAMA Moderate 0.99 (0.57 to 1.72) 1.01 (0.65 to 1.55) 0.90 (0.6 to 1.31)
LABA/LAMA vs LABA Moderate 0.78 (0.55 to 1.12) 0.78 (0.55 to 1.11) 0.72 (0.48 to 1.02)
LABA/ICS vs LAMA Low 3.05 (0.32 to 29.47) 3.05 (0.32 to 29.47) 1.25 (0.86 to 1.85)
LABA/ICS vs LABA High 1.06 (0.90 to 1.24) 1.06 (0.90 to 1.24) 1.01 (0.72 to 1.28)
LAMA vs LABA Low 0.64 (0.36 to 1.13) 0.65 (0.41 to 1.03) 0.80 (0.56 to 1.05)
SGRQ responders at 3
months, low-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class)
OR (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 1.08 (0.92 to 1.27) 1.08 (0.92 to 1.27) 1.07 (0.94 to 1.23)
LABA/LAMA vs LAMA High 1.32 (1.16 to 1.51) 1.32 (1.17 to 1.49) 1.33 (1.19 to 1.48)
LABA/LAMA vs LABA NA NA NA 0.96 (0.81 to 1.15)
LABA/ICS vs LAMA Low 1.26 (0.92 to 1.74) 1.26 (0.92 to 1.74) 1.24 (1.07 to 1.43)
LABA/ICS vs LABA Low 0.90 (0.73 to 1.11) 0.90 (0.73 to 1.11) 0.9 (0.76 to 1.06)
LAMA vs LABA High 0.73 (0.59 to 0.89) 0.73 (0.59 to 0.89) 0.73 (0.62 to 0.85)
SGRQ responders at 6
months, low-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(random-effects/
fixed-class)
OR (95% CrI)
LABA/LAMA vs LABA/
ICS
Low 1.29 (0.88 to 1.89) 1.29 (0.88 to 1.89) 1.22 (0.99 to 1.51)
LABA/LAMA vs LAMA Moderate 1.26 (1.15 to 1.37) 1.26 (1.15 to 1.37) 1.26 (1.1 to 1.42)
LABA/LAMA vs LABA Low 1.20 (1.06 to 1.37) 1.20 (1.06 to 1.37) 1.28 (1.11 to 1.47)
LABA/ICS vs LAMA NA NA NA 1.03 (0.83 to 1.27)
LABA/ICS vs LABA Moderate 1.08 (0.96 to 1.22) 1.08 (0.96 to 1.22) 1.05 (0.87 to 1.25)
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LAMA vs LABA Low 1.02 (0.89 to 1.16) 1.02 (0.93 to 1.11) 1.02 (0.9 to 1.16)
SGRQ responders at 12
months, low-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA
LABA/LAMA vs LABA/
ICS
NA NA NA NA
LABA/LAMA vs LAMA Moderate 1.13 (0.95 to 1.34) 1.13 (0.95 to 1.34) NA
LABA/LAMA vs LABA Moderate 1.19 (0.99 to 1.44) 1.19 (0.99 to 1.44) NA
LABA/ICS vs LAMA NA NA NA NA
LABA/ICS vs LABA Moderate 1.42 (1.18 to 1.70) 1.42 (1.18 to 1.70) NA
LAMA vs LABA Low 1.05 (0.88 to 1.26) 1.05 (0.88 to 1.26) NA
CFB in SGRQ at 3
months, low-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD (95% CI)
Pairwise, fixed-effect
MD (95% CI)
NMA(fixed-effect/
fixed-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
High −0.03 (−1.02 to 0.96) −0.03 (−1.02 to 0.96) 0.04 (−0.79 to 0.88)
LABA/LAMA vs LAMA Moderate −1.60 (−2.19 to −1.
01)
−1.60 (−2.19 to −1.
01)
−1.64 (−2.2 to −1.08)
LABA/LAMA vs LABA Moderate −1.29 (-4.29 to 1.71) −1.29 (-4.29 to 1.71) −0.63 (−1.86 to 0.6)
LABA/ICS vs LAMA Moderate −1.48 (-3.41 to 0.45) −1.48 (-3.41 to 0.45) −1.68 (−2.59 to −0.
78)
LABA/ICS vs LABA High −1.00 (−2.61 to 0.61) −1.00 (−2.61 to 0.61) −0.67 (−1.88 to 0.54)
LAMA vs LABA Moderate 1.84 (0.87 to 2.80) 1.84 (0.87 to 2.80) 1.01 (−0.2 to 2.22)
CFB in SGRQ at 6
months, low-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD (95% CI)
Pairwise, fixed-effect
MD (95% CI)
NMA(fixed-effect/
fixed-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
Low −0.99 (-4.12 to 2.14) −0.99 (-4.12 to 2.14) −0.22 (−1.28 to 0.82)
LABA/LAMA vs LAMA Moderate −1.20 (−1.83 to −0.
57)
−1.20 (−1.83 to −0.
57)
−1.18 (−1.8 to −0.56)
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LABA/LAMA vs LABA Moderate −1.09 (−1.96 to −0.
22)
−1.09 (−1.96 to −0.
22)
−1.36 (−2.12 to −0.
60)
LABA/ICS vs LAMA NA NA NA −0.96 (−1.98 to 0.09)
LABA/ICS vs LABA Moderate −1.18 (−1.97 to −0.
40)
−1.18 (−1.97 to −0.
40)
−1.14 (−1.90 to −0.
37)
LAMA vs LABA High −0.25 (−1.09 to 0.58) −0.23 (−0.99 to 0.54) −0.18 (−0.91 to 0.55)
CFB in SGRQ at 12
months, low-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD (95% CI)
Pairwise, fixed-effect
MD (95% CI)
NMA(fixed-effect/
fixed-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
NA NA NA 0.97 (0.48 to 2.42)
LABA/LAMA vs LAMA Very low −0.87 (−1.64 to −0.
10)
−0.87 (−1.64 to −0.
10)
−0.89 (−1.66 to −0.
11)
LABA/LAMA vs LABA High −0.69 (−1.64 to 0.25) −0.69 (−1.64 to 0.25) −0.72 (−1.64 to 0.20)
LABA/ICS vs LAMA NA NA NA −1.85 (−3.28 to −0.
43)
LABA/ICS vs LABA Moderate −1.70 (−2.82 to −0.
58)
−1.70 (−2.82 to −0.
58)
−1.69 (−2.81 to −0.
57)
LAMA vs LABA High 0.10 (−0.79 to 0.99) 0.10 (−0.79 to 0.99) 0.16 (−0.72 to 1.04)
TDI at 3 months, low-
risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD (95% CI)
Pairwise, fixed-effect
MD (95% CI)
NMA(random-effects/
fixed-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
Low 0.40 (0.02 to 0.78) 0.36 (0.16 to 0.56) 0.35 (0.12 to 0.56)
LABA/LAMA vs LAMA Moderate 0.48 (0.34 to 0.62) 0.48 (0.34 to 0.62) 0.54 (0.36 to 0.73)
LABA/LAMA vs LABA Low 0.52 (0.31 to 0.74) 0.52 (0.31 to 0.74) 0.44 (0.20 to 0.67)
LABA/ICS vs LAMA Very low 0.51 (−0.39 to 1.41) 0.51 (−0.39 to 1.41) 0.19 (−0.07 to 0.47)
LABA/ICS vs LABA High 0.13 (−0.26 to 0.52) 0.09 (−0.20 to 0.37) 0.09 (−0.18 to 0.36)
LAMA vs LABA Low −0.18 (−0.63 to 0.27) −0.06 (−0.26 to 0.14) −0.10 (−0.36 to 0.14)
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TDI at 6 months, low-
risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD (95% CI)
Pairwise, fixed-effect
MD (95% CI)
NMA(fixed-effect/
fixed-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
High 0.13 (−0.24 to 0.51) 0.13 (−0.24 to 0.51) 0.15 (−0.10 to 0.40)
LABA/LAMA vs LAMA Moderate 0.32 (0.17 to 0.46) 0.32 (0.17 to 0.46) 0.33 (0.18 to 0.47)
LABA/LAMA vs LABA Moderate 0.40 (0.23 to 0.57) 0.40 (0.23 to 0.57) 0.37 (0.21 to 0.52)
LABA/ICS vs LAMA NA NA NA 0.18 (−0.09 to 0.45)
LABA/ICS vs LABA High 0.21 (−0.09 to 0.50) 0.21 (−0.09 to 0.50) 0.22 (−0.02 to 0.46)
LAMA vs LABA Low 0.00 (−0.17 to 0.18) 0.00 (−0.17 to 0.18) 0.04 (−0.12 to 0.21)
TDI at 12months, low-
risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD (95% CI)
Pairwise, fixed-effect
MD (95% CI)
NMA(fixed-effect/
fixed-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
NA NA NA NA
LABA/LAMA vs LAMA Moderate 0.22 (0.11 to 0.34) 0.22 (0.11 to 0.34) 0.20 (0.09 to 0.32)
LABA/LAMA vs LABA Very low 0.42 (0.06 to 0.77) 0.30 (0.17 to 0.42) 0.30 (0.17 to 0.42)
LABA/ICS vs LAMA NA NA NA NA
LABA/ICS vs LABA NA NA NA NA
LAMA vs LABA High 0.15 (−0.11 to 0.40) 0.06 (−0.05 to 0.18) 0.09 (−0.02 to 0.21)
CFB in FEV1 at 3
months, low-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD (95% CI)
Pairwise, fixed-effect
MD (95% CI)
NMA random-effects/
fixed-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
Low 0.08 (0.03 to 0.12) 0.03 (0.02 to 0.04) 0.05 (0.03 to 0.07)
LABA/LAMA vs LAMA Low 0.07 (0.06 to 0.09) 0.07 (0.06 to 0.08) 0.08 (0.06 to 0.09)
LABA/LAMA vs LABA Very low 0.07 (0.03 to 0.12) 0.04 (0.03 to 0.05) 0.09 (0.07 to 0.11)
LABA/ICS vs LAMA Low 0.02 (−0.02 to 0.06) 0.06 (0.05 to 0.07) 0.02 (0 to 0.04)
LABA/ICS vs LABA Moderate 0.05 (0.04 to 0.06) 0.05 (0.04 to 0.06) 0.03 (0.01 to 0.05)
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LAMA vs LABA Low −0.00 (−0.02 to 0.02) −0.00 (−0.01 to 0.00) 0.01 (−0.01 to 0.03)
CFB in FEV1 at 6
months, low-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD (95% CI)
Pairwise, fixed-effect
MD (95% CI)
NMA(random-effects/
fixed-class)
MDa (95% CrI)
LABA/LAMA vs LABA/
ICS
High 0.10 (0.05 to 0.15) 0.10 (0.05 to 0.15) 0.05 (0.03 to 0.08)
LABA/LAMA vs LAMA Low 0.06 (0.05 to 0.07) 0.06 (0.05 to 0.07) 0.06 (0.05 to 0.08)
LABA/LAMA vs LABA Moderate 0.07 (0.06 to 0.08) 0.07 (0.06 to 0.08) 0.08 (0.06 to 0.09)
LABA/ICS vs LAMA High −0.00 (−0.06 to 0.06) −0.00 (−0.06 to 0.06) 0.01 (−0.02; 0.04)
LABA/ICS vs LABA Moderate 0.04 (0.01 to 0.07) 0.04 (0.01 to 0.07) 0.02 (−0.01 to 0.05)
LAMA vs LABA Very low 0.02 (0.00 to 0.03) 0.02 (0.01 to 0.03) 0.01 (0.00 to 0.03)
CFB in FEV1 at 12
months, low-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
MD (95% CI)
Pairwise, fixed-effect
MD (95% CI)
NMA(fixed-effect/
random-class)
MD (95% CrI)
LABA/LAMA vs LABA/
ICS
NA NA NA NA
LABA/LAMA vs LAMA Very low 0.06 (0.04 to 0.08) 0.05 (0.04 to 0.06) 0.06 (−0.01 to 0.12)
LABA/LAMA vs LABA Very low 0.07 (0.06 to 0.09) 0.07 (0.06 to 0.08) 0.08 (0.02 to 0.14)
LABA/ICS vs LAMA NA NA NA NA
LABA/ICS vs LABA NA NA NA NA
LAMA vs LABA Very low 0.02 (0.01 to 0.03) 0.02 (0.01 to 0.03) 0.02 (0.00 to 0.06)
Mortality, low-risk Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMAm (fixed-effect/
fixed-class)
OR (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 1.06 (0.35 to 3.23) 1.13 (0.42 to 3.04) 1.25 (0.79 to 2.00)
LABA/LAMA vs LAMA Moderate 0.98 (0.66 to 1.43) 0.96 (0.67 to 1.39) 0.91 (0.63 to 1.32)
LABA/LAMA vs LABA Moderate 1.19 (0.68 to 2.09) 1.15 (0.68 to 1.95) 1.16 (0.75 to 1.81)
LABA/ICS vs LAMA Moderate 0.48 (0.06 to 3.82) 0.43 (0.06 to 2.96) 0.73 (0.45 to 1.16)
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LABA/ICS vs LABA Moderate 0.93 (0.76 to 1.15) 0.93 (0.76 to 1.15) 0.93 (0.76 to 1.14)
LAMA vs LABA Moderate 1.30 (0.75 to 2.25) 1.23 (0.74 to 2.07) 1.28 (0.83 to 1.98)
Total SAEs, low-risk Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class)
OR (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.88 (0.64 to 1.22) 0.88 (0.67 to 1.16) 0.91 (0.78 to 1.05)
LABA/LAMA vs LAMA High 1.03 (0.91 to 1.16) 1.03 (0.92 to 1.15) 1.03 (0.93 to 1.15)
LABA/LAMA vs LABA High 1.06 (0.91 to 1.22) 1.06 (0.91 to 1.22) 1.02 (0.91 to 1.15)
LABA/ICS vs LAMA Moderate 0.93 (0.49 to 1.77) 0.93 (0.49 to 1.76) 1.14 (0.98 to 1.32)
LABA/ICS vs LABA Low 1.17 (0.92 to 1.47) 1.13 (1.00 to 1.28) 1.13 (1.01 to 1.27)
LAMA vs LABA High 1.01 (0.88 to 1.15) 1.01 (0.88 to 1.15) 0.99 (0.88 to 1.11)
COPD SAEs, low-risk Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class)
OR (95% CrI)
LABA/LAMA vs LABA/
ICS
Low 0.80 (0.39 to 1.64) 0.81 (0.50 to 1.31) 0.96 (0.75 to 1.22)
LABA/LAMA vs LAMA High 0.96 (0.79 to 1.17) 0.96 (0.79 to 1.17) 0.99 (0.82 to 1.19)
LABA/LAMA vs LABA Moderate 1.08 (0.83 to 1.40) 1.09 (0.84 to 1.41) 0.92 (0.75 to 1.13)
LABA/ICS vs LAMA Moderate 1.02 (0.21 to 4.99) 1.00 (0.22 to 4.41) 1.04 (0.81 to 1.32)
LABA/ICS vs LABA High 0.95 (0.83 to 1.04) 0.95 (0.80 to 1.12) 0.96 (0.82 to 1.13)
LAMA vs LABA Low 0.91(0.65 to 1.27) 0.96 (0.77 to 1.21) 0.93 (0.76 to 1.14)
Cardiac SAEs, low-risk Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class)
ORa (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.90 (0.43 to 1.89) 0.91 (0.45 to 1.83) 1.28 (0.91 to1.81)
LABA/LAMA vs LAMA Moderate 1.09 (0.82 to 1.45) 1.08 (0.82 to 1.42) 1.05 (0.80 to 1.36)
LABA/LAMA vs LABA Moderate 1.19 (0.69 to 2.07) 1.28 (0.88 to 1.88) 1.24 (0.92 to1.68)
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LABA/ICS vs LAMA Moderate 0.16 (0.02 to 1.34) 0.14 (0.02 to 1.13) 0.82 (0.58 to 1.15)
LABA/ICS vs LABA High 0.97 (0.78 to 1.21) 0.98 (0.79 to 1.21) 0.97 (0.79 to 1.19)
LAMA vs LABA Moderate 1.16 (0.83 to 1.61) 1.19 (0.86 to 1.65) 1.19 (0.89 to 1.59)
Dropouts due to AEs,
low-risk
Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(fixed-effect/
fixed-class)
OR (95% CrI)
LABA/LAMA vs LABA/
ICS
Low 0.90 (0.68 to 1.19) 0.91 (0.69 to 1.19) 0.99 (0.83 to 1.18)
LABA/LAMA vs LAMA Low 1.12 (0.96 to 1.31) 1.13 (0.97 to 1.31) 1.09 (0.95 to 1.26)
LABA/LAMA vs LABA Very low 0.94 (0.68 to 1.29) 0.93 (0.76 to 1.14) 0.91 (0.78 to 1.06)
LABA/ICS vs LAMA Low 0.78 (0.35 to 1.71) 0.80 (0.44 to 1.47) 1.11 (0.92 to 1.33)
LABA/ICS vs LABA Moderate 0.90 (0.77 to 1.06) 0.90 (0.77 to 1.06) 0.92 (0.80 to 1.06)
LAMA vs LABA Moderate 0.90 (0.73 to 1.10) 0.89 (0.75 to 1.05) 0.84 (0.72 to 0.97)
Pneumonia, low-risk Certainty of evidence
in the pairwise MA
Pairwise, random-
effects
OR (95% CI)
Pairwise, fixed-effect
OR (95% CI)
NMA(random-
effectsIP/fixed-class)
ORa (95% CrI)
LABA/LAMA vs LABA/
ICS
Moderate 0.43 (0.19 to 0.97) 0.42 (0.19 to 0.92) 0.61 (0.34 to 1.01)
LABA/LAMA vs LAMA Moderate 1.23 (0.84 to 1.81) 1.26 (0.88 to 1.79) 1.23 (0.82 to 1.84)
LABA/LAMA vs LABA Moderate 1.54 (0.95 to 2.49) 1.60 (1.01 to 2.53) 1.18 (0.75 to 1.81)
LABA/ICS vs LAMA Low 5.82 (0.70 to 48.80) 5.90 (0.71 to 49.14) 2.02 (1.16 to 3.72)
LABA/ICS vs LABA High 1.64 (1.25 to 2.14) 1.64 (1.26 to 2.14) 1.93 (1.29 to 3.22)
LAMA vs LABA Moderate 1.01 (0.61 to 1.69) 1.02 (0.64 to 1.61) 0.96 (0.62 to 1.49)
aPotential inconsistency in the date. Results should be interpreted with caution
AE: adverse event; CFB: change from baseline; HR: hazard ratio; FEV1: forced expiratory volume in one second;ICS: inhaled corti-
costeroid; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist; MA: meta-analysis; MD: mean difference;
NA: not applicable; NMA: network meta-analysis; OR: odds ratio; SAE: serious adverse event; SGRQ: St George’s Respiratory
Questionnaire; TDI: Transition Dyspnoea Index
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We made the following changes for the review.
1. We included free combinations of long-acting β-agonist/long-acting muscarinic antagonist (LABA/LAMA) and LABA/inhaled
corticosteroid (ICS).
2. We added intraclass/group comparisons (e.g. LAMA versus LAMA, LABA versus LABA) in the NMAs.
3. We added network meta-analyses (NMAs) for individual treatment effects for all outcomes.
4. We used a newly developed, shared parameter model for exacerbation outcomes.
5. We used odds ratios for dichotomous outcomes in the NMAs instead of hazard ratios after reviewing time-to-event data in the
existing clinical studies.
6. We used a binominal likelihood with a logit instead of cloglog link for dichotomous outcomes in the NMAs.
7. We cautioned readers instead of grading a level of evidence or restricting the analysis to a subset of studies in the NMAs when we
suspected an imbalance in effect modifiers between clinical studies.
8. We chose the simplest model for the NMAs when the difference in deviance information criterion (DIC) was less than 3 points
between models rather than choosing a model based on heterogeneity in the pairwise comparison.
9. We did not perform a meta-regression analysis to explore potential sources of heterogeneity due to complexity of the data and
models.
10. We included primary outcomes and pneumonia only in the ’Summary of findings’ tables rather than all outcomes as planned.
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